{"a62150169f3f45fa30e13124ba0ff6c1945f5c0e": [["a1111111111 a1111111111 a1111111111 a1111111111 a1111111111IntroductionMillions of humans are chronically infected by hepatitis C virus (HCV) worldwide [1] .", [["chronically infected by hepatitis C virus (HCV)", "DISEASE", 94, 141], ["humans", "ORGANISM", 83, 89], ["hepatitis C virus", "ORGANISM", 118, 135], ["HCV", "ORGANISM", 137, 140], ["humans", "SPECIES", 83, 89], ["hepatitis C virus", "SPECIES", 118, 135], ["humans", "SPECIES", 83, 89], ["hepatitis C virus", "SPECIES", 118, 135], ["HCV", "SPECIES", 137, 140], ["hepatitis C virus", "PROBLEM", 118, 135], ["chronically", "OBSERVATION_MODIFIER", 94, 105], ["infected", "OBSERVATION", 106, 114], ["hepatitis", "OBSERVATION", 118, 127]]], ["Chronic HCV infection is a major biomedical problem as it causes liver inflammation and fibrosis, which can lead to severe liver disease, such as cirrhosis and hepatocellular carcinoma [2, 3] .", [["liver", "ANATOMY", 65, 70], ["liver", "ANATOMY", 123, 128], ["hepatocellular carcinoma", "ANATOMY", 160, 184], ["HCV infection", "DISEASE", 8, 21], ["liver inflammation", "DISEASE", 65, 83], ["fibrosis", "DISEASE", 88, 96], ["liver disease", "DISEASE", 123, 136], ["cirrhosis", "DISEASE", 146, 155], ["hepatocellular carcinoma", "DISEASE", 160, 184], ["liver", "ORGAN", 65, 70], ["liver", "ORGAN", 123, 128], ["hepatocellular carcinoma", "CANCER", 160, 184], ["HCV", "SPECIES", 8, 11], ["Chronic HCV infection", "PROBLEM", 0, 21], ["a major biomedical problem", "PROBLEM", 25, 51], ["liver inflammation", "PROBLEM", 65, 83], ["fibrosis", "PROBLEM", 88, 96], ["severe liver disease", "PROBLEM", 116, 136], ["cirrhosis", "PROBLEM", 146, 155], ["hepatocellular carcinoma", "PROBLEM", 160, 184], ["HCV", "OBSERVATION_MODIFIER", 8, 11], ["infection", "OBSERVATION", 12, 21], ["liver", "ANATOMY", 65, 70], ["inflammation", "OBSERVATION", 71, 83], ["fibrosis", "OBSERVATION", 88, 96], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["liver", "ANATOMY", 123, 128], ["disease", "OBSERVATION", 129, 136], ["cirrhosis", "OBSERVATION", 146, 155], ["hepatocellular", "ANATOMY", 160, 174], ["carcinoma", "OBSERVATION", 175, 184]]], ["There is no vaccine against HCV and, although blood-screening tests and other prophylactic measures have reduced the dissemination of this pathogen, a number of newly acquired infections still occur associated with risk behavior or with unknown origin [4, 5] .", [["blood", "ANATOMY", 46, 51], ["HCV", "DISEASE", 28, 31], ["infections", "DISEASE", 176, 186], ["HCV", "ORGANISM", 28, 31], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["HCV", "SPECIES", 28, 31], ["vaccine", "TREATMENT", 12, 19], ["HCV", "PROBLEM", 28, 31], ["blood-screening tests", "TEST", 46, 67], ["other prophylactic measures", "TREATMENT", 72, 99], ["this pathogen", "PROBLEM", 134, 147], ["newly acquired infections", "PROBLEM", 161, 186], ["no", "UNCERTAINTY", 9, 11], ["infections", "OBSERVATION", 176, 186]]], ["However, chronic HCV infection can be successfully eradicated from chronically infected individuals through specific direct-acting antiviral (DAA) combination therapies, virtually in all treated patients [6] .", [["HCV infection", "DISEASE", 17, 30], ["chronically infected", "DISEASE", 67, 87], ["HCV", "ORGANISM", 17, 20], ["DAA", "SIMPLE_CHEMICAL", 142, 145], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["HCV", "SPECIES", 17, 20], ["chronic HCV infection", "PROBLEM", 9, 30], ["chronically infected individuals", "PROBLEM", 67, 99], ["antiviral (DAA)", "TREATMENT", 131, 146], ["therapies", "TREATMENT", 159, 168], ["chronic", "OBSERVATION_MODIFIER", 9, 16], ["HCV", "OBSERVATION_MODIFIER", 17, 20], ["infection", "OBSERVATION", 21, 30], ["chronically", "OBSERVATION_MODIFIER", 67, 78], ["infected", "OBSERVATION", 79, 87]]], ["Since these specific treatments have only been in place recently, there are no sufficient clinical data on the long-term benefit of these treatments in relieving the severity of advanced liver disease [7, 8] .IntroductionHCV is a Hepacivirus (Flaviviridae) with a positive sense, single-strand RNA genome that encodes a single open reading frame (ORF) flanked by untranslated regions (UTR), which are essential for viral polyprotein translation and viral genome replication.", [["liver", "ANATOMY", 187, 192], ["liver disease", "DISEASE", 187, 200], ["liver", "ORGAN", 187, 192], ["positive sense, single-strand RNA genome", "DNA", 264, 304], ["open reading frame", "DNA", 327, 345], ["ORF", "DNA", 347, 350], ["untranslated regions", "DNA", 363, 383], ["UTR", "DNA", 385, 388], ["these treatments", "TREATMENT", 132, 148], ["advanced liver disease", "PROBLEM", 178, 200], ["a Hepacivirus (Flaviviridae", "TREATMENT", 228, 255], ["a positive sense", "PROBLEM", 262, 278], ["single-strand RNA genome", "PROBLEM", 280, 304], ["viral polyprotein translation", "TREATMENT", 415, 444], ["viral genome replication", "TREATMENT", 449, 473], ["no", "UNCERTAINTY", 76, 78], ["advanced", "OBSERVATION_MODIFIER", 178, 186], ["liver", "ANATOMY", 187, 192], ["disease", "OBSERVATION", 193, 200], ["essential for", "UNCERTAINTY", 401, 414], ["viral polyprotein", "OBSERVATION", 415, 432], ["viral genome", "OBSERVATION", 449, 461]]], ["HCV ORF is co-and post-translationally processed by cellular and viral proteases to produce ten major proteins.", [["cellular", "ANATOMY", 52, 60], ["HCV", "ORGANISM", 0, 3], ["cellular", "CELL", 52, 60], ["HCV ORF", "DNA", 0, 7], ["cellular and viral proteases", "PROTEIN", 52, 80], ["HCV", "SPECIES", 0, 3], ["HCV ORF", "PROBLEM", 0, 7], ["viral proteases", "PROBLEM", 65, 80]]], ["These have been functionally classified in a replication module, that includes the minimal viral components of the RNA replicase (NS3, NS4A, NS4B, NS5A and NS5B) and an assembly module, which comprises the major structural components of enveloped HCV virions, the capsid protein (core) and the envelope glycoprotein complex formed by E1 and E2 heterodimers; as well as the polypeptides p7 and NS2, which are not structural components of virions but contribute to infectious particle assembly in a concerted action with the viral replicase [9] .IntroductionHCV utilizes key aspects of cellular lipid metabolism for essentially every aspect of the virus replication cycle and strongly interferes with host cell lipid homeostasis [10] [11] [12] .", [["virions", "ANATOMY", 437, 444], ["cellular", "ANATOMY", 584, 592], ["cell", "ANATOMY", 704, 708], ["NS3", "GENE_OR_GENE_PRODUCT", 130, 133], ["NS4A", "GENE_OR_GENE_PRODUCT", 135, 139], ["NS4B", "GENE_OR_GENE_PRODUCT", 141, 145], ["NS5A", "GENE_OR_GENE_PRODUCT", 147, 151], ["NS5B", "GENE_OR_GENE_PRODUCT", 156, 160], ["HCV virions", "ORGANISM", 247, 258], ["E1", "GENE_OR_GENE_PRODUCT", 334, 336], ["E2 heterodimers", "GENE_OR_GENE_PRODUCT", 341, 356], ["p7", "GENE_OR_GENE_PRODUCT", 386, 388], ["NS2", "GENE_OR_GENE_PRODUCT", 393, 396], ["cellular", "CELL", 584, 592], ["cell", "CELL", 704, 708], ["RNA replicase", "PROTEIN", 115, 128], ["NS3", "PROTEIN", 130, 133], ["NS4A", "PROTEIN", 135, 139], ["NS4B", "PROTEIN", 141, 145], ["NS5A", "PROTEIN", 147, 151], ["NS5B", "PROTEIN", 156, 160], ["assembly module", "PROTEIN", 169, 184], ["enveloped HCV virions", "PROTEIN", 237, 258], ["capsid protein", "PROTEIN", 264, 278], ["envelope glycoprotein complex", "PROTEIN", 294, 323], ["E1", "PROTEIN", 334, 336], ["E2 heterodimers", "PROTEIN", 341, 356], ["p7", "PROTEIN", 386, 388], ["NS2", "PROTEIN", 393, 396], ["HCV", "SPECIES", 247, 250], ["a replication module", "PROBLEM", 43, 63], ["the minimal viral components", "PROBLEM", 79, 107], ["the RNA replicase", "TREATMENT", 111, 128], ["NS3", "TREATMENT", 130, 133], ["NS4A", "TREATMENT", 135, 139], ["NS4B", "TREATMENT", 141, 145], ["NS5A", "TREATMENT", 147, 151], ["NS5B", "TREATMENT", 156, 160], ["an assembly module", "PROBLEM", 166, 184], ["enveloped HCV virions", "PROBLEM", 237, 258], ["the capsid protein", "TEST", 260, 278], ["the envelope glycoprotein complex", "TREATMENT", 290, 323], ["E1 and E2 heterodimers", "TREATMENT", 334, 356], ["the polypeptides p7", "TREATMENT", 369, 388], ["NS2", "PROBLEM", 393, 396], ["structural components of virions", "PROBLEM", 412, 444], ["infectious particle", "PROBLEM", 463, 482], ["the viral replicase", "TREATMENT", 519, 538], ["cellular lipid metabolism", "TREATMENT", 584, 609], ["the virus replication cycle", "TREATMENT", 642, 669], ["host cell lipid homeostasis", "TREATMENT", 699, 726], ["replication module", "OBSERVATION", 45, 63], ["minimal", "OBSERVATION_MODIFIER", 83, 90], ["viral", "OBSERVATION", 91, 96], ["enveloped", "OBSERVATION_MODIFIER", 237, 246], ["HCV virions", "OBSERVATION", 247, 258], ["infectious", "OBSERVATION", 463, 473]]], ["In fact, chronic HCV patients display high rates of liver steatosis, severity of which inversely correlates with serum liver derived-lipoprotein [13] .", [["liver", "ANATOMY", 52, 57], ["serum liver", "ANATOMY", 113, 124], ["HCV", "DISEASE", 17, 20], ["liver steatosis", "DISEASE", 52, 67], ["HCV", "ORGANISM", 17, 20], ["patients", "ORGANISM", 21, 29], ["liver", "ORGAN", 52, 57], ["serum", "ORGANISM_SUBSTANCE", 113, 118], ["liver", "ORGAN", 119, 124], ["patients", "SPECIES", 21, 29], ["HCV", "SPECIES", 17, 20], ["chronic HCV patients", "PROBLEM", 9, 29], ["liver steatosis", "PROBLEM", 52, 67], ["serum liver", "TEST", 113, 124], ["chronic", "OBSERVATION_MODIFIER", 9, 16], ["HCV", "OBSERVATION", 17, 20], ["high", "OBSERVATION_MODIFIER", 38, 42], ["liver", "ANATOMY", 52, 57], ["steatosis", "OBSERVATION", 58, 67], ["liver", "ANATOMY", 119, 124]]], ["Thus, although host immune response remains a major component in HCV pathogenesis, direct interference of HCV infection with hepatocyte lipid metabolism may contribute to overall disease progression [13] .Introductionidentified a limiting role of lipin1 PAP activity in the generation of HCV replicase complexes.", [["hepatocyte", "ANATOMY", 125, 135], ["infection", "DISEASE", 110, 119], ["HCV", "ORGANISM", 65, 68], ["HCV", "ORGANISM", 106, 109], ["hepatocyte", "CELL", 125, 135], ["lipin1 PAP", "GENE_OR_GENE_PRODUCT", 247, 257], ["HCV", "ORGANISM", 288, 291], ["lipin1", "PROTEIN", 247, 253], ["PAP", "PROTEIN", 254, 257], ["HCV replicase complexes", "PROTEIN", 288, 311], ["HCV", "SPECIES", 65, 68], ["HCV", "SPECIES", 106, 109], ["HCV", "SPECIES", 288, 291], ["HCV pathogenesis", "PROBLEM", 65, 81], ["HCV infection", "PROBLEM", 106, 119], ["hepatocyte lipid metabolism", "PROBLEM", 125, 152], ["overall disease progression", "PROBLEM", 171, 198], ["lipin1 PAP activity", "TREATMENT", 247, 266], ["HCV replicase complexes", "TREATMENT", 288, 311], ["HCV", "OBSERVATION", 65, 68], ["HCV", "OBSERVATION", 288, 291]]], ["Defective replicase assembly leads to strong inhibition of HCV propagation in lipin1-deficient cells but not that of another (+) strand RNA virus, indicating a specific role for lipin1 in HCV infection.Lipin1 is rate limiting for HCV infectionGiven the relevance of lipin1 for lipid metabolism and its steatogenic potential, we set out to independently verify data from published differential transcriptomic profile studies that suggested that HCV infection may alter LPIN1 mRNA abundance in cell culture [40, 41] .", [["lipin1-deficient cells", "ANATOMY", 78, 100], ["cell culture", "ANATOMY", 492, 504], ["HCV infection", "DISEASE", 188, 201], ["HCV infection", "DISEASE", 444, 457], ["HCV", "ORGANISM", 59, 62], ["lipin1", "GENE_OR_GENE_PRODUCT", 78, 84], ["cells", "CELL", 95, 100], ["lipin1", "GENE_OR_GENE_PRODUCT", 178, 184], ["HCV", "ORGANISM", 188, 191], ["Lipin1", "GENE_OR_GENE_PRODUCT", 202, 208], ["HCV", "ORGANISM", 230, 233], ["lipin1", "GENE_OR_GENE_PRODUCT", 266, 272], ["lipid", "SIMPLE_CHEMICAL", 277, 282], ["HCV", "ORGANISM", 444, 447], ["LPIN1", "GENE_OR_GENE_PRODUCT", 468, 473], ["cell", "CELL", 492, 496], ["lipin1-deficient cells", "CELL_LINE", 78, 100], ["lipin1", "PROTEIN", 178, 184], ["Lipin1", "PROTEIN", 202, 208], ["lipin1", "PROTEIN", 266, 272], ["LPIN1 mRNA", "RNA", 468, 478], ["HCV", "SPECIES", 59, 62], ["HCV", "SPECIES", 188, 191], ["HCV", "SPECIES", 230, 233], ["HCV", "SPECIES", 444, 447], ["Defective replicase", "PROBLEM", 0, 19], ["HCV propagation", "PROBLEM", 59, 74], ["deficient cells", "PROBLEM", 85, 100], ["strand RNA virus", "PROBLEM", 129, 145], ["lipin1", "TREATMENT", 178, 184], ["HCV infection", "PROBLEM", 188, 201], ["Lipin1", "TREATMENT", 202, 208], ["HCV infectionGiven", "PROBLEM", 230, 248], ["lipin1", "TREATMENT", 266, 272], ["lipid metabolism", "PROBLEM", 277, 293], ["transcriptomic profile studies", "TEST", 393, 423], ["HCV infection", "PROBLEM", 444, 457], ["cell culture", "TEST", 492, 504], ["HCV", "OBSERVATION", 59, 62], ["HCV", "OBSERVATION_MODIFIER", 188, 191], ["infection", "OBSERVATION", 192, 201]]], ["A specific and statistically significant LPIN1 mRNA induction (Fig 1A) was observed in Huh-7 cells after single cycle infection experiments [multiplicity of infection (MOI) 10] with a cell cultureadapted genotype 2a HCV (D183) variant [42] at the peak of the infection (48 and 72 hours post-infection) and as compared with mock-infected cells (Fig 1B) .", [["Huh-7 cells", "ANATOMY", 87, 98], ["cell", "ANATOMY", 184, 188], ["cells", "ANATOMY", 337, 342], ["infection", "DISEASE", 118, 127], ["infection", "DISEASE", 157, 166], ["infection", "DISEASE", 259, 268], ["infection", "DISEASE", 291, 300], ["LPIN1", "GENE_OR_GENE_PRODUCT", 41, 46], ["Huh-7 cells", "CELL", 87, 98], ["cell", "CELL", 184, 188], ["HCV", "ORGANISM", 216, 219], ["cells", "CELL", 337, 342], ["LPIN1 mRNA", "RNA", 41, 51], ["Huh-7 cells", "CELL_LINE", 87, 98], ["mock-infected cells", "CELL_TYPE", 323, 342], ["HCV", "SPECIES", 216, 219], ["significant LPIN1 mRNA induction", "TREATMENT", 29, 61], ["Huh", "TEST", 87, 90], ["single cycle infection experiments", "PROBLEM", 105, 139], ["infection (MOI)", "PROBLEM", 157, 172], ["a cell cultureadapted genotype", "TEST", 182, 212], ["the infection", "PROBLEM", 255, 268], ["infection", "PROBLEM", 291, 300], ["infected cells", "PROBLEM", 328, 342], ["infection", "OBSERVATION", 157, 166], ["infection", "OBSERVATION", 259, 268], ["infection", "OBSERVATION", 291, 300], ["infected cells", "OBSERVATION", 328, 342]]], ["LPIN1 mRNA induction was prevented when infected cells were treated with 1\u03bcM sofosbuvir (Fig 1C) , an HCV RNA polymerase inhibitor [43] that reduced viral RNA accumulation by more than two orders of magnitude (Fig 1D) , indicating that active HCV replication is required to induce LPIN1 mRNA accumulation.Lipin1 is rate limiting for HCV infectionLPIN1 mRNA has been shown to be upregulated by mechanisms that involve induction of reactive oxygen species (ROS), as treatment of the cells with ROS-scavenger molecule N-acetylcysteine (NAC) is capable of preventing LPIN1 mRNA induction under glucose deprivation [44] or during H 2 O 2 treatment [45] .", [["cells", "ANATOMY", 49, 54], ["cells", "ANATOMY", 481, 486], ["sofosbuvir", "CHEMICAL", 77, 87], ["oxygen", "CHEMICAL", 439, 445], ["ROS", "CHEMICAL", 455, 458], ["ROS", "CHEMICAL", 492, 495], ["N-acetylcysteine", "CHEMICAL", 515, 531], ["NAC", "CHEMICAL", 533, 536], ["glucose", "CHEMICAL", 590, 597], ["H 2 O", "CHEMICAL", 625, 630], ["sofosbuvir", "CHEMICAL", 77, 87], ["oxygen", "CHEMICAL", 439, 445], ["N-acetylcysteine", "CHEMICAL", 515, 531], ["NAC", "CHEMICAL", 533, 536], ["glucose", "CHEMICAL", 590, 597], ["H 2 O 2", "CHEMICAL", 625, 632], ["LPIN1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 49, 54], ["sofosbuvir", "SIMPLE_CHEMICAL", 77, 87], ["HCV", "ORGANISM", 243, 246], ["LPIN1", "GENE_OR_GENE_PRODUCT", 281, 286], ["Lipin1", "GENE_OR_GENE_PRODUCT", 305, 311], ["HCV", "ORGANISM", 333, 336], ["infectionLPIN1", "GENE_OR_GENE_PRODUCT", 337, 351], ["reactive oxygen species", "SIMPLE_CHEMICAL", 430, 453], ["ROS", "SIMPLE_CHEMICAL", 455, 458], ["cells", "CELL", 481, 486], ["ROS-scavenger molecule N-acetylcysteine", "SIMPLE_CHEMICAL", 492, 531], ["NAC", "SIMPLE_CHEMICAL", 533, 536], ["LPIN1", "GENE_OR_GENE_PRODUCT", 563, 568], ["glucose", "SIMPLE_CHEMICAL", 590, 597], ["H 2 O 2", "SIMPLE_CHEMICAL", 625, 632], ["LPIN1 mRNA", "RNA", 0, 10], ["infected cells", "CELL_TYPE", 40, 54], ["viral RNA", "RNA", 149, 158], ["LPIN1 mRNA", "RNA", 281, 291], ["Lipin1", "PROTEIN", 305, 311], ["HCV infectionLPIN1 mRNA", "RNA", 333, 356], ["LPIN1 mRNA", "RNA", 563, 573], ["HCV", "SPECIES", 102, 105], ["HCV", "SPECIES", 243, 246], ["HCV", "SPECIES", 333, 336], ["LPIN1 mRNA induction", "TREATMENT", 0, 20], ["infected cells", "PROBLEM", 40, 54], ["sofosbuvir (Fig 1C", "TREATMENT", 77, 95], ["an HCV RNA polymerase inhibitor", "TREATMENT", 99, 130], ["reduced viral RNA accumulation", "PROBLEM", 141, 171], ["active HCV replication", "TREATMENT", 236, 258], ["mRNA accumulation", "PROBLEM", 287, 304], ["Lipin1", "TREATMENT", 305, 311], ["HCV infectionLPIN1 mRNA", "PROBLEM", 333, 356], ["reactive oxygen species", "PROBLEM", 430, 453], ["the cells", "PROBLEM", 477, 486], ["ROS", "TEST", 492, 495], ["scavenger molecule", "TREATMENT", 496, 514], ["N-acetylcysteine (NAC)", "TREATMENT", 515, 537], ["LPIN1 mRNA induction", "TREATMENT", 563, 583], ["glucose deprivation", "TREATMENT", 590, 609], ["viral RNA accumulation", "OBSERVATION", 149, 171], ["active", "OBSERVATION_MODIFIER", 236, 242], ["HCV", "OBSERVATION", 243, 246], ["reactive", "OBSERVATION_MODIFIER", 430, 438], ["oxygen species", "OBSERVATION", 439, 453]]], ["Given that transcriptional activation of a subset of lipogenic genes during HCV infection is also prevented by addition of antioxidants [46] , we sought to determine if LPIN1 mRNA induction by HCV infection is mediated by ROS production and therefore dampened by NAC treatment.", [["HCV infection", "DISEASE", 76, 89], ["HCV infection", "DISEASE", 193, 206], ["ROS", "CHEMICAL", 222, 225], ["NAC", "CHEMICAL", 263, 266], ["NAC", "CHEMICAL", 263, 266], ["HCV", "ORGANISM", 76, 79], ["LPIN1", "GENE_OR_GENE_PRODUCT", 169, 174], ["HCV", "ORGANISM", 193, 196], ["ROS", "SIMPLE_CHEMICAL", 222, 225], ["NAC", "SIMPLE_CHEMICAL", 263, 266], ["lipogenic genes", "DNA", 53, 68], ["LPIN1 mRNA", "RNA", 169, 179], ["HCV", "SPECIES", 76, 79], ["HCV", "SPECIES", 193, 196], ["lipogenic genes", "PROBLEM", 53, 68], ["HCV infection", "PROBLEM", 76, 89], ["antioxidants", "TREATMENT", 123, 135], ["LPIN1 mRNA induction", "TREATMENT", 169, 189], ["HCV infection", "PROBLEM", 193, 206], ["NAC treatment", "TREATMENT", 263, 276]]], ["LPIN1 mRNA induction was prevented in the presence of the antioxidant (Fig 1E) , despite comparable HCV RNA accumulation in mock-treated and NAC-treated HCV-infected cells (Fig 1F) , suggesting that virus replicationinduced ROS production is required to induce LPIN1 mRNA accumulation.", [["cells", "ANATOMY", 166, 171], ["NAC", "CHEMICAL", 141, 144], ["HCV-infected", "DISEASE", 153, 165], ["ROS", "CHEMICAL", 224, 227], ["NAC", "CHEMICAL", 141, 144], ["LPIN1", "GENE_OR_GENE_PRODUCT", 0, 5], ["NAC", "SIMPLE_CHEMICAL", 141, 144], ["HCV", "ORGANISM", 153, 156], ["cells", "CELL", 166, 171], ["Fig 1F", "CELL", 173, 179], ["ROS", "SIMPLE_CHEMICAL", 224, 227], ["LPIN1", "GENE_OR_GENE_PRODUCT", 261, 266], ["LPIN1 mRNA", "RNA", 0, 10], ["HCV RNA", "RNA", 100, 107], ["NAC-treated HCV-infected cells", "CELL_LINE", 141, 171], ["LPIN1 mRNA", "RNA", 261, 271], ["HCV", "SPECIES", 100, 103], ["HCV", "SPECIES", 153, 156], ["LPIN1 mRNA induction", "TREATMENT", 0, 20], ["the antioxidant (Fig 1E", "TREATMENT", 54, 77], ["comparable HCV RNA accumulation", "PROBLEM", 89, 120], ["NAC", "TREATMENT", 141, 144], ["HCV", "PROBLEM", 153, 156], ["infected cells", "PROBLEM", 157, 171], ["virus replicationinduced ROS production", "PROBLEM", 199, 238], ["mRNA accumulation", "PROBLEM", 267, 284], ["infected cells", "OBSERVATION", 157, 171]]], ["Western-blot analysis confirmed that the observed transcriptional change leads to a correlative protein accumulation (Fig 1G and 1H) ; reinforcing the notion that acute HCV infection alters lipin1 expression.Lipin1 is rate limiting for HCV infectionIn order to determine if lipin1 subcellular localization was altered during HCV infection, we performed confocal microscopy studies in control and HCV-infected Huh-7 cells.", [["subcellular", "ANATOMY", 281, 292], ["Huh-7 cells", "ANATOMY", 409, 420], ["HCV infection", "DISEASE", 169, 182], ["Lipin1", "CHEMICAL", 208, 214], ["HCV infection", "DISEASE", 236, 249], ["HCV infection", "DISEASE", 325, 338], ["HCV", "ORGANISM", 169, 172], ["lipin1", "GENE_OR_GENE_PRODUCT", 190, 196], ["Lipin1", "GENE_OR_GENE_PRODUCT", 208, 214], ["HCV", "ORGANISM", 236, 239], ["lipin1", "GENE_OR_GENE_PRODUCT", 274, 280], ["HCV", "ORGANISM", 325, 328], ["HCV", "ORGANISM", 396, 399], ["Huh-7 cells", "CELL", 409, 420], ["lipin1", "PROTEIN", 190, 196], ["Lipin1", "PROTEIN", 208, 214], ["lipin1", "PROTEIN", 274, 280], ["HCV-infected Huh-7 cells", "CELL_LINE", 396, 420], ["HCV", "SPECIES", 169, 172], ["HCV", "SPECIES", 236, 239], ["HCV", "SPECIES", 325, 328], ["HCV", "SPECIES", 396, 399], ["Huh-7", "SPECIES", 409, 414], ["blot analysis", "TEST", 8, 21], ["the observed transcriptional change", "PROBLEM", 37, 72], ["a correlative protein accumulation", "PROBLEM", 82, 116], ["acute HCV infection", "PROBLEM", 163, 182], ["Lipin1", "TREATMENT", 208, 214], ["HCV infection", "PROBLEM", 236, 249], ["HCV infection", "PROBLEM", 325, 338], ["confocal microscopy studies", "TEST", 353, 380], ["HCV", "TEST", 396, 399], ["transcriptional change", "OBSERVATION", 50, 72], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["HCV", "OBSERVATION_MODIFIER", 169, 172], ["infection", "OBSERVATION", 173, 182], ["infection", "OBSERVATION", 240, 249]]], ["Lipin1 staining was observed as cytoplasmic punctated structures both in control and HCV-infected cells.", [["cytoplasmic punctated structures", "ANATOMY", 32, 64], ["cells", "ANATOMY", 98, 103], ["HCV-infected", "DISEASE", 85, 97], ["Lipin1", "GENE_OR_GENE_PRODUCT", 0, 6], ["cytoplasmic", "ORGANISM_SUBSTANCE", 32, 43], ["HCV", "ORGANISM", 85, 88], ["cells", "CELL", 98, 103], ["Lipin1", "PROTEIN", 0, 6], ["HCV-infected cells", "CELL_TYPE", 85, 103], ["HCV", "SPECIES", 85, 88], ["Lipin1 staining", "PROBLEM", 0, 15], ["cytoplasmic punctated structures", "PROBLEM", 32, 64], ["HCV", "PROBLEM", 85, 88], ["infected cells", "PROBLEM", 89, 103], ["HCV", "OBSERVATION", 85, 88], ["infected cells", "OBSERVATION", 89, 103]]], ["To study if lipin1 signal colocalized with viral antigens, we performed double staining with antibodies against lipin1 and double-stranded RNA (dsRNA) or replicase subunits NS3 and NS5A.", [["lipin1", "GENE_OR_GENE_PRODUCT", 12, 18], ["lipin1", "GENE_OR_GENE_PRODUCT", 112, 118], ["NS3", "GENE_OR_GENE_PRODUCT", 173, 176], ["NS5A", "GENE_OR_GENE_PRODUCT", 181, 185], ["lipin1", "PROTEIN", 12, 18], ["viral antigens", "PROTEIN", 43, 57], ["antibodies", "PROTEIN", 93, 103], ["lipin1", "PROTEIN", 112, 118], ["double-stranded RNA", "RNA", 123, 142], ["replicase subunits", "PROTEIN", 154, 172], ["NS3", "PROTEIN", 173, 176], ["NS5A", "PROTEIN", 181, 185], ["viral antigens", "PROBLEM", 43, 57], ["double staining", "TEST", 72, 87], ["antibodies", "TREATMENT", 93, 103], ["lipin1", "TREATMENT", 112, 118], ["double-stranded RNA (dsRNA", "TREATMENT", 123, 149], ["replicase subunits NS3", "TREATMENT", 154, 176], ["NS5A", "TREATMENT", 181, 185]]], ["None of the viral antigens strictly colocalized with lipin1 (Pearson\u00b4s<0.5) (S1A Fig).", [["lipin1", "GENE_OR_GENE_PRODUCT", 53, 59], ["viral antigens", "PROTEIN", 12, 26], ["lipin1", "PROTEIN", 53, 59], ["the viral antigens", "TEST", 8, 26], ["lipin1", "TEST", 53, 59], ["Pearson\u00b4s", "TEST", 61, 70], ["viral", "OBSERVATION", 12, 17]]], ["However, Mander\u00b4s coefficients indicate that the majority of lipin1 overlapped with a small fraction of NS3 and NS5A (S1C Fig).", [["lipin1", "GENE_OR_GENE_PRODUCT", 61, 67], ["NS3", "GENE_OR_GENE_PRODUCT", 104, 107], ["NS5A", "GENE_OR_GENE_PRODUCT", 112, 116], ["lipin1", "PROTEIN", 61, 67], ["NS3", "PROTEIN", 104, 107], ["NS5A", "PROTEIN", 112, 116], ["S1C Fig", "PROTEIN", 118, 125], ["lipin1", "TREATMENT", 61, 67], ["NS3", "TREATMENT", 104, 107], ["NS5A (S1C Fig", "TREATMENT", 112, 125]]], ["In contrast to lipin1, lipin2 signal did not overlap with that of viral proteins NS3 and NS5A (S1B Fig).", [["lipin1", "GENE_OR_GENE_PRODUCT", 15, 21], ["lipin2", "GENE_OR_GENE_PRODUCT", 23, 29], ["NS3", "GENE_OR_GENE_PRODUCT", 81, 84], ["NS5A", "GENE_OR_GENE_PRODUCT", 89, 93], ["lipin1", "PROTEIN", 15, 21], ["lipin2", "PROTEIN", 23, 29], ["viral proteins", "PROTEIN", 66, 80], ["NS3", "PROTEIN", 81, 84], ["NS5A", "PROTEIN", 89, 93], ["S1B Fig", "PROTEIN", 95, 102], ["viral proteins NS3", "TREATMENT", 66, 84], ["NS5A", "TEST", 89, 93]]], ["Our results indicate that no major lipin1 rearrangements are observed after HCV infection and that only a minor fraction of NS proteins colocalize with lipin1.Lipin1 is rate limiting for HCV infectionTo study if lipin1 plays any role in HCV infection, lipin1-deficient cells were generated by transducing human hepatoma (Huh-7) cells with lentiviral vectors expressing shRNAs targeting LPIN1 mRNA or a control vector expressing an irrelevant shRNA.", [["lipin1-deficient cells", "ANATOMY", 252, 274], ["hepatoma (Huh-7) cells", "ANATOMY", 311, 333], ["HCV infection", "DISEASE", 76, 89], ["Lipin1", "CHEMICAL", 159, 165], ["HCV infection", "DISEASE", 187, 200], ["lipin1", "CHEMICAL", 212, 218], ["HCV infection", "DISEASE", 237, 250], ["lipin1", "GENE_OR_GENE_PRODUCT", 35, 41], ["lipin1", "GENE_OR_GENE_PRODUCT", 152, 158], ["Lipin1", "GENE_OR_GENE_PRODUCT", 159, 165], ["HCV", "ORGANISM", 187, 190], ["lipin1", "GENE_OR_GENE_PRODUCT", 212, 218], ["HCV", "ORGANISM", 237, 240], ["lipin1", "GENE_OR_GENE_PRODUCT", 252, 258], ["cells", "CELL", 269, 274], ["human", "ORGANISM", 305, 310], ["hepatoma (Huh-7) cells", "CELL", 311, 333], ["lentiviral", "ORGANISM", 339, 349], ["shRNAs", "GENE_OR_GENE_PRODUCT", 369, 375], ["LPIN1", "GENE_OR_GENE_PRODUCT", 386, 391], ["lipin1 rearrangements", "DNA", 35, 56], ["NS proteins", "PROTEIN", 124, 135], ["lipin1", "PROTEIN", 152, 158], ["Lipin1", "PROTEIN", 159, 165], ["lipin1", "PROTEIN", 212, 218], ["lipin1-deficient cells", "CELL_LINE", 252, 274], ["human hepatoma (Huh-7) cells", "CELL_LINE", 305, 333], ["LPIN1 mRNA", "RNA", 386, 396], ["human", "SPECIES", 305, 310], ["HCV", "SPECIES", 76, 79], ["HCV", "SPECIES", 187, 190], ["HCV", "SPECIES", 237, 240], ["human", "SPECIES", 305, 310], ["major lipin1 rearrangements", "PROBLEM", 29, 56], ["HCV infection", "PROBLEM", 76, 89], ["NS proteins", "TREATMENT", 124, 135], ["lipin1", "TREATMENT", 152, 158], ["Lipin1", "TREATMENT", 159, 165], ["HCV infection", "PROBLEM", 187, 200], ["HCV infection", "PROBLEM", 237, 250], ["deficient cells", "PROBLEM", 259, 274], ["transducing human hepatoma", "PROBLEM", 293, 319], ["Huh", "TEST", 321, 324], ["lentiviral vectors", "TREATMENT", 339, 357], ["shRNAs targeting LPIN1 mRNA", "TREATMENT", 369, 396], ["a control vector", "TREATMENT", 400, 416], ["an irrelevant shRNA", "PROBLEM", 428, 447], ["infection", "OBSERVATION", 191, 200], ["hepatoma", "ANATOMY", 311, 319], ["irrelevant shRNA", "OBSERVATION", 431, 447]]], ["Lipin1 expression silencing was verified by Western-Blot, typically 7 days post-transduction (Fig 2A) .", [["Lipin1", "GENE_OR_GENE_PRODUCT", 0, 6], ["Lipin1", "PROTEIN", 0, 6], ["Lipin1 expression silencing", "TREATMENT", 0, 27]]], ["A partial (50%; shLPIN1-1) and a more profound (>95%; shLPIN1-2) reduction in lipin1 accumulation was observed after transduction with specific shRNAs as compared with the control (Fig 2B) . .", [["shLPIN1-1", "GENE_OR_GENE_PRODUCT", 16, 25], ["shLPIN1-2", "GENE_OR_GENE_PRODUCT", 54, 63], ["lipin1", "GENE_OR_GENE_PRODUCT", 78, 84], ["lipin1", "PROTEIN", 78, 84], ["shRNAs", "DNA", 144, 150], ["shLPIN1", "TEST", 16, 23], ["shLPIN1", "TEST", 54, 61], ["lipin1 accumulation", "PROBLEM", 78, 97], ["specific shRNAs", "TREATMENT", 135, 150], ["partial", "OBSERVATION_MODIFIER", 2, 9], ["profound", "OBSERVATION_MODIFIER", 38, 46], ["lipin1 accumulation", "OBSERVATION", 78, 97]]], ["RNAs from mock-infected cells and HCV infected.", [["cells", "ANATOMY", 24, 29], ["HCV infected", "DISEASE", 34, 46], ["cells", "CELL", 24, 29], ["HCV", "ORGANISM", 34, 37], ["RNAs", "RNA", 0, 4], ["mock-infected cells", "CELL_TYPE", 10, 29], ["HCV", "SPECIES", 34, 37], ["RNAs from mock", "TEST", 0, 14], ["infected cells", "PROBLEM", 15, 29], ["HCV infected", "PROBLEM", 34, 46], ["infected cells", "OBSERVATION", 15, 29], ["HCV", "OBSERVATION_MODIFIER", 34, 37], ["infected", "OBSERVATION_MODIFIER", 38, 46]]], ["Impact of sofosbuvir (1\u03bcM; DAA) (C, D) or N-acetylcysteine (10mM; NAC) treatment (E, F) on HCV RNA accumulation and LPIN1 mRNA levels.", [["sofosbuvir", "CHEMICAL", 10, 20], ["N-acetylcysteine", "CHEMICAL", 42, 58], ["NAC", "CHEMICAL", 66, 69], ["sofosbuvir", "CHEMICAL", 10, 20], ["DAA", "CHEMICAL", 27, 30], ["N-acetylcysteine", "CHEMICAL", 42, 58], ["NAC", "CHEMICAL", 66, 69], ["sofosbuvir", "SIMPLE_CHEMICAL", 10, 20], ["C, D", "SIMPLE_CHEMICAL", 33, 37], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 42, 58], ["NAC", "SIMPLE_CHEMICAL", 66, 69], ["E, F", "SIMPLE_CHEMICAL", 82, 86], ["HCV", "ORGANISM", 91, 94], ["LPIN1", "GENE_OR_GENE_PRODUCT", 116, 121], ["HCV RNA", "RNA", 91, 98], ["LPIN1 mRNA", "RNA", 116, 126], ["HCV", "SPECIES", 91, 94], ["sofosbuvir", "TREATMENT", 10, 20], ["DAA) (C, D)", "TREATMENT", 27, 38], ["N-acetylcysteine", "TREATMENT", 42, 58], ["NAC) treatment", "TREATMENT", 66, 80], ["HCV RNA accumulation", "PROBLEM", 91, 111], ["LPIN1 mRNA levels", "TEST", 116, 133]]], ["Data are shown as average and standard deviation of two independent infection experiments performed in triplicate (n = 6).", [["infection", "DISEASE", 68, 77], ["standard deviation of two independent infection experiments", "PROBLEM", 30, 89], ["infection", "OBSERVATION", 68, 77]]], ["G-Protein samples of infected and control cells collected at 48 hours post-infection were subjected to Western-blot analysis to determine lipin1 and NS3 levels, using beta-actin as loading control H-Quantitation of the relative lipin1 protein levels in mock and HCV-infected cells (n = 3).", [["samples", "ANATOMY", 10, 17], ["cells", "ANATOMY", 42, 47], ["cells", "ANATOMY", 275, 280], ["HCV-infected", "DISEASE", 262, 274], ["cells", "CELL", 42, 47], ["lipin1", "GENE_OR_GENE_PRODUCT", 138, 144], ["NS3", "GENE_OR_GENE_PRODUCT", 149, 152], ["beta-actin", "GENE_OR_GENE_PRODUCT", 167, 177], ["lipin1", "GENE_OR_GENE_PRODUCT", 228, 234], ["HCV", "ORGANISM", 262, 265], ["cells", "CELL", 275, 280], ["lipin1", "PROTEIN", 138, 144], ["NS3", "PROTEIN", 149, 152], ["beta-actin", "PROTEIN", 167, 177], ["lipin1 protein", "PROTEIN", 228, 242], ["HCV-infected cells", "CELL_TYPE", 262, 280], ["HCV", "SPECIES", 262, 265], ["G", "TEST", 0, 1], ["Protein samples", "TEST", 2, 17], ["infected and control cells", "PROBLEM", 21, 47], ["blot analysis", "TEST", 111, 124], ["lipin1", "TEST", 138, 144], ["NS3 levels", "TEST", 149, 159], ["beta-actin as loading control", "TREATMENT", 167, 196], ["the relative lipin1 protein levels", "TEST", 215, 249], ["HCV", "PROBLEM", 262, 265], ["infected cells", "PROBLEM", 266, 280], ["infected", "OBSERVATION", 21, 29], ["infected cells", "OBSERVATION", 266, 280]]], ["Statistical significance was determined using Student\u00b4s t-test ( \u00c3 p<0.05; \u00c3\u00c3 p<0.01).Lipin1 is rate limiting for HCV infectionhttps://doi.org/10.1371/journal.ppat.1007284.g001Fig 2.", [["Lipin1", "GENE_OR_GENE_PRODUCT", 86, 92], ["Lipin1", "PROTEIN", 86, 92], ["HCV", "SPECIES", 114, 117], ["Student\u00b4s t-test", "TEST", 46, 62], ["p", "TEST", 67, 68], ["Lipin1", "TREATMENT", 86, 92], ["HCV infectionhttps://doi.org/10.1371/journal.ppat.1007284.g001Fig", "PROBLEM", 114, 179]]], ["HCV propagation is limited in lipin1-deficient cells.Huh-7 cells were transduced with lentiviral vectors expressing control or LPIN1-specific shRNAs.", [["lipin1-deficient cells", "ANATOMY", 30, 52], ["Huh-7 cells", "ANATOMY", 53, 64], ["HCV", "ORGANISM", 0, 3], ["lipin1", "GENE_OR_GENE_PRODUCT", 30, 36], ["cells", "CELL", 47, 52], ["Huh-7 cells", "CELL", 53, 64], ["lentiviral", "ORGANISM", 86, 96], ["LPIN1", "GENE_OR_GENE_PRODUCT", 127, 132], ["lipin1-deficient cells", "CELL_LINE", 30, 52], ["Huh-7 cells", "CELL_LINE", 53, 64], ["LPIN1", "PROTEIN", 127, 132], ["shRNAs", "DNA", 142, 148], ["HCV", "SPECIES", 0, 3], ["HCV propagation", "PROBLEM", 0, 15], ["deficient cells", "PROBLEM", 37, 52], ["Huh", "TEST", 53, 56], ["lentiviral vectors expressing control", "TREATMENT", 86, 123], ["LPIN1", "TEST", 127, 132], ["deficient cells", "OBSERVATION", 37, 52], ["7 cells", "OBSERVATION_MODIFIER", 57, 64]]], ["Seven days after transduction samples of the cells were collected for Western-blot analysis using antibodies against lipin1 and lipin2 and actin as loading control.", [["samples", "ANATOMY", 30, 37], ["cells", "ANATOMY", 45, 50], ["cells", "CELL", 45, 50], ["lipin1", "GENE_OR_GENE_PRODUCT", 117, 123], ["lipin2", "GENE_OR_GENE_PRODUCT", 128, 134], ["actin", "GENE_OR_GENE_PRODUCT", 139, 144], ["antibodies", "PROTEIN", 98, 108], ["lipin1", "PROTEIN", 117, 123], ["lipin2", "PROTEIN", 128, 134], ["actin", "PROTEIN", 139, 144], ["transduction samples of the cells", "TEST", 17, 50], ["blot analysis", "TEST", 78, 91], ["antibodies", "TREATMENT", 98, 108], ["lipin1", "TREATMENT", 117, 123], ["lipin2", "TREATMENT", 128, 134], ["actin as loading control", "TREATMENT", 139, 163]]], ["Parallel cultures were subjected to an MTT assay to determine their viability as described in the methods section.", [["MTT", "CHEMICAL", 39, 42], ["Parallel cultures", "TEST", 0, 17], ["an MTT assay", "TEST", 36, 48]]], ["(A) Representative Western-Blot showing cellular lipin1 and lipin2 protein expression levels and a loading control (actin).", [["cellular", "ANATOMY", 40, 48], ["cellular lipin1", "CELL", 40, 55], ["lipin2", "GENE_OR_GENE_PRODUCT", 60, 66], ["actin", "GENE_OR_GENE_PRODUCT", 116, 121], ["lipin1", "PROTEIN", 49, 55], ["lipin2 protein", "PROTEIN", 60, 74], ["actin", "PROTEIN", 116, 121], ["cellular lipin1", "TREATMENT", 40, 55], ["lipin2 protein expression levels", "TREATMENT", 60, 92], ["a loading control (actin)", "TREATMENT", 97, 122]]], ["(B) Average expression values for lipin1 and lipin2 as determined by Western-Blot and cell viability as determined by an MTT assay.", [["cell", "ANATOMY", 86, 90], ["MTT", "CHEMICAL", 121, 124], ["lipin1", "GENE_OR_GENE_PRODUCT", 34, 40], ["lipin2", "GENE_OR_GENE_PRODUCT", 45, 51], ["cell", "CELL", 86, 90], ["lipin1", "PROTEIN", 34, 40], ["lipin2", "PROTEIN", 45, 51], ["lipin1", "TREATMENT", 34, 40], ["lipin2", "TREATMENT", 45, 51], ["an MTT assay", "TEST", 118, 130]]], ["(C) Huh-7 cells were transduced with lentiviral vectors expressing control or LPIN1-specific shRNAs.", [["Huh-7 cells", "ANATOMY", 4, 15], ["Huh-7 cells", "CELL", 4, 15], ["lentiviral", "ORGANISM", 37, 47], ["LPIN1", "GENE_OR_GENE_PRODUCT", 78, 83], ["(C) Huh-7 cells", "CELL_LINE", 0, 15], ["LPIN1", "PROTEIN", 78, 83], ["shRNAs", "DNA", 93, 99], ["Huh", "TEST", 4, 7], ["lentiviral vectors expressing control", "TREATMENT", 37, 74], ["LPIN1", "TEST", 78, 83]]], ["At day 3 post-transduction, cells were infected at MOI 0.01 with HCV D183 virus.", [["cells", "ANATOMY", 28, 33], ["cells", "CELL", 28, 33], ["HCV D183 virus", "ORGANISM", 65, 79], ["HCV D183 virus", "SPECIES", 65, 79], ["HCV D183 virus", "TREATMENT", 65, 79]]], ["Samples of cell supernatants were collected at days 3 and 5 post-infection to determine the extracellular infectivity titer.", [["Samples", "ANATOMY", 0, 7], ["cell supernatants", "ANATOMY", 11, 28], ["extracellular", "ANATOMY", 92, 105], ["cell supernatants", "CELL", 11, 28], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 92, 105], ["Samples of cell supernatants", "TEST", 0, 28], ["infection", "PROBLEM", 65, 74], ["the extracellular infectivity titer", "PROBLEM", 88, 123], ["cell supernatants", "OBSERVATION", 11, 28], ["infectivity titer", "OBSERVATION", 106, 123]]], ["Average and SD of the infectivity titers at day 3 and 5 of two independent infections performed in triplicate (n = 6).", [["infections", "DISEASE", 75, 85], ["the infectivity titers", "PROBLEM", 18, 40], ["two independent infections", "PROBLEM", 59, 85], ["infections", "OBSERVATION", 75, 85]]], ["(D) Huh-7.5 cells were transduced with lentiviral vectors expressing control or LPIN1-specific shRNAs.", [["Huh-7.5 cells", "ANATOMY", 4, 17], ["Huh-7.5 cells", "CELL", 4, 17], ["lentiviral", "ORGANISM", 39, 49], ["LPIN1", "GENE_OR_GENE_PRODUCT", 80, 85], ["Huh-7.5 cells", "CELL_LINE", 4, 17], ["LPIN1", "PROTEIN", 80, 85], ["shRNAs", "DNA", 95, 101], ["Huh", "TEST", 4, 7], ["lentiviral vectors expressing control", "TREATMENT", 39, 76], ["LPIN1", "TEST", 80, 85]]], ["Silenced cells were infected 7 days after transduction at MOI 0.05 with genotype 1a HCV (TNcc) in the presence or absence of 2mAde (10\u03bcM; shControl+DAA).", [["cells", "ANATOMY", 9, 14], ["2mAde", "CHEMICAL", 125, 130], ["2mAde", "CHEMICAL", 125, 130], ["shControl", "CHEMICAL", 138, 147], ["cells", "CELL", 9, 14], ["HCV", "ORGANISM", 84, 87], ["2mAde", "SIMPLE_CHEMICAL", 125, 130], ["HCV", "SPECIES", 84, 87], ["Silenced cells", "PROBLEM", 0, 14], ["transduction at MOI", "TREATMENT", 42, 61]]], ["Intracellular HCV RNA was determined by RT-qPCR 72 hours post-infection.", [["Intracellular", "ANATOMY", 0, 13], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["HCV", "ORGANISM", 14, 17], ["HCV RNA", "RNA", 14, 21], ["HCV", "SPECIES", 14, 17], ["Intracellular HCV RNA", "PROBLEM", 0, 21], ["HCV", "OBSERVATION", 14, 17]]], ["Statistical significance was determined using Student\u00b4s t-test ( \u00c3 p<0.05; \u00c3\u00c3 p<0.01).Fig 2.", [["Student\u00b4s t-test", "TEST", 46, 62], ["p", "TEST", 67, 68]]], ["HCV propagation is limited in lipin1-deficient cells.As expected, lipin1 and lipin2 expression is inversely correlated in lipin1 shRNA-expressing cells (Fig 2B) .", [["lipin1-deficient cells", "ANATOMY", 30, 52], ["cells", "ANATOMY", 146, 151], ["HCV", "ORGANISM", 0, 3], ["lipin1", "GENE_OR_GENE_PRODUCT", 30, 36], ["cells", "CELL", 47, 52], ["lipin1", "GENE_OR_GENE_PRODUCT", 66, 72], ["lipin2", "GENE_OR_GENE_PRODUCT", 77, 83], ["lipin1", "GENE_OR_GENE_PRODUCT", 122, 128], ["cells", "CELL", 146, 151], ["Fig 2B", "CELL", 153, 159], ["lipin1-deficient cells", "CELL_LINE", 30, 52], ["lipin1", "PROTEIN", 66, 72], ["lipin2", "PROTEIN", 77, 83], ["lipin1 shRNA-expressing cells", "CELL_LINE", 122, 151], ["HCV", "SPECIES", 0, 3], ["HCV propagation", "PROBLEM", 0, 15], ["deficient cells", "PROBLEM", 37, 52], ["lipin1 and lipin2 expression", "TREATMENT", 66, 94], ["deficient cells", "OBSERVATION", 37, 52]]], ["The viability of lipin-deficient cells, as determined by MTT assay [47] was comparable to that of control cells (Fig 2B) .", [["lipin-deficient cells", "ANATOMY", 17, 38], ["cells", "ANATOMY", 106, 111], ["MTT", "CHEMICAL", 57, 60], ["lipin", "GENE_OR_GENE_PRODUCT", 17, 22], ["cells", "CELL", 33, 38], ["cells", "CELL", 106, 111], ["lipin-deficient cells", "CELL_LINE", 17, 38], ["control cells", "CELL_TYPE", 98, 111], ["MTT assay", "TEST", 57, 66], ["deficient cells", "OBSERVATION", 23, 38]]], ["These results illustrate that lipin1 shRNA-expressing cells respond homeostatically to functionally compensate partial (shLPIN1-1) and more pronounced (shLPIN1-2) loss of lipin1 (Fig 2B) .Fig 2.", [["cells", "ANATOMY", 54, 59], ["lipin1", "GENE_OR_GENE_PRODUCT", 30, 36], ["cells", "CELL", 54, 59], ["shLPIN1-1", "GENE_OR_GENE_PRODUCT", 120, 129], ["shLPIN1-2", "GENE_OR_GENE_PRODUCT", 152, 161], ["lipin1 (Fig 2B", "GENE_OR_GENE_PRODUCT", 171, 185], ["lipin1 shRNA-expressing cells", "CELL_LINE", 30, 59], ["shLPIN1", "PROTEIN", 120, 127], ["lipin1", "PROTEIN", 171, 177], ["lipin1 shRNA", "TREATMENT", 30, 42], ["expressing cells", "PROBLEM", 43, 59], ["shLPIN1", "TEST", 120, 127], ["loss of lipin1", "PROBLEM", 163, 177], ["pronounced", "OBSERVATION_MODIFIER", 140, 150]]], ["HCV propagation is limited in lipin1-deficient cells.Control and lipin1-deficient cells were infected with a genotype 2a D183 at MOI 0.01 to study viral spread by determining extracellular infectivity titers at different times post infection.", [["lipin1-deficient cells", "ANATOMY", 30, 52], ["lipin1-deficient cells", "ANATOMY", 65, 87], ["extracellular", "ANATOMY", 175, 188], ["infection", "DISEASE", 232, 241], ["HCV", "ORGANISM", 0, 3], ["lipin1", "GENE_OR_GENE_PRODUCT", 30, 36], ["cells", "CELL", 47, 52], ["lipin1", "GENE_OR_GENE_PRODUCT", 65, 71], ["cells", "CELL", 82, 87], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 175, 188], ["lipin1-deficient cells", "CELL_LINE", 30, 52], ["lipin1-deficient cells", "CELL_LINE", 65, 87], ["HCV", "SPECIES", 0, 3], ["HCV propagation", "PROBLEM", 0, 15], ["deficient cells", "PROBLEM", 37, 52], ["lipin1", "TREATMENT", 65, 71], ["deficient cells", "PROBLEM", 72, 87], ["viral spread", "PROBLEM", 147, 159], ["extracellular infectivity titers", "PROBLEM", 175, 207], ["infection", "PROBLEM", 232, 241], ["deficient cells", "OBSERVATION", 37, 52], ["infectivity", "OBSERVATION", 189, 200], ["infection", "OBSERVATION", 232, 241]]], ["Fig 2C shows limited propagation of this virus in lipin1-deficient cells, with a statistically significant reduction of up to two (shLPIN1-1) and three orders of magnitude (shLPIN1-2) in viral titer between the control and lipin1-deficient cell lines at day 5 post-infection.", [["lipin1-deficient cells", "ANATOMY", 50, 72], ["cell lines", "ANATOMY", 240, 250], ["infection", "DISEASE", 265, 274], ["lipin1", "GENE_OR_GENE_PRODUCT", 50, 56], ["cells", "CELL", 67, 72], ["shLPIN1-1", "GENE_OR_GENE_PRODUCT", 131, 140], ["shLPIN1-2", "GENE_OR_GENE_PRODUCT", 173, 182], ["lipin1", "GENE_OR_GENE_PRODUCT", 223, 229], ["cell lines", "CELL", 240, 250], ["lipin1-deficient cells", "CELL_LINE", 50, 72], ["shLPIN1", "PROTEIN", 131, 138], ["lipin1-deficient cell lines", "CELL_LINE", 223, 250], ["Fig 2C", "TEST", 0, 6], ["this virus", "PROBLEM", 36, 46], ["deficient cells", "PROBLEM", 57, 72], ["shLPIN1", "TEST", 131, 138], ["magnitude", "TEST", 162, 171], ["shLPIN1", "TEST", 173, 180], ["viral titer", "TREATMENT", 187, 198], ["lipin1-deficient cell lines", "TREATMENT", 223, 250], ["infection", "PROBLEM", 265, 274], ["deficient cells", "OBSERVATION", 57, 72], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["reduction", "OBSERVATION_MODIFIER", 107, 116], ["viral titer", "OBSERVATION", 187, 198], ["deficient cell lines", "OBSERVATION", 230, 250], ["infection", "OBSERVATION", 265, 274]]], ["These results indicate that lipin1 is required for efficient HCV propagation and that homeostatic lipin2 accumulation (Fig 2B) is not sufficient to support efficient HCV infection.Fig 2.", [["lipin1", "CHEMICAL", 28, 34], ["HCV infection", "DISEASE", 166, 179], ["lipin1", "GENE_OR_GENE_PRODUCT", 28, 34], ["HCV", "ORGANISM", 61, 64], ["lipin2", "GENE_OR_GENE_PRODUCT", 98, 104], ["HCV", "ORGANISM", 166, 169], ["lipin1", "PROTEIN", 28, 34], ["lipin2", "PROTEIN", 98, 104], ["HCV", "SPECIES", 61, 64], ["HCV", "SPECIES", 166, 169], ["lipin1", "TREATMENT", 28, 34], ["efficient HCV propagation", "PROBLEM", 51, 76], ["homeostatic lipin2 accumulation (Fig 2B", "TREATMENT", 86, 125], ["efficient HCV infection", "PROBLEM", 156, 179], ["HCV", "OBSERVATION_MODIFIER", 166, 169], ["infection", "OBSERVATION", 170, 179]]], ["HCV propagation is limited in lipin1-deficient cells.Since important differences in the interaction of different HCV genotypes with cellular lipid metabolism have previously been described [48] , we set out to determine if the observations made with a JFH1-derived virus (genotype 2a) were extensive to other HCV genotypes.", [["lipin1-deficient cells", "ANATOMY", 30, 52], ["cellular", "ANATOMY", 132, 140], ["HCV", "ORGANISM", 0, 3], ["lipin1", "GENE_OR_GENE_PRODUCT", 30, 36], ["cells", "CELL", 47, 52], ["HCV", "ORGANISM", 113, 116], ["cellular", "CELL", 132, 140], ["JFH1-derived virus", "ORGANISM", 252, 270], ["genotype 2a", "ORGANISM", 272, 283], ["HCV", "ORGANISM", 309, 312], ["lipin1-deficient cells", "CELL_LINE", 30, 52], ["HCV", "SPECIES", 0, 3], ["HCV", "SPECIES", 113, 116], ["HCV", "SPECIES", 309, 312], ["HCV propagation", "PROBLEM", 0, 15], ["deficient cells", "PROBLEM", 37, 52], ["different HCV genotypes", "PROBLEM", 103, 126], ["cellular lipid metabolism", "PROBLEM", 132, 157], ["a JFH1-derived virus (genotype 2a", "TREATMENT", 250, 283], ["other HCV genotypes", "PROBLEM", 303, 322], ["deficient cells", "OBSERVATION", 37, 52], ["lipid metabolism", "OBSERVATION", 141, 157]]], ["We performed low multiplicity infections (MOI 0.05) with genotype 1a TNcc virus strain in lipin1-deficient Huh-7.5 cell lines, which are susceptible to infection by this recombinant virus [49] .", [["Huh-7.5 cell lines", "ANATOMY", 107, 125], ["low multiplicity infections", "DISEASE", 13, 40], ["infection", "DISEASE", 152, 161], ["TNcc virus", "ORGANISM", 69, 79], ["lipin1", "GENE_OR_GENE_PRODUCT", 90, 96], ["Huh-7.5 cell lines", "CELL", 107, 125], ["lipin1-deficient Huh-7.5 cell lines", "CELL_LINE", 90, 125], ["low multiplicity infections", "PROBLEM", 13, 40], ["genotype 1a TNcc virus strain", "PROBLEM", 57, 86], ["lipin1", "TEST", 90, 96], ["Huh", "TEST", 107, 110], ["infection", "PROBLEM", 152, 161], ["this recombinant virus", "PROBLEM", 165, 187], ["low multiplicity", "OBSERVATION_MODIFIER", 13, 29], ["infections", "OBSERVATION", 30, 40], ["7.5 cell lines", "OBSERVATION", 111, 125], ["infection", "OBSERVATION", 152, 161]]], ["First, we verified that Huh-7.5.1 also display a significant reduction in genotype 2a infection efficiency when lipin1 is silenced (S2B Fig) .", [["infection", "DISEASE", 86, 95], ["Huh-7.5.1", "CELL", 24, 33], ["lipin1", "GENE_OR_GENE_PRODUCT", 112, 118], ["Huh-7.5.1", "CELL_LINE", 24, 33], ["lipin1", "PROTEIN", 112, 118], ["Huh", "TEST", 24, 27], ["a significant reduction", "PROBLEM", 47, 70], ["genotype 2a infection efficiency", "PROBLEM", 74, 106], ["lipin1", "TREATMENT", 112, 118], ["significant", "OBSERVATION_MODIFIER", 49, 60], ["reduction", "OBSERVATION_MODIFIER", 61, 70], ["genotype 2a", "OBSERVATION", 74, 85], ["infection efficiency", "OBSERVATION", 86, 106]]], ["In order to determine TNcc infection efficiency, intracellular HCV RNA accumulation was determined 72 hours post-inoculation in control and lipin1-deficient Huh-7.5 cells.", [["intracellular", "ANATOMY", 49, 62], ["Huh-7.5 cells", "ANATOMY", 157, 170], ["infection", "DISEASE", 27, 36], ["TNcc", "GENE_OR_GENE_PRODUCT", 22, 26], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 49, 62], ["lipin1", "GENE_OR_GENE_PRODUCT", 140, 146], ["Huh-7.5 cells", "CELL", 157, 170], ["HCV RNA", "RNA", 63, 70], ["lipin1-deficient Huh-7.5 cells", "CELL_LINE", 140, 170], ["HCV", "SPECIES", 63, 66], ["TNcc infection efficiency", "PROBLEM", 22, 47], ["intracellular HCV RNA accumulation", "PROBLEM", 49, 83], ["lipin1", "TEST", 140, 146], ["Huh", "TEST", 157, 160], ["HCV RNA", "OBSERVATION", 63, 70]]], ["Viral RNA detected under these conditions reflects the ability of genotype 1a to infect and replicate viral RNA in the different cell lines, as treatment of control cells with an HCV polymerase inhibitor 2\u00b4-C-methyladenosine (2mAde; 10 \u03bcM) [50] reduced viral RNA content by two orders of magnitude ( Fig 2D) .", [["cell lines", "ANATOMY", 129, 139], ["cells", "ANATOMY", 165, 170], ["2\u00b4-C-methyladenosine", "CHEMICAL", 204, 224], ["2mAde", "CHEMICAL", 226, 231], ["2\u00b4-C-methyladenosine", "CHEMICAL", 204, 224], ["2mAde", "CHEMICAL", 226, 231], ["cell lines", "CELL", 129, 139], ["cells", "CELL", 165, 170], ["2\u00b4-C-methyladenosine", "SIMPLE_CHEMICAL", 204, 224], ["2mAde", "SIMPLE_CHEMICAL", 226, 231], ["Viral RNA", "RNA", 0, 9], ["viral RNA", "RNA", 102, 111], ["cell lines", "CELL_LINE", 129, 139], ["control cells", "CELL_TYPE", 157, 170], ["viral RNA", "RNA", 253, 262], ["HCV", "SPECIES", 179, 182], ["Viral RNA", "PROBLEM", 0, 9], ["genotype 1a", "PROBLEM", 66, 77], ["viral RNA", "TREATMENT", 102, 111], ["the different cell lines", "TREATMENT", 115, 139], ["treatment of control cells", "TREATMENT", 144, 170], ["an HCV polymerase inhibitor", "TREATMENT", 176, 203], ["C-methyladenosine (2mAde", "TREATMENT", 207, 231], ["reduced viral RNA content", "PROBLEM", 245, 270], ["viral RNA", "OBSERVATION", 102, 111], ["different cell lines", "OBSERVATION", 119, 139]]], ["Lipin1 silencing consistently and significantly reduced TNcc replication by approximately 3-fold both in shLPIN1-1 and shLPIN1-2 cell lines (Fig 2D) , indicating that lipin1 is also limiting for genotype 1a HCV infection.Fig 2.", [["shLPIN1-1", "ANATOMY", 105, 114], ["shLPIN1-2 cell lines", "ANATOMY", 119, 139], ["HCV infection", "DISEASE", 207, 220], ["Lipin1", "GENE_OR_GENE_PRODUCT", 0, 6], ["TNcc", "GENE_OR_GENE_PRODUCT", 56, 60], ["shLPIN1-1", "CELL", 105, 114], ["shLPIN1-2 cell lines", "CELL", 119, 139], ["Fig 2D", "CELL", 141, 147], ["lipin1", "GENE_OR_GENE_PRODUCT", 167, 173], ["1a HCV", "ORGANISM", 204, 210], ["Lipin1", "PROTEIN", 0, 6], ["TNcc", "PROTEIN", 56, 60], ["shLPIN1-1 and shLPIN1-2 cell lines", "CELL_LINE", 105, 139], ["lipin1", "PROTEIN", 167, 173], ["HCV", "SPECIES", 207, 210], ["Lipin1 silencing", "TREATMENT", 0, 16], ["significantly reduced TNcc replication", "PROBLEM", 34, 72], ["shLPIN1", "TEST", 105, 112], ["lipin1", "TREATMENT", 167, 173], ["genotype 1a HCV infection", "PROBLEM", 195, 220], ["cell lines", "OBSERVATION", 129, 139], ["HCV", "OBSERVATION_MODIFIER", 207, 210], ["infection", "OBSERVATION", 211, 220]]], ["HCV propagation is limited in lipin1-deficient cells.To determine the specificity of these observations, identical lipin1-deficient and control Huh-7 cultures were inoculated at MOI 0.01 with a human alpha-coronavirus CoV-229E bearing a GFP reporter gene (hCoV-229E-GFP) [51] .", [["lipin1-deficient cells", "ANATOMY", 30, 52], ["Huh-7 cultures", "ANATOMY", 144, 158], ["HCV", "ORGANISM", 0, 3], ["lipin1", "GENE_OR_GENE_PRODUCT", 30, 36], ["cells", "CELL", 47, 52], ["lipin1", "GENE_OR_GENE_PRODUCT", 115, 121], ["Huh-7 cultures", "CELL", 144, 158], ["human", "ORGANISM", 194, 199], ["alpha-coronavirus CoV-229E", "ORGANISM", 200, 226], ["GFP", "GENE_OR_GENE_PRODUCT", 237, 240], ["hCoV-229E-GFP", "GENE_OR_GENE_PRODUCT", 256, 269], ["lipin1-deficient cells", "CELL_LINE", 30, 52], ["lipin1-deficient and control Huh-7 cultures", "CELL_LINE", 115, 158], ["human alpha-coronavirus CoV-229E", "DNA", 194, 226], ["GFP reporter gene", "DNA", 237, 254], ["hCoV", "DNA", 256, 260], ["229E", "DNA", 261, 265], ["GFP", "DNA", 266, 269], ["human", "SPECIES", 194, 199], ["HCV", "SPECIES", 0, 3], ["human alpha-coronavirus CoV-229E", "SPECIES", 194, 226], ["HCV propagation", "PROBLEM", 0, 15], ["deficient cells", "PROBLEM", 37, 52], ["these observations", "TEST", 85, 103], ["identical lipin1", "TEST", 105, 121], ["Huh", "TEST", 144, 147], ["cultures", "TEST", 150, 158], ["a human alpha-coronavirus CoV", "TEST", 192, 221], ["hCoV", "TEST", 256, 260], ["deficient cells", "OBSERVATION", 37, 52]]], ["Inoculation of control and lipin1-deficient cells with this virus resulted in comparable progeny virus production, as determined by infectivity titration in cell supernatants 48 hours post-infection (S3 Fig) .", [["cells", "ANATOMY", 44, 49], ["cell supernatants", "ANATOMY", 157, 174], ["infection", "DISEASE", 189, 198], ["lipin1", "GENE_OR_GENE_PRODUCT", 27, 33], ["cells", "CELL", 44, 49], ["cell", "CELL", 157, 161], ["lipin1-deficient cells", "CELL_LINE", 27, 49], ["Inoculation of control", "TREATMENT", 0, 22], ["lipin1", "TREATMENT", 27, 33], ["deficient cells", "PROBLEM", 34, 49], ["this virus", "PROBLEM", 55, 65], ["comparable progeny virus production", "PROBLEM", 78, 113], ["infection", "PROBLEM", 189, 198], ["progeny virus", "OBSERVATION", 89, 102], ["infection", "OBSERVATION", 189, 198]]], ["These results suggest that lipin1 is not rate limiting for CoV-229E-GFP infection and that lipin1 expression is particularly limiting for HCV.Early aspects of HCV infection are limited in lipin1-deficient cellsTo determine which aspects of the HCV replication cycle are limited by lipin1 silencing, single cycle infection experiments were conducted by inoculating control and lipin1-deficient cell cultures at MOI 10 with genotype 2a D183 virus.", [["lipin1-deficient cells", "ANATOMY", 188, 210], ["cell cultures", "ANATOMY", 393, 406], ["lipin1", "CHEMICAL", 27, 33], ["infection", "DISEASE", 72, 81], ["HCV infection", "DISEASE", 159, 172], ["lipin1", "GENE_OR_GENE_PRODUCT", 27, 33], ["CoV-229E", "GENE_OR_GENE_PRODUCT", 59, 67], ["GFP", "GENE_OR_GENE_PRODUCT", 68, 71], ["lipin1", "GENE_OR_GENE_PRODUCT", 91, 97], ["HCV", "ORGANISM", 138, 141], ["HCV", "ORGANISM", 159, 162], ["lipin1", "GENE_OR_GENE_PRODUCT", 188, 194], ["cells", "CELL", 205, 210], ["HCV", "ORGANISM", 244, 247], ["lipin1", "GENE_OR_GENE_PRODUCT", 281, 287], ["lipin1", "GENE_OR_GENE_PRODUCT", 376, 382], ["cell cultures", "CELL", 393, 406], ["D183 virus", "ORGANISM", 434, 444], ["lipin1", "PROTEIN", 27, 33], ["lipin1", "PROTEIN", 91, 97], ["lipin1-deficient cells", "CELL_LINE", 188, 210], ["lipin1", "PROTEIN", 281, 287], ["lipin1-deficient cell cultures", "CELL_LINE", 376, 406], ["HCV", "SPECIES", 138, 141], ["HCV", "SPECIES", 159, 162], ["HCV", "SPECIES", 244, 247], ["lipin1", "TREATMENT", 27, 33], ["CoV", "TEST", 59, 62], ["GFP infection", "PROBLEM", 68, 81], ["lipin1 expression", "TREATMENT", 91, 108], ["HCV", "PROBLEM", 138, 141], ["HCV infection", "PROBLEM", 159, 172], ["deficient cells", "PROBLEM", 195, 210], ["the HCV replication cycle", "TREATMENT", 240, 265], ["lipin1 silencing", "PROBLEM", 281, 297], ["single cycle infection experiments", "PROBLEM", 299, 333], ["lipin1", "TEST", 376, 382], ["deficient cell cultures", "PROBLEM", 383, 406], ["MOI", "TEST", 410, 413], ["infection", "OBSERVATION", 72, 81], ["HCV", "OBSERVATION_MODIFIER", 159, 162], ["infection", "OBSERVATION", 163, 172], ["deficient cells", "OBSERVATION", 195, 210], ["HCV", "OBSERVATION", 244, 247], ["infection", "OBSERVATION", 312, 321]]], ["Infection efficiency was measured by titration of progeny virus infectivity present in the supernatant of infected cells and intracellular HCV RNA accumulation at 48 and 72 hours post-infection.", [["supernatant", "ANATOMY", 91, 102], ["cells", "ANATOMY", 115, 120], ["intracellular", "ANATOMY", 125, 138], ["cells", "CELL", 115, 120], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 125, 138], ["infected cells", "CELL_TYPE", 106, 120], ["HCV RNA", "RNA", 139, 146], ["HCV", "SPECIES", 139, 142], ["Infection efficiency", "PROBLEM", 0, 20], ["progeny virus infectivity", "PROBLEM", 50, 75], ["infected cells", "PROBLEM", 106, 120], ["intracellular HCV RNA accumulation", "PROBLEM", 125, 159], ["progeny virus infectivity", "OBSERVATION", 50, 75], ["infected cells", "OBSERVATION", 106, 120], ["intracellular", "OBSERVATION_MODIFIER", 125, 138], ["HCV RNA", "OBSERVATION", 139, 146], ["accumulation", "OBSERVATION_MODIFIER", 147, 159]]], ["Infection of lipin1-deficient cells resulted in a significant reduction of progeny infectious virus production in shLPIN1-1 and shLPIN1-2 cells as compared with the titers observed in the supernatants of control cells ( Fig 3A) , reinforcing the notion that lipin1 silencing interferes with HCV infection.", [["lipin1-deficient cells", "ANATOMY", 13, 35], ["shLPIN1-1", "ANATOMY", 114, 123], ["shLPIN1-2 cells", "ANATOMY", 128, 143], ["supernatants", "ANATOMY", 188, 200], ["cells", "ANATOMY", 212, 217], ["HCV infection", "DISEASE", 291, 304], ["lipin1", "GENE_OR_GENE_PRODUCT", 13, 19], ["cells", "CELL", 30, 35], ["shLPIN1-1", "CELL", 114, 123], ["shLPIN1-2 cells", "CELL", 128, 143], ["cells", "CELL", 212, 217], ["Fig 3A", "CELL", 220, 226], ["lipin1", "GENE_OR_GENE_PRODUCT", 258, 264], ["HCV", "ORGANISM", 291, 294], ["lipin1-deficient cells", "CELL_LINE", 13, 35], ["shLPIN1-1 and shLPIN1-2 cells", "CELL_LINE", 114, 143], ["control cells", "CELL_TYPE", 204, 217], ["lipin1", "PROTEIN", 258, 264], ["HCV", "SPECIES", 291, 294], ["Infection of lipin1", "PROBLEM", 0, 19], ["deficient cells", "PROBLEM", 20, 35], ["progeny infectious virus production", "PROBLEM", 75, 110], ["shLPIN1", "TEST", 114, 121], ["the titers", "TEST", 161, 171], ["HCV infection", "PROBLEM", 291, 304], ["deficient cells", "OBSERVATION", 20, 35], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["reduction", "OBSERVATION_MODIFIER", 62, 71], ["progeny", "OBSERVATION_MODIFIER", 75, 82], ["infectious virus", "OBSERVATION", 83, 99]]], ["Reduced virus production is likely due to parallel reduction of intracellular HCV RNA levels observed in lipin1-deficient cells as compared with the control cell line (Fig 3B) .", [["intracellular", "ANATOMY", 64, 77], ["lipin1-deficient cells", "ANATOMY", 105, 127], ["cell line", "ANATOMY", 157, 166], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 77], ["HCV", "ORGANISM", 78, 81], ["lipin1", "GENE_OR_GENE_PRODUCT", 105, 111], ["cells", "CELL", 122, 127], ["cell line", "CELL", 157, 166], ["Fig 3B", "CELL", 168, 174], ["HCV RNA", "RNA", 78, 85], ["lipin1-deficient cells", "CELL_LINE", 105, 127], ["control cell line", "CELL_LINE", 149, 166], ["HCV", "SPECIES", 78, 81], ["Reduced virus production", "PROBLEM", 0, 24], ["parallel reduction of intracellular HCV RNA levels", "PROBLEM", 42, 92], ["deficient cells", "PROBLEM", 112, 127], ["virus", "OBSERVATION", 8, 13], ["likely due to", "UNCERTAINTY", 28, 41], ["parallel", "OBSERVATION_MODIFIER", 42, 50], ["reduction", "OBSERVATION_MODIFIER", 51, 60], ["intracellular", "OBSERVATION", 64, 77], ["HCV RNA", "OBSERVATION", 78, 85], ["deficient cells", "OBSERVATION", 112, 127]]], ["This reduction was observed at all time points, except for that at 5 hours, indicating that the size of the inoculum and initial virus adsorption is comparable among the different cell lines (Fig 3B) .", [["cell lines", "ANATOMY", 180, 190], ["cell lines", "CELL", 180, 190], ["Fig 3B", "CELL", 192, 198], ["cell lines", "CELL_LINE", 180, 190], ["This reduction", "TREATMENT", 0, 14], ["the inoculum", "PROBLEM", 104, 116], ["initial virus adsorption", "PROBLEM", 121, 145], ["size", "OBSERVATION_MODIFIER", 96, 100], ["inoculum", "OBSERVATION", 108, 116], ["cell lines", "OBSERVATION", 180, 190]]], ["Thus, lipin1 silencing suppresses HCV infection by interfering with a step of the HCV lifecycle preceding intracellular HCV RNA accumulation.Early aspects of HCV infection are limited in lipin1-deficient cellsNext, we set out to determine if lipin1 silencing has any impact on persistent HCV infections to verify if lipin1 is also limiting for late aspects of the virus lifecycle.", [["intracellular", "ANATOMY", 106, 119], ["lipin1-deficient cells", "ANATOMY", 187, 209], ["lipin1", "CHEMICAL", 6, 12], ["HCV infection", "DISEASE", 34, 47], ["HCV infection", "DISEASE", 158, 171], ["HCV infections", "DISEASE", 288, 302], ["lipin1", "GENE_OR_GENE_PRODUCT", 6, 12], ["HCV", "ORGANISM", 34, 37], ["HCV", "ORGANISM", 82, 85], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 106, 119], ["HCV", "ORGANISM", 120, 123], ["HCV", "ORGANISM", 158, 161], ["lipin1", "GENE_OR_GENE_PRODUCT", 187, 193], ["cells", "CELL", 204, 209], ["lipin1", "GENE_OR_GENE_PRODUCT", 242, 248], ["HCV", "ORGANISM", 288, 291], ["lipin1", "GENE_OR_GENE_PRODUCT", 316, 322], ["lipin1", "PROTEIN", 6, 12], ["HCV RNA", "RNA", 120, 127], ["lipin1-deficient cells", "CELL_LINE", 187, 209], ["lipin1", "PROTEIN", 242, 248], ["lipin1", "PROTEIN", 316, 322], ["HCV", "SPECIES", 34, 37], ["HCV", "SPECIES", 82, 85], ["HCV", "SPECIES", 120, 123], ["HCV", "SPECIES", 158, 161], ["HCV", "SPECIES", 288, 291], ["lipin1 silencing", "TREATMENT", 6, 22], ["HCV infection", "PROBLEM", 34, 47], ["intracellular HCV RNA accumulation", "PROBLEM", 106, 140], ["HCV infection", "PROBLEM", 158, 171], ["deficient cells", "PROBLEM", 194, 209], ["lipin1 silencing", "PROBLEM", 242, 258], ["persistent HCV infections", "PROBLEM", 277, 302], ["lipin1", "TREATMENT", 316, 322], ["the virus lifecycle", "TREATMENT", 360, 379], ["intracellular", "OBSERVATION", 106, 119], ["HCV RNA accumulation", "OBSERVATION", 120, 140], ["HCV", "OBSERVATION_MODIFIER", 158, 161], ["infection", "OBSERVATION", 162, 171], ["deficient cells", "OBSERVATION", 194, 209], ["persistent", "OBSERVATION_MODIFIER", 277, 287], ["HCV", "OBSERVATION", 288, 291]]], ["Persistently infected cells continuously replicate viral RNA, express viral antigens and secrete infectious virions.", [["cells", "ANATOMY", 22, 27], ["virions", "ANATOMY", 108, 115], ["cells", "CELL", 22, 27], ["viral RNA", "RNA", 51, 60], ["viral antigens", "PROTEIN", 70, 84], ["Persistently infected cells", "PROBLEM", 0, 27], ["viral RNA", "PROBLEM", 51, 60], ["viral antigens and secrete infectious virions", "PROBLEM", 70, 115], ["infected cells", "OBSERVATION", 13, 27], ["viral RNA", "OBSERVATION", 51, 60], ["viral", "OBSERVATION_MODIFIER", 70, 75], ["infectious virions", "OBSERVATION", 97, 115]]], ["Thus, it is a valuable system to measure steady-state HCV RNA replication as well as infectious particle assembly and secretion.", [["HCV", "ORGANISM", 54, 57], ["HCV", "SPECIES", 54, 57], ["HCV RNA replication", "TREATMENT", 54, 73]]], ["Persistently infected cultures were transduced with the lentiviral vectors described above to produce persistently infected, lipin1-deficient cells (S4 Fig) . shown as genome equivalents per microgram of total RNA GE/\u03bcg).", [["cultures", "ANATOMY", 22, 30], ["lipin1-deficient cells", "ANATOMY", 125, 147], ["cultures", "CELL", 22, 30], ["lentiviral", "ORGANISM", 56, 66], ["lipin1", "GENE_OR_GENE_PRODUCT", 125, 131], ["cells", "CELL", 142, 147], ["lipin1-deficient cells", "CELL_LINE", 125, 147], ["Persistently infected cultures", "PROBLEM", 0, 30], ["the lentiviral vectors", "TREATMENT", 52, 74], ["persistently infected, lipin1-deficient cells", "PROBLEM", 102, 147], ["infected", "OBSERVATION", 13, 21], ["persistently", "OBSERVATION_MODIFIER", 102, 114], ["infected", "OBSERVATION", 115, 123], ["deficient cells", "OBSERVATION", 132, 147]]], ["Panels C, D-Persistently infected cultures were generated by inoculation with JFH-1 virus at MOI 0.01.", [["cultures", "ANATOMY", 34, 42], ["Panels C", "CELL", 0, 8], ["cultures", "CELL", 34, 42], ["JFH-1 virus", "ORGANISM", 78, 89], ["JFH-1 virus", "SPECIES", 78, 89], ["Panels C", "TEST", 0, 8], ["D-", "TEST", 10, 12], ["Persistently infected cultures", "PROBLEM", 12, 42], ["JFH", "TEST", 78, 81]]], ["Once cultures reached >95% of HCV-positive cells, they were transduced with lentiviral vectors expressing control, HCV RNA-targeting or LPIN1-specific shRNAs.", [["cultures", "ANATOMY", 5, 13], ["cells", "ANATOMY", 43, 48], ["HCV", "ORGANISM", 30, 33], ["cells", "CELL", 43, 48], ["lentiviral", "ORGANISM", 76, 86], ["HCV", "ORGANISM", 115, 118], ["LPIN1", "GENE_OR_GENE_PRODUCT", 136, 141], ["HCV-positive cells", "CELL_TYPE", 30, 48], ["HCV RNA", "RNA", 115, 122], ["LPIN1", "PROTEIN", 136, 141], ["shRNAs", "DNA", 151, 157], ["HCV", "SPECIES", 30, 33], ["lentiviral", "SPECIES", 76, 86], ["HCV", "SPECIES", 115, 118], ["cultures", "TEST", 5, 13], ["HCV-positive cells", "PROBLEM", 30, 48], ["lentiviral vectors expressing control", "TREATMENT", 76, 113], ["HCV RNA", "PROBLEM", 115, 122], ["LPIN1", "TEST", 136, 141], ["positive cells", "OBSERVATION", 34, 48]]], ["At day 7 post-transduction, cells were split and samples of the cells and supernatants were collected 24 hours later to determine infectious virus production rate by infectivity titration HCV (C) and RNA levels by RT-qPCR (D).", [["cells", "ANATOMY", 28, 33], ["samples", "ANATOMY", 49, 56], ["cells", "ANATOMY", 64, 69], ["supernatants", "ANATOMY", 74, 86], ["cells", "CELL", 28, 33], ["cells", "CELL", 64, 69], ["HCV", "SPECIES", 188, 191], ["cells", "PROBLEM", 28, 33], ["the cells", "TEST", 60, 69], ["supernatants", "TEST", 74, 86], ["infectious virus production rate", "PROBLEM", 130, 162], ["RNA levels", "TEST", 200, 210], ["RT", "TEST", 214, 216]]], ["All data are shown as mean and SD of 3 independent experiments performed in triplicate (n = 9).", [["All data", "TEST", 0, 8]]], ["Statistical significance was determined using Student\u00b4s t-test ( \u00c3 p<0.05; \u00c3\u00c3 p<0.01).", [["Student\u00b4s t-test", "TEST", 46, 62], ["p", "TEST", 67, 68]]], ["Analysis of extracellular infectivity titers revealed that infectivity titers in lipin1-deficient and control cells were comparable, with the exception of a marginal reduction in shLPIN1-2 expressing cells, indicating that lipin1 silencing does not strongly interfere with infectious virus production ( Fig 3C) .", [["extracellular", "ANATOMY", 12, 25], ["cells", "ANATOMY", 110, 115], ["cells", "ANATOMY", 200, 205], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 12, 25], ["lipin1", "GENE_OR_GENE_PRODUCT", 81, 87], ["cells", "CELL", 110, 115], ["shLPIN1-2", "GENE_OR_GENE_PRODUCT", 179, 188], ["cells", "CELL", 200, 205], ["lipin1", "GENE_OR_GENE_PRODUCT", 223, 229], ["lipin1-deficient and control cells", "CELL_LINE", 81, 115], ["shLPIN1", "PROTEIN", 179, 186], ["lipin1", "PROTEIN", 223, 229], ["extracellular infectivity titers", "TEST", 12, 44], ["infectivity titers", "TEST", 59, 77], ["lipin1", "TEST", 81, 87], ["deficient and control cells", "PROBLEM", 88, 115], ["a marginal reduction in shLPIN1", "PROBLEM", 155, 186], ["lipin1 silencing", "PROBLEM", 223, 239], ["infectious virus production", "PROBLEM", 273, 300], ["marginal", "OBSERVATION_MODIFIER", 157, 165], ["reduction", "OBSERVATION_MODIFIER", 166, 175]]], ["Intracellular HCV RNA levels in lipin1-deficient cells were comparable to that of the control cells (Fig 3D) , indicating that lipin1 expression is not rate limiting for HCV RNA replication once infection has been established.", [["Intracellular", "ANATOMY", 0, 13], ["lipin1-deficient cells", "ANATOMY", 32, 54], ["cells", "ANATOMY", 94, 99], ["infection", "DISEASE", 195, 204], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["HCV", "ORGANISM", 14, 17], ["lipin1", "GENE_OR_GENE_PRODUCT", 32, 38], ["cells", "CELL", 49, 54], ["cells", "CELL", 94, 99], ["lipin1", "GENE_OR_GENE_PRODUCT", 127, 133], ["HCV", "ORGANISM", 170, 173], ["HCV RNA", "RNA", 14, 21], ["lipin1-deficient cells", "CELL_LINE", 32, 54], ["control cells", "CELL_TYPE", 86, 99], ["lipin1", "PROTEIN", 127, 133], ["HCV RNA", "RNA", 170, 177], ["HCV", "SPECIES", 14, 17], ["HCV", "SPECIES", 170, 173], ["Intracellular HCV RNA levels", "TEST", 0, 28], ["lipin1", "TEST", 32, 38], ["deficient cells", "PROBLEM", 39, 54], ["HCV RNA replication", "TREATMENT", 170, 189], ["infection", "PROBLEM", 195, 204], ["HCV", "OBSERVATION", 14, 17], ["deficient cells", "OBSERVATION", 39, 54]]], ["Taken together, the results shown above indicate that lipin1 is only limiting at early steps of HCV infection leading to viral RNA accumulation.Early aspects of HCV infection are limited in lipin1-deficient cellsAs an independent verification of the hypothesis that lipin1 is limiting for early aspects of HCV infection, we used a single cycle surrogate infection model based on the production of HCV virions bearing a defective reporter genome encapsidated by trans-complementation (HCV tcp ).", [["lipin1-deficient cells", "ANATOMY", 190, 212], ["lipin1", "CHEMICAL", 54, 60], ["HCV infection", "DISEASE", 96, 109], ["HCV infection", "DISEASE", 161, 174], ["lipin1", "CHEMICAL", 266, 272], ["HCV infection", "DISEASE", 306, 319], ["infection", "DISEASE", 354, 363], ["lipin1", "GENE_OR_GENE_PRODUCT", 54, 60], ["HCV", "ORGANISM", 96, 99], ["HCV", "ORGANISM", 161, 164], ["lipin1", "GENE_OR_GENE_PRODUCT", 190, 196], ["cells", "CELL", 207, 212], ["lipin1", "GENE_OR_GENE_PRODUCT", 266, 272], ["HCV", "ORGANISM", 306, 309], ["HCV", "ORGANISM", 397, 400], ["lipin1", "PROTEIN", 54, 60], ["lipin1-deficient cells", "CELL_LINE", 190, 212], ["lipin1", "PROTEIN", 266, 272], ["defective reporter genome", "DNA", 419, 444], ["HCV", "SPECIES", 96, 99], ["HCV", "SPECIES", 161, 164], ["HCV", "SPECIES", 306, 309], ["HCV", "SPECIES", 397, 400], ["HCV", "SPECIES", 484, 487], ["HCV infection", "PROBLEM", 96, 109], ["viral RNA accumulation", "PROBLEM", 121, 143], ["HCV infection", "PROBLEM", 161, 174], ["deficient cells", "PROBLEM", 197, 212], ["lipin1", "TREATMENT", 266, 272], ["HCV infection", "PROBLEM", 306, 319], ["a single cycle surrogate infection model", "TREATMENT", 329, 369], ["HCV virions", "TREATMENT", 397, 408], ["a defective reporter genome", "TREATMENT", 417, 444], ["HCV", "OBSERVATION", 96, 99], ["viral RNA accumulation", "OBSERVATION", 121, 143], ["HCV", "OBSERVATION_MODIFIER", 161, 164], ["infection", "OBSERVATION", 165, 174], ["deficient cells", "OBSERVATION", 197, 212], ["HCV", "OBSERVATION_MODIFIER", 306, 309], ["infection", "OBSERVATION", 310, 319]]], ["HCV tcp are capable of producing abortive single-cycle infections, efficiency of which is proportional to the luciferase activity found in the target cells [52] .", [["cells", "ANATOMY", 150, 155], ["infections", "DISEASE", 55, 65], ["HCV tcp", "ORGANISM", 0, 7], ["luciferase", "GENE_OR_GENE_PRODUCT", 110, 120], ["cells", "CELL", 150, 155], ["luciferase", "PROTEIN", 110, 120], ["target cells", "CELL_TYPE", 143, 155], ["HCV", "SPECIES", 0, 3], ["HCV tcp", "PROBLEM", 0, 7], ["abortive single-cycle infections", "PROBLEM", 33, 65], ["the luciferase activity", "PROBLEM", 106, 129], ["infections", "OBSERVATION", 55, 65]]], ["As expected from the results shown in Fig 3, infection of lipin1-deficient cells with HCV tcp resulted in a 75% reduction in the reporter luciferase activity in shLPIN1-1 cells and 90% in shLPIN1-2 determined at 48 hours post-infection, proportionally to the degree of silencing in these cells ( Fig 4A and 4B ).", [["cells", "ANATOMY", 75, 80], ["shLPIN1-1 cells", "ANATOMY", 161, 176], ["cells", "ANATOMY", 288, 293], ["infection", "DISEASE", 45, 54], ["tcp", "CHEMICAL", 90, 93], ["infection", "DISEASE", 226, 235], ["lipin1", "GENE_OR_GENE_PRODUCT", 58, 64], ["cells", "CELL", 75, 80], ["HCV tcp", "ORGANISM", 86, 93], ["luciferase", "GENE_OR_GENE_PRODUCT", 138, 148], ["shLPIN1-1 cells", "CELL", 161, 176], ["shLPIN1-2", "CELL", 188, 197], ["cells", "CELL", 288, 293], ["lipin1-deficient cells", "CELL_LINE", 58, 80], ["HCV tcp", "PROTEIN", 86, 93], ["luciferase", "PROTEIN", 138, 148], ["shLPIN1-1 cells", "CELL_LINE", 161, 176], ["shLPIN1", "PROTEIN", 188, 195], ["HCV", "SPECIES", 86, 89], ["infection of lipin1", "PROBLEM", 45, 64], ["deficient cells", "PROBLEM", 65, 80], ["HCV tcp", "PROBLEM", 86, 93], ["a 75% reduction", "TREATMENT", 106, 121], ["the reporter luciferase activity", "TEST", 125, 157], ["shLPIN1", "TEST", 161, 168], ["shLPIN1", "TEST", 188, 195], ["infection", "PROBLEM", 226, 235], ["silencing in these cells", "PROBLEM", 269, 293], ["luciferase activity", "OBSERVATION", 138, 157], ["infection", "OBSERVATION", 226, 235], ["silencing", "OBSERVATION", 269, 278]]], ["These results underscore the role that lipin1 plays at early steps of HCV infection and indicate that either viral entry or a step leading to efficient HCV RNA replication is impaired in these cells.Early aspects of HCV infection are limited in lipin1-deficient cellsLPIN-1 mRNA is alternatively spliced in human liver to produce isoforms \u03b1 and \u03b2, which may differ in catalytic activity, subcellular localization and gene expression regulation [53] .", [["cells", "ANATOMY", 193, 198], ["liver", "ANATOMY", 313, 318], ["subcellular", "ANATOMY", 388, 399], ["lipin1", "CHEMICAL", 39, 45], ["HCV infection", "DISEASE", 70, 83], ["HCV infection", "DISEASE", 216, 229], ["lipin1", "GENE_OR_GENE_PRODUCT", 39, 45], ["HCV", "ORGANISM", 70, 73], ["HCV", "ORGANISM", 152, 155], ["cells", "CELL", 193, 198], ["HCV", "ORGANISM", 216, 219], ["lipin1", "GENE_OR_GENE_PRODUCT", 245, 251], ["cellsLPIN-1", "GENE_OR_GENE_PRODUCT", 262, 273], ["human", "ORGANISM", 307, 312], ["liver", "ORGAN", 313, 318], ["\u03b1", "GENE_OR_GENE_PRODUCT", 339, 340], ["\u03b2", "GENE_OR_GENE_PRODUCT", 345, 346], ["lipin1", "PROTEIN", 39, 45], ["lipin1-deficient cellsLPIN-1 mRNA", "RNA", 245, 278], ["\u03b1", "PROTEIN", 339, 340], ["\u03b2", "PROTEIN", 345, 346], ["human", "SPECIES", 307, 312], ["HCV", "SPECIES", 70, 73], ["HCV", "SPECIES", 152, 155], ["HCV", "SPECIES", 216, 219], ["human", "SPECIES", 307, 312], ["lipin1", "TREATMENT", 39, 45], ["HCV infection", "PROBLEM", 70, 83], ["viral entry", "PROBLEM", 109, 120], ["efficient HCV RNA replication", "PROBLEM", 142, 171], ["HCV infection", "PROBLEM", 216, 229], ["lipin1", "TEST", 245, 251], ["deficient cellsLPIN", "PROBLEM", 252, 271], ["HCV", "OBSERVATION_MODIFIER", 216, 219], ["infection", "OBSERVATION", 220, 229], ["liver", "ANATOMY", 313, 318]]], ["To determine the relative contribution of these isoforms to HCV infection, isoform-specific shRNAs were generated and used to transduce Huh-7 cells, as described above.", [["Huh-7 cells", "ANATOMY", 136, 147], ["HCV infection", "DISEASE", 60, 73], ["HCV", "ORGANISM", 60, 63], ["Huh-7 cells", "CELL", 136, 147], ["Huh-7 cells", "CELL_LINE", 136, 147], ["HCV", "SPECIES", 60, 63], ["HCV infection", "PROBLEM", 60, 73], ["isoform-specific shRNAs", "PROBLEM", 75, 98], ["Huh", "TEST", 136, 139]]], ["LPIN1\u03b1-specific shRNA (shLPIN1-3) reduced total lipin1 protein by 70%, while LPIN1\u03b2-specific shRNA (shLPIN1-4) reduced total lipin1 expression by only 30% (Fig 4A) .", [["LPIN1\u03b1", "GENE_OR_GENE_PRODUCT", 0, 6], ["shLPIN1-3", "GENE_OR_GENE_PRODUCT", 23, 32], ["lipin1", "GENE_OR_GENE_PRODUCT", 48, 54], ["LPIN1\u03b2", "GENE_OR_GENE_PRODUCT", 77, 83], ["shLPIN1-4", "GENE_OR_GENE_PRODUCT", 100, 109], ["lipin1", "GENE_OR_GENE_PRODUCT", 125, 131], ["LPIN1\u03b1-specific shRNA (shLPIN1-3", "DNA", 0, 32], ["lipin1 protein", "PROTEIN", 48, 62], ["LPIN1\u03b2", "PROTEIN", 77, 83], ["shLPIN1", "PROTEIN", 100, 107], ["lipin1", "PROTEIN", 125, 131], ["LPIN1", "TEST", 0, 5], ["shLPIN1", "TEST", 23, 30], ["total lipin1 protein", "TREATMENT", 42, 62], ["LPIN1", "TEST", 77, 82], ["shLPIN1", "TEST", 100, 107], ["reduced total lipin1 expression", "TREATMENT", 111, 142]]], ["Infection of control and lipin1 isoform-deficient cells with HCV tcp revealed that lipin1\u03b1 silencing resulted in a strong (85%) reduction in HCV infection while lipin1\u03b2 silencing resulted in a milder (55%) but significant reduction in HCV infection efficiency ( Fig 4B) .", [["cells", "ANATOMY", 50, 55], ["HCV infection", "DISEASE", 141, 154], ["HCV infection", "DISEASE", 235, 248], ["lipin1", "GENE_OR_GENE_PRODUCT", 25, 31], ["cells", "CELL", 50, 55], ["HCV tcp", "ORGANISM", 61, 68], ["lipin1\u03b1", "GENE_OR_GENE_PRODUCT", 83, 90], ["HCV", "ORGANISM", 141, 144], ["lipin1\u03b2", "GENE_OR_GENE_PRODUCT", 161, 168], ["HCV", "ORGANISM", 235, 238], ["lipin1 isoform-deficient cells", "CELL_TYPE", 25, 55], ["HCV tcp", "PROTEIN", 61, 68], ["lipin1\u03b1", "PROTEIN", 83, 90], ["lipin1\u03b2", "PROTEIN", 161, 168], ["HCV", "SPECIES", 61, 64], ["HCV", "SPECIES", 141, 144], ["HCV", "SPECIES", 235, 238], ["Infection of control and lipin1 isoform", "PROBLEM", 0, 39], ["deficient cells", "PROBLEM", 40, 55], ["HCV tcp", "PROBLEM", 61, 68], ["lipin1\u03b1 silencing", "TREATMENT", 83, 100], ["HCV infection", "PROBLEM", 141, 154], ["significant reduction in HCV infection efficiency", "PROBLEM", 210, 259], ["HCV", "OBSERVATION_MODIFIER", 141, 144], ["infection", "OBSERVATION", 145, 154], ["significant", "OBSERVATION_MODIFIER", 210, 221], ["reduction", "OBSERVATION_MODIFIER", 222, 231], ["HCV", "OBSERVATION_MODIFIER", 235, 238], ["infection", "OBSERVATION", 239, 248]]], ["These results indicate that both isoforms alpha and beta are limiting for HCV infection and suggest that the total amount of lipin1 present in the cell determines HCV infection efficiency.", [["cell", "ANATOMY", 147, 151], ["HCV infection", "DISEASE", 74, 87], ["infection", "DISEASE", 167, 176], ["alpha", "GENE_OR_GENE_PRODUCT", 42, 47], ["beta", "GENE_OR_GENE_PRODUCT", 52, 56], ["HCV", "ORGANISM", 74, 77], ["lipin1", "GENE_OR_GENE_PRODUCT", 125, 131], ["cell", "CELL", 147, 151], ["HCV", "ORGANISM", 163, 166], ["isoforms alpha and beta", "PROTEIN", 33, 56], ["lipin1", "PROTEIN", 125, 131], ["HCV", "SPECIES", 74, 77], ["HCV", "SPECIES", 163, 166], ["HCV infection", "PROBLEM", 74, 87], ["lipin1", "TREATMENT", 125, 131], ["HCV infection efficiency", "PROBLEM", 163, 187], ["HCV", "OBSERVATION_MODIFIER", 163, 166], ["infection", "OBSERVATION", 167, 176]]], ["Taken together, the results obtained with four different shRNAs indicate that total lipin1 expression levels strongly correlate with HCV tcp infection efficiency (Fig 4C) , underscoring a role for this host protein in early aspects of HCV infection.Lipin1 silencing interferes with initial steps of HCV RNA replicationReduced HCV RNA accumulation in a single cycle infection (Fig 3) as well as reduced HCV tcp infection (Fig 4) may be due to a defect in entry of incoming virions.", [["virions", "ANATOMY", 472, 479], ["infection", "DISEASE", 141, 150], ["HCV infection", "DISEASE", 235, 248], ["Lipin1", "CHEMICAL", 249, 255], ["infection", "DISEASE", 365, 374], ["HCV tcp infection", "DISEASE", 402, 419], ["lipin1", "GENE_OR_GENE_PRODUCT", 84, 90], ["HCV tcp", "ORGANISM", 133, 140], ["HCV", "ORGANISM", 235, 238], ["Lipin1", "GENE_OR_GENE_PRODUCT", 249, 255], ["HCV", "ORGANISM", 299, 302], ["HCV tcp", "ORGANISM", 402, 409], ["virions", "CELLULAR_COMPONENT", 472, 479], ["lipin1", "PROTEIN", 84, 90], ["Lipin1", "PROTEIN", 249, 255], ["HCV RNA", "RNA", 299, 306], ["HCV RNA", "RNA", 326, 333], ["HCV", "SPECIES", 133, 136], ["HCV", "SPECIES", 235, 238], ["HCV", "SPECIES", 299, 302], ["HCV", "SPECIES", 326, 329], ["HCV", "SPECIES", 402, 405], ["four different shRNAs", "TREATMENT", 42, 63], ["total lipin1 expression levels", "TEST", 78, 108], ["HCV tcp infection efficiency", "PROBLEM", 133, 161], ["this host protein", "TREATMENT", 197, 214], ["HCV infection", "PROBLEM", 235, 248], ["Lipin1 silencing", "TREATMENT", 249, 265], ["HCV RNA replication", "TREATMENT", 299, 318], ["Reduced HCV RNA accumulation", "PROBLEM", 318, 346], ["a single cycle infection (Fig", "TREATMENT", 350, 379], ["reduced HCV tcp infection", "PROBLEM", 394, 419], ["a defect", "PROBLEM", 442, 450], ["HCV", "OBSERVATION_MODIFIER", 235, 238], ["infection", "OBSERVATION", 239, 248], ["infection", "OBSERVATION", 410, 419], ["defect", "OBSERVATION", 444, 450]]], ["HCV E1E2-pseudotyped retroviral vectors bearing a luciferase gene (HCV pp ) were used to measure viral entry because they constitute a sound model to study viral adsorption, receptor-mediated internalization and E1E2-mediated fusion in endosomes [54] .", [["endosomes", "ANATOMY", 236, 245], ["HCV", "ORGANISM", 0, 3], ["E1E2", "GENE_OR_GENE_PRODUCT", 4, 8], ["pseudotyped", "ORGANISM", 9, 20], ["retroviral", "ORGANISM", 21, 31], ["luciferase", "GENE_OR_GENE_PRODUCT", 50, 60], ["E1E2", "GENE_OR_GENE_PRODUCT", 212, 216], ["endosomes", "CELLULAR_COMPONENT", 236, 245], ["HCV E1E2-pseudotyped retroviral vectors", "DNA", 0, 39], ["luciferase gene", "DNA", 50, 65], ["E1E2", "PROTEIN", 212, 216], ["HCV", "SPECIES", 0, 3], ["HCV", "SPECIES", 67, 70], ["HCV E1E2", "TREATMENT", 0, 8], ["pseudotyped retroviral vectors", "TREATMENT", 9, 39], ["a luciferase gene (HCV pp )", "TREATMENT", 48, 75], ["receptor-mediated internalization", "TREATMENT", 174, 207], ["E1E2-mediated fusion in endosomes", "TREATMENT", 212, 245], ["pseudotyped retroviral", "OBSERVATION", 9, 31]]], ["To assess the specificity of these observations, parallel cultures were inoculated with VSV-G pseudotyped retroviral vectors (VSV pp ).", [["VSV-G pseudotyped", "ORGANISM", 88, 105], ["retroviral", "ORGANISM", 106, 116], ["VSV", "ORGANISM", 126, 129], ["VSV-G pseudotyped retroviral", "SPECIES", 88, 116], ["VSV", "SPECIES", 126, 129], ["these observations", "TEST", 29, 47], ["parallel cultures", "TEST", 49, 66], ["VSV-G pseudotyped retroviral vectors", "TREATMENT", 88, 124]]], ["Control and lipin1-deficient cell lines were infected with HCV pp (genotype 2a; JFH-1 strain) and VSVpp.", [["lipin1-deficient cell lines", "ANATOMY", 12, 39], ["lipin1", "GENE_OR_GENE_PRODUCT", 12, 18], ["cell lines", "CELL", 29, 39], ["HCV pp (genotype 2a", "ORGANISM", 59, 78], ["JFH-1 strain", "ORGANISM", 80, 92], ["lipin1-deficient cell lines", "CELL_LINE", 12, 39], ["HCV", "SPECIES", 59, 62], ["lipin1", "TREATMENT", 12, 18], ["deficient cell lines", "TREATMENT", 19, 39], ["HCV pp", "TEST", 59, 65], ["genotype", "TEST", 67, 75], ["JFH", "TEST", 80, 83], ["VSVpp", "PROBLEM", 98, 103], ["deficient cell lines", "OBSERVATION", 19, 39]]], ["As a positive control of inhibition of HCV entry, we used hydroxyzine (5 \u03bcM), which efficiently blocks HCV infection by interfering with viral entry [55] .", [["hydroxyzine", "CHEMICAL", 58, 69], ["HCV infection", "DISEASE", 103, 116], ["hydroxyzine", "CHEMICAL", 58, 69], ["HCV", "ORGANISM", 39, 42], ["hydroxyzine", "SIMPLE_CHEMICAL", 58, 69], ["HCV", "ORGANISM", 103, 106], ["HCV", "SPECIES", 39, 42], ["HCV", "SPECIES", 103, 106], ["HCV entry", "PROBLEM", 39, 48], ["hydroxyzine", "TREATMENT", 58, 69], ["HCV infection", "PROBLEM", 103, 116], ["HCV", "OBSERVATION_MODIFIER", 103, 106], ["infection", "OBSERVATION", 107, 116]]], ["As expected, hydroxyzine selectively inhibited HCV pp infection, as shown by reduced luciferase levels 48 hours postinoculation only in HCV pp -infected cells ( Fig 5A) .", [["cells", "ANATOMY", 153, 158], ["hydroxyzine", "CHEMICAL", 13, 24], ["infection", "DISEASE", 54, 63], ["hydroxyzine", "CHEMICAL", 13, 24], ["hydroxyzine", "SIMPLE_CHEMICAL", 13, 24], ["HCV pp", "ORGANISM", 47, 53], ["luciferase", "GENE_OR_GENE_PRODUCT", 85, 95], ["HCV", "ORGANISM", 136, 139], ["cells", "CELL", 153, 158], ["luciferase", "PROTEIN", 85, 95], ["infected cells", "CELL_TYPE", 144, 158], ["HCV", "SPECIES", 47, 50], ["HCV", "SPECIES", 136, 139], ["hydroxyzine", "TREATMENT", 13, 24], ["HCV pp infection", "PROBLEM", 47, 63], ["reduced luciferase levels", "PROBLEM", 77, 102], ["HCV pp", "TEST", 136, 142], ["infection", "OBSERVATION", 54, 63], ["infected cells", "OBSERVATION", 144, 158]]], ["Interestingly, lipin1-deficient cells (shLPIN1-1 and shLPIN1-2) were fully susceptible to HCV pp and VSV pp infection, as comparable luciferase activity levels were found in all cell lines 48 hours post-inoculation ( Fig 5A) .Lipin1 silencing interferes with initial steps of HCV RNA replicationThese results indicate that lipin1 is not rate limiting for receptor binding, particle internalization or E1E2-mediated endosomal fusion, which are steps recapitulated in this model [54] .", [["lipin1-deficient cells", "ANATOMY", 15, 37], ["cell lines", "ANATOMY", 178, 188], ["endosomal", "ANATOMY", 415, 424], ["infection", "DISEASE", 108, 117], ["lipin1", "GENE_OR_GENE_PRODUCT", 15, 21], ["cells", "CELL", 32, 37], ["shLPIN1-1", "GENE_OR_GENE_PRODUCT", 39, 48], ["shLPIN1-2", "GENE_OR_GENE_PRODUCT", 53, 62], ["HCV", "ORGANISM", 90, 93], ["VSV pp", "ORGANISM", 101, 107], ["luciferase", "GENE_OR_GENE_PRODUCT", 133, 143], ["cell lines", "CELL", 178, 188], ["Lipin1", "GENE_OR_GENE_PRODUCT", 226, 232], ["HCV", "ORGANISM", 276, 279], ["lipin1", "GENE_OR_GENE_PRODUCT", 323, 329], ["E1E2", "GENE_OR_GENE_PRODUCT", 401, 405], ["endosomal", "CELLULAR_COMPONENT", 415, 424], ["lipin1-deficient cells", "CELL_LINE", 15, 37], ["shLPIN1", "PROTEIN", 39, 46], ["shLPIN1", "PROTEIN", 53, 60], ["luciferase", "PROTEIN", 133, 143], ["cell lines", "CELL_LINE", 178, 188], ["Lipin1", "PROTEIN", 226, 232], ["HCV RNA", "RNA", 276, 283], ["lipin1", "PROTEIN", 323, 329], ["E1E2", "PROTEIN", 401, 405], ["HCV", "SPECIES", 90, 93], ["VSV", "SPECIES", 101, 104], ["HCV", "SPECIES", 276, 279], ["lipin1", "TEST", 15, 21], ["deficient cells", "PROBLEM", 22, 37], ["shLPIN1", "TEST", 39, 46], ["shLPIN1", "TEST", 53, 60], ["HCV pp", "PROBLEM", 90, 96], ["VSV pp infection", "PROBLEM", 101, 117], ["Lipin1 silencing", "TREATMENT", 226, 242], ["HCV RNA replication", "TREATMENT", 276, 295], ["lipin1", "TREATMENT", 323, 329], ["receptor binding", "PROBLEM", 355, 371], ["particle internalization", "TREATMENT", 373, 397], ["E1E2-mediated endosomal fusion", "TREATMENT", 401, 431], ["deficient cells", "OBSERVATION", 22, 37], ["pp infection", "OBSERVATION", 105, 117], ["cell lines", "OBSERVATION", 178, 188], ["endosomal fusion", "OBSERVATION", 415, 431]]], ["Based on the data presented thus far, we hypothesized that lipin1 is limiting for a step in the HCV lifecycle downstream of HCV entry, leading to HCV RNA accumulation.", [["lipin1", "CHEMICAL", 59, 65], ["lipin1", "GENE_OR_GENE_PRODUCT", 59, 65], ["HCV", "ORGANISM", 96, 99], ["HCV", "ORGANISM", 124, 127], ["HCV", "ORGANISM", 146, 149], ["lipin1", "PROTEIN", 59, 65], ["HCV RNA", "RNA", 146, 153], ["HCV", "SPECIES", 96, 99], ["HCV", "SPECIES", 124, 127], ["HCV", "SPECIES", 146, 149], ["HCV entry", "PROBLEM", 124, 133], ["HCV RNA accumulation", "PROBLEM", 146, 166], ["HCV", "OBSERVATION", 96, 99], ["HCV", "OBSERVATION", 124, 127], ["HCV RNA accumulation", "OBSERVATION", 146, 166]]], ["To verify the hypothesis that lipin1 silencing causes strong reduction in initial HCV RNA accumulation by interfering with a step downstream of viral entry, we bypassed this step of the viral replication cycle by transfecting a subgenomic HCV RNA replicon bearing a reporter luciferase gene into control and lipin1-deficient cells.", [["cells", "ANATOMY", 325, 330], ["lipin1", "CHEMICAL", 30, 36], ["lipin1", "GENE_OR_GENE_PRODUCT", 30, 36], ["HCV", "ORGANISM", 82, 85], ["HCV", "ORGANISM", 239, 242], ["luciferase", "GENE_OR_GENE_PRODUCT", 275, 285], ["lipin1", "GENE_OR_GENE_PRODUCT", 308, 314], ["cells", "CELL", 325, 330], ["lipin1", "PROTEIN", 30, 36], ["HCV RNA", "RNA", 82, 89], ["subgenomic HCV RNA replicon", "DNA", 228, 255], ["reporter luciferase gene", "DNA", 266, 290], ["lipin1-deficient cells", "CELL_LINE", 308, 330], ["HCV", "SPECIES", 82, 85], ["HCV", "SPECIES", 239, 242], ["lipin1 silencing", "PROBLEM", 30, 46], ["strong reduction", "PROBLEM", 54, 70], ["initial HCV RNA accumulation", "PROBLEM", 74, 102], ["the viral replication cycle", "TREATMENT", 182, 209], ["a subgenomic HCV RNA replicon", "TREATMENT", 226, 255], ["deficient cells", "PROBLEM", 315, 330], ["strong", "OBSERVATION_MODIFIER", 54, 60], ["reduction", "OBSERVATION_MODIFIER", 61, 70], ["HCV RNA accumulation", "OBSERVATION", 82, 102], ["viral replication", "OBSERVATION", 186, 203], ["deficient cells", "OBSERVATION", 315, 330]]], ["First, we evaluated HCV-IRES driven primary translation of incoming genomes by transfection of a replication-deficient mutant replicon that bears an inactivation mutation in the catalytic site of NS5B RNA polymerase [56] .", [["HCV", "ORGANISM", 20, 23], ["IRES", "DNA", 24, 28], ["replication-deficient mutant replicon", "DNA", 97, 134], ["catalytic site", "DNA", 178, 192], ["NS5B RNA polymerase", "PROTEIN", 196, 215], ["HCV", "SPECIES", 20, 23], ["HCV", "PROBLEM", 20, 23], ["a replication-deficient mutant replicon", "TREATMENT", 95, 134], ["an inactivation mutation", "PROBLEM", 146, 170]]], ["Luciferase activity measured at 5 hours post-transfection was not reduced in any of the cell lines, indicating that transfection efficiency and HCV IRES-dependent primary translation was not significantly affected by lipin1 silencing (Fig 5B) .", [["cell lines", "ANATOMY", 88, 98], ["cell lines", "CELL", 88, 98], ["HCV", "ORGANISM", 144, 147], ["lipin1", "GENE_OR_GENE_PRODUCT", 217, 223], ["cell lines", "CELL_LINE", 88, 98], ["HCV IRES", "DNA", 144, 152], ["lipin1", "PROTEIN", 217, 223], ["HCV", "SPECIES", 144, 147], ["Luciferase activity", "TEST", 0, 19], ["transfection efficiency", "PROBLEM", 116, 139], ["HCV IRES", "PROBLEM", 144, 152], ["cell lines", "OBSERVATION", 88, 98], ["transfection efficiency", "OBSERVATION", 116, 139]]], ["A significant increase in Renilla luciferase activity was observed in shLPIN1-1 cells both when transfecting a replicon ( Fig 5B) or a plasmid expressing Renilla luciferase under a minimal RNA polymerase II promoter (S5A Fig), suggesting that the increase in luciferase activity observed in these cells is not related with HCV.", [["shLPIN1-1 cells", "ANATOMY", 70, 85], ["plasmid", "ANATOMY", 135, 142], ["cells", "ANATOMY", 297, 302], ["Renilla", "ORGANISM", 26, 33], ["luciferase", "GENE_OR_GENE_PRODUCT", 34, 44], ["shLPIN1-1 cells", "CELL", 70, 85], ["Renilla", "GENE_OR_GENE_PRODUCT", 154, 161], ["luciferase", "GENE_OR_GENE_PRODUCT", 162, 172], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 189, 206], ["S5A", "GENE_OR_GENE_PRODUCT", 217, 220], ["luciferase", "GENE_OR_GENE_PRODUCT", 259, 269], ["cells", "CELL", 297, 302], ["HCV", "ORGANISM", 323, 326], ["luciferase", "PROTEIN", 34, 44], ["shLPIN1-1 cells", "CELL_LINE", 70, 85], ["plasmid", "DNA", 135, 142], ["Renilla luciferase", "DNA", 154, 172], ["minimal RNA polymerase II promoter", "DNA", 181, 215], ["luciferase", "PROTEIN", 259, 269], ["HCV", "SPECIES", 323, 326], ["A significant increase in Renilla luciferase activity", "PROBLEM", 0, 53], ["a replicon ( Fig 5B", "TREATMENT", 109, 128], ["a plasmid expressing Renilla luciferase", "TREATMENT", 133, 172], ["a minimal RNA polymerase II promoter (S5A Fig", "TREATMENT", 179, 224], ["the increase in luciferase activity", "PROBLEM", 243, 278], ["HCV", "PROBLEM", 323, 326], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["Renilla luciferase activity", "OBSERVATION", 26, 53], ["Renilla luciferase", "OBSERVATION", 154, 172], ["increase", "OBSERVATION_MODIFIER", 247, 255], ["luciferase activity", "OBSERVATION", 259, 278], ["not related with", "UNCERTAINTY", 306, 322]]], ["HCV RNA replication was evaluated by measuring accumulation of a reporter luciferase gene at 5 and 48 hours post-transfection of a replication competent HCV subgenomic replicon.", [["HCV", "ORGANISM", 0, 3], ["luciferase", "GENE_OR_GENE_PRODUCT", 74, 84], ["HCV", "ORGANISM", 153, 156], ["HCV RNA", "RNA", 0, 7], ["reporter luciferase gene", "DNA", 65, 89], ["replication competent HCV subgenomic replicon", "DNA", 131, 176], ["HCV", "SPECIES", 0, 3], ["HCV", "SPECIES", 153, 156], ["HCV RNA replication", "TREATMENT", 0, 19], ["a reporter luciferase gene", "TREATMENT", 63, 89], ["a replication competent HCV subgenomic replicon", "TREATMENT", 129, 176], ["HCV subgenomic replicon", "OBSERVATION", 153, 176]]], ["Under these experimental conditions luciferase accumulation at 5 hours also represents HCV IRES-driven primary translation of the input RNA, while reporter luciferase activity at 48 hours depends on effective HCV RNA replication.", [["luciferase", "GENE_OR_GENE_PRODUCT", 36, 46], ["HCV", "ORGANISM", 87, 90], ["luciferase", "GENE_OR_GENE_PRODUCT", 156, 166], ["luciferase", "PROTEIN", 36, 46], ["HCV IRES", "DNA", 87, 95], ["input RNA", "RNA", 130, 139], ["luciferase", "PROTEIN", 156, 166], ["HCV RNA", "RNA", 209, 216], ["HCV", "SPECIES", 87, 90], ["HCV", "SPECIES", 209, 212], ["luciferase accumulation", "PROBLEM", 36, 59], ["HCV IRES", "PROBLEM", 87, 95], ["the input RNA", "TREATMENT", 126, 139], ["effective HCV RNA replication", "TREATMENT", 199, 228]]], ["In contrast to primary translation, HCV RNA replication inferred by luciferase activity at 48 hours was strongly reduced in lipin1-deficient cells (90% in shLPIN1-1 and 99% in shLPIN1-2 cells) (Fig 5C) , indicating that initiation of HCV replication is dependent on normal lipin1 expression.", [["lipin1-deficient cells", "ANATOMY", 124, 146], ["shLPIN1-1", "ANATOMY", 155, 164], ["shLPIN1-2 cells", "ANATOMY", 176, 191], ["HCV", "ORGANISM", 36, 39], ["luciferase", "GENE_OR_GENE_PRODUCT", 68, 78], ["lipin1", "GENE_OR_GENE_PRODUCT", 124, 130], ["cells", "CELL", 141, 146], ["shLPIN1-1", "GENE_OR_GENE_PRODUCT", 155, 164], ["shLPIN1-2 cells", "CELL", 176, 191], ["HCV", "ORGANISM", 234, 237], ["lipin1", "GENE_OR_GENE_PRODUCT", 273, 279], ["HCV RNA", "RNA", 36, 43], ["luciferase", "PROTEIN", 68, 78], ["lipin1-deficient cells", "CELL_LINE", 124, 146], ["shLPIN1", "PROTEIN", 155, 162], ["lipin1", "PROTEIN", 273, 279], ["HCV", "SPECIES", 36, 39], ["HCV", "SPECIES", 234, 237], ["HCV RNA replication", "TREATMENT", 36, 55], ["luciferase activity", "TEST", 68, 87], ["lipin1", "TEST", 124, 130], ["deficient cells", "PROBLEM", 131, 146], ["shLPIN1", "TEST", 155, 162], ["shLPIN1", "TEST", 176, 183], ["HCV replication", "PROBLEM", 234, 249], ["HCV", "OBSERVATION", 234, 237]]], ["This reduction was not due to a non-specific defect in luciferase expression, as co-transfection of a plasmid expressing Renilla luciferase lead to comparable luciferase accumulation in all cell lines, discarding the possibility that death of transfected cells or other spurious effects are responsible for the reduced luciferase activity accumulation (S5A Fig) .", [["plasmid", "ANATOMY", 102, 109], ["cell lines", "ANATOMY", 190, 200], ["cells", "ANATOMY", 255, 260], ["death", "DISEASE", 234, 239], ["luciferase", "GENE_OR_GENE_PRODUCT", 55, 65], ["Renilla", "ORGANISM", 121, 128], ["luciferase", "GENE_OR_GENE_PRODUCT", 129, 139], ["luciferase", "GENE_OR_GENE_PRODUCT", 159, 169], ["cell lines", "CELL", 190, 200], ["cells", "CELL", 255, 260], ["luciferase", "GENE_OR_GENE_PRODUCT", 319, 329], ["luciferase", "PROTEIN", 55, 65], ["plasmid", "DNA", 102, 109], ["luciferase", "PROTEIN", 129, 139], ["luciferase", "PROTEIN", 159, 169], ["cell lines", "CELL_LINE", 190, 200], ["transfected cells", "CELL_LINE", 243, 260], ["luciferase", "PROTEIN", 319, 329], ["a non-specific defect in luciferase expression", "PROBLEM", 30, 76], ["a plasmid expressing Renilla luciferase", "TREATMENT", 100, 139], ["comparable luciferase accumulation", "PROBLEM", 148, 182], ["all cell lines", "TREATMENT", 186, 200], ["transfected cells", "PROBLEM", 243, 260], ["other spurious effects", "PROBLEM", 264, 286], ["the reduced luciferase activity accumulation", "PROBLEM", 307, 351], ["not due to", "UNCERTAINTY", 19, 29], ["non-specific", "OBSERVATION_MODIFIER", 32, 44], ["defect", "OBSERVATION", 45, 51], ["luciferase expression", "OBSERVATION", 55, 76], ["Renilla luciferase", "OBSERVATION", 121, 139], ["luciferase accumulation", "OBSERVATION", 159, 182], ["all cell lines", "OBSERVATION", 186, 200], ["transfected cells", "OBSERVATION", 243, 260], ["reduced", "OBSERVATION_MODIFIER", 311, 318], ["luciferase activity", "OBSERVATION", 319, 338]]], ["Similar experiments were conducted in ATG4B-deficient cells, as this host factor was shown to be limiting for primary HCV translation [57] .", [["ATG4B-deficient cells", "ANATOMY", 38, 59], ["ATG4B", "GENE_OR_GENE_PRODUCT", 38, 43], ["cells", "CELL", 54, 59], ["HCV", "ORGANISM", 118, 121], ["ATG4B-deficient cells", "CELL_LINE", 38, 59], ["HCV", "SPECIES", 118, 121], ["deficient cells", "PROBLEM", 44, 59], ["primary HCV translation", "PROBLEM", 110, 133]]], ["Our studies confirmed that, while partial ATG4B silencing (S5B Fig Overall, these data indicate that HCV RNA replication is not initiated efficiently in lipin1-deficient cells and that blockade occurs at a step downstream translation of incoming HCV genomes.Lipin1 phosphatidate phosphatase activity is required to support HCV infectionIn order to determine if any of the known functions ascribed to lipin1 is required for HCV infection, we tested the ability to restore HCV infection susceptibility of silencing-resistant wild-type (wt) or mutant lipin1 versions bearing a mutation in the catalytic site responsible for its phosphatase activity (DXDXT) and a mutant in the LXXIL motif, which is inactive both for transcriptional activation as well as for phosphatase activity [31] .", [["lipin1-deficient cells", "ANATOMY", 153, 175], ["HCV infection", "DISEASE", 323, 336], ["lipin1", "CHEMICAL", 400, 406], ["HCV infection", "DISEASE", 423, 436], ["HCV infection", "DISEASE", 471, 484], ["ATG4B", "GENE_OR_GENE_PRODUCT", 42, 47], ["HCV", "ORGANISM", 101, 104], ["lipin1", "GENE_OR_GENE_PRODUCT", 153, 159], ["cells", "CELL", 170, 175], ["HCV", "ORGANISM", 246, 249], ["Lipin1", "GENE_OR_GENE_PRODUCT", 258, 264], ["HCV", "ORGANISM", 323, 326], ["lipin1", "GENE_OR_GENE_PRODUCT", 400, 406], ["HCV", "ORGANISM", 423, 426], ["HCV", "ORGANISM", 471, 474], ["lipin1", "GENE_OR_GENE_PRODUCT", 548, 554], ["LXXIL", "GENE_OR_GENE_PRODUCT", 674, 679], ["ATG4B", "PROTEIN", 42, 47], ["lipin1-deficient cells", "CELL_LINE", 153, 175], ["HCV genomes", "DNA", 246, 257], ["Lipin1 phosphatidate phosphatase", "PROTEIN", 258, 290], ["lipin1", "PROTEIN", 400, 406], ["mutant lipin1 versions", "PROTEIN", 541, 563], ["catalytic site", "PROTEIN", 590, 604], ["phosphatase", "PROTEIN", 625, 636], ["DXDXT", "PROTEIN", 647, 652], ["LXXIL motif", "PROTEIN", 674, 685], ["phosphatase", "PROTEIN", 756, 767], ["HCV", "SPECIES", 101, 104], ["HCV", "SPECIES", 246, 249], ["HCV", "SPECIES", 323, 326], ["HCV", "SPECIES", 423, 426], ["HCV", "SPECIES", 471, 474], ["Our studies", "TEST", 0, 11], ["partial ATG4B silencing", "PROBLEM", 34, 57], ["these data", "TEST", 76, 86], ["HCV RNA replication", "PROBLEM", 101, 120], ["deficient cells", "PROBLEM", 160, 175], ["blockade", "TREATMENT", 185, 193], ["incoming HCV genomes", "PROBLEM", 237, 257], ["Lipin1 phosphatidate phosphatase activity", "TREATMENT", 258, 299], ["HCV infection", "PROBLEM", 323, 336], ["lipin1", "TREATMENT", 400, 406], ["HCV infection", "PROBLEM", 423, 436], ["HCV infection susceptibility of silencing", "PROBLEM", 471, 512], ["mutant lipin1 versions", "TREATMENT", 541, 563], ["a mutation in the catalytic site", "PROBLEM", 572, 604], ["its phosphatase activity", "PROBLEM", 621, 645], ["the LXXIL motif", "TREATMENT", 670, 685], ["phosphatase activity", "TEST", 756, 776], ["HCV genomes", "OBSERVATION", 246, 257], ["infection", "OBSERVATION", 327, 336]]], ["Control and lipin1-deficient cells were transfected with wt lipin1 beta cDNA as well as with DXDXT and LXXIL mutants.", [["lipin1-deficient cells", "ANATOMY", 12, 34], ["lipin1", "GENE_OR_GENE_PRODUCT", 12, 18], ["cells", "CELL", 29, 34], ["lipin1 beta", "GENE_OR_GENE_PRODUCT", 60, 71], ["DXDXT", "GENE_OR_GENE_PRODUCT", 93, 98], ["LXXIL", "GENE_OR_GENE_PRODUCT", 103, 108], ["lipin1-deficient cells", "CELL_LINE", 12, 34], ["lipin1 beta cDNA", "DNA", 60, 76], ["DXDXT", "PROTEIN", 93, 98], ["LXXIL mutants", "PROTEIN", 103, 116], ["lipin1-deficient cells", "TREATMENT", 12, 34], ["wt lipin1 beta cDNA", "TREATMENT", 57, 76], ["DXDXT", "TREATMENT", 93, 98], ["LXXIL mutants", "TREATMENT", 103, 116]]], ["Comparable overexpression levels of the wt and mutant proteins was obtained in each cell line, although overexpressed lipin1 levels were consistently higher in lipin1-deficient cells (Fig 6A) .", [["cell line", "ANATOMY", 84, 93], ["lipin1-deficient cells", "ANATOMY", 160, 182], ["cell line", "CELL", 84, 93], ["lipin1", "GENE_OR_GENE_PRODUCT", 118, 124], ["lipin1", "GENE_OR_GENE_PRODUCT", 160, 166], ["cells", "CELL", 177, 182], ["mutant proteins", "PROTEIN", 47, 62], ["lipin1", "PROTEIN", 118, 124], ["lipin1-deficient cells", "CELL_LINE", 160, 182], ["the wt", "TEST", 36, 42], ["mutant proteins", "PROBLEM", 47, 62], ["overexpressed lipin1 levels", "TEST", 104, 131], ["deficient cells", "PROBLEM", 167, 182], ["cell line", "OBSERVATION", 84, 93]]], ["Cells were subsequently inoculated with HCV D183 at MOI 10 and relative infection efficiency was calculated by determining extracellular infectivity titers 48 hours post-infection.", [["Cells", "ANATOMY", 0, 5], ["extracellular", "ANATOMY", 123, 136], ["infection", "DISEASE", 72, 81], ["Cells", "CELL", 0, 5], ["HCV", "ORGANISM", 40, 43], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 123, 136], ["HCV", "SPECIES", 40, 43], ["HCV", "TEST", 40, 43], ["relative infection efficiency", "PROBLEM", 63, 92], ["extracellular infectivity titers", "PROBLEM", 123, 155], ["infection efficiency", "OBSERVATION", 72, 92]]], ["Overexpression of wt lipin1 did not significantly alter susceptibility to HCV infection in control cells, although we observed a small but consistent reduction in extracellular infectivity titers when overexpressing wt and mutant lipin1 constructs (S6A Fig Using relative infection efficiency as readout of this set of experiments, we could clearly observe a statistically significant increase (2-fold) in the relative infection susceptibility in cells overexpressing wt lipin1 cDNA as compared with mock-transfected cells or cells expressing similar or higher levels of the mutants (Fig 6A) , suggesting that wt lipin1 modestly, though significantly, rescues HCV infection while phosphatase (DXDXT) and transcriptional coactivation (LXXIL) mutants do not ( Fig 6B) .", [["cells", "ANATOMY", 99, 104], ["extracellular", "ANATOMY", 163, 176], ["cells", "ANATOMY", 447, 452], ["cells", "ANATOMY", 517, 522], ["cells", "ANATOMY", 526, 531], ["HCV infection", "DISEASE", 74, 87], ["infection", "DISEASE", 419, 428], ["HCV infection", "DISEASE", 660, 673], ["lipin1", "GENE_OR_GENE_PRODUCT", 21, 27], ["HCV", "ORGANISM", 74, 77], ["cells", "CELL", 99, 104], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 163, 176], ["lipin1", "GENE_OR_GENE_PRODUCT", 230, 236], ["cells", "CELL", 447, 452], ["lipin1", "GENE_OR_GENE_PRODUCT", 471, 477], ["cells", "CELL", 517, 522], ["cells", "CELL", 526, 531], ["lipin1", "GENE_OR_GENE_PRODUCT", 613, 619], ["HCV", "ORGANISM", 660, 663], ["DXDXT", "GENE_OR_GENE_PRODUCT", 693, 698], ["LXXIL", "GENE_OR_GENE_PRODUCT", 734, 739], ["wt lipin1", "PROTEIN", 18, 27], ["control cells", "CELL_TYPE", 91, 104], ["mutant lipin1 constructs", "DNA", 223, 247], ["lipin1 cDNA", "DNA", 471, 482], ["mock-transfected cells", "CELL_LINE", 500, 522], ["lipin1", "PROTEIN", 613, 619], ["phosphatase", "PROTEIN", 680, 691], ["DXDXT", "PROTEIN", 693, 698], ["transcriptional coactivation (LXXIL) mutants", "PROTEIN", 704, 748], ["HCV", "SPECIES", 74, 77], ["HCV", "SPECIES", 660, 663], ["Overexpression of wt lipin1", "PROBLEM", 0, 27], ["HCV infection in control cells", "PROBLEM", 74, 104], ["extracellular infectivity titers", "PROBLEM", 163, 195], ["mutant lipin1 constructs (S6A Fig", "TREATMENT", 223, 256], ["relative infection efficiency", "PROBLEM", 263, 292], ["a statistically significant increase (2-fold)", "PROBLEM", 357, 402], ["the relative infection susceptibility in cells", "PROBLEM", 406, 452], ["wt lipin1 cDNA", "TREATMENT", 468, 482], ["wt lipin1", "PROBLEM", 610, 619], ["rescues HCV infection", "PROBLEM", 652, 673], ["phosphatase", "TEST", 680, 691], ["DXDXT", "TEST", 693, 698], ["transcriptional coactivation (LXXIL) mutants", "TREATMENT", 704, 748], ["HCV", "OBSERVATION_MODIFIER", 74, 77], ["infection", "OBSERVATION", 78, 87], ["small", "OBSERVATION_MODIFIER", 129, 134], ["reduction", "OBSERVATION_MODIFIER", 150, 159], ["extracellular infectivity", "OBSERVATION", 163, 188], ["infection", "OBSERVATION", 272, 281], ["infection", "OBSERVATION", 419, 428]]], ["These results suggest that lipin1 transcriptional coactivation capacity is not sufficient to support HCV infection while lipin1 phosphatase activity is essential.", [["infection", "DISEASE", 105, 114], ["lipin1", "GENE_OR_GENE_PRODUCT", 27, 33], ["HCV", "ORGANISM", 101, 104], ["lipin1 phosphatase", "GENE_OR_GENE_PRODUCT", 121, 139], ["lipin1", "PROTEIN", 27, 33], ["lipin1 phosphatase", "PROTEIN", 121, 139], ["HCV", "SPECIES", 101, 104], ["lipin1 transcriptional coactivation capacity", "PROBLEM", 27, 71], ["HCV infection", "PROBLEM", 101, 114], ["lipin1 phosphatase activity", "TEST", 121, 148]]], ["However, given that LXXIL mutant is deficient both in transcriptional co-activation and PAP activity [31], we cannot determine if transcriptional co-activation by lipin1 is also required to support HCV infection.HCV replicase complex formation is reduced in lipin1-deficient cellsThe data described above suggest a role for lipin1 phosphatase activity in a step of HCV replication cycle between translation of the viral genome and formation of functional replicase complexes.", [["lipin1-deficient cells", "ANATOMY", 258, 280], ["HCV infection", "DISEASE", 198, 211], ["LXXIL", "GENE_OR_GENE_PRODUCT", 20, 25], ["PAP", "GENE_OR_GENE_PRODUCT", 88, 91], ["lipin1", "GENE_OR_GENE_PRODUCT", 163, 169], ["HCV", "ORGANISM", 198, 201], ["HCV", "ORGANISM", 212, 215], ["lipin1", "GENE_OR_GENE_PRODUCT", 258, 264], ["cells", "CELL", 275, 280], ["lipin1", "GENE_OR_GENE_PRODUCT", 324, 330], ["HCV", "ORGANISM", 365, 368], ["LXXIL mutant", "PROTEIN", 20, 32], ["PAP", "PROTEIN", 88, 91], ["lipin1", "PROTEIN", 163, 169], ["HCV replicase complex", "PROTEIN", 212, 233], ["lipin1-deficient cells", "CELL_LINE", 258, 280], ["lipin1 phosphatase", "PROTEIN", 324, 342], ["viral genome", "DNA", 414, 426], ["replicase complexes", "PROTEIN", 455, 474], ["HCV", "SPECIES", 198, 201], ["HCV", "SPECIES", 212, 215], ["HCV", "SPECIES", 365, 368], ["LXXIL mutant is deficient", "PROBLEM", 20, 45], ["PAP activity", "TEST", 88, 100], ["lipin1", "TREATMENT", 163, 169], ["HCV infection", "PROBLEM", 198, 211], ["HCV replicase complex formation", "PROBLEM", 212, 243], ["deficient cells", "PROBLEM", 265, 280], ["lipin1 phosphatase activity", "TREATMENT", 324, 351], ["HCV replication cycle", "TREATMENT", 365, 386], ["the viral genome", "PROBLEM", 410, 426], ["functional replicase complexes", "PROBLEM", 444, 474], ["infection", "OBSERVATION", 202, 211], ["complex", "OBSERVATION_MODIFIER", 226, 233], ["reduced", "OBSERVATION_MODIFIER", 247, 254], ["deficient cells", "OBSERVATION", 265, 280], ["viral genome", "OBSERVATION", 414, 426], ["functional replicase complexes", "OBSERVATION", 444, 474]]], ["Data regarding primary translation where inferred from a surrogate model of translation based on a reporter luciferase gene ( Fig 5B) .", [["luciferase", "GENE_OR_GENE_PRODUCT", 108, 118], ["reporter luciferase gene", "DNA", 99, 123]]], ["To address if indeed viral polyprotein is properly processed and inserted into detergent-resistant microdomains to form the characteristic membranous ultrastructures bearing the viral replicase, we used a replication-independent surrogate model of polyprotein expression.", [["microdomains", "ANATOMY", 99, 111], ["membranous ultrastructures", "ANATOMY", 139, 165], ["viral replicase", "PROTEIN", 178, 193], ["indeed viral polyprotein", "PROBLEM", 14, 38], ["detergent-resistant microdomains", "TREATMENT", 79, 111], ["the characteristic membranous ultrastructures bearing the viral replicase", "PROBLEM", 120, 193], ["a replication", "TREATMENT", 203, 216], ["resistant microdomains", "OBSERVATION", 89, 111], ["membranous", "OBSERVATION_MODIFIER", 139, 149], ["viral replicase", "OBSERVATION", 178, 193], ["polyprotein expression", "OBSERVATION", 248, 270]]], ["This system is based on a vector encoding the portion of the viral polyprotein corresponding to the replicase (NS3-NS5B) under the transcriptional control of the T7 polymerase and the translational control of encephalomyocarditis virus (EMCV) IRES (pTM-NS3/5B) [58] .", [["NS3-NS5B", "GENE_OR_GENE_PRODUCT", 111, 119], ["T7 polymerase", "GENE_OR_GENE_PRODUCT", 162, 175], ["encephalomyocarditis virus", "ORGANISM", 209, 235], ["EMCV", "ORGANISM", 237, 241], ["pTM-NS3/5B", "GENE_OR_GENE_PRODUCT", 249, 259], ["replicase", "PROTEIN", 100, 109], ["NS3", "PROTEIN", 111, 114], ["NS5B", "PROTEIN", 115, 119], ["T7 polymerase", "PROTEIN", 162, 175], ["encephalomyocarditis virus (EMCV) IRES", "DNA", 209, 247], ["pTM", "PROTEIN", 249, 252], ["NS3", "PROTEIN", 253, 256], ["encephalomyocarditis virus", "SPECIES", 209, 235], ["encephalomyocarditis virus", "SPECIES", 209, 235], ["EMCV", "SPECIES", 237, 241], ["a vector", "TREATMENT", 24, 32], ["the viral polyprotein", "PROBLEM", 57, 78], ["the replicase", "TREATMENT", 96, 109], ["NS3-NS5B", "TREATMENT", 111, 119], ["the T7 polymerase", "TREATMENT", 158, 175], ["encephalomyocarditis virus", "PROBLEM", 209, 235], ["viral polyprotein", "OBSERVATION", 61, 78], ["T7", "ANATOMY", 162, 164], ["encephalomyocarditis virus", "OBSERVATION", 209, 235]]], ["Replication-independent polyprotein overexpression Control and silenced cells were inoculated with HCV E1E2 (HCV pp ) or VSV-G-pseudotyped retroviral vectors (VSV pp ) 7 days post-transduction.", [["cells", "ANATOMY", 72, 77], ["cells", "CELL", 72, 77], ["HCV E1E2", "ORGANISM", 99, 107], ["HCV pp )", "ORGANISM", 109, 117], ["VSV-G-pseudotyped", "ORGANISM", 121, 138], ["retroviral", "ORGANISM", 139, 149], ["VSV", "ORGANISM", 159, 162], ["silenced cells", "CELL_LINE", 63, 77], ["HCV", "SPECIES", 99, 102], ["HCV", "SPECIES", 109, 112], ["VSV", "SPECIES", 159, 162], ["Replication", "TREATMENT", 0, 11], ["independent polyprotein overexpression Control", "TREATMENT", 12, 58], ["silenced cells", "PROBLEM", 63, 77], ["HCV", "PROBLEM", 99, 102], ["HCV pp", "TREATMENT", 109, 115], ["VSV", "TREATMENT", 121, 124], ["G-pseudotyped retroviral vectors", "TREATMENT", 125, 157]]], ["Control cells treated with hydroxyzine (5\u03bcM) were used as positive inhibition control.", [["cells", "ANATOMY", 8, 13], ["hydroxyzine", "CHEMICAL", 27, 38], ["hydroxyzine", "CHEMICAL", 27, 38], ["cells", "CELL", 8, 13], ["hydroxyzine", "SIMPLE_CHEMICAL", 27, 38], ["hydroxyzine", "TREATMENT", 27, 38], ["positive inhibition control", "TREATMENT", 58, 85]]], ["Luciferase activity was determined in the different cell lines at 48 hours post-inoculation.", [["cell lines", "ANATOMY", 52, 62], ["cell lines", "CELL", 52, 62], ["cell lines", "CELL_LINE", 52, 62], ["different cell lines", "OBSERVATION", 42, 62]]], ["HDX, hydroxyzine pamoate (5\u03bcM).", [["HDX", "CHEMICAL", 0, 3], ["hydroxyzine pamoate", "CHEMICAL", 5, 24], ["HDX", "CHEMICAL", 0, 3], ["hydroxyzine pamoate", "CHEMICAL", 5, 24], ["HDX", "SIMPLE_CHEMICAL", 0, 3], ["hydroxyzine pamoate", "SIMPLE_CHEMICAL", 5, 24], ["HDX", "TREATMENT", 0, 3], ["hydroxyzine pamoate", "TREATMENT", 5, 24]]], ["Panels B, C-Control and lipin1-deficient cells were transfected with a replication-deficient mutant (B) or replication competent subgenomic HCV replicon bearing a luciferase gene (C).", [["lipin1-deficient cells", "ANATOMY", 24, 46], ["Panels B", "CELL", 0, 8], ["lipin1", "GENE_OR_GENE_PRODUCT", 24, 30], ["cells", "CELL", 41, 46], ["B", "GENE_OR_GENE_PRODUCT", 101, 102], ["HCV", "ORGANISM", 140, 143], ["luciferase", "GENE_OR_GENE_PRODUCT", 163, 173], ["Panels B, C-Control and lipin1-deficient cells", "CELL_LINE", 0, 46], ["luciferase gene", "DNA", 163, 178], ["HCV", "SPECIES", 140, 143], ["Panels", "TEST", 0, 6], ["C", "TEST", 10, 11], ["lipin1-deficient cells", "TREATMENT", 24, 46], ["deficient mutant (B)", "PROBLEM", 83, 103], ["replication competent subgenomic HCV replicon", "TREATMENT", 107, 152], ["subgenomic HCV", "OBSERVATION", 129, 143]]], ["Luciferase activity was determined in the different cell lines at 5 hours post-transfection for both replicons and 48 hours post-transfection for the replication-competent replicon RNA.", [["cell lines", "ANATOMY", 52, 62], ["cell lines", "CELL", 52, 62], ["cell lines", "CELL_LINE", 52, 62], ["replication-competent replicon RNA", "RNA", 150, 184], ["Luciferase activity", "PROBLEM", 0, 19], ["the different cell lines", "TREATMENT", 38, 62], ["both replicons", "TREATMENT", 96, 110], ["transfection", "TREATMENT", 129, 141], ["the replication", "TREATMENT", 146, 161], ["cell lines", "OBSERVATION", 52, 62], ["replicon RNA", "OBSERVATION", 172, 184]]], ["Statistical significance was determined using Student\u00b4s t-test ( \u00c3 p<0.05; \u00c3\u00c3 p<0.01).HCV replicase complex formation is reduced in lipin1-deficient cellshttps://doi.org/10.1371/journal.ppat.1007284.g005 systems enable assessment of polyprotein processing as well as studying the formation of virus-derived membranous structures [16, 59] .HCV replicase complex formation is reduced in lipin1-deficient cellsControl and lipin1-deficient cells were infected with a recombinant vaccinia virus expressing T7 RNA polymerase (VacT7) and subsequently transfected with the plasmid pTM-NS3/5B to enable viral replicase expression.", [["membranous structures", "ANATOMY", 307, 328], ["lipin1-deficient cells", "ANATOMY", 385, 407], ["lipin1-deficient cells", "ANATOMY", 419, 441], ["HCV", "ORGANISM", 86, 89], ["membranous structures", "MULTI-TISSUE_STRUCTURE", 307, 328], ["HCV", "ORGANISM", 339, 342], ["lipin1", "GENE_OR_GENE_PRODUCT", 385, 391], ["cells", "CELL", 402, 407], ["lipin1", "GENE_OR_GENE_PRODUCT", 419, 425], ["cells", "CELL", 436, 441], ["vaccinia virus", "ORGANISM", 475, 489], ["VacT7", "GENE_OR_GENE_PRODUCT", 520, 525], ["pTM-NS3/5B", "GENE_OR_GENE_PRODUCT", 573, 583], ["HCV replicase complex", "PROTEIN", 86, 107], ["lipin1", "PROTEIN", 132, 138], ["HCV replicase complex", "PROTEIN", 339, 360], ["lipin1-deficient cells", "CELL_LINE", 385, 407], ["lipin1-deficient cells", "CELL_LINE", 419, 441], ["T7 RNA polymerase", "PROTEIN", 501, 518], ["VacT7", "PROTEIN", 520, 525], ["pTM", "PROTEIN", 573, 576], ["NS3", "PROTEIN", 577, 580], ["HCV", "SPECIES", 86, 89], ["HCV", "SPECIES", 339, 342], ["vaccinia virus", "SPECIES", 475, 489], ["Student\u00b4s t-test", "TEST", 46, 62], ["p", "TEST", 67, 68], ["HCV replicase complex formation", "PROBLEM", 86, 117], ["polyprotein processing", "TREATMENT", 233, 255], ["virus", "PROBLEM", 293, 298], ["HCV replicase complex formation", "PROBLEM", 339, 370], ["deficient cells", "PROBLEM", 392, 407], ["lipin1", "TREATMENT", 419, 425], ["deficient cells", "PROBLEM", 426, 441], ["a recombinant vaccinia virus", "TREATMENT", 461, 489], ["the plasmid pTM", "TREATMENT", 561, 576], ["NS3/5B", "TREATMENT", 577, 583], ["complex", "OBSERVATION_MODIFIER", 100, 107], ["reduced", "OBSERVATION_MODIFIER", 121, 128], ["virus", "OBSERVATION", 293, 298], ["complex", "OBSERVATION_MODIFIER", 353, 360], ["reduced", "OBSERVATION_MODIFIER", 374, 381], ["deficient cells", "OBSERVATION", 392, 407], ["viral replicase", "OBSERVATION", 594, 609]]], ["Sixteen hours post-transfection, cells were processed for Lipin1 is required for HCV replicase formation Western-Blot using anti-NS3.", [["cells", "ANATOMY", 33, 38], ["cells", "CELL", 33, 38], ["Lipin1", "GENE_OR_GENE_PRODUCT", 58, 64], ["HCV", "ORGANISM", 81, 84], ["anti-NS3", "GENE_OR_GENE_PRODUCT", 124, 132], ["Lipin1", "PROTEIN", 58, 64], ["NS3", "PROTEIN", 129, 132], ["HCV", "SPECIES", 81, 84], ["Lipin1", "TREATMENT", 58, 64], ["HCV replicase formation", "TREATMENT", 81, 104], ["anti-NS3", "TREATMENT", 124, 132]]], ["Accumulation of NS3 is comparable in control and both lipin1deficient cells, underscoring the notion that lipin1 is not limiting for polyprotein translation and processing (Fig 7A) .", [["lipin1deficient cells", "ANATOMY", 54, 75], ["NS3", "GENE_OR_GENE_PRODUCT", 16, 19], ["lipin1deficient cells", "CELL", 54, 75], ["lipin1", "GENE_OR_GENE_PRODUCT", 106, 112], ["NS3", "PROTEIN", 16, 19], ["lipin1deficient cells", "CELL_LINE", 54, 75], ["lipin1", "PROTEIN", 106, 112], ["NS3", "PROBLEM", 16, 19], ["lipin1", "TREATMENT", 106, 112], ["polyprotein translation", "TREATMENT", 133, 156], ["NS3", "OBSERVATION", 16, 19], ["lipin1deficient cells", "OBSERVATION", 54, 75]]], ["Similarly, NS3 and NS5A expression and subcellular distribution was similar in all cell lines (Fig 7B) .", [["subcellular", "ANATOMY", 39, 50], ["cell lines", "ANATOMY", 83, 93], ["NS3", "GENE_OR_GENE_PRODUCT", 11, 14], ["NS5A", "GENE_OR_GENE_PRODUCT", 19, 23], ["cell lines", "CELL", 83, 93], ["Fig 7B", "CELL", 95, 101], ["NS3", "PROTEIN", 11, 14], ["NS5A", "PROTEIN", 19, 23], ["cell lines", "CELL_LINE", 83, 93], ["NS3", "TREATMENT", 11, 14], ["NS5A expression", "TREATMENT", 19, 34], ["NS3", "OBSERVATION", 11, 14], ["NS5A expression", "OBSERVATION", 19, 34], ["subcellular", "OBSERVATION_MODIFIER", 39, 50], ["distribution", "OBSERVATION_MODIFIER", 51, 63], ["similar", "OBSERVATION_MODIFIER", 68, 75], ["all cell lines", "OBSERVATION", 79, 93]]], ["These results suggest that there are no major differences in accumulation of viral proteins in lipin1-deficient cells and that a step downstream is affected in these cells.HCV replicase complex formation is reduced in lipin1-deficient cellsTransmission electron microscopy (TEM) of ultrathin cell sections of cells expressing HCV replicase components shows the expected accumulation of a mixture of characteristic doublemembrane vesicles (DMV) as well as multiple membrane vesicles (MMV) (Fig 7D, 7E and 7F) that were not found in mock-transfected cells (Fig 7C) , as reported in previous studies using similar systems [16] .", [["lipin1-deficient cells", "ANATOMY", 95, 117], ["cells", "ANATOMY", 166, 171], ["lipin1-deficient cells", "ANATOMY", 218, 240], ["cell sections", "ANATOMY", 292, 305], ["cells", "ANATOMY", 309, 314], ["doublemembrane vesicles", "ANATOMY", 414, 437], ["membrane vesicles", "ANATOMY", 464, 481], ["MMV", "ANATOMY", 483, 486], ["cells", "ANATOMY", 548, 553], ["lipin1", "GENE_OR_GENE_PRODUCT", 95, 101], ["cells", "CELL", 112, 117], ["cells", "CELL", 166, 171], ["HCV", "ORGANISM", 172, 175], ["lipin1", "GENE_OR_GENE_PRODUCT", 218, 224], ["cells", "CELL", 235, 240], ["cells", "CELL", 309, 314], ["HCV", "ORGANISM", 326, 329], ["doublemembrane vesicles", "CELLULAR_COMPONENT", 414, 437], ["membrane vesicles", "CELLULAR_COMPONENT", 464, 481], ["cells", "CELL", 548, 553], ["Fig 7C", "CELL", 555, 561], ["viral proteins", "PROTEIN", 77, 91], ["lipin1-deficient cells", "CELL_LINE", 95, 117], ["HCV replicase complex", "PROTEIN", 172, 193], ["lipin1-deficient cells", "CELL_LINE", 218, 240], ["HCV replicase components", "PROTEIN", 326, 350], ["mock-transfected cells", "CELL_LINE", 531, 553], ["HCV", "SPECIES", 172, 175], ["HCV", "SPECIES", 326, 329], ["viral proteins", "PROBLEM", 77, 91], ["deficient cells", "PROBLEM", 102, 117], ["a step downstream", "PROBLEM", 127, 144], ["HCV replicase complex formation", "PROBLEM", 172, 203], ["deficient cells", "PROBLEM", 225, 240], ["Transmission electron microscopy", "TEST", 240, 272], ["ultrathin cell sections", "TEST", 282, 305], ["HCV replicase components", "PROBLEM", 326, 350], ["characteristic doublemembrane vesicles", "PROBLEM", 399, 437], ["multiple membrane vesicles", "PROBLEM", 455, 481], ["no major", "UNCERTAINTY", 37, 45], ["viral proteins", "OBSERVATION", 77, 91], ["deficient cells", "OBSERVATION", 102, 117], ["complex", "OBSERVATION_MODIFIER", 186, 193], ["reduced", "OBSERVATION_MODIFIER", 207, 214], ["deficient cells", "OBSERVATION", 225, 240], ["accumulation", "OBSERVATION_MODIFIER", 370, 382], ["doublemembrane vesicles", "OBSERVATION", 414, 437], ["multiple", "OBSERVATION_MODIFIER", 455, 463], ["membrane vesicles", "OBSERVATION", 464, 481]]], ["Individual vesicle diameter displays heterogeneous size distribution in which the predominant population is distributed between 125-150 nm (median 150 nm; average \u00b1 SD: 167 \u00b1 81 nm, n = 279) with larger vesicles being less predominant (Fig 7G and S7 Fig) .", [["vesicle", "ANATOMY", 11, 18], ["vesicles", "ANATOMY", 203, 211], ["vesicle", "CELLULAR_COMPONENT", 11, 18], ["vesicles", "CELLULAR_COMPONENT", 203, 211], ["heterogeneous size distribution", "PROBLEM", 37, 68], ["SD", "TEST", 165, 167], ["nm", "TEST", 178, 180], ["larger vesicles", "PROBLEM", 196, 211], ["Fig", "TEST", 236, 239], ["vesicle", "OBSERVATION_MODIFIER", 11, 18], ["diameter", "OBSERVATION_MODIFIER", 19, 27], ["heterogeneous", "OBSERVATION_MODIFIER", 37, 50], ["size", "OBSERVATION_MODIFIER", 51, 55], ["distribution", "OBSERVATION_MODIFIER", 56, 68], ["predominant", "OBSERVATION_MODIFIER", 82, 93], ["population", "OBSERVATION_MODIFIER", 94, 104], ["larger", "OBSERVATION_MODIFIER", 196, 202], ["vesicles", "OBSERVATION", 203, 211], ["less predominant", "OBSERVATION_MODIFIER", 218, 234]]], ["This size distribution is compatible with that observed similar replication-deficient systems and during HCV infection.", [["HCV infection", "DISEASE", 105, 118], ["HCV", "ORGANISM", 105, 108], ["HCV", "SPECIES", 105, 108], ["deficient systems", "PROBLEM", 76, 93], ["HCV infection", "PROBLEM", 105, 118], ["size", "OBSERVATION_MODIFIER", 5, 9], ["compatible with", "UNCERTAINTY", 26, 41], ["similar", "OBSERVATION_MODIFIER", 56, 63], ["replication", "OBSERVATION", 64, 75], ["HCV", "OBSERVATION_MODIFIER", 105, 108], ["infection", "OBSERVATION", 109, 118]]], ["Treatment of these cells with 100 nM daclatasvir (DCTV), resulted in a strong reduction in the number of vesicles per section area (S7B Fig) , without significantly altering the size distribution of the remaining vesicles (Fig 7G) , as reported by Berger et al. [59] .", [["cells", "ANATOMY", 19, 24], ["vesicles", "ANATOMY", 105, 113], ["section area", "ANATOMY", 118, 130], ["vesicles", "ANATOMY", 213, 221], ["daclatasvir", "CHEMICAL", 37, 48], ["DCTV", "CHEMICAL", 50, 54], ["daclatasvir", "CHEMICAL", 37, 48], ["DCTV", "CHEMICAL", 50, 54], ["cells", "CELL", 19, 24], ["daclatasvir", "SIMPLE_CHEMICAL", 37, 48], ["DCTV", "SIMPLE_CHEMICAL", 50, 54], ["vesicles", "CELLULAR_COMPONENT", 105, 113], ["vesicles", "CELLULAR_COMPONENT", 213, 221], ["these cells", "PROBLEM", 13, 24], ["100 nM daclatasvir (DCTV", "TREATMENT", 30, 54], ["a strong reduction", "PROBLEM", 69, 87], ["strong", "OBSERVATION_MODIFIER", 71, 77], ["reduction", "OBSERVATION_MODIFIER", 78, 87], ["number", "OBSERVATION_MODIFIER", 95, 101], ["without", "UNCERTAINTY", 143, 150], ["size", "OBSERVATION_MODIFIER", 178, 182], ["distribution", "OBSERVATION_MODIFIER", 183, 195], ["remaining vesicles", "ANATOMY", 203, 221]]], ["Similarly, the diameter distribution of the vesicles found in lipin1-deficient cells was comparable to that in control cells ( Fig 7G) .", [["vesicles", "ANATOMY", 44, 52], ["lipin1-deficient cells", "ANATOMY", 62, 84], ["cells", "ANATOMY", 119, 124], ["vesicles", "CELLULAR_COMPONENT", 44, 52], ["lipin1", "GENE_OR_GENE_PRODUCT", 62, 68], ["cells", "CELL", 79, 84], ["cells", "CELL", 119, 124], ["Fig 7G", "CELL", 127, 133], ["lipin1-deficient cells", "CELL_LINE", 62, 84], ["control cells", "CELL_TYPE", 111, 124], ["the vesicles", "PROBLEM", 40, 52], ["deficient cells", "PROBLEM", 69, 84], ["diameter", "OBSERVATION_MODIFIER", 15, 23], ["vesicles", "ANATOMY", 44, 52], ["deficient cells", "OBSERVATION", 69, 84]]], ["However, HCV-induced structures were significantly less abundant 16 hours post-transfection in lipin1-deficient cells than in controls cells (S7C Fig) .", [["lipin1-deficient cells", "ANATOMY", 95, 117], ["cells", "ANATOMY", 135, 140], ["HCV", "ORGANISM", 9, 12], ["lipin1", "GENE_OR_GENE_PRODUCT", 95, 101], ["cells", "CELL", 112, 117], ["cells", "CELL", 135, 140], ["S7C Fig", "CELL", 142, 149], ["lipin1-deficient cells", "CELL_LINE", 95, 117], ["controls cells", "CELL_TYPE", 126, 140], ["HCV", "SPECIES", 9, 12], ["HCV-induced structures", "PROBLEM", 9, 31], ["transfection in lipin1", "TEST", 79, 101], ["deficient cells", "PROBLEM", 102, 117], ["HCV", "OBSERVATION", 9, 12]]], ["This reduced abundance is illustrated by a significant reduction in the fraction of cells displaying vesicular structures in lipin1-deficient cell cultures (Fig 7H) despite comparable transfection efficiency and viral protein expression levels, indicating that lipin1 may be required in a critical step leading to formation of the HCV-induced vesicular compartment.HCV replicase complex formation is reduced in lipin1-deficient cellsTo validate the TEM results independently, we set out to establish a biochemical assay to evaluate replication-independent replicase complex formation.", [["cells", "ANATOMY", 84, 89], ["vesicular structures", "ANATOMY", 101, 121], ["cell cultures", "ANATOMY", 142, 155], ["vesicular compartment", "ANATOMY", 343, 364], ["lipin1-deficient cells", "ANATOMY", 411, 433], ["cells", "CELL", 84, 89], ["vesicular structures", "PATHOLOGICAL_FORMATION", 101, 121], ["lipin1", "GENE_OR_GENE_PRODUCT", 125, 131], ["cell cultures", "CELL", 142, 155], ["Fig 7H", "CELL", 157, 163], ["lipin1", "GENE_OR_GENE_PRODUCT", 261, 267], ["HCV", "ORGANISM", 331, 334], ["vesicular compartment", "MULTI-TISSUE_STRUCTURE", 343, 364], ["HCV", "ORGANISM", 365, 368], ["lipin1", "GENE_OR_GENE_PRODUCT", 411, 417], ["cells", "CELL", 428, 433], ["lipin1-deficient cell cultures", "CELL_LINE", 125, 155], ["lipin1", "PROTEIN", 261, 267], ["HCV replicase complex", "PROTEIN", 365, 386], ["lipin1-deficient cells", "CELL_LINE", 411, 433], ["replicase complex", "PROTEIN", 556, 573], ["HCV", "SPECIES", 331, 334], ["HCV", "SPECIES", 365, 368], ["a significant reduction", "PROBLEM", 41, 64], ["vesicular structures in lipin1-deficient cell cultures", "PROBLEM", 101, 155], ["comparable transfection efficiency", "PROBLEM", 173, 207], ["viral protein expression levels", "PROBLEM", 212, 243], ["lipin1", "TREATMENT", 261, 267], ["the HCV", "PROBLEM", 327, 334], ["HCV replicase complex formation", "PROBLEM", 365, 396], ["deficient cells", "PROBLEM", 418, 433], ["a biochemical assay", "TEST", 500, 519], ["reduced", "OBSERVATION_MODIFIER", 5, 12], ["abundance", "OBSERVATION", 13, 22], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["reduction", "OBSERVATION_MODIFIER", 55, 64], ["vesicular structures", "OBSERVATION", 101, 121], ["deficient cell cultures", "OBSERVATION", 132, 155], ["transfection efficiency", "OBSERVATION", 184, 207], ["viral protein expression", "OBSERVATION", 212, 236], ["HCV", "OBSERVATION", 331, 334], ["vesicular compartment", "ANATOMY", 343, 364], ["complex", "OBSERVATION_MODIFIER", 379, 386], ["reduced", "OBSERVATION_MODIFIER", 400, 407], ["deficient cells", "OBSERVATION", 418, 433]]], ["One of the characteristics of the HCV replicase complexes is that they are located in detergent-resistant membranes (DRM) [19, 20] .", [["membranes", "ANATOMY", 106, 115], ["HCV", "ORGANISM", 34, 37], ["membranes", "CELLULAR_COMPONENT", 106, 115], ["HCV replicase complexes", "PROTEIN", 34, 57], ["HCV", "SPECIES", 34, 37], ["the HCV replicase complexes", "PROBLEM", 30, 57], ["HCV", "OBSERVATION", 34, 37], ["replicase complexes", "OBSERVATION", 38, 57], ["resistant membranes", "OBSERVATION", 96, 115]]], ["In this sense, NS proteins are associated with replicase complexes that co-sediment with DRM markers such as caveolin-2 or sigma-1 receptor (SIGMAR1) in low-density fractions in isopycnic gradient ultracentrifugation experiments [19, 21] .", [["caveolin-2", "GENE_OR_GENE_PRODUCT", 109, 119], ["sigma-1 receptor", "GENE_OR_GENE_PRODUCT", 123, 139], ["SIGMAR1", "GENE_OR_GENE_PRODUCT", 141, 148], ["NS proteins", "PROTEIN", 15, 26], ["replicase complexes", "PROTEIN", 47, 66], ["DRM markers", "PROTEIN", 89, 100], ["caveolin-2 or sigma-1 receptor", "PROTEIN", 109, 139], ["SIGMAR1", "PROTEIN", 141, 148], ["NS proteins", "TREATMENT", 15, 26], ["replicase complexes", "PROBLEM", 47, 66], ["DRM markers", "TEST", 89, 100], ["caveolin", "TEST", 109, 117], ["low-density fractions", "PROBLEM", 153, 174], ["isopycnic gradient ultracentrifugation", "TREATMENT", 178, 216], ["low", "OBSERVATION_MODIFIER", 153, 156], ["density fractions", "OBSERVATION", 157, 174], ["isopycnic gradient", "OBSERVATION", 178, 196]]], ["Control and lipin1deficient cells were infected with VacT7 and subsequently transfected with limiting doses of the plasmid pTM-NS3/5B [16] .", [["lipin1deficient cells", "ANATOMY", 12, 33], ["plasmid", "ANATOMY", 115, 122], ["lipin1deficient cells", "CELL", 12, 33], ["VacT7", "GENE_OR_GENE_PRODUCT", 53, 58], ["lipin1deficient cells", "CELL_LINE", 12, 33], ["VacT7", "PROTEIN", 53, 58], ["pTM", "DNA", 123, 126], ["NS3", "PROTEIN", 127, 130], ["Control and lipin1deficient cells", "TREATMENT", 0, 33], ["VacT7", "TREATMENT", 53, 58], ["the plasmid pTM", "TREATMENT", 111, 126]]], ["Parallel samples were treated with DCTV (100 nM).", [["samples", "ANATOMY", 9, 16], ["DCTV", "CHEMICAL", 35, 39], ["DCTV", "CHEMICAL", 35, 39], ["DCTV", "SIMPLE_CHEMICAL", 35, 39], ["Parallel samples", "TEST", 0, 16], ["DCTV", "TREATMENT", 35, 39]]], ["Sixteen hours post-transfection, cell lysates were generated and subjected to equilibrium ultracentrifugation in 10-40% sucrose gradients.", [["cell lysates", "ANATOMY", 33, 45], ["sucrose", "CHEMICAL", 120, 127], ["sucrose", "CHEMICAL", 120, 127], ["cell lysates", "CELL", 33, 45], ["sucrose", "SIMPLE_CHEMICAL", 120, 127], ["cell lysates", "TEST", 33, 45], ["equilibrium ultracentrifugation", "TEST", 78, 109]]], ["Gradient fractions were collected and subjected to Western-Blot analysis to determine the impact of lipin1 silencing on NS3, SIGMAR1 and actin sedimentation profiles.", [["lipin1", "GENE_OR_GENE_PRODUCT", 100, 106], ["NS3", "GENE_OR_GENE_PRODUCT", 120, 123], ["SIGMAR1", "GENE_OR_GENE_PRODUCT", 125, 132], ["actin", "GENE_OR_GENE_PRODUCT", 137, 142], ["lipin1", "PROTEIN", 100, 106], ["NS3", "PROTEIN", 120, 123], ["SIGMAR1", "PROTEIN", 125, 132], ["actin", "PROTEIN", 137, 142], ["Gradient fractions", "TEST", 0, 18], ["Blot analysis", "TEST", 59, 72], ["lipin1 silencing", "TREATMENT", 100, 116], ["NS3", "TREATMENT", 120, 123], ["SIGMAR1", "TREATMENT", 125, 132], ["actin sedimentation profiles", "TEST", 137, 165]]], ["Fig 8A shows how, as previously shown for replicon and JFH1-infected cells, NS3 can be detected in DRM fractions (fractions 3-5), as determined by the presence of SIGMAR1 in those fractions (fractions 3-5; S8A Fig), although in this experimental system, unlike during viral infection [21] , most NS3 co-sediments together with solubilized proteins, as shown for actin (fractions 9-12; S8A Fig) .", [["cells", "ANATOMY", 69, 74], ["DRM fractions", "ANATOMY", 99, 112], ["viral infection", "DISEASE", 268, 283], ["JFH1", "ORGANISM", 55, 59], ["cells", "CELL", 69, 74], ["NS3", "GENE_OR_GENE_PRODUCT", 76, 79], ["SIGMAR1", "GENE_OR_GENE_PRODUCT", 163, 170], ["actin", "GENE_OR_GENE_PRODUCT", 362, 367], ["JFH1-infected cells", "CELL_LINE", 55, 74], ["NS3", "PROTEIN", 76, 79], ["SIGMAR1", "PROTEIN", 163, 170], ["NS3", "PROTEIN", 296, 299], ["solubilized proteins", "PROTEIN", 327, 347], ["actin", "PROTEIN", 362, 367], ["replicon", "TREATMENT", 42, 50], ["infected cells", "PROBLEM", 60, 74], ["NS3", "PROBLEM", 76, 79], ["SIGMAR1 in those fractions", "PROBLEM", 163, 189], ["viral infection", "PROBLEM", 268, 283], ["most NS3 co-sediments", "PROBLEM", 291, 312], ["solubilized proteins", "TEST", 327, 347], ["actin (fractions", "TEST", 362, 378], ["infected cells", "OBSERVATION", 60, 74]]], ["DRM-associated NS3 is reduced in DCTV-treated and lipin1-deficient cells, while total NS3 expression remains unchanged (Fig 8A) .", [["lipin1-deficient cells", "ANATOMY", 50, 72], ["DCTV", "CHEMICAL", 33, 37], ["DRM", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS3", "GENE_OR_GENE_PRODUCT", 15, 18], ["lipin1", "GENE_OR_GENE_PRODUCT", 50, 56], ["cells", "CELL", 67, 72], ["NS3", "GENE_OR_GENE_PRODUCT", 86, 89], ["DRM", "PROTEIN", 0, 3], ["NS3", "PROTEIN", 15, 18], ["DCTV-treated and lipin1-deficient cells", "CELL_LINE", 33, 72], ["NS3", "PROTEIN", 86, 89], ["DRM", "PROBLEM", 0, 3], ["NS3", "PROBLEM", 15, 18], ["DCTV", "TEST", 33, 37], ["lipin1", "TREATMENT", 50, 56], ["deficient cells", "PROBLEM", 57, 72], ["total NS3 expression", "TEST", 80, 100], ["NS3", "OBSERVATION", 15, 18], ["reduced", "OBSERVATION_MODIFIER", 22, 29], ["unchanged", "OBSERVATION_MODIFIER", 109, 118]]], ["Four independent experiments were performed in which relative-DRM associated NS3, normalized to that found in solubilized fractions, was calculated for each experimental condition (Fig 8B) .", [["NS3", "GENE_OR_GENE_PRODUCT", 77, 80], ["NS3", "PROTEIN", 77, 80], ["NS3", "PROBLEM", 77, 80]]], ["Lipin1-deficient cells display a consistent and statistically significant reduction in the DRMassociated, but not total NS3 abundance (Fig 8A and 8B; shLPIN1-1 and shLPIN1-2) , similar to that observed in control cells in the presence of DCTV (Figs 8A and 8B; shControl+DCTV) , consistent with the TEM data (Figs 7 and S7 ) and the notion that NS3 in DRM fractions may reflect the abundance of replicase complexes formed in these cells.", [["cells", "ANATOMY", 17, 22], ["cells", "ANATOMY", 213, 218], ["DRM fractions", "ANATOMY", 351, 364], ["cells", "ANATOMY", 430, 435], ["Lipin1", "GENE_OR_GENE_PRODUCT", 0, 6], ["cells", "CELL", 17, 22], ["shLPIN1-1", "GENE_OR_GENE_PRODUCT", 150, 159], ["shLPIN1-2", "GENE_OR_GENE_PRODUCT", 164, 173], ["cells", "CELL", 213, 218], ["shControl+DCTV", "GENE_OR_GENE_PRODUCT", 260, 274], ["NS3", "GENE_OR_GENE_PRODUCT", 344, 347], ["DRM", "GENE_OR_GENE_PRODUCT", 351, 354], ["cells", "CELL", 430, 435], ["Lipin1-deficient cells", "CELL_LINE", 0, 22], ["NS3", "PROTEIN", 120, 123], ["shLPIN1", "PROTEIN", 150, 157], ["shLPIN1", "PROTEIN", 164, 171], ["control cells", "CELL_TYPE", 205, 218], ["DCTV", "PROTEIN", 238, 242], ["shControl", "PROTEIN", 260, 269], ["DCTV", "PROTEIN", 270, 274], ["NS3", "PROTEIN", 344, 347], ["replicase complexes", "PROTEIN", 394, 413], ["Lipin1", "TREATMENT", 0, 6], ["deficient cells", "PROBLEM", 7, 22], ["statistically significant reduction in the DRMassociated", "PROBLEM", 48, 104], ["total NS3 abundance", "PROBLEM", 114, 133], ["Fig", "TEST", 135, 138], ["8B", "TEST", 146, 148], ["shLPIN1", "TEST", 150, 157], ["shLPIN1", "TEST", 164, 171], ["DCTV", "TEST", 238, 242], ["Figs", "TEST", 244, 248], ["the TEM data", "TEST", 294, 306], ["Figs", "TEST", 308, 312], ["NS3 in DRM fractions", "PROBLEM", 344, 364], ["replicase complexes formed in these cells", "PROBLEM", 394, 435], ["deficient cells", "OBSERVATION", 7, 22], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["reduction", "OBSERVATION", 74, 83], ["consistent with", "UNCERTAINTY", 278, 293], ["NS3", "OBSERVATION", 344, 347], ["DRM fractions", "OBSERVATION", 351, 364], ["replicase complexes", "OBSERVATION", 394, 413]]], ["This reduction is not due to an overall reduction in cellular DRM abundance in lipin1-deficient cells, as lipin1-deficient cells display similar SIGMAR1 distribution pattern as the control cells (S8 Fig).", [["cellular", "ANATOMY", 53, 61], ["lipin1-deficient cells", "ANATOMY", 79, 101], ["lipin1-deficient cells", "ANATOMY", 106, 128], ["cells", "ANATOMY", 189, 194], ["cellular", "CELL", 53, 61], ["lipin1", "GENE_OR_GENE_PRODUCT", 79, 85], ["cells", "CELL", 96, 101], ["lipin1", "GENE_OR_GENE_PRODUCT", 106, 112], ["cells", "CELL", 123, 128], ["SIGMAR1", "GENE_OR_GENE_PRODUCT", 145, 152], ["cells", "CELL", 189, 194], ["DRM", "PROTEIN", 62, 65], ["lipin1-deficient cells", "CELL_LINE", 79, 101], ["lipin1-deficient cells", "CELL_LINE", 106, 128], ["SIGMAR1", "PROTEIN", 145, 152], ["control cells", "CELL_TYPE", 181, 194], ["This reduction", "TREATMENT", 0, 14], ["an overall reduction in cellular DRM abundance", "PROBLEM", 29, 75], ["deficient cells", "PROBLEM", 86, 101], ["lipin1", "TEST", 106, 112], ["deficient cells", "PROBLEM", 113, 128], ["not due to", "UNCERTAINTY", 18, 28], ["overall", "OBSERVATION_MODIFIER", 32, 39], ["reduction", "OBSERVATION_MODIFIER", 40, 49], ["cellular DRM", "OBSERVATION", 53, 65], ["abundance", "OBSERVATION_MODIFIER", 66, 75], ["deficient cells", "OBSERVATION", 86, 101], ["similar", "OBSERVATION_MODIFIER", 137, 144], ["SIGMAR1 distribution", "OBSERVATION_MODIFIER", 145, 165]]], ["Overall, TEM data and DRM floatation assays strongly suggest that lipin1 is rate limiting for the generation of replicase complexes from fully processed polyprotein subunits.DiscussionHepatitis C virus replication cycle is tightly linked to host cell lipid metabolism and interference with cellular lipid homeostasis contributes to viral pathogenesis [3] .", [["cell", "ANATOMY", 246, 250], ["cellular", "ANATOMY", 290, 298], ["lipin1", "CHEMICAL", 66, 72], ["Hepatitis C", "DISEASE", 184, 195], ["lipin1", "SIMPLE_CHEMICAL", 66, 72], ["Hepatitis C virus", "ORGANISM", 184, 201], ["host cell", "CELL", 241, 250], ["cellular", "CELL", 290, 298], ["lipin1", "PROTEIN", 66, 72], ["replicase complexes", "PROTEIN", 112, 131], ["polyprotein subunits", "PROTEIN", 153, 173], ["Hepatitis C virus", "SPECIES", 184, 201], ["Hepatitis C virus", "SPECIES", 184, 201], ["TEM data", "TEST", 9, 17], ["DRM floatation assays", "TEST", 22, 43], ["lipin1", "TREATMENT", 66, 72], ["the generation of replicase complexes", "PROBLEM", 94, 131], ["Hepatitis C virus replication cycle", "TREATMENT", 184, 219], ["cellular lipid homeostasis", "TREATMENT", 290, 316], ["viral pathogenesis", "PROBLEM", 332, 350]]], ["One of the most evident consequences of this interference is the high prevalence of liver steatosis among chronically infected patients [13, 60] .", [["liver", "ANATOMY", 84, 89], ["liver steatosis", "DISEASE", 84, 99], ["chronically infected", "DISEASE", 106, 126], ["liver", "ORGAN", 84, 89], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["this interference", "PROBLEM", 40, 57], ["liver steatosis", "PROBLEM", 84, 99], ["most evident", "OBSERVATION_MODIFIER", 11, 23], ["liver", "ANATOMY", 84, 89], ["steatosis", "OBSERVATION", 90, 99], ["chronically", "OBSERVATION_MODIFIER", 106, 117], ["infected", "OBSERVATION", 118, 126]]], ["This clinical manifestation of the infection has been linked to, among others, chronic ER stress, mitochondrial dysfunction and metabolite depletion induced by HCV infection, which result in the activation of persistent homeostatic adaptation of the cellular lipid metabolism to permit cell survival, at the cost of pathogenic metabolic alterations [11, [61] [62] [63] [64] .DiscussionAmong the different regulatory networks that have been shown to be stimulated during HCV infection, PPAR\u03b1 [61] , PGC-1\u03b1 [65] , HIF-1 [66] and SREBP [46, 67] have also been shown to regulate transcription of LPIN1 mRNA [31, 45, 68, 69] .", [["mitochondrial", "ANATOMY", 98, 111], ["cellular", "ANATOMY", 250, 258], ["cell", "ANATOMY", 286, 290], ["infection", "DISEASE", 35, 44], ["mitochondrial dysfunction", "DISEASE", 98, 123], ["HCV infection", "DISEASE", 160, 173], ["HCV infection", "DISEASE", 470, 483], ["ER", "GENE_OR_GENE_PRODUCT", 87, 89], ["mitochondrial", "CELLULAR_COMPONENT", 98, 111], ["HCV", "ORGANISM", 160, 163], ["cellular", "CELL", 250, 258], ["cell", "CELL", 286, 290], ["HCV", "ORGANISM", 470, 473], ["PPAR\u03b1 [61]", "GENE_OR_GENE_PRODUCT", 485, 495], ["PGC-1", "GENE_OR_GENE_PRODUCT", 498, 503], ["HIF-1", "GENE_OR_GENE_PRODUCT", 512, 517], ["66", "GENE_OR_GENE_PRODUCT", 519, 521], ["SREBP [46, 67", "GENE_OR_GENE_PRODUCT", 527, 540], ["LPIN1", "GENE_OR_GENE_PRODUCT", 592, 597], ["PPAR\u03b1", "PROTEIN", 485, 490], ["HIF", "PROTEIN", 512, 515], ["SREBP", "PROTEIN", 527, 532], ["LPIN1 mRNA", "RNA", 592, 602], ["HCV", "SPECIES", 160, 163], ["HCV", "SPECIES", 470, 473], ["the infection", "PROBLEM", 31, 44], ["chronic ER stress", "PROBLEM", 79, 96], ["mitochondrial dysfunction", "PROBLEM", 98, 123], ["metabolite depletion", "PROBLEM", 128, 148], ["HCV infection", "PROBLEM", 160, 173], ["the cellular lipid metabolism", "PROBLEM", 246, 275], ["HCV infection", "PROBLEM", 470, 483], ["PPAR\u03b1", "TEST", 485, 490], ["PGC", "TEST", 498, 501], ["HIF", "TEST", 512, 515], ["SREBP", "TEST", 527, 532], ["mRNA", "TEST", 598, 602], ["infection", "OBSERVATION", 35, 44], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["mitochondrial dysfunction", "OBSERVATION", 98, 123], ["metabolite depletion", "OBSERVATION", 128, 148], ["HCV", "OBSERVATION_MODIFIER", 160, 163], ["infection", "OBSERVATION", 164, 173], ["persistent", "OBSERVATION_MODIFIER", 209, 219], ["homeostatic adaptation", "OBSERVATION", 220, 242], ["cellular lipid metabolism", "OBSERVATION", 250, 275]]], ["Thus, it is likely that stimulation of one or several of these regulatory networks by HCV infection results in the LPIN1 mRNA transcriptional activation observed in this ( Fig 1A) and other studies [40, 41] .", [["HCV infection", "DISEASE", 86, 99], ["HCV", "ORGANISM", 86, 89], ["LPIN1", "GENE_OR_GENE_PRODUCT", 115, 120], ["LPIN1 mRNA", "RNA", 115, 125], ["HCV", "SPECIES", 86, 89], ["HCV infection", "PROBLEM", 86, 99], ["the LPIN1 mRNA transcriptional activation", "PROBLEM", 111, 152], ["other studies", "TEST", 184, 197], ["is likely", "UNCERTAINTY", 9, 18]]], ["Importantly, prevention of LPIN1 mRNA accumulation with NAC ( Fig 1E) did not significantly interfere with HCV RNA replication (Fig 1F) , suggesting that enhanced LPIN1 mRNA accumulation is not required for efficient HCV infection.", [["NAC", "CHEMICAL", 56, 59], ["HCV infection", "DISEASE", 217, 230], ["NAC", "CHEMICAL", 56, 59], ["LPIN1", "GENE_OR_GENE_PRODUCT", 27, 32], ["NAC", "SIMPLE_CHEMICAL", 56, 59], ["LPIN1", "GENE_OR_GENE_PRODUCT", 163, 168], ["HCV", "ORGANISM", 217, 220], ["LPIN1 mRNA", "RNA", 27, 37], ["HCV RNA", "RNA", 107, 114], ["LPIN1 mRNA", "RNA", 163, 173], ["HCV", "SPECIES", 107, 110], ["HCV", "SPECIES", 217, 220], ["LPIN1 mRNA accumulation", "PROBLEM", 27, 50], ["NAC ( Fig 1E", "TREATMENT", 56, 68], ["HCV RNA replication", "TREATMENT", 107, 126], ["enhanced LPIN1 mRNA accumulation", "PROBLEM", 154, 186], ["efficient HCV infection", "PROBLEM", 207, 230], ["LPIN1 mRNA", "OBSERVATION", 27, 37], ["HCV", "OBSERVATION_MODIFIER", 217, 220], ["infection", "OBSERVATION", 221, 230]]], ["We favor the hypothesis that ROS induced by HCV protein accumulation actively participates in LPIN1 induction, as treatment with the antioxidant NAC prevented LPIN1 mRNA accumulation, similar to what has been shown for other SREBP-regulated genes during HCV infection [46] .", [["ROS", "CHEMICAL", 29, 32], ["NAC", "CHEMICAL", 145, 148], ["HCV infection", "DISEASE", 254, 267], ["NAC", "CHEMICAL", 145, 148], ["ROS", "SIMPLE_CHEMICAL", 29, 32], ["HCV", "ORGANISM", 44, 47], ["LPIN1", "GENE_OR_GENE_PRODUCT", 94, 99], ["NAC", "SIMPLE_CHEMICAL", 145, 148], ["LPIN1", "GENE_OR_GENE_PRODUCT", 159, 164], ["SREBP", "GENE_OR_GENE_PRODUCT", 225, 230], ["HCV", "ORGANISM", 254, 257], ["HCV protein", "PROTEIN", 44, 55], ["LPIN1", "PROTEIN", 94, 99], ["LPIN1 mRNA", "RNA", 159, 169], ["SREBP-regulated genes", "DNA", 225, 246], ["HCV", "SPECIES", 44, 47], ["HCV", "SPECIES", 254, 257], ["the hypothesis", "PROBLEM", 9, 23], ["HCV protein accumulation", "PROBLEM", 44, 68], ["LPIN1 induction", "TREATMENT", 94, 109], ["the antioxidant NAC", "TREATMENT", 129, 148], ["LPIN1 mRNA accumulation", "PROBLEM", 159, 182], ["HCV infection", "PROBLEM", 254, 267]]], ["Accumulation of LPIN1 mRNA during HCV infection results in concomitant protein accumulation (Fig 1G and 1H) .", [["HCV infection", "DISEASE", 34, 47], ["1H", "CHEMICAL", 104, 106], ["LPIN1", "GENE_OR_GENE_PRODUCT", 16, 21], ["HCV", "ORGANISM", 34, 37], ["LPIN1 mRNA", "RNA", 16, 26], ["HCV", "SPECIES", 34, 37], ["LPIN1 mRNA", "PROBLEM", 16, 26], ["HCV infection", "PROBLEM", 34, 47], ["concomitant protein accumulation", "PROBLEM", 59, 91], ["LPIN1 mRNA", "OBSERVATION", 16, 26], ["HCV", "OBSERVATION_MODIFIER", 34, 37], ["infection", "OBSERVATION", 38, 47], ["protein accumulation", "OBSERVATION", 71, 91]]], ["However, post-translational mechanisms such as phosphorylation, acetylation or sumoylation regulate lipin1 protein stability, membrane association as well as subcellular localization thus influencing the activity of lipin1 as PA-phosphatase and as transcriptional coactivator [70] .", [["membrane", "ANATOMY", 126, 134], ["subcellular", "ANATOMY", 158, 169], ["lipin1", "GENE_OR_GENE_PRODUCT", 100, 106], ["membrane", "CELLULAR_COMPONENT", 126, 134], ["lipin1", "GENE_OR_GENE_PRODUCT", 216, 222], ["PA-phosphatase", "GENE_OR_GENE_PRODUCT", 226, 240], ["lipin1 protein", "PROTEIN", 100, 114], ["lipin1", "PROTEIN", 216, 222], ["phosphatase", "PROTEIN", 229, 240], ["transcriptional coactivator", "PROTEIN", 248, 275], ["phosphorylation", "TREATMENT", 47, 62], ["acetylation", "TREATMENT", 64, 75], ["sumoylation regulate", "TREATMENT", 79, 99], ["subcellular localization", "TEST", 158, 182], ["lipin1", "TREATMENT", 216, 222], ["PA-phosphatase", "TEST", 226, 240], ["transcriptional coactivator", "TEST", 248, 275]]], ["Hence, it is difficult to predict the implications of lipin1 protein accumulation during HCV infection.", [["HCV infection", "DISEASE", 89, 102], ["lipin1", "GENE_OR_GENE_PRODUCT", 54, 60], ["HCV", "ORGANISM", 89, 92], ["lipin1 protein", "PROTEIN", 54, 68], ["HCV", "SPECIES", 89, 92], ["lipin1 protein accumulation", "PROBLEM", 54, 81], ["HCV infection", "PROBLEM", 89, 102], ["HCV", "OBSERVATION_MODIFIER", 89, 92], ["infection", "OBSERVATION", 93, 102]]], ["Thus, future studies on the interference of HCV infection with cellular lipin1 functions will be required to determine its role in HCV-related pathogenesis, particularly in its contribution to steatosis.", [["cellular", "ANATOMY", 63, 71], ["HCV infection", "DISEASE", 44, 57], ["steatosis", "DISEASE", 193, 202], ["HCV", "ORGANISM", 44, 47], ["cellular", "CELL", 63, 71], ["HCV", "ORGANISM", 131, 134], ["lipin1", "PROTEIN", 72, 78], ["HCV", "SPECIES", 44, 47], ["HCV", "SPECIES", 131, 134], ["future studies", "TEST", 6, 20], ["HCV infection", "PROBLEM", 44, 57], ["cellular lipin1 functions", "TREATMENT", 63, 88], ["HCV", "PROBLEM", 131, 134], ["pathogenesis", "PROBLEM", 143, 155], ["steatosis", "PROBLEM", 193, 202], ["HCV", "OBSERVATION", 131, 134], ["steatosis", "OBSERVATION", 193, 202]]], ["Lipin1 is required for HCV replicase formation The data presented in this study provide evidence that lipin1 is rate limiting for HCV infection at an early step of the infection leading to formation of membranous HCV replicase complexes, downstream of viral polyprotein expression and processing.", [["Lipin1", "CHEMICAL", 0, 6], ["lipin1", "CHEMICAL", 102, 108], ["HCV infection", "DISEASE", 130, 143], ["infection", "DISEASE", 168, 177], ["Lipin1", "GENE_OR_GENE_PRODUCT", 0, 6], ["HCV", "ORGANISM", 23, 26], ["lipin1", "GENE_OR_GENE_PRODUCT", 102, 108], ["HCV", "ORGANISM", 130, 133], ["Lipin1", "PROTEIN", 0, 6], ["lipin1", "PROTEIN", 102, 108], ["membranous HCV replicase complexes", "PROTEIN", 202, 236], ["HCV", "SPECIES", 23, 26], ["HCV", "SPECIES", 130, 133], ["HCV", "SPECIES", 213, 216], ["Lipin1", "TREATMENT", 0, 6], ["HCV replicase formation", "PROBLEM", 23, 46], ["this study", "TEST", 69, 79], ["lipin1", "TREATMENT", 102, 108], ["HCV infection", "PROBLEM", 130, 143], ["the infection", "PROBLEM", 164, 177], ["membranous HCV replicase complexes", "PROBLEM", 202, 236], ["viral polyprotein expression", "TREATMENT", 252, 280], ["infection", "OBSERVATION", 168, 177], ["membranous", "OBSERVATION_MODIFIER", 202, 212], ["HCV", "OBSERVATION", 213, 216], ["viral polyprotein expression", "OBSERVATION", 252, 280]]], ["We provide evidence for reduced accumulation of viral RNA during single cycle infection experiments (Fig 2D) , that is reminiscent of a faulty initiation of viral replication, as suggested by reduced replication of a transfected subgenomic replicon in lipin1-deficient cells (Fig 5D) .", [["lipin1-deficient cells", "ANATOMY", 252, 274], ["infection", "DISEASE", 78, 87], ["lipin1", "GENE_OR_GENE_PRODUCT", 252, 258], ["cells", "CELL", 269, 274], ["viral RNA", "RNA", 48, 57], ["lipin1-deficient cells", "CELL_LINE", 252, 274], ["reduced accumulation of viral RNA", "PROBLEM", 24, 57], ["single cycle infection experiments", "TREATMENT", 65, 99], ["viral replication", "TREATMENT", 157, 174], ["a transfected subgenomic replicon", "TREATMENT", 215, 248], ["lipin1-deficient cells", "TREATMENT", 252, 274], ["evidence for", "UNCERTAINTY", 11, 23], ["reduced", "OBSERVATION_MODIFIER", 24, 31], ["accumulation", "OBSERVATION_MODIFIER", 32, 44], ["viral RNA", "OBSERVATION", 48, 57], ["viral replication", "OBSERVATION", 157, 174], ["subgenomic replicon", "OBSERVATION", 229, 248]]], ["Data obtained in replication-independent polyprotein expression models suggest that generation of the membranous compartment that contains functional replicase complexes is severely limited in lipin1-deficient cells, as suggested by a significant reduction of the fraction of cells where these structures could be visualized by TEM (Figs 7 and S7 ).", [["membranous compartment", "ANATOMY", 102, 124], ["cells", "ANATOMY", 210, 215], ["cells", "ANATOMY", 276, 281], ["lipin1", "GENE_OR_GENE_PRODUCT", 193, 199], ["cells", "CELL", 210, 215], ["cells", "CELL", 276, 281], ["replicase complexes", "PROTEIN", 150, 169], ["lipin1-deficient cells", "CELL_LINE", 193, 215], ["generation of the membranous compartment", "PROBLEM", 84, 124], ["deficient cells", "PROBLEM", 200, 215], ["Figs", "TEST", 333, 337], ["polyprotein expression", "OBSERVATION", 41, 63], ["membranous", "ANATOMY_MODIFIER", 102, 112], ["functional replicase", "OBSERVATION", 139, 159], ["deficient cells", "OBSERVATION", 200, 215], ["significant", "OBSERVATION_MODIFIER", 235, 246], ["reduction", "OBSERVATION_MODIFIER", 247, 256]]], ["This hypothesis is further supported by a significant reduction in DRM-associated NS proteins in lipin1-deficient cells (Fig 8) , which may reflect limitations in the association of viral replicase subunits with cholesterol and sphingolipid-rich membranes in lipin1-deficient cells [19, 20, 71] .DiscussionFour different shRNAs targeting LPIN1 mRNA decrease susceptibility to HCV infection proportionally to their ability to reduce total lipin1 protein accumulation (Fig 4) .", [["lipin1-deficient cells", "ANATOMY", 97, 119], ["membranes", "ANATOMY", 246, 255], ["lipin1-deficient cells", "ANATOMY", 259, 281], ["cholesterol", "CHEMICAL", 212, 223], ["sphingolipid", "CHEMICAL", 228, 240], ["HCV infection", "DISEASE", 376, 389], ["cholesterol", "CHEMICAL", 212, 223], ["sphingolipid", "CHEMICAL", 228, 240], ["DRM", "GENE_OR_GENE_PRODUCT", 67, 70], ["lipin1", "GENE_OR_GENE_PRODUCT", 97, 103], ["cells", "CELL", 114, 119], ["cholesterol", "SIMPLE_CHEMICAL", 212, 223], ["sphingolipid", "SIMPLE_CHEMICAL", 228, 240], ["rich membranes", "CELLULAR_COMPONENT", 241, 255], ["lipin1", "GENE_OR_GENE_PRODUCT", 259, 265], ["cells", "CELL", 276, 281], ["LPIN1", "GENE_OR_GENE_PRODUCT", 338, 343], ["HCV", "ORGANISM", 376, 379], ["lipin1", "GENE_OR_GENE_PRODUCT", 438, 444], ["DRM", "PROTEIN", 67, 70], ["NS proteins", "PROTEIN", 82, 93], ["lipin1-deficient cells", "CELL_LINE", 97, 119], ["viral replicase subunits", "PROTEIN", 182, 206], ["lipin1-deficient cells", "CELL_LINE", 259, 281], ["shRNAs", "DNA", 321, 327], ["LPIN1 mRNA", "RNA", 338, 348], ["lipin1 protein", "PROTEIN", 438, 452], ["HCV", "SPECIES", 376, 379], ["a significant reduction in DRM", "PROBLEM", 40, 70], ["NS proteins", "TEST", 82, 93], ["lipin1", "TEST", 97, 103], ["deficient cells", "PROBLEM", 104, 119], ["Fig", "TEST", 121, 124], ["viral replicase subunits", "PROBLEM", 182, 206], ["cholesterol and sphingolipid-rich membranes", "TEST", 212, 255], ["deficient cells", "PROBLEM", 266, 281], ["different shRNAs", "TREATMENT", 311, 327], ["HCV infection", "PROBLEM", 376, 389], ["total lipin1 protein accumulation", "TREATMENT", 432, 465], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["reduction", "OBSERVATION_MODIFIER", 54, 63], ["DRM", "OBSERVATION", 67, 70], ["deficient cells", "OBSERVATION", 104, 119], ["may reflect", "UNCERTAINTY", 136, 147], ["viral replicase", "OBSERVATION", 182, 197], ["rich membranes", "OBSERVATION", 241, 255], ["HCV", "OBSERVATION_MODIFIER", 376, 379], ["infection", "OBSERVATION", 380, 389]]], ["These results, together with the cDNA rescue experiments (Fig 6) , strongly reduce the possibility of observing RNAi-associated off-target phenomena.", [["the cDNA rescue experiments", "TREATMENT", 29, 56], ["observing RNAi", "PROBLEM", 102, 116], ["target phenomena", "PROBLEM", 132, 148]]], ["Interestingly, homeostatic accumulation of lipin2 protein in lipin1-deficient cells (Fig 2A and 2B) is not sufficient to compensate for lipin1 loss to support efficient HCV infection.", [["lipin1-deficient cells", "ANATOMY", 61, 83], ["HCV infection", "DISEASE", 169, 182], ["lipin2", "GENE_OR_GENE_PRODUCT", 43, 49], ["lipin1", "GENE_OR_GENE_PRODUCT", 61, 67], ["Fig 2A", "GENE_OR_GENE_PRODUCT", 85, 91], ["lipin1", "GENE_OR_GENE_PRODUCT", 136, 142], ["HCV", "ORGANISM", 169, 172], ["lipin2 protein", "PROTEIN", 43, 57], ["lipin1-deficient cells", "CELL_LINE", 61, 83], ["lipin1", "PROTEIN", 136, 142], ["HCV", "SPECIES", 169, 172], ["lipin2 protein", "TEST", 43, 57], ["deficient cells", "PROBLEM", 68, 83], ["lipin1 loss", "PROBLEM", 136, 147], ["efficient HCV infection", "PROBLEM", 159, 182], ["homeostatic accumulation", "OBSERVATION", 15, 39], ["HCV", "OBSERVATION_MODIFIER", 169, 172], ["infection", "OBSERVATION", 173, 182]]], ["The notion that, despite being capable of mutually compensating basic liver functions [36, 37], lipin1 and lipin2 play non-redundant functions in the liver has previously been proposed [36, 72, 73] .", [["liver", "ANATOMY", 70, 75], ["liver", "ANATOMY", 150, 155], ["liver", "ORGAN", 70, 75], ["lipin1", "GENE_OR_GENE_PRODUCT", 96, 102], ["lipin2", "GENE_OR_GENE_PRODUCT", 107, 113], ["liver", "ORGAN", 150, 155], ["lipin1", "PROTEIN", 96, 102], ["lipin2", "PROTEIN", 107, 113], ["lipin1", "TREATMENT", 96, 102], ["lipin2", "TREATMENT", 107, 113], ["liver", "ANATOMY", 70, 75], ["non-redundant functions", "OBSERVATION", 119, 142], ["liver", "ANATOMY", 150, 155]]], ["Lipin1 is tightly regulated at many different levels and its activity accommodates PAP activity in response to different physiological situations such as fasting and insulin signaling [70] .", [["Lipin1", "GENE_OR_GENE_PRODUCT", 0, 6], ["PAP", "GENE_OR_GENE_PRODUCT", 83, 86], ["insulin", "GENE_OR_GENE_PRODUCT", 166, 173], ["Lipin1", "PROTEIN", 0, 6], ["PAP", "PROTEIN", 83, 86], ["Lipin1", "TREATMENT", 0, 6], ["PAP activity", "PROBLEM", 83, 95], ["different physiological situations", "PROBLEM", 111, 145], ["fasting and insulin signaling", "TEST", 154, 183]]], ["Compelling evidence indicates that, while lipin1 and lipin2 cooperate to maintain liver lipid homeostasis, the two proteins differ in many aspects.", [["liver", "ANATOMY", 82, 87], ["lipin1", "GENE_OR_GENE_PRODUCT", 42, 48], ["lipin2", "GENE_OR_GENE_PRODUCT", 53, 59], ["liver lipid", "MULTI-TISSUE_STRUCTURE", 82, 93], ["lipin1", "PROTEIN", 42, 48], ["lipin2", "PROTEIN", 53, 59], ["lipin1", "TREATMENT", 42, 48], ["lipin2", "TREATMENT", 53, 59], ["liver lipid homeostasis", "TREATMENT", 82, 105], ["liver", "ANATOMY", 82, 87], ["lipid homeostasis", "OBSERVATION", 88, 105]]], ["For instance, lipin1 is transcriptionally induced by PGC-1\u03b1 and it is also an inducible amplifier of this transcriptional network [31], whereas lipin2 is not [36] .", [["lipin1", "GENE_OR_GENE_PRODUCT", 14, 20], ["PGC-1\u03b1", "GENE_OR_GENE_PRODUCT", 53, 59], ["lipin2", "GENE_OR_GENE_PRODUCT", 144, 150], ["lipin1", "PROTEIN", 14, 20], ["PGC-1\u03b1", "PROTEIN", 53, 59], ["lipin2", "PROTEIN", 144, 150], ["lipin1", "TREATMENT", 14, 20]]], ["Lipin1 is sumoylated and sumoylation regulates its nuclear localization and function, whereas lipin2 sumoylation could not be demonstrated, despite the presence of a canonical sumoylation motif in its primary sequence [74] .", [["nuclear", "ANATOMY", 51, 58], ["Lipin1", "GENE_OR_GENE_PRODUCT", 0, 6], ["nuclear", "CELLULAR_COMPONENT", 51, 58], ["lipin2", "GENE_OR_GENE_PRODUCT", 94, 100], ["Lipin1", "PROTEIN", 0, 6], ["lipin2", "PROTEIN", 94, 100], ["canonical sumoylation motif", "PROTEIN", 166, 193], ["Lipin1", "TREATMENT", 0, 6], ["lipin2 sumoylation", "TREATMENT", 94, 112], ["a canonical sumoylation motif", "TREATMENT", 164, 193]]], ["Lipin1 enzymatic activity is blocked by mammalian target of rapamycin (mTOR)-dependent phosphorylation in response to different metabolic stimuli [30, 75], whereas lipin2 is constitutively active even when phosphorylated [76] .", [["rapamycin", "CHEMICAL", 60, 69], ["rapamycin", "CHEMICAL", 60, 69], ["Lipin1", "GENE_OR_GENE_PRODUCT", 0, 6], ["mammalian target of rapamycin", "GENE_OR_GENE_PRODUCT", 40, 69], ["mTOR", "GENE_OR_GENE_PRODUCT", 71, 75], ["lipin2", "GENE_OR_GENE_PRODUCT", 164, 170], ["Lipin1", "PROTEIN", 0, 6], ["mTOR", "PROTEIN", 71, 75], ["lipin2", "PROTEIN", 164, 170], ["Lipin1 enzymatic activity", "TREATMENT", 0, 25], ["rapamycin (mTOR)", "TREATMENT", 60, 76], ["dependent phosphorylation", "PROBLEM", 77, 102], ["different metabolic stimuli", "TEST", 118, 145]]], ["Thus, lipin2 is considered more as a constitutive phosphatidic acid phosphatase with lower specific activity than lipin1 [76] .", [["lipin2", "CHEMICAL", 6, 12], ["phosphatidic acid", "CHEMICAL", 50, 67], ["phosphatidic acid", "CHEMICAL", 50, 67], ["lipin1", "CHEMICAL", 114, 120], ["lipin2", "GENE_OR_GENE_PRODUCT", 6, 12], ["phosphatidic acid", "SIMPLE_CHEMICAL", 50, 67], ["lipin2", "PROTEIN", 6, 12], ["constitutive phosphatidic acid phosphatase", "PROTEIN", 37, 79], ["lipin2", "TREATMENT", 6, 12], ["a constitutive phosphatidic acid phosphatase", "TEST", 35, 79]]], ["In addition to these differential regulatory networks, it has been shown that in vitro PAP activity of purified lipin1 and lipin2 is differentially influenced by the composition of the substrates (liposomes and lipid-detergent micelles) as well as the pH at which the assay is performed [76] .", [["PAP", "GENE_OR_GENE_PRODUCT", 87, 90], ["lipin1", "GENE_OR_GENE_PRODUCT", 112, 118], ["lipin2", "GENE_OR_GENE_PRODUCT", 123, 129], ["liposomes", "SIMPLE_CHEMICAL", 197, 206], ["lipid", "SIMPLE_CHEMICAL", 211, 216], ["PAP", "PROTEIN", 87, 90], ["lipin1", "PROTEIN", 112, 118], ["lipin2", "PROTEIN", 123, 129], ["purified lipin1", "TREATMENT", 103, 118], ["lipin2", "TREATMENT", 123, 129], ["the substrates (liposomes and lipid-detergent micelles", "TREATMENT", 181, 235], ["the pH", "TEST", 248, 254], ["the assay", "TEST", 264, 273]]], ["This differential lipid substrate recognition may be reminiscent of the different preferential association with membranes of different subcellular compartments (S1 Fig) [73, 76] .", [["membranes", "ANATOMY", 112, 121], ["subcellular compartments", "ANATOMY", 135, 159], ["membranes", "CELLULAR_COMPONENT", 112, 121], ["subcellular compartments", "CELLULAR_COMPONENT", 135, 159], ["may be reminiscent", "UNCERTAINTY", 46, 64], ["different", "OBSERVATION_MODIFIER", 72, 81], ["preferential", "OBSERVATION_MODIFIER", 82, 94]]], ["These differences suggest that, while lipin1 and lipin2 may share some common features, they are not functionally interchangeable, particularly not in the case of HCV infection [70] .", [["HCV infection", "DISEASE", 163, 176], ["lipin1", "GENE_OR_GENE_PRODUCT", 38, 44], ["lipin2", "GENE_OR_GENE_PRODUCT", 49, 55], ["HCV", "ORGANISM", 163, 166], ["lipin1", "PROTEIN", 38, 44], ["lipin2", "PROTEIN", 49, 55], ["HCV", "SPECIES", 163, 166], ["lipin1", "TREATMENT", 38, 44], ["lipin2", "TREATMENT", 49, 55], ["HCV infection", "PROBLEM", 163, 176], ["HCV", "OBSERVATION", 163, 166]]], ["Our data support the notion that lipin1 silencing has a strong impact on HCV infection without affecting basic cellular functions (Fig 2B) or significantly interfering with infection by an unrelated virus (S3 Fig).", [["cellular", "ANATOMY", 111, 119], ["lipin1", "CHEMICAL", 33, 39], ["HCV infection", "DISEASE", 73, 86], ["infection", "DISEASE", 173, 182], ["lipin1", "GENE_OR_GENE_PRODUCT", 33, 39], ["HCV", "ORGANISM", 73, 76], ["cellular", "CELL", 111, 119], ["lipin1", "PROTEIN", 33, 39], ["HCV", "SPECIES", 73, 76], ["lipin1 silencing", "TREATMENT", 33, 49], ["HCV infection", "PROBLEM", 73, 86], ["infection", "PROBLEM", 173, 182], ["an unrelated virus", "PROBLEM", 186, 204], ["HCV", "OBSERVATION_MODIFIER", 73, 76], ["infection", "OBSERVATION", 77, 86], ["infection", "OBSERVATION", 173, 182]]], ["Despite great efforts and different overexpression systems, functional rescue of lipin1 functions by wt lipin1 cDNA overexpression in lipin1-deficient cells only lead to a small but consistent rescue of virus infection efficiency, which was only observed when overexpressing wt lipin1 (Figs 6 and S6) .", [["lipin1-deficient cells", "ANATOMY", 134, 156], ["infection", "DISEASE", 209, 218], ["lipin1", "GENE_OR_GENE_PRODUCT", 81, 87], ["lipin1", "GENE_OR_GENE_PRODUCT", 104, 110], ["lipin1", "GENE_OR_GENE_PRODUCT", 134, 140], ["cells", "CELL", 151, 156], ["lipin1", "GENE_OR_GENE_PRODUCT", 278, 284], ["Figs 6", "GENE_OR_GENE_PRODUCT", 286, 292], ["S6", "GENE_OR_GENE_PRODUCT", 297, 299], ["lipin1", "PROTEIN", 81, 87], ["lipin1 cDNA", "DNA", 104, 115], ["lipin1-deficient cells", "CELL_LINE", 134, 156], ["lipin1", "PROTEIN", 278, 284], ["Figs 6", "PROTEIN", 286, 292], ["S6", "PROTEIN", 297, 299], ["different overexpression systems", "PROBLEM", 26, 58], ["lipin1 functions", "TREATMENT", 81, 97], ["cDNA overexpression", "TEST", 111, 130], ["lipin1", "TEST", 134, 140], ["deficient cells", "PROBLEM", 141, 156], ["virus infection efficiency", "PROBLEM", 203, 229], ["Figs", "TEST", 286, 290], ["small", "OBSERVATION_MODIFIER", 172, 177], ["virus infection", "OBSERVATION", 203, 218]]], ["Given the multiple transcriptional, post-transcriptional and post-translational regulation levels existing for lipin1 expression, it is conceivable that only a fraction of the overexpressed lipin1 is fully competent to sustain HCV infection.", [["HCV infection", "DISEASE", 227, 240], ["lipin1", "GENE_OR_GENE_PRODUCT", 111, 117], ["lipin1", "GENE_OR_GENE_PRODUCT", 190, 196], ["HCV", "ORGANISM", 227, 230], ["lipin1", "PROTEIN", 111, 117], ["lipin1", "PROTEIN", 190, 196], ["HCV", "SPECIES", 227, 230], ["post-translational regulation levels", "TEST", 61, 97], ["lipin1 expression", "TREATMENT", 111, 128], ["the overexpressed lipin1", "TREATMENT", 172, 196], ["HCV infection", "PROBLEM", 227, 240], ["HCV", "OBSERVATION_MODIFIER", 227, 230], ["infection", "OBSERVATION", 231, 240]]], ["Moreover, high overexpression levels could only be achieved in lipin1-deficient cells (Fig 6A) , underscoring the notion that intracellular lipin1 levels are tightly regulated by the host.", [["lipin1-deficient cells", "ANATOMY", 63, 85], ["intracellular", "ANATOMY", 126, 139], ["lipin1", "GENE_OR_GENE_PRODUCT", 63, 69], ["cells", "CELL", 80, 85], ["Fig 6A", "CELL", 87, 93], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 126, 139], ["lipin1", "GENE_OR_GENE_PRODUCT", 140, 146], ["lipin1-deficient cells", "CELL_LINE", 63, 85], ["lipin1", "PROTEIN", 140, 146], ["high overexpression levels", "PROBLEM", 10, 36], ["deficient cells", "PROBLEM", 70, 85], ["intracellular lipin1 levels", "TEST", 126, 153]]], ["Nevertheless, overexpression of a mutant lipin1 lacking phosphatase activity (DXDXT) or a mutant inactive as transcriptional coactivator (LXXIL) were not capable of enhancing HCV infection in lipin1-deficient cells as compared with the wt lipin1 ( Fig 6B) .", [["cells", "ANATOMY", 209, 214], ["HCV infection", "DISEASE", 175, 188], ["lipin1", "GENE_OR_GENE_PRODUCT", 41, 47], ["DXDXT", "GENE_OR_GENE_PRODUCT", 78, 83], ["LXXIL", "GENE_OR_GENE_PRODUCT", 138, 143], ["HCV", "ORGANISM", 175, 178], ["lipin1", "GENE_OR_GENE_PRODUCT", 192, 198], ["cells", "CELL", 209, 214], ["lipin1 ( Fig 6B", "ORGANISM", 239, 254], ["mutant lipin1", "PROTEIN", 34, 47], ["phosphatase", "PROTEIN", 56, 67], ["DXDXT", "PROTEIN", 78, 83], ["transcriptional coactivator", "PROTEIN", 109, 136], ["LXXIL", "PROTEIN", 138, 143], ["lipin1-deficient cells", "CELL_LINE", 192, 214], ["lipin1", "PROTEIN", 239, 245], ["HCV", "SPECIES", 175, 178], ["a mutant lipin1 lacking phosphatase activity", "PROBLEM", 32, 76], ["a mutant inactive as transcriptional coactivator", "PROBLEM", 88, 136], ["enhancing HCV infection", "PROBLEM", 165, 188], ["deficient cells", "PROBLEM", 199, 214], ["enhancing", "OBSERVATION_MODIFIER", 165, 174], ["HCV", "OBSERVATION_MODIFIER", 175, 178], ["infection", "OBSERVATION", 179, 188]]], ["These data reveal that lipin1 phosphatase activity is required for lipin1 to support HCV infection and suggest that, while transcriptional co-activation by lipin1 may be important, this function is not sufficient to support HCV replication.DiscussionLipins are important enzymes in the main pathway for de novo phospholipid biosynthesis by providing DAG derived from the glycerol-3-phosphate pathway to produce PC and PE through the Kennedy pathway [70] .", [["HCV infection", "DISEASE", 85, 98], ["DiscussionLipins", "CHEMICAL", 240, 256], ["DAG", "CHEMICAL", 350, 353], ["glycerol-3-phosphate", "CHEMICAL", 371, 391], ["DAG", "CHEMICAL", 350, 353], ["glycerol-3-phosphate", "CHEMICAL", 371, 391], ["lipin1", "GENE_OR_GENE_PRODUCT", 23, 29], ["lipin1", "GENE_OR_GENE_PRODUCT", 67, 73], ["HCV", "ORGANISM", 85, 88], ["lipin1", "GENE_OR_GENE_PRODUCT", 156, 162], ["HCV", "ORGANISM", 224, 227], ["DiscussionLipins", "SIMPLE_CHEMICAL", 240, 256], ["phospholipid", "SIMPLE_CHEMICAL", 311, 323], ["DAG", "SIMPLE_CHEMICAL", 350, 353], ["glycerol-3-phosphate", "SIMPLE_CHEMICAL", 371, 391], ["PC", "SIMPLE_CHEMICAL", 411, 413], ["PE", "SIMPLE_CHEMICAL", 418, 420], ["lipin1 phosphatase", "PROTEIN", 23, 41], ["lipin1", "PROTEIN", 67, 73], ["lipin1", "PROTEIN", 156, 162], ["HCV", "SPECIES", 85, 88], ["HCV", "SPECIES", 224, 227], ["These data", "TEST", 0, 10], ["lipin1 phosphatase activity", "PROBLEM", 23, 50], ["lipin1", "TREATMENT", 67, 73], ["HCV infection", "PROBLEM", 85, 98], ["lipin1", "TREATMENT", 156, 162], ["HCV replication", "TREATMENT", 224, 239], ["de novo phospholipid biosynthesis", "TREATMENT", 303, 336], ["the glycerol-3-phosphate pathway", "TREATMENT", 367, 399], ["PC", "PROBLEM", 411, 413], ["PE", "PROBLEM", 418, 420], ["PE", "OBSERVATION", 418, 420]]], ["Production of membranous replicase compartments likely requires de novo synthesis of PC and/or PE, which are major components of biological membranes that depend on DAG biosynthesis [29] .", [["membranous replicase compartments", "ANATOMY", 14, 47], ["membranes", "ANATOMY", 140, 149], ["DAG", "CHEMICAL", 165, 168], ["DAG", "CHEMICAL", 165, 168], ["PC", "SIMPLE_CHEMICAL", 85, 87], ["PE", "GENE_OR_GENE_PRODUCT", 95, 97], ["membranes", "CELLULAR_COMPONENT", 140, 149], ["DAG", "SIMPLE_CHEMICAL", 165, 168], ["membranous replicase compartments", "PROBLEM", 14, 47], ["PC", "PROBLEM", 85, 87], ["PE", "PROBLEM", 95, 97], ["biological membranes", "PROBLEM", 129, 149], ["DAG biosynthesis", "TEST", 165, 181], ["membranous", "OBSERVATION_MODIFIER", 14, 24], ["replicase compartments", "OBSERVATION", 25, 47], ["PE", "OBSERVATION", 95, 97], ["biological membranes", "OBSERVATION", 129, 149]]], ["In fact, local PC biosynthesis is required for efficient replication of (+) RNA viruses and certain PC species accumulate in HCV-infected cells [26, 28] .", [["cells", "ANATOMY", 138, 143], ["HCV-infected", "DISEASE", 125, 137], ["PC", "CANCER", 15, 17], ["PC species", "ORGANISM", 100, 110], ["HCV", "ORGANISM", 125, 128], ["cells", "CELL", 138, 143], ["HCV-infected cells", "CELL_TYPE", 125, 143], ["HCV", "SPECIES", 125, 128], ["local PC biosynthesis", "TREATMENT", 9, 30], ["RNA viruses", "PROBLEM", 76, 87], ["certain PC species", "PROBLEM", 92, 110], ["HCV", "PROBLEM", 125, 128], ["infected cells", "PROBLEM", 129, 143], ["HCV", "OBSERVATION_MODIFIER", 125, 128], ["infected cells", "OBSERVATION", 129, 143]]], ["Although increased lipin2 accumulation may be sufficient to compensate lipin1 silencing at the whole-cell level [37], it is possible that acute, local demand of de novo synthesized phospholipids is required at defined suborganellar compartments during early steps of HCV infection and that lipin1-deficiency shortens or alters the availability of different membrane components, demand that may not be satisfied by lipin2, given the differential regulation [76] and subcellular localization of these two proteins (S2 Fig).", [["whole-cell", "ANATOMY", 95, 105], ["suborganellar compartments", "ANATOMY", 218, 244], ["membrane components", "ANATOMY", 357, 376], ["subcellular", "ANATOMY", 465, 476], ["HCV infection", "DISEASE", 267, 280], ["lipin2", "GENE_OR_GENE_PRODUCT", 19, 25], ["lipin1", "GENE_OR_GENE_PRODUCT", 71, 77], ["cell", "CELL", 101, 105], ["phospholipids", "SIMPLE_CHEMICAL", 181, 194], ["HCV", "ORGANISM", 267, 270], ["lipin1", "GENE_OR_GENE_PRODUCT", 290, 296], ["membrane components", "CELLULAR_COMPONENT", 357, 376], ["lipin2", "GENE_OR_GENE_PRODUCT", 414, 420], ["lipin2", "PROTEIN", 19, 25], ["lipin1", "PROTEIN", 71, 77], ["lipin1", "PROTEIN", 290, 296], ["lipin2", "PROTEIN", 414, 420], ["S2", "PROTEIN", 513, 515], ["HCV", "SPECIES", 267, 270], ["increased lipin2 accumulation", "PROBLEM", 9, 38], ["lipin1 silencing", "PROBLEM", 71, 87], ["de novo synthesized phospholipids", "TREATMENT", 161, 194], ["HCV infection", "PROBLEM", 267, 280], ["deficiency shortens", "PROBLEM", 297, 316], ["different membrane components", "PROBLEM", 347, 376], ["subcellular localization", "TEST", 465, 489], ["is possible", "UNCERTAINTY", 121, 132], ["acute", "OBSERVATION_MODIFIER", 138, 143], ["HCV", "OBSERVATION_MODIFIER", 267, 270], ["infection", "OBSERVATION", 271, 280]]], ["Remarkably, deletion of the yeast lipin homologs pah1/smp2 (S. cerevisae) or ned1 (S. pombe) gene, results in deregulated proliferation of the ER and nuclear envelope membranes [77, 78] , with concomitant enhancement in (+) RNA virus replication [79, 80] .", [["ER", "ANATOMY", 143, 145], ["nuclear envelope membranes", "ANATOMY", 150, 176], ["lipin", "GENE_OR_GENE_PRODUCT", 34, 39], ["pah1", "GENE_OR_GENE_PRODUCT", 49, 53], ["smp2", "GENE_OR_GENE_PRODUCT", 54, 58], ["S. cerevisae", "ORGANISM", 60, 72], ["ned1 (S. pombe", "GENE_OR_GENE_PRODUCT", 77, 91], ["ER", "GENE_OR_GENE_PRODUCT", 143, 145], ["nuclear", "CELLULAR_COMPONENT", 150, 157], ["envelope membranes", "CELLULAR_COMPONENT", 158, 176], ["yeast lipin homologs", "PROTEIN", 28, 48], ["pah1", "PROTEIN", 49, 53], ["smp2", "PROTEIN", 54, 58], ["S. cerevisae) or ned1 (S. pombe) gene", "DNA", 60, 97], ["ER", "PROTEIN", 143, 145], ["yeast", "SPECIES", 28, 33], ["S. cerevisae", "SPECIES", 60, 72], ["S. pombe", "SPECIES", 83, 91], ["yeast", "SPECIES", 28, 33], ["S. cerevisae", "SPECIES", 60, 72], ["S. pombe", "SPECIES", 83, 91], ["the yeast lipin homologs", "TEST", 24, 48], ["nuclear envelope membranes", "TEST", 150, 176], ["concomitant enhancement in (+) RNA virus replication", "PROBLEM", 193, 245], ["deregulated proliferation", "OBSERVATION", 110, 135]]], ["The membranous alterations and elevation of total phospholipid content observed in pah1-deficient yeast have been ascribed to transcriptional activation of pah1-independent alternative phospholipid biosynthetic programs due to PA accumulation [77, 80] .", [["membranous", "ANATOMY", 4, 14], ["pah1", "CHEMICAL", 83, 87], ["phospholipid", "SIMPLE_CHEMICAL", 50, 62], ["pah1", "GENE_OR_GENE_PRODUCT", 83, 87], ["pah1", "GENE_OR_GENE_PRODUCT", 156, 160], ["phospholipid", "SIMPLE_CHEMICAL", 185, 197], ["PA", "GENE_OR_GENE_PRODUCT", 227, 229], ["pah1", "PROTEIN", 83, 87], ["pah1", "PROTEIN", 156, 160], ["yeast", "SPECIES", 98, 103], ["yeast", "SPECIES", 98, 103], ["The membranous alterations", "PROBLEM", 0, 26], ["elevation of total phospholipid content", "PROBLEM", 31, 70], ["pah1-deficient yeast", "PROBLEM", 83, 103], ["pah1-independent alternative phospholipid biosynthetic programs", "TREATMENT", 156, 219], ["PA accumulation", "PROBLEM", 227, 242], ["membranous", "OBSERVATION_MODIFIER", 4, 14], ["alterations", "OBSERVATION", 15, 26], ["elevation", "OBSERVATION_MODIFIER", 31, 40], ["total phospholipid", "OBSERVATION_MODIFIER", 44, 62]]], ["Our data in mammalian cells are more compatible with a shortage of phospholipid production, which may be at the basis of the reduced abundance viral membranous structure (Figs 7 and 8) .", [["mammalian cells", "ANATOMY", 12, 27], ["mammalian cells", "CELL", 12, 27], ["phospholipid", "SIMPLE_CHEMICAL", 67, 79], ["mammalian cells", "CELL_TYPE", 12, 27], ["Our data in mammalian cells", "TEST", 0, 27], ["a shortage of phospholipid production", "PROBLEM", 53, 90], ["the reduced abundance viral membranous structure", "PROBLEM", 121, 169], ["mammalian cells", "OBSERVATION", 12, 27], ["more compatible with", "UNCERTAINTY", 32, 52], ["phospholipid production", "OBSERVATION", 67, 90], ["may be", "UNCERTAINTY", 98, 104], ["reduced", "OBSERVATION_MODIFIER", 125, 132], ["abundance", "OBSERVATION_MODIFIER", 133, 142], ["viral membranous structure", "OBSERVATION", 143, 169]]], ["This opposite outcomes of infection may derive from the fact that yeast use mainly PA (lipin1 PAP substrate) as a precursor for PC biosynthesis, while mammals mainly use DAG (lipin1 PAP product) as precursor for PC biosynthesis through the Kennedy pathway [77, [80] [81] [82] .", [["infection", "DISEASE", 26, 35], ["DAG", "CHEMICAL", 170, 173], ["DAG", "CHEMICAL", 170, 173], ["PA", "GENE_OR_GENE_PRODUCT", 83, 85], ["lipin1 PAP", "GENE_OR_GENE_PRODUCT", 87, 97], ["PC", "SIMPLE_CHEMICAL", 128, 130], ["DAG", "SIMPLE_CHEMICAL", 170, 173], ["lipin1 PAP", "GENE_OR_GENE_PRODUCT", 175, 185], ["PC", "SIMPLE_CHEMICAL", 212, 214], ["lipin1 PAP substrate", "PROTEIN", 87, 107], ["lipin1 PAP product", "PROTEIN", 175, 193], ["yeast", "SPECIES", 66, 71], ["yeast", "SPECIES", 66, 71], ["infection", "PROBLEM", 26, 35], ["PA (lipin1 PAP substrate", "TREATMENT", 83, 107], ["PC biosynthesis", "TREATMENT", 128, 143], ["DAG (lipin1 PAP product", "TREATMENT", 170, 193], ["PC biosynthesis", "TREATMENT", 212, 227], ["infection", "OBSERVATION", 26, 35]]], ["Moreover, in contrast to yeast and lower eukaryotes, which express only one lipin gene, three different lipin genes coordinate glycerolipid homeostasis in mammals [72] .", [["lipin", "GENE_OR_GENE_PRODUCT", 76, 81], ["lipin", "GENE_OR_GENE_PRODUCT", 104, 109], ["glycerolipid", "SIMPLE_CHEMICAL", 127, 139], ["lipin gene", "DNA", 76, 86], ["lipin genes", "DNA", 104, 115], ["yeast", "SPECIES", 25, 30], ["yeast", "SPECIES", 25, 30], ["lower eukaryotes", "ANATOMY", 35, 51], ["glycerolipid homeostasis", "OBSERVATION", 127, 151]]], ["Thus, interfering with expression of one of the members of the family may not be sufficient to observe the same effects observed when deleting pah1, as transcriptional and posttranslational homeostatic compensations are in place in mammals, particularly between lipin1 and lipin2 in liver tissue [36, 37] .", [["liver tissue", "ANATOMY", 283, 295], ["pah1", "GENE_OR_GENE_PRODUCT", 143, 147], ["lipin1", "GENE_OR_GENE_PRODUCT", 262, 268], ["lipin2", "GENE_OR_GENE_PRODUCT", 273, 279], ["liver tissue", "TISSUE", 283, 295], ["pah1", "PROTEIN", 143, 147], ["lipin1", "PROTEIN", 262, 268], ["lipin2", "PROTEIN", 273, 279], ["posttranslational homeostatic compensations", "PROBLEM", 172, 215], ["lipin1", "TREATMENT", 262, 268], ["liver", "ANATOMY", 283, 288]]], ["In this sense, deletion of either lipin1 or lipin2 in mouse models results in a relatively balanced liver phospholipid content while simultaneous deletion of both lipins is embryonically lethal [37] .", [["liver", "ANATOMY", 100, 105], ["lipin1", "GENE_OR_GENE_PRODUCT", 34, 40], ["lipin2", "GENE_OR_GENE_PRODUCT", 44, 50], ["mouse", "ORGANISM", 54, 59], ["liver", "ORGAN", 100, 105], ["phospholipid", "SIMPLE_CHEMICAL", 106, 118], ["lipins", "GENE_OR_GENE_PRODUCT", 163, 169], ["lipin1", "PROTEIN", 34, 40], ["lipin2", "PROTEIN", 44, 50], ["mouse", "SPECIES", 54, 59], ["mouse", "SPECIES", 54, 59], ["lipin1", "TREATMENT", 34, 40], ["lipin2", "TREATMENT", 44, 50], ["a relatively balanced liver phospholipid content", "PROBLEM", 78, 126], ["liver", "ANATOMY", 100, 105], ["phospholipid content", "OBSERVATION", 106, 126]]], ["Accordingly, only minor alterations of ER membranes [83] and no significant alterations in total PC levels [36] have been reported in lipin1-deficient mouse liver.", [["ER membranes", "ANATOMY", 39, 51], ["liver", "ANATOMY", 157, 162], ["ER", "GENE_OR_GENE_PRODUCT", 39, 41], ["PC", "GENE_OR_GENE_PRODUCT", 97, 99], ["lipin1", "GENE_OR_GENE_PRODUCT", 134, 140], ["mouse", "ORGANISM", 151, 156], ["liver", "ORGAN", 157, 162], ["ER", "PROTEIN", 39, 41], ["lipin1", "PROTEIN", 134, 140], ["mouse", "SPECIES", 151, 156], ["mouse", "SPECIES", 151, 156], ["minor alterations of ER membranes", "PROBLEM", 18, 51], ["significant alterations", "PROBLEM", 64, 87], ["total PC levels", "TEST", 91, 106], ["deficient mouse liver", "PROBLEM", 141, 162], ["minor", "OBSERVATION_MODIFIER", 18, 23], ["alterations", "OBSERVATION", 24, 35], ["no", "UNCERTAINTY", 61, 63], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["alterations", "OBSERVATION", 76, 87], ["deficient", "OBSERVATION", 141, 150], ["mouse", "ANATOMY_MODIFIER", 151, 156], ["liver", "ANATOMY", 157, 162]]], ["Given the fact that hCoV-229E is fully capable of replicating in these cells (S3 Fig), it is unlikely that a general disruption of de novo phospholipid biosynthesis occurs in lipin1-deficient cells, particularly since hCoV-229E infection also induces profound ER membrane rearrangements required for replication [84] , some of which are structurally similar to DMVs observed during HCV infection [85] .", [["cells", "ANATOMY", 71, 76], ["lipin1-deficient cells", "ANATOMY", 175, 197], ["ER membrane", "ANATOMY", 260, 271], ["hCoV-229E", "CHEMICAL", 20, 29], ["phospholipid", "CHEMICAL", 139, 151], ["hCoV-229E", "CHEMICAL", 218, 227], ["infection", "DISEASE", 228, 237], ["HCV infection", "DISEASE", 382, 395], ["hCoV-229E", "GENE_OR_GENE_PRODUCT", 20, 29], ["cells", "CELL", 71, 76], ["S3 Fig", "CELL", 78, 84], ["phospholipid", "SIMPLE_CHEMICAL", 139, 151], ["lipin1", "GENE_OR_GENE_PRODUCT", 175, 181], ["cells", "CELL", 192, 197], ["hCoV-229E", "GENE_OR_GENE_PRODUCT", 218, 227], ["ER", "GENE_OR_GENE_PRODUCT", 260, 262], ["DMVs", "CANCER", 361, 365], ["HCV", "ORGANISM", 382, 385], ["hCoV", "PROTEIN", 20, 24], ["229E", "PROTEIN", 25, 29], ["lipin1-deficient cells", "CELL_LINE", 175, 197], ["ER", "PROTEIN", 260, 262], ["DMVs", "PROTEIN", 361, 365], ["hCoV-229E", "SPECIES", 218, 227], ["HCV", "SPECIES", 382, 385], ["hCoV", "TEST", 20, 24], ["a general disruption of de novo phospholipid biosynthesis", "PROBLEM", 107, 164], ["deficient cells", "PROBLEM", 182, 197], ["hCoV", "TEST", 218, 222], ["229E infection", "PROBLEM", 223, 237], ["profound ER membrane rearrangements", "PROBLEM", 251, 286], ["DMVs", "PROBLEM", 361, 365], ["HCV infection", "PROBLEM", 382, 395], ["deficient cells", "OBSERVATION", 182, 197], ["membrane rearrangements", "OBSERVATION", 263, 286]]], ["Thus, we favor the hypothesis that a subcellular pool of glycerophospholipids is managed by lipin1 in Huh-7 cells and that lipin1 silencing perturbs local levels of PA and DAG, limiting local availability of precursors of structural components of virus-induced membranes.DiscussionAlternatively, lipin1 deficiency may alter local amounts of important signaling molecules, in particular, that of its substrate (PA) or its product (DAG).", [["subcellular", "ANATOMY", 37, 48], ["Huh-7 cells", "ANATOMY", 102, 113], ["membranes", "ANATOMY", 261, 270], ["DAG", "CHEMICAL", 172, 175], ["glycerophospholipids", "CHEMICAL", 57, 77], ["DAG", "CHEMICAL", 172, 175], ["DAG", "CHEMICAL", 430, 433], ["glycerophospholipids", "SIMPLE_CHEMICAL", 57, 77], ["lipin1", "SIMPLE_CHEMICAL", 92, 98], ["Huh-7 cells", "CELL", 102, 113], ["lipin1", "GENE_OR_GENE_PRODUCT", 123, 129], ["PA", "GENE_OR_GENE_PRODUCT", 165, 167], ["DAG", "SIMPLE_CHEMICAL", 172, 175], ["membranes", "CELLULAR_COMPONENT", 261, 270], ["lipin1", "GENE_OR_GENE_PRODUCT", 296, 302], ["PA", "GENE_OR_GENE_PRODUCT", 410, 412], ["DAG", "SIMPLE_CHEMICAL", 430, 433], ["lipin1", "PROTEIN", 92, 98], ["Huh-7 cells", "CELL_LINE", 102, 113], ["lipin1", "PROTEIN", 123, 129], ["signaling molecules", "PROTEIN", 351, 370], ["DAG", "PROTEIN", 430, 433], ["a subcellular pool of glycerophospholipids", "PROBLEM", 35, 77], ["lipin1 silencing", "TREATMENT", 123, 139], ["PA and DAG", "TEST", 165, 175], ["structural components of virus", "PROBLEM", 222, 252], ["induced membranes", "PROBLEM", 253, 270], ["lipin1 deficiency", "PROBLEM", 296, 313], ["important signaling molecules", "PROBLEM", 341, 370]]], ["Deregulation of the local PA and DAG pools may cause important alterations for the host cell, as both metabolites are potent chemical messengers that regulate different aspects of cellular homeostasis [86] [87] [88] .", [["cell", "ANATOMY", 88, 92], ["cellular", "ANATOMY", 180, 188], ["DAG", "CHEMICAL", 33, 36], ["DAG", "CHEMICAL", 33, 36], ["PA", "GENE_OR_GENE_PRODUCT", 26, 28], ["DAG", "SIMPLE_CHEMICAL", 33, 36], ["host cell", "CELL", 83, 92], ["cellular", "CELL", 180, 188], ["the local PA and DAG pools", "PROBLEM", 16, 42], ["the host cell", "PROBLEM", 79, 92], ["cellular homeostasis", "TEST", 180, 200], ["host cell", "OBSERVATION", 83, 92]]], ["Regarding PA conversion into DAG by lipins, it has been shown that pah1 (yeast lipin1 homolog) phosphatase activity is critical for transforming local pools of PA into DAG at the ER membrane to facilitate membrane fusion events mediated by SNARE complexes [89, 90] .", [["ER membrane", "ANATOMY", 179, 190], ["membrane", "ANATOMY", 205, 213], ["DAG", "CHEMICAL", 29, 32], ["DAG", "CHEMICAL", 168, 171], ["DAG", "CHEMICAL", 29, 32], ["DAG", "CHEMICAL", 168, 171], ["PA", "GENE_OR_GENE_PRODUCT", 10, 12], ["DAG", "SIMPLE_CHEMICAL", 29, 32], ["lipins", "SIMPLE_CHEMICAL", 36, 42], ["pah1", "GENE_OR_GENE_PRODUCT", 67, 71], ["yeast lipin1 homolog", "GENE_OR_GENE_PRODUCT", 73, 93], ["PA", "GENE_OR_GENE_PRODUCT", 160, 162], ["DAG", "SIMPLE_CHEMICAL", 168, 171], ["ER membrane", "CELLULAR_COMPONENT", 179, 190], ["membrane", "CELLULAR_COMPONENT", 205, 213], ["SNARE", "GENE_OR_GENE_PRODUCT", 240, 245], ["lipins", "PROTEIN", 36, 42], ["pah1", "PROTEIN", 67, 71], ["yeast lipin1 homolog", "PROTEIN", 73, 93], ["phosphatase", "PROTEIN", 95, 106], ["ER", "PROTEIN", 179, 181], ["SNARE complexes", "PROTEIN", 240, 255], ["yeast", "SPECIES", 73, 78], ["yeast", "SPECIES", 73, 78], ["pah1 (yeast lipin1 homolog", "TREATMENT", 67, 93], ["phosphatase activity", "TEST", 95, 115], ["membrane fusion events", "PROBLEM", 205, 227], ["membrane fusion", "OBSERVATION", 205, 220]]], ["Mammalian lipin1 phosphatase activity is also critical for transforming local pools of PA that accumulate at the surface of mitochondria to promote mitochondrial fission [91] or at the surface of endolysosomes to facilitate autophagy [92] .", [["surface", "ANATOMY", 113, 120], ["mitochondria", "ANATOMY", 124, 136], ["mitochondrial", "ANATOMY", 148, 161], ["surface", "ANATOMY", 185, 192], ["endolysosomes", "ANATOMY", 196, 209], ["lipin1", "GENE_OR_GENE_PRODUCT", 10, 16], ["PA", "GENE_OR_GENE_PRODUCT", 87, 89], ["surface", "CELLULAR_COMPONENT", 113, 120], ["mitochondria", "CELLULAR_COMPONENT", 124, 136], ["mitochondrial", "CELLULAR_COMPONENT", 148, 161], ["surface", "CELLULAR_COMPONENT", 185, 192], ["endolysosomes", "GENE_OR_GENE_PRODUCT", 196, 209], ["Mammalian lipin1 phosphatase", "PROTEIN", 0, 28], ["Mammalian lipin1 phosphatase activity", "TEST", 0, 37], ["autophagy", "TEST", 224, 233]]], ["Thus, lipin1 and probably other members of the lipin family modulate different aspects of intracellular membrane signaling.", [["intracellular membrane", "ANATOMY", 90, 112], ["lipin1", "GENE_OR_GENE_PRODUCT", 6, 12], ["lipin", "GENE_OR_GENE_PRODUCT", 47, 52], ["intracellular membrane", "CELLULAR_COMPONENT", 90, 112], ["lipin1", "PROTEIN", 6, 12], ["lipin family", "PROTEIN", 47, 59], ["lipin1", "TREATMENT", 6, 12], ["intracellular membrane signaling", "PROBLEM", 90, 122], ["intracellular membrane signaling", "OBSERVATION", 90, 122]]], ["Given that the function of host factors known to be involved in functional HCV replicase biogenesis, like VAPA, VAPB and OSBP [11] are indirectly regulated by local PA/DAG pools [93] , it is tempting to propose that lipin1 silencing interferes with the function of one or several of these, or other yet uncharacterized cellular factors.", [["cellular", "ANATOMY", 319, 327], ["DAG", "CHEMICAL", 168, 171], ["DAG", "CHEMICAL", 168, 171], ["HCV", "ORGANISM", 75, 78], ["VAPA", "GENE_OR_GENE_PRODUCT", 106, 110], ["VAPB", "GENE_OR_GENE_PRODUCT", 112, 116], ["OSBP [11]", "GENE_OR_GENE_PRODUCT", 121, 130], ["PA", "GENE_OR_GENE_PRODUCT", 165, 167], ["DAG", "SIMPLE_CHEMICAL", 168, 171], ["lipin1", "GENE_OR_GENE_PRODUCT", 216, 222], ["cellular", "CELL", 319, 327], ["host factors", "PROTEIN", 27, 39], ["VAPA", "PROTEIN", 106, 110], ["VAPB", "PROTEIN", 112, 116], ["lipin1", "PROTEIN", 216, 222], ["cellular factors", "PROTEIN", 319, 335], ["HCV", "SPECIES", 75, 78], ["OSBP", "TEST", 121, 125], ["local PA/DAG pools", "TEST", 159, 177], ["lipin1 silencing", "TREATMENT", 216, 232], ["cellular factors", "OBSERVATION", 319, 335]]], ["In contrast to what has been reported for other host factors required for HCV replicase complex formation [58] , we did not find evidence of lipin1 protein relocalization during HCV infection (S1 Fig).", [["HCV infection", "DISEASE", 178, 191], ["HCV replicase complex", "GENE_OR_GENE_PRODUCT", 74, 95], ["lipin1", "GENE_OR_GENE_PRODUCT", 141, 147], ["HCV", "ORGANISM", 178, 181], ["HCV replicase complex", "PROTEIN", 74, 95], ["lipin1 protein", "PROTEIN", 141, 155], ["HCV", "SPECIES", 74, 77], ["HCV", "SPECIES", 178, 181], ["other host factors", "PROBLEM", 42, 60], ["HCV replicase complex formation", "PROBLEM", 74, 105], ["lipin1 protein relocalization", "PROBLEM", 141, 170], ["HCV infection", "PROBLEM", 178, 191]]], ["Thus, determining the precise mechanism by which lipin1 regulates HCV replicase formation is challenging, as association of lipin1 with different cell membranes is transient and highly regulated by posttranslational modifications [70] .", [["cell membranes", "ANATOMY", 146, 160], ["lipin1", "GENE_OR_GENE_PRODUCT", 49, 55], ["HCV", "ORGANISM", 66, 69], ["lipin1", "GENE_OR_GENE_PRODUCT", 124, 130], ["cell membranes", "CELLULAR_COMPONENT", 146, 160], ["lipin1", "PROTEIN", 49, 55], ["lipin1", "PROTEIN", 124, 130], ["HCV", "SPECIES", 66, 69], ["lipin1 regulates HCV replicase formation", "TREATMENT", 49, 89], ["lipin1", "TREATMENT", 124, 130], ["different cell membranes", "PROBLEM", 136, 160], ["different cell membranes", "OBSERVATION", 136, 160]]], ["Moreover, some of the known lipin1 cellular functions may be compensated by other lipins, particularly lipin2 in the liver.", [["cellular", "ANATOMY", 35, 43], ["liver", "ANATOMY", 117, 122], ["lipin1 cellular", "CELL", 28, 43], ["lipins", "GENE_OR_GENE_PRODUCT", 82, 88], ["lipin2", "GENE_OR_GENE_PRODUCT", 103, 109], ["liver", "ORGAN", 117, 122], ["lipin2", "PROTEIN", 103, 109], ["the known lipin1 cellular functions", "PROBLEM", 18, 53], ["lipin1 cellular functions", "OBSERVATION", 28, 53], ["may be", "UNCERTAINTY", 54, 60], ["compensated", "OBSERVATION", 61, 72], ["liver", "ANATOMY", 117, 122]]], ["Nevertheless, our data clearly indicate that lipin1 participates at early stages of HCV replication and that the aforementioned homeostatic compensations by other lipins in regards to cellular metabolism may constitute an advantage when considering lipin1 as a host target for anti-HCV therapy.ChemicalsHCV antiviral compounds 2\u00b4-c-methyladenosine (2mAde), sofosbuvir and daclatasvir were obtained from Boc Sciences (NY, USA), Selleckchem (Texas, USA) and Medchem Express (New Jersey, USA) respectively and dissolved in DMSO to obtain 10mM stock solutions.", [["cellular", "ANATOMY", 184, 192], ["lipin1", "CHEMICAL", 45, 51], ["2\u00b4-c-methyladenosine", "CHEMICAL", 327, 347], ["2mAde", "CHEMICAL", 349, 354], ["sofosbuvir", "CHEMICAL", 357, 367], ["daclatasvir", "CHEMICAL", 372, 383], ["DMSO", "CHEMICAL", 520, 524], ["2\u00b4-c-methyladenosine", "CHEMICAL", 327, 347], ["2mAde", "CHEMICAL", 349, 354], ["sofosbuvir", "CHEMICAL", 357, 367], ["daclatasvir", "CHEMICAL", 372, 383], ["DMSO", "CHEMICAL", 520, 524], ["lipin1", "GENE_OR_GENE_PRODUCT", 45, 51], ["HCV", "ORGANISM", 84, 87], ["lipins", "GENE_OR_GENE_PRODUCT", 163, 169], ["cellular", "CELL", 184, 192], ["lipin1", "GENE_OR_GENE_PRODUCT", 249, 255], ["ChemicalsHCV", "SIMPLE_CHEMICAL", 294, 306], ["2\u00b4-c-methyladenosine", "SIMPLE_CHEMICAL", 327, 347], ["2mAde", "SIMPLE_CHEMICAL", 349, 354], ["sofosbuvir", "SIMPLE_CHEMICAL", 357, 367], ["daclatasvir", "SIMPLE_CHEMICAL", 372, 383], ["DMSO", "SIMPLE_CHEMICAL", 520, 524], ["lipin1", "PROTEIN", 45, 51], ["lipin1", "PROTEIN", 249, 255], ["HCV", "SPECIES", 84, 87], ["lipin1", "TREATMENT", 45, 51], ["HCV replication", "TREATMENT", 84, 99], ["the aforementioned homeostatic compensations", "PROBLEM", 109, 153], ["cellular metabolism", "PROBLEM", 184, 203], ["lipin1", "TREATMENT", 249, 255], ["anti-HCV therapy", "TREATMENT", 277, 293], ["ChemicalsHCV antiviral compounds", "TREATMENT", 294, 326], ["methyladenosine", "TREATMENT", 332, 347], ["sofosbuvir", "TREATMENT", 357, 367], ["daclatasvir", "TREATMENT", 372, 383], ["10mM stock solutions", "TREATMENT", 535, 555]]], ["Nacetylcysteine (NAC) and puromycin were obtained from Sigma-Aldrich (Missouri, USA), dissolved in water to a final concentration of 0.5 M and 50 mg/ml respectively.", [["Nacetylcysteine", "CHEMICAL", 0, 15], ["NAC", "CHEMICAL", 17, 20], ["puromycin", "CHEMICAL", 26, 35], ["Nacetylcysteine", "CHEMICAL", 0, 15], ["NAC", "CHEMICAL", 17, 20], ["puromycin", "CHEMICAL", 26, 35], ["Nacetylcysteine", "SIMPLE_CHEMICAL", 0, 15], ["NAC", "SIMPLE_CHEMICAL", 17, 20], ["puromycin", "SIMPLE_CHEMICAL", 26, 35], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 55, 68], ["Nacetylcysteine (NAC)", "TREATMENT", 0, 21], ["puromycin", "TREATMENT", 26, 35]]], ["Hydroxyzine pamoate was purchased from Sigma-Aldrich (Missouri, USA) and dissolved in DMSO to a final 10 mM concentration.Cells and virusesHuman hepatoma Huh-7 and derived subclones Huh-7.5, Huh-7.5.1 (clone 2) have been described [94] [95] [96] and were kindly provided by Dr. Chisari (TSRI-La Jolla, CA).", [["Cells", "ANATOMY", 122, 127], ["hepatoma Huh-7", "ANATOMY", 145, 159], ["subclones", "ANATOMY", 172, 181], ["Hydroxyzine pamoate", "CHEMICAL", 0, 19], ["DMSO", "CHEMICAL", 86, 90], ["Hydroxyzine pamoate", "CHEMICAL", 0, 19], ["DMSO", "CHEMICAL", 86, 90], ["Hydroxyzine pamoate", "SIMPLE_CHEMICAL", 0, 19], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 39, 52], ["DMSO", "SIMPLE_CHEMICAL", 86, 90], ["Cells", "CELL", 122, 127], ["Human", "ORGANISM", 139, 144], ["hepatoma Huh-7", "CELL", 145, 159], ["subclones Huh-7.5", "CELL", 172, 189], ["Huh-7.5.1", "CELL", 191, 200], ["clone 2", "CELL", 202, 209], ["Human hepatoma Huh-7", "CELL_LINE", 139, 159], ["Human", "SPECIES", 139, 144], ["Human hepatoma Huh-7", "SPECIES", 139, 159], ["Hydroxyzine pamoate", "TREATMENT", 0, 19], ["Cells", "TEST", 122, 127], ["viruses", "TEST", 132, 139], ["Human hepatoma", "TEST", 139, 153], ["Huh", "TEST", 154, 157], ["subclones Huh", "TEST", 172, 185], ["Huh", "TEST", 191, 194], ["TSRI", "TEST", 287, 291], ["hepatoma", "ANATOMY", 145, 153]]], ["HEK-293T cells [97] were kindly provided by Dr. Ortin (CNB-Madrid, Spain).", [["HEK-293T cells", "ANATOMY", 0, 14], ["HEK-293T", "CHEMICAL", 0, 8], ["HEK-293T cells", "CELL", 0, 14], ["HEK-293T cells", "CELL_LINE", 0, 14], ["HEK", "TEST", 0, 3], ["cells", "TEST", 9, 14]]], ["Cell cultures were maintained subconfluent in Dulbecco\u00b4s Modified Eagle\u00b4s Medium (Gibco) supplemented with 10 mM HEPES (Gibco), 100U/ml Penicillin/Streptomycin (Gibco), 100\u03bcM non-essential amino acids (Gibco) and 10% fetal bovine serum (Sigma-Aldrich).HCV viruses.Genotype 2a (JFH-1 strain), D183 adapted virus (D183) and genotype 1a (TNcc) virus have been described elsewhere [42, 49, 56] .", [["Cell cultures", "ANATOMY", 0, 13], ["subconfluent", "ANATOMY", 30, 42], ["fetal bovine serum", "ANATOMY", 217, 235], ["Penicillin", "CHEMICAL", 136, 146], ["Streptomycin", "CHEMICAL", 147, 159], ["amino acids", "CHEMICAL", 189, 200], ["HCV viruses", "DISEASE", 252, 263], ["HEPES", "CHEMICAL", 113, 118], ["Penicillin", "CHEMICAL", 136, 146], ["Streptomycin", "CHEMICAL", 147, 159], ["amino acids", "CHEMICAL", 189, 200], ["Cell cultures", "CELL", 0, 13], ["subconfluent", "CELL", 30, 42], ["Penicillin", "SIMPLE_CHEMICAL", 136, 146], ["Streptomycin", "SIMPLE_CHEMICAL", 147, 159], ["amino acids", "AMINO_ACID", 189, 200], ["Gibco", "ORGANISM_SUBSTANCE", 202, 207], ["bovine", "ORGANISM", 223, 229], ["serum", "ORGANISM_SUBSTANCE", 230, 235], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 237, 250], ["HCV viruses", "ORGANISM", 252, 263], ["JFH-1 strain", "ORGANISM", 277, 289], ["D183 adapted virus", "ORGANISM", 292, 310], ["genotype 1a (TNcc) virus", "ORGANISM", 322, 346], ["bovine", "SPECIES", 223, 229], ["bovine", "SPECIES", 223, 229], ["HCV", "SPECIES", 252, 255], ["Cell cultures", "TEST", 0, 13], ["Dulbecco\u00b4s Modified Eagle\u00b4s Medium (Gibco)", "TREATMENT", 46, 88], ["10 mM HEPES (Gibco)", "TREATMENT", 107, 126], ["Penicillin", "TREATMENT", 136, 146], ["Streptomycin", "TREATMENT", 147, 159], ["non-essential amino acids", "TEST", 175, 200], ["Gibco", "TEST", 202, 207], ["10% fetal bovine serum", "TREATMENT", 213, 235], ["HCV viruses", "PROBLEM", 252, 263], ["Genotype", "TEST", 264, 272], ["JFH", "TEST", 277, 280], ["genotype 1a (TNcc) virus", "PROBLEM", 322, 346], ["subconfluent", "OBSERVATION_MODIFIER", 30, 42], ["amino acids", "OBSERVATION", 189, 200], ["viruses", "OBSERVATION", 256, 263]]], ["TNcc plasmid was kindly provided by Dr. Jens Bukh (Huidovre Hospital; Copenhagen, Denmark).", [["TNcc", "GENE_OR_GENE_PRODUCT", 0, 4], ["TNcc plasmid", "DNA", 0, 12], ["TNcc plasmid", "TREATMENT", 0, 12]]], ["Recombinant viruses were generated by electroporation of an in vitro transcribed RNA as described previously [42] , using clone 2 cells (JFH-1 and D183) virus and Huh-7.5 cells for TNcc.", [["clone 2 cells", "ANATOMY", 122, 135], ["JFH-1", "ANATOMY", 137, 142], ["Huh-7.5 cells", "ANATOMY", 163, 176], ["clone 2 cells", "CELL", 122, 135], ["JFH-1", "CELL", 137, 142], ["D183", "CELL", 147, 151], ["Huh-7.5 cells", "CELL", 163, 176], ["TNcc", "CELL", 181, 185], ["in vitro transcribed RNA", "RNA", 60, 84], ["clone 2 cells", "CELL_LINE", 122, 135], ["JFH-1 and D183) virus and Huh-7.5 cells", "CELL_LINE", 137, 176], ["Recombinant viruses", "PROBLEM", 0, 19], ["an in vitro transcribed RNA", "PROBLEM", 57, 84], ["clone 2 cells", "TEST", 122, 135], ["JFH", "TEST", 137, 140], ["virus", "TEST", 153, 158], ["Huh", "TEST", 163, 166], ["TNcc", "PROBLEM", 181, 185], ["viruses", "OBSERVATION", 12, 19]]], ["Supernatants containing the infectious virus were used to inoculate naive Huh-7.5.1 clone 2 cells at low multiplicity of infection (MOI 0.01 FFU/cell) to prepare working virus stocks.", [["Supernatants", "ANATOMY", 0, 12], ["Huh-7.5.1 clone 2 cells", "ANATOMY", 74, 97], ["cell", "ANATOMY", 145, 149], ["infection", "DISEASE", 121, 130], ["Huh-7.5.1 clone 2 cells", "CELL", 74, 97], ["cell", "CELL", 145, 149], ["naive Huh-7.5.1 clone 2 cells", "CELL_LINE", 68, 97], ["Supernatants", "TREATMENT", 0, 12], ["the infectious virus", "PROBLEM", 24, 44], ["naive Huh", "TEST", 68, 77], ["infection", "PROBLEM", 121, 130], ["infectious virus", "OBSERVATION", 28, 44], ["low multiplicity", "OBSERVATION_MODIFIER", 101, 117], ["infection", "OBSERVATION", 121, 130]]], ["For TNcc infections, supernatants of electroporated cells were directly used.HCV viruses.Lentivirus production.", [["supernatants", "ANATOMY", 21, 33], ["cells", "ANATOMY", 52, 57], ["infections", "DISEASE", 9, 19], ["HCV viruses", "DISEASE", 77, 88], ["TNcc", "SIMPLE_CHEMICAL", 4, 8], ["cells", "CELL", 52, 57], ["HCV viruses", "ORGANISM", 77, 88], ["Lentivirus", "ORGANISM", 89, 99], ["electroporated cells", "CELL_LINE", 37, 57], ["HCV", "SPECIES", 77, 80], ["Lentivirus", "SPECIES", 89, 99], ["TNcc infections", "PROBLEM", 4, 19], ["supernatants of electroporated cells", "TREATMENT", 21, 57], ["HCV viruses", "PROBLEM", 77, 88], ["Lentivirus production", "PROBLEM", 89, 110], ["infections", "OBSERVATION", 9, 19], ["electroporated cells", "OBSERVATION", 37, 57], ["viruses", "OBSERVATION", 81, 88]]], ["Lentiviral vectors shRNA expression were produced by co-transfection of plasmids pMDL-RRE, pMD2G and pRSV-Rev (a gift from Didier Trono-Addgene plasmids #12251; #12253; #12259), together with the genomic plasmid (Mission pLKO-puro; Sigma-Aldrich) into HEK-293T cells [21] .", [["plasmid", "ANATOMY", 204, 211], ["HEK-293T cells", "ANATOMY", 252, 266], ["Lentiviral", "ORGANISM", 0, 10], ["pMDL-RRE", "GENE_OR_GENE_PRODUCT", 81, 89], ["pMD2G", "GENE_OR_GENE_PRODUCT", 91, 96], ["pRSV-Rev", "GENE_OR_GENE_PRODUCT", 101, 109], ["HEK-293T cells", "CELL", 252, 266], ["plasmids", "DNA", 72, 80], ["pMDL", "DNA", 81, 85], ["RRE", "DNA", 86, 89], ["pMD2G", "DNA", 91, 96], ["pRSV", "DNA", 101, 105], ["Rev", "DNA", 106, 109], ["Addgene plasmids", "DNA", 136, 152], ["#12259", "DNA", 169, 175], ["genomic plasmid", "DNA", 196, 211], ["Mission pLKO-puro; Sigma-Aldrich", "DNA", 213, 245], ["HEK-293T cells", "CELL_LINE", 252, 266], ["Lentiviral", "SPECIES", 0, 10], ["Lentiviral vectors shRNA expression", "TREATMENT", 0, 35], ["pLKO", "TEST", 221, 225]]], ["Selected shRNA target sequences are: CGAGAGAA AGTGGTTGACATA (shLPIN1-1); (CCTCAGACAGAAATGCAGTTT) shLPIN1-2; CACT CCCAGTCCTTCCGGTTC (shLPIN1-3); CCTGTTCCATCCTTCGGAAAG (shLPIN1-4).", [["shLPIN1-1", "GENE_OR_GENE_PRODUCT", 61, 70], ["shLPIN1-3", "GENE_OR_GENE_PRODUCT", 132, 141], ["shRNA target sequences", "DNA", 9, 31], ["shLPIN1", "DNA", 61, 68], ["shLPIN1", "DNA", 132, 139], ["shLPIN1", "DNA", 167, 174], ["Selected shRNA target sequences", "TEST", 0, 31], ["CGAGAGAA", "TEST", 37, 45], ["AGTGGTTGACATA", "TEST", 46, 59], ["shLPIN1", "TEST", 61, 68], ["CCTCAGACAGAAATGCAGTTT", "TEST", 74, 95], ["shLPIN1", "TEST", 97, 104], ["CCTGTTCCATCCTTCGGAAAG (shLPIN1", "TREATMENT", 144, 174]]], ["Plasmids encoding a ATG4B shRNA (ATG4B800) [57] , non-targeting shRNA (shControl) as well as an shRNA targeting HCV IRES (shHCV)were previously described [21] .", [["ATG4B", "GENE_OR_GENE_PRODUCT", 20, 25], ["HCV", "ORGANISM", 112, 115], ["ATG4B shRNA", "DNA", 20, 31], ["non-targeting shRNA", "DNA", 50, 69], ["shControl", "DNA", 71, 80], ["shRNA", "DNA", 96, 101], ["HCV IRES", "DNA", 112, 120], ["shHCV", "DNA", 122, 127], ["HCV", "SPECIES", 112, 115], ["non-targeting shRNA (shControl)", "TREATMENT", 50, 81], ["an shRNA targeting HCV IRES", "TREATMENT", 93, 120]]], ["A lentiviral vector plasmid encoding lipin1-alpha cDNA was purchased from Genecopeia (Cat Nbr: EX-T7124-Lv153).", [["plasmid", "ANATOMY", 20, 27], ["lentiviral", "ORGANISM", 2, 12], ["lipin1-alpha", "GENE_OR_GENE_PRODUCT", 37, 49], ["lentiviral vector plasmid", "DNA", 2, 27], ["lipin1", "PROTEIN", 37, 43], ["alpha cDNA", "DNA", 44, 54], ["Lv153", "DNA", 104, 109], ["Genecopeia (Cat Nbr: EX-T7124-Lv153", "SPECIES", 74, 109], ["A lentiviral vector plasmid encoding lipin1", "TREATMENT", 0, 43], ["alpha cDNA", "TREATMENT", 44, 54], ["EX", "TEST", 95, 97]]], ["To generate lipin1 beta isoform, exon 7 sequence was inserted using NEB-Q5 mutagenesis kit (NEB).", [["lipin1 beta", "GENE_OR_GENE_PRODUCT", 12, 23], ["lipin1 beta isoform", "PROTEIN", 12, 31], ["exon 7 sequence", "DNA", 33, 48], ["NEB", "PROTEIN", 68, 71], ["lipin1 beta isoform", "TREATMENT", 12, 31], ["exon 7 sequence", "TREATMENT", 33, 48], ["NEB", "TREATMENT", 68, 71], ["mutagenesis kit (NEB", "TREATMENT", 75, 95]]], ["Similarly, silent mutations were introduced in shLPIN1-2 target sequence to obtain wt lipin1beta protein expression from a cDNA resistant to silencing.", [["shLPIN1-2", "GENE_OR_GENE_PRODUCT", 47, 56], ["lipin1beta", "GENE_OR_GENE_PRODUCT", 86, 96], ["shLPIN1-2 target sequence", "DNA", 47, 72], ["lipin1beta protein", "PROTEIN", 86, 104], ["silent mutations", "PROBLEM", 11, 27], ["wt lipin1beta protein expression", "TREATMENT", 83, 115], ["a cDNA resistant to silencing", "PROBLEM", 121, 150]]], ["Mutations in the conserved motifs DXDXT (DIDGT>EIDGT) and LXXIL (LGHIL>LGHFF) were also introduced in lipin1beta cDNA using NEB-Q5 kit, based on previously described mutations [31, 98] .", [["DXDXT", "GENE_OR_GENE_PRODUCT", 34, 39], ["DIDGT>EIDGT)", "GENE_OR_GENE_PRODUCT", 41, 53], ["LXXIL (LGHIL>LGHFF", "GENE_OR_GENE_PRODUCT", 58, 76], ["lipin1beta", "GENE_OR_GENE_PRODUCT", 102, 112], ["NEB-Q5", "GENE_OR_GENE_PRODUCT", 124, 130], ["conserved motifs", "DNA", 17, 33], ["DXDXT", "DNA", 34, 39], ["DIDGT", "DNA", 41, 46], ["EIDGT", "DNA", 47, 52], ["LXXIL", "DNA", 58, 63], ["LGHIL", "DNA", 65, 70], ["LGHFF", "DNA", 71, 76], ["lipin1beta cDNA", "DNA", 102, 117], ["NEB", "PROTEIN", 124, 127], ["Mutations", "PROBLEM", 0, 9], ["DXDXT", "TEST", 34, 39], ["DIDGT>EIDGT)", "TREATMENT", 41, 53], ["LXXIL (LGHIL>LGHFF)", "TREATMENT", 58, 77], ["NEB", "TREATMENT", 124, 127]]], ["The sequence of the entire LPIN1 cDNAs was determined by Sanger sequencing before use, to assess the introduction of only the desired mutations.HCV viruses.Coronavirus 229E-GFP.", [["HCV viruses", "DISEASE", 144, 155], ["LPIN1", "GENE_OR_GENE_PRODUCT", 27, 32], ["HCV viruses", "ORGANISM", 144, 155], ["GFP", "GENE_OR_GENE_PRODUCT", 173, 176], ["LPIN1 cDNAs", "DNA", 27, 38], ["Coronavirus 229E-GFP", "DNA", 156, 176], ["HCV", "SPECIES", 144, 147], ["the desired mutations", "PROBLEM", 122, 143], ["HCV viruses", "PROBLEM", 144, 155], ["Coronavirus", "TEST", 156, 167], ["viruses", "OBSERVATION", 148, 155]]], ["Recombinant human coronavirus 229E-GFP [51] was kindly provided by Dr. Volker Thiel (University of Bern, Switzerland).", [["human", "ORGANISM", 12, 17], ["coronavirus 229E", "ORGANISM", 18, 34], ["GFP", "GENE_OR_GENE_PRODUCT", 35, 38], ["human", "SPECIES", 12, 17], ["coronavirus", "SPECIES", 18, 29], ["human coronavirus", "SPECIES", 12, 29], ["Recombinant human coronavirus", "TEST", 0, 29]]], ["Virus was propagated by infection (MOI 0.01) in Huh-7 cells.", [["Huh-7 cells", "ANATOMY", 48, 59], ["infection", "DISEASE", 24, 33], ["Virus", "ORGANISM", 0, 5], ["Huh-7 cells", "CELL", 48, 59], ["Huh-7 cells", "CELL_LINE", 48, 59], ["Huh-7", "SPECIES", 48, 53], ["Virus", "PROBLEM", 0, 5], ["infection", "PROBLEM", 24, 33], ["MOI", "TEST", 35, 38], ["Huh", "TEST", 48, 51], ["infection", "OBSERVATION", 24, 33]]], ["Supernatants were collected at different time points and titrated by end-point dilution and immunofluorescence microscopy.Production of lipin1-deficient cell linesLentiviral vectors expressing control and LPIN1-specific shRNAs were used to inoculate Huh-7 cells.", [["Supernatants", "ANATOMY", 0, 12], ["cell lines", "ANATOMY", 153, 163], ["Huh-7 cells", "ANATOMY", 250, 261], ["Supernatants", "CELL", 0, 12], ["lipin1", "GENE_OR_GENE_PRODUCT", 136, 142], ["cell lines", "CELL", 153, 163], ["Lentiviral", "ORGANISM", 163, 173], ["LPIN1", "GENE_OR_GENE_PRODUCT", 205, 210], ["Huh-7 cells", "CELL", 250, 261], ["lipin1-deficient cell lines", "CELL_LINE", 136, 163], ["LPIN1", "PROTEIN", 205, 210], ["shRNAs", "DNA", 220, 226], ["Huh-7 cells", "CELL_LINE", 250, 261], ["immunofluorescence microscopy", "TEST", 92, 121], ["lipin1-deficient cell linesLentiviral vectors", "TREATMENT", 136, 181], ["LPIN1-specific shRNAs", "TREATMENT", 205, 226], ["Huh", "TEST", 250, 253], ["deficient cell lines", "OBSERVATION", 143, 163], ["Lentiviral vectors", "OBSERVATION", 163, 181]]], ["Twenty-four hours later, cells were subjected to selection with 2.5\u03bcg/ml of puromycin to assess the lowest lentivirus dose capable of conferring puromycin resistance to 100% of the cell population.", [["cells", "ANATOMY", 25, 30], ["cell", "ANATOMY", 181, 185], ["puromycin", "CHEMICAL", 76, 85], ["puromycin", "CHEMICAL", 145, 154], ["puromycin", "CHEMICAL", 76, 85], ["puromycin", "CHEMICAL", 145, 154], ["cells", "CELL", 25, 30], ["puromycin", "SIMPLE_CHEMICAL", 76, 85], ["lentivirus", "ORGANISM", 107, 117], ["puromycin", "SIMPLE_CHEMICAL", 145, 154], ["cell", "CELL", 181, 185], ["puromycin", "TREATMENT", 76, 85], ["the lowest lentivirus dose", "TREATMENT", 96, 122], ["conferring puromycin resistance", "TREATMENT", 134, 165], ["the cell population", "TREATMENT", 177, 196], ["puromycin resistance", "OBSERVATION", 145, 165]]], ["Selected cell populations were subsequently cultured in the presence of puromycin until LPIN1 silencing was ascertained by Western-Blot using anti-lipin1 antibodies, typically at day 6-7 post lentiviral transduction, time at which all experiments were performed in the absence of puromycin.", [["cell", "ANATOMY", 9, 13], ["puromycin", "CHEMICAL", 72, 81], ["puromycin", "CHEMICAL", 280, 289], ["puromycin", "CHEMICAL", 72, 81], ["puromycin", "CHEMICAL", 280, 289], ["cell populations", "CELL", 9, 25], ["puromycin", "SIMPLE_CHEMICAL", 72, 81], ["LPIN1", "GENE_OR_GENE_PRODUCT", 88, 93], ["anti-lipin1", "GENE_OR_GENE_PRODUCT", 142, 153], ["lentiviral", "ORGANISM", 192, 202], ["puromycin", "SIMPLE_CHEMICAL", 280, 289], ["LPIN1", "PROTEIN", 88, 93], ["anti-lipin1 antibodies", "PROTEIN", 142, 164], ["Selected cell populations", "TREATMENT", 0, 25], ["puromycin", "TREATMENT", 72, 81], ["LPIN1 silencing", "PROBLEM", 88, 103], ["anti-lipin1 antibodies", "TREATMENT", 142, 164], ["lentiviral transduction", "TREATMENT", 192, 215], ["puromycin", "TREATMENT", 280, 289], ["cell populations", "OBSERVATION", 9, 25]]], ["Before execution of all the experiments shown in this study, lipin1 expression was assessed by Western-Blot.", [["lipin1", "GENE_OR_GENE_PRODUCT", 61, 67], ["lipin1", "PROTEIN", 61, 67], ["this study", "TEST", 49, 59]]], ["Cell viability was determined by a thiazolyl blue tetrazolium blue (MTT) formazan formation assay [47] .Single and multiple cycle infections with D183 virusControl and lipin1-deficient cell lines (5.", [["Cell", "ANATOMY", 0, 4], ["cell lines", "ANATOMY", 185, 195], ["thiazolyl blue tetrazolium", "CHEMICAL", 35, 61], ["MTT", "CHEMICAL", 68, 71], ["formazan", "CHEMICAL", 73, 81], ["infections", "DISEASE", 130, 140], ["thiazolyl blue tetrazolium blue", "CHEMICAL", 35, 66], ["MTT", "CHEMICAL", 68, 71], ["formazan", "CHEMICAL", 73, 81], ["Cell", "CELL", 0, 4], ["thiazolyl blue tetrazolium blue", "SIMPLE_CHEMICAL", 35, 66], ["MTT", "SIMPLE_CHEMICAL", 68, 71], ["formazan", "SIMPLE_CHEMICAL", 73, 81], ["lipin1", "GENE_OR_GENE_PRODUCT", 168, 174], ["cell lines", "CELL", 185, 195], ["D183 virusControl and lipin1-deficient cell lines", "CELL_LINE", 146, 195], ["Cell viability", "TEST", 0, 14], ["a thiazolyl blue tetrazolium blue", "TREATMENT", 33, 66], ["formazan formation assay", "TEST", 73, 97], ["Single and multiple cycle infections", "PROBLEM", 104, 140], ["D183 virusControl", "TREATMENT", 146, 163], ["lipin1", "TREATMENT", 168, 174], ["deficient cell lines", "TREATMENT", 175, 195], ["multiple", "OBSERVATION_MODIFIER", 115, 123], ["cycle", "OBSERVATION_MODIFIER", 124, 129], ["infections", "OBSERVATION", 130, 140], ["deficient cell lines", "OBSERVATION", 175, 195]]], ["10 4 cells/well) were plated onto 12-well plates and were inoculated with D183 virus at a MOI 10 FFU/cell.", [["cells", "ANATOMY", 5, 10], ["cell", "ANATOMY", 101, 105], ["cells", "CELL", 5, 10], ["cell", "CELL", 101, 105], ["D183 virus", "SPECIES", 74, 84]]], ["Samples of the cells and supernatants were collected 24, 48 and 72 hours post-infection.", [["Samples", "ANATOMY", 0, 7], ["cells", "ANATOMY", 15, 20], ["supernatants", "ANATOMY", 25, 37], ["cells", "CELL", 15, 20], ["Samples of the cells", "TEST", 0, 20], ["supernatants", "TEST", 25, 37]]], ["For multiple cycle infection experiments (MOI 0.01), samples of the supernatants were collected at day 3, 5 and 7 post-inoculation.", [["samples", "ANATOMY", 53, 60], ["supernatants", "ANATOMY", 68, 80], ["infection", "DISEASE", 19, 28], ["multiple cycle infection experiments", "PROBLEM", 4, 40], ["samples of the supernatants", "TEST", 53, 80], ["multiple", "OBSERVATION_MODIFIER", 4, 12], ["cycle", "OBSERVATION_MODIFIER", 13, 18], ["infection", "OBSERVATION", 19, 28]]], ["Cells were split 1:3 in the multiple cycle infection experiments at days 3 and 5 to maintain the cultures subconfluent.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 43, 52], ["Cells", "CELL", 0, 5], ["subconfluent", "CELL", 106, 118], ["the multiple cycle infection experiments", "TREATMENT", 24, 64], ["the cultures", "TEST", 93, 105], ["multiple", "OBSERVATION_MODIFIER", 28, 36], ["cycle", "OBSERVATION_MODIFIER", 37, 42], ["infection", "OBSERVATION", 43, 52]]], ["Extracellular infectivity titers were determined by endpoint dilution and infection foci counting as previously described [99] .", [["Extracellular", "ANATOMY", 0, 13], ["foci", "ANATOMY", 84, 88], ["infection", "DISEASE", 74, 83], ["Extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["Extracellular infectivity titers", "PROBLEM", 0, 32], ["endpoint dilution", "TEST", 52, 69], ["infection foci counting", "PROBLEM", 74, 97], ["infectivity titers", "OBSERVATION", 14, 32], ["infection", "OBSERVATION_MODIFIER", 74, 83], ["foci", "OBSERVATION", 84, 88]]], ["Intracellular HCV RNA was determined by reverse transcription and quantitative PCR (RT-qPCR) as previously described [99] .Western-BlotTotal protein samples were prepared in Laemmli buffer and separated using polyacrylamide denaturing gel electrophoresis (SDS-PAGE).", [["Intracellular", "ANATOMY", 0, 13], ["samples", "ANATOMY", 149, 156], ["polyacrylamide", "CHEMICAL", 209, 223], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["HCV", "ORGANISM", 14, 17], ["HCV RNA", "RNA", 14, 21], ["HCV", "SPECIES", 14, 17], ["Intracellular HCV RNA", "PROBLEM", 0, 21], ["quantitative PCR", "TEST", 66, 82], ["RT-qPCR", "TEST", 84, 91], ["BlotTotal protein samples", "TREATMENT", 131, 156], ["Laemmli buffer", "TREATMENT", 174, 188], ["polyacrylamide denaturing gel electrophoresis", "TREATMENT", 209, 254], ["HCV", "OBSERVATION", 14, 17]]], ["Proteins were subsequently transferred onto PVDF membranes and incubated with 5% milk (lipins) or 3% BSA in PBS-0.25% Tween20 for one hour at room temperature (RT).", [["PVDF membranes", "ANATOMY", 44, 58], ["milk", "ANATOMY", 81, 85], ["BSA", "CHEMICAL", 101, 104], ["Tween20", "CHEMICAL", 118, 125], ["PVDF", "CHEMICAL", 44, 48], ["membranes", "CELLULAR_COMPONENT", 49, 58], ["milk", "ORGANISM_SUBSTANCE", 81, 85], ["lipins", "SIMPLE_CHEMICAL", 87, 93], ["BSA", "SIMPLE_CHEMICAL", 101, 104], ["Tween20", "SIMPLE_CHEMICAL", 118, 125], ["PVDF membranes", "TREATMENT", 44, 58], ["5% milk (lipins)", "TREATMENT", 78, 94], ["3% BSA in PBS", "TREATMENT", 98, 111]]], ["Primary antibodies against lipin1 (clone B-12; Santa Cruz), lipin2 (H-160; Santa Cruz), NS3 (clone 2E3; Biofront), beta-actin (ab8226; Abcam) and tubulin (clone AA2; Sigma-Aldrich) were diluted in PBS-0.25% Tween20 and incubated for 1 hour (four hours for lipins) at RT.", [["Tween20", "CHEMICAL", 207, 214], ["lipin1", "GENE_OR_GENE_PRODUCT", 27, 33], ["lipin2", "GENE_OR_GENE_PRODUCT", 60, 66], ["Santa Cruz", "ORGANISM", 75, 85], ["NS3", "ORGANISM", 88, 91], ["Biofront", "GENE_OR_GENE_PRODUCT", 104, 112], ["beta-actin", "GENE_OR_GENE_PRODUCT", 115, 125], ["ab8226", "GENE_OR_GENE_PRODUCT", 127, 133], ["Abcam", "GENE_OR_GENE_PRODUCT", 135, 140], ["tubulin", "GENE_OR_GENE_PRODUCT", 146, 153], ["Sigma-Aldrich", "ORGANISM", 166, 179], ["Tween20", "SIMPLE_CHEMICAL", 207, 214], ["lipin1", "PROTEIN", 27, 33], ["clone B-12", "PROTEIN", 35, 45], ["Santa Cruz", "PROTEIN", 47, 57], ["lipin2", "PROTEIN", 60, 66], ["H-160", "PROTEIN", 68, 73], ["Santa Cruz", "PROTEIN", 75, 85], ["NS3", "PROTEIN", 88, 91], ["clone 2E3", "PROTEIN", 93, 102], ["Biofront", "PROTEIN", 104, 112], ["beta-actin", "PROTEIN", 115, 125], ["ab8226", "PROTEIN", 127, 133], ["Abcam", "PROTEIN", 135, 140], ["tubulin", "PROTEIN", 146, 153], ["clone AA2", "PROTEIN", 155, 164], ["Primary antibodies", "TEST", 0, 18], ["lipin1", "TEST", 27, 33], ["clone B", "TEST", 35, 42], ["lipin2", "TEST", 60, 66], ["NS3 (clone", "TEST", 88, 98], ["beta-actin", "TEST", 115, 125], ["Abcam", "TEST", 135, 140], ["tubulin (clone AA2", "TREATMENT", 146, 164], ["Sigma-Aldrich)", "TREATMENT", 166, 180]]], ["Membranes were subsequently washed for 20 minutes with PBS-0.25% Tween20 three times.", [["Membranes", "ANATOMY", 0, 9], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["PBS", "TEST", 55, 58]]], ["Horseradish peroxidase-conjugated secondary antibodies were incubated for 1 hour at room temperature in 5% milk-PBS-0.25% Tween20 and subsequently washed three times for 20 minutes at room temperature.", [["Tween20", "CHEMICAL", 122, 129], ["Horseradish peroxidase", "SIMPLE_CHEMICAL", 0, 22], ["milk", "ORGANISM_SUBSTANCE", 107, 111], ["Tween20", "SIMPLE_CHEMICAL", 122, 129], ["Horseradish peroxidase", "PROTEIN", 0, 22], ["conjugated secondary antibodies", "PROTEIN", 23, 54], ["Horseradish", "SPECIES", 0, 11], ["Horseradish peroxidase", "TREATMENT", 0, 22], ["conjugated secondary antibodies", "TREATMENT", 23, 54]]], ["Protein bands were detected using enhanced chemoluminescence reactions and exposure to photographic films.", [["Protein bands", "TEST", 0, 13], ["enhanced chemoluminescence reactions", "PROBLEM", 34, 70], ["photographic films", "TEST", 87, 105]]], ["Specific bands were quantitated using the ImageJ Software [100] on non-saturated, scanned films.", [["Specific bands", "PROBLEM", 0, 14], ["the ImageJ Software", "TEST", 38, 57], ["scanned films", "TEST", 82, 95]]], ["Confocal microscopy was performed with a Leica TCS SP8 laser scanning system (Leica Microsystems).", [["TCS", "CHEMICAL", 47, 50], ["Confocal microscopy", "TEST", 0, 19], ["a Leica TCS", "TEST", 39, 50]]], ["Images of 1024 \u00d7 1024 pixels at eight bit gray scale depth were acquired sequentially every 0.13-0.3 \u03bcm through a 63x/1.40 N.A. immersion oil lens, employing LAS AF v 2.6.0 software (Leica Microsystems).", [["Images", "TEST", 0, 6], ["pixels", "TEST", 22, 28], ["bit gray scale depth", "TEST", 38, 58], ["LAS AF v", "TEST", 158, 166]]], ["Colocalization indexes were calculated using Jacop plugin for Image J [101] from a minimum of 10 regions of interest (ROI).", [["Colocalization indexes", "TEST", 0, 22], ["Jacop plugin", "TREATMENT", 45, 57]]], ["Images were processed using ImageJ, were medians of 1 pixel were obtained for the different channels, only for illustration, not for analysis.", [["Images", "TEST", 0, 6], ["ImageJ", "TEST", 28, 34], ["analysis", "TEST", 133, 141]]], ["Color levels, brightness and contrast were manipulated for illustration using technical and biological controls as reference.RNA extraction and RT-qPCRTotal RNA extraction was performed using the GTC extraction method [102] .", [["Color levels", "TEST", 0, 12], ["contrast", "TREATMENT", 29, 37], ["RNA extraction", "TREATMENT", 125, 139], ["RT-qPCRTotal RNA extraction", "TREATMENT", 144, 171], ["the GTC extraction method", "TREATMENT", 192, 217]]], ["Purified RNA (10-500 ng) was subjected to RT-qPCR using random hexamers and a Reverse Transcription Kit (Applied Biosystems).", [["Purified RNA", "PROBLEM", 0, 12], ["random hexamers", "TREATMENT", 56, 71], ["a Reverse Transcription Kit", "TREATMENT", 76, 103]]], ["Quantitative PCR was performed using 2X Reaction Buffer from (Applied Biosystems) and specific oligonucleotides as previously described [99, 103] .", [["Quantitative PCR", "TEST", 0, 16], ["2X Reaction Buffer", "TREATMENT", 37, 55], ["specific oligonucleotides", "TREATMENT", 86, 111]]], ["Standard curves were prepared by serial dilution of a known copy number of the corresponding amplicon cloned in a plasmid vector.Infections with genotype 1a TNccControl and lipin1-deficient Huh-7.5 cells were inoculated with TNcc virus (MOI 0.05).", [["plasmid", "ANATOMY", 114, 121], ["Huh-7.5 cells", "ANATOMY", 190, 203], ["lipin1", "GENE_OR_GENE_PRODUCT", 173, 179], ["Huh-7.5 cells", "CELL", 190, 203], ["TNcc virus", "ORGANISM", 225, 235], ["plasmid vector", "DNA", 114, 128], ["lipin1-deficient Huh-7.5 cells", "CELL_LINE", 173, 203], ["the corresponding amplicon", "TREATMENT", 75, 101], ["a plasmid vector", "TREATMENT", 112, 128], ["Infections", "PROBLEM", 129, 139], ["genotype 1a TNccControl", "TREATMENT", 145, 168], ["lipin1", "TEST", 173, 179], ["Huh", "TEST", 190, 193], ["TNcc virus", "PROBLEM", 225, 235]]], ["Due to the relatively low propagation levels of the TNcc virus in this experimental setup, parallel cultures were infected and treated with 2\u00b4-C-methyladenosine (2mAde; 10\u03bcM) to determine the levels of non-replicative, background HCV RNA.", [["2\u00b4-C-methyladenosine", "CHEMICAL", 140, 160], ["2mAde", "CHEMICAL", 162, 167], ["2\u00b4-C-methyladenosine", "CHEMICAL", 140, 160], ["2mAde", "CHEMICAL", 162, 167], ["TNcc virus", "ORGANISM", 52, 62], ["2\u00b4-C-methyladenosine", "SIMPLE_CHEMICAL", 140, 160], ["2mAde", "SIMPLE_CHEMICAL", 162, 167], ["parallel cultures", "CELL_LINE", 91, 108], ["non-replicative, background HCV RNA", "RNA", 202, 237], ["TNcc virus", "SPECIES", 52, 62], ["HCV", "SPECIES", 230, 233], ["the relatively low propagation levels", "PROBLEM", 7, 44], ["the TNcc virus", "PROBLEM", 48, 62], ["this experimental setup", "TEST", 66, 89], ["parallel cultures", "TEST", 91, 108], ["methyladenosine", "TREATMENT", 145, 160], ["background HCV RNA", "PROBLEM", 219, 237], ["low propagation", "OBSERVATION_MODIFIER", 22, 37], ["HCV RNA", "OBSERVATION", 230, 237]]], ["Cells were incubated for 72 hours at 37\u02daC, time after which samples of the cells were collected to determine intracellular HCV RNA levels by RT-qPCR.Persistently infected cell culturesTo establish persistently infected cell cultures Huh-7 cells were inoculated at MOI 0.01 with JFH-1 HCV strain as previously described [24] .", [["Cells", "ANATOMY", 0, 5], ["samples", "ANATOMY", 60, 67], ["cells", "ANATOMY", 75, 80], ["intracellular", "ANATOMY", 109, 122], ["cell cultures", "ANATOMY", 171, 184], ["cell", "ANATOMY", 219, 223], ["Huh-7 cells", "ANATOMY", 233, 244], ["Cells", "CELL", 0, 5], ["cells", "CELL", 75, 80], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 109, 122], ["cell cultures", "CELL", 171, 184], ["cell", "CELL", 219, 223], ["Huh-7 cells", "CELL", 233, 244], ["HCV", "ORGANISM", 284, 287], ["HCV RNA", "RNA", 123, 130], ["Persistently infected cell cultures", "CELL_LINE", 149, 184], ["persistently infected cell cultures", "CELL_LINE", 197, 232], ["Huh-7 cells", "CELL_LINE", 233, 244], ["HCV", "SPECIES", 123, 126], ["Huh-7", "SPECIES", 233, 238], ["JFH-1 HCV", "SPECIES", 278, 287], ["the cells", "PROBLEM", 71, 80], ["RT", "TEST", 141, 143], ["Persistently infected cell cultures", "PROBLEM", 149, 184], ["persistently infected cell cultures", "PROBLEM", 197, 232], ["Huh", "TEST", 233, 236], ["MOI", "TEST", 264, 267], ["JFH", "TEST", 278, 281], ["1 HCV strain", "PROBLEM", 282, 294], ["infected cell cultures", "OBSERVATION", 162, 184], ["persistently", "OBSERVATION_MODIFIER", 197, 209], ["infected", "OBSERVATION_MODIFIER", 210, 218], ["cell cultures", "OBSERVATION", 219, 232], ["7 cells", "OBSERVATION_MODIFIER", 237, 244], ["HCV strain", "OBSERVATION", 284, 294]]], ["Cell cultures were maintained subconfluent for two weeks, time after which infection rates reach nearly 100% of the cells, as assessed by immunofluorescence microscopy.", [["Cell cultures", "ANATOMY", 0, 13], ["subconfluent", "ANATOMY", 30, 42], ["cells", "ANATOMY", 116, 121], ["infection", "DISEASE", 75, 84], ["Cell cultures", "CELL", 0, 13], ["subconfluent", "CELL", 30, 42], ["cells", "CELL", 116, 121], ["Cell cultures", "TEST", 0, 13], ["infection rates", "TEST", 75, 90], ["immunofluorescence microscopy", "TEST", 138, 167], ["subconfluent", "OBSERVATION_MODIFIER", 30, 42], ["infection", "OBSERVATION", 75, 84]]], ["At this point cells were split and transduced with the corresponding lentiviral vectors in order to generate lipin1-deficient cell cultures as well as control cell lines.", [["cells", "ANATOMY", 14, 19], ["cell cultures", "ANATOMY", 126, 139], ["cell lines", "ANATOMY", 159, 169], ["cells", "CELL", 14, 19], ["lentiviral", "ORGANISM", 69, 79], ["lipin1", "GENE_OR_GENE_PRODUCT", 109, 115], ["cell cultures", "CELL", 126, 139], ["cell lines", "CELL", 159, 169], ["lipin1-deficient cell cultures", "CELL_LINE", 109, 139], ["control cell lines", "CELL_LINE", 151, 169], ["the corresponding lentiviral vectors", "TREATMENT", 51, 87], ["lipin1-deficient cell cultures", "TREATMENT", 109, 139], ["control cell lines", "TREATMENT", 151, 169], ["cell lines", "OBSERVATION", 159, 169]]], ["Once silencing had been verified by Western-blot, typically at day 6-8 post-transduction, cells were split and samples of the cells and supernatants were collected 24 hours later to determine intracellular HCV RNA levels by RT-qPCR and extracellular infectivity titers by end-point dilution and immunofluorescence microscopy.Production of trans-complemented infectious HCV virions bearing a reporter geneInfectious, spread-deficient HCV particles produced by trans-complementation (HCV tcp ) have previously been described [52] .", [["cells", "ANATOMY", 90, 95], ["samples", "ANATOMY", 111, 118], ["cells", "ANATOMY", 126, 131], ["supernatants", "ANATOMY", 136, 148], ["intracellular", "ANATOMY", 192, 205], ["extracellular", "ANATOMY", 236, 249], ["cells", "CELL", 90, 95], ["cells", "CELL", 126, 131], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 192, 205], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 236, 249], ["HCV virions", "ORGANISM", 369, 380], ["HCV", "ORGANISM", 433, 436], ["HCV RNA", "RNA", 206, 213], ["HCV", "SPECIES", 206, 209], ["HCV", "SPECIES", 369, 372], ["HCV", "SPECIES", 433, 436], ["HCV", "SPECIES", 482, 485], ["cells", "PROBLEM", 90, 95], ["supernatants", "TEST", 136, 148], ["intracellular HCV RNA levels", "TEST", 192, 220], ["RT", "TEST", 224, 226], ["qPCR", "TEST", 227, 231], ["extracellular infectivity titers", "TEST", 236, 268], ["immunofluorescence microscopy", "TEST", 295, 324], ["complemented infectious HCV virions", "PROBLEM", 345, 380], ["deficient HCV particles", "PROBLEM", 423, 446], ["HCV tcp", "PROBLEM", 482, 489], ["infectious", "OBSERVATION_MODIFIER", 358, 368]]], ["Briefly, Huh-7.5.1 clone 2 cells expressing core-E1 and E2-NS2 regions from JFH-1 by lentiviral transduction, were electroporated with a JFH-1 subgenomic dicistronic replicon bearing a firefly luciferase gene with reagents kindly provided by Dr. Ralf Bartenschlager (U. of Heidelberg).", [["Huh-7.5.1 clone 2 cells", "ANATOMY", 9, 32], ["Huh-7.5.1 clone 2 cells", "CELL", 9, 32], ["core-E1", "GENE_OR_GENE_PRODUCT", 44, 51], ["E2", "GENE_OR_GENE_PRODUCT", 56, 58], ["JFH-1", "GENE_OR_GENE_PRODUCT", 76, 81], ["lentiviral", "ORGANISM", 85, 95], ["JFH-1", "GENE_OR_GENE_PRODUCT", 137, 142], ["luciferase", "GENE_OR_GENE_PRODUCT", 193, 203], ["Huh-7.5.1 clone 2 cells", "CELL_LINE", 9, 32], ["E1 and E2-NS2 regions", "DNA", 49, 70], ["JFH-1", "DNA", 76, 81], ["JFH-1 subgenomic dicistronic replicon", "DNA", 137, 174], ["firefly luciferase gene", "DNA", 185, 208], ["Huh", "TEST", 9, 12], ["core", "TEST", 44, 48], ["JFH", "TEST", 76, 79], ["lentiviral transduction", "TREATMENT", 85, 108], ["a JFH", "TREATMENT", 135, 140], ["1 subgenomic dicistronic replicon", "TREATMENT", 141, 174], ["NS2", "ANATOMY", 59, 62], ["regions", "ANATOMY_MODIFIER", 63, 70], ["dicistronic replicon", "OBSERVATION", 154, 174]]], ["Supernatants containing HCV tcp were collected 36, 48 and 72 hours post-electroporation, pooled and assayed for viral infectivity.", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "ORGANISM_SUBSTANCE", 0, 12], ["HCV tcp", "ORGANISM", 24, 31], ["HCV", "SPECIES", 24, 27], ["HCV tcp", "TEST", 24, 31], ["viral infectivity", "PROBLEM", 112, 129], ["HCV", "OBSERVATION_MODIFIER", 24, 27], ["viral infectivity", "OBSERVATION", 112, 129]]], ["HCV tcp infection efficiency was determined by inoculating na\u00efve Huh-7 cells with the electroporation supernatants and measuring luciferase activity 48 hours post-infection using a commercially available kit (Promega).Analysis of viral entry using HCV ppRetroviral particle production pseudotyped with different viral envelopes has previously been described [54, 55] with the materials kindly provided by Dr. F. L. Cosset (INSERM, Lyon).", [["Huh-7 cells", "ANATOMY", 65, 76], ["supernatants", "ANATOMY", 102, 114], ["infection", "DISEASE", 8, 17], ["HCV", "ORGANISM", 0, 3], ["Huh-7 cells", "CELL", 65, 76], ["luciferase", "GENE_OR_GENE_PRODUCT", 129, 139], ["HCV ppRetroviral particle", "ORGANISM", 248, 273], ["pseudotyped", "ORGANISM", 285, 296], ["na\u00efve Huh-7 cells", "CELL_LINE", 59, 76], ["luciferase", "PROTEIN", 129, 139], ["HCV", "SPECIES", 0, 3], ["HCV", "SPECIES", 248, 251], ["HCV tcp infection efficiency", "PROBLEM", 0, 28], ["the electroporation supernatants", "TREATMENT", 82, 114], ["viral entry", "PROBLEM", 230, 241], ["HCV ppRetroviral particle production pseudotyped", "TREATMENT", 248, 296], ["different viral envelopes", "PROBLEM", 302, 327], ["infection efficiency", "OBSERVATION", 8, 28], ["viral entry", "OBSERVATION", 230, 241]]], ["Control and lipin-deficient cell lines were inoculated with HCV pp and VSV pp and incubated for 48 hours, time at which total cell lysates were assayed for luciferase activity using a commercially available kit (Promega).", [["cell lines", "ANATOMY", 28, 38], ["cell lysates", "ANATOMY", 126, 138], ["lipin", "GENE_OR_GENE_PRODUCT", 12, 17], ["cell lines", "CELL", 28, 38], ["HCV", "ORGANISM", 60, 63], ["VSV", "ORGANISM", 71, 74], ["cell lysates", "ORGANISM_SUBSTANCE", 126, 138], ["luciferase", "GENE_OR_GENE_PRODUCT", 156, 166], ["lipin-deficient cell lines", "CELL_LINE", 12, 38], ["luciferase", "PROTEIN", 156, 166], ["HCV", "SPECIES", 60, 63], ["VSV", "SPECIES", 71, 74], ["lipin-deficient cell lines", "TREATMENT", 12, 38], ["HCV pp", "TREATMENT", 60, 66], ["VSV pp", "TEST", 71, 77], ["total cell lysates", "TEST", 120, 138], ["lipin", "ANATOMY", 12, 17], ["deficient cell lines", "OBSERVATION", 18, 38]]], ["A selective HCV entry inhibitor, hydroxyzine pamoate (HDX) from Sigma-Aldrich (Missouri, USA), was used as positive control of inhibition [55] .In vitro transcription and HCV RNA transfectionA plasmid containing the sequence corresponding to a subgenomic JFH-1 replicon bearing a firefly luciferase reporter gene was kindly provided by Dr. Ralf Bartenschlager (U. of Heidelberg) [52] .", [["hydroxyzine pamoate", "CHEMICAL", 33, 52], ["HDX", "CHEMICAL", 54, 57], ["hydroxyzine pamoate", "CHEMICAL", 33, 52], ["HDX", "CHEMICAL", 54, 57], ["HCV", "ORGANISM", 12, 15], ["hydroxyzine pamoate", "SIMPLE_CHEMICAL", 33, 52], ["HDX", "SIMPLE_CHEMICAL", 54, 57], ["Sigma-Aldrich", "ORGANISM", 64, 77], ["JFH-1", "ORGANISM", 255, 260], ["luciferase", "GENE_OR_GENE_PRODUCT", 288, 298], ["subgenomic JFH-1 replicon", "DNA", 244, 269], ["firefly luciferase reporter gene", "DNA", 280, 312], ["HCV", "SPECIES", 12, 15], ["HCV", "SPECIES", 171, 174], ["A selective HCV entry inhibitor", "TREATMENT", 0, 31], ["hydroxyzine pamoate (HDX", "TREATMENT", 33, 57], ["vitro transcription", "TREATMENT", 147, 166], ["HCV RNA transfection", "TREATMENT", 171, 191], ["A plasmid", "TREATMENT", 191, 200], ["a subgenomic JFH-1 replicon", "TREATMENT", 242, 269]]], ["After digestion with the restriction enzyme MluI, the linearized plasmid was transcribed in vitro using a commercial kit (Megascript T7; Ambion-Paisley, UK).", [["plasmid", "ANATOMY", 65, 72], ["MluI", "GENE_OR_GENE_PRODUCT", 44, 48], ["Ambion-Paisley", "ORGANISM", 137, 151], ["UK", "GENE_OR_GENE_PRODUCT", 153, 155], ["restriction enzyme MluI", "DNA", 25, 48], ["linearized plasmid", "DNA", 54, 72], ["the restriction enzyme MluI", "TREATMENT", 21, 48], ["the linearized plasmid", "TREATMENT", 50, 72], ["a commercial kit (Megascript T7", "TREATMENT", 104, 135]]], ["The resulting products were digested with DNAse and precipitated with LiCl.", [["LiCl", "CHEMICAL", 70, 74], ["LiCl", "CHEMICAL", 70, 74], ["DNAse", "GENE_OR_GENE_PRODUCT", 42, 47], ["LiCl", "SIMPLE_CHEMICAL", 70, 74], ["DNAse", "PROTEIN", 42, 47], ["DNAse", "TREATMENT", 42, 47], ["LiCl", "TREATMENT", 70, 74]]], ["Pelleted RNA was washed with 75% and 100% ethanol, and resuspended in nuclease-free water.", [["ethanol", "CHEMICAL", 42, 49], ["ethanol", "CHEMICAL", 42, 49], ["ethanol", "SIMPLE_CHEMICAL", 42, 49], ["nuclease", "PROTEIN", 70, 78], ["Pelleted RNA", "TREATMENT", 0, 12], ["RNA", "OBSERVATION", 9, 12]]], ["In vitro transcribed RNA was transfected into the different cell lines together with a plasmid expressing Renilla luciferase under a minimal promoter (pRL-null; Clontech-California, USA) using Lipofectamine 2000 and the manufacturer\u00b4s recommendations (Life Technologies-California, USA).", [["cell lines", "ANATOMY", 60, 70], ["plasmid", "ANATOMY", 87, 94], ["cell lines", "CELL", 60, 70], ["Renilla", "GENE_OR_GENE_PRODUCT", 106, 113], ["luciferase", "GENE_OR_GENE_PRODUCT", 114, 124], ["cell lines", "CELL_LINE", 60, 70], ["plasmid", "DNA", 87, 94], ["Renilla luciferase", "DNA", 106, 124], ["minimal promoter", "DNA", 133, 149], ["pRL", "DNA", 151, 154], ["the different cell lines", "TREATMENT", 46, 70], ["a plasmid expressing Renilla luciferase", "TREATMENT", 85, 124], ["Lipofectamine", "TREATMENT", 193, 206], ["different cell lines", "OBSERVATION", 50, 70], ["Renilla luciferase", "OBSERVATION", 106, 124]]], ["Firefly and Renilla luciferase activities were measured in the sample using a commercial kit (Dual Luciferase Assay System; Promega-Wisconsin, USA) at different times post-transfection.Lipin1 wt and mutant cDNA overexpression in lipin1-deficient cellsLipin1-deficient cells were generated by lentiviral transduction of shLPIN1-2 shRNA.", [["sample", "ANATOMY", 63, 69], ["cellsLipin1-deficient cells", "ANATOMY", 246, 273], ["Firefly", "GENE_OR_GENE_PRODUCT", 0, 7], ["luciferase", "GENE_OR_GENE_PRODUCT", 20, 30], ["Lipin1", "GENE_OR_GENE_PRODUCT", 185, 191], ["lipin1", "GENE_OR_GENE_PRODUCT", 229, 235], ["cellsLipin1", "GENE_OR_GENE_PRODUCT", 246, 257], ["lentiviral", "ORGANISM", 292, 302], ["shLPIN1-2", "GENE_OR_GENE_PRODUCT", 319, 328], ["luciferase", "PROTEIN", 20, 30], ["Lipin1 wt and mutant cDNA", "DNA", 185, 210], ["lipin1-deficient cellsLipin1-deficient cells", "CELL_LINE", 229, 273], ["shLPIN1-2 shRNA", "DNA", 319, 334], ["Renilla luciferase activities", "TEST", 12, 41], ["Lipin1 wt", "TEST", 185, 194], ["mutant cDNA overexpression", "TEST", 199, 225], ["lipin1", "TEST", 229, 235], ["deficient cellsLipin1", "PROBLEM", 236, 257], ["deficient cells", "PROBLEM", 258, 273], ["shLPIN1", "TEST", 319, 326], ["Renilla luciferase", "OBSERVATION", 12, 30]]], ["At day 3 post-transduction, control and lipin1-deficient cell populations (5 X 10 4 cells/M24 well) were transfected in suspension using lipofectamine 2000 with plasmids (800 ng/M12 well) expressing wt lipin1beta isoform shLPIN1_2-resistant cDNA or DXDXT or LXXIL motif mutants [31] .", [["cell", "ANATOMY", 57, 61], ["cells", "ANATOMY", 84, 89], ["M24", "ANATOMY", 90, 93], ["plasmids", "ANATOMY", 161, 169], ["lipin1", "GENE_OR_GENE_PRODUCT", 40, 46], ["cell populations", "CELL", 57, 73], ["cells", "CELL", 84, 89], ["lipin1beta", "GENE_OR_GENE_PRODUCT", 202, 212], ["shLPIN1_2", "GENE_OR_GENE_PRODUCT", 221, 230], ["DXDXT", "GENE_OR_GENE_PRODUCT", 249, 254], ["LXXIL", "GENE_OR_GENE_PRODUCT", 258, 263], ["lipin1-deficient cell populations", "CELL_LINE", 40, 73], ["lipin1beta isoform shLPIN1_2-resistant cDNA", "DNA", 202, 245], ["DXDXT", "DNA", 249, 254], ["control and lipin1-deficient cell populations", "TREATMENT", 28, 73], ["lipofectamine", "TREATMENT", 137, 150], ["plasmids", "TREATMENT", 161, 169], ["beta isoform shLPIN1_2", "TREATMENT", 208, 230], ["resistant cDNA", "PROBLEM", 231, 245], ["DXDXT", "TREATMENT", 249, 254], ["LXXIL motif mutants", "TREATMENT", 258, 277], ["deficient cell", "OBSERVATION", 47, 61]]], ["Transfected cell cultures were incubated for 48 hours and subsequently inoculated at MOI 10 with D183 virus.", [["cell cultures", "ANATOMY", 12, 25], ["cell cultures", "CELL", 12, 25], ["Transfected cell cultures", "CELL_LINE", 0, 25], ["D183 virus", "SPECIES", 97, 107], ["Transfected cell cultures", "TEST", 0, 25], ["D183 virus", "TREATMENT", 97, 107]]], ["Infection efficiency was determined by measuring extracellular infectivity titers 48 hours post-infection.", [["extracellular", "ANATOMY", 49, 62], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 49, 62], ["Infection efficiency", "PROBLEM", 0, 20], ["extracellular infectivity titers", "PROBLEM", 49, 81], ["infectivity", "OBSERVATION_MODIFIER", 63, 74]]], ["Parallel cultures were used to determine relative wt and mutant protein expression efficiency by Western-Blot.", [["Parallel cultures", "TEST", 0, 17], ["mutant protein expression efficiency", "PROBLEM", 57, 93]]], ["Infectivity titers were measured as described above.", [["Infectivity titers", "TEST", 0, 18]]], ["The relative impact of cDNA expression was estimated by determining the ratio between the infectivity found in lipin1-deficient cells and the control cells transfected with the same plasmid.", [["lipin1-deficient cells", "ANATOMY", 111, 133], ["cells", "ANATOMY", 150, 155], ["plasmid", "ANATOMY", 182, 189], ["lipin1", "GENE_OR_GENE_PRODUCT", 111, 117], ["cells", "CELL", 128, 133], ["cells", "CELL", 150, 155], ["cDNA", "DNA", 23, 27], ["lipin1-deficient cells", "CELL_LINE", 111, 133], ["plasmid", "DNA", 182, 189], ["cDNA expression", "PROBLEM", 23, 38], ["the infectivity", "PROBLEM", 86, 101], ["lipin1-deficient cells", "TREATMENT", 111, 133], ["the same plasmid", "TREATMENT", 173, 189], ["cDNA expression", "OBSERVATION", 23, 38], ["deficient cells", "OBSERVATION", 118, 133]]], ["In order to average experiments with different raw infection efficiency, all the experiments were referenced to the ratio in the mock-transfected cells.Human coronavirus infectionControl and lipin1-deficient Huh-7 cells were inoculated with CoV-229E (MOI 0.01) for 2 hours at 37\u02daC. Cells were washed twice with warm PBS and replenished with DMEM-10% FCS.", [["cells", "ANATOMY", 146, 151], ["Huh-7 cells", "ANATOMY", 208, 219], ["Cells", "ANATOMY", 282, 287], ["infection", "DISEASE", 51, 60], ["coronavirus infection", "DISEASE", 158, 179], ["CoV-229E", "CHEMICAL", 241, 249], ["cells", "CELL", 146, 151], ["Human coronavirus", "ORGANISM", 152, 169], ["lipin1", "GENE_OR_GENE_PRODUCT", 191, 197], ["Huh-7 cells", "CELL", 208, 219], ["CoV", "ORGANISM", 241, 244], ["Cells", "CELL", 282, 287], ["mock-transfected cells", "CELL_LINE", 129, 151], ["lipin1-deficient Huh-7 cells", "CELL_LINE", 191, 219], ["Human", "SPECIES", 152, 157], ["coronavirus", "SPECIES", 158, 169], ["Human coronavirus", "SPECIES", 152, 169], ["CoV-229E", "SPECIES", 241, 249], ["different raw infection efficiency", "PROBLEM", 37, 71], ["Human coronavirus infection", "PROBLEM", 152, 179], ["lipin1", "TEST", 191, 197], ["Huh", "TEST", 208, 211], ["CoV", "TEST", 241, 244], ["MOI", "TEST", 251, 254], ["warm PBS", "TREATMENT", 311, 319], ["DMEM", "TREATMENT", 341, 345], ["infection", "OBSERVATION", 51, 60], ["transfected cells", "OBSERVATION", 134, 151], ["coronavirus", "OBSERVATION_MODIFIER", 158, 169], ["infection", "OBSERVATION", 170, 179]]], ["Extracellular infectivity titers were determined 48 hours post-infection by end-point dilution and fluorescence microscopy in Huh-7 cells.T7-driven viral polyprotein overexpressionHuh-7 cells were inoculated at MOI 10 with a recombinant vaccinia virus expressing the T7 phage RNA polymerase (VacT7) [104] .", [["Extracellular", "ANATOMY", 0, 13], ["Huh-7 cells", "ANATOMY", 126, 137], ["Huh-7 cells", "ANATOMY", 180, 191], ["infection", "DISEASE", 63, 72], ["Extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["Huh-7 cells", "CELL", 126, 137], ["T7", "GENE_OR_GENE_PRODUCT", 138, 140], ["Huh-7 cells", "CELL", 180, 191], ["vaccinia virus", "ORGANISM", 237, 251], ["Huh-7 cells", "CELL_LINE", 126, 137], ["T7", "DNA", 138, 140], ["Huh-7 cells", "CELL_LINE", 180, 191], ["T7 phage RNA polymerase", "PROTEIN", 267, 290], ["VacT7", "PROTEIN", 292, 297], ["Huh-7", "SPECIES", 126, 131], ["vaccinia virus", "SPECIES", 237, 251], ["Extracellular infectivity titers", "PROBLEM", 0, 32], ["infection", "PROBLEM", 63, 72], ["end-point dilution", "TEST", 76, 94], ["fluorescence microscopy", "TEST", 99, 122], ["Huh", "TEST", 126, 129], ["T7", "TEST", 138, 140], ["viral polyprotein overexpression", "TEST", 148, 180], ["a recombinant vaccinia virus", "TREATMENT", 223, 251], ["infectivity", "OBSERVATION", 14, 25], ["viral polyprotein", "OBSERVATION", 148, 165], ["T7", "ANATOMY", 267, 269]]], ["Two hours later, cells were transfected with the plasmid pTM-NS3/5B [16, 58] (kindly provided by Dr. Lohmann; U. of Heidelberg) and Lipofectamine 2000 (ThermoFisher-Massachussets, USA) following the manufacturer\u00b4s recommendations in terms of total DNA per well (typically 4\u03bcg per 35mm dishes with 7.5 X 10 5 cells/well) and 50% of the recommended lipofectamine:DNA ratio.", [["cells", "ANATOMY", 17, 22], ["cells", "ANATOMY", 308, 313], ["lipofectamine", "CHEMICAL", 347, 360], ["cells", "CELL", 17, 22], ["DNA", "CELLULAR_COMPONENT", 248, 251], ["DNA", "CELLULAR_COMPONENT", 361, 364], ["plasmid pTM", "DNA", 49, 60], ["NS3", "PROTEIN", 61, 64], ["the plasmid pTM", "TEST", 45, 60], ["Lipofectamine", "TREATMENT", 132, 145], ["total DNA", "TREATMENT", 242, 251], ["DNA ratio", "TEST", 361, 370]]], ["Transfected cells were cultured in the presence of the DNA replication inhibitor cytosine \u03b2-D-arabinofuranoside (AraC; Sigma-Aldrich) for 16 hours to prevent VacT7 replication [105] .", [["cells", "ANATOMY", 12, 17], ["cytosine \u03b2-D-arabinofuranoside", "CHEMICAL", 81, 111], ["AraC", "CHEMICAL", 113, 117], ["cytosine \u03b2-D-arabinofuranoside", "CHEMICAL", 81, 111], ["AraC", "CHEMICAL", 113, 117], ["cells", "CELL", 12, 17], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["cytosine \u03b2-D-arabinofuranoside", "SIMPLE_CHEMICAL", 81, 111], ["AraC", "SIMPLE_CHEMICAL", 113, 117], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 119, 132], ["VacT7", "GENE_OR_GENE_PRODUCT", 158, 163], ["Transfected cells", "PROBLEM", 0, 17], ["the DNA replication inhibitor cytosine", "TREATMENT", 51, 89], ["arabinofuranoside (AraC", "TREATMENT", 94, 117], ["Sigma-Aldrich)", "TREATMENT", 119, 133], ["VacT7 replication", "PROBLEM", 158, 175]]], ["When indicated, media was also supplemented with 100nM daclatasvir (DCTV).", [["daclatasvir", "CHEMICAL", 55, 66], ["daclatasvir", "CHEMICAL", 55, 66], ["DCTV", "CHEMICAL", 68, 72], ["daclatasvir", "SIMPLE_CHEMICAL", 55, 66], ["DCTV", "SIMPLE_CHEMICAL", 68, 72], ["100nM daclatasvir (DCTV)", "TREATMENT", 49, 73]]], ["Total cell extracts were used to determine viral protein accumulation by Western-blot using anti-NS3 antibody (clone 2E3; Biofront) and \u03b2-actin (Abcam; ab8226) as loading control.Transmission electron microscopyFor ultrastructural electron microscopy studies, control and lipin1-deficient cells expressing NS3-5B polyprotein (see above) were cultured on glass coverslips and fixed in situ after polyprotein expression with a mixture of 2% paraformaldehyde (TAAB) and 2.5% glutaraldehyde (TAAB) (1h at room temperature), post-fixed with 1% osmium tetroxide in PBS (45 min), treated with 1% aqueous uranyl acetate (45 min), dehydrated with increasing quantities of ethanol and embedded in epoxy resin 812 (TAAB).", [["cell extracts", "ANATOMY", 6, 19], ["cells", "ANATOMY", 289, 294], ["TAAB", "CHEMICAL", 457, 461], ["glutaraldehyde", "CHEMICAL", 472, 486], ["TAAB", "CHEMICAL", 488, 492], ["osmium tetroxide", "CHEMICAL", 539, 555], ["uranyl acetate", "CHEMICAL", 597, 611], ["ethanol", "CHEMICAL", 663, 670], ["epoxy resin 812", "CHEMICAL", 687, 702], ["paraformaldehyde", "CHEMICAL", 439, 455], ["TAAB", "CHEMICAL", 457, 461], ["glutaraldehyde", "CHEMICAL", 472, 486], ["TAAB", "CHEMICAL", 488, 492], ["osmium tetroxide", "CHEMICAL", 539, 555], ["uranyl acetate", "CHEMICAL", 597, 611], ["ethanol", "CHEMICAL", 663, 670], ["epoxy resin 812", "CHEMICAL", 687, 702], ["cell extracts", "ORGANISM_SUBSTANCE", 6, 19], ["Biofront", "SIMPLE_CHEMICAL", 122, 130], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 136, 143], ["Abcam", "GENE_OR_GENE_PRODUCT", 145, 150], ["lipin1", "GENE_OR_GENE_PRODUCT", 272, 278], ["cells", "CELL", 289, 294], ["NS3-5B", "GENE_OR_GENE_PRODUCT", 306, 312], ["paraformaldehyde", "SIMPLE_CHEMICAL", 439, 455], ["TAAB", "SIMPLE_CHEMICAL", 457, 461], ["glutaraldehyde", "SIMPLE_CHEMICAL", 472, 486], ["TAAB", "SIMPLE_CHEMICAL", 488, 492], ["osmium tetroxide", "SIMPLE_CHEMICAL", 539, 555], ["aqueous uranyl acetate", "SIMPLE_CHEMICAL", 589, 611], ["ethanol", "SIMPLE_CHEMICAL", 663, 670], ["epoxy resin 812", "SIMPLE_CHEMICAL", 687, 702], ["NS3 antibody", "PROTEIN", 97, 109], ["clone 2E3", "PROTEIN", 111, 120], ["Biofront", "PROTEIN", 122, 130], ["\u03b2-actin", "PROTEIN", 136, 143], ["Abcam; ab8226", "PROTEIN", 145, 158], ["lipin1-deficient cells", "CELL_LINE", 272, 294], ["NS3-5B polyprotein", "PROTEIN", 306, 324], ["Total cell extracts", "TREATMENT", 0, 19], ["viral protein accumulation", "PROBLEM", 43, 69], ["anti-NS3 antibody", "TREATMENT", 92, 109], ["\u03b2-actin (Abcam", "TREATMENT", 136, 150], ["loading control", "TREATMENT", 163, 178], ["Transmission electron microscopy", "TEST", 179, 211], ["ultrastructural electron microscopy studies", "TEST", 215, 258], ["lipin1", "TEST", 272, 278], ["deficient cells", "PROBLEM", 279, 294], ["NS3", "TEST", 306, 309], ["glass coverslips", "TREATMENT", 354, 370], ["polyprotein expression", "TREATMENT", 395, 417], ["2% paraformaldehyde (TAAB)", "TREATMENT", 436, 462], ["1% osmium tetroxide in PBS", "TREATMENT", 536, 562], ["1% aqueous uranyl acetate", "TREATMENT", 586, 611], ["embedded in epoxy resin", "TREATMENT", 675, 698], ["polyprotein expression", "OBSERVATION", 395, 417]]], ["Ultrathin, 70-nm-thick sections were cut in parallel to the monolayer, transferred to formvar-coated EM buttonhole grids and stained with aqueous uranyl acetate (10 min) and lead citrate (3 min).", [["sections", "ANATOMY", 23, 31], ["monolayer", "ANATOMY", 60, 69], ["aqueous uranyl acetate", "CHEMICAL", 138, 160], ["citrate", "CHEMICAL", 179, 186], ["uranyl acetate", "CHEMICAL", 146, 160], ["citrate", "CHEMICAL", 179, 186], ["monolayer", "CELL", 60, 69], ["aqueous uranyl acetate", "SIMPLE_CHEMICAL", 138, 160], ["citrate", "SIMPLE_CHEMICAL", 179, 186], ["Ultrathin", "TEST", 0, 9], ["formvar-coated EM buttonhole grids", "TREATMENT", 86, 120], ["aqueous uranyl acetate", "TREATMENT", 138, 160], ["lead citrate", "TREATMENT", 174, 186]]], ["Sections were visualized on a Jeol JEM 1200 EXII electron microscope (operating at 100 kV).Transmission electron microscopyQuantitation of HCV-induced structures was performed as follows.", [["HCV", "ORGANISM", 139, 142], ["HCV", "SPECIES", 139, 142], ["Transmission electron microscopyQuantitation", "TEST", 91, 135], ["HCV", "OBSERVATION", 139, 142]]], ["To quantitate the differences in total vesicle abundance, TEM sections were visually inspected under the microscope for the presence/absence of vesicular structures.", [["vesicle", "ANATOMY", 39, 46], ["sections", "ANATOMY", 62, 70], ["vesicular structures", "ANATOMY", 144, 164], ["vesicle", "CELLULAR_COMPONENT", 39, 46], ["vesicular structures", "MULTI-TISSUE_STRUCTURE", 144, 164], ["TEM sections", "TEST", 58, 70], ["the microscope", "TEST", 101, 115], ["vesicular structures", "OBSERVATION", 144, 164]]], ["The number of positive cells and total number of cells were inserted in a 2 X 2 contingency table to determine the statistical significance of the differences between control and lipin1-deficient cells using two-tailed Fisher\u00b4s Exact Test or two-tailed Chi Square Test.", [["cells", "ANATOMY", 23, 28], ["cells", "ANATOMY", 49, 54], ["cells", "ANATOMY", 196, 201], ["cells", "CELL", 23, 28], ["cells", "CELL", 49, 54], ["lipin1", "GENE_OR_GENE_PRODUCT", 179, 185], ["cells", "CELL", 196, 201], ["positive cells", "CELL_TYPE", 14, 28], ["lipin1-deficient cells", "CELL_LINE", 179, 201], ["positive cells", "PROBLEM", 14, 28], ["total number of cells", "TREATMENT", 33, 54], ["lipin1-deficient cells", "TREATMENT", 179, 201], ["tailed Chi Square Test", "TEST", 246, 268], ["positive cells", "OBSERVATION", 14, 28]]], ["In addition, we determined the frequency of HCVinduced vesicles in DCTV-treated control cells by dividing the number of structures per inspected area and calculating the average and SD of the frequencies found in the different images.", [["HCVinduced vesicles", "ANATOMY", 44, 63], ["cells", "ANATOMY", 88, 93], ["DCTV", "CHEMICAL", 67, 71], ["HCVinduced vesicles", "CELLULAR_COMPONENT", 44, 63], ["DCTV", "SIMPLE_CHEMICAL", 67, 71], ["cells", "CELL", 88, 93], ["DCTV-treated control cells", "CELL_LINE", 67, 93], ["HCVinduced vesicles", "PROBLEM", 44, 63], ["DCTV-treated control cells", "TREATMENT", 67, 93]]], ["The diameters of individual vesicles were determined manually using size-calibrated images and Image J software.Detergent-resistant membrane (DRM) ultracentrifugationLipin1-deficient and control cells (7.5 X 10 5 cells) were infected with VacT7 virus (MOI 10) and transfected with limiting doses of pTM-NS3/5B plasmid (typically 800 ng/ well), as higher plasmid doses may difficult observing the reported differences.", [["vesicles", "ANATOMY", 28, 36], ["membrane", "ANATOMY", 132, 140], ["DRM", "ANATOMY", 142, 145], ["cells", "ANATOMY", 195, 200], ["cells", "ANATOMY", 213, 218], ["plasmid", "ANATOMY", 354, 361], ["vesicles", "CELLULAR_COMPONENT", 28, 36], ["membrane", "CELLULAR_COMPONENT", 132, 140], ["DRM", "CELLULAR_COMPONENT", 142, 145], ["ultracentrifugationLipin1", "GENE_OR_GENE_PRODUCT", 147, 172], ["cells", "CELL", 195, 200], ["cells", "CELL", 213, 218], ["VacT7 virus", "ORGANISM", 239, 250], ["pTM", "GENE_OR_GENE_PRODUCT", 299, 302], ["Detergent-resistant membrane (DRM) ultracentrifugationLipin1-deficient and control cells", "CELL_LINE", 112, 200], ["pTM-NS3/5B plasmid", "DNA", 299, 317], ["VacT7 virus", "SPECIES", 239, 250], ["Detergent-resistant membrane (DRM) ultracentrifugationLipin1", "TREATMENT", 112, 172], ["deficient and control cells", "PROBLEM", 173, 200], ["VacT7 virus", "PROBLEM", 239, 250], ["pTM", "TREATMENT", 299, 302], ["NS3/5B plasmid", "TREATMENT", 303, 317], ["higher plasmid doses", "TREATMENT", 347, 367], ["diameters", "OBSERVATION_MODIFIER", 4, 13], ["vesicles", "ANATOMY_MODIFIER", 28, 36], ["resistant membrane", "OBSERVATION", 122, 140]]], ["Cells were lysed by adding 250 \u03bcl of TNE (50mM Tris-HCl pH 7.5, NaCl 150 mM and EDTA 2 mM) buffer containing 0.5% Triton X-114 and protease inhibitors (Complete; Roche-Basel, SW).", [["Cells", "ANATOMY", 0, 5], ["TNE", "CHEMICAL", 37, 40], ["Tris-HCl", "CHEMICAL", 47, 55], ["NaCl", "CHEMICAL", 64, 68], ["Triton X-114", "CHEMICAL", 114, 126], ["TNE", "CHEMICAL", 37, 40], ["Tris-HCl", "CHEMICAL", 47, 55], ["NaCl", "CHEMICAL", 64, 68], ["EDTA", "CHEMICAL", 80, 84], ["Cells", "CELL", 0, 5], ["TNE", "SIMPLE_CHEMICAL", 37, 40], ["Triton X-114", "SIMPLE_CHEMICAL", 114, 126], ["protease inhibitors", "SIMPLE_CHEMICAL", 131, 150], ["TNE", "TEST", 37, 40], ["Tris", "TEST", 47, 51], ["pH", "TEST", 56, 58], ["NaCl", "TEST", 64, 68], ["EDTA", "TEST", 80, 84], ["buffer containing", "TREATMENT", 91, 108], ["protease inhibitors", "TREATMENT", 131, 150]]], ["Lysates were incubated for 30 minutes on ice before clearing them by 10-minute centrifugation at 12,000 r.p.m.", [["Lysates", "ANATOMY", 0, 7], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["ice", "TREATMENT", 41, 44]]], ["Clear supernatants were mixed 1:1 with 60% sucrose TNE solution.", [["supernatants", "ANATOMY", 6, 18], ["sucrose", "CHEMICAL", 43, 50], ["sucrose", "CHEMICAL", 43, 50], ["sucrose", "SIMPLE_CHEMICAL", 43, 50], ["TNE", "SIMPLE_CHEMICAL", 51, 54], ["60% sucrose TNE solution", "TREATMENT", 39, 63]]], ["This mixture was applied on top of a 40% sucrose-TNE cushion and was overlaid with 20% and 10% sucrose-TNE until completing the discontinuous gradient.", [["sucrose", "CHEMICAL", 41, 48], ["sucrose", "CHEMICAL", 95, 102], ["TNE", "CHEMICAL", 103, 106], ["sucrose", "CHEMICAL", 41, 48], ["sucrose", "CHEMICAL", 95, 102], ["sucrose", "SIMPLE_CHEMICAL", 41, 48], ["sucrose-TNE", "SIMPLE_CHEMICAL", 95, 106], ["This mixture", "TREATMENT", 0, 12], ["a 40% sucrose-TNE cushion", "TREATMENT", 35, 60], ["10% sucrose-TNE", "TREATMENT", 91, 106], ["the discontinuous gradient", "TREATMENT", 124, 150]]], ["Fourteen fractions were collected from the top and analyzed by SDS-PAGE and Western-Blot using antibodies against NS3 (clone 2E3; Biofront), SIGMAR1 (S-18; Santa-Cruz), caveolin-2 (Epitomics; 3643-1) and beta actin as described previously [21] .", [["fractions", "ANATOMY", 9, 18], ["NS3", "GENE_OR_GENE_PRODUCT", 114, 117], ["caveolin-2", "GENE_OR_GENE_PRODUCT", 169, 179], ["Epitomics; 3643-1", "GENE_OR_GENE_PRODUCT", 181, 198], ["beta actin", "GENE_OR_GENE_PRODUCT", 204, 214], ["antibodies", "PROTEIN", 95, 105], ["NS3", "PROTEIN", 114, 117], ["clone 2E3", "PROTEIN", 119, 128], ["Biofront", "PROTEIN", 130, 138], ["SIGMAR1", "PROTEIN", 141, 148], ["S-18", "PROTEIN", 150, 154], ["Santa-Cruz", "PROTEIN", 156, 166], ["caveolin-2", "PROTEIN", 169, 179], ["Epitomics", "PROTEIN", 181, 190], ["3643-1", "PROTEIN", 192, 198], ["beta actin", "PROTEIN", 204, 214], ["Fourteen fractions", "TEST", 0, 18], ["antibodies", "TEST", 95, 105], ["NS3", "TEST", 114, 117], ["clone", "TEST", 119, 124], ["Biofront", "TEST", 130, 138], ["SIGMAR1", "TEST", 141, 148], ["caveolin", "TEST", 169, 177], ["Epitomics", "TEST", 181, 190], ["beta actin", "TREATMENT", 204, 214]]], ["NS3 signal was quantitated using ImageJ software and the fraction of DRM-associated NS3 was determined as the ratio of NS3 signal in fractions 3, 4 and 5 to the total NS3 signal in the gradient.", [["NS3", "GENE_OR_GENE_PRODUCT", 0, 3], ["DRM", "GENE_OR_GENE_PRODUCT", 69, 72], ["NS3", "GENE_OR_GENE_PRODUCT", 84, 87], ["NS3", "PROTEIN", 0, 3], ["DRM", "PROTEIN", 69, 72], ["NS3", "PROTEIN", 84, 87], ["NS3", "PROTEIN", 119, 122], ["NS3", "PROTEIN", 167, 170], ["NS3 signal", "TEST", 0, 10], ["ImageJ software", "TEST", 33, 48], ["NS3", "PROBLEM", 84, 87], ["NS3 signal in fractions", "PROBLEM", 119, 142], ["DRM", "OBSERVATION", 69, 72], ["NS3", "OBSERVATION", 84, 87], ["NS3", "OBSERVATION", 119, 122], ["total", "OBSERVATION_MODIFIER", 161, 166], ["NS3", "OBSERVATION", 167, 170], ["gradient", "OBSERVATION_MODIFIER", 185, 193]]]], "PMC6308371": [["Case reportA 70 - year old woman, with a history of hypothyroidism and pemphigus (20 years ago) presented with non-productive cough which progressively worsened for one month.", [["hypothyroidism", "DISEASE", 52, 66], ["pemphigus", "DISEASE", 71, 80], ["cough", "DISEASE", 126, 131], ["woman", "ORGANISM", 27, 32], ["woman", "SPECIES", 27, 32], ["hypothyroidism", "PROBLEM", 52, 66], ["pemphigus", "PROBLEM", 71, 80], ["non-productive cough", "PROBLEM", 111, 131], ["hypothyroidism", "OBSERVATION", 52, 66], ["pemphigus", "OBSERVATION", 71, 80], ["non-productive", "OBSERVATION_MODIFIER", 111, 125], ["cough", "OBSERVATION", 126, 131], ["worsened", "OBSERVATION_MODIFIER", 152, 160]]], ["The patient was a smoker (25 pack-years).", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["She was examined by a private practice pulmonologist who reported crackles at auscultation.", [["She", "ORGANISM", 0, 3], ["crackles at", "PROBLEM", 66, 77], ["auscultation", "TEST", 78, 90], ["crackles", "OBSERVATION", 66, 74]]], ["Complete blood count revealed only mild lymphocytopenia (WBC = 6610 with 1000 lymphocytes, Hct = 47.4 and PLT = 208000) whereas biochemical tests were within normal range.", [["blood", "ANATOMY", 9, 14], ["lymphocytes", "ANATOMY", 78, 89], ["lymphocytopenia", "DISEASE", 40, 55], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["lymphocytes", "CELL", 78, 89], ["Complete blood count", "TEST", 0, 20], ["mild lymphocytopenia", "PROBLEM", 35, 55], ["WBC", "TEST", 57, 60], ["lymphocytes", "TEST", 78, 89], ["Hct", "TEST", 91, 94], ["PLT", "TEST", 106, 109], ["biochemical tests", "TEST", 128, 145], ["blood", "ANATOMY", 9, 14], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["lymphocytopenia", "OBSERVATION", 40, 55], ["normal range", "OBSERVATION", 158, 170]]], ["A chest radiograph was made and followed by a chest-CT which demonstrated lymphadenopathy up to 13mm, diffuse ground glass opacities with superimposed interlobular thickening creating a crazy paving pattern (Fig. 1).Case reportA complete lab test examination was performed including the following: erythrocyte sedimentation rate (ESR) = 10mm (normal range 0\u201320mm), C-reactive protein (CRP) = 0.39mg/dl (0.02\u20130.80 mg/dl), serum angiotensin-converting enzyme (SACE) = 7 U/L (8\u201352 U/L) and antinuclear antibodies (ANA) negative.", [["chest", "ANATOMY", 2, 7], ["interlobular", "ANATOMY", 151, 163], ["erythrocyte", "ANATOMY", 298, 309], ["serum", "ANATOMY", 421, 426], ["lymphadenopathy", "DISEASE", 74, 89], ["angiotensin", "CHEMICAL", 427, 438], ["interlobular", "MULTI-TISSUE_STRUCTURE", 151, 163], ["erythrocyte", "CELL", 298, 309], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 365, 383], ["CRP", "GENE_OR_GENE_PRODUCT", 385, 388], ["serum", "ORGANISM_SUBSTANCE", 421, 426], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 427, 456], ["antinuclear antibodies", "GENE_OR_GENE_PRODUCT", 487, 509], ["ANA", "GENE_OR_GENE_PRODUCT", 511, 514], ["C-reactive protein", "PROTEIN", 365, 383], ["CRP", "PROTEIN", 385, 388], ["serum angiotensin-converting enzyme", "PROTEIN", 421, 456], ["SACE", "PROTEIN", 458, 462], ["antinuclear antibodies", "PROTEIN", 487, 509], ["ANA", "PROTEIN", 511, 514], ["A chest radiograph", "TEST", 0, 18], ["a chest-CT", "TEST", 44, 54], ["lymphadenopathy", "PROBLEM", 74, 89], ["diffuse ground glass opacities", "PROBLEM", 102, 132], ["superimposed interlobular thickening", "PROBLEM", 138, 174], ["Case reportA complete lab test examination", "TEST", 216, 258], ["erythrocyte sedimentation rate", "TEST", 298, 328], ["ESR", "TEST", 330, 333], ["C-reactive protein", "TEST", 365, 383], ["CRP", "TEST", 385, 388], ["serum angiotensin", "TEST", 421, 438], ["enzyme", "TEST", 450, 456], ["SACE", "TEST", 458, 462], ["U/L", "TEST", 468, 471], ["U/L", "TEST", 478, 481], ["antinuclear antibodies", "TEST", 487, 509], ["ANA", "TEST", 511, 514], ["chest", "ANATOMY", 2, 7], ["chest", "ANATOMY", 46, 51], ["lymphadenopathy", "OBSERVATION", 74, 89], ["13mm", "OBSERVATION_MODIFIER", 96, 100], ["diffuse", "OBSERVATION_MODIFIER", 102, 109], ["ground glass opacities", "OBSERVATION", 110, 132], ["superimposed", "OBSERVATION_MODIFIER", 138, 150], ["interlobular", "ANATOMY_MODIFIER", 151, 163], ["thickening", "OBSERVATION", 164, 174], ["crazy", "OBSERVATION_MODIFIER", 186, 191], ["paving pattern", "OBSERVATION", 192, 206], ["Fig", "OBSERVATION_MODIFIER", 208, 211]]], ["The patient also underwent an EBUS bronchoscopy which demonstrated a high percentage of lymphocytes with no clonality in BAL (M 33%, L 58% PMN 9%, CD4/CD8: 1.91), whereas neither cytologic examination of washing and TBNA nor pathologic examination of the lymph nodes displayed malignancy.", [["lymphocytes", "ANATOMY", 88, 99], ["BAL", "ANATOMY", 121, 124], ["PMN", "ANATOMY", 139, 142], ["lymph nodes", "ANATOMY", 255, 266], ["malignancy", "DISEASE", 277, 287], ["patient", "ORGANISM", 4, 11], ["lymphocytes", "CELL", 88, 99], ["BAL", "ORGANISM_SUBSTANCE", 121, 124], ["PMN", "CELL", 139, 142], ["CD8", "GENE_OR_GENE_PRODUCT", 151, 154], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 255, 266], ["lymphocytes", "CELL_TYPE", 88, 99], ["CD4", "PROTEIN", 147, 150], ["CD8", "PROTEIN", 151, 154], ["patient", "SPECIES", 4, 11], ["an EBUS bronchoscopy", "TEST", 27, 47], ["a high percentage of lymphocytes", "PROBLEM", 67, 99], ["clonality in BAL", "PROBLEM", 108, 124], ["M", "TEST", 126, 127], ["L", "TEST", 133, 134], ["PMN", "TEST", 139, 142], ["CD4", "TEST", 147, 150], ["CD8", "TEST", 151, 154], ["cytologic examination", "TEST", 179, 200], ["washing", "TEST", 204, 211], ["TBNA", "TEST", 216, 220], ["pathologic examination", "TEST", 225, 247], ["the lymph nodes", "PROBLEM", 251, 266], ["malignancy", "PROBLEM", 277, 287], ["high", "OBSERVATION_MODIFIER", 69, 73], ["percentage", "OBSERVATION_MODIFIER", 74, 84], ["lymphocytes", "OBSERVATION", 88, 99], ["no", "UNCERTAINTY", 105, 107], ["clonality", "OBSERVATION_MODIFIER", 108, 117], ["lymph nodes", "OBSERVATION", 255, 266], ["malignancy", "OBSERVATION", 277, 287]]], ["Cultures for aerobes and anaerobes were negative and Ziehl-Neelsen stains as well as Lowenstein Jensen culture were negative for M. Tuberculosis.Case reportAfter 15 days the patient suffered of acute dyspnea and was examined in the emergency department of the regional hospital where she lived.", [["Tuberculosis", "DISEASE", 132, 144], ["dyspnea", "DISEASE", 200, 207], ["patient", "ORGANISM", 174, 181], ["patient", "SPECIES", 174, 181], ["Cultures", "TEST", 0, 8], ["aerobes", "TEST", 13, 20], ["anaerobes", "TEST", 25, 34], ["Ziehl", "TEST", 53, 58], ["Neelsen stains", "TEST", 59, 73], ["Lowenstein Jensen culture", "TEST", 85, 110], ["M. Tuberculosis", "PROBLEM", 129, 144], ["acute dyspnea", "PROBLEM", 194, 207], ["Tuberculosis", "OBSERVATION", 132, 144], ["acute", "OBSERVATION_MODIFIER", 194, 199], ["dyspnea", "OBSERVATION", 200, 207]]], ["In the emergency room she presented with acute respiratory failure with SO2 = 83% (FIO2 = 21%).", [["respiratory", "ANATOMY", 47, 58], ["respiratory failure", "DISEASE", 47, 66], ["SO2", "CHEMICAL", 72, 75], ["acute respiratory failure", "PROBLEM", 41, 66], ["SO2", "TEST", 72, 75], ["FIO2", "TEST", 83, 87], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["respiratory", "ANATOMY", 47, 58], ["failure", "OBSERVATION", 59, 66]]], ["Lab tests demonstrated WBC = 13.870 with 90% neutrophils and CRP = 4.40mg/dl.", [["neutrophils", "ANATOMY", 45, 56], ["neutrophils", "CELL", 45, 56], ["CRP", "GENE_OR_GENE_PRODUCT", 61, 64], ["neutrophils", "CELL_TYPE", 45, 56], ["CRP", "PROTEIN", 61, 64], ["Lab tests", "TEST", 0, 9], ["WBC", "TEST", 23, 26], ["neutrophils", "TEST", 45, 56], ["CRP", "TEST", 61, 64]]], ["The patient was admitted to the hospital and was treated with broad-spectrum antibiotics as well as oseltamivir.", [["oseltamivir", "CHEMICAL", 100, 111], ["oseltamivir", "CHEMICAL", 100, 111], ["patient", "ORGANISM", 4, 11], ["oseltamivir", "SIMPLE_CHEMICAL", 100, 111], ["patient", "SPECIES", 4, 11], ["broad-spectrum antibiotics", "TREATMENT", 62, 88], ["oseltamivir", "TREATMENT", 100, 111]]], ["She also presented multiple enlarged lymph nodes in the neck and therefore an ultrasound was made which demonstrated bilateral cervical lymphadenopathy up to 24mm.", [["lymph nodes", "ANATOMY", 37, 48], ["neck", "ANATOMY", 56, 60], ["cervical", "ANATOMY", 127, 135], ["lymphadenopathy", "DISEASE", 136, 151], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 37, 48], ["neck", "ORGAN", 56, 60], ["multiple enlarged lymph nodes in the neck", "PROBLEM", 19, 60], ["an ultrasound", "TEST", 75, 88], ["bilateral cervical lymphadenopathy", "PROBLEM", 117, 151], ["multiple", "OBSERVATION_MODIFIER", 19, 27], ["enlarged", "OBSERVATION_MODIFIER", 28, 36], ["lymph nodes", "OBSERVATION", 37, 48], ["neck", "ANATOMY", 56, 60], ["bilateral", "ANATOMY_MODIFIER", 117, 126], ["cervical", "ANATOMY", 127, 135], ["lymphadenopathy", "OBSERVATION", 136, 151], ["24mm", "OBSERVATION_MODIFIER", 158, 162]]], ["In addition, a chest CT was performed which showed bilateral infiltrations in lower lobes as well as diffuse ground glass opacities, pleural effusion in the right lung and multiple swollen lymph nodes.", [["chest", "ANATOMY", 15, 20], ["lower lobes", "ANATOMY", 78, 89], ["pleural effusion", "ANATOMY", 133, 149], ["right lung", "ANATOMY", 157, 167], ["lymph nodes", "ANATOMY", 189, 200], ["pleural effusion", "DISEASE", 133, 149], ["pleural", "ORGAN", 133, 140], ["lung", "ORGAN", 163, 167], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 189, 200], ["a chest CT", "TEST", 13, 23], ["bilateral infiltrations in lower lobes", "PROBLEM", 51, 89], ["diffuse ground glass opacities", "PROBLEM", 101, 131], ["pleural effusion in the right lung", "PROBLEM", 133, 167], ["multiple swollen lymph nodes", "PROBLEM", 172, 200], ["chest", "ANATOMY", 15, 20], ["bilateral", "ANATOMY_MODIFIER", 51, 60], ["infiltrations", "OBSERVATION", 61, 74], ["lower lobes", "ANATOMY", 78, 89], ["diffuse", "OBSERVATION_MODIFIER", 101, 108], ["ground glass opacities", "OBSERVATION", 109, 131], ["pleural", "ANATOMY", 133, 140], ["effusion", "OBSERVATION", 141, 149], ["right", "ANATOMY_MODIFIER", 157, 162], ["lung", "ANATOMY", 163, 167], ["multiple", "OBSERVATION_MODIFIER", 172, 180], ["swollen", "OBSERVATION_MODIFIER", 181, 188], ["lymph nodes", "OBSERVATION", 189, 200]]], ["The patient was transferred to our hospital, which is a referral center for chest diseases, for further investigation.Case reportAt the time of the admission the patient was in respiratory failure (pH = 7.43, PaO2 = 77.8, PaCO2 = 36.9, HCO3 = 25.1, Lactate acid = 2.8, Venturi Mask 50%).", [["chest", "ANATOMY", 76, 81], ["respiratory", "ANATOMY", 177, 188], ["chest diseases", "DISEASE", 76, 90], ["respiratory failure", "DISEASE", 177, 196], ["Lactate", "CHEMICAL", 249, 256], ["Lactate acid", "CHEMICAL", 249, 261], ["patient", "ORGANISM", 4, 11], ["chest", "ORGANISM_SUBDIVISION", 76, 81], ["patient", "ORGANISM", 162, 169], ["Lactate acid", "SIMPLE_CHEMICAL", 249, 261], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 162, 169], ["chest diseases", "PROBLEM", 76, 90], ["further investigation", "TEST", 96, 117], ["respiratory failure", "PROBLEM", 177, 196], ["pH", "TEST", 198, 200], ["PaO2", "TEST", 209, 213], ["PaCO2", "TEST", 222, 227], ["HCO3", "TEST", 236, 240], ["Lactate acid", "TEST", 249, 261], ["Venturi Mask", "TREATMENT", 269, 281], ["chest", "ANATOMY", 76, 81], ["diseases", "OBSERVATION", 82, 90], ["respiratory", "ANATOMY", 177, 188], ["failure", "OBSERVATION", 189, 196]]], ["Despite the step up of antibiotic therapy and the addition of corticosteroids, the patient worsened.", [["corticosteroids", "CHEMICAL", 62, 77], ["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90], ["antibiotic therapy", "TREATMENT", 23, 41], ["corticosteroids", "TREATMENT", 62, 77], ["worsened", "OBSERVATION_MODIFIER", 91, 99]]], ["After 10 days she was intubated and admitted to intensive care unit (ICU).", [["intubated", "TREATMENT", 22, 31]]], ["Cultures of sputum were negative for common pathogens and microscopic examination of sputum was negative for P. Jirovecii.", [["sputum", "ANATOMY", 12, 18], ["sputum", "ANATOMY", 85, 91], ["sputum", "ORGANISM_SUBSTANCE", 12, 18], ["sputum", "ORGANISM_SUBSTANCE", 85, 91], ["P. Jirovecii", "ORGANISM", 109, 121], ["P. Jirovecii", "SPECIES", 109, 121], ["P. Jirovecii", "SPECIES", 109, 121], ["Cultures of sputum", "TEST", 0, 18], ["common pathogens", "PROBLEM", 37, 53], ["microscopic examination of sputum", "TEST", 58, 91], ["P. Jirovecii", "PROBLEM", 109, 121], ["Jirovecii", "OBSERVATION", 112, 121]]], ["The patient underwent a new bronchoscopy and BAL was sent for PCR multiple viruses test which was positive for coronavirus.", [["BAL", "ANATOMY", 45, 48], ["coronavirus", "DISEASE", 111, 122], ["patient", "ORGANISM", 4, 11], ["coronavirus", "ORGANISM", 111, 122], ["patient", "SPECIES", 4, 11], ["a new bronchoscopy", "TEST", 22, 40], ["BAL", "TEST", 45, 48], ["PCR multiple viruses test", "PROBLEM", 62, 87], ["coronavirus", "PROBLEM", 111, 122]]], ["A chest CT was performed which demonstrated bilateral consolidations in the lower lobes, bilateral pleural effusions and lymphadenopathy.", [["chest", "ANATOMY", 2, 7], ["lower lobes", "ANATOMY", 76, 87], ["pleural effusions", "ANATOMY", 99, 116], ["pleural effusions", "DISEASE", 99, 116], ["lymphadenopathy", "DISEASE", 121, 136], ["chest", "ORGAN", 2, 7], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 76, 87], ["pleural effusions", "PATHOLOGICAL_FORMATION", 99, 116], ["A chest CT", "TEST", 0, 10], ["bilateral consolidations in the lower lobes", "PROBLEM", 44, 87], ["bilateral pleural effusions", "PROBLEM", 89, 116], ["lymphadenopathy", "PROBLEM", 121, 136], ["chest", "ANATOMY", 2, 7], ["bilateral", "ANATOMY_MODIFIER", 44, 53], ["consolidations", "OBSERVATION", 54, 68], ["lower lobes", "ANATOMY", 76, 87], ["bilateral", "ANATOMY_MODIFIER", 89, 98], ["pleural", "ANATOMY", 99, 106], ["effusions", "OBSERVATION", 107, 116], ["lymphadenopathy", "OBSERVATION", 121, 136]]], ["It seemed possible that acute worsening could be caused by a viral respiratory tract infection; however the data so far implied that the patient also suffered from an underlying disease.", [["respiratory tract", "ANATOMY", 67, 84], ["viral respiratory tract infection", "DISEASE", 61, 94], ["tract", "ORGANISM_SUBDIVISION", 79, 84], ["patient", "ORGANISM", 137, 144], ["patient", "SPECIES", 137, 144], ["acute worsening", "PROBLEM", 24, 39], ["a viral respiratory tract infection", "PROBLEM", 59, 94], ["an underlying disease", "PROBLEM", 164, 185], ["seemed possible", "UNCERTAINTY", 3, 18], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["worsening", "OBSERVATION", 30, 39], ["viral", "OBSERVATION_MODIFIER", 61, 66], ["respiratory tract", "ANATOMY", 67, 84], ["infection", "OBSERVATION", 85, 94], ["disease", "OBSERVATION", 178, 185]]], ["Therefore, a surgical biopsy of a left supraclavicular lymph node was performed and the tissue examination revealed peripheral T-cell lymphoma not otherwise specified (PTCL -NOS) (Fig. 2).", [["left supraclavicular lymph node", "ANATOMY", 34, 65], ["tissue", "ANATOMY", 88, 94], ["peripheral T-cell lymphoma", "ANATOMY", 116, 142], ["peripheral T-cell lymphoma", "DISEASE", 116, 142], ["supraclavicular lymph node", "MULTI-TISSUE_STRUCTURE", 39, 65], ["tissue", "TISSUE", 88, 94], ["peripheral T-cell lymphoma", "CANCER", 116, 142], ["PTCL -NOS", "GENE_OR_GENE_PRODUCT", 168, 177], ["a surgical biopsy", "TEST", 11, 28], ["a left supraclavicular lymph node", "PROBLEM", 32, 65], ["the tissue examination", "TEST", 84, 106], ["peripheral T-cell lymphoma", "PROBLEM", 116, 142], ["left", "ANATOMY_MODIFIER", 34, 38], ["supraclavicular", "ANATOMY", 39, 54], ["lymph node", "OBSERVATION", 55, 65], ["peripheral T-cell lymphoma", "OBSERVATION", 116, 142]]], ["After 3 weeks, the patient was successfully extubated and was transferred to the internal medicine department.Case reportThe patient was evaluated by a hematologist and was started on chemotherapy with CHOP.", [["patient", "ORGANISM", 19, 26], ["patient", "ORGANISM", 125, 132], ["CHOP", "SIMPLE_CHEMICAL", 202, 206], ["CHOP", "PROTEIN", 202, 206], ["patient", "SPECIES", 19, 26], ["patient", "SPECIES", 125, 132], ["chemotherapy", "TREATMENT", 184, 196], ["CHOP", "TREATMENT", 202, 206]]], ["After a few days the swollen cervical lymph nodes reduced in size.", [["cervical lymph nodes", "ANATOMY", 29, 49], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 29, 49], ["the swollen cervical lymph nodes", "PROBLEM", 17, 49], ["swollen", "OBSERVATION_MODIFIER", 21, 28], ["cervical", "ANATOMY", 29, 37], ["lymph nodes", "OBSERVATION", 38, 49], ["reduced", "OBSERVATION_MODIFIER", 50, 57], ["size", "OBSERVATION_MODIFIER", 61, 65]]], ["However, the patient exhibited progressive respiratory deterioration, even after the 2nd cycle of CHOP.", [["respiratory", "ANATOMY", 43, 54], ["respiratory deterioration", "DISEASE", 43, 68], ["patient", "ORGANISM", 13, 20], ["CHOP", "SIMPLE_CHEMICAL", 98, 102], ["CHOP", "PROTEIN", 98, 102], ["patient", "SPECIES", 13, 20], ["progressive respiratory deterioration", "PROBLEM", 31, 68], ["the 2nd cycle of CHOP", "TREATMENT", 81, 102], ["progressive", "OBSERVATION_MODIFIER", 31, 42], ["respiratory deterioration", "OBSERVATION", 43, 68]]], ["The differential diagnosis included infection, heart failure and lung infiltration of the known lymphoma.", [["heart", "ANATOMY", 47, 52], ["lung", "ANATOMY", 65, 69], ["lymphoma", "ANATOMY", 96, 104], ["infection", "DISEASE", 36, 45], ["heart failure", "DISEASE", 47, 60], ["lymphoma", "DISEASE", 96, 104], ["heart", "ORGAN", 47, 52], ["lung", "ORGAN", 65, 69], ["lymphoma", "CANCER", 96, 104], ["infection", "PROBLEM", 36, 45], ["heart failure", "PROBLEM", 47, 60], ["lung infiltration", "PROBLEM", 65, 82], ["the known lymphoma", "PROBLEM", 86, 104], ["differential diagnosis included", "UNCERTAINTY", 4, 35], ["infection", "OBSERVATION", 36, 45], ["heart", "ANATOMY", 47, 52], ["failure", "OBSERVATION", 53, 60], ["lung", "ANATOMY", 65, 69], ["infiltration", "OBSERVATION", 70, 82], ["lymphoma", "OBSERVATION", 96, 104]]], ["Lab testing included complete blood count (WBC = 4100), CRP = 0.69mg/dl (normal range 0.02\u20130.80mg/dl), Procalcitonin = 0.06 ng/ml (0\u20130.15ng/ml) and Brain Natriuretic Peptide = 40pg/ml (0\u2013100pg/ml).", [["blood", "ANATOMY", 30, 35], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["CRP", "GENE_OR_GENE_PRODUCT", 56, 59], ["CRP", "PROTEIN", 56, 59], ["Lab testing", "TEST", 0, 11], ["complete blood count", "TEST", 21, 41], ["WBC", "TEST", 43, 46], ["CRP", "TEST", 56, 59], ["Procalcitonin", "TEST", 103, 116], ["Brain Natriuretic Peptide", "TREATMENT", 148, 173]]], ["A new chest CT demonstrated mass-like consolidations in the right middle lobe and right lower lobe (Fig. 3).", [["chest", "ANATOMY", 6, 11], ["right middle lobe", "ANATOMY", 60, 77], ["right lower lobe", "ANATOMY", 82, 98], ["middle lobe", "MULTI-TISSUE_STRUCTURE", 66, 77], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 88, 98], ["A new chest CT", "TEST", 0, 14], ["mass-like consolidations in the right middle lobe and right lower lobe", "PROBLEM", 28, 98], ["chest", "ANATOMY", 6, 11], ["mass", "OBSERVATION", 28, 32], ["consolidations", "OBSERVATION", 38, 52], ["right middle lobe", "ANATOMY", 60, 77], ["right lower lobe", "ANATOMY", 82, 98]]], ["Although the lung is a rare site of extranodal disease, it was considered a valid possibility due to the high clinical probability and the CT findings.", [["lung", "ANATOMY", 13, 17], ["lung", "ORGAN", 13, 17], ["extranodal disease", "CANCER", 36, 54], ["extranodal disease", "PROBLEM", 36, 54], ["the high clinical probability", "PROBLEM", 101, 130], ["the CT findings", "TEST", 135, 150], ["lung", "ANATOMY", 13, 17], ["rare", "OBSERVATION_MODIFIER", 23, 27], ["extranodal disease", "OBSERVATION", 36, 54]]], ["A CT-guided trans-thoracic lung biopsy was performed in order to secure final diagnosis and thus firmly guide therapeutic options.", [["lung", "ANATOMY", 27, 31], ["A CT-guided trans-thoracic lung biopsy", "TEST", 0, 38], ["therapeutic options", "TREATMENT", 110, 129], ["thoracic", "ANATOMY", 18, 26], ["lung", "ANATOMY", 27, 31], ["biopsy", "OBSERVATION", 32, 38]]], ["Pathologic examination showed diffuse infiltration of lymphocytes in lung parenchyma with the same immunohistochemical markers as those of the lymph node biopsy (Fig. 4).", [["lymphocytes", "ANATOMY", 54, 65], ["lung parenchyma", "ANATOMY", 69, 84], ["lymph node", "ANATOMY", 143, 153], ["lymphocytes", "CELL", 54, 65], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 69, 84], ["lymph node biopsy", "MULTI-TISSUE_STRUCTURE", 143, 160], ["lymphocytes", "CELL_TYPE", 54, 65], ["immunohistochemical markers", "PROTEIN", 99, 126], ["Pathologic examination", "TEST", 0, 22], ["diffuse infiltration of lymphocytes in lung parenchyma", "PROBLEM", 30, 84], ["the lymph node biopsy", "TEST", 139, 160], ["diffuse", "OBSERVATION_MODIFIER", 30, 37], ["infiltration", "OBSERVATION", 38, 50], ["lymphocytes", "OBSERVATION", 54, 65], ["lung", "ANATOMY", 69, 73], ["parenchyma", "ANATOMY_MODIFIER", 74, 84], ["lymph node biopsy", "OBSERVATION", 143, 160]]], ["As a result, the diagnosis of PTCL with extranodal involvement of the lung parenchyma was established.", [["PTCL", "ANATOMY", 30, 34], ["lung parenchyma", "ANATOMY", 70, 85], ["PTCL", "DISEASE", 30, 34], ["PTCL", "CANCER", 30, 34], ["extranodal", "CANCER", 40, 50], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 70, 85], ["PTCL", "PROBLEM", 30, 34], ["extranodal involvement of the lung parenchyma", "PROBLEM", 40, 85], ["PTCL", "OBSERVATION", 30, 34], ["lung", "ANATOMY", 70, 74], ["parenchyma", "ANATOMY_MODIFIER", 75, 85]]], ["Two weeks after the 2nd cycle, the patient improved clinically and was in need of oxygen therapy of 2-3lt/min via nasal cannula.", [["nasal", "ANATOMY", 114, 119], ["oxygen", "CHEMICAL", 82, 88], ["oxygen", "CHEMICAL", 82, 88], ["patient", "ORGANISM", 35, 42], ["oxygen", "SIMPLE_CHEMICAL", 82, 88], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 114, 127], ["patient", "SPECIES", 35, 42], ["oxygen therapy", "TREATMENT", 82, 96], ["nasal cannula", "TREATMENT", 114, 127], ["oxygen therapy", "OBSERVATION", 82, 96], ["nasal cannula", "ANATOMY", 114, 127]]], ["She received the 3rd cycle of CHOP and was in good condition for about 2 weeks.", [["CHOP", "CHEMICAL", 30, 34], ["CHOP", "SIMPLE_CHEMICAL", 30, 34], ["CHOP", "PROTEIN", 30, 34], ["the 3rd cycle of CHOP", "TREATMENT", 13, 34]]], ["Sadly, before receiving the 4th cycle, the patient worsened and she died of respiratory failure because of disease progression.DiscussionWe report a rare case of PTCL presenting with an unusual radiologic manifestation of that of crazy paving pattern.", [["respiratory", "ANATOMY", 76, 87], ["PTCL", "ANATOMY", 162, 166], ["respiratory failure", "DISEASE", 76, 95], ["PTCL", "DISEASE", 162, 166], ["patient", "ORGANISM", 43, 50], ["PTCL", "CANCER", 162, 166], ["patient", "SPECIES", 43, 50], ["the 4th cycle", "TREATMENT", 24, 37], ["respiratory failure", "PROBLEM", 76, 95], ["disease progression", "PROBLEM", 107, 126], ["worsened", "OBSERVATION_MODIFIER", 51, 59], ["respiratory", "ANATOMY", 76, 87], ["failure", "OBSERVATION", 88, 95], ["disease", "OBSERVATION", 107, 114], ["crazy", "OBSERVATION", 230, 235]]], ["The term crazy-paving pattern refers to an image of ground glass opacities with superimposed thickening of interlobular septal lines.", [["interlobular septal lines", "ANATOMY", 107, 132], ["interlobular septal lines", "CELL", 107, 132], ["interlobular septal lines", "CELL_LINE", 107, 132], ["ground glass opacities", "PROBLEM", 52, 74], ["superimposed thickening of interlobular septal lines", "PROBLEM", 80, 132], ["term", "OBSERVATION_MODIFIER", 4, 8], ["crazy", "OBSERVATION", 9, 14], ["ground glass opacities", "OBSERVATION", 52, 74], ["superimposed", "OBSERVATION_MODIFIER", 80, 92], ["thickening", "OBSERVATION", 93, 103], ["interlobular", "ANATOMY_MODIFIER", 107, 119], ["septal lines", "OBSERVATION", 120, 132]]], ["Although it is considered typical of alveolar proteinosis the actual differential is wide including infections (pneumocystis jirovecii, viral), sanguineous causes (pulmonary edema, diffuse alveolar hemorrhage), interstitial lung diseases (organizing pneumonia, exogenous lipoid pneumonia), malignancy (adenocarcinoma with lepidic growth, lymphatic spread of the tumor) [1].", [["alveolar proteinosis", "ANATOMY", 37, 57], ["pulmonary", "ANATOMY", 164, 173], ["alveolar", "ANATOMY", 189, 197], ["interstitial lung", "ANATOMY", 211, 228], ["malignancy", "ANATOMY", 290, 300], ["adenocarcinoma", "ANATOMY", 302, 316], ["lymphatic", "ANATOMY", 338, 347], ["tumor", "ANATOMY", 362, 367], ["alveolar proteinosis", "DISEASE", 37, 57], ["infections", "DISEASE", 100, 110], ["pneumocystis jirovecii", "DISEASE", 112, 134], ["pulmonary edema", "DISEASE", 164, 179], ["alveolar hemorrhage", "DISEASE", 189, 208], ["interstitial lung diseases", "DISEASE", 211, 237], ["pneumonia", "DISEASE", 250, 259], ["lipoid pneumonia", "DISEASE", 271, 287], ["malignancy", "DISEASE", 290, 300], ["adenocarcinoma", "DISEASE", 302, 316], ["tumor", "DISEASE", 362, 367], ["alveolar proteinosis", "MULTI-TISSUE_STRUCTURE", 37, 57], ["pneumocystis jirovecii", "ORGANISM", 112, 134], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 164, 179], ["alveolar", "MULTI-TISSUE_STRUCTURE", 189, 197], ["lung", "ORGAN", 224, 228], ["adenocarcinoma", "CANCER", 302, 316], ["lymphatic", "ORGAN", 338, 347], ["tumor", "CANCER", 362, 367], ["pneumocystis jirovecii", "SPECIES", 112, 134], ["pneumocystis jirovecii", "SPECIES", 112, 134], ["alveolar proteinosis", "PROBLEM", 37, 57], ["infections (pneumocystis jirovecii", "PROBLEM", 100, 134], ["viral)", "PROBLEM", 136, 142], ["sanguineous causes", "PROBLEM", 144, 162], ["pulmonary edema", "PROBLEM", 164, 179], ["diffuse alveolar hemorrhage", "PROBLEM", 181, 208], ["interstitial lung diseases", "PROBLEM", 211, 237], ["organizing pneumonia", "PROBLEM", 239, 259], ["exogenous lipoid pneumonia)", "PROBLEM", 261, 288], ["malignancy (adenocarcinoma", "PROBLEM", 290, 316], ["lepidic growth", "PROBLEM", 322, 336], ["lymphatic spread of the tumor", "PROBLEM", 338, 367], ["considered typical of", "UNCERTAINTY", 15, 36], ["alveolar", "ANATOMY_MODIFIER", 37, 45], ["proteinosis", "OBSERVATION", 46, 57], ["infections", "OBSERVATION", 100, 110], ["pneumocystis jirovecii", "OBSERVATION", 112, 134], ["sanguineous", "OBSERVATION_MODIFIER", 144, 155], ["pulmonary", "ANATOMY", 164, 173], ["edema", "OBSERVATION", 174, 179], ["diffuse", "OBSERVATION_MODIFIER", 181, 188], ["alveolar", "ANATOMY_MODIFIER", 189, 197], ["hemorrhage", "OBSERVATION", 198, 208], ["interstitial", "ANATOMY_MODIFIER", 211, 223], ["lung", "ANATOMY", 224, 228], ["diseases", "OBSERVATION", 229, 237], ["organizing", "OBSERVATION_MODIFIER", 239, 249], ["pneumonia", "OBSERVATION", 250, 259], ["exogenous", "OBSERVATION_MODIFIER", 261, 270], ["lipoid", "OBSERVATION_MODIFIER", 271, 277], ["pneumonia", "OBSERVATION", 278, 287], ["malignancy", "OBSERVATION", 290, 300], ["adenocarcinoma", "OBSERVATION", 302, 316], ["lepidic", "OBSERVATION_MODIFIER", 322, 329], ["growth", "OBSERVATION_MODIFIER", 330, 336], ["lymphatic spread", "OBSERVATION", 338, 354], ["tumor", "OBSERVATION", 362, 367]]], ["Although the causes of this pattern are frequently indistinguishable at radiologic evaluation, incorporating data from history and clinical examination (e.g. immune status, acute vs chronic symptoms, history of cancer etc) as well as differences in the location of the characteristic attenuation in the lungs is crucial for suggesting the appropriate diagnosis [2].DiscussionPTCL, a subgroup of Non-Hodgkin Lymphoma, is a malignant lymphoproliferative disorder from post-thymic (peripheral T-cells) or mature NK cells [3].", [["cancer", "ANATOMY", 211, 217], ["lungs", "ANATOMY", 303, 308], ["Non-Hodgkin Lymphoma", "ANATOMY", 395, 415], ["malignant lymphoproliferative", "ANATOMY", 422, 451], ["thymic", "ANATOMY", 471, 477], ["peripheral T-cells", "ANATOMY", 479, 497], ["NK cells", "ANATOMY", 509, 517], ["cancer", "DISEASE", 211, 217], ["Lymphoma", "DISEASE", 407, 415], ["lymphoproliferative disorder", "DISEASE", 432, 460], ["cancer", "CANCER", 211, 217], ["lungs", "ORGAN", 303, 308], ["Non-Hodgkin Lymphoma", "CANCER", 395, 415], ["malignant lymphoproliferative", "CANCER", 422, 451], ["thymic", "CELL", 471, 477], ["peripheral T-cells", "CELL", 479, 497], ["NK cells", "CELL", 509, 517], ["peripheral T-cells", "CELL_TYPE", 479, 497], ["mature NK cells", "CELL_TYPE", 502, 517], ["radiologic evaluation", "TEST", 72, 93], ["clinical examination", "TEST", 131, 151], ["acute vs chronic symptoms", "PROBLEM", 173, 198], ["cancer", "PROBLEM", 211, 217], ["the characteristic attenuation in the lungs", "PROBLEM", 265, 308], ["Non-Hodgkin Lymphoma", "PROBLEM", 395, 415], ["a malignant lymphoproliferative disorder", "PROBLEM", 420, 460], ["thymic (peripheral T-cells", "PROBLEM", 471, 497], ["mature NK cells", "PROBLEM", 502, 517], ["acute", "OBSERVATION_MODIFIER", 173, 178], ["cancer", "OBSERVATION", 211, 217], ["characteristic", "OBSERVATION_MODIFIER", 269, 283], ["attenuation", "OBSERVATION", 284, 295], ["lungs", "ANATOMY", 303, 308], ["Non-Hodgkin Lymphoma", "OBSERVATION", 395, 415], ["malignant", "OBSERVATION_MODIFIER", 422, 431], ["lymphoproliferative disorder", "OBSERVATION", 432, 460], ["thymic", "ANATOMY", 471, 477], ["peripheral", "ANATOMY_MODIFIER", 479, 489], ["mature NK cells", "OBSERVATION", 502, 517]]], ["PTCL accounts for less than 15% of all NHLs in the United States and Europe but they are more frequent in the Far East [4,5].", [["NHLs", "ANATOMY", 39, 43], ["PTCL", "DISEASE", 0, 4], ["NHLs", "DISEASE", 39, 43], ["PTCL", "CANCER", 0, 4], ["NHLs", "CANCER", 39, 43], ["NHLs", "OBSERVATION", 39, 43]]], ["PTCL not otherwise specified (NOS) is the most common group of PTCL and it includes cases that do not correspond to any specific subtype [5,6].Despite aggressive chemotherapy, the majority of patients with most subtypes of PTCL have unfavorable prognosis [7].", [["PTCL", "ANATOMY", 63, 67], ["PTCL", "ANATOMY", 223, 227], ["PTCL", "DISEASE", 0, 4], ["PTCL", "DISEASE", 63, 67], ["PTCL", "DISEASE", 223, 227], ["PTCL", "CANCER", 0, 4], ["NOS", "GENE_OR_GENE_PRODUCT", 30, 33], ["PTCL", "CANCER", 63, 67], ["patients", "ORGANISM", 192, 200], ["PTCL", "CANCER", 223, 227], ["patients", "SPECIES", 192, 200], ["aggressive chemotherapy", "TREATMENT", 151, 174]]], ["The IPI score, including age greater than 60 years, stage III or IV disease according to Ann Arbor staging system, elevated serum LDH, ECOG/Zubrod performance status of 2, 3, or 4 and more than one extranodal site, is the most established prognostic factor, but newer prognostic models have also been proposed [8,9].DiscussionPatients with PTCL present predominantly with nodal disease, but extranodal disease is often present, with skin being the most common extranodal site [10].Pulmonary involvement is relatively rare; its frequency has been assessed from 2% to 8% of the cases, while extrapulmonary manifestations in the form of pleural effusions are present in 3%\u201312% of the individuals with this disorder [6,10].", [["serum", "ANATOMY", 124, 129], ["extranodal site", "ANATOMY", 198, 213], ["PTCL", "ANATOMY", 340, 344], ["nodal", "ANATOMY", 372, 377], ["skin", "ANATOMY", 433, 437], ["extranodal site", "ANATOMY", 460, 475], ["Pulmonary", "ANATOMY", 481, 490], ["extrapulmonary", "ANATOMY", 589, 603], ["pleural effusions", "ANATOMY", 634, 651], ["PTCL", "DISEASE", 340, 344], ["nodal disease", "DISEASE", 372, 385], ["pleural effusions", "DISEASE", 634, 651], ["serum", "ORGANISM_SUBSTANCE", 124, 129], ["LDH", "GENE_OR_GENE_PRODUCT", 130, 133], ["PTCL", "CANCER", 340, 344], ["nodal", "MULTI-TISSUE_STRUCTURE", 372, 377], ["extranodal disease", "CANCER", 391, 409], ["skin", "ORGAN", 433, 437], ["Pulmonary", "ORGAN", 481, 490], ["pleural effusions", "CANCER", 634, 651], ["IPI", "PROTEIN", 4, 7], ["The IPI score", "TEST", 0, 13], ["stage III or IV disease", "PROBLEM", 52, 75], ["Ann Arbor staging system", "TEST", 89, 113], ["elevated serum LDH", "PROBLEM", 115, 133], ["ECOG", "TEST", 135, 139], ["Zubrod performance status", "TEST", 140, 165], ["nodal disease", "PROBLEM", 372, 385], ["extranodal disease", "PROBLEM", 391, 409], ["Pulmonary involvement", "PROBLEM", 481, 502], ["extrapulmonary manifestations", "PROBLEM", 589, 618], ["pleural effusions", "PROBLEM", 634, 651], ["this disorder", "PROBLEM", 698, 711], ["nodal disease", "OBSERVATION", 372, 385], ["extranodal disease", "OBSERVATION", 391, 409], ["skin", "ANATOMY", 433, 437], ["involvement", "OBSERVATION", 491, 502], ["relatively", "OBSERVATION_MODIFIER", 506, 516], ["rare", "OBSERVATION_MODIFIER", 517, 521], ["extrapulmonary", "ANATOMY", 589, 603], ["manifestations", "OBSERVATION", 604, 618], ["pleural", "ANATOMY", 634, 641], ["effusions", "OBSERVATION", 642, 651]]], ["The chest imaging findings of PTCL have not been well characterized [11].", [["chest", "ANATOMY", 4, 9], ["PTCL", "ANATOMY", 30, 34], ["PTCL", "DISEASE", 30, 34], ["PTCL", "CANCER", 30, 34], ["The chest imaging", "TEST", 0, 17], ["PTCL", "PROBLEM", 30, 34], ["chest", "ANATOMY", 4, 9], ["PTCL", "OBSERVATION", 30, 34]]], ["It should be noted that imaging findings are frequently non-specific and require correlation with clinical findings.", [["imaging findings", "TEST", 24, 40], ["clinical findings", "TEST", 98, 115], ["frequently non-specific", "OBSERVATION_MODIFIER", 45, 68]]], ["Common CT findings include nodules or consolidation, cavitation (in aggressive forms) as well as hilar/mediastinal lymphadenopathy [12].", [["nodules", "ANATOMY", 27, 34], ["hilar", "ANATOMY", 97, 102], ["cavitation", "DISEASE", 53, 63], ["hilar/mediastinal lymphadenopathy", "DISEASE", 97, 130], ["hilar", "CANCER", 97, 102], ["Common CT findings", "TEST", 0, 18], ["nodules", "PROBLEM", 27, 34], ["consolidation", "PROBLEM", 38, 51], ["cavitation", "PROBLEM", 53, 63], ["hilar/mediastinal lymphadenopathy", "PROBLEM", 97, 130], ["nodules", "OBSERVATION", 27, 34], ["consolidation", "OBSERVATION", 38, 51], ["cavitation", "OBSERVATION_MODIFIER", 53, 63], ["aggressive", "OBSERVATION_MODIFIER", 68, 78], ["hilar", "ANATOMY", 97, 102], ["mediastinal", "ANATOMY", 103, 114], ["lymphadenopathy", "OBSERVATION", 115, 130]]], ["Lewis et al. evaluated CT findings of 31 patients with lung lymphoma and reported that the most frequent finding was a mass/masslike consolidation larger than 1 cm, while the second most common was nodules less than 1cm.The authors did not report any patient with crazy paving pattern in the chest CT [13].", [["lung lymphoma", "ANATOMY", 55, 68], ["mass", "ANATOMY", 119, 123], ["nodules", "ANATOMY", 198, 205], ["chest", "ANATOMY", 292, 297], ["lung lymphoma", "DISEASE", 55, 68], ["patients", "ORGANISM", 41, 49], ["lung lymphoma", "CANCER", 55, 68], ["nodules", "CANCER", 198, 205], ["patient", "ORGANISM", 251, 258], ["patients", "SPECIES", 41, 49], ["patient", "SPECIES", 251, 258], ["CT findings", "TEST", 23, 34], ["lung lymphoma", "PROBLEM", 55, 68], ["a mass/masslike consolidation", "PROBLEM", 117, 146], ["nodules", "PROBLEM", 198, 205], ["crazy paving pattern", "PROBLEM", 264, 284], ["the chest CT", "TEST", 288, 300], ["lung", "ANATOMY", 55, 59], ["lymphoma", "OBSERVATION", 60, 68], ["mass", "OBSERVATION", 119, 123], ["masslike", "OBSERVATION_MODIFIER", 124, 132], ["consolidation", "OBSERVATION", 133, 146], ["larger", "OBSERVATION_MODIFIER", 147, 153], ["than 1 cm", "OBSERVATION_MODIFIER", 154, 163], ["nodules", "OBSERVATION", 198, 205], ["less than 1cm", "OBSERVATION_MODIFIER", 206, 219], ["chest", "ANATOMY", 292, 297]]], ["Fu et al. (2016) reported a rare case of pneumothorax as first manifestation of PTCL [14].", [["pneumothorax", "DISEASE", 41, 53], ["PTCL", "DISEASE", 80, 84], ["PTCL", "CANCER", 80, 84], ["pneumothorax", "PROBLEM", 41, 53], ["pneumothorax", "OBSERVATION", 41, 53]]], ["Three case reports exist concerning crazy paving pattern of PTCL with lung involvement [[15], [16], [17]].", [["PTCL", "ANATOMY", 60, 64], ["lung", "ANATOMY", 70, 74], ["PTCL", "DISEASE", 60, 64], ["PTCL", "CANCER", 60, 64], ["lung", "ORGAN", 70, 74], ["[15], [16], [17]]", "SIMPLE_CHEMICAL", 88, 105], ["lung involvement", "PROBLEM", 70, 86], ["PTCL", "OBSERVATION", 60, 64], ["lung", "ANATOMY", 70, 74]]], ["Recently, Aqeel et al. reported a rare case of acute respiratory failure in the setting of antisynthetase syndrome (ASS) in a patient with PTCL where the chest CT revealed extensive bilateral ground glass opacities [18].ConclusionIn conclusion, this case report represents a rare radiologic presentation of a rare disease.", [["respiratory", "ANATOMY", 53, 64], ["PTCL", "ANATOMY", 139, 143], ["chest", "ANATOMY", 154, 159], ["respiratory failure", "DISEASE", 53, 72], ["antisynthetase syndrome", "DISEASE", 91, 114], ["ASS", "DISEASE", 116, 119], ["PTCL", "DISEASE", 139, 143], ["patient", "ORGANISM", 126, 133], ["PTCL", "CANCER", 139, 143], ["patient", "SPECIES", 126, 133], ["acute respiratory failure", "PROBLEM", 47, 72], ["antisynthetase syndrome", "PROBLEM", 91, 114], ["PTCL", "TREATMENT", 139, 143], ["the chest CT", "TEST", 150, 162], ["extensive bilateral ground glass opacities", "PROBLEM", 172, 214], ["a rare disease", "PROBLEM", 307, 321], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["respiratory failure", "OBSERVATION", 53, 72], ["chest", "ANATOMY", 154, 159], ["extensive", "OBSERVATION_MODIFIER", 172, 181], ["bilateral", "ANATOMY_MODIFIER", 182, 191], ["ground glass opacities", "OBSERVATION", 192, 214], ["rare", "OBSERVATION_MODIFIER", 309, 313], ["disease", "OBSERVATION", 314, 321]]], ["Reviewing the course of the patient, we presume that the crazy paving depicted in the initial chest CT, actually represented early lung infiltration by PTCL.", [["chest", "ANATOMY", 94, 99], ["lung", "ANATOMY", 131, 135], ["PTCL", "ANATOMY", 152, 156], ["PTCL", "DISEASE", 152, 156], ["patient", "ORGANISM", 28, 35], ["chest", "ORGAN", 94, 99], ["lung", "ORGAN", 131, 135], ["PTCL", "CANCER", 152, 156], ["patient", "SPECIES", 28, 35], ["the initial chest CT", "TEST", 82, 102], ["early lung infiltration", "PROBLEM", 125, 148], ["chest", "ANATOMY", 94, 99], ["early", "OBSERVATION_MODIFIER", 125, 130], ["lung", "ANATOMY", 131, 135], ["infiltration", "OBSERVATION", 136, 148]]], ["Due to disease progression, the radiological pattern changed from crazy paving pattern to solid consolidations after a few months.", [["disease progression", "PROBLEM", 7, 26], ["the radiological pattern", "PROBLEM", 28, 52], ["solid consolidations", "PROBLEM", 90, 110], ["disease", "OBSERVATION", 7, 14], ["solid", "OBSERVATION_MODIFIER", 90, 95], ["consolidations", "OBSERVATION", 96, 110]]], ["We conclude that PTCL of the lungs should be included in the differential of crazy paving pattern and a histological confirmation should be pursued in patients with a high pretest probability for the sake of accurate diagnosis, valid prognostication and proper management.Learning points1.EBUS has a low sensitivity in the diagnosis of lymphoma2.Embedding pre-test clinical probability in clinical practice is of utmost importance3.PTCL has grave prognosis and therefore clinical trials should evaluate newer regimensConflict of interestWe wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.", [["PTCL", "ANATOMY", 17, 21], ["lungs", "ANATOMY", 29, 34], ["lymphoma2", "ANATOMY", 336, 345], ["lymphoma2", "DISEASE", 336, 345], ["PTCL", "DISEASE", 432, 436], ["PTCL", "CANCER", 17, 21], ["lungs", "ORGAN", 29, 34], ["patients", "ORGANISM", 151, 159], ["lymphoma2", "CANCER", 336, 345], ["PTCL", "CANCER", 432, 436], ["patients", "SPECIES", 151, 159], ["PTCL of the lungs", "PROBLEM", 17, 34], ["a histological confirmation", "TEST", 102, 129], ["valid prognostication", "TREATMENT", 228, 249], ["proper management", "TREATMENT", 254, 271], ["EBUS", "TEST", 289, 293], ["a low sensitivity", "PROBLEM", 298, 315], ["lymphoma2", "PROBLEM", 336, 345], ["grave prognosis", "PROBLEM", 441, 456], ["clinical trials", "TREATMENT", 471, 486], ["newer regimens", "TREATMENT", 503, 517], ["PTCL", "OBSERVATION", 17, 21], ["lungs", "ANATOMY", 29, 34], ["low sensitivity", "OBSERVATION_MODIFIER", 300, 315], ["grave prognosis", "OBSERVATION_MODIFIER", 441, 456]]]], "43d4eadd45196bbbafecfb3c888c18274d917859": [["The impact of specific interventions on the outbreak time course, number of cases and outcome of fatalities were evaluated including that of available critical care.", [["fatalities", "DISEASE", 97, 107], ["specific interventions", "TREATMENT", 14, 36]]], ["Key findings in our results indicate that (i) universal social isolation measures appear effective in reducing total fatalities only if they are strict and the number of daily social interactions is reduced to very low numbers; (ii) selective isolation of only the elderly (at higher fatality risk) appears almost as effective in reducing total fatalities but at a much lower economic damage; (iii) an increase in the number of critical care beds could save up to eight lives per extra bed in a million population with the current parameters used; (iv) the use of protective equipment (PPE) appears effective to dramatically reduce total fatalities when implemented extensively and in a high degree; (v) infection recognition through random testing of the population, accompanied by subsequent (self) isolation of infected aware individuals, can dramatically reduce the total fatalities but only if conducted extensively to almost the entire population and sustained over time; (vi) ending isolation measures while R0 values remain above 1.0 (with a safety factor) renders the isolation measures useless and total fatality numbers return to values as if nothing was ever done; (vii) ending the isolation measures for only the population under 60 y/o at R0 values still above 1.0 increases total fatalities but only around half as much as if isolation ends for everyone; (viii) a threshold value, equivalent to that for R0, appears to exist for the daily fatality rate at which to end isolation measures, this is significant as the fatality rate is (unlike R0) very accurately known.", [["fatalities", "DISEASE", 345, 355], ["infection", "DISEASE", 704, 713], ["social isolation measures", "TREATMENT", 56, 81], ["selective isolation", "TREATMENT", 233, 252], ["a much lower economic damage", "PROBLEM", 363, 391], ["a million population", "TREATMENT", 493, 513], ["protective equipment (PPE", "TREATMENT", 564, 589], ["a high degree; (v) infection recognition", "PROBLEM", 685, 725], ["random testing", "TEST", 734, 748], ["R0 values", "TEST", 1015, 1024], ["the isolation measures", "TREATMENT", 1073, 1095], ["the isolation measures", "TREATMENT", 1190, 1212], ["R0 values", "TEST", 1253, 1262], ["R0", "TREATMENT", 1419, 1421], ["increase", "OBSERVATION_MODIFIER", 402, 410], ["high degree", "OBSERVATION_MODIFIER", 687, 698], ["infection", "OBSERVATION", 704, 713], ["infected", "OBSERVATION", 814, 822], ["significant", "OBSERVATION_MODIFIER", 1512, 1523]]]], "5edf0be95eaed7335228df123f0c4099828f8543": [["INTRODUCTIONSevere Acute Respiratory Syndrome (SARS) has resulted in huge damage, since it burst out in China.", [["Acute Respiratory Syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["Acute Respiratory Syndrome", "PROBLEM", 19, 45], ["huge damage", "PROBLEM", 69, 80], ["Acute", "OBSERVATION_MODIFIER", 19, 24], ["Respiratory Syndrome", "OBSERVATION", 25, 45], ["huge", "OBSERVATION_MODIFIER", 69, 73], ["damage", "OBSERVATION", 74, 80], ["burst", "OBSERVATION_MODIFIER", 91, 96]]], ["SARS coronavirus (SARS-CoV), a previously unrecognized coronavirus, was discovered by the etiological agent of the disease, [1] [2] [3] [4] which encodes all the sequences of functional proteins required for viral replication and transcription.", [["SARS coronavirus", "DISEASE", 0, 16], ["SARS-CoV)", "DISEASE", 18, 27], ["[1] [2] [3] [4", "CHEMICAL", 124, 138], ["SARS coronavirus", "ORGANISM", 0, 16], ["SARS-CoV", "ORGANISM", 18, 26], ["coronavirus", "ORGANISM", 55, 66], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 124, 139], ["functional proteins", "PROTEIN", 175, 194], ["SARS coronavirus", "SPECIES", 0, 16], ["SARS coronavirus", "SPECIES", 0, 16], ["SARS-CoV", "SPECIES", 18, 26], ["SARS coronavirus", "PROBLEM", 0, 16], ["a previously unrecognized coronavirus", "PROBLEM", 29, 66], ["the disease", "PROBLEM", 111, 122], ["functional proteins", "PROBLEM", 175, 194], ["viral replication", "TREATMENT", 208, 225], ["coronavirus", "OBSERVATION", 55, 66]]], ["It is also known that the functional polypeptides are released from polyprotein by extensive proteolytic processing, primarily by the SARS coronavirus main protease (SARS M pro ).", [["SARS coronavirus main protease", "PROTEIN", 134, 164], ["SARS M pro", "PROTEIN", 166, 176], ["SARS coronavirus", "SPECIES", 134, 150], ["the functional polypeptides", "PROBLEM", 22, 49], ["polyprotein", "TREATMENT", 68, 79], ["extensive proteolytic processing", "TREATMENT", 83, 115], ["the SARS coronavirus main protease", "TREATMENT", 130, 164]]], ["This protease, with a chymotrypsin fold, has similarity with the coronavirus main protease in sharing the cleavage specificity for glutamine at substrate P1 site.", [["glutamine", "CHEMICAL", 131, 140], ["glutamine", "CHEMICAL", 131, 140], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 22, 34], ["glutamine", "AMINO_ACID", 131, 140], ["protease", "PROTEIN", 5, 13], ["chymotrypsin fold", "PROTEIN", 22, 39], ["coronavirus main protease", "PROTEIN", 65, 90], ["substrate P1 site", "DNA", 144, 161], ["This protease", "TREATMENT", 0, 13], ["a chymotrypsin fold", "TREATMENT", 20, 39], ["the coronavirus main protease", "TREATMENT", 61, 90], ["glutamine at substrate P1 site", "TREATMENT", 131, 161]]], ["5, 6 For the functional importance of SARS M pro in the viral life cycle, it becomes an attractive target in drug development directly against SARS disease.", [["SARS disease", "DISEASE", 143, 155], ["SARS M pro", "TREATMENT", 38, 48], ["SARS disease", "PROBLEM", 143, 155]]], ["7-12 However, presently, neither a vaccine nor an efficacious therapy is available.", [["a vaccine", "TREATMENT", 33, 42], ["an efficacious therapy", "TREATMENT", 47, 69]]], ["So, it is still urgent to design the potential therapeutic agents against SARS.INTRODUCTIONThrough the specific intermolecular interactions between monomers, 13 SARS M pro assembles together to form an asymmetrical dimer (shown in Fig. 1 ).", [["asymmetrical dimer", "PROTEIN", 202, 220], ["therapeutic agents", "TREATMENT", 47, 65], ["an asymmetrical dimer", "PROBLEM", 199, 220], ["asymmetrical dimer", "OBSERVATION", 202, 220]]], ["Both HCoV (Human Coronavirus) and TGEV (Transmissible Gastroenteritis Virus) M pro exist as a mixture of monomer and dimer in diluted solutions.", [["HCoV", "GENE_OR_GENE_PRODUCT", 5, 9], ["Human", "ORGANISM", 11, 16], ["Coronavirus", "ORGANISM", 17, 28], ["TGEV", "ORGANISM", 34, 38], ["Transmissible Gastroenteritis Virus", "ORGANISM", 40, 75], ["HCoV", "PROTEIN", 5, 9], ["dimer", "PROTEIN", 117, 122], ["Human", "SPECIES", 11, 16], ["TGEV", "SPECIES", 34, 38], ["HCoV", "SPECIES", 5, 9], ["TGEV", "SPECIES", 34, 38], ["Both HCoV (Human Coronavirus", "PROBLEM", 0, 28], ["TGEV (Transmissible Gastroenteritis Virus", "PROBLEM", 34, 75], ["a mixture of monomer and dimer in diluted solutions", "TREATMENT", 92, 143]]], ["14 Dissection of the enzyme results in the enzyme inactive and the dimer is the main function form of the enzyme.", [["enzyme", "PROTEIN", 21, 27], ["dimer", "PROTEIN", 67, 72], ["enzyme", "PROTEIN", 106, 112], ["the enzyme", "TEST", 17, 27], ["the enzyme", "TEST", 39, 49], ["the enzyme", "TEST", 102, 112], ["Dissection", "OBSERVATION", 3, 13], ["main", "OBSERVATION_MODIFIER", 80, 84]]], ["The structural infor-mation about the monomer and dimer, especially for the residues of the active pocket, could provide some insights into the functional differences.", [["dimer", "PROTEIN", 50, 55], ["the residues of the active pocket", "PROBLEM", 72, 105], ["active", "OBSERVATION_MODIFIER", 92, 98], ["pocket", "OBSERVATION", 99, 105]]], ["The crystal structure of SARS M pro dimer has been solved, 17 while, for the monomer form, only a theoretical model of its 3D structure, based on the structures of the HCoV and TGEV M pro , has been described.", [["HCoV", "GENE_OR_GENE_PRODUCT", 168, 172], ["TGEV M pro", "GENE_OR_GENE_PRODUCT", 177, 187], ["SARS M pro dimer", "PROTEIN", 25, 41], ["HCoV", "PROTEIN", 168, 172], ["TGEV M pro", "PROTEIN", 177, 187], ["SARS M pro dimer", "PROBLEM", 25, 41], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["structure", "OBSERVATION_MODIFIER", 12, 21]]], ["18 The main difference between the monomer and the dimer is that there exist some specific intermolecular interactions between the two monomers within the dimer, while not for the isolated monomer.", [["dimer", "PROTEIN", 51, 56], ["dimer", "PROTEIN", 155, 160], ["the isolated monomer", "PROBLEM", 176, 196], ["main", "OBSERVATION_MODIFIER", 7, 11], ["difference", "OBSERVATION_MODIFIER", 12, 22], ["monomer", "OBSERVATION_MODIFIER", 35, 42], ["some", "OBSERVATION_MODIFIER", 77, 81], ["specific", "OBSERVATION_MODIFIER", 82, 90], ["intermolecular interactions", "OBSERVATION", 91, 118], ["monomer", "OBSERVATION", 189, 196]]], ["There exist a number of intermolecular interactions between the two monomers within the dimer, that is, the hydrogen bonds between active pocket and the N-terminus of another monomer, the salt bridge between domain III and N-terminus of another monomer and the specific electrostatic and hydrophobic interactions between the domains III of monomers in dimer.", [["hydrogen", "CHEMICAL", 108, 116], ["N", "CHEMICAL", 153, 154], ["N", "CHEMICAL", 223, 224], ["dimer", "PROTEIN", 88, 93], ["N-terminus", "PROTEIN", 153, 163], ["salt bridge", "PROTEIN", 188, 199], ["domain III and N-terminus", "PROTEIN", 208, 233], ["domains III", "PROTEIN", 325, 336], ["dimer", "PROTEIN", 352, 357], ["intermolecular interactions", "PROBLEM", 24, 51], ["the hydrogen bonds between active pocket", "PROBLEM", 104, 144], ["the salt bridge", "TREATMENT", 184, 199], ["number", "OBSERVATION_MODIFIER", 14, 20], ["intermolecular interactions", "OBSERVATION", 24, 51], ["hydrogen bonds", "OBSERVATION", 108, 122], ["active", "OBSERVATION_MODIFIER", 131, 137], ["pocket", "OBSERVATION_MODIFIER", 138, 144], ["salt bridge", "OBSERVATION", 188, 199], ["electrostatic", "OBSERVATION_MODIFIER", 270, 283], ["hydrophobic interactions", "OBSERVATION", 288, 312]]], ["Since any mutation or deletion of these residues involving the interactions have resulted in an inactive enzyme, 14, 19 these interactions are vital to maintain the active conformation of SARS M pro dimer and might be the ultimate reasons for the activity differences between dimer and monomer, which can be treated as new targets for the drug design against SARS-CoV.", [["SARS", "DISEASE", 359, 363], ["SARS-CoV", "ORGANISM", 359, 367], ["SARS M pro dimer", "PROTEIN", 188, 204], ["dimer", "PROTEIN", 276, 281], ["SARS-CoV", "SPECIES", 359, 367], ["any mutation", "PROBLEM", 6, 18], ["these residues", "PROBLEM", 34, 48], ["an inactive enzyme", "TEST", 93, 111], ["SARS", "PROBLEM", 359, 363]]], ["However, because of the absence of conformational information about monomer, the key functional roles of these intermolecular interactions in how to fix the dimer at active structure are still vague.INTRODUCTIONMolecular dynamics (MD) simulations are widely used to simulate the motion of molecules, which provides useful information of the chemical reactions, phase transitions, and other physical phenomena due to molecular interactions.", [["dimer", "PROTEIN", 157, 162], ["the chemical reactions", "PROBLEM", 337, 359], ["phase transitions", "PROBLEM", 361, 378], ["other physical phenomena", "PROBLEM", 384, 408]]], ["So, MD simulation can be used as a powerful tool for studying the structural variations and motions of SARS M pro .", [["SARS", "DISEASE", 103, 107], ["SARS M pro", "PROTEIN", 103, 113]]], ["Many MD studies on the enzyme have been reported [20] [21] [22] that none of them target the differences of the structure and dynamics of the active site residues of monomer relative to dimer.", [["[20] [21] [22]", "SIMPLE_CHEMICAL", 49, 63], ["dimer", "PROTEIN", 186, 191], ["the enzyme", "TEST", 19, 29], ["active site", "OBSERVATION", 142, 153]]], ["Using the X-ray structure of the enzyme dimer form and the protomer A deleting protomer B within the dimer as the starting point of dimer and monomer model, we have performed two MD simulations of dimer and monomer.", [["enzyme dimer form", "PROTEIN", 33, 50], ["protomer A", "PROTEIN", 59, 69], ["protomer B", "PROTEIN", 79, 89], ["dimer", "PROTEIN", 101, 106], ["dimer", "PROTEIN", 132, 137], ["dimer", "PROTEIN", 197, 202]]], ["Because of the absence of the crystal structure of enzyme complexed with substrate for substrate hydrolysis by SARS M pro , the substrate-analog hexapetidyl CMK inhibitor, which cannot be hydrolyzed by enzyme, was present in the structures of both MD simulations to investigate the substrate binding.INTRODUCTIONIn this research, by comparing the process of the MD simulation of monomer with dimer, our aim is to (i) find the structural variations and dynamics of the active site residues in SARS M pro monomer in contrast to the dimer, which result in an inactive monomer and provide useful information for receptor based drug design; (ii) investigate the detailed specific interactions involving the two monomers within the dimer and its functional roles in maintaining the activity of the dimer, which provides insights for the design of specific protease inhibitors using the interface of the dimer as a new target.Preparation of Enzyme-Bound ComplexesThe crystal structure of SARS M pro (PDB code 1UK4), containing protomer A and protomer B complexed with the CMK inhibitor, and the crystal structure of protomer A deleting protomer B were used as the starting structures of dimer and monomer model, respectively.", [["hexapetidyl", "CHEMICAL", 145, 156], ["hexapetidyl", "CHEMICAL", 145, 156], ["hexapetidyl CMK", "SIMPLE_CHEMICAL", 145, 160], ["Enzyme", "GENE_OR_GENE_PRODUCT", 934, 940], ["protomer B", "GENE_OR_GENE_PRODUCT", 1035, 1045], ["CMK", "GENE_OR_GENE_PRODUCT", 1065, 1068], ["enzyme", "PROTEIN", 51, 57], ["enzyme", "PROTEIN", 202, 208], ["dimer", "PROTEIN", 392, 397], ["SARS M pro monomer", "PROTEIN", 492, 510], ["dimer", "PROTEIN", 530, 535], ["dimer", "PROTEIN", 726, 731], ["dimer", "PROTEIN", 792, 797], ["dimer", "PROTEIN", 897, 902], ["Enzyme-Bound Complexes", "PROTEIN", 934, 956], ["SARS M pro", "PROTEIN", 981, 991], ["PDB code 1UK4", "PROTEIN", 993, 1006], ["protomer A", "PROTEIN", 1020, 1030], ["protomer B", "PROTEIN", 1035, 1045], ["CMK inhibitor", "PROTEIN", 1065, 1078], ["protomer A", "PROTEIN", 1109, 1119], ["protomer B", "PROTEIN", 1129, 1139], ["dimer", "PROTEIN", 1180, 1185], ["substrate hydrolysis", "PROBLEM", 87, 107], ["the substrate-analog hexapetidyl CMK inhibitor", "TREATMENT", 124, 170], ["enzyme", "TEST", 202, 208], ["the substrate binding", "PROBLEM", 278, 299], ["the active site residues", "PROBLEM", 464, 488], ["an inactive monomer", "PROBLEM", 553, 572], ["receptor based drug design", "TREATMENT", 608, 634], ["specific protease inhibitors", "TREATMENT", 841, 869], ["Enzyme", "TEST", 934, 940], ["SARS M pro (PDB code 1UK4", "TREATMENT", 981, 1006], ["protomer A and protomer B complexed", "TREATMENT", 1020, 1055], ["the CMK inhibitor", "TREATMENT", 1061, 1078], ["protomer A deleting protomer B", "TREATMENT", 1109, 1139], ["active", "OBSERVATION_MODIFIER", 468, 474], ["inactive", "OBSERVATION", 556, 564], ["Bound Complexes", "OBSERVATION_MODIFIER", 941, 956]]], ["Considering the residues around His163, the imidazole of His163 is protonated at the NE2 atom.", [["His163", "CHEMICAL", 32, 38], ["imidazole", "CHEMICAL", 44, 53], ["His163", "CHEMICAL", 57, 63], ["His", "CHEMICAL", 32, 35], ["imidazole", "CHEMICAL", 44, 53], ["His", "CHEMICAL", 57, 60], ["NE2", "CHEMICAL", 85, 88], ["imidazole", "SIMPLE_CHEMICAL", 44, 53], ["His163", "SIMPLE_CHEMICAL", 57, 63], ["NE2 atom", "SIMPLE_CHEMICAL", 85, 93], ["the imidazole", "TREATMENT", 40, 53]]], ["The experiment of Huang et al. 23 have supported the view that the nucleophile in this proteinase is the uncharged thiol, with His41 acting as a general base.", [["thiol", "CHEMICAL", 115, 120], ["His41", "CHEMICAL", 127, 132], ["thiol", "CHEMICAL", 115, 120], ["His41", "CHEMICAL", 127, 132], ["thiol", "SIMPLE_CHEMICAL", 115, 120], ["His41", "SIMPLE_CHEMICAL", 127, 132], ["proteinase", "PROTEIN", 87, 97], ["base", "ANATOMY_MODIFIER", 153, 157]]], ["Therefore, Cys145 and His41 of the catalytic dyad were left uncharged in the two MD simulations in this work.Molecular Dynamics SimulationsTwo independent 10 ns MD simulations were performed by the program AMBER7.0 24 with the force field reported by Cornell et al. 25 The same MD simulation protocol was applied for both simulations.", [["Cys145", "CHEMICAL", 11, 17], ["Cys145", "GENE_OR_GENE_PRODUCT", 11, 17], ["His41", "GENE_OR_GENE_PRODUCT", 22, 27], ["Cys145", "PROTEIN", 11, 17], ["His41", "PROTEIN", 22, 27], ["catalytic dyad", "PROTEIN", 35, 49], ["left", "ANATOMY_MODIFIER", 55, 59]]], ["For these two MD simulations, we used the NPT ensemble (pressure \u00bc 1.025 3 10 5 Pa) with explicit solvent and periodic boundary conditions.", [["the NPT ensemble (pressure \u00bc", "TREATMENT", 38, 66], ["explicit solvent", "TREATMENT", 89, 105], ["periodic boundary conditions", "TREATMENT", 110, 138]]], ["All covalent bonds involving hydrogens were fixed with the SHAKE algorithm, 26 and the integration of the equations of the motion was done with the leap-frog algorithm.", [["hydrogens", "SIMPLE_CHEMICAL", 29, 38], ["the SHAKE algorithm", "TEST", 55, 74], ["covalent bonds", "OBSERVATION", 4, 18]]], ["27 The long-range electrostatic interactions were treated with particle-mesh Ewald (PME 28 ) with a short-range spherical cutoff of 9 \u00c5 .Molecular Dynamics SimulationsThe monomer/dimer complexes were immersed in an orthorhombic box of dimensions (77 3 98 3 74 \u00c5 ) and (84 3 100 3 99 \u00c5 ), respectively, and filled with TIP3 model water molecules.", [["dimer complexes", "PROTEIN", 179, 194], ["TIP3", "PROTEIN", 318, 322], ["The long-range electrostatic interactions", "PROBLEM", 3, 44], ["a short-range spherical cutoff", "TEST", 98, 128], ["The monomer/dimer complexes", "TEST", 167, 194], ["TIP3 model water molecules", "TREATMENT", 318, 344], ["orthorhombic box", "OBSERVATION", 215, 231], ["water molecules", "OBSERVATION", 329, 344]]], ["To neutralize the total charge of the solvated systems, two and five Na \u00fe ions were randomly placed far away from the surface of the monomer/ dimer complexes.", [["surface", "ANATOMY", 118, 125], ["Na", "CHEMICAL", 69, 71], ["Na", "CHEMICAL", 69, 71], ["Na \u00fe ions", "SIMPLE_CHEMICAL", 69, 78], ["surface", "CELLULAR_COMPONENT", 118, 125], ["dimer complexes", "PROTEIN", 142, 157], ["the solvated systems", "TREATMENT", 34, 54], ["five Na \u00fe ions", "TREATMENT", 64, 78], ["dimer complexes", "OBSERVATION", 142, 157]]], ["For the simulation with the monomer complex, the entire system consisted of 4722 solute atoms (enzyme, inhibitor, and two Na \u00fe ions) and 41,496 solvent atoms, whereas for the dimer complex system, the number of solute and solvent atoms were 9411 and 67,260, respectively.", [["Na", "CHEMICAL", 122, 124], ["Na", "CHEMICAL", 122, 124], ["solute", "SIMPLE_CHEMICAL", 211, 217], ["monomer complex", "PROTEIN", 28, 43], ["dimer complex", "PROTEIN", 175, 188], ["enzyme", "TEST", 95, 101], ["inhibitor", "TEST", 103, 112]]], ["The two systems relaxed by performing 100 steps of steepest descent and 1000 steps of conjugate gradient energy minimization to reduce steric conflicts between water molecules and the solute before the MD trajectory.Molecular Dynamics SimulationsDuring the equilibration, the solute (enzyme, inhibitor, and Na \u00fe ) was constrained and the solvent (water molecules) was equilibrated for 50 ps simulation at 298 K using an integral time step of 1 fs.", [["Na", "CHEMICAL", 307, 309], ["Na", "CHEMICAL", 307, 309], ["Na \u00fe", "SIMPLE_CHEMICAL", 307, 311], ["steepest descent", "PROBLEM", 51, 67], ["conjugate gradient energy minimization", "TREATMENT", 86, 124], ["the equilibration", "TEST", 253, 270], ["the solute (enzyme, inhibitor", "TREATMENT", 272, 301], ["the solvent (water molecules", "TREATMENT", 334, 362], ["steric conflicts", "OBSERVATION", 135, 151]]], ["Then, the constraints on the solute were removed and the entire system was heated gradually from 0 to 298 K, at increments of 50 K, each for 15 ps with a 1 fs time step.", [["solute", "SIMPLE_CHEMICAL", 29, 35]]], ["Finally, the whole solvated model was subjected to a free equilibrium simulation for 10 ns, using an integral time step of 2 fs with a temperature of 298 K kept constant by a Berendsen 29 temperature coupling constant of 0.1 ps.Molecular Dynamics SimulationsThe parameters of hexapeptidyl inhibitor CMK required for dynamic simulation were generated with the program AMBER7.0.Structural AnalysisThe coordinates of the system were saved at every 1 ps from the trajectories of the MD simulations of the dimer and monomer complexes of SARS M pro for subsequent analyses.", [["hexapeptidyl", "CHEMICAL", 276, 288], ["CMK", "SIMPLE_CHEMICAL", 299, 302], ["hexapeptidyl inhibitor CMK", "PROTEIN", 276, 302], ["AMBER7", "PROTEIN", 367, 373], ["dimer", "PROTEIN", 501, 506], ["monomer complexes", "PROTEIN", 511, 528], ["a temperature", "TEST", 133, 146], ["hexapeptidyl inhibitor CMK", "TREATMENT", 276, 302], ["dynamic simulation", "TEST", 316, 334], ["Structural Analysis", "TEST", 376, 395], ["subsequent analyses", "TEST", 547, 566]]], ["For the calculation of the root-meansquare deviation (rmsd) values, the structures were least-squares fit using the Ca atoms.", [["root", "ANATOMY", 27, 31], ["Ca", "CHEMICAL", 116, 118], ["Ca", "CHEMICAL", 116, 118], ["Ca atoms", "SIMPLE_CHEMICAL", 116, 124], ["the Ca atoms", "TREATMENT", 112, 124], ["root", "ANATOMY", 27, 31], ["meansquare deviation", "OBSERVATION", 32, 52]]], ["In case of the dimer, only the rmsd value of protomer A is calculated.", [["dimer", "PROTEIN", 15, 20], ["protomer A", "PROTEIN", 45, 55]]], ["The averaged structures were minimized by 500 steps of conjugate gradient energy minimization.RESULTS AND DISCUSSIONThe rmsd of the backbone heavy atoms during MD simulations of protomer A within the SARS M pro dimer model and monomer model relative to the crystal structure are shown in Figure 2 .", [["protomer A", "PROTEIN", 178, 188], ["conjugate gradient energy minimization", "TREATMENT", 55, 93], ["rmsd", "OBSERVATION_MODIFIER", 120, 124], ["backbone", "ANATOMY_MODIFIER", 132, 140]]], ["In the first 0.5 ns, the rmsd value increases quickly, which means that the structure of the enzyme dissolved in solution relaxes and is differ- ent from the crystal structure.", [["enzyme", "PROTEIN", 93, 99], ["the rmsd value", "TEST", 21, 35], ["dissolved", "OBSERVATION_MODIFIER", 100, 109]]], ["From the plot, the fluctuation of rmsd values is low after 1 ns, fluctuating around 1.8-2.2 \u00c5 in protomer A within dimer and higher values around 1.7-2.7 \u00c5 in monomer.", [["protomer A", "PROTEIN", 97, 107], ["dimer", "PROTEIN", 115, 120], ["the plot", "TEST", 5, 13], ["the fluctuation of rmsd values", "TEST", 15, 45], ["fluctuation", "OBSERVATION_MODIFIER", 19, 30], ["low", "OBSERVATION_MODIFIER", 49, 52], ["higher", "OBSERVATION_MODIFIER", 125, 131]]], ["It can be deduced that the magnitude of changes in the conformation of monomer is larger than that in protomer A within dimer, which means that the monomer shows greater motions than protomer A.RESULTS AND DISCUSSIONThese two models exhibit different dynamics behavior: the dimer model displays conformational rigidity higher than that of the monomer model, which has been further confirmed by the root-mean-square fluctuations of the Ca atoms for each residue during MD simulations.", [["rigidity", "DISEASE", 310, 318], ["Ca", "CHEMICAL", 435, 437], ["Ca", "CHEMICAL", 435, 437], ["Ca atoms", "SIMPLE_CHEMICAL", 435, 443], ["protomer A", "PROTEIN", 102, 112], ["dimer", "PROTEIN", 120, 125], ["the dimer model", "TEST", 270, 285], ["conformational rigidity", "PROBLEM", 295, 318], ["the Ca atoms", "TREATMENT", 431, 443], ["each residue", "PROBLEM", 448, 460], ["larger", "OBSERVATION_MODIFIER", 82, 88], ["conformational rigidity", "OBSERVATION", 295, 318], ["root", "ANATOMY", 398, 402]]], ["Figure 3 compares the calculated B-factors with the experimental ones from the X-ray structure.", [["B-factors", "GENE_OR_GENE_PRODUCT", 33, 42], ["B-factors", "PROTEIN", 33, 42], ["the X-ray structure", "TEST", 75, 94]]], ["It is obvious from the plot in Figure 3 that the B-factors from the dimer MD simulation are little higher than the crystallographic B-factors except for segment 120:170, where the calculated fluctuations are close to the experimental ones.", [["B-factors", "GENE_OR_GENE_PRODUCT", 49, 58], ["B-factors", "GENE_OR_GENE_PRODUCT", 132, 141], ["B-factors", "PROTEIN", 49, 58], ["crystallographic B-factors", "PROTEIN", 115, 141], ["the calculated fluctuations", "PROBLEM", 176, 203], ["little", "OBSERVATION_MODIFIER", 92, 98], ["higher", "OBSERVATION_MODIFIER", 99, 105]]], ["The 120:170 segment corresponds to the domain II of SARS M pro (the interfacial region of SARS M pro dimer), which is buried in the dimer interior thus not exposed to the solvent.", [["SARS", "DISEASE", 52, 56], ["120:170 segment", "DNA", 4, 19], ["domain II", "PROTEIN", 39, 48], ["SARS M pro", "PROTEIN", 52, 62], ["interfacial region", "PROTEIN", 68, 86], ["SARS M pro dimer", "PROTEIN", 90, 106], ["SARS M pro", "TREATMENT", 52, 62]]], ["While for the monomer model, the B-factors of the whole protein, including the segment 120:170, show considerable larger fluctuations than the dimer model.", [["B-factors", "GENE_OR_GENE_PRODUCT", 33, 42], ["B-factors", "PROTEIN", 33, 42], ["segment 120:170", "PROTEIN", 79, 94], ["the whole protein", "TEST", 46, 63], ["considerable larger fluctuations than the dimer model", "PROBLEM", 101, 154], ["considerable", "OBSERVATION_MODIFIER", 101, 113], ["larger", "OBSERVATION_MODIFIER", 114, 120], ["fluctuations", "OBSERVATION", 121, 133]]], ["This is expected because, for the loss of the counter monomer, the whole protein exposes to and interacts strongly with solvent.RESULTS AND DISCUSSIONAs shown in Figure 1 (b), the active site of SARS M pro comprises loop 140-146, loop 184-197, and b-strand 163-172.", [["SARS", "DISEASE", 195, 199], ["b-strand 163-172", "CHEMICAL", 248, 264], ["the counter monomer", "TREATMENT", 42, 61], ["loop", "TEST", 216, 220], ["loop", "TEST", 230, 234], ["b-strand", "TEST", 248, 256]]], ["There exist some residues important to the substrate binding and hydrolysis in these loops and b-strand, with the ''oxyanion hole'' and the catalytic site Cys145 in loop 140-146; His163 and Glu166 residues specific for glutamine at substrate P1 site in b-strand 163-173; and potential catalytic site Asp187 and other important S3 subsite of substrate binding in loop 184-197.", [["loop 140-146", "CHEMICAL", 165, 177], ["glutamine", "CHEMICAL", 219, 228], ["b-strand 163-173", "CHEMICAL", 253, 269], ["loop 184-197", "CHEMICAL", 362, 374], ["Cys", "CHEMICAL", 155, 158], ["His", "CHEMICAL", 179, 182], ["Glu166", "CHEMICAL", 190, 196], ["glutamine", "CHEMICAL", 219, 228], ["Asp", "CHEMICAL", 300, 303], ["Cys145", "AMINO_ACID", 155, 161], ["His163", "AMINO_ACID", 179, 185], ["Glu166", "AMINO_ACID", 190, 196], ["glutamine", "AMINO_ACID", 219, 228], ["Asp187", "AMINO_ACID", 300, 306], ["catalytic site", "PROTEIN", 140, 154], ["S3 subsite", "PROTEIN", 327, 337], ["some residues", "PROBLEM", 12, 25], ["the substrate binding", "PROBLEM", 39, 60], ["the ''oxyanion hole", "TREATMENT", 110, 129], ["Cys", "TEST", 155, 158], ["loop", "TEST", 165, 169], ["glutamine at substrate P1 site", "PROBLEM", 219, 249], ["potential catalytic site Asp", "TEST", 275, 303]]], ["Other residues in and around the substrate-binding pocket, such as Tyr161 and the N-terminus of the other monomer, in the position to form hydrogen bonds with His163 and Glu166, are also important for enzyme activity.", [["Tyr161", "CHEMICAL", 67, 73], ["N", "CHEMICAL", 82, 83], ["hydrogen", "CHEMICAL", 139, 147], ["His", "CHEMICAL", 159, 162], ["Glu166", "CHEMICAL", 170, 176], ["Tyr161", "GENE_OR_GENE_PRODUCT", 67, 73], ["His163", "SIMPLE_CHEMICAL", 159, 165], ["Glu166", "GENE_OR_GENE_PRODUCT", 170, 176], ["substrate-binding pocket", "PROTEIN", 33, 57], ["Tyr161", "PROTEIN", 67, 73], ["N-terminus", "PROTEIN", 82, 92], ["enzyme", "PROTEIN", 201, 207], ["Other residues in and around the substrate-binding pocket", "PROBLEM", 0, 57], ["residues", "OBSERVATION", 6, 14], ["binding pocket", "OBSERVATION", 43, 57], ["hydrogen bonds", "OBSERVATION", 139, 153]]], ["These three segments are all located at the dimer interfacial region 120:170 and are affected by the intermolecular interactions with the counter monomer (see Fig. 3 ).", [["dimer interfacial region 120:170", "PROTEIN", 44, 76], ["segments", "ANATOMY_MODIFIER", 12, 20], ["all", "OBSERVATION_MODIFIER", 25, 28], ["dimer", "ANATOMY_MODIFIER", 44, 49], ["interfacial", "ANATOMY_MODIFIER", 50, 61], ["region", "ANATOMY_MODIFIER", 62, 68], ["intermolecular interactions", "OBSERVATION", 101, 128]]], ["Noticeably, only the conformational variations of protomer A during the MD simulation of SARS M pro dimer complex are used to compare with that of monomer.Dynamic Behavior of the Catalytic SiteThe catalytic site of coronavirus M pro is similar to those of the picornavirus 3C proteinase and assumed to have two properties, (i) unlike proteinases of the papain family in which an asparagine is the third member of the catalytic triad, a buried water molecule is found in the place that normally would be occupied by the side chain of the third member of the catalytic triad in a number of crystal structures of SARS M pro [ Fig. 4(a,b) ].", [["asparagine", "CHEMICAL", 379, 389], ["SARS", "DISEASE", 610, 614], ["asparagine", "CHEMICAL", 379, 389], ["coronavirus", "ORGANISM", 215, 226], ["picornavirus 3C proteinase", "GENE_OR_GENE_PRODUCT", 260, 286], ["papain", "GENE_OR_GENE_PRODUCT", 353, 359], ["asparagine", "AMINO_ACID", 379, 389], ["protomer A", "PROTEIN", 50, 60], ["SARS M pro dimer complex", "PROTEIN", 89, 113], ["Catalytic Site", "DNA", 179, 193], ["catalytic site", "PROTEIN", 197, 211], ["coronavirus M pro", "PROTEIN", 215, 232], ["picornavirus 3C proteinase", "PROTEIN", 260, 286], ["proteinases", "PROTEIN", 334, 345], ["papain family", "PROTEIN", 353, 366], ["catalytic triad", "PROTEIN", 417, 432], ["buried water molecule", "PROTEIN", 436, 457], ["side chain", "PROTEIN", 519, 529], ["catalytic triad", "PROTEIN", 557, 572], ["coronavirus M pro", "PROBLEM", 215, 232], ["the picornavirus 3C proteinase", "TREATMENT", 256, 286], ["the papain family", "TREATMENT", 349, 366], ["a buried water molecule", "PROBLEM", 434, 457], ["the catalytic triad", "PROBLEM", 553, 572], ["coronavirus", "OBSERVATION", 215, 226], ["picornavirus", "OBSERVATION", 260, 272]]], ["Thus, SARS M pro is assumed to be a viral cysteine proteinase employing only a catalytic dyad 14 ; and (ii) in the various crystal structures of SARS M pro , the cysteinehistidine distance is between 3.6 and 3.9 \u00c5 , which might be important to the substrate hydrolysis by SARS M pro by a general-base mechanism.", [["SARS", "DISEASE", 145, 149], ["cysteinehistidine", "CHEMICAL", 162, 179], ["cysteine", "CHEMICAL", 42, 50], ["cysteinehistidine", "CHEMICAL", 162, 179], ["SARS M pro", "GENE_OR_GENE_PRODUCT", 6, 16], ["cysteinehistidine", "SIMPLE_CHEMICAL", 162, 179], ["SARS M pro", "PROTEIN", 6, 16], ["viral cysteine proteinase", "PROTEIN", 36, 61], ["catalytic dyad 14", "PROTEIN", 79, 96], ["a viral cysteine proteinase", "PROBLEM", 34, 61], ["the cysteinehistidine distance", "TEST", 158, 188]]], ["23 In the MD simulation of SARS M pro dimer complex, the distance between NE2 of His41 and SG of Cys145 fluctuates in the range of 3.5-4.5 \u00c5 [shown in Fig. 5 (a)], which agrees well with the experimental observations made by X-ray crystallography.", [["SARS", "DISEASE", 27, 31], ["Cys145", "CHEMICAL", 97, 103], ["His41", "CHEMICAL", 81, 86], ["Cys145", "CHEMICAL", 97, 103], ["Cys145", "AMINO_ACID", 97, 103], ["SARS M pro dimer complex", "PROTEIN", 27, 51], ["NE2", "PROTEIN", 74, 77], ["His41", "PROTEIN", 81, 86], ["Cys145", "PROTEIN", 97, 103], ["His41", "TEST", 81, 86], ["SG", "TEST", 91, 93], ["X-ray crystallography", "TEST", 225, 246]]], ["The dihedral angle CA-CB-CG-CD2 of His41 averages 73.48 and the averaged distance between NE2 of His41 and SG of Cys145 is 3.72 \u00c5 , indicating the presence of a weak hydrogen bond [occupancy of 36.4%, shown in Fig. 4(c) ].", [["His41", "CHEMICAL", 35, 40], ["His41", "CHEMICAL", 97, 102], ["Cys145", "CHEMICAL", 113, 119], ["hydrogen", "CHEMICAL", 166, 174], ["Cys145", "AMINO_ACID", 113, 119], ["CD2", "PROTEIN", 28, 31], ["NE2", "PROTEIN", 90, 93], ["His41", "PROTEIN", 97, 102], ["The dihedral angle CA", "TEST", 0, 21], ["CB-", "TEST", 22, 25], ["CG", "TEST", 25, 27], ["NE2", "TEST", 90, 93], ["His41", "TEST", 97, 102], ["SG", "TEST", 107, 109], ["Cys145", "TEST", 113, 119], ["a weak hydrogen bond [occupancy", "PROBLEM", 159, 190], ["SG", "ANATOMY_MODIFIER", 107, 109], ["weak", "OBSERVATION_MODIFIER", 161, 165], ["hydrogen bond", "OBSERVATION", 166, 179]]], ["In the crystal structure, a water molecule entrapped by Asp187 and His41 shields Asp187 from the catalytic dyad of SARS M pro [ Fig. 4(a,b) ].", [["Asp187", "CHEMICAL", 56, 62], ["Asp187", "CHEMICAL", 81, 87], ["Asp", "CHEMICAL", 56, 59], ["His41", "CHEMICAL", 67, 72], ["Asp", "CHEMICAL", 81, 84], ["Asp187", "AMINO_ACID", 56, 62], ["His41", "AMINO_ACID", 67, 72], ["Asp187", "AMINO_ACID", 81, 87], ["catalytic dyad", "PROTEIN", 97, 111], ["Asp", "TEST", 56, 59], ["His41 shields Asp", "TEST", 67, 84], ["crystal", "ANATOMY_MODIFIER", 7, 14], ["water molecule", "OBSERVATION", 28, 42]]], ["However, an interesting phenomenon found in the MD simulation is that the distance between ND1 of His41 and OE2 of Asp187 averages 2.79 \u00c5 , supporting the presence of a stable hydrogen bond with occupancy of 83.2% (Table I) .Dynamic Behavior of the Catalytic SiteMonitoring the orientation of the His41 flip by the dihedral angel CG-CB-CA-N, it is shown that this angle remains nearly constantly around 58.28 during the MD simulation of the dimer complex.", [["His41", "CHEMICAL", 98, 103], ["Asp187", "CHEMICAL", 115, 121], ["hydrogen", "CHEMICAL", 176, 184], ["His41", "CHEMICAL", 297, 302], ["CG-CB-CA-N", "CHEMICAL", 330, 340], ["ND1", "GENE_OR_GENE_PRODUCT", 91, 94], ["His41", "GENE_OR_GENE_PRODUCT", 98, 103], ["His41", "GENE_OR_GENE_PRODUCT", 297, 302], ["His41", "PROTEIN", 98, 103], ["OE2", "PROTEIN", 108, 111], ["Asp187", "PROTEIN", 115, 121], ["His41 flip", "PROTEIN", 297, 307], ["CB", "PROTEIN", 333, 335], ["CA", "PROTEIN", 336, 338], ["dimer complex", "PROTEIN", 441, 454], ["an interesting phenomenon", "PROBLEM", 9, 34], ["the dihedral angel CG", "TEST", 311, 332], ["stable", "OBSERVATION_MODIFIER", 169, 175], ["hydrogen bond", "OBSERVATION", 176, 189]]], ["In contrast to the angle of $908 in crystal structure, the imidazole ring of His41 turns toward Asp187.", [["imidazole", "CHEMICAL", 59, 68], ["His41", "CHEMICAL", 77, 82], ["Asp187", "CHEMICAL", 96, 102], ["imidazole", "CHEMICAL", 59, 68], ["His41", "CHEMICAL", 77, 82], ["Asp", "CHEMICAL", 96, 99], ["His41", "SIMPLE_CHEMICAL", 77, 82], ["Asp187", "AMINO_ACID", 96, 102], ["the imidazole ring", "TREATMENT", 55, 73], ["Asp", "TEST", 96, 99], ["angle", "OBSERVATION_MODIFIER", 19, 24]]], ["This turn helps to form a stable hydrogen bond between His41 and Asp187 [ Fig. 4(c) ].", [["Asp187", "CHEMICAL", 65, 71], ["hydrogen", "CHEMICAL", 33, 41], ["His41", "CHEMICAL", 55, 60], ["Asp", "CHEMICAL", 65, 68], ["His41", "SIMPLE_CHEMICAL", 55, 60], ["Asp187", "AMINO_ACID", 65, 71], ["Asp", "TEST", 65, 68]]], ["So, it can be seen from the MD simulation that, in solution, when the active pocket of SARS M pro combines with substrate, to bind substrate tightly and hydrolyze it efficiently, His41 might regulate itself to turn toward Asp187 and squeeze the water molecule out, thus converting the catalytic site from the dyad (His41 and Cys145) to a more efficient catalytic triad (His41, Cys145, and Asp187).", [["His41", "CHEMICAL", 179, 184], ["Cys145", "CHEMICAL", 325, 331], ["Asp187", "CHEMICAL", 222, 228], ["His41", "CHEMICAL", 315, 320], ["Cys", "CHEMICAL", 325, 328], ["His41", "CHEMICAL", 370, 375], ["Cys", "CHEMICAL", 377, 380], ["Asp", "CHEMICAL", 389, 392], ["His41", "SIMPLE_CHEMICAL", 179, 184], ["Asp187", "GENE_OR_GENE_PRODUCT", 222, 228], ["Cys145", "AMINO_ACID", 377, 383], ["Asp187", "AMINO_ACID", 389, 395], ["SARS M pro", "PROTEIN", 87, 97], ["His41", "PROTEIN", 179, 184], ["Asp187", "PROTEIN", 222, 228], ["catalytic site", "PROTEIN", 285, 299], ["catalytic triad", "PROTEIN", 353, 368], ["Cys", "TEST", 325, 328], ["Cys", "TEST", 377, 380], ["Asp", "TEST", 389, 392], ["active", "OBSERVATION_MODIFIER", 70, 76], ["pocket", "OBSERVATION_MODIFIER", 77, 83]]], ["Although it still has not been confirmed by experiment, it can be hypothesized that the catalytic efficiency of the SARS M pro is regulated by substrate binding, which is in accordance with the results found in the MD simulations of SARS M pro modeled by homology complexed with its designed substrate 22 and is helpful in inhibitor design for SARS M pro .Dynamic Behavior of the Catalytic SiteThere is a similar turn of His41 toward Asp187 in the MD simulation of monomer complexed with substrate analog.", [["SARS", "DISEASE", 116, 120], ["SARS", "DISEASE", 233, 237], ["Asp187", "CHEMICAL", 434, 440], ["His41", "CHEMICAL", 421, 426], ["Asp", "CHEMICAL", 434, 437], ["His41", "SIMPLE_CHEMICAL", 421, 426], ["Asp187", "AMINO_ACID", 434, 440], ["SARS M pro", "PROTEIN", 116, 126], ["His41", "PROTEIN", 421, 426], ["the catalytic efficiency", "PROBLEM", 84, 108], ["the SARS M pro", "PROBLEM", 112, 126], ["SARS M pro", "TREATMENT", 344, 354], ["Asp", "TEST", 434, 437], ["substrate analog", "TREATMENT", 488, 504]]], ["A stable hydrogen bond is formed between the two entities (average distance of 2.95 \u00c5 , occupancy of 89.5%, Table II ).", [["hydrogen", "CHEMICAL", 9, 17], ["occupancy", "TEST", 88, 97], ["stable", "OBSERVATION_MODIFIER", 2, 8], ["hydrogen bond", "OBSERVATION", 9, 22], ["two", "OBSERVATION_MODIFIER", 45, 48], ["entities", "OBSERVATION_MODIFIER", 49, 57]]], ["However, the average dihedral angle CA-CB-CG-CD2 of His41 is 91.38, flipping $208 relative to the dimer [ Fig. 4(d) ].", [["His41", "CHEMICAL", 52, 57], ["CB", "PROTEIN", 39, 41], ["CD2", "PROTEIN", 45, 48], ["dimer", "PROTEIN", 98, 103], ["the average dihedral angle CA", "TEST", 9, 38], ["CB", "TEST", 39, 41], ["CG", "TEST", 42, 44], ["His41", "TEST", 52, 57], ["flipping", "TEST", 68, 76]]], ["In this turned orientation, the imidazole ring of His41 rotates away from the side chain of Cys145, and as a consequence, the imidazole moiety NE2 of His41 is on average 4.75 \u00c5 from the SG atom of Cys145 [ Fig. 5(b) ], resulting in a disruption of the weak hydrogen bond between the two entities (occupancy of 6.3%, Table II ).", [["imidazole", "CHEMICAL", 32, 41], ["His41", "CHEMICAL", 50, 55], ["Cys145", "CHEMICAL", 92, 98], ["imidazole", "CHEMICAL", 126, 135], ["NE2", "CHEMICAL", 143, 146], ["His41", "CHEMICAL", 150, 155], ["Cys145", "CHEMICAL", 197, 203], ["imidazole", "CHEMICAL", 32, 41], ["His41", "CHEMICAL", 50, 55], ["Cys", "CHEMICAL", 92, 95], ["imidazole", "CHEMICAL", 126, 135], ["NE2", "CHEMICAL", 143, 146], ["His41", "CHEMICAL", 150, 155], ["Cy", "CHEMICAL", 197, 199], ["hydrogen", "CHEMICAL", 257, 265], ["His41", "SIMPLE_CHEMICAL", 50, 55], ["Cys145", "AMINO_ACID", 92, 98], ["imidazole moiety NE2", "SIMPLE_CHEMICAL", 126, 146], ["His41", "SIMPLE_CHEMICAL", 150, 155], ["5(b)", "SIMPLE_CHEMICAL", 211, 215], ["the imidazole ring", "TREATMENT", 28, 46], ["Cys", "TEST", 92, 95], ["the imidazole moiety NE2", "TREATMENT", 122, 146], ["Cys", "TEST", 197, 200], ["the weak hydrogen bond", "PROBLEM", 248, 270], ["occupancy", "TEST", 297, 306]]], ["This longer distance deviates the experimental observations made by X-ray crystallography so much that the capability of substrate hydrolysis by SARS M pro monomer might be decreased.Conformational Characteristics of His163 and Glu166It has been shown that, in the coronavirus M pro , the imidazole side chain of histidine interacts with the P1 carboxamide side chain of the substrate, which is generally accepted to determine the coronavirus M pro specificity for glutamine at P1.", [["His163", "CHEMICAL", 217, 223], ["imidazole", "CHEMICAL", 289, 298], ["histidine", "CHEMICAL", 313, 322], ["glutamine", "CHEMICAL", 465, 474], ["His163", "CHEMICAL", 217, 223], ["imidazole", "CHEMICAL", 289, 298], ["histidine", "CHEMICAL", 313, 322], ["carboxamide", "CHEMICAL", 345, 356], ["glutamine", "CHEMICAL", 465, 474], ["His163", "GENE_OR_GENE_PRODUCT", 217, 223], ["Glu166It", "GENE_OR_GENE_PRODUCT", 228, 236], ["histidine", "AMINO_ACID", 313, 322], ["glutamine", "AMINO_ACID", 465, 474], ["His163", "PROTEIN", 217, 223], ["Glu166It", "PROTEIN", 228, 236], ["coronavirus M pro", "PROTEIN", 265, 282], ["P1 carboxamide side chain", "PROTEIN", 342, 367], ["X-ray crystallography", "TEST", 68, 89], ["substrate hydrolysis", "PROBLEM", 121, 141], ["SARS M pro monomer", "TREATMENT", 145, 163], ["His163", "TEST", 217, 223], ["Glu166It", "TEST", 228, 236], ["the coronavirus M pro", "TREATMENT", 261, 282], ["the imidazole side chain of histidine", "TREATMENT", 285, 322], ["the P1 carboxamide side chain", "TREATMENT", 338, 367], ["glutamine at P1", "TREATMENT", 465, 480], ["decreased", "OBSERVATION_MODIFIER", 173, 182]]], ["14 During the MD simulation of the SARS M pro dimer complex, the distance between the NE2 of His163 and the OE1 of glutamine at the substrate analog P1 site shows little fluctuation around time-averaged distance 2.76 \u00c5 (see Fig. 6 ).", [["SARS", "DISEASE", 35, 39], ["NE2 of His163", "CHEMICAL", 86, 99], ["glutamine", "CHEMICAL", 115, 124], ["His", "CHEMICAL", 93, 96], ["glutamine", "CHEMICAL", 115, 124], ["glutamine", "AMINO_ACID", 115, 124], ["SARS M pro dimer complex", "PROTEIN", 35, 59], ["NE2", "PROTEIN", 86, 89], ["OE1", "PROTEIN", 108, 111], ["glutamine", "TREATMENT", 115, 124], ["little fluctuation", "PROBLEM", 163, 181], ["little", "OBSERVATION_MODIFIER", 163, 169], ["fluctuation", "OBSERVATION_MODIFIER", 170, 181]]], ["NE2 of His163 donates a proton to OE1 of glutamine at the substrate analog P1 site to form a strong hydrogen bond [ Fig. 7(a) ], with the occupancy of 99.9%.", [["NE2 of His163", "CHEMICAL", 0, 13], ["OE1", "CHEMICAL", 34, 37], ["glutamine", "CHEMICAL", 41, 50], ["His", "CHEMICAL", 7, 10], ["OE1", "CHEMICAL", 34, 37], ["glutamine", "CHEMICAL", 41, 50], ["hydrogen", "CHEMICAL", 100, 108], ["glutamine", "AMINO_ACID", 41, 50], ["Fig. 7(a)", "SIMPLE_CHEMICAL", 116, 125], ["a proton", "TREATMENT", 22, 30], ["glutamine", "TREATMENT", 41, 50], ["the substrate analog P1 site", "TREATMENT", 54, 82], ["the occupancy", "TEST", 134, 147]]], ["From plots of dihedral angle CA-CB-CG-CD2 of His163 versus times [ Fig. 8(a) ], it is obvious that the imidazole ring of His163 flip remains in the orientation required for the NE2(His163). . .OE1(Gln-P1) hydrogen bond throughout the MD simulation of SARS M pro dimer complex.Conformational Characteristics of His163 and Glu166In the average structure of protomer A within the dimer, the carboxylate group of Glu166 is also found to approach the carboxamide side chain of glutamine at substrate analog P1site.", [["imidazole", "CHEMICAL", 103, 112], ["His163", "CHEMICAL", 121, 127], ["OE1", "CHEMICAL", 193, 196], ["Gln-P1", "CHEMICAL", 197, 203], ["carboxylate", "CHEMICAL", 388, 399], ["Glu166", "CHEMICAL", 409, 415], ["glutamine", "CHEMICAL", 472, 481], ["His", "CHEMICAL", 45, 48], ["imidazole", "CHEMICAL", 103, 112], ["His", "CHEMICAL", 121, 124], ["NE2", "CHEMICAL", 177, 180], ["His", "CHEMICAL", 181, 184], ["Gln", "CHEMICAL", 197, 200], ["hydrogen", "CHEMICAL", 205, 213], ["His163", "CHEMICAL", 310, 316], ["Glu166In", "CHEMICAL", 321, 329], ["carboxylate", "CHEMICAL", 388, 399], ["Glu166", "CHEMICAL", 409, 415], ["carboxamide", "CHEMICAL", 446, 457], ["glutamine", "CHEMICAL", 472, 481], ["OE1", "SIMPLE_CHEMICAL", 193, 196], ["Gln-P1", "SIMPLE_CHEMICAL", 197, 203], ["His163", "GENE_OR_GENE_PRODUCT", 310, 316], ["Glu166In", "AMINO_ACID", 321, 329], ["Glu166", "SIMPLE_CHEMICAL", 409, 415], ["glutamine", "AMINO_ACID", 472, 481], ["CB", "PROTEIN", 32, 34], ["CD2", "PROTEIN", 38, 41], ["NE2", "PROTEIN", 177, 180], ["SARS M pro dimer complex", "PROTEIN", 251, 275], ["His163", "PROTEIN", 310, 316], ["protomer A", "PROTEIN", 355, 365], ["dimer", "PROTEIN", 377, 382], ["dihedral angle", "TEST", 14, 28], ["CA", "TEST", 29, 31], ["CB", "TEST", 32, 34], ["CG", "TEST", 35, 37], ["CD2", "TEST", 38, 41], ["His", "TEST", 45, 48], ["Fig.", "TEST", 67, 71], ["the imidazole ring", "TREATMENT", 99, 117], ["Gln-P1) hydrogen bond", "TREATMENT", 197, 218], ["His163", "TEST", 310, 316], ["the carboxamide side chain", "TREATMENT", 442, 468], ["glutamine", "TREATMENT", 472, 481]]], ["The OE2 of Glu166 accepts a stable hydrogen bond from side-chain NE2 of glutamine at substrate analog P1site, with the average distance of 3.01 \u00c5 and occupancy of 65.0% (Fig. 9 , Table I ).", [["Glu166", "CHEMICAL", 11, 17], ["glutamine", "CHEMICAL", 72, 81], ["Glu166", "CHEMICAL", 11, 17], ["hydrogen", "CHEMICAL", 35, 43], ["glutamine", "CHEMICAL", 72, 81], ["Glu166", "SIMPLE_CHEMICAL", 11, 17], ["glutamine", "AMINO_ACID", 72, 81], ["P1site", "SIMPLE_CHEMICAL", 102, 108], ["OE2", "PROTEIN", 4, 7], ["glutamine", "TREATMENT", 72, 81], ["occupancy", "TEST", 150, 159], ["stable", "OBSERVATION_MODIFIER", 28, 34], ["hydrogen bond", "OBSERVATION", 35, 48]]], ["The turn of the Glu166 has been monitored by the change in the dihedral angle CD-CG-CB-CA of Glu166.", [["Glu166", "CHEMICAL", 16, 22], ["Glu166", "CHEMICAL", 93, 99], ["Glu166", "CHEMICAL", 16, 22], ["Glu", "CHEMICAL", 93, 96], ["Glu166", "GENE_OR_GENE_PRODUCT", 16, 22], ["Glu166", "AMINO_ACID", 93, 99], ["Glu166", "PROTEIN", 16, 22], ["CB", "PROTEIN", 84, 86], ["the dihedral angle CD", "TEST", 59, 80], ["CG", "TEST", 81, 83], ["CB", "TEST", 84, 86], ["Glu", "TEST", 93, 96]]], ["For the majority of the simulation time (see Fig. 10 ), the distribution of the angle concentrates mainly at the value around 1808, required for the OE2(Glu166). . .NE2(Gln-P1) hydrogen bond.", [["NE2", "CHEMICAL", 165, 168], ["Gln-P1", "CHEMICAL", 169, 175], ["Glu166", "CHEMICAL", 153, 159], ["NE2", "CHEMICAL", 165, 168], ["Gln-P1", "CHEMICAL", 169, 175], ["hydrogen", "CHEMICAL", 177, 185], ["OE2", "GENE_OR_GENE_PRODUCT", 149, 152], ["NE2", "SIMPLE_CHEMICAL", 165, 168], ["Gln-P1", "SIMPLE_CHEMICAL", 169, 175], ["OE2", "PROTEIN", 149, 152], ["NE2(Gln-P1) hydrogen bond", "TREATMENT", 165, 190], ["angle", "OBSERVATION_MODIFIER", 80, 85], ["hydrogen bond", "OBSERVATION", 177, 190]]], ["These two hydrogen bonds mentioned above determine the specificity for glutamine of the substrate at the P1 site.Conformational Characteristics of His163 and Glu166The conformational properties for His163 and Glu166 specific recognition of glutamine at the substrate P1 site are partially characterized by a distance NE2(His163) . . .OE2(Glu166) of 6.5-8.7 \u00c5 and a dihedral angle NE2 (His163). . .NE2(His163)-CD2(His163)-CG(His-163) of (180 AE 30)8 [ Fig. 11(a) ].", [["glutamine", "CHEMICAL", 71, 80], ["Glu166", "CHEMICAL", 209, 215], ["glutamine", "CHEMICAL", 240, 249], ["Glu166", "CHEMICAL", 338, 344], ["hydrogen", "CHEMICAL", 10, 18], ["glutamine", "CHEMICAL", 71, 80], ["His163", "CHEMICAL", 147, 153], ["Glu166", "CHEMICAL", 158, 164], ["His", "CHEMICAL", 198, 201], ["Glu166", "CHEMICAL", 209, 215], ["glutamine", "CHEMICAL", 240, 249], ["His", "CHEMICAL", 321, 324], ["Glu166", "CHEMICAL", 338, 344], ["His", "CHEMICAL", 385, 388], ["NE2", "CHEMICAL", 397, 400], ["His", "CHEMICAL", 401, 404], ["His", "CHEMICAL", 413, 416], ["His-163", "CHEMICAL", 424, 431], ["(180 AE 30)8", "CHEMICAL", 436, 448], ["glutamine", "AMINO_ACID", 71, 80], ["His163", "GENE_OR_GENE_PRODUCT", 147, 153], ["Glu166", "AMINO_ACID", 158, 164], ["His163", "SIMPLE_CHEMICAL", 198, 204], ["Glu166", "AMINO_ACID", 209, 215], ["glutamine", "AMINO_ACID", 240, 249], ["OE2", "SIMPLE_CHEMICAL", 334, 337], ["NE2", "SIMPLE_CHEMICAL", 397, 400], ["P1 site", "DNA", 105, 112], ["His163", "PROTEIN", 147, 153], ["substrate P1 site", "DNA", 257, 274], ["CD2", "PROTEIN", 409, 412], ["These two hydrogen bonds", "PROBLEM", 0, 24], ["His163", "TEST", 147, 153], ["glutamine", "TREATMENT", 240, 249], ["a dihedral angle NE2", "TEST", 363, 383], ["His", "TEST", 413, 416], ["CG", "TEST", 421, 423], ["His", "TEST", 424, 427], ["Fig.", "TEST", 451, 455], ["hydrogen bonds", "OBSERVATION", 10, 24]]], ["OE2 of Glu166 is nearly copla- nar with the imidazole of His163.", [["Glu166", "CHEMICAL", 7, 13], ["imidazole", "CHEMICAL", 44, 53], ["His163", "CHEMICAL", 57, 63], ["Glu166", "CHEMICAL", 7, 13], ["imidazole", "CHEMICAL", 44, 53], ["His", "CHEMICAL", 57, 60], ["Glu166", "SIMPLE_CHEMICAL", 7, 13], ["His163", "SIMPLE_CHEMICAL", 57, 63], ["OE2", "PROTEIN", 0, 3], ["the imidazole", "TREATMENT", 40, 53]]], ["This structure is able to properly accommodate the carboxamide side chain of glutamine at substrate analog P1 site and forms a strong hydrogen bond with it.", [["carboxamide", "CHEMICAL", 51, 62], ["glutamine", "CHEMICAL", 77, 86], ["carboxamide", "CHEMICAL", 51, 62], ["glutamine", "CHEMICAL", 77, 86], ["hydrogen", "CHEMICAL", 134, 142], ["glutamine", "AMINO_ACID", 77, 86], ["the carboxamide side chain", "TREATMENT", 47, 73], ["glutamine at substrate analog P1 site", "TREATMENT", 77, 114]]], ["The dimer conformers are highly characterized that His163 and Glu166 form the ''tooth'' protruding into the ''mouth'' shaped void, the residues of S1 pocket of protomer A within the dimer.", [["tooth", "ANATOMY", 80, 85], ["His", "CHEMICAL", 51, 54], ["Glu166", "CHEMICAL", 62, 68], ["His163", "GENE_OR_GENE_PRODUCT", 51, 57], ["Glu166", "AMINO_ACID", 62, 68], ["S1 pocket", "PROTEIN", 147, 156], ["protomer A", "PROTEIN", 160, 170], ["dimer", "PROTEIN", 182, 187], ["S1", "OBSERVATION_MODIFIER", 147, 149], ["pocket", "OBSERVATION_MODIFIER", 150, 156]]], ["Throughout the entire MD simulation of dimer complex, the ''mouth'' is closed all the time, with the ''tooth'' fastening the glutamine residue.", [["tooth", "ANATOMY", 103, 108], ["glutamine", "CHEMICAL", 125, 134], ["glutamine", "CHEMICAL", 125, 134], ["glutamine", "AMINO_ACID", 125, 134], ["residue", "AMINO_ACID", 135, 142], ["dimer complex", "PROTEIN", 39, 52], ["the glutamine residue", "PROBLEM", 121, 142], ["closed", "OBSERVATION", 71, 77], ["glutamine residue", "OBSERVATION", 125, 142]]], ["The properties of His163 in the MD simulation of the SARS M pro dimer complex are consistent with the fact that the interactions between histidine and gluta-mine determine the coronavirus M pro specificity for glutamine at substrate P1 site.", [["His163", "CHEMICAL", 18, 24], ["histidine", "CHEMICAL", 137, 146], ["glutamine", "CHEMICAL", 210, 219], ["His163", "CHEMICAL", 18, 24], ["histidine", "CHEMICAL", 137, 146], ["glutamine", "CHEMICAL", 210, 219], ["His163", "SIMPLE_CHEMICAL", 18, 24], ["histidine", "AMINO_ACID", 137, 146], ["gluta", "SIMPLE_CHEMICAL", 151, 156], ["coronavirus", "ORGANISM", 176, 187], ["glutamine", "AMINO_ACID", 210, 219], ["SARS M pro dimer complex", "PROTEIN", 53, 77], ["substrate P1 site", "DNA", 223, 240], ["the SARS M pro dimer complex", "PROBLEM", 49, 77], ["histidine and gluta-mine", "TREATMENT", 137, 161], ["glutamine at substrate P1 site", "TREATMENT", 210, 240], ["consistent with", "UNCERTAINTY", 82, 97]]], ["14 However, during the entire MD simulation of the SARS M pro monomer, the dihedral angle CA-CB-CG-CD2 of His163 is almost constantly around value 1508, compared with the dimer this amounts to a change of $308 [ Fig. 8(b) ].", [["SARS", "DISEASE", 51, 55], ["His163", "CHEMICAL", 106, 112], ["His", "CHEMICAL", 106, 109], ["CD2", "PROTEIN", 99, 102], ["the dihedral angle CA", "TEST", 71, 92], ["CB-", "TEST", 93, 96], ["CG", "TEST", 96, 98]]], ["The imidazole ring of His163 rotates away from the carboxamide side chain of glutamine at P1 [ Fig. 7(b) ].", [["imidazole", "CHEMICAL", 4, 13], ["His163", "CHEMICAL", 22, 28], ["glutamine", "CHEMICAL", 77, 86], ["imidazole", "CHEMICAL", 4, 13], ["His", "CHEMICAL", 22, 25], ["carboxamide", "CHEMICAL", 51, 62], ["glutamine", "CHEMICAL", 77, 86], ["imidazole ring", "SIMPLE_CHEMICAL", 4, 18], ["His163", "SIMPLE_CHEMICAL", 22, 28], ["glutamine", "AMINO_ACID", 77, 86], ["The imidazole ring", "TREATMENT", 0, 18], ["the carboxamide side chain", "TREATMENT", 47, 73], ["glutamine at P1", "TREATMENT", 77, 92]]], ["In this turned orientation, the distance between the imidazole moiety NE2 of His163 and OE1 of glutamine at P1 averages 7.90 \u00c5 (see Fig. 6 ), resulting in the disruption of the hydrogen bond.", [["imidazole", "CHEMICAL", 53, 62], ["NE2 of His163", "CHEMICAL", 70, 83], ["glutamine", "CHEMICAL", 95, 104], ["imidazole", "CHEMICAL", 53, 62], ["NE2", "CHEMICAL", 70, 73], ["His", "CHEMICAL", 77, 80], ["OE1", "CHEMICAL", 88, 91], ["glutamine", "CHEMICAL", 95, 104], ["hydrogen", "CHEMICAL", 177, 185], ["His163", "SIMPLE_CHEMICAL", 77, 83], ["OE1", "AMINO_ACID", 88, 91], ["glutamine", "AMINO_ACID", 95, 104], ["the imidazole moiety", "TREATMENT", 49, 69], ["glutamine", "TREATMENT", 95, 104], ["the disruption of the hydrogen bond", "PROBLEM", 155, 190], ["disruption", "OBSERVATION", 159, 169], ["hydrogen bond", "OBSERVATION", 177, 190]]], ["The NE2 of imidazole cannot donate the proton to bind glutamine at substrate analog P1 site.Conformational Characteristics of His163 and Glu166In the conformational change of Glu166, the dihedral angle CD-CG-CB-CA of Glu166 shows a bimodal distribution at around 180 and 2658 in monomer [ Fig. 10(b) ], where the 2658 modal is dominant.", [["NE2 of imidazole", "CHEMICAL", 4, 20], ["glutamine", "CHEMICAL", 54, 63], ["Glu166", "CHEMICAL", 175, 181], ["Glu166", "CHEMICAL", 217, 223], ["imidazole", "CHEMICAL", 11, 20], ["glutamine", "CHEMICAL", 54, 63], ["His163", "CHEMICAL", 126, 132], ["Glu166In", "CHEMICAL", 137, 145], ["Glu166", "CHEMICAL", 175, 181], ["Glu166", "CHEMICAL", 217, 223], ["NE2", "SIMPLE_CHEMICAL", 4, 7], ["imidazole", "SIMPLE_CHEMICAL", 11, 20], ["proton", "SIMPLE_CHEMICAL", 39, 45], ["glutamine", "AMINO_ACID", 54, 63], ["His163", "SIMPLE_CHEMICAL", 126, 132], ["Glu166In", "AMINO_ACID", 137, 145], ["Glu166", "SIMPLE_CHEMICAL", 175, 181], ["Glu166", "AMINO_ACID", 217, 223], ["CG", "PROTEIN", 205, 207], ["CB", "PROTEIN", 208, 210], ["CA", "PROTEIN", 211, 213], ["Glu166", "PROTEIN", 217, 223], ["The NE2 of imidazole", "TREATMENT", 0, 20], ["the proton", "TREATMENT", 35, 45], ["bind glutamine", "TREATMENT", 49, 63], ["His163", "TEST", 126, 132], ["Glu166", "TEST", 175, 181], ["the dihedral angle CD", "TEST", 183, 204], ["CG", "TEST", 205, 207], ["CB", "TEST", 208, 210], ["CA", "TEST", 211, 213], ["bimodal distribution", "OBSERVATION", 232, 252], ["dominant", "OBSERVATION", 327, 335]]], ["In the case of dimer, single modal around 175.68 is found.", [["dimer", "PROTEIN", 15, 20]]], ["Associated conformational changes are that the OE2 of Glu166 averages 4.18 \u00c5 from the side-chain NE2 of glutamine at substrate analog P1 site (Fig. 9 , Table I ).", [["glutamine", "CHEMICAL", 104, 113], ["Glu166", "CHEMICAL", 54, 60], ["glutamine", "CHEMICAL", 104, 113], ["glutamine", "AMINO_ACID", 104, 113], ["OE2", "PROTEIN", 47, 50], ["Glu166", "PROTEIN", 54, 60], ["side-chain NE2", "PROTEIN", 86, 100], ["Associated conformational changes", "PROBLEM", 0, 33], ["glutamine at substrate analog P1 site", "TREATMENT", 104, 141]]], ["The side-chain carbonyl of Glu166 cannot accept a hydrogen bond from side-chain NE2 of glutamine at substrate analog P1site.Conformational Characteristics of His163 and Glu166It is the flip of the imidazole ring of His163 and the turn of the carbonate group of Glu166 that destroy the ''tooth'' conformational properties of His163 and Glu166 required in the active form of SARS M pro .", [["tooth", "ANATOMY", 287, 292], ["Glu166", "CHEMICAL", 27, 33], ["glutamine", "CHEMICAL", 87, 96], ["His163", "CHEMICAL", 158, 164], ["Glu", "CHEMICAL", 169, 172], ["imidazole", "CHEMICAL", 197, 206], ["His163", "CHEMICAL", 215, 221], ["carbonate", "CHEMICAL", 242, 251], ["Glu166", "CHEMICAL", 261, 267], ["Glu166", "CHEMICAL", 335, 341], ["carbonyl", "CHEMICAL", 15, 23], ["Glu166", "CHEMICAL", 27, 33], ["hydrogen", "CHEMICAL", 50, 58], ["glutamine", "CHEMICAL", 87, 96], ["His163", "CHEMICAL", 158, 164], ["Glu", "CHEMICAL", 169, 172], ["imidazole", "CHEMICAL", 197, 206], ["His", "CHEMICAL", 215, 218], ["carbonate", "CHEMICAL", 242, 251], ["Glu166", "CHEMICAL", 261, 267], ["His", "CHEMICAL", 324, 327], ["Glu166", "CHEMICAL", 335, 341], ["Glu166", "SIMPLE_CHEMICAL", 27, 33], ["side-chain NE2", "SIMPLE_CHEMICAL", 69, 83], ["glutamine", "AMINO_ACID", 87, 96], ["His163", "AMINO_ACID", 158, 164], ["Glu", "AMINO_ACID", 169, 172], ["166It", "AMINO_ACID", 172, 177], ["His163", "AMINO_ACID", 215, 221], ["carbonate", "SIMPLE_CHEMICAL", 242, 251], ["Glu166", "SIMPLE_CHEMICAL", 261, 267], ["His163", "AMINO_ACID", 324, 330], ["Glu166", "AMINO_ACID", 335, 341], ["SARS M pro", "PROTEIN", 373, 383], ["a hydrogen bond", "TREATMENT", 48, 63], ["glutamine", "TREATMENT", 87, 96], ["His163", "TEST", 158, 164], ["Glu", "TEST", 169, 172], ["the imidazole ring", "TREATMENT", 193, 211], ["the carbonate group of Glu166", "TREATMENT", 238, 267]]], ["As shown in Figure 11 (b), the distance NE2(His163). . .OE2(Glu166) becomes 8.0-10 \u00c5 and the dihedral angle NE2(His163). . .NE2(His163)-CD2(His163)-CG(His163) becomes disorder and unsystematic, which indicates that the destruction of the coplanarity between the side chain of Glu166 and the imidazole of His163.", [["Glu166", "CHEMICAL", 60, 66], ["NE2", "CHEMICAL", 124, 127], ["disorder", "DISEASE", 167, 175], ["Glu166", "CHEMICAL", 276, 282], ["imidazole", "CHEMICAL", 291, 300], ["His163", "CHEMICAL", 304, 310], ["His", "CHEMICAL", 44, 47], ["Glu166", "CHEMICAL", 60, 66], ["His", "CHEMICAL", 112, 115], ["NE2", "CHEMICAL", 124, 127], ["His163)-CD2(His163)-CG", "CHEMICAL", 128, 150], ["His", "CHEMICAL", 151, 154], ["Glu166", "CHEMICAL", 276, 282], ["imidazole", "CHEMICAL", 291, 300], ["His", "CHEMICAL", 304, 307], ["OE2", "SIMPLE_CHEMICAL", 56, 59], ["NE2", "SIMPLE_CHEMICAL", 124, 127], ["Glu166", "SIMPLE_CHEMICAL", 276, 282], ["His163", "SIMPLE_CHEMICAL", 304, 310], ["CD2", "PROTEIN", 136, 139], ["CD2", "TEST", 136, 139], ["CG", "TEST", 148, 150], ["disorder", "PROBLEM", 167, 175], ["unsystematic", "PROBLEM", 180, 192], ["the destruction of the coplanarity", "PROBLEM", 215, 249], ["Glu166", "TEST", 276, 282], ["the imidazole", "TREATMENT", 287, 300], ["destruction", "OBSERVATION", 219, 230]]], ["This induces the ''mouth'' open and ''tooth'' loosely packed, which fails to bind tightly with glutamine at substrate P1 site.", [["mouth", "ANATOMY", 19, 24], ["tooth", "ANATOMY", 38, 43], ["glutamine", "CHEMICAL", 95, 104], ["glutamine", "CHEMICAL", 95, 104], ["glutamine", "AMINO_ACID", 95, 104], ["substrate P1 site", "DNA", 108, 125], ["glutamine at substrate P1 site", "TREATMENT", 95, 125]]], ["This should be one possible reason to make the monomer inactive, and has been proven by the mutational experiment that any replacement of His163 completely abolished the proteolytic activities of the HCoV and feline infectious peritonitis virus (FIPV) main protease.", [["His163", "CHEMICAL", 138, 144], ["infectious peritonitis", "DISEASE", 216, 238], ["His", "CHEMICAL", 138, 141], ["His163", "SIMPLE_CHEMICAL", 138, 144], ["HCoV", "GENE_OR_GENE_PRODUCT", 200, 204], ["feline infectious peritonitis virus", "ORGANISM", 209, 244], ["HCoV", "PROTEIN", 200, 204], ["feline infectious peritonitis virus (FIPV) main protease", "PROTEIN", 209, 265], ["feline infectious peritonitis virus", "SPECIES", 209, 244], ["feline infectious peritonitis virus", "SPECIES", 209, 244], ["FIPV", "SPECIES", 246, 250], ["any replacement", "TREATMENT", 119, 134], ["the HCoV", "TREATMENT", 196, 204], ["feline infectious peritonitis virus", "PROBLEM", 209, 244], ["infectious", "OBSERVATION_MODIFIER", 216, 226], ["peritonitis", "OBSERVATION", 227, 238]]], ["30, 31 Conformational Variations of Substrate-Binding PocketConformational Characteristics of His163 and Glu166In the dimer, the size of the substrate-binding pocket has been monitored by the distance between the Ca atom of Asn142 in loop140-146 and the Ca atom of Thr188 in loop184-197 (see Fig. 12 ), and the distance averages 17.75 \u00c5 , which means that the space of substrate-binding pocket is large enough to accommodate the substrate analog.", [["Ca", "CHEMICAL", 213, 215], ["Asn142", "CHEMICAL", 224, 230], ["loop140-146", "CHEMICAL", 234, 245], ["Ca", "CHEMICAL", 254, 256], ["Thr", "CHEMICAL", 265, 268], ["His163", "CHEMICAL", 94, 100], ["Ca", "CHEMICAL", 213, 215], ["Asn142", "CHEMICAL", 224, 230], ["loop140-146", "CHEMICAL", 234, 245], ["Ca", "CHEMICAL", 254, 256], ["Thr", "CHEMICAL", 265, 268], ["His163", "SIMPLE_CHEMICAL", 94, 100], ["Glu166In", "SIMPLE_CHEMICAL", 105, 113], ["Asn142", "SIMPLE_CHEMICAL", 224, 230], ["Thr188", "AMINO_ACID", 265, 271], ["His163", "PROTEIN", 94, 100], ["Glu166In", "PROTEIN", 105, 113], ["dimer", "PROTEIN", 118, 123], ["substrate-binding pocket", "PROTEIN", 141, 165], ["loop140", "PROTEIN", 234, 241], ["substrate-binding pocket", "PROTEIN", 369, 393], ["His163", "TEST", 94, 100], ["the substrate-binding pocket", "PROBLEM", 137, 165], ["the Ca atom", "TEST", 209, 220], ["the Ca atom", "TEST", 250, 261], ["Thr", "TEST", 265, 268], ["substrate-binding pocket", "PROBLEM", 369, 393], ["the substrate analog", "TREATMENT", 425, 445], ["size", "OBSERVATION_MODIFIER", 129, 133], ["binding pocket", "OBSERVATION", 151, 165], ["binding pocket", "OBSERVATION", 379, 393], ["large", "OBSERVATION_MODIFIER", 397, 402]]], ["As seen in Figure 13 , the ''oxyanion hole'' at loop140-146, comprising Gly143, Ser144, and Cys145, which is generally accepted to stabilize the covalent tetrahedral intermediate resulting from substrate hydrolysis by enzyme, 14 Table I ).", [["loop140-146", "CHEMICAL", 48, 59], ["Cys145", "CHEMICAL", 92, 98], ["loop140-146", "CHEMICAL", 48, 59], ["Gly", "CHEMICAL", 72, 75], ["Ser144", "CHEMICAL", 80, 86], ["Cys", "CHEMICAL", 92, 95], ["Gly143", "AMINO_ACID", 72, 78], ["Ser144", "AMINO_ACID", 80, 86], ["Cys145", "AMINO_ACID", 92, 98], ["enzyme", "PROTEIN", 218, 224], ["the ''oxyanion hole", "TREATMENT", 23, 42], ["Gly", "TEST", 72, 75], ["Cys", "TEST", 92, 95]]], ["The space is also large enough to accommodate the intermediate, oxyanion, and these three strong hydrogen bonds are important to stabilize the oxyanion.", [["hydrogen", "CHEMICAL", 97, 105], ["the oxyanion", "TREATMENT", 139, 151], ["space", "OBSERVATION", 4, 9], ["large", "OBSERVATION", 18, 23], ["intermediate", "OBSERVATION_MODIFIER", 50, 62], ["hydrogen bonds", "OBSERVATION", 97, 111]]], ["Comparing the partially solvent-accessible structure of leucine at substrate analog P2 site in crystal structure, the side chain of leucine at substrate analog P2 site is well accommodated in the hydrophobic pocket formed by Thr25, Leu27, Val42, and Ala44.", [["leucine", "CHEMICAL", 56, 63], ["leucine", "CHEMICAL", 132, 139], ["leucine", "CHEMICAL", 56, 63], ["leucine", "CHEMICAL", 132, 139], ["Thr25", "CHEMICAL", 225, 230], ["Leu27", "CHEMICAL", 232, 237], ["Val42", "CHEMICAL", 239, 244], ["Ala44", "CHEMICAL", 250, 255], ["leucine", "AMINO_ACID", 56, 63], ["leucine", "AMINO_ACID", 132, 139], ["Thr25", "GENE_OR_GENE_PRODUCT", 225, 230], ["Leu27", "GENE_OR_GENE_PRODUCT", 232, 237], ["Val42", "GENE_OR_GENE_PRODUCT", 239, 244], ["Ala44", "GENE_OR_GENE_PRODUCT", 250, 255], ["P2 site", "DNA", 84, 91], ["Thr25", "PROTEIN", 225, 230], ["Leu27", "PROTEIN", 232, 237], ["Val42", "PROTEIN", 239, 244], ["Ala44", "PROTEIN", 250, 255], ["leucine at substrate analog P2 site", "PROBLEM", 56, 91], ["leucine at substrate analog P2 site", "TREATMENT", 132, 167], ["Leu27", "TEST", 232, 237], ["Val42", "TEST", 239, 244], ["Ala44", "TEST", 250, 255], ["crystal structure", "OBSERVATION", 95, 112], ["side", "OBSERVATION_MODIFIER", 118, 122], ["chain", "OBSERVATION_MODIFIER", 123, 128], ["hydrophobic pocket", "OBSERVATION", 196, 214]]], ["The S3 pocket formed by the side chain of Asp187, Gln189, and the main chain of Arg188 at loop 184-197, which has been verified to be indispensable for proteolytic activity, 14 can accommodate well the side chain of threonine at substrate analog P3 site.Conformational Characteristics of His163 and Glu166In the monomer, the distance between the Ca atom of Asn142 and the Ca atom of Thr188 decreases largely relative to dimer (see Fig. 12 ), with a maximum value of more than 4 \u00c5 , showing the size of substrate-binding pocket is reduced largely.", [["Asp187", "CHEMICAL", 42, 48], ["Arg188", "CHEMICAL", 80, 86], ["loop 184-197", "CHEMICAL", 90, 102], ["threonine", "CHEMICAL", 216, 225], ["Ca", "CHEMICAL", 346, 348], ["Asn142", "CHEMICAL", 357, 363], ["Ca", "CHEMICAL", 372, 374], ["Thr", "CHEMICAL", 383, 386], ["Asp", "CHEMICAL", 42, 45], ["Gln189", "CHEMICAL", 50, 56], ["Arg", "CHEMICAL", 80, 83], ["threonine", "CHEMICAL", 216, 225], ["His163", "CHEMICAL", 288, 294], ["Glu166In", "CHEMICAL", 299, 307], ["Ca", "CHEMICAL", 346, 348], ["Asn142", "CHEMICAL", 357, 363], ["Ca", "CHEMICAL", 372, 374], ["Thr", "CHEMICAL", 383, 386], ["Asp187", "AMINO_ACID", 42, 48], ["Gln189", "AMINO_ACID", 50, 56], ["Arg188", "AMINO_ACID", 80, 86], ["loop 184-197", "AMINO_ACID", 90, 102], ["threonine", "AMINO_ACID", 216, 225], ["His163", "SIMPLE_CHEMICAL", 288, 294], ["Glu166In", "AMINO_ACID", 299, 307], ["Asn142", "SIMPLE_CHEMICAL", 357, 363], ["Thr188", "AMINO_ACID", 383, 389], ["His163", "PROTEIN", 288, 294], ["Asn142", "PROTEIN", 357, 363], ["dimer", "PROTEIN", 420, 425], ["substrate-binding pocket", "PROTEIN", 502, 526], ["The S3 pocket", "PROBLEM", 0, 13], ["Asp", "TEST", 42, 45], ["Arg", "TEST", 80, 83], ["threonine at substrate analog P3 site", "TREATMENT", 216, 253], ["His163", "TEST", 288, 294], ["the Ca atom", "TEST", 342, 353], ["the Ca atom of Thr", "TEST", 368, 386], ["a maximum value", "TEST", 447, 462], ["substrate-binding pocket", "PROBLEM", 502, 526], ["S3", "OBSERVATION_MODIFIER", 4, 6], ["pocket", "OBSERVATION_MODIFIER", 7, 13], ["side chain", "OBSERVATION_MODIFIER", 28, 38], ["main", "OBSERVATION_MODIFIER", 66, 70], ["chain", "OBSERVATION_MODIFIER", 71, 76], ["decreases", "OBSERVATION_MODIFIER", 390, 399], ["size", "OBSERVATION_MODIFIER", 494, 498], ["binding pocket", "OBSERVATION", 512, 526], ["reduced", "OBSERVATION_MODIFIER", 530, 537], ["largely", "OBSERVATION_MODIFIER", 538, 545]]], ["As shown in Figure 13 , the loop 140-146 and loop 184-197 all move toward the active site, which has the consequences for the residues of the ''oxyanion hole'' and the S3 pocket, particularly for Gly143, with the movement of 2.74 \u00c5 toward active site contrast to the counterpart in dimer.", [["loop 140-146", "CHEMICAL", 28, 40], ["loop 184-197", "CHEMICAL", 45, 57], ["Gly143", "CHEMICAL", 196, 202], ["Gly", "CHEMICAL", 196, 199], ["Gly143", "AMINO_ACID", 196, 202], ["S3 pocket", "PROTEIN", 168, 177], ["dimer", "PROTEIN", 282, 287], ["the loop", "TEST", 24, 32], ["loop", "TEST", 45, 49], ["the ''oxyanion hole", "TREATMENT", 138, 157], ["the S3 pocket", "PROBLEM", 164, 177], ["Gly", "TEST", 196, 199], ["active site", "OBSERVATION_MODIFIER", 78, 89], ["S3", "ANATOMY", 168, 170], ["pocket", "ANATOMY_MODIFIER", 171, 177]]], ["The collapse of the ''oxyanion hole'' and the S3 pocket leaves no space to accommodate the glutamine and threonine of the substrate analog, squeezing glutamine at the substrate analog P1 site away from the S1 pocket of enzyme and threonine at substrate analog P3 site into bulk solvent, respectively.", [["glutamine", "CHEMICAL", 91, 100], ["threonine", "CHEMICAL", 105, 114], ["glutamine", "CHEMICAL", 150, 159], ["threonine", "CHEMICAL", 230, 239], ["glutamine", "CHEMICAL", 91, 100], ["threonine", "CHEMICAL", 105, 114], ["glutamine", "CHEMICAL", 150, 159], ["threonine", "CHEMICAL", 230, 239], ["glutamine", "AMINO_ACID", 91, 100], ["threonine", "AMINO_ACID", 105, 114], ["glutamine", "AMINO_ACID", 150, 159], ["threonine", "AMINO_ACID", 230, 239], ["enzyme", "PROTEIN", 219, 225], ["the ''oxyanion hole", "TREATMENT", 16, 35], ["the S3 pocket", "PROBLEM", 42, 55], ["space", "PROBLEM", 66, 71], ["the glutamine", "TREATMENT", 87, 100], ["the substrate analog", "TREATMENT", 118, 138], ["squeezing glutamine", "TREATMENT", 140, 159], ["enzyme", "TEST", 219, 225], ["threonine", "TREATMENT", 230, 239], ["collapse", "OBSERVATION", 4, 12], ["S3", "ANATOMY", 46, 48], ["pocket", "ANATOMY_MODIFIER", 49, 55], ["S1", "ANATOMY", 206, 208], ["bulk solvent", "OBSERVATION", 273, 285]]], ["Furthermore, the collapse of the ''oxyanion hole'' leaves no space for a tetrahedral intermediate.Conformational Characteristics of His163 and Glu166As a consequence, the threonine at the substrate analog P2 site switches from the S2 hydrophobic pocket and is oriented toward bulk solvent, moreover, serine at the substrate analog P4 site and asparagine at the substrate analog P5 site become disorder.", [["threonine", "CHEMICAL", 171, 180], ["asparagine", "CHEMICAL", 343, 353], ["His163", "CHEMICAL", 132, 138], ["Glu166As", "CHEMICAL", 143, 151], ["threonine", "CHEMICAL", 171, 180], ["serine", "CHEMICAL", 300, 306], ["asparagine", "CHEMICAL", 343, 353], ["His163", "GENE_OR_GENE_PRODUCT", 132, 138], ["Glu166As", "AMINO_ACID", 143, 151], ["threonine", "AMINO_ACID", 171, 180], ["serine", "AMINO_ACID", 300, 306], ["asparagine", "AMINO_ACID", 343, 353], ["P2 site", "DNA", 205, 212], ["S2 hydrophobic pocket", "PROTEIN", 231, 252], ["the ''oxyanion hole", "TREATMENT", 29, 48], ["space", "PROBLEM", 61, 66], ["a tetrahedral intermediate", "TREATMENT", 71, 97], ["His163", "TEST", 132, 138], ["the threonine", "TREATMENT", 167, 180], ["the substrate analog P2 site", "TREATMENT", 184, 212], ["the S2 hydrophobic pocket", "PROBLEM", 227, 252], ["disorder", "PROBLEM", 393, 401], ["collapse", "OBSERVATION", 17, 25], ["S2", "ANATOMY", 231, 233], ["hydrophobic pocket", "OBSERVATION", 234, 252], ["disorder", "OBSERVATION", 393, 401]]], ["It can be seen that the reduced substrate-binding pocket in monomer cannot bind the substrate because of the collapses of ''oxyanion hole'' and S3 pocket.", [["S3 pocket", "CELLULAR_COMPONENT", 144, 153], ["the reduced substrate-binding pocket", "PROBLEM", 20, 56], ["the collapses of ''oxyanion hole'' and S3 pocket", "PROBLEM", 105, 153], ["reduced", "OBSERVATION_MODIFIER", 24, 31], ["binding pocket", "OBSERVATION", 42, 56], ["collapses", "OBSERVATION", 109, 118], ["pocket", "OBSERVATION_MODIFIER", 147, 153]]], ["This is verified by the fact that the substrate cannot bind to the N-terminus deleted proteinase.", [["N", "CHEMICAL", 67, 68], ["N-terminus", "PROTEIN", 67, 77], ["proteinase", "PROTEIN", 86, 96]]], ["32 According to our proceeding analysis, it can be deduced that the reduction of substrate-binding pocket of monomer is caused by the loss of N-terminus of counter partner.Conformational Characteristics of His163 and Glu166We conclude that in the SARS M pro monomer, due to the longer distance between Cys145 and His41, the destruction of the ''tooth'' conformational properties of His163 and Glu166 and the reduction of the substratebinding pocket, the process of substrate specific recognition, combination and hydrolysis is destroyed, which results in the inactivation of monomer.Analysis of Intermolecular Interactions between the Two Monomers within DimerTo further investigate the reasons that cause the conformational variations between monomer and dimer, we superimpose the MD averaged structure of SARS M pro monomer with dimer.", [["tooth", "ANATOMY", 345, 350], ["His163", "CHEMICAL", 382, 388], ["Glu166", "CHEMICAL", 393, 399], ["N", "CHEMICAL", 142, 143], ["His163", "CHEMICAL", 206, 212], ["Glu166We", "CHEMICAL", 217, 225], ["Cys", "CHEMICAL", 302, 305], ["His41", "CHEMICAL", 313, 318], ["His", "CHEMICAL", 382, 385], ["Glu166", "CHEMICAL", 393, 399], ["His163", "GENE_OR_GENE_PRODUCT", 206, 212], ["Glu166We", "AMINO_ACID", 217, 225], ["Cys145", "AMINO_ACID", 302, 308], ["His41", "AMINO_ACID", 313, 318], ["His163", "GENE_OR_GENE_PRODUCT", 382, 388], ["Glu166", "AMINO_ACID", 393, 399], ["N-terminus", "PROTEIN", 142, 152], ["counter partner", "PROTEIN", 156, 171], ["SARS M pro monomer", "PROTEIN", 247, 265], ["substratebinding pocket", "PROTEIN", 425, 448], ["DimerTo", "PROTEIN", 655, 662], ["dimer", "PROTEIN", 756, 761], ["dimer", "PROTEIN", 831, 836], ["our proceeding analysis", "TEST", 16, 39], ["substrate-binding pocket", "PROBLEM", 81, 105], ["His163", "TEST", 206, 212], ["Cys", "TEST", 302, 305], ["His41", "TEST", 313, 318], ["the destruction of the ''tooth", "PROBLEM", 320, 350], ["Glu166", "TEST", 393, 399], ["the substratebinding pocket", "PROBLEM", 421, 448], ["hydrolysis", "PROBLEM", 513, 523], ["the inactivation of monomer", "PROBLEM", 555, 582], ["Intermolecular Interactions", "PROBLEM", 595, 622], ["the conformational variations between monomer and dimer", "PROBLEM", 706, 761], ["binding pocket", "OBSERVATION", 91, 105], ["reduction", "OBSERVATION_MODIFIER", 408, 417], ["substratebinding pocket", "OBSERVATION", 425, 448], ["Intermolecular Interactions", "OBSERVATION", 595, 622]]], ["Domains II and III of one monomer interact with the same domains and the N-terminus of the other monomer, the latter plays dominant role because N-terminus is close to substrate-binding pocket of the other monomer.", [["N", "CHEMICAL", 73, 74], ["N", "CHEMICAL", 145, 146], ["Domains II and III", "PROTEIN", 0, 18], ["N-terminus", "PROTEIN", 73, 83], ["N-terminus", "PROTEIN", 145, 155], ["substrate-binding pocket", "PROTEIN", 168, 192], ["dominant", "OBSERVATION_MODIFIER", 123, 131]]], ["These intermolecular interactions may be probably the key factors that cause the differences between monomer and dimer.Stabilization of His163 by N-terminusTo interact with the glutamine at substrate P1 site, the imidazole ring of His163 has to maintain the conformational stability.", [["glutamine", "CHEMICAL", 177, 186], ["imidazole", "CHEMICAL", 213, 222], ["His163", "CHEMICAL", 231, 237], ["His163", "CHEMICAL", 136, 142], ["glutamine", "CHEMICAL", 177, 186], ["imidazole", "CHEMICAL", 213, 222], ["His", "CHEMICAL", 231, 234], ["His163", "GENE_OR_GENE_PRODUCT", 136, 142], ["glutamine", "AMINO_ACID", 177, 186], ["His163", "AMINO_ACID", 231, 237], ["dimer", "PROTEIN", 113, 118], ["His163", "PROTEIN", 136, 142], ["N-terminus", "PROTEIN", 146, 156], ["substrate P1 site", "DNA", 190, 207], ["the glutamine at substrate P1 site", "TREATMENT", 173, 207], ["the imidazole ring", "TREATMENT", 209, 227]]], ["This is achieved by two interactions: (i) stacking onto the phenyl ring of Phe140 and (ii) accepting a hydrogen bond from the Tyr161 hydroxyl group which has no other hydrogen-bonding partner.", [["Phe140", "CHEMICAL", 75, 81], ["hydroxyl", "CHEMICAL", 133, 141], ["phenyl", "CHEMICAL", 60, 66], ["Phe140", "CHEMICAL", 75, 81], ["hydrogen", "CHEMICAL", 103, 111], ["Tyr161 hydroxyl", "CHEMICAL", 126, 141], ["hydrogen", "CHEMICAL", 167, 175], ["Phe140", "SIMPLE_CHEMICAL", 75, 81], ["Tyr161 hydroxyl", "SIMPLE_CHEMICAL", 126, 141], ["a hydrogen bond", "TREATMENT", 101, 116]]], ["14 Two strong hydrogen bonds are observed between Ser1B of N-terminus of protomer B and Phe140 of protomer A during the entire MD simulation of SARS M pro dimer complex [ Fig. 7(a) ].", [["hydrogen", "CHEMICAL", 14, 22], ["N", "CHEMICAL", 59, 60], ["Phe140", "AMINO_ACID", 88, 94], ["Ser1B", "PROTEIN", 50, 55], ["N-terminus", "PROTEIN", 59, 69], ["protomer B", "PROTEIN", 73, 83], ["Phe140", "PROTEIN", 88, 94], ["protomer A", "PROTEIN", 98, 108], ["SARS M pro dimer complex", "PROTEIN", 144, 168], ["strong hydrogen bonds", "TREATMENT", 7, 28], ["hydrogen bonds", "OBSERVATION", 14, 28]]], ["The main chain N atom of Ser1B donates a 2.76 \u00c5 hydrogen bond to the main chain O atom of Phe140, and the main chain O atom of Ser1B accepts a 2.90 \u00c5 hydrogen bond from the main chain N atom of Phe140 (Table I) , which results in a stable conformation of the phenyl ring of Phe140.", [["Ser1B", "CHEMICAL", 25, 30], ["Phe140", "CHEMICAL", 90, 96], ["Ser1B", "CHEMICAL", 127, 132], ["Phe140", "CHEMICAL", 274, 280], ["N", "CHEMICAL", 15, 16], ["Ser1B", "CHEMICAL", 25, 30], ["hydrogen", "CHEMICAL", 48, 56], ["O", "CHEMICAL", 80, 81], ["Phe140", "CHEMICAL", 90, 96], ["O", "CHEMICAL", 117, 118], ["Ser1B", "CHEMICAL", 127, 132], ["hydrogen", "CHEMICAL", 150, 158], ["N", "CHEMICAL", 184, 185], ["Phe140", "CHEMICAL", 194, 200], ["phenyl", "CHEMICAL", 259, 265], ["Phe140", "CHEMICAL", 274, 280], ["Ser1B", "AMINO_ACID", 25, 30], ["Phe140", "SIMPLE_CHEMICAL", 90, 96], ["Ser1B", "AMINO_ACID", 127, 132], ["Phe140", "SIMPLE_CHEMICAL", 194, 200], ["Phe140", "SIMPLE_CHEMICAL", 274, 280], ["Ser1B", "PROTEIN", 127, 132], ["Phe140", "TEST", 90, 96], ["the phenyl ring of Phe140", "TREATMENT", 255, 280], ["main", "OBSERVATION_MODIFIER", 4, 8], ["chain", "OBSERVATION_MODIFIER", 9, 14], ["main", "ANATOMY_MODIFIER", 69, 73], ["chain", "ANATOMY_MODIFIER", 74, 79], ["atom", "ANATOMY_MODIFIER", 82, 86], ["main", "OBSERVATION_MODIFIER", 106, 110], ["atom", "ANATOMY_MODIFIER", 119, 123], ["stable", "OBSERVATION", 232, 238], ["phenyl ring", "OBSERVATION", 259, 270]]], ["As shown in Figure 14 , during the whole MD simulation of the SARS M pro dimer complex, the dihedral angle CD1-CG-CB-CA of Phe140 remains at a value for p-p stacking interaction with imidazole ring of His163, ensuring that His163 can maintain a neutral state at physiological pH.Stabilization of His163 by N-terminusAnalysis of the intermolecular interactions between Nterminus of protomer B and protomer A shows that a special water molecule is always sandwiched between the two protomer during the entire MD simulation of SARS M pro dimer complex, which plays an important role in binding of the N-terminus of protomer B with protomer A. Water 829 forms a stable water bridge, linking the main chain N atom of Leu2B with the main chain O atom of Gly170 (Table I) .", [["SARS", "DISEASE", 62, 66], ["Phe140", "CHEMICAL", 123, 129], ["imidazole", "CHEMICAL", 183, 192], ["His163", "CHEMICAL", 201, 207], ["His163", "CHEMICAL", 223, 229], ["His163", "CHEMICAL", 296, 302], ["SARS", "DISEASE", 524, 528], ["Leu2B", "CHEMICAL", 712, 717], ["Phe140", "CHEMICAL", 123, 129], ["imidazole", "CHEMICAL", 183, 192], ["His", "CHEMICAL", 201, 204], ["His", "CHEMICAL", 223, 226], ["His", "CHEMICAL", 296, 299], ["N", "CHEMICAL", 598, 599], ["N", "CHEMICAL", 702, 703], ["Leu2B", "CHEMICAL", 712, 717], ["O", "CHEMICAL", 738, 739], ["Gly", "CHEMICAL", 748, 751], ["Phe140", "SIMPLE_CHEMICAL", 123, 129], ["imidazole ring", "SIMPLE_CHEMICAL", 183, 197], ["His163", "SIMPLE_CHEMICAL", 201, 207], ["His163", "SIMPLE_CHEMICAL", 223, 229], ["Leu2B", "SIMPLE_CHEMICAL", 712, 717], ["Gly170", "AMINO_ACID", 748, 754], ["SARS M pro dimer complex", "PROTEIN", 62, 86], ["dihedral angle CD1", "PROTEIN", 92, 110], ["CB", "PROTEIN", 114, 116], ["Nterminus", "PROTEIN", 368, 377], ["protomer B", "PROTEIN", 381, 391], ["protomer A", "PROTEIN", 396, 406], ["SARS M pro dimer complex", "PROTEIN", 524, 548], ["N-terminus", "PROTEIN", 598, 608], ["protomer B", "PROTEIN", 612, 622], ["Leu2B", "PROTEIN", 712, 717], ["the dihedral angle CD1", "TEST", 88, 110], ["CB", "TEST", 114, 116], ["CA", "TEST", 117, 119], ["imidazole ring", "TREATMENT", 183, 197], ["N-terminusAnalysis", "TEST", 306, 324], ["a special water molecule", "TREATMENT", 418, 442], ["the N-terminus of protomer B with protomer A. Water", "TREATMENT", 594, 645], ["a stable water bridge", "TREATMENT", 656, 677]]], ["Through the waterbridge, the conformation of the b-strand 163-172 is stabilized, avoiding the movement of His172 toward Tyr161 and the formation of hydrogen bond between these two entities.", [["b-strand 163-172", "CHEMICAL", 49, 65], ["His172", "CHEMICAL", 106, 112], ["Tyr161", "CHEMICAL", 120, 126], ["hydrogen", "CHEMICAL", 148, 156], ["His172", "SIMPLE_CHEMICAL", 106, 112], ["Tyr161", "AMINO_ACID", 120, 126], ["hydrogen bond", "OBSERVATION", 148, 161]]], ["As a consequence, the hydrogen bond between the OH atom of Tyr161 and the ND1 atom of His163 is stable during the entire MD simulation of the SARS M pro dimer complex (see Fig. 15 ), with an average distance of 3.07 \u00c5 and an occupancy of 95.9% (Table I) .Stabilization of His163 by N-terminusBecause of the strong OH (Tyr161). . .ND1(His163) hydrogen bond and the stable p-p stacking interaction between the phenyl ring of Phe140 and the imidazole ring of His163, the conformation of the imidazole ring of His163 can be kept stable at the request for the binding glutamine of substrate at P1 site.", [["OH", "CHEMICAL", 48, 50], ["Tyr161", "CHEMICAL", 59, 65], ["His163", "CHEMICAL", 86, 92], ["His163", "CHEMICAL", 272, 278], ["phenyl", "CHEMICAL", 408, 414], ["Phe140", "CHEMICAL", 423, 429], ["imidazole", "CHEMICAL", 438, 447], ["His163", "CHEMICAL", 456, 462], ["imidazole", "CHEMICAL", 488, 497], ["His163", "CHEMICAL", 506, 512], ["glutamine", "CHEMICAL", 563, 572], ["hydrogen", "CHEMICAL", 22, 30], ["OH", "CHEMICAL", 48, 50], ["Tyr161", "CHEMICAL", 59, 65], ["ND1", "CHEMICAL", 74, 77], ["His", "CHEMICAL", 86, 89], ["His", "CHEMICAL", 272, 275], ["OH", "CHEMICAL", 314, 316], ["Tyr161", "CHEMICAL", 318, 324], ["His", "CHEMICAL", 334, 337], ["hydrogen", "CHEMICAL", 342, 350], ["phenyl", "CHEMICAL", 408, 414], ["Phe140", "CHEMICAL", 423, 429], ["imidazole", "CHEMICAL", 438, 447], ["His", "CHEMICAL", 456, 459], ["imidazole", "CHEMICAL", 488, 497], ["His", "CHEMICAL", 506, 509], ["glutamine", "CHEMICAL", 563, 572], ["OH", "SIMPLE_CHEMICAL", 48, 50], ["Tyr161", "SIMPLE_CHEMICAL", 59, 65], ["His163", "SIMPLE_CHEMICAL", 86, 92], ["OH", "SIMPLE_CHEMICAL", 314, 316], ["Tyr161", "AMINO_ACID", 318, 324], ["ND1", "GENE_OR_GENE_PRODUCT", 330, 333], ["Phe140", "SIMPLE_CHEMICAL", 423, 429], ["His163", "SIMPLE_CHEMICAL", 456, 462], ["His163", "SIMPLE_CHEMICAL", 506, 512], ["glutamine", "AMINO_ACID", 563, 572], ["SARS M pro dimer complex", "PROTEIN", 142, 166], ["His163", "PROTEIN", 272, 278], ["N-terminus", "PROTEIN", 282, 292], ["P1 site", "DNA", 589, 596], ["the hydrogen bond between the OH atom", "TEST", 18, 55], ["an occupancy", "TEST", 222, 234], ["ND1", "TEST", 330, 333], ["hydrogen bond", "TEST", 342, 355], ["the phenyl ring of Phe140", "TREATMENT", 404, 429], ["the imidazole ring", "TREATMENT", 434, 452], ["the imidazole ring", "TREATMENT", 484, 502], ["the binding glutamine of substrate at P1 site", "TREATMENT", 551, 596], ["hydrogen bond", "OBSERVATION", 22, 35], ["stable", "OBSERVATION_MODIFIER", 96, 102], ["stable", "OBSERVATION_MODIFIER", 364, 370]]], ["Either of these two interactions is destroyed, the conformation of the imidazole ring of His163 will be caused unstable, which will decrease the enzyme activity or make it inactive.", [["imidazole", "CHEMICAL", 71, 80], ["His163", "CHEMICAL", 89, 95], ["imidazole", "CHEMICAL", 71, 80], ["His", "CHEMICAL", 89, 92], ["His163", "SIMPLE_CHEMICAL", 89, 95], ["the imidazole ring", "TREATMENT", 67, 85]]], ["A good evidence for this is that the mutation of Tyr161 makes the enzyme almost inactive.", [["Tyr161", "GENE_OR_GENE_PRODUCT", 49, 55], ["Tyr161", "PROTEIN", 49, 55], ["the mutation of Tyr161", "PROBLEM", 33, 55], ["the enzyme", "TEST", 62, 72]]], ["31 In the monomer, because of the absence of the interactions with the N-terminus of protomer B, the conformation of Phe140 is instable.", [["Phe140", "CHEMICAL", 117, 123], ["N", "CHEMICAL", 71, 72], ["Phe140", "CHEMICAL", 117, 123], ["protomer B", "GENE_OR_GENE_PRODUCT", 85, 95], ["Phe140", "AMINO_ACID", 117, 123], ["N-terminus", "PROTEIN", 71, 81], ["protomer B", "PROTEIN", 85, 95], ["Phe140", "PROTEIN", 117, 123], ["the N-terminus of protomer B", "TREATMENT", 67, 95], ["instable", "OBSERVATION_MODIFIER", 127, 135]]], ["As shown in Figure 14 , the phenyl ring of Phe140 has a $408 increment in the average dihedral angle CD1-CG-CB-CA of Phe140.", [["phenyl", "CHEMICAL", 28, 34], ["Phe140", "CHEMICAL", 43, 49], ["phenyl", "CHEMICAL", 28, 34], ["Phe140", "CHEMICAL", 43, 49], ["Phe140", "CHEMICAL", 117, 123], ["Phe140", "SIMPLE_CHEMICAL", 43, 49], ["Phe140", "SIMPLE_CHEMICAL", 117, 123], ["CD1", "PROTEIN", 101, 104], ["CB", "PROTEIN", 108, 110], ["CA", "PROTEIN", 111, 113], ["Phe140", "PROTEIN", 117, 123], ["CD1", "TEST", 101, 104], ["CG", "TEST", 105, 107], ["CB", "TEST", 108, 110], ["CA", "TEST", 111, 113], ["Phe140", "TEST", 117, 123]]], ["In this turned orientation [ Fig. 7(b) ], the phenyl ring of Phe140 rotates away from the imidazole ring of His163 and cannot stack onto the imidazole ring of His163.", [["phenyl", "CHEMICAL", 46, 52], ["Phe140", "CHEMICAL", 61, 67], ["imidazole", "CHEMICAL", 90, 99], ["His163", "CHEMICAL", 108, 114], ["imidazole", "CHEMICAL", 141, 150], ["His163", "CHEMICAL", 159, 165], ["phenyl", "CHEMICAL", 46, 52], ["Phe140", "CHEMICAL", 61, 67], ["imidazole", "CHEMICAL", 90, 99], ["His", "CHEMICAL", 108, 111], ["imidazole", "CHEMICAL", 141, 150], ["His", "CHEMICAL", 159, 162], ["Fig. 7(b)", "SIMPLE_CHEMICAL", 29, 38], ["phenyl ring", "SIMPLE_CHEMICAL", 46, 57], ["Phe140", "SIMPLE_CHEMICAL", 61, 67], ["His163", "SIMPLE_CHEMICAL", 108, 114], ["His163", "SIMPLE_CHEMICAL", 159, 165], ["the phenyl ring of Phe140", "TREATMENT", 42, 67], ["the imidazole ring", "TREATMENT", 86, 104], ["the imidazole ring", "TREATMENT", 137, 155]]], ["Furthermore, without the interaction of the N-terminus through the water-bridge, b-strand 163-172 becomes partly disordered and moves towards Tyr161.", [["b-strand 163-172", "CHEMICAL", 81, 97], ["Tyr161", "CHEMICAL", 142, 148], ["N", "CHEMICAL", 44, 45], ["Tyr", "CHEMICAL", 142, 145], ["water", "SIMPLE_CHEMICAL", 67, 72], ["Tyr161", "AMINO_ACID", 142, 148], ["N-terminus", "PROTEIN", 44, 54], ["the N-terminus", "TREATMENT", 40, 54], ["the water-bridge", "TREATMENT", 63, 79], ["b-strand", "TEST", 81, 89], ["partly disordered", "PROBLEM", 106, 123], ["Tyr", "TEST", 142, 145]]], ["The main chain O atom of His172 competes with ND1 atom of His163 by forming stable hydrogen bond with the OH atom of Tyr161 (Table II) , resulting in the disruption of the OH(Tyr161). . .ND1(His163) hydrogen bond (Fig. 15 , Table II ).", [["His172", "CHEMICAL", 25, 31], ["ND1 atom of His163", "CHEMICAL", 46, 64], ["Tyr161", "CHEMICAL", 175, 181], ["O", "CHEMICAL", 15, 16], ["His172", "CHEMICAL", 25, 31], ["ND1", "CHEMICAL", 46, 49], ["His", "CHEMICAL", 58, 61], ["hydrogen", "CHEMICAL", 83, 91], ["OH", "CHEMICAL", 106, 108], ["Tyr161", "CHEMICAL", 117, 123], ["OH", "CHEMICAL", 172, 174], ["Tyr", "CHEMICAL", 175, 178], ["His", "CHEMICAL", 191, 194], ["hydrogen", "CHEMICAL", 199, 207], ["His172", "SIMPLE_CHEMICAL", 25, 31], ["ND1", "AMINO_ACID", 46, 49], ["His163", "AMINO_ACID", 58, 64], ["OH", "SIMPLE_CHEMICAL", 106, 108], ["Tyr161", "SIMPLE_CHEMICAL", 117, 123], ["ND1", "GENE_OR_GENE_PRODUCT", 187, 190], ["ND1", "TEST", 187, 190], ["hydrogen bond (Fig.", "TEST", 199, 218], ["main", "OBSERVATION_MODIFIER", 4, 8], ["chain", "OBSERVATION_MODIFIER", 9, 14], ["atom", "ANATOMY_MODIFIER", 17, 21], ["stable", "OBSERVATION_MODIFIER", 76, 82], ["hydrogen bond", "OBSERVATION", 83, 96], ["disruption", "OBSERVATION", 154, 164]]], ["In the monomer, since the two interactions that maintain the stable conformation of the imidazole ring of His163 are destroyed, the conformation of the imidazole ring of His163 is not stable, making the turn mentioned above.Stabilization of Glu166 by N-TerminusThe main chain O atom of SerB1 is also found to approach the hydrogen atom of Glu166 and maintain a stable hydrogen bond during the MD simulation of the SARS M pro dimer complex, with an occupancy of 61.3% [ Fig. 7(a) , Table I ].", [["imidazole", "CHEMICAL", 88, 97], ["His163", "CHEMICAL", 106, 112], ["imidazole", "CHEMICAL", 152, 161], ["His163", "CHEMICAL", 170, 176], ["Glu166", "CHEMICAL", 241, 247], ["N-Terminus", "CHEMICAL", 251, 261], ["Glu166", "CHEMICAL", 339, 345], ["imidazole", "CHEMICAL", 88, 97], ["His", "CHEMICAL", 106, 109], ["imidazole", "CHEMICAL", 152, 161], ["His163", "CHEMICAL", 170, 176], ["Glu166", "CHEMICAL", 241, 247], ["N-Terminus", "CHEMICAL", 251, 261], ["O", "CHEMICAL", 276, 277], ["SerB1", "CHEMICAL", 286, 291], ["hydrogen", "CHEMICAL", 322, 330], ["Glu166", "CHEMICAL", 339, 345], ["hydrogen", "CHEMICAL", 368, 376], ["His163", "AMINO_ACID", 106, 112], ["His163", "SIMPLE_CHEMICAL", 170, 176], ["Glu166", "GENE_OR_GENE_PRODUCT", 241, 247], ["SerB1", "AMINO_ACID", 286, 291], ["Glu166", "SIMPLE_CHEMICAL", 339, 345], ["Glu166", "PROTEIN", 241, 247], ["SerB1", "PROTEIN", 286, 291], ["SARS M pro dimer complex", "PROTEIN", 414, 438], ["the imidazole ring", "TREATMENT", 84, 102], ["the imidazole ring", "TREATMENT", 148, 166], ["an occupancy", "TEST", 445, 457], ["stable", "OBSERVATION_MODIFIER", 61, 67], ["stable", "OBSERVATION_MODIFIER", 184, 190], ["main", "OBSERVATION_MODIFIER", 265, 269], ["chain", "OBSERVATION_MODIFIER", 270, 275], ["stable", "OBSERVATION_MODIFIER", 361, 367], ["hydrogen bond", "OBSERVATION", 368, 381]]], ["The hydrogen bond is indispensable for the stability of side chain carbonyl of Glu166 at request for accepting a hydrogen bond from side-chain NE2 of glutamine at substrate analog P1site.", [["Glu166", "CHEMICAL", 79, 85], ["glutamine", "CHEMICAL", 150, 159], ["hydrogen", "CHEMICAL", 4, 12], ["carbonyl", "CHEMICAL", 67, 75], ["Glu166", "CHEMICAL", 79, 85], ["hydrogen", "CHEMICAL", 113, 121], ["glutamine", "CHEMICAL", 150, 159], ["side chain carbonyl", "SIMPLE_CHEMICAL", 56, 75], ["Glu166", "SIMPLE_CHEMICAL", 79, 85], ["side-chain NE2", "SIMPLE_CHEMICAL", 132, 146], ["glutamine", "AMINO_ACID", 150, 159], ["P1site", "SIMPLE_CHEMICAL", 180, 186], ["a hydrogen bond", "TREATMENT", 111, 126], ["glutamine", "TREATMENT", 150, 159], ["hydrogen bond", "OBSERVATION", 4, 17], ["stability", "OBSERVATION_MODIFIER", 43, 52]]], ["In the monomer, for the absence of this hydrogen, the conformation of side chain carbonyl of Glu166 is unstable, making the turn mentioned above.Stabilization of Glu166 by N-TerminusThus it can be concluded that through stabilizing the conformation of the imidazole ring of His163 and the side chain carbonyl of Gly166, the N-terminus of protomer B plays an important role in stabilizing the ''tooth'' conformation between His163 and Glu166 required at discriminating specific glutamine at substrate P1site.Effect on Conformation at Variations of Substrate-Binding Pocket by N-Terminus and Domain IIIThe substrate-binding pocket is reduced by the movements of loop 140-146 and loop 184-197 towards the active site.", [["tooth", "ANATOMY", 394, 399], ["hydrogen", "CHEMICAL", 40, 48], ["Glu166", "CHEMICAL", 93, 99], ["Glu166", "CHEMICAL", 162, 168], ["N-Terminus", "CHEMICAL", 172, 182], ["imidazole", "CHEMICAL", 256, 265], ["His163", "CHEMICAL", 274, 280], ["Gly166", "CHEMICAL", 312, 318], ["glutamine", "CHEMICAL", 477, 486], ["loop 140-146 and loop 184-197", "CHEMICAL", 660, 689], ["hydrogen", "CHEMICAL", 40, 48], ["carbonyl", "CHEMICAL", 81, 89], ["Glu166", "CHEMICAL", 93, 99], ["Glu166", "CHEMICAL", 162, 168], ["N-Terminus", "CHEMICAL", 172, 182], ["imidazole", "CHEMICAL", 256, 265], ["His", "CHEMICAL", 274, 277], ["carbonyl", "CHEMICAL", 300, 308], ["Gly", "CHEMICAL", 312, 315], ["N", "CHEMICAL", 324, 325], ["His", "CHEMICAL", 423, 426], ["Glu166", "CHEMICAL", 434, 440], ["glutamine", "CHEMICAL", 477, 486], ["hydrogen", "SIMPLE_CHEMICAL", 40, 48], ["side chain carbonyl", "SIMPLE_CHEMICAL", 70, 89], ["Glu166", "SIMPLE_CHEMICAL", 93, 99], ["Glu166", "GENE_OR_GENE_PRODUCT", 162, 168], ["His163", "AMINO_ACID", 274, 280], ["Gly166", "AMINO_ACID", 312, 318], ["protomer B", "GENE_OR_GENE_PRODUCT", 338, 348], ["His163", "AMINO_ACID", 423, 429], ["Glu166", "AMINO_ACID", 434, 440], ["glutamine", "AMINO_ACID", 477, 486], ["184-197", "AMINO_ACID", 682, 689], ["Glu166", "PROTEIN", 162, 168], ["N-terminus", "PROTEIN", 324, 334], ["protomer B", "PROTEIN", 338, 348], ["substrate P1site", "PROTEIN", 490, 506], ["Substrate-Binding Pocket", "PROTEIN", 547, 571], ["N-Terminus", "PROTEIN", 575, 585], ["Domain IIIThe substrate-binding pocket", "PROTEIN", 590, 628], ["this hydrogen", "TREATMENT", 35, 48], ["side chain carbonyl of Glu166", "TEST", 70, 99], ["the imidazole ring", "TREATMENT", 252, 270], ["the N-terminus of protomer B", "TREATMENT", 320, 348], ["Substrate-Binding Pocket", "TREATMENT", 547, 571], ["N-Terminus", "TREATMENT", 575, 585], ["Domain IIIThe substrate-binding pocket", "TREATMENT", 590, 628], ["loop", "TEST", 660, 664], ["loop", "TEST", 677, 681], ["unstable", "OBSERVATION_MODIFIER", 103, 111], ["binding pocket", "OBSERVATION", 614, 628], ["reduced", "OBSERVATION_MODIFIER", 632, 639]]], ["In the dimer, the hydrogen bond between the main chain of Ser1B and the main chain of Phe140 can stabilize not only the conformation of the phenyl ring of Phe140, but also that of loop 140-146, which makes the ''oxyanion hole'' in this loop keep proper conformation to accommodate glutamine at substrate analog P1 site and a tetrahedral intermediate.", [["Phe140", "CHEMICAL", 86, 92], ["Phe140", "CHEMICAL", 155, 161], ["loop 140-146", "CHEMICAL", 180, 192], ["glutamine", "CHEMICAL", 281, 290], ["hydrogen", "CHEMICAL", 18, 26], ["Phe140", "CHEMICAL", 86, 92], ["phenyl", "CHEMICAL", 140, 146], ["Phe140", "CHEMICAL", 155, 161], ["glutamine", "CHEMICAL", 281, 290], ["Ser1B", "GENE_OR_GENE_PRODUCT", 58, 63], ["Phe140", "SIMPLE_CHEMICAL", 86, 92], ["Phe140", "SIMPLE_CHEMICAL", 155, 161], ["glutamine", "AMINO_ACID", 281, 290], ["Ser1B", "PROTEIN", 58, 63], ["Phe140", "PROTEIN", 86, 92], ["the phenyl ring of Phe140", "TREATMENT", 136, 161], ["loop", "TEST", 180, 184], ["the ''oxyanion hole", "TREATMENT", 206, 225], ["glutamine at substrate analog P1 site", "TREATMENT", 281, 318], ["a tetrahedral intermediate", "TREATMENT", 323, 349], ["hydrogen bond", "OBSERVATION", 18, 31], ["main", "OBSERVATION_MODIFIER", 44, 48], ["chain", "OBSERVATION_MODIFIER", 49, 54], ["main", "OBSERVATION_MODIFIER", 72, 76], ["chain", "OBSERVATION_MODIFIER", 77, 82], ["phenyl ring", "OBSERVATION", 140, 151]]], ["In the monomer, because of the absence of these two hydrogen bonds, the whole 140-146 loop moves a lot toward the active site, resulting in the collapse of the ''oxyanion hole''.Effect on Conformation at Variations of Substrate-Binding Pocket by N-Terminus and Domain IIIThe loss of the activity of the coronavirus main protease deleted domain III might be caused by the conformational variations of loop 184-197, 14 which means that domain III is important to the stability of loop 184-197.", [["140-146", "CHEMICAL", 78, 85], ["loop 184-197", "CHEMICAL", 478, 490], ["hydrogen", "CHEMICAL", 52, 60], ["N", "CHEMICAL", 246, 247], ["whole 140-146 loop", "PROTEIN", 72, 90], ["Substrate-Binding Pocket", "PROTEIN", 218, 242], ["N-Terminus", "PROTEIN", 246, 256], ["Domain IIIThe", "PROTEIN", 261, 274], ["coronavirus main protease deleted domain III", "PROTEIN", 303, 347], ["domain III", "PROTEIN", 434, 444], ["the collapse of the ''oxyanion hole''", "PROBLEM", 140, 177], ["Substrate-Binding Pocket", "TREATMENT", 218, 242], ["N-Terminus", "TREATMENT", 246, 256], ["the conformational variations of loop", "PROBLEM", 367, 404], ["loop", "TEST", 478, 482], ["hydrogen bonds", "OBSERVATION", 52, 66], ["collapse", "OBSERVATION", 144, 152]]], ["In the dimer, there exist two type of intermolecular interactions between the two monomers to fix the domain III: (i) the salt-bridge between Arg4 at the N-terminus of protomer B and Glu290 at domain III in protomer A 19 , which in this MD simulation of the SARS M pro dimer, possesses the occupancy of 100% and average distance of 2.71 \u00c5 (Table I) and (ii) the specific electrostatic and hydrophobic interactions between the domains III of the monomers.", [["Arg4", "CHEMICAL", 142, 146], ["Arg4", "CHEMICAL", 142, 146], ["N", "CHEMICAL", 154, 155], ["Glu290", "CHEMICAL", 183, 189], ["Arg4", "SIMPLE_CHEMICAL", 142, 146], ["Glu290", "AMINO_ACID", 183, 189], ["domain III", "PROTEIN", 102, 112], ["salt-bridge", "PROTEIN", 122, 133], ["Arg4", "PROTEIN", 142, 146], ["N-terminus", "PROTEIN", 154, 164], ["protomer B", "PROTEIN", 168, 178], ["Glu290", "PROTEIN", 183, 189], ["domain III", "PROTEIN", 193, 203], ["protomer A 19", "PROTEIN", 207, 220], ["SARS M pro dimer", "PROTEIN", 258, 274], ["domains III", "PROTEIN", 426, 437], ["intermolecular interactions", "PROBLEM", 38, 65], ["Arg4", "TREATMENT", 142, 146], ["intermolecular interactions", "OBSERVATION", 38, 65], ["occupancy", "OBSERVATION_MODIFIER", 290, 299], ["electrostatic", "OBSERVATION_MODIFIER", 371, 384], ["hydrophobic interactions", "OBSERVATION", 389, 413]]], ["13 By these intermolecular interactions, the domain III is fixed in a proper conformation required for stabilization of loop 184-197, which makes the S3 pocket in this loop keep the proper conformation to accommodate threonine at the substrate analog P3 site.", [["loop 184-197", "CHEMICAL", 120, 132], ["threonine", "CHEMICAL", 217, 226], ["threonine", "CHEMICAL", 217, 226], ["184-197", "AMINO_ACID", 125, 132], ["threonine", "AMINO_ACID", 217, 226], ["domain III", "PROTEIN", 45, 55], ["substrate analog P3 site", "PROTEIN", 234, 258], ["stabilization of loop", "TREATMENT", 103, 124], ["the S3 pocket", "PROBLEM", 146, 159], ["threonine", "TREATMENT", 217, 226], ["intermolecular interactions", "OBSERVATION", 12, 39]]], ["In the monomer, because of the absence of these intermolecular interactions, the whole 184-197 loop moves toward the active site, resulting in the collapse of the S3 pocket.", [["184-197", "CHEMICAL", 87, 94], ["whole 184-197 loop", "PROTEIN", 81, 99], ["S3 pocket", "PROTEIN", 163, 172], ["these intermolecular interactions", "PROBLEM", 42, 75], ["the collapse of the S3 pocket", "PROBLEM", 143, 172], ["active site", "OBSERVATION_MODIFIER", 117, 128], ["collapse", "OBSERVATION", 147, 155], ["S3 pocket", "OBSERVATION", 163, 172]]], ["A good evidence for this is that any mutant of Glu290 abolishes completely the activity of the SARS main protease.", [["Glu290", "CHEMICAL", 47, 53], ["SARS", "DISEASE", 95, 99], ["Glu290", "CHEMICAL", 47, 53], ["Glu290", "GENE_OR_GENE_PRODUCT", 47, 53], ["Glu290", "PROTEIN", 47, 53], ["SARS main protease", "PROTEIN", 95, 113], ["any mutant of Glu290 abolishes", "PROBLEM", 33, 63]]], ["19 From the analysis, a reasonable conclusion can be got that the intermolecular interactions between the two monomers in the dimer, especially for the interactions around N-terminus and domain III of one monomer, are key to stabilizing the residues of the active pocket of the other monomer in the active form, therefore insuring the successful proceeding of the combination and hydrolysis of the substrate in the dimer.", [["N", "CHEMICAL", 172, 173], ["dimer", "PROTEIN", 126, 131], ["N-terminus", "PROTEIN", 172, 182], ["domain III", "PROTEIN", 187, 197], ["dimer", "PROTEIN", 415, 420], ["the analysis", "TEST", 8, 20], ["the intermolecular interactions", "PROBLEM", 62, 93], ["hydrolysis of the substrate in the dimer", "TREATMENT", 380, 420], ["active", "OBSERVATION_MODIFIER", 257, 263], ["pocket", "OBSERVATION_MODIFIER", 264, 270], ["active", "OBSERVATION_MODIFIER", 299, 305]]], ["This is well verified by the experiments that a deletion mutant of D1-5 residues or domain III of the related TGEV M pro are almost completely inactive.", [["D1-5", "GENE_OR_GENE_PRODUCT", 67, 71], ["TGEV", "ORGANISM", 110, 114], ["D1", "PROTEIN", 67, 69], ["domain III", "PROTEIN", 84, 94], ["TGEV M pro", "PROTEIN", 110, 120], ["D1-5 residues", "TREATMENT", 67, 80]]], ["14 Thus, in SARS M pro dimer, the enzyme is switched from the inactive form (monomer) to the active form (dimer) by the intermolecular interactions between the two monomers within the dimer.", [["SARS M pro dimer", "PROTEIN", 12, 28], ["enzyme", "PROTEIN", 34, 40], ["inactive form", "PROTEIN", 62, 75], ["dimer", "PROTEIN", 106, 111], ["dimer", "PROTEIN", 184, 189], ["the enzyme", "TEST", 30, 40], ["active", "OBSERVATION_MODIFIER", 93, 99]]], ["The interface of the SARS M pro dimer can be treated as a new target for the design of specific protease inhibitors.CONCLUSIONSIn the dimer, through the water-bridge, the N-terminus of one monomer stabilizes the conformation of the bstrand 163-172 of the other.", [["bstrand 163-172", "CHEMICAL", 232, 247], ["N", "CHEMICAL", 171, 172], ["SARS M pro dimer", "PROTEIN", 21, 37], ["dimer", "PROTEIN", 134, 139], ["N-terminus", "PROTEIN", 171, 181], ["bstrand 163-172", "PROTEIN", 232, 247], ["specific protease inhibitors", "TREATMENT", 87, 115], ["the water-bridge", "TREATMENT", 149, 165], ["dimer", "OBSERVATION_MODIFIER", 134, 139]]], ["This prevents His170 competing with His163 and forming H-bond with Tyr161 and maintains the stable hydrogen bond between Tyr161 and His163.", [["His", "CHEMICAL", 14, 17], ["His", "CHEMICAL", 36, 39], ["H", "CHEMICAL", 55, 56], ["Tyr161", "CHEMICAL", 67, 73], ["hydrogen", "CHEMICAL", 99, 107], ["Tyr161", "CHEMICAL", 121, 127], ["His", "CHEMICAL", 132, 135], ["Tyr161", "AMINO_ACID", 67, 73], ["Tyr161", "SIMPLE_CHEMICAL", 121, 127], ["His163", "SIMPLE_CHEMICAL", 132, 138], ["Tyr161", "PROTEIN", 67, 73], ["stable", "OBSERVATION", 92, 98]]], ["Furthermore, the N-terminus of the counter monomer interacts directly with Phe140, making the conformation of the phenyl ring of Phe140 stable and stack onto the imidazole ring of His163.", [["Phe140", "CHEMICAL", 75, 81], ["Phe140", "CHEMICAL", 129, 135], ["imidazole", "CHEMICAL", 162, 171], ["His163", "CHEMICAL", 180, 186], ["N", "CHEMICAL", 17, 18], ["Phe140", "CHEMICAL", 75, 81], ["phenyl", "CHEMICAL", 114, 120], ["Phe140", "CHEMICAL", 129, 135], ["imidazole", "CHEMICAL", 162, 171], ["His", "CHEMICAL", 180, 183], ["Phe140", "SIMPLE_CHEMICAL", 75, 81], ["Phe140", "SIMPLE_CHEMICAL", 129, 135], ["His163", "SIMPLE_CHEMICAL", 180, 186], ["N-terminus", "PROTEIN", 17, 27], ["Phe140", "PROTEIN", 75, 81], ["the phenyl ring of Phe140", "TREATMENT", 110, 135], ["the imidazole ring", "TREATMENT", 158, 176]]], ["Just for these two interactions, the imidazole ring of His163 can maintain the conformation required for donating the proton to bind glutamine at the substrate analog P1 site.", [["imidazole", "CHEMICAL", 37, 46], ["His163", "CHEMICAL", 55, 61], ["glutamine", "CHEMICAL", 133, 142], ["imidazole", "CHEMICAL", 37, 46], ["His", "CHEMICAL", 55, 58], ["glutamine", "CHEMICAL", 133, 142], ["His163", "SIMPLE_CHEMICAL", 55, 61], ["proton", "SIMPLE_CHEMICAL", 118, 124], ["glutamine", "AMINO_ACID", 133, 142], ["the imidazole ring", "TREATMENT", 33, 51], ["the proton to bind glutamine", "TREATMENT", 114, 142]]], ["The N-terminus of the counter monomer also forms a stable hydrogen bond with Glu166, which stabilizes the proper conformation of the side chain carbonate group of Glu166 required for accepting a hydrogen bond from glutamine at the substrate analog P1 site.", [["Glu166", "CHEMICAL", 77, 83], ["Glu166", "CHEMICAL", 163, 169], ["glutamine", "CHEMICAL", 214, 223], ["N", "CHEMICAL", 4, 5], ["hydrogen", "CHEMICAL", 58, 66], ["Glu166", "CHEMICAL", 77, 83], ["carbonate", "CHEMICAL", 144, 153], ["Glu166", "CHEMICAL", 163, 169], ["hydrogen", "CHEMICAL", 195, 203], ["glutamine", "CHEMICAL", 214, 223], ["Glu166", "SIMPLE_CHEMICAL", 77, 83], ["carbonate", "SIMPLE_CHEMICAL", 144, 153], ["Glu166", "SIMPLE_CHEMICAL", 163, 169], ["glutamine", "AMINO_ACID", 214, 223], ["N-terminus", "PROTEIN", 4, 14], ["a hydrogen bond from glutamine", "TREATMENT", 193, 223], ["stable", "OBSERVATION_MODIFIER", 51, 57], ["hydrogen bond", "OBSERVATION", 58, 71]]], ["His163 and Glu166 form the ''tooth'' conformation characteristics and result in the specificity for glutamine at the substrate P1 site.", [["tooth", "ANATOMY", 29, 34], ["glutamine", "CHEMICAL", 100, 109], ["His", "CHEMICAL", 0, 3], ["glutamine", "CHEMICAL", 100, 109], ["Glu166", "GENE_OR_GENE_PRODUCT", 11, 17], ["glutamine", "AMINO_ACID", 100, 109], ["substrate P1 site", "DNA", 117, 134], ["glutamine at the substrate P1 site", "TREATMENT", 100, 134]]], ["While in the monomer, because of the lack of the stabilization of the N-terminus of the counter monomer to His163 and Gly166, the ''tooth'' conformation is destroyed, resulting in a destruction of the specific recognition of the glutamine of the substrate at the P1 site and the inactivation of monomer.", [["tooth", "ANATOMY", 132, 137], ["His163", "CHEMICAL", 107, 113], ["Gly166", "CHEMICAL", 118, 124], ["glutamine", "CHEMICAL", 229, 238], ["N", "CHEMICAL", 70, 71], ["His", "CHEMICAL", 107, 110], ["Gly", "CHEMICAL", 118, 121], ["glutamine", "CHEMICAL", 229, 238], ["His163", "AMINO_ACID", 107, 113], ["Gly166", "AMINO_ACID", 118, 124], ["glutamine", "AMINO_ACID", 229, 238], ["N-terminus", "PROTEIN", 70, 80], ["P1 site", "DNA", 263, 270], ["Gly", "TEST", 118, 121], ["a destruction", "PROBLEM", 180, 193], ["destruction", "OBSERVATION", 182, 193], ["P1", "ANATOMY", 263, 265]]], ["Furthermore, it is the lack of the stabilization of the N-terminus of the counter monomer to Phe140 that makes the loop 140-146 move a lot toward the active site, which causes the collapse of the ''oxyanion hole'' and leaves no space to accommodate glutamine at the substrate analog P1 site and a tetrahedral intermediate.", [["Phe140", "CHEMICAL", 93, 99], ["loop 140-146", "CHEMICAL", 115, 127], ["glutamine", "CHEMICAL", 249, 258], ["N", "CHEMICAL", 56, 57], ["Phe140", "CHEMICAL", 93, 99], ["glutamine", "CHEMICAL", 249, 258], ["Phe140", "SIMPLE_CHEMICAL", 93, 99], ["glutamine", "AMINO_ACID", 249, 258], ["N-terminus", "PROTEIN", 56, 66], ["Phe140", "PROTEIN", 93, 99], ["substrate analog P1 site", "PROTEIN", 266, 290], ["the N-terminus of the counter monomer", "TREATMENT", 52, 89], ["the ''oxyanion hole", "TREATMENT", 192, 211], ["space", "PROBLEM", 228, 233], ["glutamine", "TREATMENT", 249, 258], ["collapse", "OBSERVATION", 180, 188]]], ["Because of the loss of the salt-bridge between the N-terminus of counter monomer and domain III and the specific electrostatic and hydrophobic interactions between domain III of monomers within the dimer, the conformation of domain III cannot be fixed.", [["N", "CHEMICAL", 51, 52], ["N-terminus", "PROTEIN", 51, 61], ["counter monomer", "PROTEIN", 65, 80], ["domain III", "PROTEIN", 85, 95], ["domain III", "PROTEIN", 164, 174], ["dimer", "PROTEIN", 198, 203], ["domain III", "PROTEIN", 225, 235], ["the salt-bridge", "TREATMENT", 23, 38], ["the N-terminus of counter monomer", "TREATMENT", 47, 80], ["hydrophobic interactions", "OBSERVATION", 131, 155]]], ["As a consequence, the loop 184-197 becomes disorder and the S3 pocket collapses, leaving no space to accommodate the threonine at the substrate analog P3 site.", [["loop 184-197", "CHEMICAL", 22, 34], ["disorder", "DISEASE", 43, 51], ["threonine", "CHEMICAL", 117, 126], ["threonine", "CHEMICAL", 117, 126], ["threonine", "AMINO_ACID", 117, 126], ["substrate analog P3 site", "PROTEIN", 134, 158], ["the loop", "TEST", 18, 26], ["disorder", "PROBLEM", 43, 51], ["the S3 pocket collapses", "PROBLEM", 56, 79], ["space", "PROBLEM", 92, 97], ["the threonine", "TREATMENT", 113, 126], ["S3", "OBSERVATION_MODIFIER", 60, 62], ["pocket", "OBSERVATION_MODIFIER", 63, 69], ["collapses", "OBSERVATION", 70, 79]]], ["The movements of loop 140-146 and loop 184-197 toward the active site induce the reduction of substrate-binding pocket.", [["loop 140-146 and loop 184-197", "CHEMICAL", 17, 46], ["184-197", "AMINO_ACID", 39, 46], ["substrate-binding pocket", "PROTEIN", 94, 118], ["The movements of loop", "TEST", 0, 21], ["loop", "TEST", 34, 38], ["substrate-binding pocket", "PROBLEM", 94, 118], ["movements", "OBSERVATION_MODIFIER", 4, 13], ["reduction", "OBSERVATION_MODIFIER", 81, 90], ["binding pocket", "OBSERVATION", 104, 118]]], ["As a consequence, the SARS M pro monomer cannot bind the substrate.", [["SARS M pro monomer", "PROTEIN", 22, 40], ["the SARS M pro monomer", "TREATMENT", 18, 40]]], ["In the dimer, the distance between NE2 of His41 and SG of Cys145 averages 3.72 \u00c5 , which agrees well with the experimental observations made by X-ray crystallography.", [["His41", "CHEMICAL", 42, 47], ["Cys145", "CHEMICAL", 58, 64], ["dimer", "PROTEIN", 7, 12], ["NE2", "PROTEIN", 35, 38], ["His41", "PROTEIN", 42, 47], ["SG", "PROTEIN", 52, 54], ["Cys145", "PROTEIN", 58, 64], ["X-ray crystallography", "TEST", 144, 165]]], ["While in the monomer, the longer distance between the two entities deviates a lot from the crystal structure and might be unfavorable to substrate hydrolysis by the monomer by a general-base mechanism.CONCLUSIONSIn this study, by comparing MD simulation of dimer and monomer, the indirect reasons for the inactivation of the monomer have been found, that is the conformational variations of the active site in the monomer relative to dimer.", [["dimer", "PROTEIN", 257, 262], ["dimer", "PROTEIN", 434, 439], ["this study", "TEST", 215, 225], ["might be", "UNCERTAINTY", 113, 121], ["active", "OBSERVATION_MODIFIER", 395, 401], ["site", "OBSERVATION_MODIFIER", 402, 406]]], ["Furthermore, the ultimate reasons that cause the conformational differences between dimer and monomer, the intermolecular interactions between the two monomers within the dimer and their important roles in how to stabilize the active pocket, have been investigated, which provides useful insight for the design of specific protease inhibitors using the interface of the SARS M pro dimer as a new target.", [["dimer", "PROTEIN", 84, 89], ["dimer", "PROTEIN", 171, 176], ["SARS M pro dimer", "PROTEIN", 370, 386], ["the conformational differences between dimer and monomer", "PROBLEM", 45, 101], ["the active pocket", "PROBLEM", 223, 240], ["specific protease inhibitors", "TREATMENT", 314, 342], ["active", "OBSERVATION_MODIFIER", 227, 233], ["pocket", "OBSERVATION", 234, 240]]]], "PMC4926188": [], "PMC7132726": [["Subjects were recruited from a variety of sources, including state school nurse associations, state departments of education, and individual school Web sites for school nurse contact information.", [["Subjects", "ORGANISM", 0, 8]]], ["Twenty-five school nurse organizations agreed to assist by sending out a recruitment e-mail to their members/contacts or posting a recruitment statement on their organization's Web site.", [["Web site", "DNA", 177, 185]]], ["A modified Dillman total design method was used to maximize response rates.21 Two recruitment e-mails (sent 2-4 weeks apart) were distributed to school nurses for whom an e-mail address was available.", [["A modified Dillman total design method", "TREATMENT", 0, 38]]], ["The Saint Louis University Institutional Review Board approved this study.InstrumentSurveys used in earlier studies examining school disaster preparedness14, 15 served as the basis for our questionnaire.", [["this study", "TEST", 63, 73]]], ["CDC recommendations related to pandemic planning for schools22 and colleges/universities23 also were incorporated into the questionnaire.", [["pandemic", "DISEASE", 31, 39]]], ["Finally, questions specific to the purposes of this study were added.", [["this study", "TEST", 47, 57]]], ["A content validity index (CVI) was computed for each item24; no items had a CVI below 0.80, and so no items were deleted.", [["CVI", "DISEASE", 76, 79], ["A content validity index", "TEST", 0, 24], ["a CVI", "TEST", 74, 79]]], ["Feedback from pilot testing was used to further refine the instrument.InstrumentThe survey assessed the following areas: (1) school disaster preparedness, (2) school pandemic preparedness, (3) school plan to function as a point of dispensing (POD) in a future disaster, (4) personal protective equipment (PPE) stockpiled by the school, (5) access to and cost of seasonal influenza vaccine, and (6) existence of a mandatory influenza vaccination policy for a variety of school employees.", [["influenza", "DISEASE", 371, 380], ["Feedback from pilot testing", "TEST", 0, 27], ["seasonal influenza vaccine", "TREATMENT", 362, 388], ["a mandatory influenza vaccination policy", "TREATMENT", 411, 451]]], ["The components of school preparedness were categorical items, with most answer options \u201cyes\u201d or \u201cno\u201d: (1) written disaster plan, (2) plan coordinated with local and regional agencies, (3) participation in regional disaster exercise in previous 2 years, (4) plan addresses pandemics, (5) plan updated since/in response to the 2009 H1N1 pandemic, (6) infectious disease scenario used in a disaster drill in the previous 2 years, (7) medications stockpiled/available from district, (8) PPE stored/available, (9) school nurse mandated to receive seasonal influenza vaccine, (10) plan to increase environmental decontamination/cleaning during pandemic, and (11) participation in a community syndromic surveillance program.", [["H1N1", "DISEASE", 330, 334], ["influenza", "DISEASE", 551, 560], ["infectious disease scenario", "PROBLEM", 349, 376], ["medications", "TREATMENT", 431, 442], ["seasonal influenza vaccine", "TREATMENT", 542, 568], ["environmental decontamination", "TREATMENT", 592, 621]]], ["The remaining school preparedness indicators were categorical variables that had nominal answer categories: (1) frequency that school plan is reviewed/updated (every 1, 2, or 3 or more years), (2) staff receiving disaster plan training (all, some, or none), (3) frequency with which school conducts a disaster drill/exercise (every month, quarter, semester, year, or less than once per year), (4) continuity of operations plan and/or distance-based program (yes, no, or currently working on it), (5) staff receiving respiratory hygiene training (all, some, or none), (6) frequency with which students receive infection prevention training (less than once per year or 1, 2, or 3 times per year).", [["respiratory", "ANATOMY", 516, 527], ["infection", "DISEASE", 609, 618], ["disaster plan training", "TREATMENT", 213, 235], ["respiratory hygiene training", "TREATMENT", 516, 544], ["infection prevention training", "TREATMENT", 609, 638], ["infection", "OBSERVATION", 609, 618]]], ["Pandemic preparedness was assessed using a subset of the school preparedness indicators, namely the items specific to an infectious disease disaster (eg, having a pandemic preparedness plan).InstrumentThe temporal stability of the instrument was assessed using a 2-week test-retest procedure among 57 school nurses from the across the United States.", [["infectious disease disaster", "DISEASE", 121, 148], ["a pandemic preparedness plan", "TREATMENT", 161, 189], ["retest procedure", "TREATMENT", 275, 291], ["temporal", "OBSERVATION_MODIFIER", 205, 213], ["stability", "OBSERVATION_MODIFIER", 214, 223]]], ["The questionnaire demonstrated good temporal stability, with correlation coefficients varying from 0.84 to 0.96.Data analysisSPSS version 19.0 (IBM, Armonk, NY) was used for all analyses.", [["correlation coefficients", "TEST", 61, 85], ["Data analysisSPSS version", "TEST", 112, 137], ["all analyses", "TEST", 174, 186], ["good", "OBSERVATION_MODIFIER", 31, 35], ["temporal", "OBSERVATION_MODIFIER", 36, 44], ["stability", "OBSERVATION", 45, 54]]], ["These indicators included disaster plan and respiratory hygiene training for staff (all staff trained, 1; some staff trained, 0.5; no staff trained, 0), school nurse mandatory influenza vaccination policy (immunization mandated, 1; encouraged, but not mandated, 0.5; neither mandated nor encouraged, 0), and continuity of operations plan (distance-based program in place, 1; working on plan, 0.5; no plan for distance education, 0).", [["influenza", "DISEASE", 176, 185], ["disaster plan", "TREATMENT", 26, 39], ["respiratory hygiene training", "TREATMENT", 44, 72]]], ["The highest possible score for school disaster was 17, and that for pandemic preparedness was 11 (ie, 1 point for each of the 17 or 11 components).", [["pandemic", "DISEASE", 68, 76]]], ["Descriptive statistics were computed for each question and used to describe the components of the school's disaster and pandemic preparedness and the plan to function as a POD in a future disaster.", [["pandemic preparedness", "TREATMENT", 120, 141]]], ["Fisher's exact test was used to compare rates of mandating vaccine across the types of school employees (eg, nurses, teachers, counselors).", [["Fisher's exact test", "TEST", 0, 19]]], ["The \u03c72 test was used to identify any differences between public versus private schools when comparing the stockpiling of infection prevention supplies.", [["infection", "DISEASE", 121, 130], ["The \u03c72 test", "TEST", 0, 11], ["infection prevention supplies", "TREATMENT", 121, 150], ["infection", "OBSERVATION", 121, 130]]], ["Linear regression was used to describe factors associated with higher school and pandemic preparedness scores.", [["Linear regression", "PROBLEM", 0, 17], ["regression", "OBSERVATION", 7, 17]]], ["Nonsignificant variables were not included in the final models; only final models are reported.School disaster and pandemic preparedness ::: ResultsThis survey included 17 indicators of school preparedness, for a maximum total preparedness score of 17 points.", [["Nonsignificant variables", "PROBLEM", 0, 24], ["a maximum total preparedness score", "TEST", 211, 245]]], ["School preparedness scores ranged from 0 to 15.5, with an average score of 7.7.", [["School preparedness scores", "TEST", 0, 26], ["an average score", "TEST", 55, 71]]], ["Of the 17 school preparedness indicators, 11 were specific to pandemic preparedness; thus, the maximum pandemic preparedness score was 11 points.", [["pandemic", "DISEASE", 62, 70], ["the maximum pandemic preparedness score", "TEST", 91, 130]]], ["School pandemic preparedness scores ranged from 0 to 10 points, with an average score of 4.3.", [["an average score", "TEST", 69, 85]]], ["Components of school disaster and pandemic preparedness plans and the frequency with which schools reported having each component are listed in Table 1.", [["school disaster", "OBSERVATION", 14, 29]]], ["Infection prevention supplies that schools have stockpiled or would have access to during a disaster are presented in Table 2.", [["Infection prevention", "TREATMENT", 0, 20]]], ["Private schools were more likely than public schools to report having stockpiled alcohol-based hand rub (P < .05), eye protection (P < .05), and gloves (P < .05) (Table 2).School disaster and pandemic preparedness ::: ResultsAlthough it is not a direct indicator of pandemic preparedness, school designation as a POD during a future pandemic was assessed because of the belief that schools designated as a POD need to have worked closely with community disaster planners; this collaboration between schools and disaster planners may increase awareness of the need for pandemic preparation and subsequent preparedness.", [["hand", "ANATOMY", 95, 99], ["eye", "ANATOMY", 115, 118], ["alcohol", "CHEMICAL", 81, 88], ["alcohol", "CHEMICAL", 81, 88], ["alcohol", "SIMPLE_CHEMICAL", 81, 88], ["hand", "ORGANISM_SUBDIVISION", 95, 99], ["eye", "ORGAN", 115, 118], ["eye protection", "TEST", 115, 129], ["pandemic preparation", "TREATMENT", 568, 588], ["eye", "ANATOMY", 115, 118]]], ["Schools designated to serve as a POD had significantly higher pandemic preparedness scores than schools not so designated (5.1 vs 4.1; t = 9.3; P < .001).", [["significantly higher pandemic preparedness scores", "PROBLEM", 41, 90], ["t", "TEST", 135, 136], ["P", "TEST", 144, 145]]], ["Determinants of school disaster and pandemic preparedness were identified as (1) located in a southern state, (2) designated to be a POD during a future pandemic, (3) experienced multiple student or employee hospitalizations and/or deaths related to H1N1 during the pandemic, (4) had a lead nurse complete the survey, and (5) had the school nurse study participant as a member of the school disaster planning committee (Table 3).Seasonal influenza vaccine ::: ResultsThree-quarters of the nurses (74.5%; n = 1,488) reported that their school, district, or employer offered the seasonal influenza vaccine during the 2010-11 season, and almost as many (73.7%; n = 1,472) reported receiving the vaccination.", [["deaths", "DISEASE", 232, 238], ["H1N1", "DISEASE", 250, 254], ["influenza", "DISEASE", 586, 595], ["H1N1", "PROBLEM", 250, 254], ["Seasonal influenza vaccine", "TREATMENT", 429, 455], ["the seasonal influenza vaccine", "TREATMENT", 573, 603], ["the vaccination", "TREATMENT", 688, 703]]], ["Of the nurses who were offered the vaccine and were vaccinated, 64.5% (n = 949) reported receiving the vaccine free of charge.", [["the vaccine", "TREATMENT", 31, 42], ["the vaccine", "TREATMENT", 99, 110]]], ["Nurses were more likely than all other school employees (P < .001) to be mandated to receive the seasonal influenza vaccine (Table 4).", [["influenza", "DISEASE", 106, 115], ["the seasonal influenza vaccine", "TREATMENT", 93, 123], ["more likely", "UNCERTAINTY", 12, 23]]], ["Most nurses (80.6%; n = 1,609) reported being encouraged by their employer to receive the seasonal influenza vaccine, but 17.3% (n = 345) reported being neither mandated nor encouraged to get immunized.DiscussionSimilar to previous research,15 the present study found that most schools have a written disaster plan in place.", [["influenza", "DISEASE", 99, 108], ["the seasonal influenza vaccine", "TREATMENT", 86, 116], ["the present study", "TEST", 244, 261]]], ["The previous study reported similar findings regarding the need to improve schools' written plans and increase staff disaster plan training.15 These are areas of school preparedness that do not appear to be improving much, despite the increased number of disasters over the past few years, including the H1N1 pandemic.", [["H1N1", "DISEASE", 304, 308], ["The previous study", "TEST", 0, 18], ["the H1N1 pandemic", "PROBLEM", 300, 317], ["areas", "OBSERVATION_MODIFIER", 153, 158], ["increased", "OBSERVATION_MODIFIER", 235, 244], ["number", "OBSERVATION_MODIFIER", 245, 251], ["H1N1", "OBSERVATION", 304, 308]]], ["It is vital that schools become more actively involved in disaster preparedness and coordinate these efforts with regional response agencies, to increase their ability to respond effectively to a future event.DiscussionPerhaps even more important than improving overall school disaster preparedness is improving preparedness for a biological event.", [["a biological event", "PROBLEM", 329, 347]]], ["Findings from this study suggest that most schools are even less prepared for an infectious disease disaster, such as a pandemic, compared with a natural disaster or other type of event.", [["infectious disease disaster", "DISEASE", 81, 108], ["this study", "TEST", 14, 24], ["an infectious disease disaster", "PROBLEM", 78, 108], ["a pandemic", "PROBLEM", 118, 128], ["infectious", "OBSERVATION", 81, 91]]], ["Despite the recent H1N1 pandemic, which disproportionately affected school-aged children, many schools do not have an adequate plan in place for a future biological event.", [["children", "ORGANISM", 80, 88], ["children", "SPECIES", 80, 88]]], ["Less than half of the participating schools reported having a plan to address biological events or updating their existing plan in response to the H1N1 pandemic, and almost no schools reported using an infectious disease scenario in a school disaster exercise to test their plan.", [["H1N1", "DISEASE", 147, 151]]], ["These actions are basic tenets of disaster and pandemic preparedness,22, 25 and schools need to be encouraged to examine these more complex issues involved in disaster preparedness.DiscussionThe present study also found that less than half of all responding schools were participating in a community syndromic surveillance program, such as reporting numbers of students experiencing influenza-like illness, gastrointestinal illness, or absenteeism rates.", [["gastrointestinal", "ANATOMY", 407, 423], ["influenza-like illness", "DISEASE", 383, 405], ["gastrointestinal illness", "DISEASE", 407, 431], ["gastrointestinal", "ORGAN", 407, 423], ["The present study", "TEST", 191, 208], ["influenza", "PROBLEM", 383, 392], ["gastrointestinal illness", "PROBLEM", 407, 431], ["absenteeism rates", "PROBLEM", 436, 453], ["gastrointestinal", "ANATOMY", 407, 423]]], ["School-based syndromic surveillance programs are effective early detection systems for identifying outbreaks of emerging pathogens,26, 27 and the CDC recommends that schools consider implementing such a system in conjunction with local public health agencies.22 Schools' participation in community syndromic surveillance programs would strengthen community pandemic preparedness by providing more accurate syndromic surveillance data and potentially increasing the speed with which a biological event is detected in the community.", [["emerging pathogens", "PROBLEM", 112, 130]]], ["Lack of coordination between school and community disaster plans has been identified as a gap in disaster planning.15 Schools should partner with local public health agencies in sharing absenteeism information and/or other syndromic surveillance indicators when feasible.DiscussionMost of the schools in this study reported lacking access to supplies needed to respond to a biological event, including medications and PPE, a finding that was also reported by Kano et al,15 indicating that schools need to make prearrangements to ensure access to supplies during a disaster.", [["this study", "TEST", 304, 314], ["a biological event", "PROBLEM", 372, 390], ["medications", "TREATMENT", 402, 413], ["PPE", "TREATMENT", 418, 421], ["coordination", "OBSERVATION_MODIFIER", 8, 20]]], ["Although the majority of schools reported training all staff on respiratory hygiene practices, many do not provide annual student training on basic infection prevention practices.", [["infection", "DISEASE", 148, 157], ["respiratory hygiene practices", "TREATMENT", 64, 93], ["annual student training", "TREATMENT", 115, 138], ["basic infection prevention practices", "TREATMENT", 142, 178], ["infection", "OBSERVATION", 148, 157]]], ["Infection prevention training and access to PPE are important not only for disaster preparedness, but also for everyday minimization of infection transmission in schools.", [["infection", "DISEASE", 136, 145], ["Infection prevention training", "TREATMENT", 0, 29], ["access to PPE", "TREATMENT", 34, 47], ["infection", "PROBLEM", 136, 145], ["infection", "OBSERVATION", 136, 145]]], ["In 2002, Robinson28 asserted that it is the role of school nurses to develop and implement infection prevention policies and programs to decrease disease transmission in schools, including educational programs such as respiratory hygiene.", [["respiratory", "ANATOMY", 218, 229], ["infection", "DISEASE", 91, 100], ["infection prevention policies", "TREATMENT", 91, 120], ["educational programs", "TREATMENT", 189, 209]]], ["Schools need to partner with local planning agencies to ensure that they will have access to supplies during a disaster, including being designated as a priority group for receiving pandemic-related vaccines or medication and PPE.DiscussionIn this study, schools that reported being better prepared for a future disaster or pandemic were more likely to be designated as a POD and to have experienced increased student or employee morbidity or mortality related to H1N1 during the pandemic.", [["H1N1", "DISEASE", 464, 468], ["pandemic-related vaccines", "TREATMENT", 182, 207], ["medication", "TREATMENT", 211, 221], ["PPE", "TREATMENT", 226, 229], ["this study", "TEST", 243, 253], ["pandemic", "PROBLEM", 324, 332], ["H1N1", "PROBLEM", 464, 468], ["the pandemic", "PROBLEM", 476, 488]]], ["The POD designation may be a significant factor in readying schools for disasters or pandemics, because it requires that the school be actively engaged in local or regional disaster planning efforts.", [["disasters", "PROBLEM", 72, 81], ["pandemics", "PROBLEM", 85, 94]]], ["This involvement likely influences the school in preparing for future disasters and may provide additional guidance to the school on disaster planning efforts, such as plan development and testing, through interaction with regional emergency managers/experts.DiscussionSchools with better disaster and pandemic preparedness scores were also more likely to have had a lead nurse or a school nurse involved in the school disaster planning committee complete the survey compared with schools that had a non-lead nurse or a nurse not on the disaster planning committee participate in the study.", [["testing", "TEST", 189, 196], ["the study", "TEST", 580, 589]]], ["School nurses are the health professionals responsible for implementing policies and programs to prevent infection transmission in schools,28 and thus are those best able to inform school disaster planning committees on aspects of plan development that will affect infection transmission.", [["infection", "DISEASE", 105, 114], ["infection", "DISEASE", 265, 274], ["infection transmission", "PROBLEM", 265, 287]]], ["In addition, the National Association of School Nurses recommends that school nurses be involved in school disaster preparedness activities.29 School nurses may require additional training in pandemic planning to feel comfortable in this role.", [["additional training", "TREATMENT", 169, 188]]], ["Future research should evaluate competencies for school nurses related to pandemic planning and assess school nurses' current comfort and ability related to performing in this crucial role.DiscussionSimilar to previous research,30 this study found that many school nurses have access to and are receiving the seasonal influenza vaccine.", [["influenza", "DISEASE", 318, 327], ["pandemic planning", "TREATMENT", 74, 91], ["this study", "TEST", 231, 241], ["the seasonal influenza vaccine", "TREATMENT", 305, 335]]], ["Although three-quarters of the school nurses in this study reported receiving the seasonal influenza vaccine during the 2010-11 season, the uptake rate remains well below the target of 90% compliance outlined in Healthy People 2020.31 It is essential that school districts work to increase influenza vaccine uptake among school nurses, because this will likely result in decreased influenza-related morbidity and mortality.", [["influenza", "DISEASE", 91, 100], ["influenza", "DISEASE", 290, 299], ["influenza", "DISEASE", 381, 390], ["People", "SPECIES", 220, 226], ["this study", "TEST", 48, 58], ["the seasonal influenza vaccine", "TREATMENT", 78, 108], ["the uptake rate", "TEST", 136, 151], ["decreased influenza", "PROBLEM", 371, 390], ["decreased", "OBSERVATION_MODIFIER", 371, 380], ["influenza", "OBSERVATION", 381, 390]]], ["One factor that may be influencing school nurse influenza vaccine uptake is the low prevalence of mandatory vaccine policies reported by the school nurses in this study.", [["influenza", "DISEASE", 48, 57], ["this study", "TEST", 158, 168], ["may be", "UNCERTAINTY", 16, 22]]], ["Previous research indicates that approximately 12% of nonhospital agencies have a mandatory vaccination policy,30, 32, 33 yet only approximately 2% of the school nurses in this study reported having such a policy.", [["this study", "TEST", 172, 182]]], ["Mandatory vaccination policies have been found to be very strong predictors of vaccine uptake,30 and multiple organizations, including the CDC34 and the Society for Healthcare Epidemiology of America,35 recommend that all health care workers be vaccinated against influenza every year.", [["influenza", "DISEASE", 264, 273], ["influenza", "PROBLEM", 264, 273]]], ["School administrators should consider implementing a seasonal influenza vaccination policy for nurses that is a condition of employment.35 School districts also should create a system to track nurses' seasonal influenza vaccine compliance, a recommendation made by the CDC for US health care agencies.36, 37 This will facilitate vaccine compliance during a disaster or pandemic, which should decrease event-related morbidity and mortality.", [["influenza", "DISEASE", 210, 219], ["a seasonal influenza vaccination policy", "TREATMENT", 51, 90], ["seasonal influenza vaccine compliance", "TREATMENT", 201, 238], ["vaccine compliance", "TREATMENT", 329, 347], ["pandemic", "PROBLEM", 369, 377]]], ["It also may be prudent for schools to mandate seasonal influenza vaccination for teachers and other staff who have close contact with students.", [["influenza", "DISEASE", 55, 64], ["seasonal influenza vaccination", "TREATMENT", 46, 76]]], ["Influenza can readily spread within schools when staff and students are in close proximity to each other; vaccination of key staff would decrease infection transmission.DiscussionThis study has several notable strengths.", [["Influenza", "DISEASE", 0, 9], ["infection", "DISEASE", 146, 155], ["Influenza", "PROBLEM", 0, 9], ["decrease infection transmission", "PROBLEM", 137, 168], ["This study", "TEST", 179, 189], ["infection", "OBSERVATION", 146, 155]]], ["None of the limited studies available on school-wide disaster response examined pandemic planning.", [["the limited studies", "TEST", 8, 27], ["pandemic planning", "TREATMENT", 80, 97]]], ["This is the first study to examine school pandemic preparedness.", [["the first study", "TEST", 8, 23]]], ["The use of a national sample increases the generalizability of our findings.", [["a national sample", "TREATMENT", 11, 28]]], ["Several limitations of this study must be noted.", [["this study", "TEST", 23, 33]]], ["One limitation is the potential issue of nonresponder bias.", [["nonresponder bias", "PROBLEM", 41, 58], ["nonresponder bias", "OBSERVATION", 41, 58]]], ["Very few nurses who work with college or university students participated in this study; thus, the findings may not be generalizable to institutions of higher learning.", [["this study", "TEST", 77, 87]]], ["There was a low response rate in some states, namely those states that posted a link about the study rather than sending an e-mail recruitment letter to their members.", [["a low response rate", "PROBLEM", 10, 29], ["the study", "TEST", 91, 100], ["low response", "OBSERVATION_MODIFIER", 12, 24]]], ["This low response rate may reflect school nurses' unawareness of the study, a selection bias, or some other bias.", [["the study", "TEST", 65, 74], ["a selection bias", "TEST", 76, 92]]], ["In addition, because only US school nurses were invited to participate in this study, the findings might not be generalizable to school preparedness in other countries.", [["this study", "TEST", 74, 84]]], ["Despite these limitations, this study provides a foundation for future work examining school pandemic preparedness.ConclusionSchool preparedness for disasters and infectious disease emergencies is essential, yet many schools are lacking in adequate plans.", [["infectious disease emergencies", "DISEASE", 163, 193], ["this study", "TEST", 27, 37], ["disasters", "PROBLEM", 149, 158]]], ["US schools must continue to address gaps in infectious disease emergency planning, including developing better plans, coordinating these plans with local and regional disaster response agency plans, and testing the plans through disaster drills and exercises.", [["infectious", "OBSERVATION_MODIFIER", 44, 54]]], ["Whenever possible, school nurses should be involved in these planning efforts, because health care professionals can best inform school administrators about unique aspects of pandemic planning that need to be included in school disaster plans.", [["pandemic planning", "TREATMENT", 175, 192]]]], "45b4b6a49cc3373b0f67b014910073336dbca667": [["INTRODUCTIONTransposable elements comprise at least 45 and 37.5% of the human and mouse genomes, respectively (1, 2) .", [["human", "ORGANISM", 72, 77], ["mouse", "ORGANISM", 82, 87], ["INTRODUCTIONTransposable elements", "DNA", 0, 33], ["human and mouse genomes", "DNA", 72, 95], ["human", "SPECIES", 72, 77], ["mouse", "SPECIES", 82, 87], ["human", "SPECIES", 72, 77], ["mouse", "SPECIES", 82, 87]]], ["They are classified by whether they replicate via a DNA (transposons) or an RNA intermediate (retrotransposons) [reviewed in (3) ].", [["DNA", "CELLULAR_COMPONENT", 52, 55], ["transposons", "CELLULAR_COMPONENT", 57, 68], ["transposons", "DNA", 57, 68], ["RNA intermediate", "RNA", 76, 92], ["retrotransposons", "DNA", 94, 110], ["a DNA (transposons", "TREATMENT", 50, 68]]], ["DNA transposons originally were discovered in maize as mutable loci capable of mobilizing to new genomic locations (3, 4) .", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA transposons", "DNA", 0, 15], ["maize", "SPECIES", 46, 51], ["DNA transposons", "PROBLEM", 0, 15], ["mobilizing", "OBSERVATION_MODIFIER", 79, 89], ["new", "OBSERVATION_MODIFIER", 93, 96]]], ["DNA transposons comprise $3% of the human genome (1) and were active during primate evolution until $37 million years ago (5) .", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["human", "ORGANISM", 36, 41], ["DNA transposons", "DNA", 0, 15], ["human genome", "DNA", 36, 48], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["human genome", "ANATOMY", 36, 48], ["active", "OBSERVATION_MODIFIER", 62, 68]]], ["However, with the exception of certain bat species (6) , DNA transposons appear to be inactive in most mammalian genomes (1) .INTRODUCTIONUnlike the 'cut-and-paste' mobility mechanism used by DNA transposons, retrotransposons mobilize via a 'copyand-paste' mechanism that uses an RNA intermediate [reviewed in (7) ].", [["DNA", "CELLULAR_COMPONENT", 57, 60], ["DNA", "CELLULAR_COMPONENT", 192, 195], ["retrotransposons", "CELLULAR_COMPONENT", 209, 225], ["DNA transposons", "DNA", 57, 72], ["mammalian genomes", "DNA", 103, 120], ["DNA transposons", "DNA", 192, 207], ["retrotransposons", "DNA", 209, 225], ["certain bat species", "PROBLEM", 31, 50], ["DNA transposons", "PROBLEM", 57, 72], ["the 'cut-and-paste' mobility mechanism", "TREATMENT", 145, 183], ["a 'copyand-paste' mechanism", "TREATMENT", 239, 266], ["inactive", "OBSERVATION", 86, 94]]], ["There are two major groups of retrotransposons that are distinguishable by the presence or absence of long terminal repeats (LTRs).", [["long terminal repeats", "ANATOMY", 102, 123], ["long terminal repeats", "CELLULAR_COMPONENT", 102, 123], ["LTRs", "CELLULAR_COMPONENT", 125, 129], ["retrotransposons", "DNA", 30, 46], ["long terminal repeats", "DNA", 102, 123], ["LTRs", "DNA", 125, 129], ["long terminal repeats (LTRs", "PROBLEM", 102, 129], ["two", "OBSERVATION_MODIFIER", 10, 13], ["major", "OBSERVATION_MODIFIER", 14, 19], ["retrotransposons", "OBSERVATION", 30, 46]]], ["LTR-retrotransposons include human endogenous retroviruses (HERVs) as well as murine intracisternal A-particle (IAP) and MusD sequences [reviewed in (8) (9) (10) ].", [["LTR", "CELLULAR_COMPONENT", 0, 3], ["human endogenous retroviruses", "ORGANISM", 29, 58], ["HERVs", "GENE_OR_GENE_PRODUCT", 60, 65], ["murine", "ORGANISM", 78, 84], ["intracisternal A-particle", "GENE_OR_GENE_PRODUCT", 85, 110], ["IAP", "GENE_OR_GENE_PRODUCT", 112, 115], ["LTR", "DNA", 0, 3], ["retrotransposons", "DNA", 4, 20], ["HERVs", "DNA", 60, 65], ["murine intracisternal A-particle (IAP) and MusD sequences", "DNA", 78, 135], ["human", "SPECIES", 29, 34], ["murine", "SPECIES", 78, 84], ["human", "SPECIES", 29, 34], ["human endogenous retroviruses (HERVs)", "TREATMENT", 29, 66], ["murine intracisternal A-particle (IAP)", "TREATMENT", 78, 116], ["MusD sequences", "TEST", 121, 135], ["retrotransposons", "OBSERVATION", 4, 20], ["endogenous retroviruses", "OBSERVATION", 35, 58]]], ["Endogenous LTRretrotransposons are structurally similar to retroviruses, but generally lack or contain a defective envelope (env) gene, which relegates them to intracellular replication [reviewed in (11) ].", [["intracellular", "ANATOMY", 160, 173], ["LTRretrotransposons", "GENE_OR_GENE_PRODUCT", 11, 30], ["retroviruses", "ORGANISM", 59, 71], ["env", "GENE_OR_GENE_PRODUCT", 125, 128], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 160, 173], ["LTRretrotransposons", "PROTEIN", 11, 30], ["defective envelope (env) gene", "DNA", 105, 134], ["Endogenous LTRretrotransposons", "PROBLEM", 0, 30], ["a defective envelope", "PROBLEM", 103, 123], ["retroviruses", "OBSERVATION", 59, 71]]], ["While HERVs appear to be inactive in the human genome, it is estimated that $300 copies of IAP and 10 copies of MusD remain functional in the mouse genome (12) (13) (14) .INTRODUCTIONNon-LTR retrotransposons, including Long INterspersed Element-1 (LINE-1 or L1) and the Small INterspersed Elements (SINEs), account for about one-third of human genomic DNA (1) .", [["HERVs", "GENE_OR_GENE_PRODUCT", 6, 11], ["human", "ORGANISM", 41, 46], ["IAP", "GENE_OR_GENE_PRODUCT", 91, 94], ["MusD", "GENE_OR_GENE_PRODUCT", 112, 116], ["mouse", "ORGANISM", 142, 147], ["Long INterspersed Element-1", "GENE_OR_GENE_PRODUCT", 219, 246], ["LINE-1", "GENE_OR_GENE_PRODUCT", 248, 254], ["human", "ORGANISM", 338, 343], ["DNA", "CELLULAR_COMPONENT", 352, 355], ["HERVs", "PROTEIN", 6, 11], ["human genome", "DNA", 41, 53], ["IAP", "DNA", 91, 94], ["MusD", "DNA", 112, 116], ["mouse genome", "DNA", 142, 154], ["INTRODUCTIONNon-LTR retrotransposons", "DNA", 171, 207], ["Long INterspersed Element-1", "DNA", 219, 246], ["LINE", "DNA", 248, 252], ["L1", "DNA", 258, 260], ["Small INterspersed Elements", "DNA", 270, 297], ["SINEs", "DNA", 299, 304], ["human genomic DNA", "DNA", 338, 355], ["human", "SPECIES", 41, 46], ["mouse", "SPECIES", 142, 147], ["human", "SPECIES", 338, 343], ["human", "SPECIES", 41, 46], ["mouse", "SPECIES", 142, 147], ["human", "SPECIES", 338, 343], ["IAP", "TEST", 91, 94], ["LTR retrotransposons", "TREATMENT", 187, 207], ["Long INterspersed Element", "PROBLEM", 219, 244], ["appear to be", "UNCERTAINTY", 12, 24], ["inactive", "OBSERVATION", 25, 33], ["LTR retrotransposons", "OBSERVATION", 187, 207], ["L1", "ANATOMY", 258, 260], ["Small", "OBSERVATION_MODIFIER", 270, 275]]], ["L1 elements are the only class of autonomously active human retrotransposons [reviewed in (10) ].", [["human", "ORGANISM", 54, 59], ["L1 elements", "DNA", 0, 11], ["human retrotransposons", "DNA", 54, 76], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59]]], ["The L1-encoded proteins (ORF1p and/or ORF2p) can also mobilize certain SINEs (e.g. Alu and SVA elements) (10, (15) (16) (17) .", [["ORF1p", "GENE_OR_GENE_PRODUCT", 25, 30], ["ORF2p", "GENE_OR_GENE_PRODUCT", 38, 43], ["SINEs", "CELLULAR_COMPONENT", 71, 76], ["Alu", "CELLULAR_COMPONENT", 83, 86], ["L1-encoded proteins", "PROTEIN", 4, 23], ["ORF1p", "PROTEIN", 25, 30], ["/", "PROTEIN", 34, 35], ["ORF2p", "PROTEIN", 38, 43], ["SINEs", "DNA", 71, 76], ["Alu", "DNA", 83, 86], ["SVA elements", "DNA", 91, 103], ["L1", "ANATOMY", 4, 6]]], ["Importantly, L1-mediated retrotransposition events continue to cause insertional mutagenesis and genetic disorders in humans [reviewed in (18) ].INTRODUCTIONHuman L1 sequences represent $17% of human genomic DNA (1) .", [["genetic disorders", "DISEASE", 97, 114], ["L1", "GENE_OR_GENE_PRODUCT", 13, 15], ["humans", "ORGANISM", 118, 124], ["human", "ORGANISM", 194, 199], ["DNA", "CELLULAR_COMPONENT", 208, 211], ["L1", "DNA", 13, 15], ["INTRODUCTIONHuman L1 sequences", "DNA", 145, 175], ["human genomic DNA", "DNA", 194, 211], ["humans", "SPECIES", 118, 124], ["human", "SPECIES", 194, 199], ["humans", "SPECIES", 118, 124], ["human", "SPECIES", 194, 199], ["L1-mediated retrotransposition events", "PROBLEM", 13, 50], ["insertional mutagenesis", "PROBLEM", 69, 92], ["genetic disorders in humans", "PROBLEM", 97, 124], ["human genomic DNA", "TREATMENT", 194, 211], ["L1", "ANATOMY", 13, 15], ["retrotransposition", "OBSERVATION", 25, 43]]], ["While the vast majority of L1s are molecular fossils incapable of retrotransposition, it is estimated that $80-100 L1s remain retrotranspositioncompetent (19, 20) .", [["L1s", "CELL", 27, 30], ["L1s", "DNA", 27, 30], ["fossils", "OBSERVATION", 45, 52], ["retrotransposition", "OBSERVATION", 66, 84]]], ["Full-length human L1s are $6 kb in length (21, 22) .", [["human", "ORGANISM", 12, 17], ["L1s", "CELL", 18, 21], ["human L1s", "DNA", 12, 21], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17]]], ["They contain an internal sense-strand promoter (SP) located within their 5 0 -untranslated region (UTR) (23) (24) (25) (26) (27) .", [["internal sense-strand promoter", "DNA", 16, 46], ["SP", "DNA", 48, 50], ["5 0 -untranslated region", "DNA", 73, 97], ["UTR", "DNA", 99, 102], ["internal", "OBSERVATION_MODIFIER", 16, 24], ["strand promoter", "OBSERVATION", 31, 46]]], ["Transcription generates a bicistronic mRNA that consists of the L1 5 0 -UTR, two open reading frames (ORF1 and ORF2) and a 3 0 -UTR that ends in a poly (A) tail (21, 22) .", [["ORF2", "GENE_OR_GENE_PRODUCT", 111, 115], ["bicistronic mRNA", "RNA", 26, 42], ["L1 5 0 -UTR", "DNA", 64, 75], ["open reading frames", "DNA", 81, 100], ["ORF1", "DNA", 102, 106], ["ORF2", "DNA", 111, 115], ["3 0 -UTR", "DNA", 123, 131], ["poly (A) tail", "DNA", 147, 160], ["a bicistronic mRNA", "PROBLEM", 24, 42], ["ORF1", "TEST", 102, 106], ["ORF2", "TEST", 111, 115], ["a 3 0 -UTR", "TREATMENT", 121, 131], ["bicistronic mRNA", "OBSERVATION", 26, 42], ["L1", "ANATOMY", 64, 66], ["poly", "ANATOMY_MODIFIER", 147, 151], ["tail", "ANATOMY", 156, 160]]], ["The L1 5 0 -UTR also contains an antisense promoter (ASP), which drives the production of an RNA containing a region of the 5 0 -UTR conjoined to an mRNA sequence derived from genomic sequences located upstream of the L1 integration site (28) [see pJM101/L1.3 gene map in Figure 1A (top)].INTRODUCTIONHuman ORF1 encodes an $40 kDa RNA binding protein (ORF1p) with nucleic acid chaperone activity (29) (30) (31) .", [["nucleic acid", "CHEMICAL", 364, 376], ["ASP", "GENE_OR_GENE_PRODUCT", 53, 56], ["ORF1p", "GENE_OR_GENE_PRODUCT", 352, 357], ["L1 5 0 -UTR", "DNA", 4, 15], ["antisense promoter", "DNA", 33, 51], ["ASP", "DNA", 53, 56], ["5 0 -UTR", "DNA", 124, 132], ["mRNA sequence", "DNA", 149, 162], ["genomic sequences", "DNA", 176, 193], ["L1 integration site", "DNA", 218, 237], ["pJM101", "DNA", 248, 254], ["L1.3 gene map", "DNA", 255, 268], ["Figure 1A", "DNA", 272, 281], ["ORF1", "DNA", 307, 311], ["$40 kDa RNA binding protein", "PROTEIN", 323, 350], ["ORF1p", "PROTEIN", 352, 357], ["an antisense promoter (ASP)", "PROBLEM", 30, 57], ["an RNA", "PROBLEM", 90, 96], ["an mRNA sequence", "TEST", 146, 162], ["pJM101", "TEST", 248, 254], ["RNA binding protein", "TEST", 331, 350], ["nucleic acid chaperone activity", "TEST", 364, 395], ["L1", "ANATOMY", 4, 6], ["antisense promoter", "OBSERVATION", 33, 51], ["RNA", "OBSERVATION", 93, 96], ["L1", "ANATOMY", 218, 220]]], ["ORF2 encodes an $150 kDa protein (ORF2p) that contains both endonuclease (32) and reverse transcriptase (33) activities.", [["ORF2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ORF2p", "GENE_OR_GENE_PRODUCT", 34, 39], ["ORF2", "DNA", 0, 4], ["$150 kDa protein", "PROTEIN", 16, 32], ["ORF2p", "PROTEIN", 34, 39], ["endonuclease", "PROTEIN", 60, 72], ["reverse transcriptase", "PROTEIN", 82, 103], ["an $150 kDa protein (ORF2p)", "TREATMENT", 13, 40], ["reverse transcriptase", "TREATMENT", 82, 103]]], ["ORF1p and ORF2p preferentially bind to their encoding L1 mRNA by a process termed cis-preference (34) (35) (36) , which leads to the formation of an L1 ribonucleoprotein particle (RNP) (30, 37, 38) .", [["ORF1p", "GENE_OR_GENE_PRODUCT", 0, 5], ["ORF2p", "GENE_OR_GENE_PRODUCT", 10, 15], ["RNP", "CELLULAR_COMPONENT", 180, 183], ["ORF1p", "PROTEIN", 0, 5], ["ORF2p", "PROTEIN", 10, 15], ["L1 mRNA", "RNA", 54, 61], ["L1 ribonucleoprotein particle", "PROTEIN", 149, 178], ["RNP", "PROTEIN", 180, 183], ["ORF2p", "TREATMENT", 10, 15], ["L1", "ANATOMY", 54, 56], ["L1", "ANATOMY", 149, 151], ["ribonucleoprotein particle", "OBSERVATION", 152, 178]]], ["The resultant L1 RNPs are transported into the nucleus, where L1 integration is completed by target-site primed reverse transcription (32, 39, 40) .", [["nucleus", "ANATOMY", 47, 54], ["nucleus", "CELLULAR_COMPONENT", 47, 54], ["L1", "CELLULAR_COMPONENT", 62, 64], ["L1 RNPs", "PROTEIN", 14, 21], ["L1", "DNA", 62, 64], ["target-site", "DNA", 93, 104], ["The resultant L1 RNPs", "TREATMENT", 0, 21], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["L1 RNPs", "OBSERVATION", 14, 21], ["nucleus", "ANATOMY", 47, 54], ["L1", "ANATOMY", 62, 64]]], ["The activities associated with ORF1p and ORF2p are both required for efficient L1 retrotransposition (41) .INTRODUCTIONL1 retrotransposition can lead to local genomic rearrangements (e.g. deletions and inversions) at their integration sites [reviewed in (10) ].", [["ORF1p", "GENE_OR_GENE_PRODUCT", 31, 36], ["ORF2p", "GENE_OR_GENE_PRODUCT", 41, 46], ["ORF1p", "PROTEIN", 31, 36], ["ORF2p", "PROTEIN", 41, 46], ["ORF1p and ORF2p", "TREATMENT", 31, 46], ["efficient L1 retrotransposition", "TREATMENT", 69, 100], ["retrotransposition", "TREATMENT", 122, 140], ["local genomic rearrangements", "PROBLEM", 153, 181]]], ["Moreover, L1 retrotransposition events may influence the expression of genes near the integration sites [reviewed in (10) ].", [["L1", "DNA", 10, 12], ["integration sites", "DNA", 86, 103], ["L1 retrotransposition events", "PROBLEM", 10, 38], ["L1", "ANATOMY", 10, 12], ["retrotransposition", "OBSERVATION", 13, 31]]], ["Thus far, 96 L1-mediated retrotransposition events have been reported to be responsible for a wide range of single-gene diseases in humans [reviewed in (18) ].", [["humans", "ORGANISM", 132, 138], ["L1", "DNA", 13, 15], ["humans", "SPECIES", 132, 138], ["humans", "SPECIES", 132, 138], ["single-gene diseases in humans", "PROBLEM", 108, 138]]], ["In addition, ORF2p may generate double-strand breaks in genomic DNA, which have the potential to be mutagenic (42, 43) .INTRODUCTIONThe host cell has evolved various strategies to regulate retrotransposon activity at both the transcriptional and posttranscriptional levels [reviewed in (7) ].", [["cell", "ANATOMY", 141, 145], ["ORF2p", "GENE_OR_GENE_PRODUCT", 13, 18], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["host cell", "CELL", 136, 145], ["ORF2p", "PROTEIN", 13, 18], ["genomic DNA", "DNA", 56, 67], ["retrotransposon", "DNA", 189, 204], ["ORF2p", "TREATMENT", 13, 18], ["double-strand breaks in genomic DNA", "PROBLEM", 32, 67], ["strand breaks", "OBSERVATION", 39, 52], ["host cell", "OBSERVATION", 136, 145], ["retrotransposon activity", "OBSERVATION", 189, 213]]], ["For example, retrotransposon-derived Piwi interacting RNAs, in conjunction with Piwi proteins, can degrade L1 and other transposable element transcripts in the germ line of mice and flies, and they are thought to be involved in the epigenetic silencing of retrotransposons via promoter methylation in murine embryonic male germ cells [reviewed in (44, 45) ].", [["germ line", "ANATOMY", 160, 169], ["embryonic male germ cells", "ANATOMY", 308, 333], ["retrotransposon", "CELLULAR_COMPONENT", 13, 28], ["Piwi", "GENE_OR_GENE_PRODUCT", 37, 41], ["Piwi", "GENE_OR_GENE_PRODUCT", 80, 84], ["L1", "GENE_OR_GENE_PRODUCT", 107, 109], ["germ line", "CELL", 160, 169], ["mice", "ORGANISM", 173, 177], ["retrotransposons", "CELLULAR_COMPONENT", 256, 272], ["murine", "ORGANISM", 301, 307], ["embryonic male germ cells", "CELL", 308, 333], ["retrotransposon", "DNA", 13, 28], ["Piwi interacting RNAs", "RNA", 37, 58], ["Piwi proteins", "PROTEIN", 80, 93], ["L1", "DNA", 107, 109], ["transposable element transcripts", "RNA", 120, 152], ["retrotransposons", "DNA", 256, 272], ["murine embryonic male germ cells", "CELL_TYPE", 301, 333], ["mice", "SPECIES", 173, 177], ["murine", "SPECIES", 301, 307], ["mice", "SPECIES", 173, 177], ["Piwi interacting RNAs", "PROBLEM", 37, 58], ["Piwi proteins", "PROBLEM", 80, 93], ["promoter methylation in murine embryonic male germ cells", "TREATMENT", 277, 333], ["interacting RNAs", "OBSERVATION", 42, 58], ["transposable element transcripts", "OBSERVATION", 120, 152], ["germ line", "OBSERVATION", 160, 169], ["germ cells", "OBSERVATION", 323, 333]]], ["It also is proposed that hybridization of the L1 sense and antisense transcripts may serve as double-strand RNA triggers for Dicer-dependent RNA interference mediated regulation of L1 retrotransposition (46) , although this supposition requires further study.", [["Dicer", "GENE_OR_GENE_PRODUCT", 125, 130], ["L1 sense and antisense transcripts", "RNA", 46, 80], ["Dicer", "PROTEIN", 125, 130], ["hybridization of the L1 sense", "TREATMENT", 25, 54], ["antisense transcripts", "TREATMENT", 59, 80], ["double-strand RNA triggers", "TREATMENT", 94, 120], ["Dicer-dependent RNA interference mediated regulation of L1 retrotransposition", "TREATMENT", 125, 202], ["further study", "TEST", 245, 258], ["L1", "ANATOMY", 181, 183]]], ["Besides these small RNA-based inhibition pathways, L1 retrotransposition can be inhibited by several proteins, including the apolipoprotein B mRNA editing enzyme 3 (APOBEC3) family of cytidine deaminases [reviewed in (47) ], Trex1 (48) and MOV10 (49) (50) (51) .", [["cytidine", "CHEMICAL", 184, 192], ["cytidine", "CHEMICAL", 184, 192], ["apolipoprotein B mRNA editing enzyme 3", "GENE_OR_GENE_PRODUCT", 125, 163], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 165, 172], ["cytidine deaminases", "SIMPLE_CHEMICAL", 184, 203], ["(47) ]", "SIMPLE_CHEMICAL", 217, 223], ["L1", "DNA", 51, 53], ["apolipoprotein B mRNA editing enzyme 3 (APOBEC3) family", "PROTEIN", 125, 180], ["cytidine deaminases", "PROTEIN", 184, 203], ["these small RNA-based inhibition pathways", "PROBLEM", 8, 49], ["L1 retrotransposition", "PROBLEM", 51, 72], ["several proteins", "PROBLEM", 93, 109], ["the apolipoprotein B mRNA editing enzyme", "TEST", 121, 161], ["cytidine deaminases", "TEST", 184, 203], ["Trex1", "TEST", 225, 230], ["MOV10", "TEST", 240, 245], ["small", "OBSERVATION_MODIFIER", 14, 19], ["RNA", "OBSERVATION", 20, 23], ["L1", "ANATOMY", 51, 53]]], ["Recent evidence also suggests the ataxia telangiectasia mutated protein may limit the length and/or number of engineered L1 retrotransposition events in cultured cells (52) .", [["cells", "ANATOMY", 162, 167], ["ataxia telangiectasia", "DISEASE", 34, 55], ["cells", "CELL", 162, 167], ["ataxia telangiectasia mutated protein", "PROTEIN", 34, 71], ["cultured cells", "CELL_LINE", 153, 167], ["the ataxia telangiectasia mutated protein", "PROBLEM", 30, 71], ["engineered L1 retrotransposition events", "PROBLEM", 110, 149], ["cultured cells", "TEST", 153, 167], ["ataxia", "OBSERVATION_MODIFIER", 34, 40], ["telangiectasia", "OBSERVATION", 41, 55], ["L1 retrotransposition", "OBSERVATION", 121, 142]]], ["In addition, heterogeneous nuclear ribonucleoprotein L (hnRNPL) binds L1 RNA and interferes with L1 retrotransposition (53, 54) .", [["heterogeneous nuclear ribonucleoprotein L", "GENE_OR_GENE_PRODUCT", 13, 54], ["hnRNPL", "GENE_OR_GENE_PRODUCT", 56, 62], ["heterogeneous nuclear ribonucleoprotein L", "PROTEIN", 13, 54], ["hnRNPL", "PROTEIN", 56, 62], ["L1 RNA", "RNA", 70, 76], ["L1 retrotransposition", "DNA", 97, 118], ["heterogeneous nuclear ribonucleoprotein L (hnRNPL) binds L1 RNA", "PROBLEM", 13, 76], ["L1 retrotransposition", "TREATMENT", 97, 118], ["heterogeneous", "OBSERVATION_MODIFIER", 13, 26], ["nuclear", "OBSERVATION_MODIFIER", 27, 34], ["ribonucleoprotein L", "OBSERVATION", 35, 54], ["L1 RNA", "ANATOMY", 70, 76], ["L1", "ANATOMY_MODIFIER", 97, 99]]], ["HnRNPL and several other cellular inhibitors of L1 retrotransposition were also identified in the L1 ORF1 protein interactome (54) .", [["cellular", "ANATOMY", 25, 33], ["HnRNPL", "CHEMICAL", 0, 6], ["HnRNPL", "GENE_OR_GENE_PRODUCT", 0, 6], ["cellular", "CELL", 25, 33], ["L1", "GENE_OR_GENE_PRODUCT", 48, 50], ["L1", "DNA", 48, 50], ["L1 ORF1 protein", "PROTEIN", 98, 113], ["HnRNPL", "TREATMENT", 0, 6], ["several other cellular inhibitors of L1 retrotransposition", "TREATMENT", 11, 69], ["cellular inhibitors", "OBSERVATION", 25, 44], ["L1 retrotransposition", "OBSERVATION", 48, 69], ["L1", "ANATOMY_MODIFIER", 98, 100]]], ["In contrast, the poly(A) binding protein C1 was recently shown to promote L1 retrotransposition (55) .INTRODUCTIONThe interferon (IFN) regulated 2 0 ,5 0 -oligoadenylate (2-5A) synthetase (OAS)-RNase L system inhibits viral replication, but it is unclear whether it restricts retrotransposon activity [reviewed in (56) ].", [["poly(A", "CHEMICAL", 17, 23], ["poly(A)", "CHEMICAL", 17, 24], ["poly(A) binding protein C1", "GENE_OR_GENE_PRODUCT", 17, 43], ["interferon", "GENE_OR_GENE_PRODUCT", 118, 128], ["IFN", "GENE_OR_GENE_PRODUCT", 130, 133], ["2 0 ,5 0 -oligoadenylate", "SIMPLE_CHEMICAL", 145, 169], ["2-5A) synthetase", "GENE_OR_GENE_PRODUCT", 171, 187], ["RNase L", "GENE_OR_GENE_PRODUCT", 194, 201], ["poly(A) binding protein C1", "PROTEIN", 17, 43], ["interferon (IFN) regulated 2 0 ,5 0 -oligoadenylate (2-5A) synthetase", "PROTEIN", 118, 187], ["OAS", "PROTEIN", 189, 192], ["RNase L", "PROTEIN", 194, 201], ["retrotransposon", "DNA", 276, 291], ["the poly(A) binding protein C1", "PROBLEM", 13, 43], ["INTRODUCTIONThe interferon (IFN)", "TREATMENT", 102, 134], ["synthetase (OAS)", "TREATMENT", 177, 193], ["RNase L system", "TREATMENT", 194, 208], ["viral replication", "PROBLEM", 218, 235], ["L1 retrotransposition", "OBSERVATION", 74, 95], ["viral replication", "OBSERVATION", 218, 235]]], ["The OAS genes encode IFN inducible enzymes that are expressed at basal levels in many mammalian cell types (57) .", [["cell", "ANATOMY", 96, 100], ["IFN inducible enzymes", "GENE_OR_GENE_PRODUCT", 21, 42], ["mammalian cell", "CELL", 86, 100], ["OAS genes", "DNA", 4, 13], ["IFN inducible enzymes", "PROTEIN", 21, 42], ["The OAS genes encode IFN inducible enzymes", "PROBLEM", 0, 42], ["mammalian cell types", "OBSERVATION", 86, 106]]], ["Viral dsRNAs activate OAS-1, -2 and -3, which use ATP to generate 2-5A molecules with the following structures: [p x 5 0 A(2 0 p5 0 A) n ; x = 1-3; n ! 2] (58).", [["ATP", "CHEMICAL", 50, 53], ["ATP", "CHEMICAL", 50, 53], ["OAS-1", "GENE_OR_GENE_PRODUCT", 22, 27], ["-2", "GENE_OR_GENE_PRODUCT", 29, 31], ["-3", "GENE_OR_GENE_PRODUCT", 36, 38], ["ATP", "SIMPLE_CHEMICAL", 50, 53], ["Viral dsRNAs", "DNA", 0, 12], ["OAS-1, -2 and -3", "DNA", 22, 38], ["Viral dsRNAs activate OAS", "TEST", 0, 25], ["ATP", "TEST", 50, 53]]], ["The 2-5A then binds to the ankyrin repeat domain of latent RNase L, causing it to form an enzymatically active dimer (59) .", [["2-5A", "SIMPLE_CHEMICAL", 4, 8], ["ankyrin", "GENE_OR_GENE_PRODUCT", 27, 34], ["latent RNase L", "GENE_OR_GENE_PRODUCT", 52, 66], ["ankyrin repeat domain", "PROTEIN", 27, 48], ["latent RNase L", "PROTEIN", 52, 66], ["latent RNase L", "PROBLEM", 52, 66], ["active dimer", "OBSERVATION", 104, 116]]], ["Active RNase L cleaves single-strand regions of viral and cellular RNA, suppressing viral protein synthesis, replication and spread [reviewed in (56) ].", [["cellular", "ANATOMY", 58, 66], ["RNase L", "GENE_OR_GENE_PRODUCT", 7, 14], ["cellular", "CELL", 58, 66], ["RNase L", "PROTEIN", 7, 14], ["single-strand regions", "DNA", 23, 44], ["viral and cellular RNA", "RNA", 48, 70], ["Active RNase L cleaves", "PROBLEM", 0, 22], ["viral and cellular RNA", "PROBLEM", 48, 70], ["suppressing viral protein synthesis", "PROBLEM", 72, 107], ["viral", "OBSERVATION", 48, 53], ["cellular RNA", "OBSERVATION", 58, 70]]], ["Moreover, cleavage products generated by RNase L, mostly short duplex RNAs with 3 0 -phosphoryl groups, can bind and activate the RIG-I and MDA5 helicases (60) .", [["3 0 -phosphoryl", "CHEMICAL", 80, 95], ["3 0 -phosphoryl", "CHEMICAL", 80, 95], ["RNase L", "GENE_OR_GENE_PRODUCT", 41, 48], ["RIG-I", "GENE_OR_GENE_PRODUCT", 130, 135], ["MDA5", "GENE_OR_GENE_PRODUCT", 140, 144], ["cleavage products", "PROTEIN", 10, 27], ["RNase L", "PROTEIN", 41, 48], ["RIG-I and MDA5 helicases", "PROTEIN", 130, 154], ["cleavage products", "TREATMENT", 10, 27], ["mostly short duplex RNAs", "PROBLEM", 50, 74], ["3 0 -phosphoryl groups", "TREATMENT", 80, 102]]], ["Interaction of these helicases with the mitochondrial adapter MAVS then results in a signaling cascade, allowing type I IFN production (60) .", [["mitochondrial", "ANATOMY", 40, 53], ["mitochondrial", "CELLULAR_COMPONENT", 40, 53], ["MAVS", "GENE_OR_GENE_PRODUCT", 62, 66], ["type I IFN", "GENE_OR_GENE_PRODUCT", 113, 123], ["mitochondrial adapter MAVS", "PROTEIN", 40, 66], ["IFN", "PROTEIN", 120, 123], ["a signaling cascade", "PROBLEM", 83, 102], ["type I IFN production", "PROBLEM", 113, 134]]], ["The prolonged activation of RNase L results in cell death through apoptosis, leading to the elimination of virusinfected cells (61) (62) (63) .INTRODUCTIONThe antiviral activity of the OAS-RNase L pathway combats the infectivity of numerous RNA and DNA viruses [reviewed in (56) ].", [["cell", "ANATOMY", 47, 51], ["cells", "ANATOMY", 121, 126], ["death", "DISEASE", 52, 57], ["RNase L", "GENE_OR_GENE_PRODUCT", 28, 35], ["cell", "CELL", 47, 51], ["cells", "CELL", 121, 126], ["OAS-RNase L", "GENE_OR_GENE_PRODUCT", 185, 196], ["DNA", "CELLULAR_COMPONENT", 249, 252], ["RNase L", "PROTEIN", 28, 35], ["virusinfected cells", "CELL_TYPE", 107, 126], ["OAS", "PROTEIN", 185, 188], ["RNase L", "PROTEIN", 189, 196], ["cell death", "PROBLEM", 47, 57], ["apoptosis", "PROBLEM", 66, 75], ["virusinfected cells", "PROBLEM", 107, 126], ["RNase L pathway", "TREATMENT", 189, 204], ["the infectivity of numerous RNA and DNA viruses", "PROBLEM", 213, 260], ["antiviral activity", "OBSERVATION", 159, 177]]], ["Here we demonstrate that wild type (WT) RNase L and a constitutively active (N\u00c1385) RNase L mutant potently restrict both L1 and IAP retrotransposition in cultured human cells.", [["cells", "ANATOMY", 170, 175], ["wild type (WT)", "ORGANISM", 25, 39], ["RNase L", "GENE_OR_GENE_PRODUCT", 40, 47], ["constitutively active (N\u00c1385) RNase L", "GENE_OR_GENE_PRODUCT", 54, 91], ["IAP", "GENE_OR_GENE_PRODUCT", 129, 132], ["human", "ORGANISM", 164, 169], ["cells", "CELL", 170, 175], ["wild type (WT) RNase L", "PROTEIN", 25, 47], ["constitutively active (N\u00c1385) RNase L mutant", "PROTEIN", 54, 98], ["L1", "DNA", 122, 124], ["IAP", "DNA", 129, 132], ["cultured human cells", "CELL_LINE", 155, 175], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 164, 169], ["RNase L mutant", "TREATMENT", 84, 98], ["IAP retrotransposition", "TREATMENT", 129, 151], ["active", "OBSERVATION_MODIFIER", 69, 75], ["L1", "ANATOMY", 122, 124], ["IAP retrotransposition", "OBSERVATION", 129, 151], ["human cells", "OBSERVATION", 164, 175]]], ["In contrast, RNase L (R667A), catalytically inactive due to a mutation in the active site, does not restrict L1 or IAP retrotransposition.", [["RNase L", "GENE_OR_GENE_PRODUCT", 13, 20], ["R667A", "GENE_OR_GENE_PRODUCT", 22, 27], ["IAP", "GENE_OR_GENE_PRODUCT", 115, 118], ["RNase L (R667A)", "PROTEIN", 13, 28], ["L1", "DNA", 109, 111], ["IAP", "PROTEIN", 115, 118], ["catalytically inactive", "PROBLEM", 30, 52], ["a mutation in the active site", "PROBLEM", 60, 89], ["mutation", "OBSERVATION", 62, 70], ["active site", "OBSERVATION", 78, 89], ["L1", "ANATOMY", 109, 111], ["IAP", "ANATOMY", 115, 118], ["retrotransposition", "OBSERVATION", 119, 137]]], ["Consistent with the above observations, siRNA-mediated knockdown of endogenous RNase L leads to a $2-fold increase in L1 retrotransposition.", [["RNase L", "GENE_OR_GENE_PRODUCT", 79, 86], ["RNase L", "PROTEIN", 79, 86], ["L1 retrotransposition", "DNA", 118, 139], ["the above observations", "TEST", 16, 38], ["siRNA", "TEST", 40, 45], ["endogenous RNase", "PROBLEM", 68, 84], ["a $2-fold increase in L1 retrotransposition", "TREATMENT", 96, 139], ["endogenous RNase", "OBSERVATION", 68, 84], ["increase", "OBSERVATION_MODIFIER", 106, 114], ["L1", "ANATOMY", 118, 120], ["retrotransposition", "OBSERVATION", 121, 139]]], ["Finally, the expression of active forms of RNase L, but not the R667A RNase L mutant, leads to the degradation of L1 mRNA, which, in turn, leads to a decrease in the expression of L1 ORF1p and ORF2p.", [["RNase L", "GENE_OR_GENE_PRODUCT", 43, 50], ["R667A RNase L", "GENE_OR_GENE_PRODUCT", 64, 77], ["L1", "GENE_OR_GENE_PRODUCT", 114, 116], ["L1 ORF1p", "GENE_OR_GENE_PRODUCT", 180, 188], ["ORF2p", "GENE_OR_GENE_PRODUCT", 193, 198], ["RNase L", "PROTEIN", 43, 50], ["R667A RNase L mutant", "PROTEIN", 64, 84], ["L1 mRNA", "RNA", 114, 121], ["L1", "PROTEIN", 180, 182], ["ORF1p", "PROTEIN", 183, 188], ["ORF2p", "PROTEIN", 193, 198], ["active forms of RNase L", "PROBLEM", 27, 50], ["the degradation of L1 mRNA", "PROBLEM", 95, 121], ["a decrease", "PROBLEM", 148, 158], ["ORF2p", "TREATMENT", 193, 198], ["active", "OBSERVATION_MODIFIER", 27, 33], ["L1 mRNA", "ANATOMY", 114, 121], ["decrease", "OBSERVATION_MODIFIER", 150, 158], ["L1", "ANATOMY", 180, 182]]], ["Thus, in addition to its role in restricting the infectivity of several viruses, RNase L may act to restrict the retrotransposition of certain endogenous retrotransposons.Plasmid constructsSchematic maps of L1 and IAP plasmids used in this study are shown ( Figure 1A and B and Supplementary Figures S4A and S5A ).", [["RNase L", "GENE_OR_GENE_PRODUCT", 81, 88], ["IAP", "GENE_OR_GENE_PRODUCT", 214, 217], ["S5A", "GENE_OR_GENE_PRODUCT", 308, 311], ["RNase L", "PROTEIN", 81, 88], ["endogenous retrotransposons", "DNA", 143, 170], ["L1", "DNA", 207, 209], ["IAP plasmids", "DNA", 214, 226], ["S5A", "PROTEIN", 308, 311], ["several viruses", "PROBLEM", 64, 79], ["RNase L", "TREATMENT", 81, 88], ["Plasmid constructsSchematic maps of L1", "TREATMENT", 171, 209], ["IAP plasmids", "TREATMENT", 214, 226], ["this study", "TEST", 235, 245], ["Figure 1A", "TEST", 258, 267], ["several", "OBSERVATION_MODIFIER", 64, 71], ["viruses", "OBSERVATION", 72, 79], ["endogenous retrotransposons", "OBSERVATION", 143, 170], ["L1", "ANATOMY", 207, 209], ["IAP plasmids", "OBSERVATION", 214, 226]]], ["Brief descriptions of each plasmid used in Figure 1 .", [["plasmid", "ANATOMY", 27, 34], ["plasmid", "DNA", 27, 34]]], ["An overview of the L1 and IAP retrotransposition assays.", [["IAP", "GENE_OR_GENE_PRODUCT", 26, 29], ["L1", "DNA", 19, 21], ["the L1 and IAP retrotransposition assays", "TEST", 15, 55], ["L1", "ANATOMY", 19, 21]]], ["(A) Schematics of L1 and IAP constructs: The L1 and IAP constructs contain a NEObased (mneoI) or EGFP-based (mEGFPI) retrotransposition indicator cassette near their 3 0 ends.", [["IAP", "GENE_OR_GENE_PRODUCT", 52, 55], ["NEObased", "GENE_OR_GENE_PRODUCT", 77, 85], ["mneoI", "GENE_OR_GENE_PRODUCT", 87, 92], ["EGFP", "GENE_OR_GENE_PRODUCT", 97, 101], ["mEGFPI", "GENE_OR_GENE_PRODUCT", 109, 115], ["L1 and IAP constructs", "DNA", 18, 39], ["L1 and IAP constructs", "DNA", 45, 66], ["NEObased (mneoI) or EGFP-based (mEGFPI) retrotransposition indicator cassette", "DNA", 77, 154], ["3 0 ends", "DNA", 166, 174], ["a NEObased (mneoI)", "TREATMENT", 75, 93], ["EGFP", "TEST", 97, 101], ["L1", "ANATOMY", 18, 20], ["L1", "ANATOMY", 45, 47], ["IAP constructs", "OBSERVATION", 52, 66]]], ["The indicator cassettes are in an anti-sense (backward) orientation relative to the transcriptional orientation of the L1 or IAP elements.", [["IAP", "GENE_OR_GENE_PRODUCT", 125, 128], ["L1", "DNA", 119, 121], ["IAP elements", "DNA", 125, 137], ["The indicator cassettes", "TREATMENT", 0, 23], ["an anti-sense (backward) orientation", "TREATMENT", 31, 67], ["L1", "ANATOMY", 119, 121], ["IAP elements", "ANATOMY", 125, 137]]], ["The indicator cassettes also contain an intron that is in the same transcriptional orientation as the retroelement.", [["retroelement", "DNA", 102, 114], ["The indicator cassettes", "TREATMENT", 0, 23], ["an intron", "TREATMENT", 37, 46], ["retroelement", "OBSERVATION", 102, 114]]], ["SD and SA indicate the splice donor and splice acceptor sites of the intron, respectively.", [["SD", "DISEASE", 0, 2], ["SA", "GENE_OR_GENE_PRODUCT", 7, 9], ["splice donor and splice acceptor sites", "DNA", 23, 61], ["intron", "DNA", 69, 75], ["the splice donor", "TREATMENT", 19, 35]]], ["Pr 0 indicates the promoter driving the expression of the retrotransposition indicator cassette.", [["Pr 0", "GENE_OR_GENE_PRODUCT", 0, 4], ["Pr 0", "DNA", 0, 4], ["retrotransposition indicator cassette", "DNA", 58, 95]]], ["Closed lollipops indicate the polyadenylation signal on the indicator cassette.", [["lollipops", "GENE_OR_GENE_PRODUCT", 7, 16], ["Closed lollipops", "TREATMENT", 0, 16], ["the polyadenylation signal", "PROBLEM", 26, 52], ["polyadenylation signal", "OBSERVATION", 30, 52]]], ["A CMV promoter enhances the expression of the pJM101/L1.3, pAD2TE1, pES2TE1 and pAD3TE1 L1 vectors.", [["CMV", "ORGANISM", 2, 5], ["pJM101", "GENE_OR_GENE_PRODUCT", 46, 52], ["L1.3", "GENE_OR_GENE_PRODUCT", 53, 57], ["pAD2TE1", "GENE_OR_GENE_PRODUCT", 59, 66], ["pES2TE1", "GENE_OR_GENE_PRODUCT", 68, 75], ["pAD3TE1 L1", "GENE_OR_GENE_PRODUCT", 80, 90], ["CMV promoter", "DNA", 2, 14], ["pJM101", "DNA", 46, 52], ["L1.3", "DNA", 53, 57], ["pAD2TE1", "DNA", 59, 66], ["pES2TE1", "DNA", 68, 75], ["pAD3TE1 L1 vectors", "DNA", 80, 98], ["A CMV promoter", "TREATMENT", 0, 14], ["the pJM101", "TEST", 42, 52], ["pAD2TE1", "TEST", 59, 66], ["pES2TE1", "TEST", 68, 75], ["CMV", "OBSERVATION", 2, 5]]], ["An SV40 polyadenylation signal is present at the 3 0 end of each L1 expression cassette.", [["SV40", "ORGANISM", 3, 7], ["3 0 end", "DNA", 49, 56], ["L1 expression cassette", "DNA", 65, 87], ["An SV40 polyadenylation signal", "PROBLEM", 0, 30], ["SV40", "OBSERVATION", 3, 7], ["polyadenylation signal", "OBSERVATION", 8, 30], ["L1", "ANATOMY", 65, 67], ["expression cassette", "OBSERVATION", 68, 87]]], ["Notably, the mneoI-based L1 vectors are expressed from a pCEP4 vector that contains a HYG and an EBNA-1 Nucleic Acids Research, 2014, Vol.", [["mneoI", "GENE_OR_GENE_PRODUCT", 13, 18], ["pCEP4", "GENE_OR_GENE_PRODUCT", 57, 62], ["EBNA-1", "GENE_OR_GENE_PRODUCT", 97, 103], ["mneoI", "DNA", 13, 18], ["L1 vectors", "DNA", 25, 35], ["pCEP4 vector", "DNA", 57, 69], ["HYG", "DNA", 86, 89], ["EBNA", "PROTEIN", 97, 101], ["the mneoI-based L1 vectors", "TREATMENT", 9, 35], ["an EBNA", "TEST", 94, 101], ["L1 vectors", "ANATOMY", 25, 35], ["EBNA", "OBSERVATION", 97, 101]]], ["42, No. 6 3805 (continued) this study and the original references describing the plasmid construction are provided below.Plasmid constructspCEP4: is a mammalian expression vector (Gibco/Life Technologies/InVitrogen) used to construct some of the L1 plasmids (as indicated below) and contains a cytomegalovirus (CMV) promoter and an SV40 polyadenylation signal.", [["plasmids", "ANATOMY", 249, 257], ["cytomegalovirus", "ORGANISM", 294, 309], ["CMV", "ORGANISM", 311, 314], ["SV40", "ORGANISM", 332, 336], ["constructspCEP4", "DNA", 129, 144], ["mammalian expression vector", "DNA", 151, 178], ["InVitrogen", "DNA", 204, 214], ["L1 plasmids", "DNA", 246, 257], ["cytomegalovirus (CMV) promoter", "DNA", 294, 324], ["CMV", "SPECIES", 311, 314], ["this study", "TEST", 27, 37], ["the plasmid construction", "TREATMENT", 77, 101], ["a mammalian expression vector", "TREATMENT", 149, 178], ["Gibco/Life Technologies", "TREATMENT", 180, 203], ["InVitrogen", "TREATMENT", 204, 214], ["a cytomegalovirus (CMV) promoter", "PROBLEM", 292, 324], ["an SV40 polyadenylation signal", "PROBLEM", 329, 359], ["L1 plasmids", "ANATOMY", 246, 257], ["cytomegalovirus", "OBSERVATION", 294, 309], ["SV40", "OBSERVATION", 332, 336], ["polyadenylation signal", "OBSERVATION", 337, 359]]], ["The plasmid backbone also contains a hygromycin resistance gene (HYG) and the Epstein Barr Virus Nuclear Antigen-1 gene (EBNA-1). pJM101/L1.3: is a pCEP4-based plasmid that contains an active human L1 (L1.3) equipped with an mneoI retrotransposition indicator cassette (20, 64) .Plasmid constructspLRE3-mEGFPI: is a pCEP4-based plasmid that contains an active human L1 (LRE3) equipped with an mEGFPI retrotransposition indicator cassette (65) .", [["plasmid", "ANATOMY", 4, 11], ["plasmid", "ANATOMY", 160, 167], ["plasmid", "ANATOMY", 328, 335], ["hygromycin", "CHEMICAL", 37, 47], ["hygromycin", "CHEMICAL", 37, 47], ["hygromycin", "GENE_OR_GENE_PRODUCT", 37, 47], ["Epstein Barr Virus Nuclear Antigen-1", "GENE_OR_GENE_PRODUCT", 78, 114], ["EBNA-1", "GENE_OR_GENE_PRODUCT", 121, 127], ["pJM101", "GENE_OR_GENE_PRODUCT", 130, 136], ["L1.3", "GENE_OR_GENE_PRODUCT", 137, 141], ["pCEP4", "GENE_OR_GENE_PRODUCT", 148, 153], ["human", "ORGANISM", 192, 197], ["mneoI", "GENE_OR_GENE_PRODUCT", 225, 230], ["pCEP4", "GENE_OR_GENE_PRODUCT", 316, 321], ["human", "ORGANISM", 360, 365], ["LRE3", "GENE_OR_GENE_PRODUCT", 370, 374], ["mEGFPI", "GENE_OR_GENE_PRODUCT", 393, 399], ["hygromycin resistance gene", "DNA", 37, 63], ["HYG", "DNA", 65, 68], ["Epstein Barr Virus Nuclear Antigen-1 gene", "DNA", 78, 119], ["EBNA", "DNA", 121, 125], ["pJM101", "DNA", 130, 136], ["L1.3", "DNA", 137, 141], ["pCEP4-based plasmid", "DNA", 148, 167], ["human L1", "DNA", 192, 200], ["L1.3", "DNA", 202, 206], ["mneoI retrotransposition indicator cassette", "DNA", 225, 268], ["Plasmid constructspLRE3-mEGFPI", "DNA", 279, 309], ["pCEP4-based plasmid", "DNA", 316, 335], ["human L1", "DNA", 360, 368], ["LRE3", "DNA", 370, 374], ["mEGFPI retrotransposition indicator cassette", "DNA", 393, 437], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 360, 365], ["Epstein Barr Virus", "SPECIES", 78, 96], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 360, 365], ["The plasmid backbone", "TREATMENT", 0, 20], ["a hygromycin resistance gene (HYG)", "PROBLEM", 35, 69], ["the Epstein Barr Virus Nuclear Antigen", "TEST", 74, 112], ["EBNA", "TEST", 121, 125], ["a pCEP4-based plasmid", "TREATMENT", 146, 167], ["a pCEP4-based plasmid", "TREATMENT", 314, 335], ["an mEGFPI retrotransposition indicator cassette", "TREATMENT", 390, 437], ["plasmid backbone", "OBSERVATION", 4, 20], ["hygromycin resistance", "OBSERVATION", 37, 58], ["Epstein Barr Virus", "OBSERVATION", 78, 96], ["plasmid", "OBSERVATION", 160, 167], ["active", "OBSERVATION_MODIFIER", 185, 191], ["L1", "ANATOMY_MODIFIER", 198, 200], ["plasmid", "OBSERVATION", 328, 335], ["active", "OBSERVATION_MODIFIER", 353, 359], ["L1", "ANATOMY", 366, 368]]], ["The pCEP4 backbone was modified to contain a puromycin resistance (PURO) gene in place of the HYG.", [["puromycin", "CHEMICAL", 45, 54], ["puromycin", "CHEMICAL", 45, 54], ["pCEP4", "GENE_OR_GENE_PRODUCT", 4, 9], ["puromycin", "SIMPLE_CHEMICAL", 45, 54], ["pCEP4 backbone", "DNA", 4, 18], ["puromycin resistance (PURO) gene", "DNA", 45, 77], ["HYG", "DNA", 94, 97], ["The pCEP4 backbone", "TREATMENT", 0, 18], ["a puromycin resistance (PURO) gene", "TREATMENT", 43, 77], ["puromycin resistance", "OBSERVATION", 45, 65]]], ["The CMV promoter also was deleted from the vector; thus, L1 expression is only driven by its native 5 0 -UTR (65) .Plasmid constructspAD2TE1: is a pCEP4-based plasmid similar to pJM101/ L1.3.", [["plasmid", "ANATOMY", 159, 166], ["CMV", "ORGANISM", 4, 7], ["constructspAD2TE1", "GENE_OR_GENE_PRODUCT", 123, 140], ["pCEP4", "GENE_OR_GENE_PRODUCT", 147, 152], ["CMV promoter", "DNA", 4, 16], ["L1", "DNA", 57, 59], ["5 0 -UTR", "DNA", 100, 108], ["constructspAD2TE1", "DNA", 123, 140], ["pCEP4-based plasmid", "DNA", 147, 166], ["pJM101", "DNA", 178, 184], ["L1", "DNA", 186, 188], ["The CMV promoter", "TREATMENT", 0, 16], ["a pCEP4", "TEST", 145, 152], ["CMV promoter", "OBSERVATION", 4, 16], ["L1", "ANATOMY", 57, 59], ["L1", "ANATOMY", 186, 188]]], ["It was modified to contain a T7 gene10 epitope-tag on the carboxyl-terminus of ORF1p and a TAP epitopetag on the carboxyl-terminus of ORF2p.", [["carboxyl", "CHEMICAL", 58, 66], ["carboxyl", "CHEMICAL", 113, 121], ["ORF1p", "GENE_OR_GENE_PRODUCT", 79, 84], ["TAP", "GENE_OR_GENE_PRODUCT", 91, 94], ["ORF2p", "GENE_OR_GENE_PRODUCT", 134, 139], ["T7 gene10 epitope", "PROTEIN", 29, 46], ["carboxyl-terminus", "PROTEIN", 58, 75], ["ORF1p", "PROTEIN", 79, 84], ["TAP epitopetag", "PROTEIN", 91, 105], ["carboxyl-terminus", "PROTEIN", 113, 130], ["ORF2p", "PROTEIN", 134, 139], ["a T7 gene10 epitope-tag", "TREATMENT", 27, 50], ["the carboxyl-terminus of ORF1p", "TREATMENT", 54, 84], ["a TAP epitopetag", "TREATMENT", 89, 105], ["the carboxyl-terminus of ORF2p", "TREATMENT", 109, 139], ["T7", "ANATOMY", 29, 31]]], ["Its 3 0 -UTR contains the mneol retrotransposition indicator cassette (66) . pES2TE1: is identical to pAD2TE1, but was modified to replace the TAP tag on the carboxyl-terminus of ORF2p with a FLAG-HA tag (66) . pAD3TE1: is identical to pAD2TE1, but was modified to contain 24 copies of the MS2 stem-loop RNA binding repeats upstream of the mneoI indicator cassette (66) .Plasmid constructspDJ33/440N1neo TNF : is a gift from Thierry Heidmann (Institut Gustave Roussy, Paris, France).", [["carboxyl", "CHEMICAL", 158, 166], ["mneol", "GENE_OR_GENE_PRODUCT", 26, 31], ["pES2TE1", "GENE_OR_GENE_PRODUCT", 77, 84], ["pAD2TE1", "GENE_OR_GENE_PRODUCT", 102, 109], ["TAP", "GENE_OR_GENE_PRODUCT", 143, 146], ["ORF2p", "GENE_OR_GENE_PRODUCT", 179, 184], ["pAD3TE1", "GENE_OR_GENE_PRODUCT", 211, 218], ["pAD2TE1", "GENE_OR_GENE_PRODUCT", 236, 243], ["mneoI", "GENE_OR_GENE_PRODUCT", 340, 345], ["TNF", "GENE_OR_GENE_PRODUCT", 404, 407], ["3 0 -UTR", "DNA", 4, 12], ["mneol retrotransposition indicator cassette", "DNA", 26, 69], ["pES2TE1", "PROTEIN", 77, 84], ["pAD2TE1", "PROTEIN", 102, 109], ["TAP tag", "PROTEIN", 143, 150], ["carboxyl-terminus", "PROTEIN", 158, 175], ["ORF2p", "PROTEIN", 179, 184], ["FLAG", "PROTEIN", 192, 196], ["HA tag", "PROTEIN", 197, 203], ["pAD3TE1", "PROTEIN", 211, 218], ["pAD2TE1", "DNA", 236, 243], ["MS2 stem-loop RNA binding repeats", "DNA", 290, 323], ["mneoI indicator cassette", "DNA", 340, 364], ["TNF", "PROTEIN", 404, 407], ["the TAP tag", "TREATMENT", 139, 150], ["a FLAG-HA tag", "TEST", 190, 203]]], ["It contains a mouse IAP tagged with a neomycin resistance gene (NEO) retrotransposition indicator cassette similar to the one present in pJM101/L1.3 (13) .Plasmid constructspJM111-LRE3-mEGFPI: is identical to pLRE3-mEGFPI, but contains two missense mutations in ORF1p (RR261-262AA), which render the L1 retrotransposition-defective (41) .", [["neomycin", "CHEMICAL", 38, 46], ["neomycin", "CHEMICAL", 38, 46], ["mouse", "ORGANISM", 14, 19], ["IAP", "GENE_OR_GENE_PRODUCT", 20, 23], ["neomycin", "GENE_OR_GENE_PRODUCT", 38, 46], ["NEO", "GENE_OR_GENE_PRODUCT", 64, 67], ["pLRE3-mEGFPI", "GENE_OR_GENE_PRODUCT", 209, 221], ["ORF1p", "GENE_OR_GENE_PRODUCT", 262, 267], ["RR261-262AA", "GENE_OR_GENE_PRODUCT", 269, 280], ["mouse IAP", "DNA", 14, 23], ["neomycin resistance gene (NEO) retrotransposition indicator cassette", "DNA", 38, 106], ["pJM101", "DNA", 137, 143], ["Plasmid constructspJM111-LRE3-mEGFPI", "DNA", 155, 191], ["pLRE3", "DNA", 209, 214], ["mEGFPI", "DNA", 215, 221], ["ORF1p", "DNA", 262, 267], ["RR261", "DNA", 269, 274], ["L1 retrotransposition", "DNA", 300, 321], ["mouse", "SPECIES", 14, 19], ["mouse", "SPECIES", 14, 19], ["a mouse IAP", "TREATMENT", 12, 23], ["a neomycin resistance gene (NEO) retrotransposition indicator cassette", "TREATMENT", 36, 106], ["two missense mutations", "PROBLEM", 236, 258], ["missense mutations", "OBSERVATION", 240, 258], ["L1", "ANATOMY", 300, 302], ["defective", "OBSERVATION", 322, 331]]], ["Mr William Giblin (University of Michigan) made the plasmid. pDK500: is a pCEP4-based ORF1 expression plasmid.", [["plasmid", "ANATOMY", 52, 59], ["pDK500", "CHEMICAL", 61, 67], ["pDK500", "SIMPLE_CHEMICAL", 61, 67], ["pCEP4", "GENE_OR_GENE_PRODUCT", 74, 79], ["ORF1", "GENE_OR_GENE_PRODUCT", 86, 90], ["plasmid", "DNA", 52, 59], ["pDK500", "DNA", 61, 67], ["pCEP4-based ORF1 expression plasmid", "DNA", 74, 109], ["the plasmid", "TREATMENT", 48, 59], ["a pCEP4", "TREATMENT", 72, 79], ["ORF1 expression plasmid", "TREATMENT", 86, 109], ["expression plasmid", "OBSERVATION", 91, 109]]], ["It contains the L1.3 5 0 -UTR, ORF1 containing a T7 gene 10 epitope-tag at its carboxyl-terminus and the mneoI retrotransposition cassette (38) . pAD500: is a pCEP4-based ORF2 expression plasmid.", [["pAD500", "CHEMICAL", 146, 152], ["carboxyl", "CHEMICAL", 79, 87], ["ORF1", "GENE_OR_GENE_PRODUCT", 31, 35], ["mneoI", "GENE_OR_GENE_PRODUCT", 105, 110], ["pAD500", "SIMPLE_CHEMICAL", 146, 152], ["pCEP4", "GENE_OR_GENE_PRODUCT", 159, 164], ["ORF2", "GENE_OR_GENE_PRODUCT", 171, 175], ["L1.3 5 0 -UTR", "DNA", 16, 29], ["ORF1", "DNA", 31, 35], ["T7 gene 10 epitope", "DNA", 49, 67], ["carboxyl-terminus", "PROTEIN", 79, 96], ["mneoI retrotransposition cassette", "DNA", 105, 138], ["pAD500", "DNA", 146, 152], ["pCEP4", "DNA", 159, 164], ["ORF2 expression plasmid", "DNA", 171, 194], ["ORF1", "TREATMENT", 31, 35], ["a T7 gene 10 epitope-tag at its carboxyl-terminus", "TREATMENT", 47, 96], ["the mneoI retrotransposition cassette", "TREATMENT", 101, 138], ["a pCEP4", "TREATMENT", 157, 164], ["ORF2 expression plasmid", "TREATMENT", 171, 194], ["T7", "ANATOMY", 49, 51]]], ["It contains the L1.3 5 0 -UTR, ORF2 containing a TAP epitope-tag at its carboxyl-terminus and the mneoI retrotransposition cassette (66) .Plasmid constructspMS2-GFP: was obtained from Addgene (plasmid 27121), and was originally deposited by Robert Singer (67) .", [["carboxyl", "CHEMICAL", 72, 80], ["ORF2", "GENE_OR_GENE_PRODUCT", 31, 35], ["TAP", "GENE_OR_GENE_PRODUCT", 49, 52], ["mneoI", "GENE_OR_GENE_PRODUCT", 98, 103], ["GFP", "GENE_OR_GENE_PRODUCT", 161, 164], ["Addgene", "GENE_OR_GENE_PRODUCT", 184, 191], ["L1.3 5 0 -UTR", "DNA", 16, 29], ["ORF2", "DNA", 31, 35], ["TAP epitope", "PROTEIN", 49, 60], ["carboxyl-terminus", "PROTEIN", 72, 89], ["mneoI retrotransposition cassette", "DNA", 98, 131], ["Plasmid constructspMS2-GFP:", "DNA", 138, 165], ["Addgene (plasmid 27121", "DNA", 184, 206], ["ORF2", "TREATMENT", 31, 35], ["a TAP epitope-tag", "TREATMENT", 47, 64], ["the mneoI retrotransposition cassette", "TREATMENT", 94, 131], ["Plasmid constructspMS2", "TEST", 138, 160]]], ["It encodes a nuclear localized MS2-GFP fusion protein.Plasmid constructsThe human HA epitope-tagged APOBEC3A (A3A) expression plasmid was obtained from Dr Bryan Cullen at Duke University (68) .", [["nuclear", "ANATOMY", 13, 20], ["nuclear", "CELLULAR_COMPONENT", 13, 20], ["MS2", "GENE_OR_GENE_PRODUCT", 31, 34], ["GFP", "GENE_OR_GENE_PRODUCT", 35, 38], ["human", "ORGANISM", 76, 81], ["HA epitope-tagged APOBEC3A (A3A)", "GENE_OR_GENE_PRODUCT", 82, 114], ["nuclear localized MS2-GFP fusion protein", "PROTEIN", 13, 53], ["Plasmid constructs", "DNA", 54, 72], ["human HA epitope-tagged APOBEC3A (A3A) expression plasmid", "DNA", 76, 133], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["Plasmid constructs", "TREATMENT", 54, 72], ["The human HA epitope", "TEST", 72, 92], ["expression plasmid", "PROBLEM", 115, 133], ["GFP fusion", "OBSERVATION", 35, 45]]], ["The A3A cDNA was subcloned into pFLAG-CMV-2 (Sigma-Aldrich) to ensure that it was expressed from the same context as the RNase L constructs used in this study.Plasmid constructsThe human cDNAs for RNase L (69), A3A and RIG-I (a gift from Michael Gale, Seattle, WA, USA) were cloned into pFLAG-CMV-2 (Sigma Aldrich).", [["A3A", "GENE_OR_GENE_PRODUCT", 4, 7], ["CMV", "ORGANISM", 38, 41], ["-2", "GENE_OR_GENE_PRODUCT", 41, 43], ["Sigma-Aldrich", "ORGANISM", 45, 58], ["RNase L", "GENE_OR_GENE_PRODUCT", 121, 128], ["human", "ORGANISM", 181, 186], ["RNase L (69)", "GENE_OR_GENE_PRODUCT", 197, 209], ["A3A", "GENE_OR_GENE_PRODUCT", 211, 214], ["RIG-I", "GENE_OR_GENE_PRODUCT", 219, 224], ["CMV", "ORGANISM", 293, 296], ["Sigma Aldrich", "ORGANISM", 300, 313], ["A3A cDNA", "DNA", 4, 12], ["pFLAG-CMV-2", "DNA", 32, 43], ["RNase L constructs", "DNA", 121, 139], ["Plasmid constructs", "DNA", 159, 177], ["human cDNAs", "DNA", 181, 192], ["RNase L", "PROTEIN", 197, 204], ["A3A", "PROTEIN", 211, 214], ["RIG-I", "PROTEIN", 219, 224], ["pFLAG", "PROTEIN", 287, 292], ["human", "SPECIES", 181, 186], ["human", "SPECIES", 181, 186], ["The A3A cDNA", "TEST", 0, 12], ["pFLAG", "TEST", 32, 37], ["CMV", "TEST", 38, 41], ["the RNase L constructs", "TREATMENT", 117, 139], ["this study", "TEST", 148, 158], ["Plasmid constructs", "TREATMENT", 159, 177], ["The human cDNAs", "TEST", 177, 192], ["RNase", "TEST", 197, 202], ["A3A", "TEST", 211, 214], ["RIG", "TEST", 219, 222], ["pFLAG", "TEST", 287, 292], ["CMV", "TEST", 293, 296], ["CMV", "OBSERVATION", 293, 296]]], ["They all contain a FLAG tag at their amino terminus.", [["amino", "CHEMICAL", 37, 42], ["FLAG", "GENE_OR_GENE_PRODUCT", 19, 23], ["amino terminus", "AMINO_ACID", 37, 51], ["FLAG tag", "PROTEIN", 19, 27], ["amino terminus", "PROTEIN", 37, 51], ["a FLAG tag", "TREATMENT", 17, 27], ["FLAG tag", "OBSERVATION", 19, 27]]], ["Plasmid pIREShyg (Clontech) contains a hygromycin B phosphotransferease gene under control of a CMV promoter and downstream of an internal ribosome entry site from encephalomyocarditis virus.Plasmid constructsThe catalytically inactive (R667A) RNase L mutant (70) was generated by site-directed mutagenesis and verified by DNA sequence analysis.", [["ribosome", "ANATOMY", 139, 147], ["hygromycin B", "CHEMICAL", 39, 51], ["hygromycin B", "CHEMICAL", 39, 51], ["Clontech", "GENE_OR_GENE_PRODUCT", 18, 26], ["hygromycin B phosphotransferease", "GENE_OR_GENE_PRODUCT", 39, 71], ["CMV", "ORGANISM", 96, 99], ["encephalomyocarditis virus", "ORGANISM", 164, 190], ["RNase L", "GENE_OR_GENE_PRODUCT", 244, 251], ["DNA", "CELLULAR_COMPONENT", 323, 326], ["pIREShyg", "DNA", 8, 16], ["Clontech", "DNA", 18, 26], ["hygromycin B phosphotransferease gene", "DNA", 39, 76], ["CMV promoter", "DNA", 96, 108], ["internal ribosome entry site", "DNA", 130, 158], ["Plasmid constructs", "DNA", 191, 209], ["catalytically inactive (R667A) RNase L mutant", "PROTEIN", 213, 258], ["encephalomyocarditis virus", "SPECIES", 164, 190], ["encephalomyocarditis virus", "SPECIES", 164, 190], ["Plasmid pIREShyg (Clontech)", "TREATMENT", 0, 27], ["a hygromycin B phosphotransferease gene", "TREATMENT", 37, 76], ["a CMV promoter", "TREATMENT", 94, 108], ["an internal ribosome entry site", "PROBLEM", 127, 158], ["encephalomyocarditis virus", "PROBLEM", 164, 190], ["Plasmid constructs", "TREATMENT", 191, 209], ["DNA sequence analysis", "TEST", 323, 344], ["CMV promoter", "OBSERVATION", 96, 108], ["internal ribosome", "ANATOMY", 130, 147], ["entry site", "OBSERVATION", 148, 158], ["encephalomyocarditis virus", "OBSERVATION", 164, 190], ["inactive", "OBSERVATION_MODIFIER", 227, 235]]], ["The constitutively active (N\u00c1385) RNase L mutant was described in the same study (70) .Plasmid constructsMyc-tagged WT and mutant RNase L cDNAs were cloned into a modified pcDNA 3.0 (Gibco/Life Technologies/InVitrogen) vector that lacks a NEO using standard molecular cloning protocols.", [["constitutively active (N\u00c1385) RNase L", "GENE_OR_GENE_PRODUCT", 4, 41], ["Myc", "GENE_OR_GENE_PRODUCT", 105, 108], ["RNase L", "GENE_OR_GENE_PRODUCT", 130, 137], ["pcDNA", "ORGANISM", 172, 177], ["InVitrogen", "GENE_OR_GENE_PRODUCT", 207, 217], ["NEO", "GENE_OR_GENE_PRODUCT", 239, 242], ["constitutively active (N\u00c1385) RNase L mutant", "PROTEIN", 4, 48], ["Plasmid constructs", "DNA", 87, 105], ["Myc-tagged WT and mutant RNase L cDNAs", "DNA", 105, 143], ["pcDNA 3.0 (Gibco/Life Technologies/InVitrogen) vector", "DNA", 172, 225], ["NEO", "DNA", 239, 242], ["The constitutively active (N\u00c1385) RNase L mutant", "PROBLEM", 0, 48], ["the same study", "TEST", 66, 80], ["Plasmid constructs", "TREATMENT", 87, 105], ["Myc", "TEST", 105, 108], ["tagged WT", "TEST", 109, 118], ["mutant RNase L cDNAs", "TREATMENT", 123, 143], ["a modified pcDNA", "TREATMENT", 161, 177], ["Gibco/Life Technologies", "TREATMENT", 183, 206], ["InVitrogen) vector", "TREATMENT", 207, 225], ["a NEO", "TREATMENT", 237, 242], ["standard molecular cloning protocols", "TREATMENT", 249, 285], ["constitutively", "OBSERVATION_MODIFIER", 4, 18], ["active", "OBSERVATION_MODIFIER", 19, 25]]], ["Briefly, the plasmids were double digested with BstBI and SfoI, followed by 3 0 end filling with Klenow fragment of DNA polymerase, and blunt-end cloned into the modified pcDNA 3.0 vector using T4 DNA ligase (New England BioLabs).Cells and culture mediaHeLa-M cells, which are deficient for RNase L (71), and Hey1b cells (a human ovarian cancer cell line that was a gift from Alexander Marks, University of Toronto, Toronto, Canada) (72) were maintained in Dulbecco's modified Eagle's medium (DMEM) and RPMI medium, respectively.", [["plasmids", "ANATOMY", 13, 21], ["Cells", "ANATOMY", 230, 235], ["mediaHeLa-M cells", "ANATOMY", 248, 265], ["Hey1b cells", "ANATOMY", 309, 320], ["ovarian cancer cell line", "ANATOMY", 330, 354], ["ovarian cancer", "DISEASE", 330, 344], ["BstBI", "GENE_OR_GENE_PRODUCT", 48, 53], ["SfoI", "SIMPLE_CHEMICAL", 58, 62], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["pcDNA", "GENE_OR_GENE_PRODUCT", 171, 176], ["T4", "GENE_OR_GENE_PRODUCT", 194, 196], ["DNA", "CELLULAR_COMPONENT", 197, 200], ["Cells", "CELL", 230, 235], ["culture mediaHeLa-M cells", "CELL", 240, 265], ["RNase L (71)", "GENE_OR_GENE_PRODUCT", 291, 303], ["Hey1b cells", "CELL", 309, 320], ["human", "ORGANISM", 324, 329], ["ovarian cancer cell line", "CELL", 330, 354], ["plasmids", "DNA", 13, 21], ["BstBI", "DNA", 48, 53], ["SfoI", "DNA", 58, 62], ["Klenow fragment", "DNA", 97, 112], ["DNA polymerase", "PROTEIN", 116, 130], ["blunt-end", "DNA", 136, 145], ["pcDNA 3.0 vector", "DNA", 171, 187], ["T4 DNA ligase", "PROTEIN", 194, 207], ["New England BioLabs", "PROTEIN", 209, 228], ["mediaHeLa-M cells", "CELL_LINE", 248, 265], ["RNase L", "PROTEIN", 291, 298], ["Hey1b cells", "CELL_LINE", 309, 320], ["human ovarian cancer cell line", "CELL_LINE", 324, 354], ["human", "SPECIES", 324, 329], ["human", "SPECIES", 324, 329], ["the plasmids", "TREATMENT", 9, 21], ["BstBI", "TREATMENT", 48, 53], ["SfoI", "TREATMENT", 58, 62], ["Klenow fragment of DNA polymerase", "PROBLEM", 97, 130], ["blunt", "PROBLEM", 136, 141], ["the modified pcDNA 3.0 vector", "TREATMENT", 158, 187], ["T4 DNA ligase", "TREATMENT", 194, 207], ["New England BioLabs", "TREATMENT", 209, 228], ["Cells", "TEST", 230, 235], ["culture mediaHeLa", "TEST", 240, 257], ["M cells", "TEST", 258, 265], ["RNase", "TEST", 291, 296], ["Hey1b cells", "PROBLEM", 309, 320], ["a human ovarian cancer cell line", "TREATMENT", 322, 354], ["RPMI medium", "TREATMENT", 503, 514], ["Klenow fragment", "OBSERVATION", 97, 112], ["ligase", "OBSERVATION_MODIFIER", 201, 207], ["ovarian", "ANATOMY", 330, 337], ["cancer cell line", "OBSERVATION", 338, 354]]], ["The complete medium was supplemented with 10% fetal bovine serum (FBS), 50 U/ml of penicillin, Figure 1 .", [["fetal bovine serum", "ANATOMY", 46, 64], ["FBS", "ANATOMY", 66, 69], ["penicillin", "CHEMICAL", 83, 93], ["penicillin", "CHEMICAL", 83, 93], ["bovine", "ORGANISM", 52, 58], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["FBS", "ORGANISM_SUBSTANCE", 66, 69], ["penicillin", "SIMPLE_CHEMICAL", 83, 93], ["bovine", "SPECIES", 52, 58], ["10% fetal bovine serum (FBS", "TREATMENT", 42, 69], ["penicillin", "TREATMENT", 83, 93]]], ["The mEGFPI-based L1 vectors are expressed from a pCEP4 vector that was modified to contain a PURO gene; it also contains the EBNA-1 gene.", [["mEGFPI", "GENE_OR_GENE_PRODUCT", 4, 10], ["pCEP4", "GENE_OR_GENE_PRODUCT", 49, 54], ["PURO", "GENE_OR_GENE_PRODUCT", 93, 97], ["EBNA-1", "GENE_OR_GENE_PRODUCT", 125, 131], ["mEGFPI-based L1 vectors", "DNA", 4, 27], ["pCEP4 vector", "DNA", 49, 61], ["PURO gene", "DNA", 93, 102], ["EBNA-1 gene", "DNA", 125, 136], ["The mEGFPI-based L1 vectors", "TREATMENT", 0, 27], ["a pCEP4 vector", "TREATMENT", 47, 61], ["the EBNA", "TEST", 121, 129], ["based", "ANATOMY_MODIFIER", 11, 16], ["L1 vectors", "ANATOMY", 17, 27], ["EBNA", "ANATOMY", 125, 129]]], ["Flag symbols indicate the names of epitope-tags present in some L1 vectors.", [["Flag", "GENE_OR_GENE_PRODUCT", 0, 4], ["epitope-tags", "PROBLEM", 35, 47], ["L1 vectors", "ANATOMY", 64, 74]]], ["The SP and ASP labels indicate the sense and anti-sense promoters located in the L1 5 0 -UTR.", [["SP and ASP labels", "RNA", 4, 21], ["anti-sense promoters", "DNA", 45, 65], ["L1 5 0 -UTR", "DNA", 81, 92], ["The SP and ASP labels", "TEST", 0, 21], ["anti-sense promoters", "TREATMENT", 45, 65], ["L1", "ANATOMY", 81, 83]]], ["The MS2 24x designation indicates the 24 copies of the MS2-GFP RNA binding motif in the pAD3TE1 construct.", [["GFP", "GENE_OR_GENE_PRODUCT", 59, 62], ["pAD3TE1", "GENE_OR_GENE_PRODUCT", 88, 95], ["MS2 24x designation", "DNA", 4, 23], ["MS2-GFP RNA binding motif", "DNA", 55, 80], ["pAD3TE1 construct", "DNA", 88, 105], ["The MS2", "TEST", 0, 7], ["the MS2", "TEST", 51, 58]]], ["The PCR primers for pAD2TE1 are labeled F1, R1, F2 and R2 (see 'Materials and Methods' section for details).", [["pAD2TE1", "GENE_OR_GENE_PRODUCT", 20, 27], ["PCR primers", "DNA", 4, 15], ["pAD2TE1", "DNA", 20, 27], ["R1", "DNA", 44, 46], ["R2", "DNA", 55, 57], ["The PCR primers", "TEST", 0, 15], ["pAD2TE1", "TEST", 20, 27]]], ["In the IAP vector [pDJ33/440N1neo TNF (13) ], Pr indicates the viral LTR promoter.", [["LTR", "ANATOMY", 69, 72], ["IAP", "GENE_OR_GENE_PRODUCT", 7, 10], ["TNF (13)", "GENE_OR_GENE_PRODUCT", 34, 42], ["LTR", "CELLULAR_COMPONENT", 69, 72], ["IAP vector", "DNA", 7, 17], ["pDJ33", "DNA", 19, 24], ["Pr", "DNA", 46, 48], ["viral LTR promoter", "DNA", 63, 81], ["TNF", "TEST", 34, 37], ["the viral LTR promoter", "TREATMENT", 59, 81], ["viral LTR promoter", "OBSERVATION", 63, 81]]], ["The IAP GAG and POL genes also are indicated.", [["IAP GAG", "GENE_OR_GENE_PRODUCT", 4, 11], ["POL", "GENE_OR_GENE_PRODUCT", 16, 19], ["IAP GAG and POL genes", "DNA", 4, 25], ["The IAP GAG", "TEST", 0, 11], ["GAG", "OBSERVATION", 8, 11]]], ["(B) Rationale of the assay: Transcription from a promoter driving L1 or IAP expression allows splicing of the intron from either the mneoI-or EGFP-based indicator cassettes.", [["L1", "GENE_OR_GENE_PRODUCT", 66, 68], ["IAP", "GENE_OR_GENE_PRODUCT", 72, 75], ["mneoI", "GENE_OR_GENE_PRODUCT", 133, 138], ["EGFP", "GENE_OR_GENE_PRODUCT", 142, 146], ["promoter", "DNA", 49, 57], ["L1", "DNA", 66, 68], ["IAP", "DNA", 72, 75], ["intron", "DNA", 110, 116], ["mneoI-or EGFP-based indicator cassettes", "DNA", 133, 172], ["a promoter driving L1", "TREATMENT", 47, 68], ["IAP expression", "TREATMENT", 72, 86]]], ["Retrotransposition of the resultant RNA leads to activation of the reporter gene, conferring either G418-resistance or EGFP-positivity to host cells.", [["cells", "ANATOMY", 143, 148], ["G418", "CHEMICAL", 100, 104], ["EGFP", "GENE_OR_GENE_PRODUCT", 119, 123], ["host cells", "CELL", 138, 148], ["reporter gene", "DNA", 67, 80], ["EGFP", "DNA", 119, 123], ["host cells", "CELL_TYPE", 138, 148], ["the resultant RNA", "PROBLEM", 22, 39], ["EGFP", "TEST", 119, 123], ["resultant", "OBSERVATION_MODIFIER", 26, 35], ["RNA leads", "OBSERVATION", 36, 45], ["host cells", "OBSERVATION", 138, 148]]], ["TSD indicates a target site duplication flanking the retrotransposed L1.", [["TSD", "DNA", 0, 3], ["target site duplication", "DNA", 16, 39], ["retrotransposed L1", "DNA", 53, 71], ["TSD", "PROBLEM", 0, 3], ["a target site duplication flanking the retrotransposed L1", "PROBLEM", 14, 71], ["duplication flanking", "OBSERVATION", 28, 48], ["retrotransposed", "ANATOMY_MODIFIER", 53, 68], ["L1", "ANATOMY", 69, 71]]], ["(C) Experimental protocols to detect L1 retrotransposition: Cells were co-transfected with an engineered L1 or IAP retroelement and either an empty vector (pFLAG-CMV-2) or amino-terminal FLAG-tagged RNase L expression plasmid.", [["Cells", "ANATOMY", 60, 65], ["amino-terminal", "CHEMICAL", 172, 186], ["amino", "CHEMICAL", 172, 177], ["Cells", "CELL", 60, 65], ["IAP", "GENE_OR_GENE_PRODUCT", 111, 114], ["pFLAG-CMV-2", "GENE_OR_GENE_PRODUCT", 156, 167], ["RNase L", "GENE_OR_GENE_PRODUCT", 199, 206], ["L1", "DNA", 105, 107], ["IAP retroelement", "DNA", 111, 127], ["empty vector (pFLAG-CMV-2", "DNA", 142, 167], ["amino-terminal FLAG-tagged RNase L expression plasmid", "DNA", 172, 225], ["Experimental protocols", "TREATMENT", 4, 26], ["an engineered L1", "TREATMENT", 91, 107], ["IAP retroelement", "TREATMENT", 111, 127], ["an empty vector", "TREATMENT", 139, 154], ["pFLAG", "TEST", 156, 161], ["CMV", "TEST", 162, 165], ["amino-terminal FLAG", "TREATMENT", 172, 191], ["tagged RNase L expression plasmid", "TREATMENT", 192, 225], ["L1", "ANATOMY", 37, 39], ["L1", "ANATOMY", 105, 107], ["IAP retroelement", "OBSERVATION", 111, 127], ["empty vector", "OBSERVATION", 142, 154]]], ["For the mneoI-based assays, the transfected cells were subjected to G418 selection 2 days after transfection.", [["cells", "ANATOMY", 44, 49], ["G418", "CHEMICAL", 68, 72], ["G418", "CHEMICAL", 68, 72], ["cells", "CELL", 44, 49], ["mneoI", "DNA", 8, 13], ["transfected cells", "CELL_LINE", 32, 49], ["the mneoI-based assays", "TEST", 4, 26], ["the transfected cells", "PROBLEM", 28, 49], ["transfection", "TREATMENT", 96, 108]]], ["The numbers of G418-resistant foci serve as a readout of retrotransposition efficiency.", [["foci", "ANATOMY", 30, 34], ["G418", "CHEMICAL", 15, 19], ["G418", "CHEMICAL", 15, 19], ["foci", "CELL", 30, 34], ["resistant foci", "PROBLEM", 20, 34], ["retrotransposition efficiency", "PROBLEM", 57, 86], ["resistant", "OBSERVATION_MODIFIER", 20, 29], ["foci", "OBSERVATION", 30, 34], ["retrotransposition efficiency", "OBSERVATION", 57, 86]]], ["For the mEGFPI-based assays, FACS analysis was used to measure the percentage of EGFP-positive cells 4 days after transfection (See 'Materials and Methods' section for further details about each assay).", [["cells", "ANATOMY", 95, 100], ["mEGFPI", "SIMPLE_CHEMICAL", 8, 14], ["EGFP", "GENE_OR_GENE_PRODUCT", 81, 85], ["mEGFPI", "PROTEIN", 8, 14], ["EGFP", "PROTEIN", 81, 85], ["the mEGFPI-based assays", "TEST", 4, 27], ["FACS analysis", "TEST", 29, 42], ["EGFP", "TEST", 81, 85], ["positive cells", "PROBLEM", 86, 100], ["positive cells", "OBSERVATION", 86, 100]]], ["50 mg/ml of streptomycin and 2 mM L-glutamine (Gibco/ Life Technologies).Retrotransposition assaysRetrotransposition assays were performed as described previously with minor modifications (65, 73) .", [["streptomycin", "CHEMICAL", 12, 24], ["L-glutamine", "CHEMICAL", 34, 45], ["streptomycin", "CHEMICAL", 12, 24], ["L-glutamine", "CHEMICAL", 34, 45], ["streptomycin", "SIMPLE_CHEMICAL", 12, 24], ["L-glutamine", "SIMPLE_CHEMICAL", 34, 45], ["streptomycin", "TREATMENT", 12, 24], ["2 mM L-glutamine (Gibco/ Life Technologies", "TREATMENT", 29, 71], ["Retrotransposition assays", "TEST", 73, 98], ["Retrotransposition assays", "TEST", 98, 123]]], ["Briefly, for G418-resistance-based retrotransposition assays, HeLa-M cells ($8 \u00c2 10 4 per well) were seeded into two sets of six-well plates.", [["HeLa-M cells", "ANATOMY", 62, 74], ["G418", "CHEMICAL", 13, 17], ["G418", "CHEMICAL", 13, 17], ["HeLa-M cells", "CELL", 62, 74], ["HeLa-M cells", "CELL_LINE", 62, 74], ["G418-resistance", "TREATMENT", 13, 28], ["retrotransposition assays", "TEST", 35, 60], ["HeLa-M cells", "TREATMENT", 62, 74]]], ["The next day, the cells were co-transfected with 0.5 mg of the indicated L1 or IAP expression plasmid and 0.5 mg of a corresponding expression plasmid for RNase L, A3A, RIG-I or an empty vector (pFLAG-CMV-2) using 3 ml of the Fugene6 transfection reagent (Roche) per well.", [["cells", "ANATOMY", 18, 23], ["plasmid", "ANATOMY", 143, 150], ["cells", "CELL", 18, 23], ["IAP", "GENE_OR_GENE_PRODUCT", 79, 82], ["RNase L", "GENE_OR_GENE_PRODUCT", 155, 162], ["A3A", "GENE_OR_GENE_PRODUCT", 164, 167], ["RIG-I", "GENE_OR_GENE_PRODUCT", 169, 174], ["IAP expression plasmid", "DNA", 79, 101], ["expression plasmid", "DNA", 132, 150], ["RNase L, A3A, RIG-I", "DNA", 155, 174], ["pFLAG", "DNA", 195, 200], ["the cells", "TREATMENT", 14, 23], ["IAP expression plasmid", "TREATMENT", 79, 101], ["a corresponding expression plasmid", "TREATMENT", 116, 150], ["RNase L", "TEST", 155, 162], ["A3A", "TEST", 164, 167], ["RIG", "TEST", 169, 172], ["an empty vector", "TREATMENT", 178, 193], ["the Fugene6 transfection reagent", "TREATMENT", 222, 254], ["empty", "OBSERVATION", 181, 186]]], ["Forty-eight hours after transfection, the cells were collected from one set of plates and were analyzed for protein expression in western blot experiments.", [["cells", "ANATOMY", 42, 47], ["cells", "CELL", 42, 47], ["transfection", "TREATMENT", 24, 36], ["the cells", "PROBLEM", 38, 47], ["protein expression", "PROBLEM", 108, 126]]], ["Cells from the other set of plates were trypsinized and resuspended in complete DMEM medium supplemented with G418 (500 mg/ml) (Gibco/ Life Technologies).", [["Cells", "ANATOMY", 0, 5], ["G418", "CHEMICAL", 110, 114], ["G418", "CHEMICAL", 110, 114], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["G418", "TREATMENT", 110, 114]]], ["Cells from each well were split into three 10-cm tissue culture dishes, generating triplicate cultures.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["tissue culture dishes", "TEST", 49, 70], ["triplicate cultures", "TEST", 83, 102]]], ["After 10 days of G418 selection, the remaining cells were treated with 10% neutral buffered formalin for 5 min to fix them to tissue culture plates and then were stained with 0.05% crystal violet for 30 min to facilitate their visualization.", [["cells", "ANATOMY", 47, 52], ["tissue culture", "ANATOMY", 126, 140], ["G418", "CHEMICAL", 17, 21], ["G418", "CHEMICAL", 17, 21], ["formalin", "CHEMICAL", 92, 100], ["cells", "CELL", 47, 52], ["formalin", "SIMPLE_CHEMICAL", 92, 100], ["G418 selection", "TREATMENT", 17, 31], ["the remaining cells", "TREATMENT", 33, 52], ["10% neutral buffered formalin", "TREATMENT", 71, 100], ["tissue culture plates", "TEST", 126, 147], ["0.05% crystal violet", "TREATMENT", 175, 195], ["their visualization", "TEST", 221, 240]]], ["The dishes were washed in phosphate buffered saline (PBS), scanned and foci numbers were determined using Integrated Colony Enumerator software (National Institute of Standards and Technology) (74) .", [["foci", "ANATOMY", 71, 75], ["phosphate", "CHEMICAL", 26, 35], ["phosphate", "CHEMICAL", 26, 35], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 26, 51], ["The dishes", "TREATMENT", 0, 10], ["phosphate buffered saline (PBS", "TREATMENT", 26, 56], ["foci numbers", "TEST", 71, 83]]], ["Notably, toxicity control reactions were performed in a similar manner (in triplicate).", [["toxicity", "DISEASE", 9, 17], ["toxicity control reactions", "PROBLEM", 9, 35]]], ["Briefly HeLa-M cells were co-transfected with 0.5 mg of the pcDNA 3.0 NEO expression vector and 0.5 mg of the RNase L expression plasmids using 3 ml of the Fugene6 transfection reagent per well (Roche).", [["HeLa-M cells", "ANATOMY", 8, 20], ["HeLa-M cells", "CELL", 8, 20], ["pcDNA", "ORGANISM", 60, 65], ["NEO", "GENE_OR_GENE_PRODUCT", 70, 73], ["RNase L", "GENE_OR_GENE_PRODUCT", 110, 117], ["HeLa-M cells", "CELL_LINE", 8, 20], ["pcDNA 3.0 NEO expression vector", "DNA", 60, 91], ["RNase L expression plasmids", "DNA", 110, 137], ["the pcDNA 3.0 NEO expression vector", "TREATMENT", 56, 91], ["the RNase L expression plasmids", "TREATMENT", 106, 137], ["the Fugene6 transfection reagent", "TREATMENT", 152, 184]]], ["After G418 selection (500 mg/ml) for 10 days, the remaining cells were fixed, stained and counted.Retrotransposition assaysFor enhanced green fluorescent protein (EGFP)-based retrotransposition assays, HeLa-M cells were transfected with 0.5 mg of an active (pLRE3-mEGFPI) or inactive (pJM111-LRE3-mEGFPI) L1 expression plasmid and 0.5 mg of a corresponding RNase L expression plasmid, using 3 ml of Fugene6 transfection reagent (Roche) per well.", [["cells", "ANATOMY", 60, 65], ["HeLa-M cells", "ANATOMY", 202, 214], ["G418", "CHEMICAL", 6, 10], ["G418", "CHEMICAL", 6, 10], ["cells", "CELL", 60, 65], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 136, 161], ["EGFP", "GENE_OR_GENE_PRODUCT", 163, 167], ["HeLa-M cells", "CELL", 202, 214], ["pLRE3-mEGFPI", "GENE_OR_GENE_PRODUCT", 258, 270], ["RNase L", "GENE_OR_GENE_PRODUCT", 357, 364], ["Fugene6", "SIMPLE_CHEMICAL", 399, 406], ["green fluorescent protein", "PROTEIN", 136, 161], ["EGFP", "PROTEIN", 163, 167], ["HeLa-M cells", "CELL_LINE", 202, 214], ["pLRE3", "PROTEIN", 258, 263], ["mEGFPI", "PROTEIN", 264, 270], ["inactive (pJM111-LRE3-mEGFPI) L1 expression plasmid", "DNA", 275, 326], ["RNase L expression plasmid", "DNA", 357, 383], ["G418 selection", "TREATMENT", 6, 20], ["Retrotransposition assays", "TEST", 98, 123], ["enhanced green fluorescent protein", "TEST", 127, 161], ["EGFP)", "TEST", 163, 168], ["based retrotransposition assays", "TEST", 169, 200], ["HeLa-M cells", "TREATMENT", 202, 214], ["an active (pLRE3-mEGFPI)", "TREATMENT", 247, 271], ["inactive (pJM111-LRE3-mEGFPI) L1 expression plasmid", "TREATMENT", 275, 326], ["a corresponding RNase L expression plasmid", "TREATMENT", 341, 383], ["Fugene6 transfection reagent", "TREATMENT", 399, 427]]], ["The transfected cells then were subjected to puromycin selection (1 mg/ml) (Gibco/Life Technologies) to enrich for cells containing the L1 expression plasmids.", [["cells", "ANATOMY", 16, 21], ["cells", "ANATOMY", 115, 120], ["plasmids", "ANATOMY", 150, 158], ["puromycin", "CHEMICAL", 45, 54], ["puromycin", "CHEMICAL", 45, 54], ["cells", "CELL", 16, 21], ["puromycin", "SIMPLE_CHEMICAL", 45, 54], ["cells", "CELL", 115, 120], ["transfected cells", "CELL_LINE", 4, 21], ["L1 expression plasmids", "DNA", 136, 158], ["The transfected cells", "PROBLEM", 0, 21], ["puromycin selection", "TREATMENT", 45, 64], ["Gibco/Life Technologies", "TREATMENT", 76, 99], ["cells", "PROBLEM", 115, 120], ["the L1 expression plasmids", "TREATMENT", 132, 158], ["transfected cells", "OBSERVATION", 4, 21], ["L1", "ANATOMY", 136, 138]]], ["After 4 days, the cells from each well were detached with a nonenzymatic cell dissociation solution (Cellgro), washed with PBS containing 1% FBS and analyzed on a FACScan (Becton-Dickinson) without fixation.", [["cells", "ANATOMY", 18, 23], ["cell", "ANATOMY", 73, 77], ["FBS", "ANATOMY", 141, 144], ["cells", "CELL", 18, 23], ["cell", "CELL", 73, 77], ["Cellgro", "SIMPLE_CHEMICAL", 101, 108], ["FBS", "ORGANISM_SUBSTANCE", 141, 144], ["a nonenzymatic cell dissociation solution", "TREATMENT", 58, 99], ["PBS", "TREATMENT", 123, 126], ["1% FBS", "TREATMENT", 138, 144], ["a FACScan", "TEST", 161, 170], ["fixation", "TREATMENT", 198, 206], ["nonenzymatic cell dissociation", "OBSERVATION", 60, 90]]], ["For each sample, 2 \u00c2 10 5 cells were analyzed.", [["sample", "ANATOMY", 9, 15], ["cells", "ANATOMY", 26, 31], ["cells", "CELL", 26, 31]]], ["Data were analyzed with FlowJo software (TreeStar Inc.).Retrotransposition assaysIn experiments to study the effect of endogenous RNase L on L1 retrotransposition, Hey1b cells (4 \u00c2 10 5 cells/well) were plated in a six-well tissue culture dish.", [["Hey1b cells", "ANATOMY", 164, 175], ["cells", "ANATOMY", 186, 191], ["tissue", "ANATOMY", 224, 230], ["RNase L", "GENE_OR_GENE_PRODUCT", 130, 137], ["Hey1b cells", "CELL", 164, 175], ["cells", "CELL", 186, 191], ["tissue", "TISSUE", 224, 230], ["RNase L", "PROTEIN", 130, 137], ["Hey1b cells", "CELL_LINE", 164, 175], ["Retrotransposition assays", "TEST", 56, 81], ["endogenous RNase L on L1 retrotransposition", "TREATMENT", 119, 162], ["Hey1b cells", "TEST", 164, 175], ["L1", "ANATOMY", 141, 143], ["well tissue", "OBSERVATION_MODIFIER", 219, 230]]], ["The next day, the cells were transfected with 50 nM of a control siRNA pool (sc-37007, Santa Cruz Biotechnology) or an siRNA pool against RNase L (sc-45965, Santa Cruz Biotechnology) using the DharmaFECT 1 transfection reagent (Thermo Scientific).", [["cells", "ANATOMY", 18, 23], ["sc-37007", "CHEMICAL", 77, 85], ["sc-45965", "CHEMICAL", 147, 155], ["cells", "CELL", 18, 23], ["RNase L", "GENE_OR_GENE_PRODUCT", 138, 145], ["Santa Cruz Biotechnology", "PROTEIN", 87, 111], ["RNase L", "PROTEIN", 138, 145], ["Santa Cruz Biotechnology", "PROTEIN", 157, 181], ["the DharmaFECT 1 transfection reagent", "TREATMENT", 189, 226]]], ["Twenty-four hours later, the cells in each well were transfected with pLRE3-mEGFPI or pJM111-LRE3-mEGFPI (1 mg), using 3 ml of the Fugene6 transfection reagent (Roche).", [["cells", "ANATOMY", 29, 34], ["pJM111-LRE3-mEGFPI", "CHEMICAL", 86, 104], ["cells", "CELL", 29, 34], ["pLRE3-mEGFPI", "GENE_OR_GENE_PRODUCT", 70, 82], ["pJM111-LRE3-mEGFPI", "SIMPLE_CHEMICAL", 86, 104], ["pLRE3", "PROTEIN", 70, 75], ["mEGFPI", "PROTEIN", 76, 82], ["pJM111", "PROTEIN", 86, 92], ["LRE3", "PROTEIN", 93, 97], ["mEGFPI", "PROTEIN", 98, 104], ["pLRE3", "TREATMENT", 70, 75], ["mEGFPI", "TREATMENT", 76, 82], ["pJM111", "TREATMENT", 86, 92], ["LRE3", "TREATMENT", 93, 97], ["mEGFPI", "TREATMENT", 98, 104], ["the Fugene6 transfection reagent", "TREATMENT", 127, 159]]], ["After another 12 h, cells were trypsinized and counted as noted above.", [["cells", "ANATOMY", 20, 25], ["cells", "CELL", 20, 25]]], ["An aliquot of the cells (one-tenth) was used to monitor the endogenous RNase L protein level.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["RNase L", "GENE_OR_GENE_PRODUCT", 71, 78], ["RNase L protein", "PROTEIN", 71, 86], ["An aliquot of the cells", "TREATMENT", 0, 23], ["the endogenous RNase L protein level", "TEST", 56, 92]]], ["The remaining cells were replated (one well was split into three wells to generate triplicate technical replicates) and were subjected to 4 days of puromycin selection (1 mg/ml, Gibco/Life Technologies).", [["cells", "ANATOMY", 14, 19], ["puromycin", "CHEMICAL", 148, 157], ["puromycin", "CHEMICAL", 148, 157], ["cells", "CELL", 14, 19], ["puromycin", "SIMPLE_CHEMICAL", 148, 157], ["puromycin selection", "TREATMENT", 148, 167], ["Gibco/Life Technologies", "TREATMENT", 178, 201], ["remaining cells", "OBSERVATION", 4, 19]]], ["After 4 days of puromycin selection (5 and 6 days after transfection with L1 construct and siRNA, respectively), the percentage of GFP positive cells was determined by flow cytometry as described above.Retrotransposition assaysPreparation of L1 RNPs, total cell lysates and western blot assays L1 RNPs were isolated as described previously (38) with some modifications.", [["GFP positive cells", "ANATOMY", 131, 149], ["cell lysates", "ANATOMY", 257, 269], ["puromycin", "CHEMICAL", 16, 25], ["puromycin", "CHEMICAL", 16, 25], ["puromycin", "SIMPLE_CHEMICAL", 16, 25], ["GFP", "GENE_OR_GENE_PRODUCT", 131, 134], ["cells", "CELL", 144, 149], ["L1 construct", "DNA", 74, 86], ["GFP positive cells", "CELL_LINE", 131, 149], ["L1 RNPs", "PROTEIN", 242, 249], ["puromycin selection", "TREATMENT", 16, 35], ["transfection with L1 construct and siRNA", "TREATMENT", 56, 96], ["GFP positive cells", "PROBLEM", 131, 149], ["flow cytometry", "TEST", 168, 182], ["Retrotransposition assays", "TEST", 202, 227], ["L1 RNPs", "TREATMENT", 242, 249], ["total cell lysates", "TREATMENT", 251, 269], ["western blot assays", "TEST", 274, 293], ["positive cells", "OBSERVATION", 135, 149], ["flow cytometry", "OBSERVATION", 168, 182], ["L1", "ANATOMY", 242, 244]]], ["Briefly, HeLa-M cells were plated into two identical sets of six-well plates.", [["HeLa-M cells", "ANATOMY", 9, 21], ["HeLa-M cells", "CELL", 9, 21], ["HeLa-M cells", "CELL_LINE", 9, 21], ["HeLa-M cells", "TREATMENT", 9, 21]]], ["The next day, the cells in each well were co-transfected with 0.5 mg of an engineered L1 expression construct (pAD2TE1, pDK500 or pAD500) and 0.5 mg of a corresponding RNase L plasmid (FLAG-WT RNase L, FLAG-RNase L R667A or FLAG-RNase L N\u00c1385) using 3 ml of the Fugene6 transfection reagent (Roche).", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["RNase L", "GENE_OR_GENE_PRODUCT", 168, 175], ["FLAG", "GENE_OR_GENE_PRODUCT", 185, 189], ["RNase L", "GENE_OR_GENE_PRODUCT", 193, 200], ["FLAG-RNase L R667A", "GENE_OR_GENE_PRODUCT", 202, 220], ["FLAG-RNase L N\u00c1385", "GENE_OR_GENE_PRODUCT", 224, 242], ["L1 expression construct", "DNA", 86, 109], ["pAD2TE1", "PROTEIN", 111, 118], ["RNase L plasmid", "DNA", 168, 183], ["FLAG", "PROTEIN", 185, 189], ["WT RNase L", "PROTEIN", 190, 200], ["FLAG", "PROTEIN", 202, 206], ["RNase L R667A", "PROTEIN", 207, 220], ["FLAG", "PROTEIN", 224, 228], ["RNase L N\u00c1385", "PROTEIN", 229, 242], ["the cells", "TREATMENT", 14, 23], ["an engineered L1 expression construct", "TREATMENT", 72, 109], ["a corresponding RNase L plasmid", "TREATMENT", 152, 183], ["FLAG", "TEST", 185, 189], ["FLAG", "TEST", 202, 206], ["RNase", "TEST", 207, 212], ["FLAG", "TEST", 224, 228], ["the Fugene6 transfection reagent", "TREATMENT", 258, 290]]], ["The cells in one set of plates were harvested 48 h after transfection, and RNase L expression was monitored using an RNase L monoclonal antibody by western blot.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["RNase L", "GENE_OR_GENE_PRODUCT", 75, 82], ["RNase L", "GENE_OR_GENE_PRODUCT", 117, 124], ["RNase L", "PROTEIN", 75, 82], ["RNase L monoclonal antibody", "PROTEIN", 117, 144], ["The cells", "TREATMENT", 0, 9], ["transfection", "TEST", 57, 69], ["RNase L expression", "TEST", 75, 93], ["an RNase L monoclonal antibody", "TEST", 114, 144], ["plates", "OBSERVATION_MODIFIER", 24, 30], ["monoclonal antibody", "OBSERVATION", 125, 144]]], ["Cells from the other set of plates were replated into a 10-cm dish and were subjected to selection in DMEM medium supplemented with hygromycin (200 mg/ml) (Gibco/Life Technologies) for four additional days to detect L1 protein expression 6 days after transfection.", [["Cells", "ANATOMY", 0, 5], ["hygromycin", "CHEMICAL", 132, 142], ["hygromycin", "CHEMICAL", 132, 142], ["Cells", "CELL", 0, 5], ["hygromycin", "SIMPLE_CHEMICAL", 132, 142], ["L1 protein", "PROTEIN", 216, 226], ["Cells", "TEST", 0, 5], ["selection in DMEM medium", "TREATMENT", 89, 113], ["hygromycin", "TREATMENT", 132, 142], ["Gibco/Life Technologies", "TREATMENT", 156, 179], ["L1 protein expression", "PROBLEM", 216, 237], ["plates", "OBSERVATION", 28, 34], ["10-cm dish", "OBSERVATION_MODIFIER", 56, 66]]], ["The remaining cells then were harvested and were resuspended in 1 ml of lysis buffer (20 mM HEPES, pH 7.5; 1.5 mM KCl; 2.5 mM MgCl 2 ; 0.5% NP-40) containing complete mini EDTA-free protease inhibitor cocktail (Roche) per 0.5 ml of packed cell volume.", [["cells", "ANATOMY", 14, 19], ["cell", "ANATOMY", 239, 243], ["KCl", "CHEMICAL", 114, 117], ["NP-40", "CHEMICAL", 140, 145], ["HEPES", "CHEMICAL", 92, 97], ["KCl", "CHEMICAL", 114, 117], ["MgCl 2", "CHEMICAL", 126, 132], ["EDTA", "CHEMICAL", 172, 176], ["cells", "CELL", 14, 19], ["NP-40", "SIMPLE_CHEMICAL", 140, 145], ["EDTA", "SIMPLE_CHEMICAL", 172, 176], ["cell", "CELL", 239, 243], ["lysis buffer", "TREATMENT", 72, 84], ["HEPES", "TEST", 92, 97], ["pH", "TEST", 99, 101], ["KCl", "TEST", 114, 117], ["MgCl", "TEST", 126, 130], ["complete mini EDTA", "TREATMENT", 158, 176], ["free protease inhibitor cocktail", "TREATMENT", 177, 209], ["packed cell volume", "TREATMENT", 232, 250], ["remaining cells", "OBSERVATION", 4, 19]]], ["After incubation on ice for 10 min, cell lysates were centrifuged at 3000 \u00c2 g for 10 min at 4 C to remove cell debris.", [["cell lysates", "ANATOMY", 36, 48], ["cell", "ANATOMY", 106, 110], ["cell lysates", "ORGANISM_SUBSTANCE", 36, 48], ["cell", "CELL", 106, 110], ["ice", "TREATMENT", 20, 23], ["cell lysates", "TREATMENT", 36, 48], ["cell debris", "PROBLEM", 106, 117], ["cell debris", "OBSERVATION", 106, 117]]], ["Protein concentrations were determined with Bradford assays (Biorad).", [["Protein concentrations", "TEST", 0, 22], ["Bradford assays", "TEST", 44, 59]]], ["One-fiftieth of the supernatants ($50 mg of total protein) was used for protein analysis (total cell lysates in Figure 8 and Supplementary Figures S4 and S5) .", [["supernatants", "ANATOMY", 20, 32], ["cell lysates", "ANATOMY", 96, 108], ["S5", "PROTEIN", 154, 156], ["total protein)", "TREATMENT", 44, 58], ["protein analysis", "TEST", 72, 88], ["total cell lysates", "TEST", 90, 108], ["Figure", "TEST", 112, 118]]], ["Aliquots of total cell lysate ($150 mg) were ultracentrifuged at 160 000 \u00c2 g for 90 min to concentrate the L1 RNP fraction.", [["Aliquots", "ANATOMY", 0, 8], ["cell lysate", "ANATOMY", 18, 29], ["cell", "CELL", 18, 22], ["total cell lysate", "TREATMENT", 12, 29], ["L1", "ANATOMY", 107, 109], ["RNP fraction", "OBSERVATION", 110, 122]]], ["After ultracentrifugation, the supernatants were removed, the pellets were resuspended with 50 ml 1 \u00c2 sodium dodecyl sulphatepolyacrylamide gel electrophoresis sample buffer (Novagen) and 20 ml were used for western blot analysis (RNP fractions in Figure 8 and Supplementary Figures S4 and S5 ).Retrotransposition assaysFor control experiments, an EGFP-encoding plasmid, pEGFP-C1 (Clontech), was co-transfected with a corresponding RNase L expression plasmid (WT, R667A and N\u00c1385) into HeLa-M cells.", [["supernatants", "ANATOMY", 31, 43], ["HeLa-M cells", "ANATOMY", 486, 498], ["sodium dodecyl sulphatepolyacrylamide", "CHEMICAL", 102, 139], ["sodium dodecyl sulphatepolyacrylamide", "CHEMICAL", 102, 139], ["sodium dodecyl sulphatepolyacrylamide", "SIMPLE_CHEMICAL", 102, 139], ["EGFP", "GENE_OR_GENE_PRODUCT", 348, 352], ["pEGFP-C1", "GENE_OR_GENE_PRODUCT", 371, 379], ["Clontech", "GENE_OR_GENE_PRODUCT", 381, 389], ["RNase L", "GENE_OR_GENE_PRODUCT", 432, 439], ["HeLa-M cells", "CELL", 486, 498], ["EGFP-encoding plasmid", "DNA", 348, 369], ["pEGFP", "DNA", 371, 376], ["C1", "DNA", 377, 379], ["Clontech", "DNA", 381, 389], ["RNase L expression plasmid", "DNA", 432, 458], ["R667A", "DNA", 464, 469], ["N\u00c1385", "DNA", 474, 479], ["HeLa-M cells", "CELL_LINE", 486, 498], ["ultracentrifugation", "TREATMENT", 6, 25], ["the supernatants", "TREATMENT", 27, 43], ["the pellets", "TREATMENT", 58, 69], ["sodium dodecyl sulphatepolyacrylamide gel electrophoresis sample buffer (Novagen)", "TREATMENT", 102, 183], ["blot analysis", "TEST", 216, 229], ["RNP fractions", "TEST", 231, 244], ["Retrotransposition assays", "TEST", 295, 320], ["control experiments", "TEST", 324, 343], ["an EGFP", "TEST", 345, 352], ["encoding plasmid", "TREATMENT", 353, 369], ["a corresponding RNase L expression plasmid", "TREATMENT", 416, 458], ["WT", "TEST", 460, 462], ["C1", "ANATOMY", 377, 379]]], ["Total cell lysates were prepared 48 h after transfection (as described above) and were analyzed in western blots.Retrotransposition assaysIn general, western blots were developed using the ECL substrate (GE Healthcare) and exposed to autoradiography film (Denville Scientific).", [["cell lysates", "ANATOMY", 6, 18], ["cell lysates", "ORGANISM_SUBSTANCE", 6, 18], ["Total cell lysates", "TREATMENT", 0, 18], ["Retrotransposition assays", "TEST", 113, 138], ["western blots", "PROBLEM", 150, 163], ["the ECL substrate (GE Healthcare", "TREATMENT", 185, 217], ["autoradiography film", "TEST", 234, 254]]], ["The Western Bright ECL HRP Substrate (Advansta) was used to detect ORF1p expressed from the pAD2TE1 and pDK500 expression constructs, as well as ORF2p from the pAD500 expression construct.", [["HRP", "GENE_OR_GENE_PRODUCT", 23, 26], ["ORF1p", "GENE_OR_GENE_PRODUCT", 67, 72], ["pAD2TE1", "GENE_OR_GENE_PRODUCT", 92, 99], ["pDK500", "GENE_OR_GENE_PRODUCT", 104, 110], ["ORF2p", "GENE_OR_GENE_PRODUCT", 145, 150], ["pAD500", "GENE_OR_GENE_PRODUCT", 160, 166], ["ORF1p", "PROTEIN", 67, 72], ["pAD2TE1 and pDK500 expression constructs", "DNA", 92, 132], ["ORF2p", "DNA", 145, 150], ["pAD500 expression construct", "DNA", 160, 187], ["Bright ECL HRP Substrate (Advansta)", "TREATMENT", 12, 47]]], ["The SuperSignal West Pico Chemiluminescent Substrate (Pierce) was used to detect ORF2p expressed from pAD2TE1 construct.Retrotransposition assaysThe following antibodies were used in western blotting experiments: mouse anti-T7 (1:5000 dilution, Novagen), Quantitative real time polymerase chain reaction to detect L1 RNA HeLa-M cells were co-transfected with 0.5 mg of pAD2TE1 and 0.5 mg of one of the following vectors: pFLAG-CMV-2 empty vector, FLAG-tagged WT RNase L or FLAG-tagged RNase L R667A.", [["HeLa-M cells", "ANATOMY", 321, 333], ["pAD2TE1", "CHEMICAL", 369, 376], ["pAD2TE1", "CHEMICAL", 369, 376], ["ORF2p", "GENE_OR_GENE_PRODUCT", 81, 86], ["pAD2TE1", "GENE_OR_GENE_PRODUCT", 102, 109], ["mouse", "ORGANISM", 213, 218], ["Novagen", "GENE_OR_GENE_PRODUCT", 245, 252], ["HeLa-M cells", "CELL", 321, 333], ["pAD2TE1", "SIMPLE_CHEMICAL", 369, 376], ["CMV", "ORGANISM", 427, 430], ["FLAG", "GENE_OR_GENE_PRODUCT", 447, 451], ["RNase L", "GENE_OR_GENE_PRODUCT", 462, 469], ["FLAG", "GENE_OR_GENE_PRODUCT", 473, 477], ["RNase L R667A", "GENE_OR_GENE_PRODUCT", 485, 498], ["ORF2p", "PROTEIN", 81, 86], ["pAD2TE1 construct", "DNA", 102, 119], ["mouse anti-T7", "PROTEIN", 213, 226], ["Novagen", "PROTEIN", 245, 252], ["M cells", "CELL_LINE", 326, 333], ["pFLAG-CMV-2 empty vector", "DNA", 421, 445], ["FLAG-tagged WT RNase L", "PROTEIN", 447, 469], ["FLAG", "PROTEIN", 473, 477], ["RNase L R667A", "PROTEIN", 485, 498], ["mouse", "SPECIES", 213, 218], ["mouse", "SPECIES", 213, 218], ["The SuperSignal West Pico Chemiluminescent Substrate (Pierce)", "TREATMENT", 0, 61], ["Retrotransposition assays", "TEST", 120, 145], ["The following antibodies", "TREATMENT", 145, 169], ["mouse anti-T7 (1:5000 dilution", "TREATMENT", 213, 243], ["Novagen", "TREATMENT", 245, 252], ["Quantitative real time polymerase chain reaction", "PROBLEM", 255, 303], ["pAD2TE1", "TREATMENT", 369, 376], ["pFLAG", "TEST", 421, 426], ["CMV", "TEST", 427, 430], ["FLAG", "TEST", 447, 451], ["FLAG", "TEST", 473, 477]]], ["Forty-eight hours later, total RNA was prepared with Trizol (Gibco/ Life Technologies) according to manufacturer's protocol.", [["total RNA", "TREATMENT", 25, 34], ["Trizol (Gibco/ Life Technologies", "TREATMENT", 53, 85], ["manufacturer's protocol", "TREATMENT", 100, 123]]], ["After contaminating DNA was removed using a Turbo DNA-free kit (Ambion), cDNA was synthesized using the High Capacity cDNA Reverse Transcription (RT) kit (Gibco/Life Technologies).", [["DNA", "CELLULAR_COMPONENT", 20, 23], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["Ambion", "ORGANISM", 64, 70], ["Turbo DNA-free kit", "DNA", 44, 62], ["cDNA", "DNA", 73, 77], ["contaminating DNA", "PROBLEM", 6, 23], ["a Turbo DNA", "TREATMENT", 42, 53], ["free kit (Ambion)", "TREATMENT", 54, 71], ["cDNA", "TREATMENT", 73, 77], ["the High Capacity cDNA Reverse Transcription (RT) kit (Gibco/Life Technologies", "TREATMENT", 100, 178]]], ["The resultant cDNA was amplified using Sybr Green PCR master mix (Gibco/Life Technologies) on a StepOnePlus system according to manufacturer's protocol.", [["cDNA", "DNA", 14, 18], ["The resultant cDNA", "TREATMENT", 0, 18], ["Gibco/Life Technologies", "TREATMENT", 66, 89], ["a StepOnePlus system", "TREATMENT", 94, 114], ["manufacturer's protocol", "TREATMENT", 128, 151]]], ["Primers were designed to amplify a 91-bp fragment specific to pAD2TE1 mRNA.", [["pAD2TE1", "GENE_OR_GENE_PRODUCT", 62, 69], ["91-bp fragment", "DNA", 35, 49], ["pAD2TE1 mRNA", "RNA", 62, 74], ["a 91-bp fragment", "TREATMENT", 33, 49]]], ["The product spanned the junction of L1 ORF2 gene and the coding sequences of the engineered TAP epitope-tag in pAD2TE1 ( Figure 1A ).Retrotransposition assaysThe following primers were used to detect L1 RNA from pAD2TE1:Retrotransposition assaysThe following primers were used to detect the HYG mRNA from the pCEP4 backbone: forward primer (F2), 5 0 -CA GCGAGAGCCTGACCTATTG-3 0 ; reverse primer (R2), 5 0 -CAGGCAGGTCTTGCAACGT-3 0 .Retrotransposition assaysAll the primers were designed with Primer Express 3.0 software (Applied Biosystems) and data were analyzed with the 2 -\u00c1\u00c1CT method (75) .ImmunofluorescenceImmunofluorescence experiments to detect the co-expression of the L1 and RNase L proteins were performed as described previously with minor modifications (66) .", [["TAP", "GENE_OR_GENE_PRODUCT", 92, 95], ["L1", "GENE_OR_GENE_PRODUCT", 677, 679], ["RNase L", "GENE_OR_GENE_PRODUCT", 684, 691], ["L1 ORF2 gene", "DNA", 36, 48], ["TAP epitope", "PROTEIN", 92, 103], ["pAD2TE1", "PROTEIN", 111, 118], ["Figure 1A", "PROTEIN", 121, 130], ["L1 RNA", "RNA", 200, 206], ["pAD2TE1", "DNA", 212, 219], ["HYG mRNA", "RNA", 291, 299], ["pCEP4 backbone", "DNA", 309, 323], ["reverse primer", "DNA", 380, 394], ["L1", "PROTEIN", 677, 679], ["RNase L proteins", "PROTEIN", 684, 700], ["the engineered TAP epitope", "TREATMENT", 77, 103], ["Retrotransposition assays", "TEST", 133, 158], ["The following primers", "TREATMENT", 158, 179], ["Retrotransposition assays", "TEST", 220, 245], ["the HYG mRNA", "TEST", 287, 299], ["GCGAGAGCCTGACCTATTG", "TEST", 354, 373], ["CAGGCAGGTCTTGCAACGT", "TEST", 406, 425], ["Retrotransposition assays", "TEST", 431, 456], ["ImmunofluorescenceImmunofluorescence experiments", "TEST", 593, 641], ["RNase L proteins", "TEST", 684, 700], ["junction", "ANATOMY_MODIFIER", 24, 32], ["L1 ORF2", "ANATOMY", 36, 43], ["L1", "ANATOMY", 200, 202], ["Retrotransposition assays", "OBSERVATION", 220, 245], ["L1", "ANATOMY", 677, 679]]], ["Briefly, HeLa-M cells (8 \u00c2 10 4 ) were plated onto sterile glass cover slips in each well of six-well tissue culture plates.", [["HeLa-M cells", "ANATOMY", 9, 21], ["HeLa-M cells", "CELL", 9, 21], ["HeLa-M cells", "CELL_LINE", 9, 21], ["HeLa-M cells", "TREATMENT", 9, 21], ["sterile glass cover slips", "TREATMENT", 51, 76]]], ["The next day, adherent cells were co-transfected with 1 mg of pES2TE1 and 1 mg of one of the following constructs: an empty vector (pcDNA 3.0) (Gibco/Life Technologies/InVitrogen), a Myc-tagged WT RNase L or a Myc-tagged catalytically inactive RNase L mutant (R667A), using 6 ml of the Fugene6 transfection reagent.", [["cells", "ANATOMY", 23, 28], ["pES2TE1", "CHEMICAL", 62, 69], ["pES2TE1", "CHEMICAL", 62, 69], ["cells", "CELL", 23, 28], ["InVitrogen", "GENE_OR_GENE_PRODUCT", 168, 178], ["RNase L", "GENE_OR_GENE_PRODUCT", 197, 204], ["RNase L", "GENE_OR_GENE_PRODUCT", 244, 251], ["adherent cells", "CELL_TYPE", 14, 28], ["InVitrogen", "PROTEIN", 168, 178], ["Myc-tagged WT RNase L", "PROTEIN", 183, 204], ["Myc-tagged catalytically inactive RNase L mutant", "PROTEIN", 210, 258], ["R667A", "PROTEIN", 260, 265], ["adherent cells", "PROBLEM", 14, 28], ["pES2TE1", "TREATMENT", 62, 69], ["an empty vector (pcDNA", "TREATMENT", 115, 137], ["Gibco/Life Technologies", "TREATMENT", 144, 167], ["the Fugene6 transfection reagent", "TREATMENT", 282, 314]]], ["Forty-eight hours after transfection, the cells were fixed with freshly prepared 4% paraformaldehyde (Electron Microscopy Sciences) in 1 \u00c2 PBS for 10 min at room temperature.", [["cells", "ANATOMY", 42, 47], ["paraformaldehyde", "CHEMICAL", 84, 100], ["cells", "CELL", 42, 47], ["paraformaldehyde", "SIMPLE_CHEMICAL", 84, 100], ["transfection", "TREATMENT", 24, 36]]], ["The fixed cells were washed three times with PBS and permeabilized by treatment with ice-cold anhydrous methanol for 1 min at \u00c020 C. After another 1 \u00c2 PBS wash, cells were blocked by incubation with 3% goat serum and 0.1% Triton X-100 in 1 \u00c2 PBS for 1 h at room temperature.", [["cells", "ANATOMY", 10, 15], ["cells", "ANATOMY", 161, 166], ["serum", "ANATOMY", 207, 212], ["anhydrous methanol", "CHEMICAL", 94, 112], ["Triton X-100", "CHEMICAL", 222, 234], ["methanol", "CHEMICAL", 104, 112], ["cells", "CELL", 10, 15], ["methanol", "SIMPLE_CHEMICAL", 104, 112], ["cells", "CELL", 161, 166], ["goat", "ORGANISM", 202, 206], ["serum", "ORGANISM_SUBSTANCE", 207, 212], ["Triton X-100", "SIMPLE_CHEMICAL", 222, 234], ["goat", "SPECIES", 202, 206], ["goat", "SPECIES", 202, 206], ["The fixed cells", "TREATMENT", 0, 15], ["PBS", "TREATMENT", 45, 48], ["ice-cold anhydrous methanol", "TREATMENT", 85, 112], ["another 1 \u00c2 PBS wash", "TREATMENT", 139, 159], ["serum", "TEST", 207, 212], ["fixed cells", "OBSERVATION", 4, 15]]], ["The permeabilized cells then were incubated with primary antibodies overnight at 4 C in a humidified chamber.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["permeabilized cells", "CELL_LINE", 4, 23], ["primary antibodies", "PROTEIN", 49, 67], ["primary antibodies", "TEST", 49, 67], ["a humidified chamber", "TREATMENT", 88, 108], ["permeabilized cells", "OBSERVATION", 4, 23]]], ["The cells were washed three times with 1 \u00c2 PBS and incubated with secondary antibodies for 1 h at 37 C in the dark.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["secondary antibodies", "PROTEIN", 66, 86], ["1 \u00c2 PBS", "TREATMENT", 39, 46], ["secondary antibodies", "PROBLEM", 66, 86]]], ["After four 1 \u00c2 PBS washes, the coverslips were mounted with Vectashield mounting media with DAPI (Vector Labs) and sealed with nail polish to prevent drying.ImmunofluorescenceL1 RNA was detected with the MS2-GFP labeling technique (66, 76) .", [["DAPI", "CHEMICAL", 92, 96], ["DAPI", "SIMPLE_CHEMICAL", 92, 96], ["ImmunofluorescenceL1", "GENE_OR_GENE_PRODUCT", 157, 177], ["GFP", "GENE_OR_GENE_PRODUCT", 208, 211], ["ImmunofluorescenceL1 RNA", "RNA", 157, 181], ["1 \u00c2 PBS washes", "TREATMENT", 11, 25], ["the coverslips", "TREATMENT", 27, 41], ["Vectashield mounting media", "TREATMENT", 60, 86], ["DAPI (Vector Labs", "TEST", 92, 109], ["ImmunofluorescenceL1 RNA", "TEST", 157, 181], ["the MS2", "TEST", 200, 207], ["nail", "ANATOMY", 127, 131]]], ["HeLa-M cells were co-transfected with pAD3TE1 and pMS2-GFP as noted above.", [["HeLa-M cells", "ANATOMY", 0, 12], ["HeLa-M cells", "CELL", 0, 12], ["pAD3TE1", "GENE_OR_GENE_PRODUCT", 38, 45], ["pMS2-GFP", "GENE_OR_GENE_PRODUCT", 50, 58], ["HeLa", "CELL_LINE", 0, 4], ["M cells", "CELL_LINE", 5, 12], ["pAD3TE1", "PROTEIN", 38, 45], ["pMS2", "DNA", 50, 54], ["GFP", "PROTEIN", 55, 58], ["HeLa-M cells", "TEST", 0, 12], ["pAD3TE1", "TEST", 38, 45], ["pMS2", "TEST", 50, 54], ["GFP", "TEST", 55, 58]]], ["A nuclearlocalization signal restricts GFP-MS2 chimera to the nucleus, where it associates with L1 RNA through MS2binding sites present in the pAD3TE1 3 0 -UTR (66) .", [["nucleus", "ANATOMY", 62, 69], ["GFP", "GENE_OR_GENE_PRODUCT", 39, 42], ["nucleus", "CELLULAR_COMPONENT", 62, 69], ["MS2binding", "GENE_OR_GENE_PRODUCT", 111, 121], ["GFP", "PROTEIN", 39, 42], ["MS2 chimera", "PROTEIN", 43, 54], ["L1 RNA", "RNA", 96, 102], ["MS2binding sites", "DNA", 111, 127], ["pAD3TE1 3 0 -UTR", "DNA", 143, 159], ["A nuclearlocalization signal restricts GFP", "TEST", 0, 42], ["L1 RNA through MS2binding sites", "PROBLEM", 96, 127], ["MS2 chimera", "OBSERVATION", 43, 54], ["nucleus", "ANATOMY", 62, 69], ["L1 RNA", "OBSERVATION", 96, 102]]], ["Cytoplasmic GFP signals (white arrows, Figure 7 ) indicate the location of engineered L1 RNA after nuclear export.ImmunofluorescenceAll the primary and secondary antibodies were diluted in blocking buffer (3% goat serum, 0.1% Triton X-100 in 1\u00c2 PBS).", [["Cytoplasmic", "ANATOMY", 0, 11], ["nuclear", "ANATOMY", 99, 106], ["serum", "ANATOMY", 214, 219], ["Triton X-100", "CHEMICAL", 226, 238], ["GFP", "GENE_OR_GENE_PRODUCT", 12, 15], ["nuclear", "CELLULAR_COMPONENT", 99, 106], ["goat", "ORGANISM", 209, 213], ["serum", "ORGANISM_SUBSTANCE", 214, 219], ["Triton X-100", "SIMPLE_CHEMICAL", 226, 238], ["L1 RNA", "RNA", 86, 92], ["primary and secondary antibodies", "PROTEIN", 140, 172], ["goat", "SPECIES", 209, 213], ["goat", "SPECIES", 209, 213], ["Cytoplasmic GFP signals", "TEST", 0, 23], ["white arrows", "PROBLEM", 25, 37], ["Immunofluorescence", "TEST", 114, 132], ["secondary antibodies", "TREATMENT", 152, 172], ["blocking buffer", "TREATMENT", 189, 204], ["serum", "TEST", 214, 219], ["GFP signals", "OBSERVATION", 12, 23], ["L1 RNA", "ANATOMY", 86, 92]]], ["The following primary antibodies were used: rat anti-HA (clone 3F10, 1:100 dilution, Roche), mouse anti-EBV nuclear antigen (EBNA-1, 1:100 dilution, Abcam) and rabbit anti-Myc (1:200 dilution, Cell Signaling Technology).", [["Cell", "ANATOMY", 193, 197], ["rat", "ORGANISM", 44, 47], ["anti-HA", "GENE_OR_GENE_PRODUCT", 48, 55], ["mouse", "ORGANISM", 93, 98], ["anti-EBV nuclear antigen", "GENE_OR_GENE_PRODUCT", 99, 123], ["EBNA-1", "GENE_OR_GENE_PRODUCT", 125, 131], ["Abcam", "GENE_OR_GENE_PRODUCT", 149, 154], ["rabbit", "ORGANISM", 160, 166], ["Myc", "GENE_OR_GENE_PRODUCT", 172, 175], ["Cell", "CELL", 193, 197], ["primary antibodies", "PROTEIN", 14, 32], ["rat anti-HA", "PROTEIN", 44, 55], ["clone 3F10", "PROTEIN", 57, 67], ["mouse anti-EBV nuclear antigen", "PROTEIN", 93, 123], ["EBNA", "PROTEIN", 125, 129], ["Abcam", "PROTEIN", 149, 154], ["Myc", "PROTEIN", 172, 175], ["rat", "SPECIES", 44, 47], ["mouse", "SPECIES", 93, 98], ["rabbit", "SPECIES", 160, 166], ["rat", "SPECIES", 44, 47], ["mouse", "SPECIES", 93, 98], ["anti-EBV", "SPECIES", 99, 107], ["rabbit", "SPECIES", 160, 166], ["rat anti-HA", "TREATMENT", 44, 55], ["mouse anti-EBV nuclear antigen", "TEST", 93, 123], ["EBNA", "TEST", 125, 129], ["Abcam", "TEST", 149, 154], ["rabbit anti-Myc", "TREATMENT", 160, 175]]], ["Highly cross-absorbed Alexa Fluor Dyes linked to goat IgG (H+L) secondary antibodies were used at 1:1000 dilution, including Alexa Fluor 488 goat anti-mouse, Alexa Fluor 568 goat anti-mouse, Alexa Fluor 568 goat anti-rat and Alexa Fluor 647 goat antirabbit (Molecular Probes).", [["H+", "CHEMICAL", 59, 61], ["Alexa Fluor 488", "CHEMICAL", 125, 140], ["Alexa Fluor 647", "CHEMICAL", 225, 240], ["Alexa Fluor Dyes", "SIMPLE_CHEMICAL", 22, 38], ["goat", "ORGANISM", 49, 53], ["IgG", "SIMPLE_CHEMICAL", 54, 57], ["H+L", "SIMPLE_CHEMICAL", 59, 62], ["Alexa Fluor", "SIMPLE_CHEMICAL", 125, 136], ["Alexa Fluor", "SIMPLE_CHEMICAL", 158, 169], ["Alexa Fluor", "SIMPLE_CHEMICAL", 191, 202], ["Alexa Fluor", "SIMPLE_CHEMICAL", 225, 236], ["Molecular Probes", "ORGANISM", 258, 274], ["cross-absorbed Alexa Fluor Dyes", "PROTEIN", 7, 38], ["goat IgG (H+L) secondary antibodies", "PROTEIN", 49, 84], ["Alexa Fluor 488 goat anti-mouse", "PROTEIN", 125, 156], ["Alexa Fluor 568 goat anti-mouse", "PROTEIN", 158, 189], ["Alexa Fluor 568 goat anti-rat", "PROTEIN", 191, 220], ["Alexa Fluor 647 goat antirabbit", "PROTEIN", 225, 256], ["Molecular Probes", "PROTEIN", 258, 274], ["goat", "SPECIES", 49, 53], ["goat", "SPECIES", 141, 145], ["anti-mouse", "SPECIES", 146, 156], ["goat", "SPECIES", 174, 178], ["anti-mouse", "SPECIES", 179, 189], ["goat", "SPECIES", 207, 211], ["goat", "SPECIES", 241, 245], ["goat", "SPECIES", 49, 53], ["Alexa Fluor 488", "SPECIES", 125, 140], ["goat", "SPECIES", 141, 145], ["Alexa Fluor 568", "SPECIES", 158, 173], ["goat", "SPECIES", 174, 178], ["Alexa Fluor 568 goat", "SPECIES", 191, 211], ["Alexa Fluor 647 goat antirabbit", "SPECIES", 225, 256], ["Highly cross-absorbed Alexa Fluor Dyes", "TREATMENT", 0, 38], ["goat IgG", "TEST", 49, 57], ["secondary antibodies", "PROBLEM", 64, 84], ["Alexa Fluor", "TREATMENT", 125, 136], ["Alexa Fluor", "TREATMENT", 158, 169], ["Alexa Fluor", "TREATMENT", 191, 202], ["anti-rat and Alexa Fluor", "TREATMENT", 212, 236]]], ["Notably, the entire slide was examined and representative images of each sample slide were captured using a Leica TCS-SP confocal microscope with fluorescent filters.RNase L suppresses the retrotransposition of engineered L1 and IAP elementsWe used previously established cell culture assays to determine whether the expression of an RNase L cDNA affects the retrotransposition of engineered human L1 and mouse IAP retrotransposons ( Figure 1) (13,41,73) .", [["cell", "ANATOMY", 272, 276], ["RNase L", "GENE_OR_GENE_PRODUCT", 166, 173], ["IAP", "GENE_OR_GENE_PRODUCT", 229, 232], ["cell", "CELL", 272, 276], ["RNase L", "GENE_OR_GENE_PRODUCT", 334, 341], ["human", "ORGANISM", 392, 397], ["mouse", "ORGANISM", 405, 410], ["IAP", "GENE_OR_GENE_PRODUCT", 411, 414], ["RNase L", "PROTEIN", 166, 173], ["L1", "DNA", 222, 224], ["IAP elements", "DNA", 229, 241], ["RNase L cDNA", "DNA", 334, 346], ["human L1", "DNA", 392, 400], ["mouse IAP retrotransposons", "DNA", 405, 431], ["human", "SPECIES", 392, 397], ["mouse", "SPECIES", 405, 410], ["human", "SPECIES", 392, 397], ["mouse", "SPECIES", 405, 410], ["each sample slide", "TEST", 68, 85], ["a Leica TCS", "TREATMENT", 106, 117], ["fluorescent filters", "TREATMENT", 146, 165], ["RNase L suppresses the retrotransposition of engineered L1 and IAP elements", "TREATMENT", 166, 241], ["previously established cell culture assays", "TEST", 249, 291], ["an RNase L cDNA", "TREATMENT", 331, 346], ["engineered human L1", "TREATMENT", 381, 400], ["mouse IAP retrotransposons", "PROBLEM", 405, 431], ["fluorescent filters", "OBSERVATION", 146, 165], ["retrotransposition", "OBSERVATION", 189, 207], ["L1", "ANATOMY", 222, 224], ["IAP elements", "ANATOMY_MODIFIER", 229, 241]]], ["Briefly, HeLa-M cells, which are deficient in endogenous RNase L expression (71) ( Figure 3C , Lane 1), were cotransfected with either an engineered retrotransposon [human L1 pJM101/L1.3 (20) ] or mouse IAP [pDJ33/ 440N1neo TNF (13)] and either an empty vector (pFLAG-CMV-2) or a plasmid that expresses an amino-terminal FLAG-tagged version of RNase L [WT RNase L, a catalytically inactive RNase L mutant (R667A), or constitutively active (N\u00c1385) RNase L mutant (70) ].", [["HeLa-M cells", "ANATOMY", 9, 21], ["plasmid", "ANATOMY", 280, 287], ["amino", "CHEMICAL", 306, 311], ["HeLa-M cells", "CELL", 9, 21], ["RNase L", "GENE_OR_GENE_PRODUCT", 57, 64], ["Lane 1", "GENE_OR_GENE_PRODUCT", 95, 101], ["human", "ORGANISM", 166, 171], ["L1.3 (20)", "GENE_OR_GENE_PRODUCT", 182, 191], ["mouse", "ORGANISM", 197, 202], ["IAP", "GENE_OR_GENE_PRODUCT", 203, 206], ["TNF (13)", "GENE_OR_GENE_PRODUCT", 224, 232], ["pFLAG-CMV-2", "GENE_OR_GENE_PRODUCT", 262, 273], ["FLAG", "GENE_OR_GENE_PRODUCT", 321, 325], ["RNase L", "GENE_OR_GENE_PRODUCT", 344, 351], ["WT RNase L", "GENE_OR_GENE_PRODUCT", 353, 363], ["RNase L", "GENE_OR_GENE_PRODUCT", 390, 397], ["HeLa-M cells", "CELL_LINE", 9, 21], ["RNase L", "PROTEIN", 57, 64], ["engineered retrotransposon", "DNA", 138, 164], ["human L1 pJM101", "DNA", 166, 181], ["mouse IAP", "DNA", 197, 206], ["pDJ33", "DNA", 208, 213], ["440N1neo TNF (13)", "DNA", 215, 232], ["empty vector", "DNA", 248, 260], ["pFLAG-CMV-2", "DNA", 262, 273], ["plasmid", "DNA", 280, 287], ["amino-terminal FLAG", "PROTEIN", 306, 325], ["RNase L", "PROTEIN", 344, 351], ["WT RNase L", "PROTEIN", 353, 363], ["catalytically inactive RNase L mutant", "PROTEIN", 367, 404], ["R667A", "PROTEIN", 406, 411], ["N\u00c1385", "PROTEIN", 440, 445], ["RNase L", "PROTEIN", 447, 454], ["human", "SPECIES", 166, 171], ["mouse", "SPECIES", 197, 202], ["human L1 pJM101/L1.3", "SPECIES", 166, 186], ["mouse", "SPECIES", 197, 202], ["an engineered retrotransposon [human L1 pJM101", "TREATMENT", 135, 181], ["mouse IAP", "TREATMENT", 197, 206], ["N1neo TNF", "TREATMENT", 218, 227], ["an empty vector (pFLAG-CMV", "TREATMENT", 245, 271], ["a plasmid", "TREATMENT", 278, 287], ["an amino-terminal FLAG", "TREATMENT", 303, 325], ["RNase L [WT RNase L", "TREATMENT", 344, 363], ["a catalytically inactive RNase L mutant", "PROBLEM", 365, 404]]], ["While the HeLa-M cells used in this study are deficient in RNase L, it should be noted that other types of HeLa cells (including ATCC CCL-2 and S3) express normal levels of endogenous RNase L (77, 78) .", [["HeLa-M cells", "ANATOMY", 10, 22], ["HeLa cells", "ANATOMY", 107, 117], ["ATCC CCL-2", "ANATOMY", 129, 139], ["HeLa-M cells", "CELL", 10, 22], ["RNase L", "GENE_OR_GENE_PRODUCT", 59, 66], ["HeLa cells", "CELL", 107, 117], ["ATCC CCL-2", "CELL", 129, 139], ["S3", "CELL", 144, 146], ["RNase L", "GENE_OR_GENE_PRODUCT", 184, 191], ["HeLa-M cells", "CELL_LINE", 10, 22], ["RNase L", "PROTEIN", 59, 66], ["HeLa cells", "CELL_LINE", 107, 117], ["ATCC CCL-2", "CELL_LINE", 129, 139], ["S3", "CELL_LINE", 144, 146], ["RNase L", "PROTEIN", 184, 191], ["the HeLa-M cells", "TREATMENT", 6, 22], ["this study", "TEST", 31, 41], ["deficient in RNase L", "PROBLEM", 46, 66], ["HeLa cells", "TEST", 107, 117], ["ATCC CCL", "TEST", 129, 137], ["HeLa cells", "OBSERVATION", 107, 117], ["normal", "OBSERVATION", 156, 162], ["endogenous RNase", "OBSERVATION", 173, 189]]], ["Both the L1 and IAP constructs contain a retrotransposition indicator cassette in their 3 0 ends (Figure 1 ).", [["IAP", "GENE_OR_GENE_PRODUCT", 16, 19], ["L1 and IAP constructs", "DNA", 9, 30], ["retrotransposition indicator cassette", "DNA", 41, 78], ["3 0 ends", "DNA", 88, 96], ["a retrotransposition indicator cassette", "TREATMENT", 39, 78], ["L1", "ANATOMY", 9, 11], ["IAP constructs", "OBSERVATION", 16, 30], ["retrotransposition", "OBSERVATION", 41, 59]]], ["The indicator cassette consists of either an antisense copy of a neomycin phosphotransferase gene (mneoI) or an enhanced green fluorescent protein-coding gene (mEGFPI) equipped with a heterologous promoter (Pr 0 ) and polyadenylation signal (lollipop symbol, Figure 1A ) (41, 65, 79) .", [["neomycin", "CHEMICAL", 65, 73], ["neomycin", "CHEMICAL", 65, 73], ["neomycin phosphotransferase", "GENE_OR_GENE_PRODUCT", 65, 92], ["mneoI", "GENE_OR_GENE_PRODUCT", 99, 104], ["green fluorescent protein-coding gene", "GENE_OR_GENE_PRODUCT", 121, 158], ["Pr 0", "GENE_OR_GENE_PRODUCT", 207, 211], ["neomycin phosphotransferase gene", "DNA", 65, 97], ["mneoI", "DNA", 99, 104], ["enhanced green fluorescent protein-coding gene", "DNA", 112, 158], ["mEGFPI", "DNA", 160, 166], ["heterologous promoter", "DNA", 184, 205], ["Pr 0", "DNA", 207, 211], ["lollipop symbol", "DNA", 242, 257], ["a neomycin phosphotransferase gene", "TREATMENT", 63, 97], ["an enhanced green fluorescent protein", "PROBLEM", 109, 146], ["a heterologous promoter", "TREATMENT", 182, 205], ["polyadenylation signal", "TEST", 218, 240]]], ["Notably, both the mneoI and mEGFPI indicator cassettes are disrupted by an intron [IVS2 of the g-globin gene in the L1 constructs (41) and intron 2 of the murine tumor necrosis factor beta (TNF-b) gene in the IAP construct (80) ] that is in the same transcriptional orientation as the L1 or IAP retrotransposon.", [["tumor", "DISEASE", 162, 167], ["mneoI", "GENE_OR_GENE_PRODUCT", 18, 23], ["mEGFPI", "GENE_OR_GENE_PRODUCT", 28, 34], ["g-globin", "GENE_OR_GENE_PRODUCT", 95, 103], ["murine tumor necrosis factor beta", "GENE_OR_GENE_PRODUCT", 155, 188], ["TNF-b", "GENE_OR_GENE_PRODUCT", 190, 195], ["IAP construct (80)", "GENE_OR_GENE_PRODUCT", 209, 227], ["IAP", "GENE_OR_GENE_PRODUCT", 291, 294], ["mneoI and mEGFPI indicator cassettes", "DNA", 18, 54], ["intron", "DNA", 75, 81], ["IVS2", "DNA", 83, 87], ["g-globin gene", "DNA", 95, 108], ["L1 constructs", "DNA", 116, 129], ["41", "DNA", 131, 133], ["intron 2", "DNA", 139, 147], ["murine tumor necrosis factor beta (TNF-b) gene", "DNA", 155, 201], ["IAP construct", "DNA", 209, 222], ["L1", "DNA", 285, 287], ["IAP retrotransposon", "DNA", 291, 310], ["murine", "SPECIES", 155, 161], ["an intron [IVS2 of the g-globin gene in the L1 constructs", "TREATMENT", 72, 129], ["intron", "TREATMENT", 139, 145], ["the murine tumor necrosis", "PROBLEM", 151, 176], ["TNF", "TEST", 190, 193], ["the IAP construct", "TEST", 205, 222], ["L1", "ANATOMY", 116, 118], ["tumor", "OBSERVATION_MODIFIER", 162, 167], ["necrosis", "OBSERVATION", 168, 176], ["IAP", "ANATOMY", 209, 212], ["L1", "ANATOMY", 285, 287], ["IAP retrotransposon", "OBSERVATION", 291, 310]]], ["This arrangement ensures that the reporter gene only will become activated and expressed if the retrotransposon RNA is reverse transcribed and integrated into genomic DNA ( Figure 1B) .", [["retrotransposon", "CELLULAR_COMPONENT", 96, 111], ["DNA", "CELLULAR_COMPONENT", 167, 170], ["reporter gene", "DNA", 34, 47], ["retrotransposon RNA", "RNA", 96, 115], ["genomic DNA", "DNA", 159, 170], ["the retrotransposon RNA", "PROBLEM", 92, 115]]], ["The resultant numbers of G418-resistant foci or EGFP-positive cells serve as a read out of L1 or IAP retrotransposition efficiency ( Figure 1C ) (41, 65) .RNase L suppresses the retrotransposition of engineered L1 and IAP elementsRetrotransposition assays revealed that expression of FLAG-tagged WT or constitutively active RNase L mutant (N\u00c1385) proteins (70) led to a reduction in L1 retrotransposition efficiency in the mneoI-based reporter assays ($72 and $97%, respectively) (Figure 2A and B) .", [["foci", "ANATOMY", 40, 44], ["EGFP-positive cells", "ANATOMY", 48, 67], ["G418", "CHEMICAL", 25, 29], ["G418", "CHEMICAL", 25, 29], ["foci", "CELL", 40, 44], ["EGFP", "GENE_OR_GENE_PRODUCT", 48, 52], ["cells", "CELL", 62, 67], ["IAP", "GENE_OR_GENE_PRODUCT", 97, 100], ["RNase L", "GENE_OR_GENE_PRODUCT", 155, 162], ["IAP", "GENE_OR_GENE_PRODUCT", 218, 221], ["FLAG", "GENE_OR_GENE_PRODUCT", 284, 288], ["RNase L mutant (N\u00c1385)", "GENE_OR_GENE_PRODUCT", 324, 346], ["mneoI", "GENE_OR_GENE_PRODUCT", 423, 428], ["EGFP-positive cells", "CELL_LINE", 48, 67], ["L1", "DNA", 91, 93], ["IAP", "DNA", 97, 100], ["RNase L", "PROTEIN", 155, 162], ["L1", "DNA", 211, 213], ["IAP elements", "DNA", 218, 230], ["FLAG", "PROTEIN", 284, 288], ["tagged WT", "PROTEIN", 289, 298], ["RNase L mutant (N\u00c1385) proteins", "PROTEIN", 324, 355], ["mneoI", "DNA", 423, 428], ["G418", "TEST", 25, 29], ["resistant foci", "PROBLEM", 30, 44], ["EGFP", "TEST", 48, 52], ["positive cells", "PROBLEM", 53, 67], ["IAP retrotransposition efficiency", "PROBLEM", 97, 130], ["RNase L suppresses the retrotransposition of engineered L1 and IAP elements", "TREATMENT", 155, 230], ["Retrotransposition assays", "TEST", 230, 255], ["FLAG", "TEST", 284, 288], ["tagged WT", "TEST", 289, 298], ["constitutively active RNase L mutant (N\u00c1385) proteins", "PROBLEM", 302, 355], ["a reduction in L1 retrotransposition efficiency", "PROBLEM", 368, 415], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["numbers", "OBSERVATION_MODIFIER", 14, 21], ["resistant", "OBSERVATION_MODIFIER", 30, 39], ["foci", "OBSERVATION", 40, 44], ["positive cells", "OBSERVATION", 53, 67], ["L1", "ANATOMY", 91, 93], ["IAP", "ANATOMY", 97, 100], ["retrotransposition efficiency", "OBSERVATION", 101, 130], ["retrotransposition", "OBSERVATION", 178, 196], ["L1", "ANATOMY", 211, 213], ["IAP elements", "ANATOMY_MODIFIER", 218, 230], ["reduction", "OBSERVATION_MODIFIER", 370, 379], ["L1", "ANATOMY", 383, 385], ["retrotransposition efficiency", "OBSERVATION", 386, 415]]], ["In contrast, the FLAG-tagged catalytically inactive RNase L mutant (R667A) did not significantly inhibit L1 retrotransposition (Figure 2A and B) .", [["FLAG", "GENE_OR_GENE_PRODUCT", 17, 21], ["RNase L", "GENE_OR_GENE_PRODUCT", 52, 59], ["FLAG", "PROTEIN", 17, 21], ["catalytically inactive RNase L mutant", "PROTEIN", 29, 66], ["L1 retrotransposition", "DNA", 105, 126], ["the FLAG", "TEST", 13, 21]]], ["As a positive control, we demonstrated that the expression of a FLAG-tagged A3A protein reduced L1 retrotransposition by $50%.", [["FLAG", "GENE_OR_GENE_PRODUCT", 64, 68], ["A3A", "GENE_OR_GENE_PRODUCT", 76, 79], ["FLAG", "PROTEIN", 64, 68], ["A3A protein", "PROTEIN", 76, 87], ["L1 retrotransposition", "DNA", 96, 117], ["a FLAG", "TEST", 62, 68], ["tagged A3A protein reduced L1 retrotransposition", "TREATMENT", 69, 117]]], ["The lower level of A3A expression ( Figure 2C ) may lead to its reduced suppression of L1 retrotransposition when compared with previous studies (68, 81) .", [["A3A", "GENE_OR_GENE_PRODUCT", 19, 22], ["A3A", "PROTEIN", 19, 22], ["L1", "DNA", 87, 89], ["its reduced suppression of L1 retrotransposition", "PROBLEM", 60, 108], ["previous studies", "TEST", 128, 144], ["lower", "ANATOMY_MODIFIER", 4, 9], ["reduced", "OBSERVATION_MODIFIER", 64, 71], ["suppression", "OBSERVATION_MODIFIER", 72, 83], ["L1 retrotransposition", "OBSERVATION", 87, 108]]], ["As a negative control, we demonstrated that the expression of FLAG-tagged RIG-I protein (82), a pathogen recognition receptor for viral RNA, had no significant effect on L1 retrotransposition.", [["FLAG", "GENE_OR_GENE_PRODUCT", 62, 66], ["RIG-I protein (82)", "GENE_OR_GENE_PRODUCT", 74, 92], ["FLAG", "PROTEIN", 62, 66], ["RIG-I protein", "PROTEIN", 74, 87], ["82", "PROTEIN", 89, 91], ["pathogen recognition receptor", "PROTEIN", 96, 125], ["viral RNA", "RNA", 130, 139], ["FLAG", "TEST", 62, 66], ["tagged RIG-I protein", "TEST", 67, 87], ["a pathogen recognition receptor", "TEST", 94, 125], ["viral RNA", "PROBLEM", 130, 139], ["significant effect on L1 retrotransposition", "PROBLEM", 148, 191], ["viral RNA", "OBSERVATION", 130, 139], ["no", "UNCERTAINTY", 145, 147], ["significant", "OBSERVATION_MODIFIER", 148, 159], ["L1", "ANATOMY", 170, 172], ["retrotransposition", "OBSERVATION", 173, 191]]], ["Western blot analyses confirmed that FLAG-tagged RNase L, A3A and RIG proteins were expressed in Hela-M cells ( Figure 2C) .", [["Hela-M cells", "ANATOMY", 97, 109], ["FLAG", "GENE_OR_GENE_PRODUCT", 37, 41], ["RNase L", "GENE_OR_GENE_PRODUCT", 49, 56], ["A3A", "GENE_OR_GENE_PRODUCT", 58, 61], ["RIG", "GENE_OR_GENE_PRODUCT", 66, 69], ["Hela-M cells", "CELL", 97, 109], ["Figure 2C", "CELL", 112, 121], ["FLAG", "PROTEIN", 37, 41], ["RNase L", "PROTEIN", 49, 56], ["A3A", "PROTEIN", 58, 61], ["RIG proteins", "PROTEIN", 66, 78], ["Hela-M cells", "CELL_LINE", 97, 109], ["Western blot analyses", "TEST", 0, 21], ["FLAG", "TEST", 37, 41], ["A3A", "TEST", 58, 61], ["RIG proteins", "PROBLEM", 66, 78]]], ["Moreover, the expression of the RNase L proteins did not significantly impact cell viability ( Figure 3 ).", [["cell", "ANATOMY", 78, 82], ["RNase L", "GENE_OR_GENE_PRODUCT", 32, 39], ["cell", "CELL", 78, 82], ["RNase L proteins", "PROTEIN", 32, 48], ["the RNase L proteins", "PROBLEM", 28, 48], ["cell viability", "OBSERVATION", 78, 92]]], ["To corroborate the above findings, we next tested whether the expression of FLAG-tagged WT RNase L, constitutively active RNase L mutant (N\u00c1385) and catalytically inactive RNase L mutant (R667A) proteins could inhibit the mobility of an engineered human L1 that contains the mEGFPI-based retrotransposition cassette located in the 3 0 -UTR ( Figure 1A ; pLRE3-mEGFPI) (19, 65) .", [["FLAG", "GENE_OR_GENE_PRODUCT", 76, 80], ["RNase L", "GENE_OR_GENE_PRODUCT", 91, 98], ["RNase L mutant (N\u00c1385)", "GENE_OR_GENE_PRODUCT", 122, 144], ["RNase L mutant (R667A)", "GENE_OR_GENE_PRODUCT", 172, 194], ["human", "ORGANISM", 248, 253], ["mEGFPI", "GENE_OR_GENE_PRODUCT", 275, 281], ["pLRE3-mEGFPI", "GENE_OR_GENE_PRODUCT", 354, 366], ["FLAG", "PROTEIN", 76, 80], ["tagged WT RNase L", "PROTEIN", 81, 98], ["RNase L mutant", "PROTEIN", 122, 136], ["N\u00c1385", "PROTEIN", 138, 143], ["catalytically inactive RNase L mutant (R667A) proteins", "PROTEIN", 149, 203], ["human L1", "DNA", 248, 256], ["mEGFPI-based retrotransposition cassette", "DNA", 275, 315], ["3 0 -UTR", "DNA", 331, 339], ["pLRE3", "DNA", 354, 359], ["mEGFPI", "DNA", 360, 366], ["human", "SPECIES", 248, 253], ["human", "SPECIES", 248, 253], ["FLAG", "TEST", 76, 80], ["constitutively active RNase L mutant (N\u00c1385)", "PROBLEM", 100, 144], ["catalytically inactive RNase L mutant (R667A) proteins", "PROBLEM", 149, 203], ["an engineered human L1", "PROBLEM", 234, 256], ["the mEGFPI-based retrotransposition cassette", "TREATMENT", 271, 315], ["mobility", "OBSERVATION_MODIFIER", 222, 230], ["L1", "ANATOMY", 254, 256]]], ["Once again, we found that both the WT and N\u00c1385 RNase L proteins inhibited L1 retrotransposition and that the catalytically inactive R667A RNase L mutant did not ( Figure 4A and Supplementary Figure S1 ).", [["N\u00c1385 RNase L", "GENE_OR_GENE_PRODUCT", 42, 55], ["R667A RNase L", "GENE_OR_GENE_PRODUCT", 133, 146], ["N\u00c1385 RNase L proteins", "PROTEIN", 42, 64], ["L1", "DNA", 75, 77], ["catalytically inactive R667A RNase L mutant", "PROTEIN", 110, 153], ["the WT", "TEST", 31, 37], ["RNase L proteins", "TEST", 48, 64], ["L1 retrotransposition", "PROBLEM", 75, 96]]], ["The control plasmid (pJM111-LRE3-mEGFPI), which carries two missense mutations in ORF1p rendering it inactive, showed only background EGFP expression.RNase L suppresses the retrotransposition of engineered L1 and IAP elementsWestern blot analyses confirmed that the epitope-tagged RNase L and A3A proteins were expressed ( Figure 4B) .", [["pJM111-LRE3-mEGFPI", "GENE_OR_GENE_PRODUCT", 21, 39], ["ORF1p", "GENE_OR_GENE_PRODUCT", 82, 87], ["EGFP", "GENE_OR_GENE_PRODUCT", 134, 138], ["RNase L", "GENE_OR_GENE_PRODUCT", 150, 157], ["IAP", "GENE_OR_GENE_PRODUCT", 213, 216], ["RNase L", "GENE_OR_GENE_PRODUCT", 281, 288], ["A3A", "GENE_OR_GENE_PRODUCT", 293, 296], ["control plasmid", "DNA", 4, 19], ["pJM111", "DNA", 21, 27], ["LRE3", "DNA", 28, 32], ["mEGFPI", "DNA", 33, 39], ["ORF1p", "DNA", 82, 87], ["EGFP", "DNA", 134, 138], ["RNase L", "PROTEIN", 150, 157], ["L1", "DNA", 206, 208], ["IAP elements", "DNA", 213, 225], ["epitope", "PROTEIN", 266, 273], ["RNase L", "PROTEIN", 281, 288], ["A3A proteins", "PROTEIN", 293, 305], ["The control plasmid", "TREATMENT", 0, 19], ["pJM111", "TEST", 21, 27], ["two missense mutations", "PROBLEM", 56, 78], ["RNase L suppresses the retrotransposition of engineered L1 and IAP elements", "TREATMENT", 150, 225], ["Western blot analyses", "TEST", 225, 246], ["the epitope", "TEST", 262, 273], ["tagged RNase L and A3A proteins", "TREATMENT", 274, 305], ["missense mutations", "OBSERVATION", 60, 78], ["EGFP expression", "OBSERVATION", 134, 149], ["retrotransposition", "OBSERVATION", 173, 191], ["L1", "ANATOMY", 206, 208], ["IAP elements", "ANATOMY_MODIFIER", 213, 225]]], ["Notably, the decrease in retrotransposition efficiency ($50%) caused by RNase L expression was less pronounced in the EGFP-based retrotransposition assays when compared with the mneoI-based retrotransposition assay.", [["RNase L", "GENE_OR_GENE_PRODUCT", 72, 79], ["EGFP", "GENE_OR_GENE_PRODUCT", 118, 122], ["RNase L", "PROTEIN", 72, 79], ["EGFP", "DNA", 118, 122], ["mneoI", "DNA", 178, 183], ["the decrease in retrotransposition efficiency", "PROBLEM", 9, 54], ["RNase L expression", "PROBLEM", 72, 90], ["the mneoI", "TEST", 174, 183], ["decrease", "OBSERVATION_MODIFIER", 13, 21], ["retrotransposition efficiency", "OBSERVATION", 25, 54], ["less pronounced", "OBSERVATION_MODIFIER", 95, 110], ["retrotransposition", "OBSERVATION", 129, 147], ["retrotransposition", "OBSERVATION", 190, 208]]], ["These differences may be due to the shorter time duration of the mEGFPI-based retrotransposition assays (6 days) when compared with mneoI-based (12 day) assays.RNase L suppresses the retrotransposition of engineered L1 and IAP elementsTo test whether endogenous RNase L restricts L1 retrotransposition, we used siRNA-based experiments to deplete RNase L in a human ovarian cancer cell line, Hey1b (Supplementary Figure S2) .", [["ovarian cancer cell line", "ANATOMY", 365, 389], ["Hey1b", "ANATOMY", 391, 396], ["mEGFPI", "CHEMICAL", 65, 71], ["ovarian cancer", "DISEASE", 365, 379], ["mEGFPI", "GENE_OR_GENE_PRODUCT", 65, 71], ["RNase L", "GENE_OR_GENE_PRODUCT", 160, 167], ["IAP", "GENE_OR_GENE_PRODUCT", 223, 226], ["RNase L", "GENE_OR_GENE_PRODUCT", 262, 269], ["L1", "GENE_OR_GENE_PRODUCT", 280, 282], ["RNase L", "GENE_OR_GENE_PRODUCT", 346, 353], ["human", "ORGANISM", 359, 364], ["ovarian cancer cell line", "CELL", 365, 389], ["Hey1b", "CELL", 391, 396], ["mEGFPI", "PROTEIN", 65, 71], ["mneoI", "PROTEIN", 132, 137], ["RNase L", "PROTEIN", 160, 167], ["L1", "DNA", 216, 218], ["IAP elements", "DNA", 223, 235], ["RNase L", "PROTEIN", 262, 269], ["L1", "DNA", 280, 282], ["RNase L", "PROTEIN", 346, 353], ["human ovarian cancer cell line", "CELL_LINE", 359, 389], ["Hey1b", "CELL_LINE", 391, 396], ["human", "SPECIES", 359, 364], ["human", "SPECIES", 359, 364], ["the mEGFPI-based retrotransposition assays", "TREATMENT", 61, 103], ["RNase L suppresses the retrotransposition of engineered L1 and IAP elements", "TREATMENT", 160, 235], ["endogenous RNase L restricts L1 retrotransposition", "TREATMENT", 251, 301], ["siRNA", "TREATMENT", 311, 316], ["RNase L", "TREATMENT", 346, 353], ["a human ovarian cancer cell line", "TREATMENT", 357, 389], ["may be due to", "UNCERTAINTY", 18, 31], ["retrotransposition assays", "OBSERVATION", 78, 103], ["retrotransposition", "OBSERVATION", 183, 201], ["L1", "ANATOMY", 216, 218], ["IAP elements", "ANATOMY_MODIFIER", 223, 235], ["ovarian", "ANATOMY", 365, 372], ["cancer cell line", "OBSERVATION", 373, 389]]], ["Hey1b cells express relatively high levels of RNase L typical of some human cancer cell lines, in contrast, RNase L is barely detectable in HeLa-M cells (71) .", [["Hey1b cells", "ANATOMY", 0, 11], ["cancer cell lines", "ANATOMY", 76, 93], ["HeLa-M cells", "ANATOMY", 140, 152], ["cancer", "DISEASE", 76, 82], ["Hey1b cells", "CELL", 0, 11], ["RNase L", "GENE_OR_GENE_PRODUCT", 46, 53], ["human", "ORGANISM", 70, 75], ["cancer cell lines", "CELL", 76, 93], ["RNase L", "GENE_OR_GENE_PRODUCT", 108, 115], ["HeLa-M cells", "CELL", 140, 152], ["Hey1b cells", "CELL_LINE", 0, 11], ["RNase L", "PROTEIN", 46, 53], ["human cancer cell lines", "CELL_LINE", 70, 93], ["RNase L", "PROTEIN", 108, 115], ["HeLa-M cells", "CELL_LINE", 140, 152], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["Hey1b cells", "TEST", 0, 11], ["some human cancer cell lines", "PROBLEM", 65, 93], ["RNase L", "TEST", 108, 115], ["relatively", "OBSERVATION_MODIFIER", 20, 30], ["high levels", "OBSERVATION_MODIFIER", 31, 42], ["RNase L typical", "OBSERVATION_MODIFIER", 46, 61], ["some human", "OBSERVATION_MODIFIER", 65, 75], ["cancer cell lines", "OBSERVATION", 76, 93], ["detectable", "OBSERVATION_MODIFIER", 126, 136]]], ["Western blot analyses, using a monoclonal antibody that detects endogenous RNase L, revealed that cells transfected with an siRNA pool that targets RNase L exhibited an $90% reduction in endogenous RNase L protein levels when compared with cells transfected with a control siRNA pool ( Figure 5A ).", [["cells", "ANATOMY", 98, 103], ["cells", "ANATOMY", 240, 245], ["RNase L", "GENE_OR_GENE_PRODUCT", 75, 82], ["cells", "CELL", 98, 103], ["RNase L", "GENE_OR_GENE_PRODUCT", 148, 155], ["RNase L", "GENE_OR_GENE_PRODUCT", 198, 205], ["cells", "CELL", 240, 245], ["monoclonal antibody", "PROTEIN", 31, 50], ["RNase L", "PROTEIN", 75, 82], ["RNase L", "PROTEIN", 148, 155], ["RNase L", "PROTEIN", 198, 205], ["Western blot analyses", "TEST", 0, 21], ["a monoclonal antibody", "TEST", 29, 50], ["endogenous RNase L", "PROBLEM", 64, 82], ["an siRNA pool", "PROBLEM", 121, 134], ["RNase", "TEST", 148, 153], ["an $90% reduction", "TREATMENT", 166, 183], ["endogenous RNase L protein levels", "TEST", 187, 220]]], ["Reduction of the endogenous RNase L protein level was evident 24 h after transfection and was maintained for $96 h (data not shown).", [["RNase L", "GENE_OR_GENE_PRODUCT", 28, 35], ["RNase L protein", "PROTEIN", 28, 43], ["the endogenous RNase L protein level", "TEST", 13, 49]]], ["Retrotransposition assays using pLRE3-mEGFPI (19, 65) revealed that $0.4% of cells treated with control siRNA became EGFP-positive after 4 days of puromycin drug selection ( Figure 5B and C and Supplementary Figure S2 ), which enriched for cells containing the L1 expression plasmid.", [["cells", "ANATOMY", 77, 82], ["cells", "ANATOMY", 240, 245], ["puromycin", "CHEMICAL", 147, 156], ["puromycin", "CHEMICAL", 147, 156], ["pLRE3-mEGFPI", "GENE_OR_GENE_PRODUCT", 32, 44], ["cells", "CELL", 77, 82], ["EGFP", "GENE_OR_GENE_PRODUCT", 117, 121], ["puromycin", "SIMPLE_CHEMICAL", 147, 156], ["cells", "CELL", 240, 245], ["pLRE3", "PROTEIN", 32, 37], ["mEGFPI", "DNA", 38, 44], ["EGFP", "DNA", 117, 121], ["L1 expression plasmid", "DNA", 261, 282], ["Retrotransposition assays", "TEST", 0, 25], ["control siRNA", "TREATMENT", 96, 109], ["EGFP", "TEST", 117, 121], ["puromycin drug selection", "TREATMENT", 147, 171], ["Figure 5B", "TEST", 174, 183], ["the L1 expression plasmid", "TREATMENT", 257, 282], ["L1", "ANATOMY", 261, 263]]], ["In contrast, $0.75% of cells treated with siRNA against RNase L were EGFPpositive ( Figure 5B and C).", [["cells", "ANATOMY", 23, 28], ["cells", "CELL", 23, 28], ["RNase L", "GENE_OR_GENE_PRODUCT", 56, 63], ["RNase L", "PROTEIN", 56, 63], ["siRNA", "TREATMENT", 42, 47], ["RNase", "TEST", 56, 61], ["EGFPpositive", "TEST", 69, 81]]], ["As expected, the retrotransposition-defective L1 (pJM111-LRE3-mEGFPI) only exhibited background EGFP expression levels regardless of RNase L depletion ( Figure 5B ).RNase L suppresses the retrotransposition of engineered L1 and IAP elementsWe next determined if RNase L was able to repress the retrotransposition of an engineered mouse IAP element ( Figure 1A , construct pDJ33/440N1neo TNF ).", [["pJM111-LRE3-mEGFPI", "GENE_OR_GENE_PRODUCT", 50, 68], ["EGFP", "GENE_OR_GENE_PRODUCT", 96, 100], ["RNase L", "GENE_OR_GENE_PRODUCT", 133, 140], ["RNase L", "GENE_OR_GENE_PRODUCT", 165, 172], ["IAP", "GENE_OR_GENE_PRODUCT", 228, 231], ["RNase L", "GENE_OR_GENE_PRODUCT", 262, 269], ["mouse", "ORGANISM", 330, 335], ["N1neo TNF", "GENE_OR_GENE_PRODUCT", 381, 390], ["L1", "DNA", 46, 48], ["pJM111", "DNA", 50, 56], ["LRE3", "DNA", 57, 61], ["mEGFPI", "DNA", 62, 68], ["EGFP", "PROTEIN", 96, 100], ["RNase L", "PROTEIN", 133, 140], ["RNase L", "PROTEIN", 165, 172], ["L1", "DNA", 221, 223], ["IAP elements", "DNA", 228, 240], ["RNase L", "PROTEIN", 262, 269], ["mouse IAP element", "DNA", 330, 347], ["Figure 1A", "DNA", 350, 359], ["pDJ33", "DNA", 372, 377], ["440N1neo TNF", "DNA", 378, 390], ["mouse", "SPECIES", 330, 335], ["mouse", "SPECIES", 330, 335], ["the retrotransposition", "TEST", 13, 35], ["pJM111", "TEST", 50, 56], ["background EGFP expression levels", "PROBLEM", 85, 118], ["RNase L depletion", "PROBLEM", 133, 150], ["RNase L suppresses the retrotransposition of engineered L1 and IAP elements", "TREATMENT", 165, 240], ["RNase L", "PROBLEM", 262, 269], ["an engineered mouse IAP element", "TREATMENT", 316, 347], ["L1", "ANATOMY", 46, 48], ["EGFP expression", "OBSERVATION", 96, 111], ["retrotransposition", "OBSERVATION", 188, 206], ["L1", "ANATOMY", 221, 223], ["IAP elements", "ANATOMY_MODIFIER", 228, 240]]], ["Consistent with our L1 findings, expression of the WT and constitutively active RNase L proteins severely reduced IAP retrotransposition efficiency by $90% (Figure 6 ).", [["RNase L", "GENE_OR_GENE_PRODUCT", 80, 87], ["IAP", "GENE_OR_GENE_PRODUCT", 114, 117], ["RNase L proteins", "PROTEIN", 80, 96], ["IAP", "PROTEIN", 114, 117], ["the WT", "TEST", 47, 53], ["constitutively active RNase L proteins severely reduced IAP retrotransposition efficiency", "PROBLEM", 58, 147], ["L1", "ANATOMY", 20, 22]]], ["The catalytically inactive RNase L (R667A) mutant did not significantly affect IAP retrotransposition.", [["RNase L", "GENE_OR_GENE_PRODUCT", 27, 34], ["IAP", "GENE_OR_GENE_PRODUCT", 79, 82], ["catalytically inactive RNase L (R667A) mutant", "PROTEIN", 4, 49], ["IAP", "PROTEIN", 79, 82], ["IAP retrotransposition", "PROBLEM", 79, 101], ["catalytically", "OBSERVATION_MODIFIER", 4, 17], ["inactive", "OBSERVATION", 18, 26], ["retrotransposition", "OBSERVATION", 83, 101]]], ["Again, controls indicated that the expression of A3A reduced IAP retrotransposition, whereas RIG-I expression did not significantly affect retrotransposition ( Figure 6B ).", [["A3A", "GENE_OR_GENE_PRODUCT", 49, 52], ["IAP", "GENE_OR_GENE_PRODUCT", 61, 64], ["RIG-I", "GENE_OR_GENE_PRODUCT", 93, 98], ["A3A", "PROTEIN", 49, 52], ["IAP", "DNA", 61, 64], ["RIG", "PROTEIN", 93, 96], ["A3A reduced IAP retrotransposition", "PROBLEM", 49, 83]]], ["Together, the above data strongly suggest that RNase L is a potent inhibitor of engineered L1 and IAP retrotransposition and that this inhibition requires RNase L nuclease activity.RNase L reduces levels of L1 RNASince RNase L is a ribonuclease, we next asked if its expression affected steady state L1 mRNA levels in transfected cells.", [["cells", "ANATOMY", 330, 335], ["RNase L", "GENE_OR_GENE_PRODUCT", 47, 54], ["IAP", "GENE_OR_GENE_PRODUCT", 98, 101], ["RNase L nuclease", "GENE_OR_GENE_PRODUCT", 155, 171], ["RNase L", "GENE_OR_GENE_PRODUCT", 181, 188], ["RNase L", "GENE_OR_GENE_PRODUCT", 219, 226], ["ribonuclease", "GENE_OR_GENE_PRODUCT", 232, 244], ["L1", "GENE_OR_GENE_PRODUCT", 300, 302], ["cells", "CELL", 330, 335], ["RNase L", "PROTEIN", 47, 54], ["L1", "DNA", 91, 93], ["RNase L", "PROTEIN", 155, 162], ["RNase L", "PROTEIN", 181, 188], ["L1", "DNA", 207, 209], ["RNase L", "PROTEIN", 219, 226], ["ribonuclease", "PROTEIN", 232, 244], ["L1 mRNA", "RNA", 300, 307], ["transfected cells", "CELL_LINE", 318, 335], ["the above data", "TEST", 10, 24], ["a potent inhibitor of engineered L1 and IAP retrotransposition", "TREATMENT", 58, 120], ["RNase L nuclease activity", "TREATMENT", 155, 180], ["RNase L reduces levels", "TEST", 181, 203], ["a ribonuclease", "TREATMENT", 230, 244], ["L1", "ANATOMY", 207, 209], ["transfected cells", "OBSERVATION", 318, 335]]], ["To accomplish this goal, we designed primers that would amplify a 91-bp fragment that spans the junction of the ORF2/TAP-tag coding region in a transfected L1 expression construct (pAD2TE1) (66) .", [["ORF2", "GENE_OR_GENE_PRODUCT", 112, 116], ["TAP", "GENE_OR_GENE_PRODUCT", 117, 120], ["91-bp fragment", "DNA", 66, 80], ["ORF2", "DNA", 112, 116], ["TAP-tag coding region", "DNA", 117, 138], ["transfected L1 expression construct", "DNA", 144, 179], ["pAD2TE1", "DNA", 181, 188], ["a 91-bp fragment", "TREATMENT", 64, 80], ["the ORF2/TAP", "TREATMENT", 108, 120], ["tag coding region", "PROBLEM", 121, 138], ["junction", "ANATOMY_MODIFIER", 96, 104], ["ORF2", "ANATOMY", 112, 116], ["TAP", "OBSERVATION", 117, 120], ["L1", "ANATOMY", 156, 158]]], ["Notably, these primers should specifically amplify L1 mRNA derived from pAD2TE1 and should not amplify endogenous L1 mRNAs, which lack the TAP epitope-tag at the end of the ORF2 coding sequence.", [["pAD2TE1", "GENE_OR_GENE_PRODUCT", 72, 79], ["TAP", "GENE_OR_GENE_PRODUCT", 139, 142], ["L1 mRNA", "RNA", 51, 58], ["pAD2TE1", "DNA", 72, 79], ["endogenous L1 mRNAs", "RNA", 103, 122], ["TAP epitope", "PROTEIN", 139, 150], ["ORF2 coding sequence", "DNA", 173, 193], ["pAD2TE1", "TREATMENT", 72, 79], ["endogenous L1 mRNAs", "PROBLEM", 103, 122], ["the TAP epitope", "TREATMENT", 135, 150]]], ["Primers capable of amplifying mRNA from the hygromycin phosphotransferase gene (HYG) present on the pCEP4 L1 expression plasmid backbone served as an internal/ normalization control.", [["hygromycin", "CHEMICAL", 44, 54], ["hygromycin", "CHEMICAL", 44, 54], ["hygromycin phosphotransferase", "GENE_OR_GENE_PRODUCT", 44, 73], ["pCEP4 L1", "GENE_OR_GENE_PRODUCT", 100, 108], ["mRNA", "RNA", 30, 34], ["hygromycin phosphotransferase gene", "DNA", 44, 78], ["HYG", "DNA", 80, 83], ["pCEP4 L1 expression plasmid backbone", "DNA", 100, 136], ["the hygromycin phosphotransferase gene", "TREATMENT", 40, 78], ["the pCEP4 L1 expression plasmid backbone", "TREATMENT", 96, 136], ["an internal/ normalization control", "TREATMENT", 147, 181], ["normalization", "OBSERVATION", 160, 173]]], ["[The polymerase chain reaction (PCR) strategy is illustrated in Figure 1A , see PCR primers beneath the map of pAD2TE1.]", [["PCR primers", "DNA", 80, 91], ["pAD2TE1", "DNA", 111, 118], ["The polymerase chain reaction (PCR) strategy", "TREATMENT", 1, 45], ["PCR primers", "TEST", 80, 91]]], ["Quantitative reverse transcriptase PCR (RT-PCR) analysis revealed that the expression of WT RNase L reduced L1 mRNA levels by $80% ( Figure 7A ).", [["RNase L", "GENE_OR_GENE_PRODUCT", 92, 99], ["L1", "GENE_OR_GENE_PRODUCT", 108, 110], ["WT RNase L", "PROTEIN", 89, 99], ["L1 mRNA", "RNA", 108, 115], ["Quantitative reverse transcriptase PCR", "TEST", 0, 38], ["RT-PCR", "TEST", 40, 46], ["analysis", "TEST", 48, 56], ["WT RNase L reduced L1 mRNA levels", "PROBLEM", 89, 122]]], ["However, expression of the catalytically inactive R667A RNase L mutant failed to significantly reduce L1 mRNA levels ( Figure 7A ).", [["R667A RNase L", "GENE_OR_GENE_PRODUCT", 50, 63], ["catalytically inactive R667A RNase L mutant", "PROTEIN", 27, 70], ["L1 mRNA", "RNA", 102, 109], ["the catalytically inactive R667A RNase L mutant", "PROBLEM", 23, 70], ["L1 mRNA levels", "PROBLEM", 102, 116]]], ["In a separate control experiment, we demonstrated that cotransfection of WT RNase L did not affect HYG mRNA levels expressed from pIREShyg (Clontech) (Supplementary Figure S3) .", [["RNase L", "GENE_OR_GENE_PRODUCT", 76, 83], ["HYG", "GENE_OR_GENE_PRODUCT", 99, 102], ["WT RNase L", "PROTEIN", 73, 83], ["HYG mRNA", "RNA", 99, 107], ["pIREShyg", "PROTEIN", 130, 138], ["cotransfection of WT RNase L", "PROBLEM", 55, 83], ["mRNA levels", "TEST", 103, 114]]], ["These data suggest that RNase L preferentially targets L1 mRNA for degradation, and that its nuclease activity is required for the decrease in L1 mRNA levels.RNase L reduces levels of L1 RNATo validate our quantitative RT-PCR (qRT-PCR) findings, we analyzed the effect of RNase L on the accumulation of L1 mRNA in the cytoplasm of cells.", [["cytoplasm", "ANATOMY", 318, 327], ["cells", "ANATOMY", 331, 336], ["RNase L", "GENE_OR_GENE_PRODUCT", 24, 31], ["L1", "GENE_OR_GENE_PRODUCT", 55, 57], ["RNase L", "GENE_OR_GENE_PRODUCT", 158, 165], ["L1 RNATo", "GENE_OR_GENE_PRODUCT", 184, 192], ["RNase L", "GENE_OR_GENE_PRODUCT", 272, 279], ["cytoplasm", "ORGANISM_SUBSTANCE", 318, 327], ["cells", "CELL", 331, 336], ["RNase L", "PROTEIN", 24, 31], ["L1 mRNA", "RNA", 55, 62], ["nuclease", "PROTEIN", 93, 101], ["L1 mRNA", "RNA", 143, 150], ["RNase L", "PROTEIN", 158, 165], ["L1 RNATo", "PROTEIN", 184, 192], ["RNase L", "PROTEIN", 272, 279], ["L1 mRNA", "RNA", 303, 310], ["These data", "TEST", 0, 10], ["RNase L preferentially targets L1 mRNA", "PROBLEM", 24, 62], ["its nuclease activity", "PROBLEM", 89, 110], ["the decrease in L1 mRNA levels", "PROBLEM", 127, 157], ["RNase L reduces levels", "TEST", 158, 180], ["our quantitative RT-PCR", "TEST", 202, 225], ["qRT", "TEST", 227, 230], ["RNase L", "TREATMENT", 272, 279], ["the accumulation of L1 mRNA", "TREATMENT", 283, 310], ["L1", "ANATOMY", 143, 145], ["L1", "ANATOMY", 184, 186], ["L1 mRNA", "OBSERVATION", 303, 310], ["cytoplasm of cells", "OBSERVATION", 318, 336]]], ["To visualize the L1 mRNA, we took advantage of a previously described construct, pAD3TE1, which encodes an L1 element that contains 24 copies of MS2 RNA binding element in its 3 0 -UTR ( Figure 1A ) (66) .", [["pAD3TE1", "GENE_OR_GENE_PRODUCT", 81, 88], ["L1 mRNA", "RNA", 17, 24], ["pAD3TE1", "DNA", 81, 88], ["L1 element", "DNA", 107, 117], ["MS2 RNA binding element", "DNA", 145, 168], ["3 0 -UTR", "DNA", 176, 184], ["a previously described construct, pAD3TE1", "PROBLEM", 47, 88], ["L1 mRNA", "ANATOMY", 17, 24], ["L1", "ANATOMY", 107, 109]]], ["The coexpression of pAD3TE1 and a plasmid encoding a nuclear localized MS2-GFP protein would allow the MS2-GFP protein to bind the MS2 RNA sequences in pAD3TE1 mRNA, allowing the indirect visualization of the L1 mRNA via immunofluorescent confocal microscopy (66) .", [["plasmid", "ANATOMY", 34, 41], ["nuclear", "ANATOMY", 53, 60], ["pAD3TE1", "GENE_OR_GENE_PRODUCT", 20, 27], ["nuclear", "CELLULAR_COMPONENT", 53, 60], ["MS2-GFP", "GENE_OR_GENE_PRODUCT", 71, 78], ["MS2-GFP", "GENE_OR_GENE_PRODUCT", 103, 110], ["pAD3TE1", "GENE_OR_GENE_PRODUCT", 152, 159], ["pAD3TE1", "DNA", 20, 27], ["plasmid", "DNA", 34, 41], ["nuclear localized MS2-GFP protein", "PROTEIN", 53, 86], ["MS2", "PROTEIN", 103, 106], ["GFP protein", "PROTEIN", 107, 118], ["MS2 RNA sequences", "RNA", 131, 148], ["pAD3TE1 mRNA", "RNA", 152, 164], ["L1 mRNA", "RNA", 209, 216], ["pAD3TE1", "TEST", 20, 27], ["the MS2", "TEST", 99, 106], ["the MS2 RNA sequences", "TEST", 127, 148], ["the indirect visualization", "TEST", 175, 201], ["immunofluorescent confocal microscopy", "TEST", 221, 258], ["L1 mRNA", "ANATOMY", 209, 216]]], ["We observed punctate L1 cytoplasmic foci in cells cotransfected with pAD3TE1, the MS2-GFP protein expression construct and either the empty vector pcDNA 3.0 or the inactive RNase L R667A mutant ( Figure 7B ).", [["punctate L1 cytoplasmic foci", "ANATOMY", 12, 40], ["cells", "ANATOMY", 44, 49], ["cytoplasmic", "ORGANISM_SUBSTANCE", 24, 35], ["cells", "CELL", 44, 49], ["pAD3TE1", "GENE_OR_GENE_PRODUCT", 69, 76], ["MS2-GFP", "GENE_OR_GENE_PRODUCT", 82, 89], ["pcDNA", "GENE_OR_GENE_PRODUCT", 147, 152], ["RNase L R667A", "GENE_OR_GENE_PRODUCT", 173, 186], ["pAD3TE1", "DNA", 69, 76], ["MS2-GFP protein expression construct", "DNA", 82, 118], ["inactive RNase L R667A mutant", "PROTEIN", 164, 193], ["Figure 7B", "PROTEIN", 196, 205], ["punctate L1 cytoplasmic foci in cells", "PROBLEM", 12, 49], ["pAD3TE1", "TEST", 69, 76], ["the MS2", "TEST", 78, 85], ["the empty vector pcDNA", "TEST", 130, 152], ["punctate", "OBSERVATION_MODIFIER", 12, 20], ["L1", "OBSERVATION_MODIFIER", 21, 23], ["cytoplasmic", "OBSERVATION_MODIFIER", 24, 35], ["foci", "OBSERVATION", 36, 40], ["cells cotransfected", "OBSERVATION", 44, 63]]], ["In contrast, we did not observe punctate L1 cytoplasmic foci in cells co-transfected with pAD3TE1, the MS2-GFP protein expression construct and the WT RNase L expression construct ($200 cells were examined per slide and representative images were captured) ( Figure 7B ).", [["punctate L1 cytoplasmic foci", "ANATOMY", 32, 60], ["cells", "ANATOMY", 64, 69], ["cells", "ANATOMY", 186, 191], ["cytoplasmic", "ORGANISM_SUBSTANCE", 44, 55], ["cells", "CELL", 64, 69], ["pAD3TE1", "GENE_OR_GENE_PRODUCT", 90, 97], ["MS2-GFP", "GENE_OR_GENE_PRODUCT", 103, 110], ["RNase L", "GENE_OR_GENE_PRODUCT", 151, 158], ["cells", "CELL", 186, 191], ["pAD3TE1", "DNA", 90, 97], ["MS2-GFP protein expression construct", "DNA", 103, 139], ["WT RNase L expression construct", "DNA", 148, 179], ["punctate L1 cytoplasmic foci in cells", "PROBLEM", 32, 69], ["pAD3TE1", "TEST", 90, 97], ["the MS2", "TEST", 99, 106], ["the WT RNase L expression construct", "TREATMENT", 144, 179], ["representative images", "TEST", 220, 241], ["punctate", "OBSERVATION_MODIFIER", 32, 40], ["L1", "ANATOMY", 41, 43], ["cytoplasmic", "OBSERVATION_MODIFIER", 44, 55], ["foci", "OBSERVATION", 56, 60]]], ["As an additional control for this experiment, we determined that EBNA-1, which is present on the backbone of the pAD3TE1 expression vector, was still expressed in the presence of WT RNase L. Together, these data indicate a ribonuclease-dependent effect of RNase L on L1 RNA levels and likely explain, in part, how RNase L adversely affects L1 retrotransposition.Expression of RNase L leads to a decrease in L1 protein expressionDuring viral infections, the OAS-RNase L system degrades certain viral and cellular mRNAs, thereby preventing protein synthesis [reviewed in (56) ].", [["cellular", "ANATOMY", 503, 511], ["viral infections", "DISEASE", 435, 451], ["EBNA-1", "GENE_OR_GENE_PRODUCT", 65, 71], ["pAD3TE1", "GENE_OR_GENE_PRODUCT", 113, 120], ["RNase L.", "GENE_OR_GENE_PRODUCT", 182, 190], ["ribonuclease", "GENE_OR_GENE_PRODUCT", 223, 235], ["RNase L", "GENE_OR_GENE_PRODUCT", 256, 263], ["RNase L", "GENE_OR_GENE_PRODUCT", 314, 321], ["RNase L", "GENE_OR_GENE_PRODUCT", 376, 383], ["OAS-RNase L", "GENE_OR_GENE_PRODUCT", 457, 468], ["cellular", "CELL", 503, 511], ["EBNA", "PROTEIN", 65, 69], ["pAD3TE1 expression vector", "DNA", 113, 138], ["ribonuclease", "PROTEIN", 223, 235], ["RNase L", "PROTEIN", 256, 263], ["L1 RNA", "RNA", 267, 273], ["RNase L", "PROTEIN", 314, 321], ["L1", "DNA", 340, 342], ["RNase L", "PROTEIN", 376, 383], ["L1 protein", "PROTEIN", 407, 417], ["OAS", "PROTEIN", 457, 460], ["RNase L", "PROTEIN", 461, 468], ["viral and cellular mRNAs", "RNA", 493, 517], ["EBNA", "TEST", 65, 69], ["WT RNase L.", "PROBLEM", 179, 190], ["these data", "TEST", 201, 211], ["a ribonuclease-dependent effect of RNase L on L1 RNA levels", "PROBLEM", 221, 280], ["RNase L leads", "PROBLEM", 376, 389], ["a decrease in L1 protein expressionDuring viral infections", "PROBLEM", 393, 451], ["the OAS", "TEST", 453, 460], ["RNase L system", "TREATMENT", 461, 475], ["certain viral and cellular mRNAs", "PROBLEM", 485, 517], ["protein synthesis", "TEST", 538, 555], ["dependent effect", "OBSERVATION_MODIFIER", 236, 252], ["likely explain", "UNCERTAINTY", 285, 299], ["L1 retrotransposition", "OBSERVATION", 340, 361], ["RNase L", "OBSERVATION_MODIFIER", 376, 383], ["decrease", "OBSERVATION_MODIFIER", 395, 403], ["L1", "ANATOMY", 407, 409], ["viral infections", "OBSERVATION", 435, 451], ["cellular mRNAs", "OBSERVATION", 503, 517]]], ["Thus, we performed western blot analyses to determine if the observed reduction in L1 mRNA correlated with a reduction in the accumulation of the L1-encoded proteins.", [["L1", "GENE_OR_GENE_PRODUCT", 83, 85], ["L1 mRNA", "RNA", 83, 90], ["L1-encoded proteins", "PROTEIN", 146, 165], ["western blot analyses", "TEST", 19, 40], ["the observed reduction in L1 mRNA", "PROBLEM", 57, 90], ["a reduction", "TREATMENT", 107, 118], ["L1", "ANATOMY", 83, 85], ["reduction", "OBSERVATION_MODIFIER", 109, 118], ["L1", "ANATOMY", 146, 148]]], ["To accomplish this goal, we co-transfected HeLa-M cells with pAD2TE1 (66) and either an empty vector (pFLAG-CMV-2) or a FLAG-tagged RNase L expression construct (WT, the constitutively active N\u00c1385 RNase L mutant or the catalytically inactive R667A RNase L mutant).", [["HeLa-M cells", "ANATOMY", 43, 55], ["HeLa-M cells", "CELL", 43, 55], ["FLAG", "GENE_OR_GENE_PRODUCT", 120, 124], ["RNase L", "GENE_OR_GENE_PRODUCT", 132, 139], ["N\u00c1385 RNase L", "GENE_OR_GENE_PRODUCT", 192, 205], ["R667A RNase L", "GENE_OR_GENE_PRODUCT", 243, 256], ["HeLa-M cells", "CELL_LINE", 43, 55], ["pFLAG-CMV-2", "DNA", 102, 113], ["FLAG-tagged RNase L expression construct", "DNA", 120, 160], ["N\u00c1385 RNase L mutant", "PROTEIN", 192, 212], ["catalytically inactive R667A RNase L mutant", "PROTEIN", 220, 263], ["pAD2TE1", "TEST", 61, 68], ["an empty vector", "TREATMENT", 85, 100], ["CMV", "TEST", 108, 111], ["a FLAG", "TEST", 118, 124], ["tagged RNase L expression construct", "TREATMENT", 125, 160], ["WT", "TEST", 162, 164], ["RNase L mutant", "TREATMENT", 198, 212], ["empty", "OBSERVATION", 88, 93]]], ["The transfected cells then were subjected to selection in hygromycin B containing medium.", [["cells", "ANATOMY", 16, 21], ["hygromycin B", "CHEMICAL", 58, 70], ["hygromycin B", "CHEMICAL", 58, 70], ["cells", "CELL", 16, 21], ["hygromycin B", "SIMPLE_CHEMICAL", 58, 70], ["transfected cells", "CELL_LINE", 4, 21], ["The transfected cells", "PROBLEM", 0, 21], ["hygromycin B containing medium", "TREATMENT", 58, 88], ["transfected cells", "OBSERVATION", 4, 21], ["medium", "OBSERVATION_MODIFIER", 82, 88]]], ["The total cell lysates and L1 RNP preparations then were subjected to western blot analyses (see 'Materials and Methods' section).Expression of RNase L leads to a decrease in L1 protein expressionAn anti-T7 antibody detected the $40 kDa ORF1p in both total cell lysates and RNP fractions derived from cells co-transfected with pAD2TE1 and either an empty vector (pFLAG-CMV-2) or the catalytically inactive RNase L (R667A) mutant ( Figure 8A) .", [["cell lysates", "ANATOMY", 10, 22], ["cell lysates", "ANATOMY", 257, 269], ["RNP fractions", "ANATOMY", 274, 287], ["cells", "ANATOMY", 301, 306], ["cell lysates", "ORGANISM_SUBSTANCE", 10, 22], ["RNase L", "GENE_OR_GENE_PRODUCT", 144, 151], ["ORF1p", "GENE_OR_GENE_PRODUCT", 237, 242], ["cell lysates", "ORGANISM_SUBSTANCE", 257, 269], ["cells", "CELL", 301, 306], ["pAD2TE1", "GENE_OR_GENE_PRODUCT", 327, 334], ["pFLAG-CMV-2", "GENE_OR_GENE_PRODUCT", 363, 374], ["RNase L", "GENE_OR_GENE_PRODUCT", 406, 413], ["L1 RNP", "PROTEIN", 27, 33], ["RNase L", "PROTEIN", 144, 151], ["L1 protein", "PROTEIN", 175, 185], ["anti-T7 antibody", "PROTEIN", 199, 215], ["$40 kDa ORF1p", "PROTEIN", 229, 242], ["pAD2TE1", "PROTEIN", 327, 334], ["pFLAG", "DNA", 363, 368], ["catalytically inactive RNase L (R667A) mutant", "PROTEIN", 383, 428], ["Figure 8A", "PROTEIN", 431, 440], ["The total cell lysates", "TREATMENT", 0, 22], ["L1 RNP preparations", "TREATMENT", 27, 46], ["blot analyses", "TEST", 78, 91], ["RNase L leads", "PROBLEM", 144, 157], ["a decrease", "PROBLEM", 161, 171], ["antibody", "TEST", 207, 215], ["kDa ORF1p", "TREATMENT", 233, 242], ["both total cell lysates", "TREATMENT", 246, 269], ["RNP fractions", "TEST", 274, 287], ["pAD2TE1", "TEST", 327, 334], ["pFLAG", "TEST", 363, 368], ["CMV", "TEST", 369, 372], ["L1", "ANATOMY", 27, 29], ["decrease", "OBSERVATION_MODIFIER", 163, 171], ["L1", "ANATOMY", 175, 177], ["RNP fractions", "OBSERVATION", 274, 287], ["empty", "OBSERVATION", 349, 354]]], ["Similarly, an anti-TAP antibody detected the $170 kDa ORF2p in both total cell lysates and RNP fractions.", [["cell lysates", "ANATOMY", 74, 86], ["RNP", "ANATOMY", 91, 94], ["anti-TAP antibody", "GENE_OR_GENE_PRODUCT", 14, 31], ["ORF2p", "GENE_OR_GENE_PRODUCT", 54, 59], ["cell lysates", "ORGANISM_SUBSTANCE", 74, 86], ["anti-TAP antibody", "PROTEIN", 14, 31], ["$170 kDa ORF2p", "PROTEIN", 45, 59], ["an anti-TAP antibody", "TEST", 11, 31], ["kDa ORF2p", "TREATMENT", 50, 59], ["both total cell lysates", "TREATMENT", 63, 86], ["RNP fractions", "TREATMENT", 91, 104], ["total cell lysates", "OBSERVATION", 68, 86], ["RNP fractions", "OBSERVATION", 91, 104]]], ["In contrast, ORF1p and ORF2p were markedly reduced in cells transfected with pAD2TE1 and either the WT RNase L or constitutively active N\u00c1385 RNase L mutant.", [["cells", "ANATOMY", 54, 59], ["ORF1p", "GENE_OR_GENE_PRODUCT", 13, 18], ["ORF2p", "GENE_OR_GENE_PRODUCT", 23, 28], ["cells", "CELL", 54, 59], ["pAD2TE1", "GENE_OR_GENE_PRODUCT", 77, 84], ["RNase L", "GENE_OR_GENE_PRODUCT", 103, 110], ["N\u00c1385 RNase L", "GENE_OR_GENE_PRODUCT", 136, 149], ["ORF1p", "PROTEIN", 13, 18], ["ORF2p", "PROTEIN", 23, 28], ["pAD2TE1", "PROTEIN", 77, 84], ["WT RNase L", "PROTEIN", 100, 110], ["N\u00c1385 RNase L mutant", "PROTEIN", 136, 156], ["ORF1p", "TEST", 13, 18], ["ORF2p", "TREATMENT", 23, 28], ["markedly reduced in cells", "PROBLEM", 34, 59], ["pAD2TE1", "TREATMENT", 77, 84]]], ["Notably, RNase L did not affect the level of endogenous ribosomal S6 protein in total cell lysates and RNP fractions.", [["ribosomal", "ANATOMY", 56, 65], ["cell lysates", "ANATOMY", 86, 98], ["RNP", "ANATOMY", 103, 106], ["RNase L", "GENE_OR_GENE_PRODUCT", 9, 16], ["ribosomal S6", "GENE_OR_GENE_PRODUCT", 56, 68], ["cell lysates", "ORGANISM_SUBSTANCE", 86, 98], ["RNase L", "PROTEIN", 9, 16], ["endogenous ribosomal S6 protein", "PROTEIN", 45, 76], ["endogenous ribosomal S6 protein", "PROBLEM", 45, 76], ["total cell lysates", "TREATMENT", 80, 98], ["RNP fractions", "TREATMENT", 103, 116], ["ribosomal S6 protein", "OBSERVATION", 56, 76], ["total cell lysates", "OBSERVATION", 80, 98], ["RNP fractions", "OBSERVATION", 103, 116]]], ["We also observed an RNase L-dependent reduction of ORF1p in cells transfected with pDK500 (a T7-gene 10 epitopetagged ORF1p expression construct), as well as a reduction in ORF2p in cells transfected with pAD500 (a TAP epitope-tagged ORF2p expression construct) (Supplementary Figures S4 and S5, respectively) .", [["cells", "ANATOMY", 60, 65], ["cells", "ANATOMY", 182, 187], ["RNase", "GENE_OR_GENE_PRODUCT", 20, 25], ["ORF1p", "GENE_OR_GENE_PRODUCT", 51, 56], ["cells", "CELL", 60, 65], ["pDK500", "GENE_OR_GENE_PRODUCT", 83, 89], ["ORF1p", "GENE_OR_GENE_PRODUCT", 118, 123], ["ORF2p", "GENE_OR_GENE_PRODUCT", 173, 178], ["cells", "CELL", 182, 187], ["pAD500", "GENE_OR_GENE_PRODUCT", 205, 211], ["TAP", "GENE_OR_GENE_PRODUCT", 215, 218], ["ORF2p", "GENE_OR_GENE_PRODUCT", 234, 239], ["RNase", "PROTEIN", 20, 25], ["ORF1p", "PROTEIN", 51, 56], ["pDK500", "DNA", 83, 89], ["T7-gene 10", "DNA", 93, 103], ["ORF1p expression construct", "DNA", 118, 144], ["ORF2p", "PROTEIN", 173, 178], ["pAD500", "PROTEIN", 205, 211], ["TAP epitope", "PROTEIN", 215, 226], ["ORF2p expression construct", "DNA", 234, 260], ["an RNase L-dependent reduction", "TREATMENT", 17, 47], ["ORF1p in cells", "TREATMENT", 51, 65], ["a T7-gene 10 epitopetagged ORF1p expression construct", "TREATMENT", 91, 144], ["a reduction in ORF2p in cells", "TREATMENT", 158, 187], ["pAD500", "TREATMENT", 205, 211], ["a TAP epitope", "TREATMENT", 213, 226], ["tagged ORF2p expression construct", "TREATMENT", 227, 260], ["RNase L-dependent", "OBSERVATION_MODIFIER", 20, 37], ["reduction", "OBSERVATION_MODIFIER", 38, 47], ["reduction", "OBSERVATION_MODIFIER", 160, 169], ["S5", "ANATOMY", 292, 294]]], ["Control assays again demonstrated that the WT and mutant FLAG-tagged RNase L proteins are expressed at Figure 2B .", [["FLAG", "GENE_OR_GENE_PRODUCT", 57, 61], ["RNase L", "GENE_OR_GENE_PRODUCT", 69, 76], ["mutant FLAG", "PROTEIN", 50, 61], ["RNase L proteins", "PROTEIN", 69, 85], ["Control assays", "TEST", 0, 14], ["the WT", "TEST", 39, 45], ["mutant FLAG", "TEST", 50, 61], ["RNase L proteins", "TEST", 69, 85]]], ["Data are shown as the mean \u00b1 standard deviation (SD) from a single experiment with three technical replicates.", [["the mean \u00b1 standard deviation (SD)", "PROBLEM", 18, 52]]], ["No statistically significant difference was found with one-way ANOVA and post hoc tests.", [["post hoc tests", "TEST", 73, 87], ["statistically", "OBSERVATION_MODIFIER", 3, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["difference", "OBSERVATION", 29, 39]]], ["(C) Protein expression analyses: The WT RNase L, catalytically inactive RNase L mutant (R667A) and constitutively active (N\u00c1385) RNase L mutant were detected from total cell lysates in western blots with anti-RNase L antibody 2 days after transfection. b-Actin served as loading and transfer control.", [["cell lysates", "ANATOMY", 169, 181], ["RNase L", "GENE_OR_GENE_PRODUCT", 40, 47], ["RNase L", "GENE_OR_GENE_PRODUCT", 72, 79], ["constitutively active (N\u00c1385) RNase L", "GENE_OR_GENE_PRODUCT", 99, 136], ["cell lysates", "ORGANISM_SUBSTANCE", 169, 181], ["anti-RNase L antibody", "GENE_OR_GENE_PRODUCT", 204, 225], ["b-Actin", "GENE_OR_GENE_PRODUCT", 253, 260], ["WT RNase L", "PROTEIN", 37, 47], ["catalytically inactive RNase L mutant", "PROTEIN", 49, 86], ["R667A", "PROTEIN", 88, 93], ["constitutively active (N\u00c1385) RNase L mutant", "PROTEIN", 99, 143], ["RNase L antibody", "PROTEIN", 209, 225], ["Actin", "PROTEIN", 255, 260], ["Protein expression analyses", "TEST", 4, 31], ["The WT RNase L", "TEST", 33, 47], ["catalytically inactive RNase L mutant", "PROBLEM", 49, 86], ["constitutively active (N\u00c1385) RNase L mutant", "PROBLEM", 99, 143], ["total cell lysates", "TEST", 163, 181], ["western blots", "TEST", 185, 198], ["anti-RNase L antibody", "TREATMENT", 204, 225], ["b-Actin served as loading and transfer control", "TREATMENT", 253, 299], ["active", "OBSERVATION_MODIFIER", 114, 120]]], ["Size standards are indicated in kDa at the left of the gel. similar levels in total cell lysates 2 days after transfection ( Figure 8B ).", [["cell lysates", "ANATOMY", 84, 96], ["cell", "CELL", 84, 88], ["similar levels", "PROBLEM", 60, 74], ["total cell lysates", "TREATMENT", 78, 96], ["left", "ANATOMY_MODIFIER", 43, 47], ["gel", "ANATOMY", 55, 58], ["total cell lysates", "OBSERVATION", 78, 96]]], ["Importantly, we did not observe an RNase L-dependent reduction in HeLa-M cells co-transfected with pEGFP-C1, suggesting that RNase L may preferentially target L1 RNA, thereby adversely affecting the expression of the L1 proteins ( Figure 8B ).Expression of RNase L prevents the formation of L1 cytoplasmic fociPrevious immunofluorescence studies demonstrated that the L1-encoded proteins and L1 RNA begin to appear as discrete cytoplasmic foci that often associate with stress granules and/or processing bodies (P-bodies) at 48 h posttransfection (66, 85) .", [["HeLa-M cells", "ANATOMY", 66, 78], ["cytoplasmic", "ANATOMY", 294, 305], ["cytoplasmic foci", "ANATOMY", 427, 443], ["stress granules", "ANATOMY", 470, 485], ["bodies", "ANATOMY", 504, 510], ["P-bodies", "ANATOMY", 512, 520], ["RNase L", "GENE_OR_GENE_PRODUCT", 35, 42], ["HeLa-M cells", "CELL", 66, 78], ["pEGFP-C1", "GENE_OR_GENE_PRODUCT", 99, 107], ["RNase L", "GENE_OR_GENE_PRODUCT", 125, 132], ["Figure 8B", "GENE_OR_GENE_PRODUCT", 231, 240], ["RNase L", "GENE_OR_GENE_PRODUCT", 257, 264], ["cytoplasmic", "ORGANISM_SUBSTANCE", 427, 438], ["stress granules", "CELLULAR_COMPONENT", 470, 485], ["RNase L", "PROTEIN", 35, 42], ["HeLa-M cells", "CELL_LINE", 66, 78], ["pEGFP", "PROTEIN", 99, 104], ["RNase L", "PROTEIN", 125, 132], ["L1 RNA", "RNA", 159, 165], ["L1 proteins", "PROTEIN", 217, 228], ["Figure 8B", "PROTEIN", 231, 240], ["RNase L", "PROTEIN", 257, 264], ["L1", "DNA", 368, 370], ["L1 RNA", "RNA", 392, 398], ["an RNase L-dependent reduction", "TREATMENT", 32, 62], ["RNase L prevents", "TREATMENT", 257, 273], ["L1 cytoplasmic fociPrevious immunofluorescence studies", "TEST", 291, 345], ["the L1-encoded proteins and L1 RNA", "PROBLEM", 364, 398], ["discrete cytoplasmic foci", "PROBLEM", 418, 443], ["stress granules and/or processing bodies", "PROBLEM", 470, 510], ["-dependent", "OBSERVATION_MODIFIER", 42, 52], ["reduction", "OBSERVATION_MODIFIER", 53, 62], ["L1 RNA", "OBSERVATION", 159, 165], ["L1", "ANATOMY", 217, 219], ["RNase L", "OBSERVATION_MODIFIER", 257, 264], ["L1", "ANATOMY", 368, 370], ["L1", "ANATOMY", 392, 394], ["discrete", "OBSERVATION_MODIFIER", 418, 426], ["cytoplasmic", "OBSERVATION_MODIFIER", 427, 438], ["foci", "OBSERVATION", 439, 443], ["stress granules", "OBSERVATION", 470, 485]]], ["Because the expression of RNase L adversely affected L1 mRNA levels and, in turn, ORF1p and ORF2p protein accumulation, we next examined whether RNase L expression adversely affects L1 cytoplasmic foci accumulation.", [["cytoplasmic foci", "ANATOMY", 185, 201], ["RNase L", "GENE_OR_GENE_PRODUCT", 26, 33], ["L1", "GENE_OR_GENE_PRODUCT", 53, 55], ["ORF1p", "GENE_OR_GENE_PRODUCT", 82, 87], ["ORF2p", "GENE_OR_GENE_PRODUCT", 92, 97], ["RNase L", "GENE_OR_GENE_PRODUCT", 145, 152], ["cytoplasmic", "ORGANISM_SUBSTANCE", 185, 196], ["RNase L", "PROTEIN", 26, 33], ["L1 mRNA", "RNA", 53, 60], ["ORF1p", "PROTEIN", 82, 87], ["ORF2p", "PROTEIN", 92, 97], ["RNase L", "PROTEIN", 145, 152], ["RNase L adversely affected L1 mRNA levels", "PROBLEM", 26, 67], ["ORF1p", "TEST", 82, 87], ["ORF2p protein accumulation", "PROBLEM", 92, 118], ["RNase L expression", "PROBLEM", 145, 163], ["L1 cytoplasmic foci accumulation", "PROBLEM", 182, 214], ["L1", "ANATOMY", 182, 184], ["cytoplasmic", "OBSERVATION_MODIFIER", 185, 196], ["foci", "OBSERVATION", 197, 201]]], ["To accomplish this goal, we co-transfected HeLa-M cells with an L1 expression vector (pES2TE1) (66) including an HA-tagged ORF2p, and an empty vector (pcDNA 3.0), a plasmid HeLa-M cells were co-transfected with an expression construct containing an active human L1 (pLRE3-mEGFPI) and an empty vector (pFLAG-CMV-2), a plasmid encoding an amino-terminal FLAGtagged RNase L expression plasmid or an amino-terminal HA-tagged A3A expression plasmid.", [["HeLa-M cells", "ANATOMY", 43, 55], ["HeLa-M cells", "ANATOMY", 173, 185], ["plasmid", "ANATOMY", 317, 324], ["amino", "CHEMICAL", 337, 342], ["amino", "CHEMICAL", 396, 401], ["HeLa-M cells", "CELL", 43, 55], ["HA", "GENE_OR_GENE_PRODUCT", 113, 115], ["ORF2p", "GENE_OR_GENE_PRODUCT", 123, 128], ["pcDNA", "GENE_OR_GENE_PRODUCT", 151, 156], ["HeLa-M cells", "CELL", 173, 185], ["human", "ORGANISM", 256, 261], ["pLRE3-mEGFPI", "GENE_OR_GENE_PRODUCT", 266, 278], ["RNase L", "GENE_OR_GENE_PRODUCT", 363, 370], ["A3A", "GENE_OR_GENE_PRODUCT", 421, 424], ["HeLa-M cells", "CELL_LINE", 43, 55], ["L1 expression vector", "DNA", 64, 84], ["pES2TE1", "DNA", 86, 93], ["HA", "DNA", 113, 115], ["ORF2p", "DNA", 123, 128], ["empty vector", "DNA", 137, 149], ["pcDNA 3.0", "DNA", 151, 160], ["M cells", "CELL_LINE", 178, 185], ["human L1", "DNA", 256, 264], ["pLRE3", "DNA", 266, 271], ["mEGFPI", "DNA", 272, 278], ["empty vector", "DNA", 287, 299], ["pFLAG-CMV-2", "DNA", 301, 312], ["plasmid", "DNA", 317, 324], ["amino-terminal FLAGtagged RNase L expression plasmid", "DNA", 337, 389], ["amino-terminal HA-tagged A3A expression plasmid", "DNA", 396, 443], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 256, 261], ["an L1 expression vector", "TREATMENT", 61, 84], ["an HA", "PROBLEM", 110, 115], ["an empty vector", "TREATMENT", 134, 149], ["a plasmid HeLa-M cells", "TREATMENT", 163, 185], ["an expression construct", "TREATMENT", 211, 234], ["an active human L1", "TREATMENT", 246, 264], ["an empty vector", "TREATMENT", 284, 299], ["a plasmid", "TREATMENT", 315, 324], ["an amino-terminal FLAGtagged RNase L expression plasmid", "TREATMENT", 334, 389], ["an amino-terminal HA", "TREATMENT", 393, 413], ["tagged A3A expression plasmid", "TREATMENT", 414, 443]]], ["Experiments with a retrotransposition-defective L1 pJM111-LRE3-mEGFPI served as a negative control.", [["L1 pJM111", "DNA", 48, 57], ["LRE3", "DNA", 58, 62], ["mEGFPI", "DNA", 63, 69], ["a retrotransposition", "TREATMENT", 17, 37], ["defective L1 pJM", "PROBLEM", 38, 54], ["mEGFPI", "TREATMENT", 63, 69], ["L1", "ANATOMY", 48, 50]]], ["The cells were subjected to puromycin selection for 4 days after transfection.", [["cells", "ANATOMY", 4, 9], ["puromycin", "CHEMICAL", 28, 37], ["puromycin", "CHEMICAL", 28, 37], ["cells", "CELL", 4, 9], ["puromycin", "SIMPLE_CHEMICAL", 28, 37], ["puromycin selection", "TREATMENT", 28, 47], ["transfection", "TREATMENT", 65, 77]]], ["Fluorescence Activated Cell Sorting (FACS) was then used to screen for EGFP-positive cells.", [["Cell", "ANATOMY", 23, 27], ["cells", "ANATOMY", 85, 90], ["Cell", "CELL", 23, 27], ["EGFP", "GENE_OR_GENE_PRODUCT", 71, 75], ["cells", "CELL", 85, 90], ["EGFP", "PROTEIN", 71, 75], ["Fluorescence Activated Cell Sorting (FACS)", "TREATMENT", 0, 42], ["EGFP", "TEST", 71, 75], ["positive cells", "PROBLEM", 76, 90], ["positive cells", "OBSERVATION", 76, 90]]], ["The X-axis indicates the construct name.", [["X-axis", "DNA", 4, 10]]], ["The Y-axis indicates the percentage of EGFP-positive cells.", [["EGFP-positive cells", "ANATOMY", 39, 58], ["EGFP", "GENE_OR_GENE_PRODUCT", 39, 43], ["EGFP-positive cells", "CELL_LINE", 39, 58], ["The Y-axis", "TEST", 0, 10], ["EGFP", "TEST", 39, 43], ["positive cells", "PROBLEM", 44, 58], ["positive cells", "OBSERVATION", 44, 58]]], ["For each sample, 2 \u00c2 10 5 cells were analyzed and the percentage of EGFP-positive cells was calculated with using the FlowJo software package.", [["sample", "ANATOMY", 9, 15], ["cells", "ANATOMY", 26, 31], ["EGFP-positive cells", "ANATOMY", 68, 87], ["cells", "CELL", 26, 31], ["EGFP", "GENE_OR_GENE_PRODUCT", 68, 72], ["EGFP-positive cells", "CELL_LINE", 68, 87], ["each sample", "TEST", 4, 15], ["EGFP", "TEST", 68, 72], ["positive cells", "PROBLEM", 73, 87], ["the FlowJo software package", "TREATMENT", 114, 141], ["positive cells", "OBSERVATION", 73, 87]]], ["Data were analyzed with one-way ANOVA with post hoc tests and are shown as mean \u00b1 SD from a single experiment with three technical replicates. *P < 0.01 (Dunnett's Multiple Comparison Test).", [["post hoc tests", "TEST", 43, 57]]], ["(B) Protein expression analyses: The WT RNase L, catalytically inactive RNase L mutant (R667A), and constitutively active (N\u00c1385) RNase L mutants were detected in total cell lysates by western blot with anti-RNase L antibody 2 days after transfection.", [["cell lysates", "ANATOMY", 169, 181], ["RNase L", "GENE_OR_GENE_PRODUCT", 40, 47], ["RNase L", "GENE_OR_GENE_PRODUCT", 72, 79], ["constitutively active (N\u00c1385) RNase L", "GENE_OR_GENE_PRODUCT", 100, 137], ["cell lysates", "ORGANISM_SUBSTANCE", 169, 181], ["anti-RNase L antibody", "GENE_OR_GENE_PRODUCT", 203, 224], ["WT RNase L", "PROTEIN", 37, 47], ["catalytically inactive RNase L mutant", "PROTEIN", 49, 86], ["R667A", "PROTEIN", 88, 93], ["constitutively active (N\u00c1385) RNase L mutants", "PROTEIN", 100, 145], ["RNase L antibody", "PROTEIN", 208, 224], ["Protein expression analyses", "TEST", 4, 31], ["The WT RNase L", "TEST", 33, 47], ["constitutively active (N\u00c1385) RNase L mutants", "PROBLEM", 100, 145], ["total cell lysates", "TREATMENT", 163, 181], ["western blot", "TEST", 185, 197], ["anti-RNase L antibody", "TREATMENT", 203, 224], ["active", "OBSERVATION_MODIFIER", 115, 121]]], ["The A3A protein was detected using an anti-HA antibody. b-Actin served as loading and transfer control.", [["A3A", "GENE_OR_GENE_PRODUCT", 4, 7], ["b-Actin", "GENE_OR_GENE_PRODUCT", 56, 63], ["A3A protein", "PROTEIN", 4, 15], ["anti-HA antibody", "PROTEIN", 38, 54], ["Actin", "PROTEIN", 58, 63], ["The A3A protein", "TEST", 0, 15], ["an anti-HA antibody", "TEST", 35, 54], ["b-Actin served as loading and transfer control", "TREATMENT", 56, 102], ["anti-HA antibody", "OBSERVATION", 38, 54]]], ["Size standards are indicated in kDa at the left of the gel. expressing the amino-terminal Myc-tagged WT RNase L or a catalytically inactive R667A RNase L mutant expression construct.", [["RNase L", "GENE_OR_GENE_PRODUCT", 104, 111], ["R667A RNase L", "GENE_OR_GENE_PRODUCT", 140, 153], ["amino-terminal Myc-tagged WT RNase L", "PROTEIN", 75, 111], ["catalytically inactive R667A RNase L mutant expression construct", "DNA", 117, 181], ["left", "ANATOMY_MODIFIER", 43, 47], ["gel", "ANATOMY", 55, 58]]], ["Consistent with the findings reported above, immunofluorescent confocal microscopy revealed the presence of ORF2p cytoplasmic foci in the presence of the empty vector and the catalytically inactive R667A RNase L mutant expression construct (Figure 9 ).", [["cytoplasmic foci", "ANATOMY", 114, 130], ["ORF2p", "GENE_OR_GENE_PRODUCT", 108, 113], ["cytoplasmic", "ORGANISM_SUBSTANCE", 114, 125], ["R667A RNase L", "GENE_OR_GENE_PRODUCT", 198, 211], ["ORF2p", "PROTEIN", 108, 113], ["catalytically inactive R667A RNase L mutant expression construct", "DNA", 175, 239], ["immunofluorescent confocal microscopy", "TEST", 45, 82], ["ORF2p cytoplasmic foci", "PROBLEM", 108, 130], ["RNase L mutant expression construct", "TREATMENT", 204, 239], ["cytoplasmic", "OBSERVATION_MODIFIER", 114, 125], ["foci", "OBSERVATION", 126, 130], ["empty vector", "OBSERVATION", 154, 166]]], ["In contrast, L1 ORF2p foci were not observed on co-expression of WT RNase L.Expression of RNase L prevents the formation of L1 cytoplasmic fociAdditional control experiments revealed expression of the EBNA-1 protein from the pCEP4 plasmid backbone in either the presence or absence of WT RNase L (Figure 9 , green signal), confirming that the plasmids were successfully transfected into cells.", [["cytoplasmic", "ANATOMY", 127, 138], ["plasmids", "ANATOMY", 343, 351], ["cells", "ANATOMY", 387, 392], ["ORF2p", "GENE_OR_GENE_PRODUCT", 16, 21], ["RNase", "GENE_OR_GENE_PRODUCT", 68, 73], ["RNase L", "GENE_OR_GENE_PRODUCT", 90, 97], ["cytoplasmic", "ORGANISM_SUBSTANCE", 127, 138], ["EBNA-1", "GENE_OR_GENE_PRODUCT", 201, 207], ["pCEP4", "GENE_OR_GENE_PRODUCT", 225, 230], ["RNase L", "GENE_OR_GENE_PRODUCT", 288, 295], ["cells", "CELL", 387, 392], ["RNase L", "PROTEIN", 90, 97], ["EBNA-1 protein", "PROTEIN", 201, 215], ["pCEP4 plasmid backbone", "DNA", 225, 247], ["WT RNase L", "PROTEIN", 285, 295], ["Figure 9", "PROTEIN", 297, 305], ["plasmids", "DNA", 343, 351], ["WT RNase", "TREATMENT", 65, 73], ["RNase L prevents", "TREATMENT", 90, 106], ["L1 cytoplasmic fociAdditional control", "TREATMENT", 124, 161], ["the EBNA", "TEST", 197, 205], ["the pCEP4 plasmid backbone", "TREATMENT", 221, 247], ["green signal", "TEST", 308, 320], ["the plasmids", "TREATMENT", 339, 351], ["L1", "ANATOMY", 13, 15], ["foci", "OBSERVATION", 22, 26], ["L1", "ANATOMY", 124, 126]]], ["Moreover, we confirmed that both the WT and R667A RNase L mutant were expressed in Hela-M cells, and exhibited a diffuse cytoplasmic localization (Figure 9 , magenta signal).", [["Hela-M cells", "ANATOMY", 83, 95], ["cytoplasmic", "ANATOMY", 121, 132], ["R667A RNase L", "GENE_OR_GENE_PRODUCT", 44, 57], ["Hela-M cells", "CELL", 83, 95], ["cytoplasmic", "ORGANISM_SUBSTANCE", 121, 132], ["R667A RNase L mutant", "PROTEIN", 44, 64], ["Hela-M cells", "CELL_LINE", 83, 95], ["the WT", "TEST", 33, 39], ["a diffuse cytoplasmic localization", "PROBLEM", 111, 145], ["Figure", "TEST", 147, 153], ["diffuse", "OBSERVATION_MODIFIER", 113, 120], ["cytoplasmic localization", "OBSERVATION", 121, 145]]], ["Although RNase L previously was reported to associate with stress granules after viral infection (86), we did not detect co-localization of RNase L and ORF2p, possibly because RNase L degraded L1 RNA, thereby inhibiting L1 protein expression and RNP formation.", [["stress granules", "ANATOMY", 59, 74], ["RNP", "ANATOMY", 246, 249], ["viral infection", "DISEASE", 81, 96], ["RNase L", "GENE_OR_GENE_PRODUCT", 9, 16], ["stress granules", "CELLULAR_COMPONENT", 59, 74], ["RNase L", "GENE_OR_GENE_PRODUCT", 140, 147], ["ORF2p", "GENE_OR_GENE_PRODUCT", 152, 157], ["RNase L", "GENE_OR_GENE_PRODUCT", 176, 183], ["RNP", "CELLULAR_COMPONENT", 246, 249], ["RNase L", "PROTEIN", 9, 16], ["RNase L", "PROTEIN", 140, 147], ["ORF2p", "PROTEIN", 152, 157], ["RNase L", "PROTEIN", 176, 183], ["L1 RNA", "RNA", 193, 199], ["L1 protein", "PROTEIN", 220, 230], ["stress granules", "PROBLEM", 59, 74], ["viral infection", "PROBLEM", 81, 96], ["co-localization of RNase L and ORF2p", "PROBLEM", 121, 157], ["RNase L degraded L1 RNA", "PROBLEM", 176, 199], ["L1 protein expression", "PROBLEM", 220, 241], ["viral infection", "OBSERVATION", 81, 96], ["L1 RNA", "OBSERVATION", 193, 199], ["L1", "ANATOMY", 220, 222], ["protein expression", "OBSERVATION", 223, 241], ["RNP formation", "OBSERVATION", 246, 259]]], ["Together, the above data are not inconsistent with the conclusion that RNase L may preferentially target L1 transcripts for degradation.Mechanism of L1 restriction by RNase LOur findings strongly suggest that the relatively general antiviral pathway mediated by RNase L may also restrict certain non-LTR and LTR retrotransposons.", [["LTR", "ANATOMY", 308, 311], ["RNase L", "GENE_OR_GENE_PRODUCT", 71, 78], ["RNase", "GENE_OR_GENE_PRODUCT", 167, 172], ["RNase L", "GENE_OR_GENE_PRODUCT", 262, 269], ["non-LTR", "CELLULAR_COMPONENT", 296, 303], ["LTR", "CELLULAR_COMPONENT", 308, 311], ["RNase L", "PROTEIN", 71, 78], ["L1 transcripts", "RNA", 105, 119], ["L1", "DNA", 149, 151], ["RNase", "PROTEIN", 167, 172], ["RNase L", "PROTEIN", 262, 269], ["non-LTR and LTR retrotransposons", "DNA", 296, 328], ["the above data", "TEST", 10, 24], ["RNase L", "TREATMENT", 71, 78], ["L1", "ANATOMY", 149, 151], ["LTR retrotransposons", "OBSERVATION", 308, 328]]], ["The available data indicate that transient expression of RNase L inhibits both L1 and IAP retrotransposition (Figures 2, 4 and 6) .", [["RNase L", "GENE_OR_GENE_PRODUCT", 57, 64], ["IAP", "GENE_OR_GENE_PRODUCT", 86, 89], ["RNase L", "PROTEIN", 57, 64], ["L1", "DNA", 79, 81], ["IAP", "DNA", 86, 89], ["The available data", "TEST", 0, 18], ["transient expression of RNase L inhibits", "PROBLEM", 33, 73], ["L1", "ANATOMY", 79, 81], ["IAP retrotransposition", "ANATOMY", 86, 108]]], ["Conversely, the siRNA-mediated knockdown of endogenous RNase L increased L1 retrotransposition by $87% (Figure 5 ).", [["RNase L", "GENE_OR_GENE_PRODUCT", 55, 62], ["RNase L", "PROTEIN", 55, 62], ["L1", "DNA", 73, 75], ["the siRNA", "TEST", 12, 21], ["endogenous RNase L increased L1 retrotransposition", "TREATMENT", 44, 94], ["increased", "OBSERVATION_MODIFIER", 63, 72], ["L1 retrotransposition", "OBSERVATION", 73, 94]]], ["Regarding our IAP results, while there are limitations in drawing conclusions from cross species transfection experiments, our findings suggest a relatively general role for RNase L in restricting retrotransposons that have different integration mechanisms.", [["RNase L", "GENE_OR_GENE_PRODUCT", 174, 181], ["retrotransposons", "CELLULAR_COMPONENT", 197, 213], ["RNase L", "PROTEIN", 174, 181], ["retrotransposons", "DNA", 197, 213], ["our IAP results", "TEST", 10, 25], ["RNase L in restricting retrotransposons", "TREATMENT", 174, 213]]], ["IAP elements in mice are the result of transmission of the viral progenitor IAPE (87) , and therefore, inhibition of IAP transposition by RNase L is not inconsistent with its antiviral function.Mechanism of L1 restriction by RNase LL1 and IAP retrotransposition are not suppressed in the presence of an RNase L containing a single amino acid substitution (R667A), which abrogates its enzymatic activity.", [["progenitor", "ANATOMY", 65, 75], ["amino acid", "CHEMICAL", 331, 341], ["amino acid", "CHEMICAL", 331, 341], ["IAP", "GENE_OR_GENE_PRODUCT", 0, 3], ["mice", "ORGANISM", 16, 20], ["IAP", "GENE_OR_GENE_PRODUCT", 117, 120], ["RNase L", "GENE_OR_GENE_PRODUCT", 138, 145], ["RNase LL1", "GENE_OR_GENE_PRODUCT", 225, 234], ["IAP", "GENE_OR_GENE_PRODUCT", 239, 242], ["RNase L", "GENE_OR_GENE_PRODUCT", 303, 310], ["amino acid", "AMINO_ACID", 331, 341], ["R667A", "AMINO_ACID", 356, 361], ["IAP elements", "DNA", 0, 12], ["IAP", "PROTEIN", 117, 120], ["RNase L", "PROTEIN", 138, 145], ["L1", "DNA", 207, 209], ["RNase LL1", "PROTEIN", 225, 234], ["IAP retrotransposition", "DNA", 239, 261], ["RNase L", "PROTEIN", 303, 310], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["IAP elements in mice", "PROBLEM", 0, 20], ["the viral progenitor IAPE", "TEST", 55, 80], ["IAP transposition", "TREATMENT", 117, 134], ["L1 restriction", "TREATMENT", 207, 221], ["RNase LL1", "TREATMENT", 225, 234], ["IAP retrotransposition", "TREATMENT", 239, 261], ["an RNase L", "TREATMENT", 300, 310], ["a single amino acid substitution", "TREATMENT", 322, 354], ["viral progenitor", "OBSERVATION", 59, 75], ["antiviral function", "OBSERVATION", 175, 193], ["L1", "ANATOMY", 207, 209], ["IAP retrotransposition", "OBSERVATION", 239, 261], ["not", "UNCERTAINTY", 266, 269], ["suppressed", "OBSERVATION_MODIFIER", 270, 280], ["enzymatic activity", "OBSERVATION", 384, 402]]], ["These data indicate that a principal mechanism by which RNase L inhibits L1 and IAP retrotransposition likely involves the posttranscriptional cleavage of retrotransposon RNA.", [["RNase L", "GENE_OR_GENE_PRODUCT", 56, 63], ["L1", "GENE_OR_GENE_PRODUCT", 73, 75], ["IAP", "GENE_OR_GENE_PRODUCT", 80, 83], ["RNase L", "PROTEIN", 56, 63], ["L1", "DNA", 73, 75], ["IAP", "DNA", 80, 83], ["retrotransposon RNA", "RNA", 155, 174], ["RNase L inhibits L1", "TREATMENT", 56, 75], ["IAP retrotransposition", "TREATMENT", 80, 102], ["the posttranscriptional cleavage of retrotransposon RNA", "PROBLEM", 119, 174], ["L1", "ANATOMY", 73, 75], ["IAP retrotransposition", "OBSERVATION", 80, 102], ["posttranscriptional cleavage", "OBSERVATION", 123, 151], ["retrotransposon RNA", "OBSERVATION", 155, 174]]], ["In addition, it is unknown if R667A also affects RNA binding, but if it does it could explain why the catalytically inactive mutant cannot be co-localized with L1 RNA.", [["R667A", "GENE_OR_GENE_PRODUCT", 30, 35], ["R667A", "PROTEIN", 30, 35], ["catalytically inactive mutant", "PROTEIN", 102, 131], ["L1 RNA", "RNA", 160, 166], ["RNA binding", "PROBLEM", 49, 60], ["the catalytically inactive mutant", "PROBLEM", 98, 131], ["L1 RNA", "ANATOMY", 160, 166]]], ["The expression of WT RNase L, as well as a constitutively active RNase L mutant (N\u00c1385), led to a reduction in L1 RNA levels; this reduction, in turn, led to a decrease in both ORF1p and ORF2p expression (Figures 7, 8 and 9 ).", [["RNase L", "GENE_OR_GENE_PRODUCT", 21, 28], ["RNase L", "GENE_OR_GENE_PRODUCT", 65, 72], ["ORF1p", "GENE_OR_GENE_PRODUCT", 177, 182], ["ORF2p", "GENE_OR_GENE_PRODUCT", 187, 192], ["WT RNase L", "PROTEIN", 18, 28], ["RNase L mutant", "PROTEIN", 65, 79], ["N\u00c1385", "PROTEIN", 81, 86], ["L1 RNA", "RNA", 111, 117], ["ORF1p", "PROTEIN", 177, 182], ["ORF2p", "PROTEIN", 187, 192], ["WT RNase L", "TREATMENT", 18, 28], ["a constitutively active RNase L mutant", "PROBLEM", 41, 79], ["a reduction in L1 RNA levels", "TREATMENT", 96, 124], ["this reduction", "TREATMENT", 126, 140], ["a decrease", "PROBLEM", 158, 168], ["Figures", "TEST", 205, 212], ["reduction", "OBSERVATION_MODIFIER", 98, 107], ["L1 RNA", "ANATOMY", 111, 117], ["decrease", "OBSERVATION_MODIFIER", 160, 168]]], ["In contrast, RNase L expression had little effect on HYG mRNA, which also is expressed from the L1 expression construct (pCEP4) backbone (Figure 7) .", [["RNase L", "GENE_OR_GENE_PRODUCT", 13, 20], ["HYG", "GENE_OR_GENE_PRODUCT", 53, 56], ["pCEP4", "GENE_OR_GENE_PRODUCT", 121, 126], ["RNase L", "PROTEIN", 13, 20], ["HYG mRNA", "RNA", 53, 61], ["L1 expression construct", "DNA", 96, 119], ["pCEP4", "DNA", 121, 126], ["little effect on HYG mRNA", "PROBLEM", 36, 61], ["little effect", "OBSERVATION_MODIFIER", 36, 49], ["HYG mRNA", "OBSERVATION_MODIFIER", 53, 61], ["L1", "ANATOMY", 96, 98]]], ["These findings and a lack of ribosomal RNA cleavage products (data not shown) suggest that RNase L preferentially targets L1 RNA for degradation.Mechanism of L1 restriction by RNase LThe specificity of RNase L has been previously studied (88, 89) .", [["ribosomal", "ANATOMY", 29, 38], ["ribosomal", "CELLULAR_COMPONENT", 29, 38], ["RNase L", "GENE_OR_GENE_PRODUCT", 91, 98], ["RNase", "GENE_OR_GENE_PRODUCT", 176, 181], ["RNase L", "GENE_OR_GENE_PRODUCT", 202, 209], ["ribosomal RNA", "RNA", 29, 42], ["RNase L", "PROTEIN", 91, 98], ["L1 RNA", "RNA", 122, 128], ["L1", "DNA", 158, 160], ["RNase", "PROTEIN", 176, 181], ["RNase L", "PROTEIN", 202, 209], ["ribosomal RNA cleavage products", "TREATMENT", 29, 60], ["RNase L preferentially targets L1 RNA", "PROBLEM", 91, 128], ["Mechanism of L1 restriction", "PROBLEM", 145, 172], ["L1", "ANATOMY", 158, 160], ["RNase L", "OBSERVATION_MODIFIER", 202, 209]]], ["RNase L cleaves single-strand RNA, predominantly after UpAp and UpUp dinucleotide sequences (88, 89) .", [["dinucleotide", "CHEMICAL", 69, 81], ["RNase L", "GENE_OR_GENE_PRODUCT", 0, 7], ["UpAp", "GENE_OR_GENE_PRODUCT", 55, 59], ["RNase L", "PROTEIN", 0, 7], ["single-strand RNA", "RNA", 16, 33], ["UpAp and UpUp dinucleotide sequences", "DNA", 55, 91], ["RNase", "TEST", 0, 5], ["UpAp and UpUp dinucleotide sequences", "TEST", 55, 91], ["strand RNA", "OBSERVATION_MODIFIER", 23, 33]]], ["However, the structural context of the RNA substrate greatly influences the choice of cleavage sites (90) .", [["cleavage sites", "PROTEIN", 86, 100], ["the RNA substrate", "PROBLEM", 35, 52]]], ["Certain viral and cellular single-strand RNAs are subject to degradation.", [["cellular", "ANATOMY", 18, 26], ["cellular", "CELL", 18, 26], ["viral and cellular single-strand RNAs", "RNA", 8, 45], ["Certain viral and cellular single-strand RNAs", "PROBLEM", 0, 45], ["viral", "OBSERVATION", 8, 13], ["cellular", "OBSERVATION_MODIFIER", 18, 26], ["strand RNAs", "OBSERVATION", 34, 45]]], ["For example, ribosomal RNA present in intact ribosomes can be cleaved by RNase L producing a characteristic pattern of discrete products in some IFN-treated and virus-infected cells (91, 92) .", [["ribosomal", "ANATOMY", 13, 22], ["ribosomes", "ANATOMY", 45, 54], ["cells", "ANATOMY", 176, 181], ["IFN", "CHEMICAL", 145, 148], ["ribosomal", "CELLULAR_COMPONENT", 13, 22], ["ribosomes", "CELLULAR_COMPONENT", 45, 54], ["RNase L", "GENE_OR_GENE_PRODUCT", 73, 80], ["IFN", "GENE_OR_GENE_PRODUCT", 145, 148], ["cells", "CELL", 176, 181], ["ribosomal RNA", "RNA", 13, 26], ["RNase L", "PROTEIN", 73, 80], ["IFN-treated and virus-infected cells", "CELL_LINE", 145, 181], ["ribosomal RNA", "PROBLEM", 13, 26], ["discrete products", "PROBLEM", 119, 136], ["some IFN", "PROBLEM", 140, 148], ["virus", "PROBLEM", 161, 166], ["infected cells", "PROBLEM", 167, 181], ["ribosomal RNA", "OBSERVATION", 13, 26], ["intact ribosomes", "OBSERVATION", 38, 54], ["RNase L", "OBSERVATION_MODIFIER", 73, 80], ["discrete", "OBSERVATION_MODIFIER", 119, 127], ["products", "OBSERVATION_MODIFIER", 128, 136], ["some IFN", "OBSERVATION_MODIFIER", 140, 148], ["infected cells", "OBSERVATION", 167, 181]]], ["The molecular mechanism by which RNase L targets L1 RNA requires further study.", [["RNase L", "GENE_OR_GENE_PRODUCT", 33, 40], ["L1", "GENE_OR_GENE_PRODUCT", 49, 51], ["RNase L", "PROTEIN", 33, 40], ["L1 RNA", "RNA", 49, 55], ["RNase L targets L1 RNA", "TREATMENT", 33, 55], ["further study", "TEST", 65, 78]]], ["We hypothesize that doublestranded structures (e.g. stem loops) within L1 RNA may activate OAS to produce microdomains of 2-5A (an activator of RNase L) from ATP.", [["stem loops", "ANATOMY", 52, 62], ["ATP", "CHEMICAL", 158, 161], ["ATP", "CHEMICAL", 158, 161], ["OAS", "GENE_OR_GENE_PRODUCT", 91, 94], ["2-5A", "GENE_OR_GENE_PRODUCT", 122, 126], ["RNase L", "GENE_OR_GENE_PRODUCT", 144, 151], ["ATP", "SIMPLE_CHEMICAL", 158, 161], ["L1 RNA", "RNA", 71, 77], ["OAS", "PROTEIN", 91, 94], ["RNase L", "PROTEIN", 144, 151], ["doublestranded structures (e.g. stem loops) within L1 RNA", "PROBLEM", 20, 77], ["ATP", "PROBLEM", 158, 161], ["stem loops", "OBSERVATION", 52, 62], ["L1 RNA", "ANATOMY", 71, 77]]], ["Alternatively, RNAs produced from the L1 sense and antisense promoters (SP and ASP, respectively) (46) may hybridize to form a Figure 8 .", [["RNAs", "RNA", 15, 19], ["L1", "DNA", 38, 40], ["antisense promoters", "DNA", 51, 70], ["SP", "DNA", 72, 74], ["ASP", "DNA", 79, 82]]], ["Expression of RNase L reduces L1 protein expression.", [["RNase L", "GENE_OR_GENE_PRODUCT", 14, 21], ["L1", "GENE_OR_GENE_PRODUCT", 30, 32], ["RNase L", "PROTEIN", 14, 21], ["L1 protein", "PROTEIN", 30, 40], ["RNase L reduces L1 protein expression", "PROBLEM", 14, 51], ["RNase L", "OBSERVATION_MODIFIER", 14, 21], ["reduces", "OBSERVATION_MODIFIER", 22, 29], ["L1", "ANATOMY_MODIFIER", 30, 32], ["protein expression", "OBSERVATION", 33, 51]]], ["(A) L1 protein expression: HeLa-M cells were co-transfected with pAD2TE1 and either an empty vector (pFLAG-CMV-2) or a plasmid that encodes an amino-terminal FLAG-tagged RNase L expression plasmid.", [["HeLa-M cells", "ANATOMY", 27, 39], ["plasmid", "ANATOMY", 119, 126], ["amino", "CHEMICAL", 143, 148], ["HeLa-M cells", "CELL", 27, 39], ["pAD2TE1", "GENE_OR_GENE_PRODUCT", 65, 72], ["pFLAG-CMV-2", "GENE_OR_GENE_PRODUCT", 101, 112], ["RNase L", "GENE_OR_GENE_PRODUCT", 170, 177], ["L1 protein", "PROTEIN", 4, 14], ["HeLa-M cells", "CELL_LINE", 27, 39], ["pAD2TE1", "DNA", 65, 72], ["empty vector", "DNA", 87, 99], ["pFLAG-CMV-2", "DNA", 101, 112], ["plasmid", "DNA", 119, 126], ["amino-terminal FLAG-tagged RNase L expression plasmid", "DNA", 143, 196], ["HeLa-M cells", "TREATMENT", 27, 39], ["pAD2TE1", "TREATMENT", 65, 72], ["a plasmid", "TREATMENT", 117, 126], ["an amino-terminal FLAG", "TREATMENT", 140, 162], ["tagged RNase L expression plasmid", "TREATMENT", 163, 196], ["L1", "ANATOMY", 4, 6], ["empty", "OBSERVATION", 87, 92]]], ["Two days after transfection, cells were selected with hygromycin containing medium for an additional 4 days when total cell lysates and L1 RNPs were prepared.", [["cells", "ANATOMY", 29, 34], ["cell lysates", "ANATOMY", 119, 131], ["RNPs", "ANATOMY", 139, 143], ["hygromycin", "CHEMICAL", 54, 64], ["hygromycin", "CHEMICAL", 54, 64], ["cells", "CELL", 29, 34], ["hygromycin", "SIMPLE_CHEMICAL", 54, 64], ["cell lysates", "ORGANISM_SUBSTANCE", 119, 131], ["L1 RNPs", "PROTEIN", 136, 143], ["transfection, cells", "TREATMENT", 15, 34], ["hygromycin containing medium", "TREATMENT", 54, 82], ["total cell lysates", "TREATMENT", 113, 131], ["L1 RNPs", "TREATMENT", 136, 143], ["L1", "ANATOMY", 136, 138]]], ["Western blotting, using anti-T7 and anti-TAP antibodies, was used to detect ORF1p and ORF2p, respectively.", [["anti-T7", "GENE_OR_GENE_PRODUCT", 24, 31], ["anti-TAP antibodies", "GENE_OR_GENE_PRODUCT", 36, 55], ["ORF1p", "GENE_OR_GENE_PRODUCT", 76, 81], ["ORF2p", "GENE_OR_GENE_PRODUCT", 86, 91], ["anti-T7", "PROTEIN", 24, 31], ["anti-TAP antibodies", "PROTEIN", 36, 55], ["ORF1p", "PROTEIN", 76, 81], ["ORF2p", "PROTEIN", 86, 91], ["anti-T7 and anti-TAP antibodies", "TREATMENT", 24, 55]]], ["Shown are two exposures of the ORF2p anti-TAP western blot.", [["ORF2p", "PROTEIN", 31, 36]]], ["Endogenous ribosomal S6 protein was used as the loading/transfer control. b-Actin detection discriminated the total cell lysate (left side of panel) from the L1 RNP fractions (right side of panel).", [["ribosomal", "ANATOMY", 11, 20], ["cell lysate", "ANATOMY", 116, 127], ["left", "ANATOMY", 129, 133], ["L1 RNP fractions", "ANATOMY", 158, 174], ["ribosomal S6", "GENE_OR_GENE_PRODUCT", 11, 23], ["Actin", "GENE_OR_GENE_PRODUCT", 76, 81], ["cell lysate", "ORGANISM_SUBSTANCE", 116, 127], ["ribosomal S6 protein", "PROTEIN", 11, 31], ["Actin", "PROTEIN", 76, 81], ["L1 RNP", "PROTEIN", 158, 164], ["Endogenous ribosomal S6 protein", "TREATMENT", 0, 31], ["the loading/transfer control", "TREATMENT", 44, 72], ["b-Actin detection", "TEST", 74, 91], ["the total cell lysate", "TREATMENT", 106, 127], ["ribosomal S6 protein", "OBSERVATION", 11, 31], ["L1", "ANATOMY", 158, 160], ["RNP fractions", "OBSERVATION", 161, 174], ["right", "ANATOMY_MODIFIER", 176, 181]]], ["(B) RNase L does not inhibit exogenous EGFP protein expression: HeLa-M cells were co-transfected with pEGFP-C1 and either an empty vector (pFLAG-CMV-2) or a plasmid that encodes an amino-terminal FLAG-tagged RNase L expression plasmid.", [["HeLa-M cells", "ANATOMY", 64, 76], ["plasmid", "ANATOMY", 157, 164], ["amino", "CHEMICAL", 181, 186], ["RNase L", "GENE_OR_GENE_PRODUCT", 4, 11], ["EGFP", "GENE_OR_GENE_PRODUCT", 39, 43], ["HeLa-M cells", "CELL", 64, 76], ["pEGFP-C1", "GENE_OR_GENE_PRODUCT", 102, 110], ["pFLAG-CMV-2", "GENE_OR_GENE_PRODUCT", 139, 150], ["RNase L", "GENE_OR_GENE_PRODUCT", 208, 215], ["RNase L", "PROTEIN", 4, 11], ["EGFP protein", "PROTEIN", 39, 51], ["HeLa-M cells", "CELL_LINE", 64, 76], ["pEGFP", "DNA", 102, 107], ["C1", "DNA", 108, 110], ["empty vector", "DNA", 125, 137], ["pFLAG-CMV-2", "DNA", 139, 150], ["plasmid", "DNA", 157, 164], ["amino-terminal FLAG-tagged RNase L expression plasmid", "DNA", 181, 234], ["HeLa-M cells", "TEST", 64, 76], ["pEGFP", "TEST", 102, 107], ["a plasmid", "TREATMENT", 155, 164], ["an amino-terminal FLAG", "TREATMENT", 178, 200], ["tagged RNase L expression plasmid", "TREATMENT", 201, 234], ["C1", "ANATOMY", 108, 110], ["empty", "OBSERVATION", 125, 130]]], ["Total cell lysates were harvested and the expression of RNase L and GFP was detected in western blot experiments using anti-RNase L and anti-GFP antibodies at 48 h after transfection.", [["cell lysates", "ANATOMY", 6, 18], ["cell lysates", "ORGANISM_SUBSTANCE", 6, 18], ["RNase L", "GENE_OR_GENE_PRODUCT", 56, 63], ["GFP", "GENE_OR_GENE_PRODUCT", 68, 71], ["anti-RNase L", "GENE_OR_GENE_PRODUCT", 119, 131], ["anti-GFP", "GENE_OR_GENE_PRODUCT", 136, 144], ["RNase L", "PROTEIN", 56, 63], ["GFP", "PROTEIN", 68, 71], ["RNase L", "PROTEIN", 124, 131], ["anti-GFP antibodies", "PROTEIN", 136, 155], ["Total cell lysates", "TREATMENT", 0, 18], ["RNase L and GFP", "PROBLEM", 56, 71], ["anti-RNase L and anti-GFP antibodies", "TREATMENT", 119, 155], ["cell lysates", "OBSERVATION", 6, 18]]], ["GAPDH served as a loading and transfer control. region of dsRNA that activates OAS (46, 93) .", [["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["GAPDH", "PROTEIN", 0, 5], ["OAS", "DNA", 79, 82], ["GAPDH", "PROBLEM", 0, 5], ["a loading and transfer control", "TREATMENT", 16, 46], ["dsRNA", "PROBLEM", 58, 63], ["dsRNA", "OBSERVATION", 58, 63]]], ["This proposed localized activation of OAS, and RNase L may then result in the targeted degradation of L1 RNA.Mechanism of L1 restriction by RNase LThe above model has precedent.", [["OAS", "GENE_OR_GENE_PRODUCT", 38, 41], ["RNase L", "GENE_OR_GENE_PRODUCT", 47, 54], ["RNase LThe", "GENE_OR_GENE_PRODUCT", 140, 150], ["OAS", "PROTEIN", 38, 41], ["RNase L", "PROTEIN", 47, 54], ["L1 RNA", "RNA", 102, 108], ["L1", "DNA", 122, 124], ["RNase", "PROTEIN", 140, 145], ["OAS", "PROBLEM", 38, 41], ["the targeted degradation of L1 RNA", "PROBLEM", 74, 108], ["L1 restriction", "PROBLEM", 122, 136], ["L1 RNA", "ANATOMY", 102, 108], ["L1", "ANATOMY", 122, 124]]], ["For example, it previously was hypothesized that partially double-stranded RNAs, such as replicative intermediates from certain picornaviruses including encephalomyocarditis virus, could lead to localized OAS-RNase L activation (94, 95) .", [["encephalomyocarditis virus", "DISEASE", 153, 179], ["encephalomyocarditis virus", "ORGANISM", 153, 179], ["OAS-RNase L", "GENE_OR_GENE_PRODUCT", 205, 216], ["double-stranded RNAs", "RNA", 59, 79], ["OAS", "PROTEIN", 205, 208], ["RNase L", "PROTEIN", 209, 216], ["encephalomyocarditis virus", "SPECIES", 153, 179], ["encephalomyocarditis virus", "SPECIES", 153, 179], ["partially double-stranded RNAs", "PROBLEM", 49, 79], ["replicative intermediates", "PROBLEM", 89, 114], ["certain picornaviruses", "PROBLEM", 120, 142], ["encephalomyocarditis virus", "PROBLEM", 153, 179], ["RNase L activation", "TEST", 209, 227], ["stranded RNAs", "OBSERVATION", 66, 79], ["encephalomyocarditis virus", "OBSERVATION", 153, 179]]], ["RNAs linked to double-strand RNA were preferentially degraded by RNase L when compared with singlestranded RNAs lacking a double-strand segment (94) .", [["RNase L", "GENE_OR_GENE_PRODUCT", 65, 72], ["RNAs", "RNA", 0, 4], ["double-strand RNA", "RNA", 15, 32], ["RNase L", "PROTEIN", 65, 72], ["singlestranded RNAs", "RNA", 92, 111], ["double-strand segment", "DNA", 122, 143], ["double-strand RNA", "TREATMENT", 15, 32], ["strand RNA", "OBSERVATION_MODIFIER", 22, 32]]], ["By analogy, there is evidence for another localized activation model involving production of a different small molecule second messenger, cyclic adenosine monophosphate (cAMP).", [["cyclic adenosine monophosphate", "CHEMICAL", 138, 168], ["cAMP", "CHEMICAL", 170, 174], ["cyclic adenosine monophosphate", "CHEMICAL", 138, 168], ["cAMP", "CHEMICAL", 170, 174], ["cyclic adenosine monophosphate", "GENE_OR_GENE_PRODUCT", 138, 168], ["cAMP", "SIMPLE_CHEMICAL", 170, 174], ["another localized activation model", "PROBLEM", 34, 68], ["a different small molecule second messenger", "PROBLEM", 93, 136], ["cyclic adenosine monophosphate (cAMP", "TREATMENT", 138, 174], ["evidence for", "UNCERTAINTY", 21, 33], ["activation model", "OBSERVATION", 52, 68], ["small", "OBSERVATION_MODIFIER", 105, 110]]], ["The distribution in rat neonatal cardiac myocytes of enzymes that synthesize and degrade cAMP produce microdomains of cAMP that specifically activate a subset of localized protein kinase A molecules (96) .", [["neonatal cardiac myocytes", "ANATOMY", 24, 49], ["cAMP", "CHEMICAL", 89, 93], ["cAMP", "CHEMICAL", 118, 122], ["cAMP", "CHEMICAL", 89, 93], ["cAMP", "CHEMICAL", 118, 122], ["rat", "ORGANISM", 20, 23], ["cardiac myocytes", "CELL", 33, 49], ["cAMP", "SIMPLE_CHEMICAL", 89, 93], ["cAMP", "SIMPLE_CHEMICAL", 118, 122], ["protein kinase A molecules", "GENE_OR_GENE_PRODUCT", 172, 198], ["enzymes", "PROTEIN", 53, 60], ["protein kinase A molecules", "PROTEIN", 172, 198], ["rat", "SPECIES", 20, 23], ["rat", "SPECIES", 20, 23], ["degrade cAMP produce microdomains of cAMP", "PROBLEM", 81, 122], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["cardiac myocytes", "ANATOMY", 33, 49], ["protein kinase", "OBSERVATION", 172, 186]]], ["Thus, in principle, 2-5A microdomains would form near the sites of OAS complexed with its RNA activators.", [["2-5A", "SIMPLE_CHEMICAL", 20, 24], ["OAS", "PROTEIN", 67, 70], ["RNA activators", "PROTEIN", 90, 104]]], ["Within these 2-5A microdomains, RNase L would become active causing cleavage of the RNA stimulators of OAS, in this case L1 RNA.", [["RNase L", "GENE_OR_GENE_PRODUCT", 32, 39], ["OAS", "GENE_OR_GENE_PRODUCT", 103, 106], ["RNase L", "PROTEIN", 32, 39], ["RNA stimulators", "RNA", 84, 99], ["OAS", "PROTEIN", 103, 106], ["L1 RNA", "RNA", 121, 127], ["RNase L", "TREATMENT", 32, 39], ["the RNA stimulators", "TREATMENT", 80, 99], ["OAS", "PROBLEM", 103, 106], ["active", "OBSERVATION", 53, 59], ["RNA stimulators", "OBSERVATION", 84, 99]]], ["This model could be relevant to both retrotransposition and viral infections and warrants further investigation.", [["viral infections", "DISEASE", 60, 76], ["viral infections", "PROBLEM", 60, 76], ["further investigation", "TEST", 90, 111], ["could be relevant to", "UNCERTAINTY", 11, 31], ["both", "OBSERVATION_MODIFIER", 32, 36], ["retrotransposition", "OBSERVATION", 37, 55], ["viral", "OBSERVATION_MODIFIER", 60, 65], ["infections", "OBSERVATION", 66, 76]]], ["Finally, it is noteworthy that RNase L may not be the only host protein that regulates L1 retrotransposition by nucleic acid degradation.", [["nucleic acid", "CHEMICAL", 112, 124], ["RNase L", "GENE_OR_GENE_PRODUCT", 31, 38], ["nucleic acid", "SIMPLE_CHEMICAL", 112, 124], ["RNase L", "PROTEIN", 31, 38], ["L1", "DNA", 87, 89], ["RNase L", "PROBLEM", 31, 38], ["nucleic acid degradation", "PROBLEM", 112, 136], ["may not be", "UNCERTAINTY", 39, 49], ["L1 retrotransposition", "OBSERVATION", 87, 108], ["nucleic acid", "OBSERVATION", 112, 124]]], ["For example, it is hypothesized that the 3 0 -5 0 exonuclease Trex1 inhibits L1 retrotransposition by degrading L1 cDNA intermediates (48) .Mechanism of L1 restriction by RNase LNotably, we did not observe co-localization of RNase L with L1 cytoplasmic foci (Figures 7 and 8 ).", [["cytoplasmic foci", "ANATOMY", 241, 257], ["Trex1", "GENE_OR_GENE_PRODUCT", 62, 67], ["RNase", "GENE_OR_GENE_PRODUCT", 171, 176], ["RNase L", "GENE_OR_GENE_PRODUCT", 225, 232], ["3 0 -5 0 exonuclease", "PROTEIN", 41, 61], ["Trex1", "PROTEIN", 62, 67], ["L1", "DNA", 77, 79], ["L1 cDNA", "DNA", 112, 119], ["L1", "DNA", 153, 155], ["RNase", "PROTEIN", 171, 176], ["RNase L", "PROTEIN", 225, 232], ["L1", "PROTEIN", 238, 240], ["exonuclease Trex1 inhibits L1 retrotransposition", "TREATMENT", 50, 98], ["L1 cytoplasmic foci", "PROBLEM", 238, 257], ["Figures", "TEST", 259, 266], ["L1", "ANATOMY", 77, 79], ["L1", "ANATOMY", 153, 155], ["L1", "ANATOMY", 238, 240], ["cytoplasmic", "OBSERVATION_MODIFIER", 241, 252], ["foci", "OBSERVATION", 253, 257]]], ["First, the degradation of L1 RNA by WT or constitutively active RNase L would be predicted to inhibit the formation of L1 RNPs, thereby hampering the visualization of colocalized foci.", [["RNPs", "ANATOMY", 122, 126], ["foci", "ANATOMY", 179, 183], ["RNase L", "GENE_OR_GENE_PRODUCT", 64, 71], ["foci", "CELL", 179, 183], ["L1 RNA", "RNA", 26, 32], ["RNase L", "PROTEIN", 64, 71], ["L1 RNPs", "PROTEIN", 119, 126], ["the degradation of L1 RNA", "PROBLEM", 7, 32], ["constitutively active RNase L", "PROBLEM", 42, 71], ["colocalized foci", "PROBLEM", 167, 183], ["L1", "ANATOMY", 26, 28], ["L1", "ANATOMY", 119, 121], ["colocalized", "OBSERVATION_MODIFIER", 167, 178], ["foci", "OBSERVATION", 179, 183]]], ["Second, the inability to observe co-localization of L1 cytoplasmic foci with the catalytically inactive R667A RNase L mutant could reflect the transient nature of the association of RNase L with its RNA substrate (97) .", [["cytoplasmic foci", "ANATOMY", 55, 71], ["R667A RNase L", "GENE_OR_GENE_PRODUCT", 104, 117], ["RNase L", "GENE_OR_GENE_PRODUCT", 182, 189], ["L1 cytoplasmic foci", "PROTEIN", 52, 71], ["catalytically inactive R667A RNase L mutant", "PROTEIN", 81, 124], ["RNase L", "PROTEIN", 182, 189], ["L1 cytoplasmic foci", "PROBLEM", 52, 71], ["L1", "ANATOMY", 52, 54], ["cytoplasmic", "OBSERVATION_MODIFIER", 55, 66], ["foci", "OBSERVATION", 67, 71], ["transient", "OBSERVATION_MODIFIER", 143, 152]]], ["Similarly, the absence of RNase L in the interactome from isolated L1 ORF1 protein and its RNPs is not inconsistent with a transient interaction between in L1 RNA and RNase L (54).", [["RNase L", "GENE_OR_GENE_PRODUCT", 26, 33], ["RNase L (54)", "GENE_OR_GENE_PRODUCT", 167, 179], ["RNase L", "PROTEIN", 26, 33], ["L1 ORF1 protein", "PROTEIN", 67, 82], ["RNPs", "PROTEIN", 91, 95], ["L1 RNA", "RNA", 156, 162], ["RNase L", "PROTEIN", 167, 174], ["RNase L in the interactome", "PROBLEM", 26, 52], ["isolated L1 ORF1 protein", "TEST", 58, 82], ["a transient interaction", "PROBLEM", 121, 144], ["RNase L", "OBSERVATION_MODIFIER", 26, 33], ["L1", "ANATOMY_MODIFIER", 67, 69], ["transient", "OBSERVATION_MODIFIER", 123, 132], ["interaction", "OBSERVATION", 133, 144], ["L1 RNA", "ANATOMY", 156, 162]]], ["Lastly, it remains possible that the ectopic expression of RNase L leads to an artifactual degradation of L1 RNA.", [["RNase L", "GENE_OR_GENE_PRODUCT", 59, 66], ["RNase L", "PROTEIN", 59, 66], ["L1 RNA", "RNA", 106, 112], ["the ectopic expression of RNase", "PROBLEM", 33, 64], ["an artifactual degradation of L1 RNA", "PROBLEM", 76, 112], ["ectopic", "OBSERVATION", 37, 44], ["artifactual degradation", "OBSERVATION", 79, 102], ["L1 RNA", "OBSERVATION", 106, 112]]], ["However, this scenario is unlikely because RNase L did not inhibit HYG mRNA production or EGFP protein production, and siRNAmediated depletion of RNase L from Hey1b cell led to Figure 9 .", [["Hey1b cell", "ANATOMY", 159, 169], ["RNase L", "GENE_OR_GENE_PRODUCT", 43, 50], ["HYG", "GENE_OR_GENE_PRODUCT", 67, 70], ["EGFP", "GENE_OR_GENE_PRODUCT", 90, 94], ["RNase L", "GENE_OR_GENE_PRODUCT", 146, 153], ["Hey1b cell", "CELL", 159, 169], ["RNase L", "PROTEIN", 43, 50], ["HYG mRNA", "RNA", 67, 75], ["EGFP protein", "PROTEIN", 90, 102], ["RNase L", "PROTEIN", 146, 153], ["Hey1b cell", "CELL_LINE", 159, 169], ["HYG mRNA production", "PROBLEM", 67, 86], ["EGFP protein production", "PROBLEM", 90, 113], ["RNase L from Hey1b cell", "TREATMENT", 146, 169]]], ["Expression of RNase L blocks L1 RNP formation.", [["RNP", "ANATOMY", 32, 35], ["RNase L", "GENE_OR_GENE_PRODUCT", 14, 21], ["L1 RNP", "GENE_OR_GENE_PRODUCT", 29, 35], ["RNase L", "PROTEIN", 14, 21], ["L1 RNP", "PROTEIN", 29, 35], ["RNase L blocks L1 RNP formation", "TREATMENT", 14, 45], ["RNase L blocks", "OBSERVATION_MODIFIER", 14, 28], ["L1 RNP", "OBSERVATION", 29, 35]]], ["HeLa-M cells were co-transfected with pES2TE1 and either an empty vector (pcDNA 3.0) or a plasmid that encodes an amino-terminal Myc-tagged RNase L expression plasmid.", [["HeLa-M cells", "ANATOMY", 0, 12], ["plasmid", "ANATOMY", 90, 97], ["amino", "CHEMICAL", 114, 119], ["HeLa-M cells", "CELL", 0, 12], ["pES2TE1", "GENE_OR_GENE_PRODUCT", 38, 45], ["pcDNA", "GENE_OR_GENE_PRODUCT", 74, 79], ["RNase L", "GENE_OR_GENE_PRODUCT", 140, 147], ["HeLa-M cells", "CELL_LINE", 0, 12], ["pES2TE1", "DNA", 38, 45], ["empty vector", "DNA", 60, 72], ["pcDNA 3.0", "DNA", 74, 83], ["plasmid", "DNA", 90, 97], ["amino-terminal Myc-tagged RNase L expression plasmid", "DNA", 114, 166], ["pES2TE1", "TEST", 38, 45], ["a plasmid", "TREATMENT", 88, 97], ["an amino-terminal Myc-tagged RNase L expression plasmid", "TREATMENT", 111, 166]]], ["Immunofluorescent confocal microscopy was used to examine L1 ORF2p accumulation in cytoplasmic foci by exploiting the FLAG-HA epitope-tag in pES2TE1 48 h after transfection.", [["cytoplasmic foci", "ANATOMY", 83, 99], ["ORF2p", "GENE_OR_GENE_PRODUCT", 61, 66], ["cytoplasmic", "ORGANISM_SUBSTANCE", 83, 94], ["FLAG", "GENE_OR_GENE_PRODUCT", 118, 122], ["ORF2p", "PROTEIN", 61, 66], ["FLAG", "PROTEIN", 118, 122], ["HA epitope", "PROTEIN", 123, 133], ["Immunofluorescent confocal microscopy", "TEST", 0, 37], ["cytoplasmic foci", "PROBLEM", 83, 99], ["the FLAG", "TEST", 114, 122], ["cytoplasmic foci", "OBSERVATION", 83, 99]]], ["The top labels indicate the antibodies used to detect the indicated proteins: anti-HA-ORF2p, red; anti-EBNA-1, green; anti-Myc RNase L, magenta.", [["anti-HA-ORF2p", "GENE_OR_GENE_PRODUCT", 78, 91], ["anti-EBNA-1", "GENE_OR_GENE_PRODUCT", 98, 109], ["Myc RNase L", "GENE_OR_GENE_PRODUCT", 123, 134], ["antibodies", "PROTEIN", 28, 38], ["anti-HA", "PROTEIN", 78, 85], ["ORF2p", "PROTEIN", 86, 91], ["red", "PROTEIN", 93, 96], ["anti-EBNA", "PROTEIN", 98, 107], ["Myc RNase L", "PROTEIN", 123, 134], ["the antibodies", "TEST", 24, 38], ["anti-HA", "TEST", 78, 85], ["anti-EBNA", "TEST", 98, 107], ["magenta", "TREATMENT", 136, 143]]], ["The labels on the left side of the figure indicate the empty vector or RNase L constructs that were co-transfected into cells.", [["cells", "ANATOMY", 120, 125], ["RNase L", "GENE_OR_GENE_PRODUCT", 71, 78], ["cells", "CELL", 120, 125], ["RNase L constructs", "DNA", 71, 89], ["RNase L constructs", "TREATMENT", 71, 89], ["left", "ANATOMY_MODIFIER", 18, 22], ["empty", "OBSERVATION", 55, 60]]], ["The rightmost column indicates the merged overlay staining.", [["the merged overlay staining", "PROBLEM", 31, 58], ["rightmost column", "OBSERVATION_MODIFIER", 4, 20], ["merged", "OBSERVATION_MODIFIER", 35, 41], ["overlay staining", "OBSERVATION", 42, 58]]], ["L1 ORF2p formed discrete cytoplasmic punctate localization in co-transfection experiments performed with the empty vector and RNase L catalytically inactive mutant (R667A), but not with WT RNase L. For each condition, either two or three slides were examined per experiment.", [["cytoplasmic", "ANATOMY", 25, 36], ["ORF2p", "GENE_OR_GENE_PRODUCT", 3, 8], ["cytoplasmic", "ORGANISM_SUBSTANCE", 25, 36], ["RNase L", "GENE_OR_GENE_PRODUCT", 126, 133], ["RNase L.", "GENE_OR_GENE_PRODUCT", 189, 197], ["L1 ORF2p", "PROTEIN", 0, 8], ["RNase L catalytically inactive mutant", "PROTEIN", 126, 163], ["R667A", "PROTEIN", 165, 170], ["RNase", "PROTEIN", 189, 194], ["discrete cytoplasmic punctate localization in co-transfection experiments", "PROBLEM", 16, 89], ["the empty vector", "TREATMENT", 105, 121], ["RNase L catalytically", "TREATMENT", 126, 147], ["discrete", "OBSERVATION_MODIFIER", 16, 24], ["cytoplasmic", "OBSERVATION_MODIFIER", 25, 36], ["punctate", "OBSERVATION_MODIFIER", 37, 45], ["co-transfection experiments", "OBSERVATION", 62, 89]]], ["About 200 cells were examined per slide and representative images were captured.", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15], ["representative images", "TEST", 44, 65]]], ["The experiment was conducted three times (biological replicates) with similar results. a modest increase in L1 retrotransposition ( Figures 5, 7A and 8B).Implications for RNase L in the control of retrotransposonsRNase L was previously suggested to be involved in prostate carcinogenesis after being mapped to the hereditary prostate cancer 1 locus (98) .", [["prostate", "ANATOMY", 264, 272], ["prostate cancer", "ANATOMY", 325, 340], ["prostate carcinogenesis", "DISEASE", 264, 287], ["hereditary prostate cancer", "DISEASE", 314, 340], ["RNase L", "GENE_OR_GENE_PRODUCT", 171, 178], ["RNase L", "GENE_OR_GENE_PRODUCT", 213, 220], ["prostate", "CANCER", 264, 272], ["prostate cancer", "CANCER", 325, 340], ["L1 retrotransposition", "DNA", 108, 129], ["RNase L", "PROTEIN", 171, 178], ["retrotransposons", "DNA", 197, 213], ["RNase L", "PROTEIN", 213, 220], ["a modest increase in L1 retrotransposition", "PROBLEM", 87, 129], ["RNase L", "TREATMENT", 171, 178], ["prostate carcinogenesis", "PROBLEM", 264, 287], ["the hereditary prostate cancer", "PROBLEM", 310, 340], ["modest", "OBSERVATION_MODIFIER", 89, 95], ["increase", "OBSERVATION_MODIFIER", 96, 104], ["L1 retrotransposition", "OBSERVATION", 108, 129], ["prostate", "ANATOMY", 264, 272], ["carcinogenesis", "OBSERVATION", 273, 287], ["hereditary", "OBSERVATION_MODIFIER", 314, 324], ["prostate", "ANATOMY", 325, 333], ["cancer", "OBSERVATION", 334, 340]]], ["Mutations in RNase L discovered from linkage analysis include two protein inactivating mutations (\u00c1157-164X and E265X), a mutation that abrogates translation (M1I) and a missense variant 1385G!A (R462Q) that reduce RNase L activity by 3-fold (99) .", [["RNase L", "GENE_OR_GENE_PRODUCT", 13, 20], ["\u00c1157-164X", "GENE_OR_GENE_PRODUCT", 98, 107], ["RNase L", "GENE_OR_GENE_PRODUCT", 215, 222], ["RNase L", "PROTEIN", 13, 20], ["M1I", "DNA", 159, 162], ["RNase L", "PROTEIN", 215, 222], ["Mutations in RNase L", "PROBLEM", 0, 20], ["linkage analysis", "TEST", 37, 53], ["two protein inactivating mutations", "PROBLEM", 62, 96], ["a mutation", "PROBLEM", 120, 130], ["a missense variant", "PROBLEM", 168, 186]]], ["The connection between RNase L and prostate cancer was further expanded to other types of cancer.", [["prostate cancer", "ANATOMY", 35, 50], ["cancer", "ANATOMY", 90, 96], ["prostate cancer", "DISEASE", 35, 50], ["cancer", "DISEASE", 90, 96], ["RNase L", "GENE_OR_GENE_PRODUCT", 23, 30], ["prostate cancer", "CANCER", 35, 50], ["cancer", "CANCER", 90, 96], ["RNase L", "PROTEIN", 23, 30], ["The connection between RNase L and prostate cancer", "PROBLEM", 0, 50], ["cancer", "PROBLEM", 90, 96], ["RNase L", "OBSERVATION_MODIFIER", 23, 30], ["prostate", "ANATOMY", 35, 43], ["cancer", "OBSERVATION", 44, 50], ["cancer", "OBSERVATION", 90, 96]]], ["Genetic variations in RNASEL have been identified in cancers of head and neck, uterus, cervix and breast (100) .", [["cancers", "ANATOMY", 53, 60], ["head", "ANATOMY", 64, 68], ["neck", "ANATOMY", 73, 77], ["uterus", "ANATOMY", 79, 85], ["cervix", "ANATOMY", 87, 93], ["breast", "ANATOMY", 98, 104], ["cancers of head and neck, uterus, cervix and breast", "DISEASE", 53, 104], ["RNASEL", "GENE_OR_GENE_PRODUCT", 22, 28], ["cancers", "CANCER", 53, 60], ["head", "ORGANISM_SUBDIVISION", 64, 68], ["neck", "ORGAN", 73, 77], ["uterus", "ORGAN", 79, 85], ["cervix", "CANCER", 87, 93], ["breast", "ORGAN", 98, 104], ["RNASEL", "DNA", 22, 28], ["Genetic variations in RNASEL", "PROBLEM", 0, 28], ["cancers of head and neck, uterus, cervix and breast", "PROBLEM", 53, 104], ["cancers", "OBSERVATION", 53, 60], ["head", "ANATOMY", 64, 68], ["neck", "ANATOMY", 73, 77], ["uterus", "ANATOMY", 79, 85], ["cervix", "ANATOMY", 87, 93], ["breast", "ANATOMY", 98, 104]]], ["They are also associated with disease aggressiveness and metastasis in familial pancreatic cancer (101) and with age of onset of hereditary nonpolyposis colon cancer (102) .Implications for RNase L in the control of retrotransposonsStudies from our group and others found that loss-offunction mutations in RNASEL potentially contributed to cancer development by dysregulating apoptosis of cancer cells (71, (103) (104) (105) .", [["pancreatic cancer", "ANATOMY", 80, 97], ["nonpolyposis colon cancer", "ANATOMY", 140, 165], ["cancer", "ANATOMY", 340, 346], ["cancer cells", "ANATOMY", 389, 401], ["aggressiveness", "DISEASE", 38, 52], ["familial pancreatic cancer", "DISEASE", 71, 97], ["hereditary nonpolyposis colon cancer", "DISEASE", 129, 165], ["RNASEL", "CHEMICAL", 306, 312], ["cancer", "DISEASE", 340, 346], ["cancer", "DISEASE", 389, 395], ["pancreatic cancer", "CANCER", 80, 97], ["hereditary nonpolyposis colon cancer", "CANCER", 129, 165], ["RNase L", "GENE_OR_GENE_PRODUCT", 190, 197], ["RNASEL", "GENE_OR_GENE_PRODUCT", 306, 312], ["cancer", "CANCER", 340, 346], ["cancer cells", "CELL", 389, 401], ["RNase L", "PROTEIN", 190, 197], ["retrotransposons", "DNA", 216, 232], ["RNASEL", "PROTEIN", 306, 312], ["cancer cells", "CELL_TYPE", 389, 401], ["disease aggressiveness", "PROBLEM", 30, 52], ["metastasis", "PROBLEM", 57, 67], ["familial pancreatic cancer", "PROBLEM", 71, 97], ["hereditary nonpolyposis colon cancer", "PROBLEM", 129, 165], ["RNase L", "TREATMENT", 190, 197], ["retrotransposonsStudies", "TEST", 216, 239], ["loss-offunction mutations", "PROBLEM", 277, 302], ["cancer development", "PROBLEM", 340, 358], ["dysregulating apoptosis of cancer cells", "PROBLEM", 362, 401], ["associated with", "UNCERTAINTY", 14, 29], ["metastasis", "OBSERVATION", 57, 67], ["familial", "OBSERVATION_MODIFIER", 71, 79], ["pancreatic", "ANATOMY", 80, 90], ["cancer", "OBSERVATION", 91, 97], ["hereditary", "OBSERVATION_MODIFIER", 129, 139], ["nonpolyposis", "OBSERVATION", 140, 152], ["colon", "ANATOMY", 153, 158], ["cancer", "OBSERVATION", 159, 165], ["cancer", "OBSERVATION", 340, 346]]], ["However, inconsistent findings on the same RNASEL mutations among studies, some that show an association with cancer and others that do not, suggest that RNase L might act as a modifier of disease progression with possible interactions between environmental factors and genetics [reviewed in (99, 106) ].", [["cancer", "ANATOMY", 110, 116], ["cancer", "DISEASE", 110, 116], ["RNASEL", "GENE_OR_GENE_PRODUCT", 43, 49], ["cancer", "CANCER", 110, 116], ["RNase L", "GENE_OR_GENE_PRODUCT", 154, 161], ["RNase L", "PROTEIN", 154, 161], ["cancer", "PROBLEM", 110, 116], ["disease progression", "PROBLEM", 189, 208], ["cancer", "OBSERVATION", 110, 116]]], ["In this regard, it would be interesting to see if a loss of RNase L activity correlates with an increase in L1 retrotransposition activity in certain tumors.", [["tumors", "ANATOMY", 150, 156], ["tumors", "DISEASE", 150, 156], ["RNase L", "GENE_OR_GENE_PRODUCT", 60, 67], ["tumors", "CANCER", 150, 156], ["RNase L", "PROTEIN", 60, 67], ["L1", "DNA", 108, 110], ["a loss of RNase L activity", "PROBLEM", 50, 76], ["an increase in L1 retrotransposition activity in certain tumors", "PROBLEM", 93, 156], ["increase", "OBSERVATION_MODIFIER", 96, 104], ["L1", "ANATOMY", 108, 110], ["retrotransposition activity", "OBSERVATION", 111, 138], ["tumors", "OBSERVATION", 150, 156]]], ["Recent studies have shown somatic L1 retrotransposition activity in a subset of colorectal, liver and lung tumors (107) (108) (109) (110) .Implications for RNase L in the control of retrotransposonsIn conclusion, we have identified a potential restriction mechanism for retrotransposition involving the antiviral protein RNase L. These findings emphasize the complex and dynamic interplay between retrotransposons and the cell.", [["colorectal", "ANATOMY", 80, 90], ["liver", "ANATOMY", 92, 97], ["lung tumors", "ANATOMY", 102, 113], ["cell", "ANATOMY", 422, 426], ["colorectal, liver and lung tumors", "DISEASE", 80, 113], ["colorectal", "CANCER", 80, 90], ["liver", "ORGAN", 92, 97], ["lung tumors", "CANCER", 102, 113], ["RNase L", "GENE_OR_GENE_PRODUCT", 156, 163], ["RNase L.", "GENE_OR_GENE_PRODUCT", 321, 329], ["retrotransposons", "CELLULAR_COMPONENT", 397, 413], ["cell", "CELL", 422, 426], ["L1", "DNA", 34, 36], ["RNase L", "PROTEIN", 156, 163], ["retrotransposons", "DNA", 182, 198], ["antiviral protein", "PROTEIN", 303, 320], ["RNase", "PROTEIN", 321, 326], ["retrotransposons", "DNA", 397, 413], ["Recent studies", "TEST", 0, 14], ["somatic L1 retrotransposition activity", "PROBLEM", 26, 64], ["colorectal, liver and lung tumors", "PROBLEM", 80, 113], ["RNase L", "TREATMENT", 156, 163], ["a potential restriction mechanism", "TREATMENT", 232, 265], ["retrotransposition", "TREATMENT", 270, 288], ["the antiviral protein RNase L.", "TREATMENT", 299, 329], ["L1 retrotransposition", "OBSERVATION", 34, 55], ["activity", "OBSERVATION_MODIFIER", 56, 64], ["subset", "OBSERVATION_MODIFIER", 70, 76], ["colorectal", "ANATOMY", 80, 90], ["liver", "ANATOMY", 92, 97], ["lung", "ANATOMY", 102, 106], ["tumors", "OBSERVATION", 107, 113], ["cell", "ANATOMY", 422, 426]]], ["Our data provide evidence that RNase L inhibits L1 RNA accumulation and the subsequent formation of L1 RNPs, thereby impairing the completion of the L1 retrotransposition cycle.", [["RNase L", "GENE_OR_GENE_PRODUCT", 31, 38], ["L1 RNPs", "GENE_OR_GENE_PRODUCT", 100, 107], ["RNase L", "PROTEIN", 31, 38], ["L1 RNA", "RNA", 48, 54], ["L1 RNPs", "PROTEIN", 100, 107], ["Our data", "TEST", 0, 8], ["RNase L inhibits L1 RNA accumulation", "PROBLEM", 31, 67], ["L1 RNPs", "PROBLEM", 100, 107], ["the L1 retrotransposition cycle", "TREATMENT", 145, 176], ["L1 RNA", "OBSERVATION_MODIFIER", 48, 54], ["accumulation", "OBSERVATION_MODIFIER", 55, 67], ["L1 RNPs", "OBSERVATION", 100, 107], ["L1", "ANATOMY", 149, 151]]], ["By inhibiting L1 retrotransposition in somatic cells, RNase L might contribute to the maintenance of genomic stability.", [["somatic cells", "ANATOMY", 39, 52], ["somatic cells", "CELL", 39, 52], ["RNase L", "GENE_OR_GENE_PRODUCT", 54, 61], ["L1", "DNA", 14, 16], ["somatic cells", "CELL_TYPE", 39, 52], ["RNase L", "PROTEIN", 54, 61], ["L1 retrotransposition in somatic cells", "PROBLEM", 14, 52], ["L1", "ANATOMY", 14, 16], ["retrotransposition", "OBSERVATION", 17, 35], ["somatic cells", "OBSERVATION", 39, 52], ["genomic stability", "OBSERVATION", 101, 118]]]], "90f4515256d0386bdc16f87a981ab2d6a55e2b44": [["IntroductionThe cause of death for Intensive Care Unit (ICU) patients is primarily associated with their critical illness, for which they have been admitted, and secondly, related hospital illness such as nosocomial infection.", [["death", "DISEASE", 25, 30], ["nosocomial infection", "DISEASE", 205, 225], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["nosocomial infection", "PROBLEM", 205, 225], ["nosocomial", "OBSERVATION_MODIFIER", 205, 215], ["infection", "OBSERVATION", 216, 225]]], ["Pneumonia, an infection in one or both lungs, is the second most common nosocomial infection, affecting one of four of all critically ill patients.", [["lungs", "ANATOMY", 39, 44], ["Pneumonia", "DISEASE", 0, 9], ["infection", "DISEASE", 14, 23], ["nosocomial infection", "DISEASE", 72, 92], ["critically ill", "DISEASE", 123, 137], ["lungs", "ORGAN", 39, 44], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["Pneumonia", "PROBLEM", 0, 9], ["an infection", "PROBLEM", 11, 23], ["common nosocomial infection", "PROBLEM", 65, 92], ["infection", "OBSERVATION", 14, 23], ["both", "ANATOMY_MODIFIER", 34, 38], ["lungs", "ANATOMY", 39, 44], ["most common", "OBSERVATION_MODIFIER", 60, 71], ["nosocomial", "OBSERVATION_MODIFIER", 72, 82], ["infection", "OBSERVATION", 83, 92]]], ["Ventilatorassociated pneumonia (VAP) is a nosocomial infection associated with mechanical ventilation, responsible for 86% of all nosocomial pneumonias inside the hospital [1] .", [["pneumonia", "DISEASE", 21, 30], ["VAP", "DISEASE", 32, 35], ["infection", "DISEASE", 53, 62], ["pneumonias", "DISEASE", 141, 151], ["Ventilatorassociated pneumonia", "PROBLEM", 0, 30], ["VAP", "PROBLEM", 32, 35], ["a nosocomial infection", "PROBLEM", 40, 62], ["mechanical ventilation", "TREATMENT", 79, 101], ["all nosocomial pneumonias", "PROBLEM", 126, 151], ["pneumonia", "OBSERVATION", 21, 30], ["VAP", "OBSERVATION", 32, 35], ["nosocomial", "OBSERVATION_MODIFIER", 42, 52], ["infection", "OBSERVATION", 53, 62], ["mechanical ventilation", "OBSERVATION", 79, 101], ["nosocomial", "OBSERVATION_MODIFIER", 130, 140], ["pneumonias", "OBSERVATION", 141, 151]]], ["This condition develops mostly after 48 hours after initiation of mechanical ventilation and endotracheal intubation.", [["endotracheal", "ANATOMY", 93, 105], ["mechanical ventilation", "TREATMENT", 66, 88], ["endotracheal intubation", "TREATMENT", 93, 116], ["mechanical ventilation", "OBSERVATION", 66, 88], ["endotracheal intubation", "OBSERVATION", 93, 116]]], ["VAP increases morbidity, mortality, hospital, and ICU stay, and by this increasing healthcare cost, making it to be a serious medical condition, with attributable risk for mortality of 33-50% [2] .", [["VAP", "DISEASE", 0, 3], ["VAP", "PROBLEM", 0, 3], ["a serious medical condition", "PROBLEM", 116, 143], ["increases", "OBSERVATION_MODIFIER", 4, 13], ["morbidity", "OBSERVATION_MODIFIER", 14, 23]]], ["Economically, the supplementary costs associated with VAP are between $5,000 and $20,000 per diagnosis, and treating this condition is of critical importance, along with the clinical side [1] .VAP PathophysiologyThe insertion of an endotracheal tube remains the strongest risk factor of this disease.", [["endotracheal tube", "ANATOMY", 232, 249], ["VAP", "DISEASE", 54, 57], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 232, 249], ["VAP", "PROBLEM", 54, 57], ["an endotracheal tube", "TREATMENT", 229, 249], ["this disease", "PROBLEM", 287, 299], ["insertion", "OBSERVATION_MODIFIER", 216, 225], ["endotracheal tube", "OBSERVATION", 232, 249], ["disease", "OBSERVATION", 292, 299]]], ["The natural defense mechanism, such as the cough reflex, is being violated and is enabling infectious bacteria to make its way into the lower respiratory tract.", [["lower respiratory tract", "ANATOMY", 136, 159], ["cough", "DISEASE", 43, 48], ["lower", "ORGANISM_SUBDIVISION", 136, 141], ["respiratory tract", "ORGANISM_SUBDIVISION", 142, 159], ["the cough reflex", "PROBLEM", 39, 55], ["enabling infectious bacteria", "PROBLEM", 82, 110], ["natural defense mechanism", "OBSERVATION", 4, 29], ["lower", "ANATOMY_MODIFIER", 136, 141], ["respiratory tract", "ANATOMY", 142, 159]]], ["Typically, there are four ways in which the This article is part of the Topical Collection on Medicine microorganism invades the lungs: (1) A pool of secretions around the tube, (2) Micro-aspirations that usually happen when the tube is inserted, (3) A biofilm of gram-negative bacteria within the tube, and (4) the impairment of mucociliary clearance to secrete the mucus flow, especially when the patient is lying down [3] .", [["lungs", "ANATOMY", 129, 134], ["secretions", "ANATOMY", 150, 160], ["tube", "ANATOMY", 172, 176], ["tube", "ANATOMY", 229, 233], ["tube", "ANATOMY", 298, 302], ["mucociliary", "ANATOMY", 330, 341], ["mucus", "ANATOMY", 367, 372], ["lungs", "ORGAN", 129, 134], ["secretions", "ORGANISM_SUBSTANCE", 150, 160], ["tube", "TISSUE", 172, 176], ["tube", "TISSUE", 229, 233], ["tube", "TISSUE", 298, 302], ["mucociliary", "ORGAN", 330, 341], ["mucus", "ORGANISM_SUBSTANCE", 367, 372], ["patient", "ORGANISM", 399, 406], ["patient", "SPECIES", 399, 406], ["secretions around the tube", "PROBLEM", 150, 176], ["Micro-aspirations", "TREATMENT", 182, 199], ["the tube", "TREATMENT", 225, 233], ["A biofilm of gram", "TEST", 251, 268], ["negative bacteria", "PROBLEM", 269, 286], ["the tube", "TREATMENT", 294, 302], ["mucociliary clearance", "PROBLEM", 330, 351], ["the mucus flow", "TEST", 363, 377], ["Topical", "OBSERVATION_MODIFIER", 72, 79], ["Collection", "OBSERVATION", 80, 90], ["lungs", "ANATOMY", 129, 134], ["secretions", "OBSERVATION", 150, 160], ["tube", "OBSERVATION", 172, 176], ["tube", "OBSERVATION", 229, 233], ["negative bacteria", "OBSERVATION_MODIFIER", 269, 286], ["tube", "OBSERVATION", 298, 302], ["mucociliary clearance", "OBSERVATION", 330, 351], ["mucus flow", "OBSERVATION", 367, 377]]], ["Normal host microbial flora changes because of illness and the use of antibiotic therapy along with the management of airway protection and clearance mechanisms due to mechanical ventilation.", [["airway", "ANATOMY", 118, 124], ["illness", "DISEASE", 47, 54], ["airway", "MULTI-TISSUE_STRUCTURE", 118, 124], ["illness", "PROBLEM", 47, 54], ["antibiotic therapy", "TREATMENT", 70, 88], ["the management", "TREATMENT", 100, 114], ["airway protection", "TREATMENT", 118, 135], ["clearance mechanisms", "PROBLEM", 140, 160], ["mechanical ventilation", "TREATMENT", 168, 190], ["host microbial flora", "OBSERVATION", 7, 27], ["airway", "ANATOMY", 118, 124], ["mechanical ventilation", "OBSERVATION", 168, 190]]], ["The flora of the oropharynx is usually low in virulence.", [["oropharynx", "ANATOMY", 17, 27], ["oropharynx", "ORGAN", 17, 27], ["flora", "OBSERVATION", 4, 9], ["oropharynx", "ANATOMY", 17, 27], ["low", "OBSERVATION_MODIFIER", 39, 42], ["virulence", "OBSERVATION", 46, 55]]], ["In ICU patients, the flora is overgrown by high virulence endogenic aerobic gram-negative bacilli, often causing lung infections.", [["lung", "ANATOMY", 113, 117], ["lung infections", "DISEASE", 113, 128], ["patients", "ORGANISM", 7, 15], ["lung", "ORGAN", 113, 117], ["patients", "SPECIES", 7, 15], ["the flora", "PROBLEM", 17, 26], ["high virulence endogenic aerobic gram-negative bacilli", "PROBLEM", 43, 97], ["lung infections", "PROBLEM", 113, 128], ["negative bacilli", "OBSERVATION", 81, 97], ["lung", "ANATOMY", 113, 117], ["infections", "OBSERVATION", 118, 128]]], ["Colonization and infection of nosocomial bacterial pathogens can be caused by exogenous transmission from environmental sources, or they can be passed by healthcare workers treating different patients.", [["infection", "DISEASE", 17, 26], ["nosocomial bacterial pathogens", "DISEASE", 30, 60], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 192, 200], ["Colonization", "PROBLEM", 0, 12], ["infection", "PROBLEM", 17, 26], ["nosocomial bacterial pathogens", "PROBLEM", 30, 60], ["infection", "OBSERVATION", 17, 26], ["nosocomial bacterial pathogens", "OBSERVATION", 30, 60]]], ["The bacterium-enriched secretions are being \"pushed\" by the positive pressure ventilation, reaching moving quickly to the lower respiratory tract, initializing a lung infection [3, 4] .", [["secretions", "ANATOMY", 23, 33], ["lower respiratory tract", "ANATOMY", 122, 145], ["lung", "ANATOMY", 162, 166], ["lung infection", "DISEASE", 162, 176], ["secretions", "ORGANISM", 23, 33], ["lower", "ORGANISM_SUBDIVISION", 122, 127], ["respiratory tract", "ORGANISM_SUBDIVISION", 128, 145], ["lung", "ORGAN", 162, 166], ["The bacterium", "PROBLEM", 0, 13], ["enriched secretions", "PROBLEM", 14, 33], ["the positive pressure ventilation", "TREATMENT", 56, 89], ["a lung infection", "PROBLEM", 160, 176], ["bacterium", "OBSERVATION_MODIFIER", 4, 13], ["enriched secretions", "OBSERVATION", 14, 33], ["pressure ventilation", "OBSERVATION", 69, 89], ["lower", "ANATOMY_MODIFIER", 122, 127], ["respiratory tract", "ANATOMY", 128, 145], ["lung", "ANATOMY", 162, 166], ["infection", "OBSERVATION", 167, 176]]], ["Immunologic factors that are damaged by the infecting organisms have a strong effect upon the initiation of this disease.", [["Immunologic factors", "PROTEIN", 0, 19], ["Immunologic factors", "PROBLEM", 0, 19], ["the infecting organisms", "PROBLEM", 40, 63], ["this disease", "PROBLEM", 108, 120]]], ["Impaired phagocytosis by neutrophils, caused by the anaphylatoxin c5a from the microorganisms followed by elevation of regulatory T-cells and monocyte deactivation will predict the initiation of nosocomial infection in those patients [3] .Streptococcus pneumoniaeA Gram-negative diplococcus pathogen who is the main cause for the early onset VAP, typically a few days after intubation.Haemophilus influenzaeGram negative coccobacillus, a fast-growing bacterium, induces VAP quickly after intubation.EnterobacteriaceaeEnteric gram-negative bacilli reside mostly in the lower gastrointestinal tract.Staphylococcus aureusGram-positive coccus is an important virulent factor to nosocomial infection, especially VAP.Acinetobacter SpeciesAerobic non-fermenting gram-negative bacilli are very effective in causing nosocomial infection in critically ill patients who are admitted in ICU units.Pseudomonas aeruginosaAerobic, non-fermenting gram negative bacillus, the most common VAP causing pathogen, which is also resistant to antibiotics, is also the deadliest cause of VAP pathogen.", [["neutrophils", "ANATOMY", 25, 36], ["T-cells", "ANATOMY", 130, 137], ["monocyte", "ANATOMY", 142, 150], ["lower gastrointestinal tract", "ANATOMY", 568, 596], ["nosocomial infection", "DISEASE", 195, 215], ["VAP", "DISEASE", 342, 345], ["coccobacillus", "CHEMICAL", 421, 434], ["VAP", "DISEASE", 470, 473], ["nosocomial infection", "DISEASE", 674, 694], ["VAP", "DISEASE", 707, 710], ["nosocomial infection", "DISEASE", 807, 827], ["critically ill", "DISEASE", 831, 845], ["aeruginosaAerobic", "CHEMICAL", 897, 914], ["VAP", "DISEASE", 971, 974], ["VAP", "DISEASE", 1064, 1067], ["neutrophils", "CELL", 25, 36], ["anaphylatoxin c5a", "GENE_OR_GENE_PRODUCT", 52, 69], ["T-cells", "CELL", 130, 137], ["monocyte", "CELL", 142, 150], ["patients", "ORGANISM", 225, 233], ["Streptococcus pneumoniaeA", "ORGANISM", 239, 264], ["Gram", "GENE_OR_GENE_PRODUCT", 265, 269], ["Haemophilus influenzaeGram", "ORGANISM", 385, 411], ["coccobacillus", "GENE_OR_GENE_PRODUCT", 421, 434], ["lower", "ORGANISM_SUBDIVISION", 568, 573], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 574, 596], ["Staphylococcus aureusGram-positive coccus", "ORGANISM", 597, 638], ["Acinetobacter SpeciesAerobic", "ORGANISM", 711, 739], ["patients", "ORGANISM", 846, 854], ["Pseudomonas aeruginosaAerobic", "ORGANISM", 885, 914], ["gram negative bacillus", "ORGANISM", 931, 953], ["neutrophils", "CELL_TYPE", 25, 36], ["anaphylatoxin c5a", "PROTEIN", 52, 69], ["regulatory T-cells", "CELL_TYPE", 119, 137], ["patients", "SPECIES", 225, 233], ["Streptococcus pneumoniaeA", "SPECIES", 239, 264], ["Haemophilus influenzaeGram", "SPECIES", 385, 411], ["Staphylococcus aureusGram-positive coccus", "SPECIES", 597, 638], ["patients", "SPECIES", 846, 854], ["Streptococcus pneumoniaeA", "SPECIES", 239, 264], ["Staphylococcus aureusGram-positive coccus", "SPECIES", 597, 638], ["Impaired phagocytosis", "PROBLEM", 0, 21], ["the anaphylatoxin c5a", "PROBLEM", 48, 69], ["the microorganisms", "PROBLEM", 75, 93], ["elevation of regulatory T-cells", "PROBLEM", 106, 137], ["monocyte deactivation", "PROBLEM", 142, 163], ["nosocomial infection", "PROBLEM", 195, 215], ["Streptococcus pneumoniaeA Gram", "TEST", 239, 269], ["negative diplococcus pathogen", "PROBLEM", 270, 299], ["the early onset VAP", "PROBLEM", 326, 345], ["intubation", "TREATMENT", 374, 384], ["Haemophilus influenzaeGram", "TEST", 385, 411], ["coccobacillus", "PROBLEM", 421, 434], ["a fast-growing bacterium", "PROBLEM", 436, 460], ["VAP", "PROBLEM", 470, 473], ["intubation", "TREATMENT", 488, 498], ["EnterobacteriaceaeEnteric gram-negative bacilli", "PROBLEM", 499, 546], ["Staphylococcus aureusGram-positive coccus", "PROBLEM", 597, 638], ["nosocomial infection", "PROBLEM", 674, 694], ["VAP", "PROBLEM", 707, 710], ["Acinetobacter", "TEST", 711, 724], ["gram", "TEST", 755, 759], ["negative bacilli", "PROBLEM", 760, 776], ["nosocomial infection", "PROBLEM", 807, 827], ["Pseudomonas aeruginosaAerobic", "PROBLEM", 885, 914], ["non-fermenting gram negative bacillus", "PROBLEM", 916, 953], ["pathogen", "PROBLEM", 983, 991], ["antibiotics", "TREATMENT", 1020, 1031], ["VAP pathogen", "PROBLEM", 1064, 1076], ["phagocytosis", "OBSERVATION", 9, 21], ["nosocomial", "OBSERVATION_MODIFIER", 195, 205], ["infection", "OBSERVATION", 206, 215], ["negative diplococcus", "OBSERVATION_MODIFIER", 270, 290], ["early", "OBSERVATION_MODIFIER", 330, 335], ["onset", "OBSERVATION_MODIFIER", 336, 341], ["VAP", "OBSERVATION", 342, 345], ["negative bacilli", "OBSERVATION", 530, 546], ["lower", "ANATOMY_MODIFIER", 568, 573], ["gastrointestinal tract", "ANATOMY", 574, 596], ["coccus", "OBSERVATION", 632, 638], ["important", "OBSERVATION_MODIFIER", 645, 654], ["virulent", "OBSERVATION_MODIFIER", 655, 663], ["nosocomial", "OBSERVATION_MODIFIER", 674, 684], ["infection", "OBSERVATION", 685, 694], ["negative bacilli", "OBSERVATION", 760, 776], ["nosocomial", "OBSERVATION_MODIFIER", 807, 817], ["infection", "OBSERVATION", 818, 827], ["gram", "OBSERVATION_MODIFIER", 931, 935], ["negative bacillus", "OBSERVATION", 936, 953], ["most common", "OBSERVATION_MODIFIER", 959, 970], ["pathogen", "OBSERVATION", 983, 991], ["VAP", "OBSERVATION", 1064, 1067]]], ["[3] [4].Pathogen Profile of Oral Dental PlaqueIn the study of Sands et al. [5] different tests were taken to map the microbiology of the dental plaque residing in the oral cavity of VAP patients.", [["dental plaque", "ANATOMY", 137, 150], ["oral cavity", "ANATOMY", 167, 178], ["VAP", "DISEASE", 182, 185], ["dental plaque", "PATHOLOGICAL_FORMATION", 137, 150], ["oral cavity", "ORGANISM_SUBDIVISION", 167, 178], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 186, 194], ["different tests", "TEST", 79, 94], ["the dental plaque", "PROBLEM", 133, 150], ["dental", "ANATOMY", 137, 143], ["plaque", "OBSERVATION", 144, 150], ["oral cavity", "ANATOMY", 167, 178], ["VAP", "OBSERVATION", 182, 185]]], ["Five different bacterial phyla were studied from the specimens of 13 patients.", [["specimens", "ANATOMY", 53, 62], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["Five different bacterial phyla", "PROBLEM", 0, 30], ["the specimens", "TEST", 49, 62], ["bacterial phyla", "OBSERVATION", 15, 30]]], ["Forty genres, six of which were not part of the normal oral plaque community and the following four major species were documented in 38 dental plaque specimens: Streptococcus pseudopneumoniae (66 %), Enterococcus faecalis (37 %), and Escherichia coli and Shigella flexneri (32 %).From the study (Sands et al.) , it was concluded that there is a difference in the profile of the pathogen in the beginning of the intubation versus the end of it.", [["oral plaque community", "ANATOMY", 55, 76], ["plaque specimens", "ANATOMY", 143, 159], ["oral plaque", "DISEASE", 55, 66], ["plaque", "DISEASE", 143, 149], ["Streptococcus pseudopneumoniae", "DISEASE", 161, 191], ["Enterococcus faecalis", "DISEASE", 200, 221], ["oral plaque", "PATHOLOGICAL_FORMATION", 55, 66], ["Streptococcus pseudopneumoniae", "ORGANISM", 161, 191], ["Enterococcus faecalis", "ORGANISM", 200, 221], ["Escherichia coli", "ORGANISM", 234, 250], ["Shigella flexneri", "ORGANISM", 255, 272], ["Streptococcus pseudopneumoniae", "SPECIES", 161, 191], ["Enterococcus faecalis", "SPECIES", 200, 221], ["Escherichia coli", "SPECIES", 234, 250], ["Shigella flexneri", "SPECIES", 255, 272], ["Streptococcus pseudopneumoniae", "SPECIES", 161, 191], ["Enterococcus faecalis", "SPECIES", 200, 221], ["Escherichia coli", "SPECIES", 234, 250], ["Shigella flexneri", "SPECIES", 255, 272], ["dental plaque specimens", "TEST", 136, 159], ["Streptococcus pseudopneumoniae", "TEST", 161, 191], ["Enterococcus faecalis", "PROBLEM", 200, 221], ["Escherichia coli", "PROBLEM", 234, 250], ["Shigella flexneri", "PROBLEM", 255, 272], ["the study", "TEST", 285, 294], ["the pathogen", "PROBLEM", 374, 386], ["the intubation", "TREATMENT", 407, 421], ["normal", "OBSERVATION_MODIFIER", 48, 54], ["oral", "OBSERVATION_MODIFIER", 55, 59], ["plaque", "OBSERVATION", 60, 66], ["Escherichia coli", "OBSERVATION", 234, 250], ["pathogen", "OBSERVATION", 378, 386], ["intubation", "OBSERVATION", 411, 421]]], ["Another interesting evidence extracted from this article, is that Pseudomonas aeruginosa was not identified in the dental plaque of these patients, although past studies demonstrated this bacterial species is a predominant colonizer in the dental plaque of ventilated, critically ill patients, as well as a major .", [["dental plaque", "ANATOMY", 115, 128], ["colonizer", "ANATOMY", 223, 232], ["dental plaque", "ANATOMY", 240, 253], ["critically ill", "DISEASE", 269, 283], ["Pseudomonas aeruginosa", "ORGANISM", 66, 88], ["dental plaque", "PATHOLOGICAL_FORMATION", 115, 128], ["patients", "ORGANISM", 138, 146], ["dental plaque", "PATHOLOGICAL_FORMATION", 240, 253], ["patients", "ORGANISM", 284, 292], ["Pseudomonas aeruginosa", "SPECIES", 66, 88], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 284, 292], ["Pseudomonas aeruginosa", "SPECIES", 66, 88], ["Pseudomonas aeruginosa", "PROBLEM", 66, 88], ["past studies", "TEST", 157, 169], ["this bacterial species", "PROBLEM", 183, 205], ["the dental plaque", "PROBLEM", 236, 253], ["Pseudomonas", "OBSERVATION_MODIFIER", 66, 77], ["aeruginosa", "OBSERVATION", 78, 88], ["bacterial species", "OBSERVATION", 188, 205], ["predominant", "OBSERVATION_MODIFIER", 211, 222], ["colonizer", "OBSERVATION_MODIFIER", 223, 232], ["dental", "ANATOMY", 240, 246], ["plaque", "OBSERVATION", 247, 253]]], ["Information about the profile of the pathogens involved in the oral plaque of these patients will help create intervention strategies to offset the incidence of VAP [5] .Common Methods for Prevention of VAPStrategies for the prevention of ventilator-associated pneumonia includes the following: prophylactic antibiotic administration, sedation interruption, head-end elevation, limitation of ventilation times, performing endotracheal suctioning, avoiding gastric overdistention, draining ventilator tube condensate, Kinetic bed therapy, and other factors that deals with the ventilator machine itself [1, 2] .Oral Care for Prevention of VAPComprehensive oral care is considered a vital component in the prevention of VAP.", [["oral plaque", "ANATOMY", 63, 74], ["head", "ANATOMY", 358, 362], ["endotracheal", "ANATOMY", 422, 434], ["gastric", "ANATOMY", 456, 463], ["oral", "ANATOMY", 655, 659], ["VAP", "DISEASE", 161, 164], ["pneumonia", "DISEASE", 261, 270], ["VAP", "DISEASE", 718, 721], ["oral plaque", "PATHOLOGICAL_FORMATION", 63, 74], ["patients", "ORGANISM", 84, 92], ["head", "ORGANISM_SUBDIVISION", 358, 362], ["gastric", "ORGAN", 456, 463], ["oral", "ORGANISM_SUBDIVISION", 655, 659], ["patients", "SPECIES", 84, 92], ["the pathogens", "PROBLEM", 33, 46], ["intervention strategies", "TREATMENT", 110, 133], ["VAP", "PROBLEM", 161, 164], ["Common Methods", "TREATMENT", 170, 184], ["VAPStrategies", "TREATMENT", 203, 216], ["ventilator-associated pneumonia", "PROBLEM", 239, 270], ["prophylactic antibiotic administration", "TREATMENT", 295, 333], ["sedation interruption", "TREATMENT", 335, 356], ["head-end elevation", "TREATMENT", 358, 376], ["ventilation times", "TREATMENT", 392, 409], ["endotracheal suctioning", "TREATMENT", 422, 445], ["gastric overdistention", "TREATMENT", 456, 478], ["draining ventilator tube condensate", "TREATMENT", 480, 515], ["Kinetic bed therapy", "TREATMENT", 517, 536], ["the ventilator machine", "TREATMENT", 572, 594], ["Oral Care", "TREATMENT", 610, 619], ["VAPComprehensive oral care", "TREATMENT", 638, 664], ["a vital component", "TREATMENT", 679, 696], ["VAP", "PROBLEM", 718, 721], ["pneumonia", "OBSERVATION", 261, 270], ["elevation", "OBSERVATION", 367, 376], ["gastric", "ANATOMY", 456, 463], ["ventilator tube", "OBSERVATION", 489, 504], ["VAP", "OBSERVATION", 718, 721]]], ["The most common measure is suction of the oropharyngeal secretions that is \"rich\" with bacterial load.", [["oropharyngeal secretions", "ANATOMY", 42, 66], ["oropharyngeal secretions", "ORGAN", 42, 66], ["the oropharyngeal secretions", "PROBLEM", 38, 66], ["bacterial load", "PROBLEM", 87, 101], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["suction", "OBSERVATION", 27, 34], ["oropharyngeal", "ANATOMY", 42, 55], ["secretions", "OBSERVATION", 56, 66], ["bacterial load", "OBSERVATION", 87, 101]]], ["Other methods of oral care for preventing ventilatorassociated pneumonia that are commonly used for ventilated patients include the following: chlorhexidine as monotherapy in different concentrations of 0.12%,0.2%,1%, and 2% that can be applicate as oral rinse, gel, or foam and mechanical debridement in the form of toothbrushing manual or electric, as monotherapy or in conjunction with chlorhexidine.", [["oral", "ANATOMY", 17, 21], ["oral", "ANATOMY", 250, 254], ["pneumonia", "DISEASE", 63, 72], ["chlorhexidine", "CHEMICAL", 143, 156], ["foam", "CHEMICAL", 270, 274], ["chlorhexidine", "CHEMICAL", 389, 402], ["chlorhexidine", "CHEMICAL", 143, 156], ["chlorhexidine", "CHEMICAL", 389, 402], ["oral", "ORGANISM_SUBDIVISION", 17, 21], ["patients", "ORGANISM", 111, 119], ["chlorhexidine", "SIMPLE_CHEMICAL", 143, 156], ["oral", "ORGANISM_SUBDIVISION", 250, 254], ["chlorhexidine", "SIMPLE_CHEMICAL", 389, 402], ["patients", "SPECIES", 111, 119], ["oral care", "TREATMENT", 17, 26], ["ventilatorassociated pneumonia", "PROBLEM", 42, 72], ["chlorhexidine", "TREATMENT", 143, 156], ["monotherapy in different concentrations", "TREATMENT", 160, 199], ["oral rinse", "TREATMENT", 250, 260], ["gel", "TREATMENT", 262, 265], ["foam", "TREATMENT", 270, 274], ["mechanical debridement", "TREATMENT", 279, 301], ["monotherapy", "TREATMENT", 354, 365], ["chlorhexidine", "TREATMENT", 389, 402], ["pneumonia", "OBSERVATION", 63, 72], ["debridement", "OBSERVATION", 290, 301]]], ["Other decontamination agent includes povidone-iodine 10%, and other forms of mouthwash [1, 2, 6] .ObjectivesThe objective of this study is to assess the beneficial effects of various oral care methods on the incidence of VAP in critically ill patients receiving mechanical ventilation in intensive care units in hospitals.Search Methods and Selection CriteriaAn exhaustive literature search was undertaken using MEDLINE as well as a manual review of the relevant literature and citations.", [["oral", "ANATOMY", 183, 187], ["povidone-iodine", "CHEMICAL", 37, 52], ["VAP", "DISEASE", 221, 224], ["critically ill", "DISEASE", 228, 242], ["povidone-iodine", "CHEMICAL", 37, 52], ["povidone-iodine", "SIMPLE_CHEMICAL", 37, 52], ["oral", "ORGANISM_SUBDIVISION", 183, 187], ["patients", "ORGANISM", 243, 251], ["patients", "SPECIES", 243, 251], ["Other decontamination agent", "TREATMENT", 0, 27], ["povidone", "TREATMENT", 37, 45], ["iodine", "TREATMENT", 46, 52], ["this study", "TEST", 125, 135], ["various oral care methods", "TREATMENT", 175, 200], ["VAP", "PROBLEM", 221, 224], ["mechanical ventilation", "TREATMENT", 262, 284]]], ["The cited articles were published in medical literature from 2008 to 2018 regarding VAP and oral care.", [["oral", "ANATOMY", 92, 96], ["VAP", "DISEASE", 84, 87], ["oral", "ORGANISM_SUBDIVISION", 92, 96], ["VAP", "TREATMENT", 84, 87], ["oral care", "TREATMENT", 92, 101]]], ["Study selection was made independently by the three authors (RG, NY, and MF).Search Methods and Selection CriteriaTo find and filter unrelated articles, we used keywords from the medical subject headings (mesh): (((Ventilator Associated Pneumonia) OR (VAP)) and ((Oral Care) or (Oral Hygiene) or (Oral Rinse) or (Mouthwash)) and ((Intensive Care Unit) or (ICU))).", [["Pneumonia", "DISEASE", 237, 246], ["VAP", "DISEASE", 252, 255], ["Study selection", "TEST", 0, 15], ["Ventilator Associated Pneumonia)", "PROBLEM", 215, 247], ["((Oral Care)", "TREATMENT", 262, 274], ["(Oral Hygiene)", "TREATMENT", 278, 292], ["Pneumonia", "OBSERVATION", 237, 246]]], ["Selection of the studies started with search in MEDLINE using the keyword \"mesh.\"Search Methods and Selection CriteriaWhen the query was entered, the first result produced 235 articles containing the word mesh.", [["the studies", "TEST", 13, 24], ["the word mesh", "TREATMENT", 196, 209], ["mesh", "OBSERVATION", 75, 79], ["word mesh", "OBSERVATION", 200, 209]]], ["The first filter applied was only for full-text articles which resulted in eight articles being excluded.", [["The first filter", "TREATMENT", 0, 16], ["filter", "OBSERVATION", 10, 16]]], ["The next filters were as follows: The type of infection (ventilator associated pneumonia), article type (randomized control trials), age (adult aged 19+), treatment agent (oral care decontamination), type of patients (ventilated patient in the ICU's), and studies which were concluded in the last 10 years.", [["oral", "ANATOMY", 172, 176], ["infection", "DISEASE", 46, 55], ["pneumonia", "DISEASE", 79, 88], ["oral", "ORGANISM_SUBDIVISION", 172, 176], ["patients", "ORGANISM", 208, 216], ["patient", "ORGANISM", 229, 236], ["patients", "SPECIES", 208, 216], ["patient", "SPECIES", 229, 236], ["infection (ventilator associated pneumonia)", "PROBLEM", 46, 89], ["article type (randomized control trials", "TREATMENT", 91, 130], ["treatment agent", "TREATMENT", 155, 170], ["oral care decontamination", "TREATMENT", 172, 197], ["studies", "TEST", 256, 263], ["infection", "OBSERVATION", 46, 55], ["pneumonia", "OBSERVATION", 79, 88]]], ["After using those filters, 219 articles were excluded, and eight studies were included in the qualitative synthesis.", [["those filters", "TREATMENT", 12, 25], ["eight studies", "TEST", 59, 72]]], ["Discussion about the results and their importance to the study question was the final part of this review.ResultsSearching studies for this review came up with 235 references in MEDLINE (Fig. 1) .", [["the study", "TEST", 53, 62], ["this review", "TEST", 135, 146]]], ["After reviewing the inclusion criteria, eight publications were selected for this review.EndpointsThe primary endpoint in all the studies was the incidence of VAP.", [["VAP", "DISEASE", 159, 162], ["this review", "TEST", 77, 88], ["the studies", "TEST", 126, 137], ["VAP", "PROBLEM", 159, 162], ["VAP", "OBSERVATION", 159, 162]]], ["Secondary endpoints that were measured were mortality rate [7, 8, [11] [12] [13] , length of ICU stay [8, [11] [12] [13] , antibiotics free days [7] , mechanical ventilation free days [7, 11] ,common microorganism colonization [9, 11, 13] , clinical periodontal measurements [13] , and rate of tracheobronchitis or acute respiratory stress disorder [10] .", [["periodontal", "ANATOMY", 250, 261], ["respiratory", "ANATOMY", 321, 332], ["tracheobronchitis", "DISEASE", 294, 311], ["respiratory stress disorder", "DISEASE", 321, 348], ["Secondary endpoints", "PROBLEM", 0, 19], ["mortality rate", "TEST", 44, 58], ["antibiotics free days", "TREATMENT", 123, 144], ["mechanical ventilation", "TREATMENT", 151, 173], ["common microorganism colonization", "PROBLEM", 193, 226], ["clinical periodontal measurements", "TEST", 241, 274], ["tracheobronchitis", "PROBLEM", 294, 311], ["acute respiratory stress disorder", "PROBLEM", 315, 348], ["tracheobronchitis", "OBSERVATION", 294, 311], ["acute", "OBSERVATION_MODIFIER", 315, 320], ["respiratory stress", "OBSERVATION", 321, 339]]], ["In this study our only interest was in the primary endpoint that was the incidence of VAP and ignored the rest of the data.Differentiation of Oral Prevention MethodsDifferent oral care methods for preventing VAP were the subject of this review.", [["Oral", "ANATOMY", 142, 146], ["oral", "ANATOMY", 175, 179], ["VAP", "DISEASE", 86, 89], ["VAP", "DISEASE", 208, 211], ["oral", "ORGANISM_SUBDIVISION", 175, 179], ["this study", "TEST", 3, 13], ["VAP", "PROBLEM", 86, 89], ["Oral Prevention", "TREATMENT", 142, 157], ["Different oral care methods", "TREATMENT", 165, 192], ["VAP", "PROBLEM", 208, 211], ["VAP", "OBSERVATION", 86, 89]]], ["The main oral agent in the intervention groups was presented accordingly: 25% of all reported methods demonstrated the use of chlorhexidine 0.12% rinse, 37.5% were with chlorhexidine 0.2% rinse, and 12.5% were with chlorhexidine 2% rinse.", [["oral", "ANATOMY", 9, 13], ["chlorhexidine", "CHEMICAL", 126, 139], ["chlorhexidine", "CHEMICAL", 169, 182], ["chlorhexidine", "CHEMICAL", 215, 228], ["chlorhexidine", "CHEMICAL", 126, 139], ["chlorhexidine", "CHEMICAL", 169, 182], ["chlorhexidine", "CHEMICAL", 215, 228], ["oral", "ORGANISM_SUBDIVISION", 9, 13], ["chlorhexidine", "SIMPLE_CHEMICAL", 126, 139], ["chlorhexidine", "SIMPLE_CHEMICAL", 169, 182], ["chlorhexidine", "SIMPLE_CHEMICAL", 215, 228], ["chlorhexidine", "TREATMENT", 126, 139], ["chlorhexidine", "TREATMENT", 169, 182], ["chlorhexidine", "TREATMENT", 215, 228], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The others were treated with 12.5% povidone-iodine and 12.5% mechanical intervention by use of a toothbrush.", [["povidone-iodine", "CHEMICAL", 35, 50], ["povidone-iodine", "CHEMICAL", 35, 50], ["povidone-iodine", "SIMPLE_CHEMICAL", 35, 50], ["12.5% povidone", "TREATMENT", 29, 43], ["iodine", "TREATMENT", 44, 50], ["12.5% mechanical intervention", "TREATMENT", 55, 84], ["a toothbrush", "TREATMENT", 95, 107]]], ["Of those treated, 87.5% of the cases were initialized with suction of the oropharyngeal secretions, when only in the povidone-iodine intervention, suction of the secretions did not happen.", [["oropharyngeal secretions", "ANATOMY", 74, 98], ["secretions", "ANATOMY", 162, 172], ["povidone-iodine", "CHEMICAL", 117, 132], ["povidone-iodine", "CHEMICAL", 117, 132], ["oropharyngeal secretions", "ORGANISM_SUBDIVISION", 74, 98], ["povidone-iodine", "SIMPLE_CHEMICAL", 117, 132], ["suction", "TREATMENT", 59, 66], ["the oropharyngeal secretions", "PROBLEM", 70, 98], ["the povidone-iodine intervention", "TREATMENT", 113, 145], ["suction", "TREATMENT", 147, 154], ["the secretions", "PROBLEM", 158, 172], ["oropharyngeal", "ANATOMY", 74, 87], ["secretions", "OBSERVATION", 88, 98]]], ["A combination of two main interventions occurred when chlorhexidine and a toothbrush combined in 62.5% of the cases and a toothbrush with sodium bicarbonate mouthwash in 12.5% of the cases.", [["chlorhexidine", "CHEMICAL", 54, 67], ["sodium bicarbonate", "CHEMICAL", 138, 156], ["chlorhexidine", "CHEMICAL", 54, 67], ["sodium bicarbonate", "CHEMICAL", 138, 156], ["chlorhexidine", "SIMPLE_CHEMICAL", 54, 67], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 138, 156], ["two main interventions", "TREATMENT", 17, 39], ["chlorhexidine", "TREATMENT", 54, 67], ["a toothbrush", "TREATMENT", 72, 84], ["sodium bicarbonate mouthwash", "TREATMENT", 138, 166], ["two", "OBSERVATION_MODIFIER", 17, 20], ["main", "OBSERVATION_MODIFIER", 21, 25]]], ["In the control group, 25% of the groups treated with CHX (i.e., chlorhexidine) 0.2% and 37.5% with CHX 0.12%.", [["CHX", "CHEMICAL", 53, 56], ["chlorhexidine", "CHEMICAL", 64, 77], ["CHX", "CHEMICAL", 99, 102], ["CHX", "CHEMICAL", 53, 56], ["chlorhexidine", "CHEMICAL", 64, 77], ["CHX", "CHEMICAL", 99, 102], ["CHX", "SIMPLE_CHEMICAL", 53, 56], ["chlorhexidine", "SIMPLE_CHEMICAL", 64, 77], ["CHX", "SIMPLE_CHEMICAL", 99, 102], ["CHX", "TREATMENT", 53, 56], ["chlorhexidine", "TREATMENT", 64, 77], ["CHX", "TREATMENT", 99, 102]]], ["The rest of the control groups were given a placebo gel, sterile water, and saline.CHX 2% + Mechanical ToothbrushAnalysis of the results demonstrated the following conclusions.", [["CHX", "CHEMICAL", 83, 86], ["CHX", "CHEMICAL", 83, 86], ["saline", "SIMPLE_CHEMICAL", 76, 82], ["CHX", "SIMPLE_CHEMICAL", 83, 86], ["a placebo gel", "TREATMENT", 42, 55], ["sterile water", "TREATMENT", 57, 70], ["saline", "TREATMENT", 76, 82], ["CHX", "TEST", 83, 86]]], ["In the study of Zand et al. [11] , 114 patients were allocated into two groups.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["the study", "TEST", 3, 12]]], ["Both the intervention and control groups received oral care in the way of suctioning the oropharyngeal secretions as well as brushing the oral cavity and teeth.", [["oral", "ANATOMY", 50, 54], ["oropharyngeal secretions", "ANATOMY", 89, 113], ["oral cavity", "ANATOMY", 138, 149], ["teeth", "ANATOMY", 154, 159], ["oral", "ORGANISM_SUBDIVISION", 50, 54], ["oropharyngeal secretions", "ORGANISM_SUBDIVISION", 89, 113], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 138, 149], ["teeth", "ORGAN", 154, 159], ["the intervention", "TREATMENT", 5, 21], ["control groups", "TREATMENT", 26, 40], ["oral care", "TREATMENT", 50, 59], ["suctioning the oropharyngeal secretions", "PROBLEM", 74, 113], ["oropharyngeal", "ANATOMY", 89, 102], ["secretions", "OBSERVATION", 103, 113], ["oral cavity", "ANATOMY", 138, 149], ["teeth", "ANATOMY", 154, 159]]], ["The intervention group was treated with CHX 2% and the control group with CHX 0.2%.", [["CHX", "CHEMICAL", 40, 43], ["CHX", "CHEMICAL", 74, 77], ["CHX", "CHEMICAL", 40, 43], ["CHX", "CHEMICAL", 74, 77], ["CHX", "SIMPLE_CHEMICAL", 40, 43], ["CHX", "SIMPLE_CHEMICAL", 74, 77], ["CHX", "TREATMENT", 40, 43], ["CHX", "TREATMENT", 74, 77]]], ["This study showed a significant difference regarding the incidence of VAP between the two study groups although there was no significant difference between the two groups regarding mean ventilation days, or 28 days following ventilation therapy.", [["VAP", "DISEASE", 70, 73], ["This study", "TEST", 0, 10], ["VAP", "PROBLEM", 70, 73], ["the two study groups", "TEST", 82, 102], ["ventilation therapy", "TREATMENT", 225, 244], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["difference", "OBSERVATION", 32, 42], ["VAP", "OBSERVATION", 70, 73], ["no", "UNCERTAINTY", 122, 124], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["difference", "OBSERVATION", 137, 147]]], ["In the control group the incidence of VAP was 22.8%, and in the intervention group only 5.3%.", [["VAP", "DISEASE", 38, 41], ["VAP", "TEST", 38, 41], ["VAP", "OBSERVATION", 38, 41]]], ["This result was statistically significant (P value = 0.007).CHX 0.12% + Mechanical ToothbrushIn the study of Lacerda Vidal et al. [12] , 213 patients were allocated into two groups: Control (n = 108) and study group (n = 105).", [["CHX", "CHEMICAL", 60, 63], ["CHX", "CHEMICAL", 60, 63], ["CHX", "SIMPLE_CHEMICAL", 60, 63], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["P value", "TEST", 43, 50], ["CHX", "TEST", 60, 63], ["the study", "TEST", 96, 105], ["significant", "OBSERVATION_MODIFIER", 30, 41]]], ["They received oral care with suction oropharyngeal secretions and a mouth swab with CHX 0.12%.", [["oral", "ANATOMY", 14, 18], ["oropharyngeal", "ANATOMY", 37, 50], ["mouth swab", "ANATOMY", 68, 78], ["CHX", "CHEMICAL", 84, 87], ["CHX", "CHEMICAL", 84, 87], ["oral", "ORGANISM_SUBDIVISION", 14, 18], ["oropharyngeal", "ORGANISM_SUBDIVISION", 37, 50], ["secretions", "ORGANISM_SUBSTANCE", 51, 61], ["CHX", "SIMPLE_CHEMICAL", 84, 87], ["oral care", "TREATMENT", 14, 23], ["suction oropharyngeal secretions", "PROBLEM", 29, 61], ["a mouth swab", "TEST", 66, 78], ["CHX", "TREATMENT", 84, 87], ["mouth", "ANATOMY", 68, 73]]], ["The intervention group was treated with a thorough toothbrushing and cleansing of the oral cavity.", [["oral cavity", "ANATOMY", 86, 97], ["oral cavity", "ORGANISM_SUBDIVISION", 86, 97], ["a thorough toothbrushing", "TREATMENT", 40, 64], ["cleansing of the oral cavity", "TREATMENT", 69, 97], ["oral cavity", "ANATOMY", 86, 97]]], ["In this study, the control group's incidence of VAP was higher than the intervention group (25.9% and 16.19%, respectively) although the statistical difference was not significant (P value = 0.084).CHX 0.12% + Mechanical ToothbrushIn the study of Lorente et al. [8] , the authors compared an intervention group (N = 217) who were given oral care with CHX 0.12% with toothbrushing and suctioning of oropharyngeal secretions with a control group (N = 219) with suctioning of oropharyngeal secretions and rinsing and swabbing with CHX 0.12%, without toothbrushing.", [["oral", "ANATOMY", 336, 340], ["oropharyngeal secretions", "ANATOMY", 398, 422], ["oropharyngeal secretions", "ANATOMY", 473, 497], ["VAP", "DISEASE", 48, 51], ["CHX", "CHEMICAL", 198, 201], ["CHX", "CHEMICAL", 351, 354], ["CHX", "CHEMICAL", 528, 531], ["CHX", "CHEMICAL", 198, 201], ["CHX", "CHEMICAL", 351, 354], ["CHX", "CHEMICAL", 528, 531], ["CHX", "SIMPLE_CHEMICAL", 198, 201], ["oral", "ORGANISM_SUBDIVISION", 336, 340], ["CHX", "SIMPLE_CHEMICAL", 351, 354], ["oropharyngeal secretions", "ORGANISM_SUBDIVISION", 398, 422], ["CHX", "SIMPLE_CHEMICAL", 528, 531], ["this study", "TEST", 3, 13], ["VAP", "PROBLEM", 48, 51], ["P value", "TEST", 181, 188], ["CHX", "TEST", 198, 201], ["the study", "TEST", 234, 243], ["oral care", "TREATMENT", 336, 345], ["CHX", "TREATMENT", 351, 354], ["toothbrushing", "TREATMENT", 366, 379], ["oropharyngeal secretions", "PROBLEM", 398, 422], ["suctioning of oropharyngeal secretions", "PROBLEM", 459, 497], ["rinsing", "TREATMENT", 502, 509], ["CHX", "TREATMENT", 528, 531], ["VAP", "OBSERVATION", 48, 51], ["oropharyngeal", "ANATOMY", 398, 411], ["oropharyngeal secretions", "ANATOMY", 473, 497]]], ["There was no significant difference between the groups regarding the incidence of VAP.CHX 0.12% + Mechanical ToothbrushIn the case study of Pobo et al. [7] , where the intervention group contained 74 patients and the control group contained 73 patients, electric toothbrushing was the mechanical agent rather than a manual one.", [["VAP", "DISEASE", 82, 85], ["CHX", "CHEMICAL", 86, 89], ["CHX", "CHEMICAL", 86, 89], ["CHX", "SIMPLE_CHEMICAL", 86, 89], ["patients", "ORGANISM", 200, 208], ["patients", "ORGANISM", 244, 252], ["patients", "SPECIES", 200, 208], ["patients", "SPECIES", 244, 252], ["VAP", "PROBLEM", 82, 85], ["CHX", "TEST", 86, 89], ["electric toothbrushing", "TREATMENT", 254, 276], ["the mechanical agent", "TREATMENT", 281, 301], ["a manual one", "TREATMENT", 314, 326], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION", 25, 35], ["VAP", "OBSERVATION", 82, 85]]], ["A difference was not found between the study and the control group.", [["the study", "TEST", 35, 44]]], ["Additionally, the control group showed lower VAP incidence relative to the study group (20.3% and 24.7%, respectively).CHX 0.2%In a study conducted by Ozcaka et al. [13] 29 patients in the intervention group, and 32 patients in the control group, were the target population.", [["VAP", "DISEASE", 45, 48], ["CHX", "CHEMICAL", 119, 122], ["CHX", "CHEMICAL", 119, 122], ["CHX", "SIMPLE_CHEMICAL", 119, 122], ["patients", "ORGANISM", 173, 181], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 173, 181], ["patients", "SPECIES", 216, 224], ["lower VAP incidence", "PROBLEM", 39, 58], ["the study group", "TEST", 71, 86], ["CHX", "TREATMENT", 119, 122], ["a study", "TEST", 130, 137], ["lower", "OBSERVATION_MODIFIER", 39, 44], ["VAP", "OBSERVATION", 45, 48]]], ["Routine oropharyngeal suction of oral secretions was conducted both in the control and intervention groups.", [["oropharyngeal", "ANATOMY", 8, 21], ["oral secretions", "ANATOMY", 33, 48], ["oropharyngeal", "ORGANISM_SUBDIVISION", 8, 21], ["oral", "ORGANISM_SUBDIVISION", 33, 37], ["secretions", "ORGANISM_SUBSTANCE", 38, 48], ["Routine oropharyngeal suction", "TREATMENT", 0, 29], ["oral secretions", "PROBLEM", 33, 48], ["oropharyngeal", "ANATOMY", 8, 21]]], ["The difference was the use of mouth swab and oral rinse with CHX 0.2% in the intervention group.", [["mouth swab", "ANATOMY", 30, 40], ["oral", "ANATOMY", 45, 49], ["CHX", "CHEMICAL", 61, 64], ["CHX", "CHEMICAL", 61, 64], ["mouth", "ORGANISM_SUBDIVISION", 30, 35], ["swab", "ORGANISM_SUBSTANCE", 36, 40], ["oral", "ORGANISM_SUBDIVISION", 45, 49], ["CHX", "SIMPLE_CHEMICAL", 61, 64], ["mouth swab", "TREATMENT", 30, 40], ["oral rinse", "TREATMENT", 45, 55], ["CHX", "TREATMENT", 61, 64]]], ["The result from this study demonstrated a higher incidence of VAP in the control group relative to the intervention group (study, 41.4%; control, 68.8%), in a statistically significant way (P value = 0.03).CHX 0.2% + Mechanical ToothbrushIn the study of Chacko et al. [6] a comparison between the intervention group consisted of 104 patients who were given oral care in the form of suctioning of the oropharyngeal secretions, a mouth swab containing CHX 0.2% and an oral cavity cleaning with manual toothbrush.", [["oral", "ANATOMY", 357, 361], ["oropharyngeal secretions", "ANATOMY", 400, 424], ["mouth swab", "ANATOMY", 428, 438], ["oral", "ANATOMY", 466, 470], ["VAP", "DISEASE", 62, 65], ["CHX", "CHEMICAL", 206, 209], ["CHX", "CHEMICAL", 450, 453], ["CHX", "CHEMICAL", 206, 209], ["CHX", "CHEMICAL", 450, 453], ["CHX", "SIMPLE_CHEMICAL", 206, 209], ["patients", "ORGANISM", 333, 341], ["oral", "ORGANISM_SUBDIVISION", 357, 361], ["oropharyngeal secretions", "ORGANISM_SUBDIVISION", 400, 424], ["CHX", "SIMPLE_CHEMICAL", 450, 453], ["oral", "ORGANISM_SUBDIVISION", 466, 470], ["cavity", "ORGANISM_SUBDIVISION", 471, 477], ["patients", "SPECIES", 333, 341], ["this study", "TEST", 16, 26], ["VAP", "PROBLEM", 62, 65], ["study", "TEST", 123, 128], ["P value", "TEST", 190, 197], ["CHX", "TEST", 206, 209], ["the study", "TEST", 241, 250], ["oral care", "TREATMENT", 357, 366], ["suctioning", "TREATMENT", 382, 392], ["the oropharyngeal secretions", "PROBLEM", 396, 424], ["a mouth swab containing CHX", "TREATMENT", 426, 453], ["an oral cavity cleaning", "TREATMENT", 463, 486], ["manual toothbrush", "TREATMENT", 492, 509], ["higher", "OBSERVATION_MODIFIER", 42, 48], ["VAP", "OBSERVATION", 62, 65], ["oropharyngeal secretions", "ANATOMY", 400, 424]]], ["A control group of 102 patients were given the standard oral care of a mouth swab cleaning with CHX 0.2%.", [["oral", "ANATOMY", 56, 60], ["mouth swab", "ANATOMY", 71, 81], ["CHX", "CHEMICAL", 96, 99], ["CHX", "CHEMICAL", 96, 99], ["patients", "ORGANISM", 23, 31], ["oral", "ORGANISM_SUBDIVISION", 56, 60], ["CHX", "SIMPLE_CHEMICAL", 96, 99], ["patients", "SPECIES", 23, 31], ["a mouth swab cleaning", "TREATMENT", 69, 90], ["CHX", "TREATMENT", 96, 99]]], ["Inclusion criteria in this study is mechanical ventilation of ad list 4-6 h.", [["this study", "TEST", 22, 32], ["mechanical ventilation", "TREATMENT", 36, 58], ["mechanical ventilation", "OBSERVATION", 36, 58]]], ["The authors did not find strong statistical differences between the groups (p value = 0.82), suggesting that toothbrushing and suctioning of the oropharyngeal secretions did not have any more effect to standard oral care.CHX 0.12%/Sodium Bicarbonate + Mechanical ToothbrushIn the study of Berry et al. [9] , the author noted that using different kinds of mouth rinses (CHX 0.12%, sodium bicarbonate, and saline) along with mechanical toothbrushing did not affect the incidence of VAP in any significant way.", [["oropharyngeal secretions", "ANATOMY", 145, 169], ["oral", "ANATOMY", 211, 215], ["mouth", "ANATOMY", 355, 360], ["CHX", "CHEMICAL", 221, 224], ["Sodium Bicarbonate", "CHEMICAL", 231, 249], ["CHX", "CHEMICAL", 369, 372], ["sodium bicarbonate", "CHEMICAL", 380, 398], ["VAP", "DISEASE", 480, 483], ["CHX", "CHEMICAL", 221, 224], ["Sodium Bicarbonate", "CHEMICAL", 231, 249], ["CHX", "CHEMICAL", 369, 372], ["sodium bicarbonate", "CHEMICAL", 380, 398], ["oral", "ORGANISM_SUBDIVISION", 211, 215], ["CHX", "SIMPLE_CHEMICAL", 221, 224], ["Sodium Bicarbonate", "SIMPLE_CHEMICAL", 231, 249], ["CHX", "SIMPLE_CHEMICAL", 369, 372], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 380, 398], ["saline", "SIMPLE_CHEMICAL", 404, 410], ["the oropharyngeal secretions", "PROBLEM", 141, 169], ["standard oral care", "TREATMENT", 202, 220], ["CHX", "TREATMENT", 221, 224], ["Sodium Bicarbonate", "TREATMENT", 231, 249], ["mouth rinses", "TREATMENT", 355, 367], ["CHX", "TREATMENT", 369, 372], ["sodium bicarbonate", "TREATMENT", 380, 398], ["saline", "TREATMENT", 404, 410], ["mechanical toothbrushing", "TREATMENT", 423, 447], ["VAP", "PROBLEM", 480, 483], ["oropharyngeal", "ANATOMY", 145, 158], ["secretions", "OBSERVATION", 159, 169], ["VAP", "OBSERVATION", 480, 483]]], ["It was concluded that brushing had the most effect on lowering the incidence of VAP.Povodine-Iodine 10%In the study of Seguin et al. [10] , with 150 patients consisting of 78 patients in the intervention group and 72 in the control group, the oral agent was iodine-povidone 10% compared with placebo gel with sterile water.", [["oral", "ANATOMY", 243, 247], ["VAP", "DISEASE", 80, 83], ["Povodine-Iodine", "CHEMICAL", 84, 99], ["iodine-povidone", "CHEMICAL", 258, 273], ["Povodine", "CHEMICAL", 84, 92], ["Iodine", "CHEMICAL", 93, 99], ["iodine", "CHEMICAL", 258, 264], ["povidone", "CHEMICAL", 265, 273], ["Povodine", "SIMPLE_CHEMICAL", 84, 92], ["patients", "ORGANISM", 149, 157], ["patients", "ORGANISM", 175, 183], ["oral", "ORGANISM_SUBDIVISION", 243, 247], ["iodine-povidone", "SIMPLE_CHEMICAL", 258, 273], ["patients", "SPECIES", 149, 157], ["patients", "SPECIES", 175, 183], ["brushing", "TREATMENT", 22, 30], ["VAP", "PROBLEM", 80, 83], ["Povodine", "TREATMENT", 84, 92], ["Iodine", "TREATMENT", 93, 99], ["the oral agent", "TREATMENT", 239, 253], ["iodine", "TREATMENT", 258, 264], ["povidone", "TREATMENT", 265, 273], ["placebo gel", "TREATMENT", 292, 303], ["sterile water", "TREATMENT", 309, 322], ["most effect", "OBSERVATION_MODIFIER", 39, 50], ["VAP", "OBSERVATION", 80, 83]]], ["The authors concluded there was no significant difference in the incidence of VAP to the intervention group (p value = 0.69).", [["VAP", "DISEASE", 78, 81], ["VAP", "PROBLEM", 78, 81], ["p value", "TEST", 109, 116], ["no", "UNCERTAINTY", 32, 34], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["difference", "OBSERVATION_MODIFIER", 47, 57]]], ["This study showed that povidone-iodine lowered the oropharyngeal colonization but not the endotracheal colonization, and the use of povidone-iodine and this did not change the incidence of VAP in the study group.", [["oropharyngeal", "ANATOMY", 51, 64], ["endotracheal", "ANATOMY", 90, 102], ["povidone-iodine", "CHEMICAL", 23, 38], ["povidone-iodine", "CHEMICAL", 132, 147], ["VAP", "DISEASE", 189, 192], ["povidone-iodine", "CHEMICAL", 23, 38], ["povidone-iodine", "CHEMICAL", 132, 147], ["povidone-iodine", "SIMPLE_CHEMICAL", 23, 38], ["oropharyngeal", "ORGANISM_SUBDIVISION", 51, 64], ["povidone-iodine", "SIMPLE_CHEMICAL", 132, 147], ["This study", "TEST", 0, 10], ["povidone", "TREATMENT", 23, 31], ["iodine", "TREATMENT", 32, 38], ["the oropharyngeal colonization", "PROBLEM", 47, 77], ["the endotracheal colonization", "PROBLEM", 86, 115], ["povidone", "TREATMENT", 132, 140], ["iodine", "TREATMENT", 141, 147], ["VAP", "PROBLEM", 189, 192], ["oropharyngeal", "ANATOMY", 51, 64], ["colonization", "OBSERVATION", 65, 77], ["endotracheal colonization", "OBSERVATION", 90, 115], ["VAP", "OBSERVATION", 189, 192]]], ["Also, it was demonstrated that povidone-iodine can cause an acute respiratory disorder and is not recommended to be used as a decontamination agent.DiscussionThe proper oral care treatment of ventilated patients in the intensive care units for prevention of ventilator-associated pneumonia became an important line of defense for the eradication of antibiotic-resistant microorganisms, decreasing morbidity and mortality among patients in the ICU as well as the lowering of health care costs.", [["respiratory", "ANATOMY", 66, 77], ["oral", "ANATOMY", 169, 173], ["povidone-iodine", "CHEMICAL", 31, 46], ["respiratory disorder", "DISEASE", 66, 86], ["pneumonia", "DISEASE", 280, 289], ["povidone-iodine", "CHEMICAL", 31, 46], ["povidone-iodine", "SIMPLE_CHEMICAL", 31, 46], ["oral", "ORGANISM_SUBDIVISION", 169, 173], ["patients", "ORGANISM", 203, 211], ["patients", "ORGANISM", 427, 435], ["patients", "SPECIES", 203, 211], ["patients", "SPECIES", 427, 435], ["povidone", "TREATMENT", 31, 39], ["iodine", "TREATMENT", 40, 46], ["an acute respiratory disorder", "PROBLEM", 57, 86], ["a decontamination agent", "TREATMENT", 124, 147], ["ventilated", "TREATMENT", 192, 202], ["ventilator-associated pneumonia", "PROBLEM", 258, 289], ["antibiotic", "TREATMENT", 349, 359], ["resistant microorganisms", "PROBLEM", 360, 384], ["decreasing morbidity", "PROBLEM", 386, 406], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory disorder", "OBSERVATION", 66, 86], ["pneumonia", "OBSERVATION", 280, 289]]], ["In this review, different methods of oral care were given to ventilated patients in various intensive care units by the care takers in the units.", [["oral", "ANATOMY", 37, 41], ["oral", "ORGANISM_SUBDIVISION", 37, 41], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["oral care", "TREATMENT", 37, 46]]], ["Randomized control trials which test different kind of oral care are presented in Table 1 .DiscussionTwo studies that were reviewed in this article showed significant statistical difference between the intervention group and the control group regarding different oral care for prevention of VAP.", [["oral", "ANATOMY", 55, 59], ["oral", "ANATOMY", 263, 267], ["VAP", "DISEASE", 291, 294], ["oral", "ORGANISM_SUBDIVISION", 55, 59], ["oral", "ORGANISM_SUBDIVISION", 263, 267], ["Randomized control trials", "TREATMENT", 0, 25], ["oral care", "TREATMENT", 55, 64], ["Two studies", "TEST", 101, 112], ["the intervention group", "TREATMENT", 198, 220], ["the control group", "TREATMENT", 225, 242], ["different oral care", "TREATMENT", 253, 272], ["VAP", "PROBLEM", 291, 294], ["VAP", "OBSERVATION", 291, 294]]], ["Zand et al. [11] gave different concentrations of chlorhexidine orally to the intervention group and the control group (2%, 0.2%), respectively, and found that the incidence of VAP decreased dramatically, proving that not only the type of oral care while on a ventilator is important but also the concentration amount of the agent has a critical role for decreasing morbidity.", [["oral", "ANATOMY", 239, 243], ["chlorhexidine", "CHEMICAL", 50, 63], ["VAP", "DISEASE", 177, 180], ["chlorhexidine", "CHEMICAL", 50, 63], ["chlorhexidine", "SIMPLE_CHEMICAL", 50, 63], ["oral", "ORGANISM_SUBDIVISION", 239, 243], ["chlorhexidine", "TREATMENT", 50, 63], ["the intervention group", "TREATMENT", 74, 96], ["VAP", "PROBLEM", 177, 180], ["oral care", "TREATMENT", 239, 248], ["a ventilator", "TREATMENT", 258, 270], ["decreasing morbidity", "PROBLEM", 355, 375], ["VAP", "OBSERVATION", 177, 180]]], ["In the study of Ozcaka et al. [13] significant statistical differences occurred between the intervention group and the control group.", [["the study", "TEST", 3, 12], ["significant statistical differences", "PROBLEM", 35, 70]]], ["The intervention group was treated with mouth swab of chlorohexidine 0.2%, and in this study, there was a strong connection for the number of ventilated days of the incidence of VAP.", [["mouth swab", "ANATOMY", 40, 50], ["chlorohexidine", "CHEMICAL", 54, 68], ["VAP", "DISEASE", 178, 181], ["chlorohexidine", "CHEMICAL", 54, 68], ["chlorohexidine", "SIMPLE_CHEMICAL", 54, 68], ["mouth swab of chlorohexidine", "TREATMENT", 40, 68], ["this study", "TEST", 82, 92], ["VAP", "PROBLEM", 178, 181], ["VAP", "OBSERVATION", 178, 181]]], ["There was more effectivity in providing a mouth swab to a patient than regular rinse because it reached and penetrated more tissue.", [["mouth swab", "ANATOMY", 42, 52], ["tissue", "ANATOMY", 124, 130], ["patient", "ORGANISM", 58, 65], ["tissue", "TISSUE", 124, 130], ["patient", "SPECIES", 58, 65], ["a mouth swab", "TREATMENT", 40, 52], ["regular rinse", "TREATMENT", 71, 84], ["more effectivity", "OBSERVATION_MODIFIER", 10, 26]]], ["There is a noticeable difference in the number of times a day an oral CHX swab was given.", [["oral", "ANATOMY", 65, 69], ["CHX", "CHEMICAL", 70, 73], ["CHX", "CHEMICAL", 70, 73], ["oral", "ORGANISM_SUBDIVISION", 65, 69], ["an oral CHX swab", "TREATMENT", 62, 78], ["noticeable", "OBSERVATION_MODIFIER", 11, 21], ["difference", "OBSERVATION_MODIFIER", 22, 32]]], ["It was also concluded that lowering the offset of VAP is in strong connection with a more experienced and professional care takers responsible to the oral care that was given.DiscussionIn three other studies [7, 8, 12] , presenting an intervention group given mechanical debridement (manual or electric toothbrush) along with the antiseptic agent, there was no significant difference between the intervention and the control group.", [["oral", "ANATOMY", 150, 154], ["VAP", "DISEASE", 50, 53], ["oral", "ORGANISM_SUBDIVISION", 150, 154], ["VAP", "PROBLEM", 50, 53], ["the oral care", "TREATMENT", 146, 159], ["three other studies", "TEST", 188, 207], ["an intervention group", "TREATMENT", 232, 253], ["mechanical debridement", "TREATMENT", 260, 282], ["manual or electric toothbrush", "TREATMENT", 284, 313], ["the antiseptic agent", "TREATMENT", 326, 346], ["the intervention", "TREATMENT", 392, 408], ["VAP", "OBSERVATION", 50, 53], ["debridement", "OBSERVATION", 271, 282], ["no", "UNCERTAINTY", 358, 360], ["significant", "OBSERVATION_MODIFIER", 361, 372], ["difference", "OBSERVATION", 373, 383]]], ["In those studies, it was proven that adding a toothbrush (electric or manual) did not contribute more than the CHX already did.", [["CHX", "CHEMICAL", 111, 114], ["CHX", "CHEMICAL", 111, 114], ["CHX", "SIMPLE_CHEMICAL", 111, 114], ["those studies", "TEST", 3, 16], ["a toothbrush (electric", "TREATMENT", 44, 66]]], ["Also, it was concluded that the chemical effect of CHX is effective for \"moving\" microorganisms and does not affect the oral plaque that is built up as a biofilm.", [["oral plaque", "ANATOMY", 120, 131], ["biofilm", "ANATOMY", 154, 161], ["CHX", "CHEMICAL", 51, 54], ["CHX", "CHEMICAL", 51, 54], ["CHX", "SIMPLE_CHEMICAL", 51, 54], ["oral plaque", "PATHOLOGICAL_FORMATION", 120, 131], ["CHX", "TREATMENT", 51, 54], ["moving\" microorganisms", "PROBLEM", 73, 95], ["the oral plaque", "PROBLEM", 116, 131], ["oral", "ANATOMY", 120, 124], ["plaque", "OBSERVATION", 125, 131]]], ["The effectivity of the CHX is only noticeable after mechanical debridement by breaking the thick biofilm that is the reservoir for the respiratory pathogens.", [["biofilm", "ANATOMY", 97, 104], ["respiratory", "ANATOMY", 135, 146], ["CHX", "CHEMICAL", 23, 26], ["CHX", "CHEMICAL", 23, 26], ["CHX", "SIMPLE_CHEMICAL", 23, 26], ["the CHX", "TREATMENT", 19, 26], ["mechanical debridement", "TREATMENT", 52, 74], ["breaking the thick biofilm", "TREATMENT", 78, 104], ["the reservoir", "TREATMENT", 113, 126], ["the respiratory pathogens", "PROBLEM", 131, 156], ["debridement", "OBSERVATION", 63, 74], ["respiratory", "ANATOMY", 135, 146], ["pathogens", "OBSERVATION", 147, 156]]], ["Another important conclusion from the studies was noting that the presenting patient admitted to the ICU had poor oral health, which contributed to accumulation of dental plaque, which later was a reservoir for respiratory pathogens and later aspirated into the lungs causing VAP.DiscussionIn contrast to those studies, Barry et al. [9] tested if there is a difference between different oral rinses in decreasing the incidence of VAP and found no statistical significance.", [["oral", "ANATOMY", 114, 118], ["dental plaque", "ANATOMY", 164, 177], ["respiratory", "ANATOMY", 211, 222], ["lungs", "ANATOMY", 262, 267], ["oral", "ANATOMY", 387, 391], ["plaque", "DISEASE", 171, 177], ["respiratory pathogens", "DISEASE", 211, 232], ["VAP", "DISEASE", 276, 279], ["VAP", "DISEASE", 430, 433], ["patient", "ORGANISM", 77, 84], ["oral", "ORGANISM_SUBDIVISION", 114, 118], ["dental plaque", "PATHOLOGICAL_FORMATION", 164, 177], ["lungs", "ORGAN", 262, 267], ["oral", "ORGANISM_SUBDIVISION", 387, 391], ["patient", "SPECIES", 77, 84], ["the studies", "TEST", 34, 45], ["poor oral health", "PROBLEM", 109, 125], ["dental plaque", "PROBLEM", 164, 177], ["a reservoir", "TREATMENT", 195, 206], ["respiratory pathogens", "PROBLEM", 211, 232], ["VAP", "PROBLEM", 276, 279], ["those studies", "TEST", 305, 318], ["different oral rinses", "TREATMENT", 377, 398], ["VAP", "PROBLEM", 430, 433], ["dental plaque", "OBSERVATION", 164, 177], ["lungs", "ANATOMY", 262, 267], ["VAP", "OBSERVATION", 276, 279]]], ["The author concluded that the mechanical debridement of oral plaque (toothbrushing) had the most effect decreasing the incidence of VAP.DiscussionChacko et al. [6] did not find significant differences between the intervention group receiving mechanical (toothbrushing) and chemical (mouth swab of CHX 0.2%) debridement and the control group receiving only mechanical debridement (toothbrushing).", [["oral plaque", "ANATOMY", 56, 67], ["VAP", "DISEASE", 132, 135], ["CHX", "CHEMICAL", 297, 300], ["CHX", "CHEMICAL", 297, 300], ["oral", "ORGANISM_SUBDIVISION", 56, 60], ["plaque", "PATHOLOGICAL_FORMATION", 61, 67], ["the mechanical debridement", "TREATMENT", 26, 52], ["oral plaque", "PROBLEM", 56, 67], ["VAP", "PROBLEM", 132, 135], ["mechanical (toothbrushing)", "TREATMENT", 242, 268], ["chemical (mouth swab of CHX", "TREATMENT", 273, 300], ["debridement", "TREATMENT", 307, 318], ["the control group", "TREATMENT", 323, 340], ["mechanical debridement", "TREATMENT", 356, 378], ["mechanical", "OBSERVATION_MODIFIER", 30, 40], ["debridement", "OBSERVATION", 41, 52], ["oral", "ANATOMY", 56, 60], ["plaque", "OBSERVATION", 61, 67], ["VAP", "OBSERVATION", 132, 135], ["debridement", "OBSERVATION", 367, 378]]], ["The authors discovered that the risk of having VAP while on mechanical ventilation increased everyday by 1.3, suggesting that the method of the oral care did not had the strongest effect on the incidence of VAP, but the number of ventilation days.", [["oral", "ANATOMY", 144, 148], ["VAP", "DISEASE", 47, 50], ["VAP", "DISEASE", 207, 210], ["oral", "ORGANISM_SUBDIVISION", 144, 148], ["VAP", "PROBLEM", 47, 50], ["mechanical ventilation", "TREATMENT", 60, 82], ["the oral care", "TREATMENT", 140, 153], ["VAP", "PROBLEM", 207, 210], ["VAP", "OBSERVATION", 47, 50], ["VAP", "OBSERVATION", 207, 210]]], ["In this study, the incidence of VAP relatively to general ICU population was low but it was concluded that a potential caregiver bias influenced on this study.DiscussionIn the study of Seguin et al. [10] , again no statistical difference was found between the intervention and the control group regarding the use of povidone-iodine as the oral antiseptic.", [["oral", "ANATOMY", 339, 343], ["VAP", "DISEASE", 32, 35], ["povidone-iodine", "CHEMICAL", 316, 331], ["povidone-iodine", "CHEMICAL", 316, 331], ["povidone-iodine", "SIMPLE_CHEMICAL", 316, 331], ["oral", "ORGANISM_SUBDIVISION", 339, 343], ["this study", "TEST", 3, 13], ["VAP", "PROBLEM", 32, 35], ["a potential caregiver bias", "PROBLEM", 107, 133], ["this study", "TEST", 148, 158], ["the study", "TEST", 172, 181], ["the intervention", "TREATMENT", 256, 272], ["povidone", "TREATMENT", 316, 324], ["iodine", "TREATMENT", 325, 331], ["the oral antiseptic", "TREATMENT", 335, 354], ["VAP", "OBSERVATION", 32, 35]]], ["The author had found that the more ventilation days, the higher dental plaque accumulated in the oral cavity and there was a connection between dental plaque pathogens and respiratory pathogens responsible for causing VAP.DiscussionWe concluded from this review that if a patient is admitted to the ICU who suffers from poor oral hygiene, they contribute to the harmful accumulation of oral plaque and this is also responsible for the pathogens which eventually cause the initiation of VAP and more ventilation days.", [["dental plaque", "ANATOMY", 64, 77], ["oral cavity", "ANATOMY", 97, 108], ["plaque", "ANATOMY", 151, 157], ["respiratory", "ANATOMY", 172, 183], ["oral", "ANATOMY", 325, 329], ["oral plaque", "ANATOMY", 386, 397], ["plaque", "DISEASE", 151, 157], ["respiratory pathogens", "DISEASE", 172, 193], ["VAP", "DISEASE", 218, 221], ["oral plaque", "DISEASE", 386, 397], ["VAP", "DISEASE", 486, 489], ["dental plaque", "PATHOLOGICAL_FORMATION", 64, 77], ["oral cavity", "ORGANISM_SUBDIVISION", 97, 108], ["patient", "ORGANISM", 272, 279], ["oral", "ORGANISM_SUBDIVISION", 325, 329], ["oral plaque", "PATHOLOGICAL_FORMATION", 386, 397], ["patient", "SPECIES", 272, 279], ["the higher dental plaque", "PROBLEM", 53, 77], ["dental plaque pathogens", "PROBLEM", 144, 167], ["respiratory pathogens", "PROBLEM", 172, 193], ["VAP", "PROBLEM", 218, 221], ["poor oral hygiene", "PROBLEM", 320, 337], ["oral plaque", "PROBLEM", 386, 397], ["the pathogens", "PROBLEM", 431, 444], ["VAP", "PROBLEM", 486, 489], ["higher", "OBSERVATION_MODIFIER", 57, 63], ["dental", "OBSERVATION_MODIFIER", 64, 70], ["plaque", "OBSERVATION", 71, 77], ["oral cavity", "ANATOMY", 97, 108], ["plaque", "OBSERVATION", 151, 157], ["harmful", "OBSERVATION_MODIFIER", 362, 369], ["accumulation", "OBSERVATION_MODIFIER", 370, 382], ["oral", "ANATOMY", 386, 390], ["plaque", "OBSERVATION", 391, 397]]], ["This data confirms that the incidence of VAP influenced more by the number of ventilation days.", [["VAP", "DISEASE", 41, 44], ["VAP", "PROBLEM", 41, 44], ["VAP", "OBSERVATION", 41, 44]]], ["Lowering dental plaque by proper oral care will lower the incidence of VAP.DiscussionBecause of that conclusion, it is extremely important for ventilated patients in the ICU to be given proper oral care by qualified care givers for the prevention of VAP.", [["dental plaque", "ANATOMY", 9, 22], ["oral", "ANATOMY", 33, 37], ["oral", "ANATOMY", 193, 197], ["plaque", "DISEASE", 16, 22], ["VAP", "DISEASE", 71, 74], ["VAP", "DISEASE", 250, 253], ["dental plaque", "PATHOLOGICAL_FORMATION", 9, 22], ["oral", "ORGANISM_SUBDIVISION", 33, 37], ["patients", "ORGANISM", 154, 162], ["oral", "ORGANISM_SUBDIVISION", 193, 197], ["patients", "SPECIES", 154, 162], ["Lowering dental plaque", "PROBLEM", 0, 22], ["proper oral care", "TREATMENT", 26, 42], ["VAP", "PROBLEM", 71, 74], ["proper oral care", "TREATMENT", 186, 202], ["VAP", "PROBLEM", 250, 253], ["dental", "OBSERVATION_MODIFIER", 9, 15], ["plaque", "OBSERVATION", 16, 22], ["VAP", "OBSERVATION", 71, 74], ["VAP", "OBSERVATION", 250, 253]]], ["Administration of chlorohexidine in different concentrations alongside the suction of oropharyngeal secretions and mechanical debridement gave good results in the lowering of the accumulation of the pathogens responsible for the initiation of VAP.", [["oropharyngeal secretions", "ANATOMY", 86, 110], ["chlorohexidine", "CHEMICAL", 18, 32], ["VAP", "DISEASE", 243, 246], ["chlorohexidine", "CHEMICAL", 18, 32], ["chlorohexidine", "SIMPLE_CHEMICAL", 18, 32], ["oropharyngeal secretions", "ORGANISM_SUBDIVISION", 86, 110], ["chlorohexidine", "TREATMENT", 18, 32], ["different concentrations", "TREATMENT", 36, 60], ["the suction of oropharyngeal secretions", "TREATMENT", 71, 110], ["mechanical debridement", "TREATMENT", 115, 137], ["the pathogens", "PROBLEM", 195, 208], ["VAP", "PROBLEM", 243, 246], ["oropharyngeal", "ANATOMY", 86, 99], ["secretions", "OBSERVATION", 100, 110], ["debridement", "OBSERVATION", 126, 137], ["VAP", "OBSERVATION", 243, 246]]], ["Also, it was concluded from this review that the more professional and experienced caretakers providing proper oral care protocols, the lower incidence of VAP will occur.DiscussionIn conclusion, proper oral care needs to be considered part of the medical treatment plan when a patient is admitted to the ICU to lower the incidence rates of VAP.Compliance with Ethical StandardsConflict of Interest Author Ron Gershonovitch declares that he has no conflict of interest.", [["oral", "ANATOMY", 111, 115], ["oral", "ANATOMY", 202, 206], ["VAP", "DISEASE", 155, 158], ["VAP", "DISEASE", 340, 343], ["oral", "ORGANISM_SUBDIVISION", 111, 115], ["oral", "ORGANISM_SUBDIVISION", 202, 206], ["patient", "ORGANISM", 277, 284], ["patient", "SPECIES", 277, 284], ["proper oral care protocols", "TREATMENT", 104, 130], ["VAP", "PROBLEM", 155, 158], ["the medical treatment plan", "TREATMENT", 243, 269], ["VAP", "PROBLEM", 340, 343], ["VAP", "OBSERVATION", 155, 158], ["VAP", "OBSERVATION", 340, 343]]], ["Author Mordechai Findler declares that he has no conflict of interest.Compliance with Ethical StandardsWe wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.Funding InformationThe work was supported by the oral medicine unit, sheba medical center, tel hashomer, israel.Funding InformationEthical Approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Funding InformationInformed Consent For this type of study, formal consent is not required.", [["oral", "ANATOMY", 355, 359], ["oral", "ORGANISM_SUBDIVISION", 355, 359], ["human", "ORGANISM", 500, 505], ["human", "SPECIES", 500, 505], ["participants", "SPECIES", 506, 518], ["human", "SPECIES", 500, 505], ["Ethical Standards", "TREATMENT", 86, 103], ["study", "TEST", 770, 775], ["no", "UNCERTAINTY", 220, 222]]]], "PMC7507487": []}